

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:09:10 ; Search time 1392 Seconds

(without alignments)  
3.908 Million cell updates/sec

Title: us-10-664-775-2

Perfect score: 3572  
Sequence: 1 gtcaggagggcgcagtg.....gcacacacgagaaagctt 3572

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 1612 seqs, 761339 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries

Database : rngdb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|-------------|
| C 1        | 28.8  | 0.8         | 612    | 1     | ABQ47969    |
| C 2        | 28.8  | 0.8         | 612    | 1     | ABQ47968    |
| C 3        | 28.7  | 0.8         | 267    | 1     | AAK45604    |
| C 4        | 28.7  | 0.8         | 267    | 1     | AAK19599    |
| C 5        | 28.7  | 0.8         | 267    | 1     | ABK48294    |
| C 6        | 28.7  | 0.8         | 267    | 1     | ABK19876    |
| C 7        | 28.6  | 0.8         | 373    | 1     | ABL80716    |
| C 8        | 28.6  | 0.8         | 517    | 1     | ABV98643    |
| C 9        | 27.7  | 0.8         | 1843   | 1     | AAAF54035   |
| C 10       | 27.7  | 0.8         | 1843   | 1     | AAAF54050   |
| C 11       | 27.7  | 0.8         | 1843   | 1     | ABN97175    |
| C 12       | 27.2  | 0.8         | 387    | 1     | ABK30271    |
| C 13       | 26.2  | 0.7         | 237    | 1     | ABK68927    |
| C 14       | 26.2  | 0.7         | 683    | 1     | AAQ63794    |
| C 15       | 26.2  | 0.7         | 699    | 1     | AAA08526    |
| C 16       | 26.2  | 0.7         | 699    | 1     | AAF81479    |
| C 17       | 26.2  | 0.7         | 701    | 1     | AAQ63795    |
| C 18       | 26.2  | 0.7         | 702    | 1     | AAA08525    |
| C 19       | 26.2  | 0.7         | 828    | 1     | AAQ07168    |
| C 20       | 26.2  | 0.7         | 1151   | 1     | AAQ08286    |
| C 21       | 25.8  | 0.7         | 497    | 1     | ABV97824    |
| C 22       | 25.6  | 0.7         | 2438   | 1     | AAK60065    |
| C 23       | 25.4  | 0.7         | 265    | 1     | AAK94395    |
| C 24       | 25.4  | 0.7         | 1036   | 1     | AAA61697    |
| C 25       | 25.2  | 0.7         | 1036   | 1     | AAA61697    |
| C 26       | 25.2  | 0.7         | 448    | 1     | ABV97809    |
| C 27       | 25.8  | 0.7         | 882    | 1     | ABN85394    |
| C 28       | 24.8  | 0.7         | 2177   | 1     | AAK60063    |
| C 29       | 24.6  | 0.7         | 1151   | 1     | AAQ08286    |
| C 30       | 24.6  | 0.7         | 1352   | 1     | AAK41085    |
| C 31       | 24.6  | 0.7         | 1352   | 1     | AAK25942    |
| C 32       | 24.6  | 0.7         | 1352   | 1     | ABK72087    |
| C 33       | 24.6  | 0.7         | 1352   | 1     | ABK91679    |

|     |      |     |      |   |          |                     |
|-----|------|-----|------|---|----------|---------------------|
| 34  | 24.6 | 0.7 | 1352 | 1 | AAK41621 | cDNA encoding nove  |
| 35  | 24.6 | 0.7 | 1352 | 1 | AAK26943 | Human cDNA encodin  |
| 36  | 24.6 | 0.7 | 1378 | 1 | AAK87259 | cDNA clone encodin  |
| 37  | 24.6 | 0.7 | 1378 | 1 | AAK52262 | Protein PRO343 CDN  |
| 38  | 24.6 | 0.7 | 1378 | 1 | AAK46914 | cDNA encoding nove  |
| 39  | 24.6 | 0.7 | 1378 | 1 | ADC78574 | Human PRO343 cDNA.  |
| 40  | 24.6 | 0.7 | 1378 | 1 | AAK72420 | Human PRO343 cDNA.  |
| 41  | 24.6 | 0.7 | 1378 | 1 | ACA59110 | Human PRO polynucl  |
| 42  | 24.6 | 0.7 | 1378 | 1 | ACA58507 | cDNA encoding huma  |
| 43  | 24.6 | 0.7 | 1378 | 1 | ACA60214 | Novel human secret  |
| 44  | 24.6 | 0.7 | 1378 | 1 | ACD07614 | Human cDNA encodin  |
| 45  | 24.6 | 0.7 | 1378 | 1 | ABX71662 | Human secreted/tra  |
| 46  | 24.6 | 0.7 | 1378 | 1 | ACH06594 | Human secreted/tra  |
| 47  | 24.6 | 0.7 | 1378 | 1 | ABX96231 | cDNA encoding huma  |
| 48  | 24.6 | 0.7 | 1378 | 1 | ACA05552 | Human secreted / t  |
| 49  | 24.6 | 0.7 | 1378 | 1 | ACD20219 | Novel human secret  |
| 50  | 24.6 | 0.7 | 1378 | 1 | ACA55022 | Human secreted / t  |
| 51  | 24.6 | 0.7 | 1378 | 1 | ACD19857 | Human secreted/tra  |
| 52  | 24.6 | 0.7 | 1378 | 1 | ADK29467 | Human secreted/tra  |
| 53  | 24.6 | 0.7 | 1378 | 1 | ADA18323 | Human cDNA encodin  |
| 54  | 24.6 | 0.7 | 1378 | 1 | ACD67004 | Human PRO polynucl  |
| 55  | 24.6 | 0.7 | 1378 | 1 | ADA16298 | Human secreted/tra  |
| 56  | 24.6 | 0.7 | 1378 | 1 | ADA16298 | Human secreted/tra  |
| 57  | 24.6 | 0.7 | 1378 | 1 | ADA42443 | Human PRO polynucl  |
| 58  | 24.6 | 0.7 | 1378 | 1 | ACD23343 | Human secreted/tra  |
| 59  | 24.6 | 0.7 | 1378 | 1 | ADA16722 | Human secreted/tra  |
| 60  | 24.6 | 0.7 | 1378 | 1 | ADA13151 | Human secreted/tra  |
| 61  | 24.6 | 0.7 | 1378 | 1 | ADA42019 | Human secreted/tra  |
| 62  | 24.6 | 0.7 | 1378 | 1 | ADA17366 | Human secreted/tra  |
| 63  | 24.6 | 0.7 | 1378 | 1 | ADA42869 | Human secreted/tra  |
| 64  | 24.6 | 0.7 | 1378 | 1 | ACD23705 | Human PRO polynucl  |
| 65  | 24.6 | 0.7 | 1378 | 1 | ADK77788 | Human secreted/tra  |
| 66  | 24.6 | 0.7 | 1378 | 1 | ADK74924 | Human secreted/tra  |
| 67  | 24.6 | 0.7 | 1378 | 1 | ADC28570 | Human secreted/tra  |
| 68  | 24.6 | 0.7 | 1378 | 1 | ADC39770 | Human secreted/tra  |
| 69  | 24.6 | 0.7 | 1378 | 1 | ADC40284 | Human secreted/tra  |
| 70  | 24.6 | 0.7 | 1378 | 1 | ADC19108 | Human secreted/tra  |
| 71  | 24.6 | 0.7 | 1378 | 1 | ADC44408 | Human secreted/tra  |
| 72  | 24.6 | 0.7 | 1378 | 1 | ADC29463 | Human secreted/tra  |
| 73  | 24.6 | 0.7 | 1378 | 1 | ADC28994 | Human secreted/tra  |
| 74  | 24.6 | 0.7 | 1378 | 1 | ADC40879 | Human secreted/tra  |
| 75  | 24.6 | 0.7 | 1378 | 1 | ADC19536 | Human secreted/tra  |
| 76  | 24.6 | 0.7 | 1378 | 1 | ADC33984 | Human secreted/tra  |
| 77  | 24.6 | 0.7 | 1378 | 1 | ADC13054 | Human secreted/tra  |
| 78  | 24.6 | 0.7 | 1378 | 1 | ADC12506 | Human secreted/tra  |
| 79  | 24.6 | 0.7 | 1378 | 1 | ADD05061 | Human secreted/tra  |
| 80  | 24.6 | 0.7 | 1378 | 1 | ADD04067 | Human secreted/tra  |
| 81  | 24.6 | 0.7 | 1378 | 1 | ADD03643 | Human secreted/tra  |
| 82  | 24.6 | 0.7 | 1378 | 1 | ADE34895 | Human secreted/tra  |
| 83  | 24.6 | 0.7 | 1378 | 1 | ADE79340 | Human secreted/tra  |
| 84  | 24.6 | 0.7 | 1378 | 1 | ADE79764 | Human secreted/tra  |
| 85  | 24.6 | 0.7 | 1378 | 1 | ADE73440 | Human secreted/tra  |
| 86  | 24.6 | 0.7 | 1378 | 1 | ADK73975 | Human secreted/tra  |
| 87  | 24.6 | 0.7 | 132  | 1 | AAK72590 | Novel growth facto  |
| 88  | 23.6 | 0.7 | 260  | 1 | AAK11550 | Plant microsateili  |
| 89  | 23.6 | 0.7 | 361  | 1 | ABX42370 | Bovine EST associat |
| 90  | 23.4 | 0.7 | 596  | 1 | AAI29377 | Colon tumour relat  |
| 91  | 23.4 | 0.7 | 596  | 1 | ABK33563 | Human colon tumour  |
| 92  | 23.4 | 0.7 | 882  | 1 | ABN85395 | Partial Human NOV1  |
| 93  | 23.4 | 0.7 | 1142 | 1 | AAK87796 | Activation constru  |
| 94  | 23.4 | 0.7 | 1142 | 1 | AAK52628 | Nucleotide sequenc  |
| 95  | 23.4 | 0.7 | 1161 | 1 | ABN85393 | Human NOV14b, pros  |
| 96  | 23.4 | 0.7 | 1169 | 1 | AAK87795 | Activation constru  |
| 97  | 23.4 | 0.7 | 1169 | 1 | AAK5267  | Nucleotide sequenc  |
| 98  | 23.4 | 0.7 | 1507 | 1 | AAK45031 | Human factor X cod  |
| 99  | 23.4 | 0.7 | 1507 | 1 | ABK35322 | Human gene express  |
| 100 | 23.2 | 0.7 | 1507 | 1 | ABK35322 | Farnesyl transfera  |
| 101 | 23.2 | 0.6 | 375  | 1 | ABV98444 | Human pancreatic c  |
| 102 | 23   | 0.6 | 244  | 1 | AAK38186 | Histocompatibility  |
| 103 | 23   | 0.6 | 250  | 1 | AAK76438 | Substance P antise  |
| 104 | 23   | 0.6 | 250  | 1 | AAK54759 | Human adenosine re  |
| 105 | 23   | 0.6 | 250  | 1 | AAK44206 | Human substance P   |
| 106 | 23   | 0.6 | 250  | 1 | AAK20328 |                     |

|       |      |     |      |   |           |                     |       |      |     |      |   |           |                     |
|-------|------|-----|------|---|-----------|---------------------|-------|------|-----|------|---|-----------|---------------------|
| C 107 | 23   | 0.6 | 250  | 1 | ABZ96022  | Human substance P   | 180   | 21.2 | 0.6 | 1529 | 1 | AAQ12680  | PAP-I-protein C fu  |
| C 108 | 23   | 0.6 | 370  | 1 | ABX46375  | Bovine EST associa  | C 181 | 21.2 | 0.6 | 6098 | 1 | ABX14193  | Plasmid pLN174 for  |
| C 109 | 23   | 0.6 | 381  | 1 | ABV97874  | Bovine pancreatic c | C 182 | 21   | 0.6 | 237  | 1 | ABL28111  | Drosophila melanog  |
| C 110 | 23   | 0.6 | 2438 | 1 | ANM60065  | Factor IX/Factor V  | C 183 | 21   | 0.6 | 291  | 1 | ASZ72491  | Sorghum melaconog   |
| C 111 | 22.8 | 0.6 | 231  | 1 | AC55669   | Human differential  | C 184 | 21   | 0.6 | 292  | 1 | AAH57326  | Human pancreas spe  |
| C 112 | 22.8 | 0.6 | 231  | 1 | ACD81661  | Human destructive   | C 185 | 21   | 0.6 | 631  | 1 | ACC46452  | Human dithp protei  |
| C 113 | 22.8 | 0.6 | 255  | 1 | AD54232   | Streptomyces amphi  | C 186 | 21   | 0.6 | 850  | 1 | ABL65438  | Lung cancer relate  |
| C 114 | 22.8 | 0.6 | 356  | 1 | ABX36877  | Bovine EST associa  | C 187 | 21   | 0.6 | 933  | 1 | AAV59135  | Nucleotide sequenc  |
| C 115 | 22.8 | 0.6 | 399  | 1 | ABX35924  | Bovine EST associa  | C 188 | 21   | 0.6 | 951  | 1 | ADA05757  | Human NOV25a encod  |
| C 116 | 22.6 | 0.6 | 468  | 1 | AA111607  | Probe #1540 for ge  | C 189 | 21   | 0.6 | 1551 | 1 | AA506059  | Angiotensin conver  |
| C 117 | 22.6 | 0.6 | 468  | 1 | ABR53297  | Human foetal liver  | C 190 | 21   | 0.6 | 2422 | 1 | AAQ80396  | cDNA encoding fact  |
| C 118 | 22.6 | 0.6 | 468  | 1 | ABR53297  | Probe #1586 used t  | C 191 | 21   | 0.6 | 2422 | 1 | AAQ80396  | cDNA encoding fact  |
| C 119 | 22.6 | 0.6 | 468  | 1 | ABA42875  | Human breast cell   | C 192 | 21   | 0.6 | 2422 | 1 | AAV02230  | Human sapiens cDNA  |
| C 120 | 22.6 | 0.6 | 468  | 1 | AA23070   | Probe #1536 for ge  | C 193 | 21   | 0.6 | 2422 | 1 | AAV57385  | Factor VII encodin  |
| C 121 | 22.6 | 0.6 | 468  | 1 | AAK01557  | Human brain expres  | C 194 | 21   | 0.6 | 2422 | 1 | AAV57099  | Human Factor VII p  |
| C 122 | 22.6 | 0.6 | 468  | 1 | AA101533  | Probe #1524 used t  | C 195 | 21   | 0.6 | 2422 | 1 | ADC24226  | Factor VII cDNA of  |
| C 123 | 22.6 | 0.6 | 2177 | 1 | AA600663  | Partial Factor VII  | C 196 | 20.9 | 0.6 | 2432 | 1 | AA600664  | Bovine EST associa  |
| C 124 | 22.4 | 0.6 | 186  | 1 | ABN76724  | Human ORF1671 cDNA  | C 197 | 20.8 | 0.6 | 197  | 1 | ABV97483  | Human pancreatic c  |
| C 125 | 22.4 | 0.6 | 317  | 1 | ABV97959  | Human pancreatic c  | C 198 | 20.8 | 0.6 | 252  | 1 | ABN18436  | Human ORFX polynuc  |
| C 126 | 22.3 | 0.6 | 253  | 1 | ABV70944  | Single nucleotide   | C 199 | 20.8 | 0.6 | 281  | 1 | ABU74708  | Corn tassal-derive  |
| C 127 | 22.2 | 0.6 | 397  | 1 | ABV97709  | Human pancreatic c  | C 200 | 20.8 | 0.6 | 323  | 1 | AA404441  | Human secreted pro  |
| C 128 | 22   | 0.6 | 234  | 1 | ABV98476  | Human pancreatic c  | C 201 | 20.8 | 0.6 | 380  | 1 | AA559116  | Human cancer relat  |
| C 129 | 22   | 0.6 | 397  | 1 | ABV08821  | Human prostate exp  | C 202 | 20.8 | 0.6 | 396  | 1 | ABX44887  | Bovine EST associa  |
| C 130 | 22   | 0.6 | 432  | 1 | ABX49447  | Bovine EST associa  | C 203 | 20.8 | 0.6 | 400  | 1 | AA559112  | Human cancer relat  |
| C 131 | 22   | 0.6 | 534  | 1 | ABX44157  | cDNA #97 encoding   | C 204 | 20.8 | 0.6 | 545  | 1 | ABA67855  | Human foetal liver  |
| C 132 | 22   | 0.6 | 741  | 1 | ABN1633   | Human spleen cryps  | C 205 | 20.8 | 0.6 | 545  | 1 | ABX41612  | Human liver single  |
| C 133 | 22   | 0.6 | 744  | 1 | AA104001  | Human pancreatic t  | C 206 | 20.8 | 0.6 | 1338 | 1 | AA199982  | Human FVII encodin  |
| C 134 | 22   | 0.6 | 744  | 1 | AA104000  | Human pancreatic t  | C 207 | 20.8 | 0.6 | 1352 | 1 | AA541085  | cDNA encoding nove  |
| C 135 | 22   | 0.6 | 744  | 1 | AA103999  | Human pancreatic t  | C 208 | 20.8 | 0.6 | 1352 | 1 | AA526342  | Human cDNA encodin  |
| C 136 | 22   | 0.6 | 790  | 1 | AA24548   | Trypsinogen-like p  | C 209 | 20.8 | 0.6 | 1352 | 1 | ABK72087  | Human cDNA encodin  |
| C 137 | 22   | 0.6 | 853  | 1 | ABZ35087  | Human gene expres   | C 210 | 20.8 | 0.6 | 1352 | 1 | ABK91679  | cDNA encoding nove  |
| C 138 | 21.8 | 0.6 | 121  | 1 | ABA79599  | Factor IX mutation  | C 211 | 20.8 | 0.6 | 1352 | 1 | AA541621  | cDNA encoding nove  |
| C 139 | 21.8 | 0.6 | 121  | 1 | ABA79602  | Factor IX mutation  | C 212 | 20.8 | 0.6 | 1352 | 1 | AA526943  | Human cDNA encodin  |
| C 140 | 21.8 | 0.6 | 121  | 1 | ABA79603  | Factor IX mutation  | C 213 | 20.8 | 0.6 | 1357 | 1 | AA199983  | Human FVII express  |
| C 141 | 21.8 | 0.6 | 121  | 1 | ABA79598  | Factor IX mutation  | C 214 | 20.8 | 0.6 | 1366 | 1 | AA232168  | Human low density   |
| C 142 | 21.8 | 0.6 | 224  | 1 | AA124712  | Probe #14645 for g  | C 215 | 20.8 | 0.6 | 1754 | 1 | AAQ13357  | Human protein C ge  |
| C 143 | 21.8 | 0.6 | 224  | 1 | ABR6962   | Human foetal liver  | C 216 | 20.8 | 0.6 | 1754 | 1 | AAQ12849  | Protein C precursor |
| C 144 | 21.8 | 0.6 | 224  | 1 | AA150074  | Probe #18760 used   | C 217 | 20.8 | 0.6 | 1755 | 1 | AAQ12878  | Human protein C     |
| C 145 | 21.8 | 0.6 | 224  | 1 | ABA36799  | Probe #15285 for g  | C 218 | 20.8 | 0.6 | 1755 | 1 | AAQ12878  | Human protein C     |
| C 146 | 21.8 | 0.6 | 224  | 1 | AAK40064  | Human bone marrow   | C 219 | 20.8 | 0.6 | 1756 | 1 | AAAT32795 | Human protein C     |
| C 147 | 21.8 | 0.6 | 224  | 1 | AAK18172  | Human brain expres  | C 220 | 20.6 | 0.6 | 228  | 1 | AAQ02548  | cDNA sequence enco  |
| C 148 | 21.8 | 0.6 | 224  | 1 | ABZ3718   | Human liver single  | C 221 | 20.6 | 0.6 | 271  | 1 | AAQ93747  | Human secreted pro  |
| C 149 | 21.8 | 0.6 | 224  | 1 | ABZ18297  | Human genome-deriv  | C 222 | 20.6 | 0.6 | 312  | 1 | ADA49305  | Maize gene conferr  |
| C 150 | 21.8 | 0.6 | 361  | 1 | ABX42370  | Bovine EST associa  | C 223 | 20.6 | 0.6 | 396  | 1 | ABX44887  | Bovine EST associa  |
| C 151 | 21.8 | 0.6 | 522  | 1 | ABK4151   | cDNA #91 encoding   | C 224 | 20.6 | 0.6 | 717  | 1 | AAQ13346  | Single nucleotide   |
| C 152 | 21.8 | 0.6 | 711  | 1 | AA148492  | Human serine prote  | C 225 | 20.6 | 0.6 | 1843 | 1 | AAAS4035  | Human protein C co  |
| C 153 | 21.6 | 0.6 | 268  | 1 | AAQ43935  | Mettir human prota  | C 226 | 20.6 | 0.6 | 1843 | 1 | AAFS4050  | Human protein C ge  |
| C 154 | 21.6 | 0.6 | 281  | 1 | AAQ05663  | Human proinsulin g  | C 227 | 20.6 | 0.6 | 1843 | 1 | ABN97175  | Gene #3673 used to  |
| C 155 | 21.6 | 0.6 | 360  | 1 | AAQ38310  | hpi gene, Homo sa   | C 228 | 20.6 | 0.6 | 1982 | 1 | AD79050   | Human protein modi  |
| C 156 | 21.6 | 0.6 | 360  | 1 | AC035359  | Synthetic DNA ecod  | C 229 | 20.4 | 0.6 | 121  | 1 | ABA79567  | Factor IX mutation  |
| C 157 | 21.6 | 0.6 | 360  | 1 | AC078504  | HIV p15RnaseH, opt  | C 230 | 20.4 | 0.6 | 121  | 1 | ABA79566  | Factor IX mutation  |
| C 158 | 21.6 | 0.6 | 372  | 1 | ABX37095  | Bovine EST associa  | C 231 | 20.4 | 0.6 | 121  | 1 | ABA79583  | Factor IX mutation  |
| C 159 | 21.6 | 0.6 | 427  | 1 | ABX37095  | Bovine EST associa  | C 232 | 20.4 | 0.6 | 121  | 1 | ABA79595  | Factor IX mutation  |
| C 160 | 21.6 | 0.6 | 6098 | 1 | ABX14193  | Murine transport a  | C 233 | 20.4 | 0.6 | 121  | 1 | ABA79591  | Factor IX mutation  |
| C 161 | 21.4 | 0.6 | 144  | 1 | ABR84477  | Plasmid pLN174 for  | C 234 | 20.4 | 0.6 | 121  | 1 | ABA79578  | Factor IX mutation  |
| C 162 | 21.4 | 0.6 | 172  | 1 | AA58758   | Human estrogen re   | C 235 | 20.4 | 0.6 | 121  | 1 | ABA79590  | Factor IX mutation  |
| C 163 | 21.4 | 0.6 | 243  | 1 | AAA49060  | Snut O-N-lang DNA   | C 236 | 20.4 | 0.6 | 121  | 1 | ABA79579  | Factor IX mutation  |
| C 164 | 21.4 | 0.6 | 380  | 1 | ABV98158  | Human pancreatic c  | C 237 | 20.4 | 0.6 | 121  | 1 | ABA79582  | Factor IX mutation  |
| C 165 | 21.4 | 0.6 | 612  | 1 | ABQ47966  | Oligonucleotide fo  | C 238 | 20.4 | 0.6 | 121  | 1 | ABA79586  | Factor IX mutation  |
| C 166 | 21.4 | 0.6 | 612  | 1 | ABQ47967  | Oligonucleotide fo  | C 239 | 20.4 | 0.6 | 121  | 1 | ABA79594  | Factor IX mutation  |
| C 167 | 21.2 | 0.6 | 177  | 1 | ABA74567  | Human foetal liver  | C 240 | 20.4 | 0.6 | 121  | 1 | ABA79587  | Factor IX mutation  |
| C 168 | 21.2 | 0.6 | 177  | 1 | AA155048  | Probe #23734 used   | C 241 | 20.4 | 0.6 | 268  | 1 | AAQ72259  | Single nucleotide   |
| C 169 | 21.2 | 0.6 | 177  | 1 | ABK48213  | Human bone marrow   | C 242 | 20.4 | 0.6 | 270  | 1 | AD49152   | Maize gene conferr  |
| C 170 | 21.2 | 0.6 | 177  | 1 | ABK48856  | Human liver single  | C 243 | 20.4 | 0.6 | 285  | 1 | AAH57325  | Human pancreas spe  |
| C 171 | 21.2 | 0.6 | 231  | 1 | ABK76610  | Bacillus lichenifo  | C 244 | 20.4 | 0.6 | 290  | 1 | ABL71211  | Human tassal-derive |
| C 172 | 21.2 | 0.6 | 273  | 1 | AAAL2284  | Human ORFX polynuc  | C 245 | 20.4 | 0.6 | 334  | 1 | AAV62325  | Gene fragment HEPA  |
| C 173 | 21.2 | 0.6 | 280  | 1 | AAAL2284  | Human breast cance  | C 246 | 20.4 | 0.6 | 335  | 1 | AAV89281  | EST clone CG175     |
| C 174 | 21.2 | 0.6 | 505  | 1 | ABK30273  | Human G-protein-co  | C 247 | 20.4 | 0.6 | 394  | 1 | AAAD58761 | Human transmembran  |
| C 175 | 21.2 | 0.6 | 609  | 1 | ADA50533  | Human protease gen  | C 248 | 20.4 | 0.6 | 717  | 1 | AAA61659  | cDNA encoding mous  |
| C 176 | 21.2 | 0.6 | 888  | 1 | ABK31769  | DNA encoding novel  | C 249 | 20.4 | 0.6 | 1383 | 1 | ABX86038  | Synthetic DNA enco  |
| C 177 | 21.2 | 0.6 | 918  | 1 | AA167198  | Nucleotide sequenc  | C 250 | 20.4 | 0.6 | 1386 | 1 | AAAN90024 | Nascent human prot  |
| C 178 | 21.2 | 0.6 | 1130 | 1 | ABP77000  | Fusion gene of pro  |       |      |     |      |   |           |                     |
| C 179 | 21.2 | 0.6 | 1166 | 1 | AAAD02991 | Zymogen activation  |       |      |     |      |   |           |                     |



ALIGNMENTS

RESULT 1  
ABQ47969/C  
ID ABQ47969 standard; DNA; 612 BP.  
XX AC ABQ47969;  
XX DT 12-JUL-2002 (first entry)  
XX DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34560.  
XX KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;  
XX drug; side effect; cancer; central nervous system; cardiovascular;  
XX gastrointestinal; respiratory system; single nucleotide polymorphism;  
XX SNP; cell differentiation; ds.  
XX OS Homo sapiens.  
XX PN WO200218632-A2.  
XX PD 07-MAR-2002.  
XX PF 01-SEP-2001; 2001WO-EP010074.  
XX PR 01-SEP-2000; 2000DE-01043826.  
XX PR 05-SEP-2000; 2000DE-01044543.  
XX PA (EPiG-) EPIGENOMICS AG.  
XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;  
XX WPI; 2002-371829/40.  
XX DR Determining the degree of cytosine methylation in genomic DNA, useful for  
XX PT diagnosis and prognosis, comprises selective hybridization of amplicons  
XX PT from chemically treated DNA.  
XX PS Claim 12; 56pp + Sequence Listing; 56pp; German.  
XX CC This invention describes a novel method for determining the degree of  
XX methylation of a particular cytosine in a motif 5'-CpG-3', present in a  
XX genomic sample of DNA. The sample is treated chemically to convert  
XX cytosine (C) but not methylated C, to uracil, then part of the genomic  
XX DNA that contains the target C is amplified to form a labeled amplicon.  
XX The amplicon is hybridised to two classes, each with at least one member,  
XX of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the  
XX degree of hybridisation to both classes is determined from the label on  
XX the amplicon. From the ratio of labels hybridised to the two classes of  
XX oligomers, the degree of methylation is calculated. The method is used:  
XX (i) for diagnosis and/or prognosis of side effects of therapeutic drugs  
XX and of a wide range of diseases, e.g. cancer, disorders of the central  
XX nervous, cardiovascular, gastrointestinal and respiratory systems etc.,  
XX particularly by detecting mutations or single nucleotide polymorphisms  
XX (SNP's); and (ii) for differentiation of cell or tissue types and for  
XX investigating cell differentiation. The method allows the methylation  
XX status of many C residues to be determined simultaneously. ABQ13410-  
XX ABQ54121 represent genomic DNA sequences used to illustrate the method  
XX for determining the degree of cytosine methylation described in the  
XX disclosure of the invention  
XX SQ Sequence 612 BP; 232 A; 219 C; 72 G; 89 T; 0 U; 0 Other;  
Query Match 0.8%; Score 28.8; DB 1; Length 612;  
Best Local Similarity 58.0%; Pred. No. 1.6;  
Matches 51; Conservative 0; Mismatches 37; Indels 0; Gaps 0;  
QY 3207 TCTTTGATACAGCTTCAGTTCATGCTTTTAAATAAGTTTTTTTTTTTTTTTA 3266  
D8 280 TTTTGAAGATTTTCGGGTTTTTCGAAGGAGTATGTTTTTTTGTATTTTTTTT 221  
QY 3267 AAGATGTCATCTTTGTGAGTTTTGA 3294

Db 220 AGGAGTTCGTCGTAGTTTTTTTAGGA 193  
RESULT 2  
ABQ47968  
ID ABQ47968 standard; DNA; 612 BP.  
XX AC ABQ47968;  
XX DT 12-JUL-2002 (first entry)  
XX DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34559.  
XX KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;  
XX drug; side effect; cancer; central nervous system; cardiovascular;  
XX gastrointestinal; respiratory system; single nucleotide polymorphism;  
XX SNP; cell differentiation; ds.  
XX OS Homo sapiens.  
XX PN WO200218632-A2.  
XX PD 07-MAR-2002.  
XX PF 01-SEP-2001; 2001WO-EP010074.  
XX PR 01-SEP-2000; 2000DE-01043826.  
XX PR 05-SEP-2000; 2000DE-01044543.  
XX PA (EPiG-) EPIGENOMICS AG.  
XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;  
XX WPI; 2002-371829/40.  
XX DR Determining the degree of cytosine methylation in genomic DNA, useful for  
XX PT diagnosis and prognosis, comprises selective hybridization of amplicons  
XX PT from chemically treated DNA.  
XX PS Claim 12; 56pp + Sequence Listing; 56pp; German.  
XX CC This invention describes a novel method for determining the degree of  
XX methylation of a particular cytosine in a motif 5'-CpG-3', present in a  
XX genomic sample of DNA. The sample is treated chemically to convert  
XX cytosine (C) but not methylated C, to uracil, then part of the genomic  
XX DNA that contains the target C is amplified to form a labeled amplicon.  
XX The amplicon is hybridised to two classes, each with at least one member,  
XX of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the  
XX degree of hybridisation to both classes is determined from the label on  
XX the amplicon. From the ratio of labels hybridised to the two classes of  
XX oligomers, the degree of methylation is calculated. The method is used:  
XX (i) for diagnosis and/or prognosis of side effects of therapeutic drugs  
XX and of a wide range of diseases, e.g. cancer, disorders of the central  
XX nervous, cardiovascular, gastrointestinal and respiratory systems etc.,  
XX particularly by detecting mutations or single nucleotide polymorphisms  
XX (SNP's); and (ii) for differentiation of cell or tissue types and for  
XX investigating cell differentiation. The method allows the methylation  
XX status of many C residues to be determined simultaneously. ABQ13410-  
XX ABQ54121 represent genomic DNA sequences used to illustrate the method  
XX for determining the degree of cytosine methylation described in the  
XX disclosure of the invention  
XX SQ Sequence 612 BP; 89 A; 72 C; 219 G; 232 T; 0 U; 0 Other;  
Query Match 0.8%; Score 28.8; DB 1; Length 612;  
Best Local Similarity 58.0%; Pred. No. 1.6;  
Matches 51; Conservative 0; Mismatches 37; Indels 0; Gaps 0;  
QY 3207 TCTTTGATACAGCTTCAGTTCATGCTTTTAAATAAGTTTTTTTTTTTTTTTA 3266  
D8 333 TTTTGAAGATTTTCGGGTTTTTCGAAGGAGTATGTTTTTTTGTATTTTTTTT 392



[illegible]





RESULT 14  
AAQ63794  
ID AAQ63794 standard; DNA; 683 BP.  
XX  
AC AAQ63794;  
XX  
XX 25-MAR-2003 (revised)  
DT 01-DEC-1994 (first entry)  
XX  
XX Bovine trypsin gene.  
DE  
XX Cattle; cow; trypsin; enzyme; protease; proinsulin; insulin; hormone;  
KW plasmid PRMG4; ds.  
XX  
OS Bos taurus.  
XX  
XX Key Location/Qualifiers  
FH CDS 4..675  
FT /\*tag= a  
FT  
XX EP597681-A1.  
PN  
XX 18-MAY-1994.  
PD  
XX 10-NOV-1993; 93EP-00308959.  
PF  
XX 13-NOV-1992; 92US-00977703.  
PR  
XX (ELIL ) LILLY & CO ELI.  
PA  
XX Greaney MG, Rosteck PR;  
PI  
XX WPI; 1994-160671/20.  
DR  
XX Expression vectors for bovine trypsin and bovine trypsinogen - for  
PT cleavage of zymogens into active drugs, e.g. pro-insulin conversion into  
PT insulin.  
XX  
XX Disclosure; Page 25; 35pp; English.  
PS  
XX This gene is expressed in a recombinant host, e.g. E. coli, using plasmid  
CC PRMG4. The encoded bovine trypsin gene may be expressed recombinantly and  
CC is able to cleave zymogens into active drugs, e.g. pro-insulin conversion  
CC into insulin. (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 683 BP; 134 A; 223 C; 172 G; 154 T; 0 U; 0 Other;  
Query Match 0.7%; Score 26.2; DB 1; Length 683;  
Best Local Similarity 53.4%; Pred. No. 8;  
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;  
Qy 821 TCCAGGCAACCAATTCATATACAGTATCCAAAGTCATGCCCCCAACAGTATGCTG 880  
Db 208 TCCAAAGTCCATCGTGCAACCGCTCTAGCACTCCCAACCTCTGAACATGACATCATGCTG 267  
Qy 881 AAGAAGCTGAAGTTGAACGGTCCCTATCAAGACCTTACAGACCT 923  
Db 268 ATCAAGCTCAAGTCGCGCGCATCCCTGAACTCCGCGTGCCT 310  
RESULT 15  
AAA08526  
ID AAA08526 standard; DNA; 699 BP.  
XX  
AC AAA08526;  
XX  
XX 19-JUL-2000 (first entry)  
DT  
XX DNA encoding recombinant trypsin.  
DE  
XX Recombinant trypsin; trypsinogen analogue; mutated bovine trypsinogen;  
KW leader sequence; trypsin activity; recombinant protein production;  
XX

XX inactive zymogen; ss.  
XX  
OS Synthetic.  
OS Bos taurus.  
XX  
XX Key Location/Qualifiers  
FH CDS 4..699  
FT /\*tag= a  
FT /product= "trypsin"  
FT sig\_peptide 10..24  
FT /\*tag= b  
FT /note= "leader sequence"  
FT mat\_peptide 25..696  
FT /\*tag= c  
FT /product= "trypsin"  
XX  
PN WO200017332-A1.  
XX  
XX 30-MAR-2000.  
PD  
XX 15-SEP-1999; 99WO-US021047.  
PF  
XX 21-SEP-1998; 98US-0101213P.  
PR  
XX (ELIL ) LILLY & CO ELI.  
PA  
XX Hanquier JM, Hershberger CL, Desplancq D, Larson JL, Rosteck PR;  
PI  
XX WPI; 2000-283565/24.  
DR P-PSDB; AAY91926.  
XX  
XX New trypsinogen analog useful for the production of recombinant trypsin  
PT has a modified leader sequence not cleavable by trypsin or trypsin-like  
PT enzymes.  
XX  
XX Claim 11; Page 49-50; 56pp; English.  
PS  
XX This sequence encodes a claimed recombinant trypsin. The trypsin is  
CC produced by cleavage of a trypsinogen analogue (AAY91925). A wild type  
CC bovine trypsinogen was mutated to destroy the trypsin cleavage site. The  
CC lys residue present in the leader sequence of the native bovine  
CC trypsinogen protein was mutated to an Asp residue. The vector was  
CC constructed such that DNA encoding a (Glu-Ala)2 peptide was inserted  
CC between the C-terminus of the alpha factor signal and the N-terminus of  
CC the trypsinogen analogue leader sequence to improve the yield of the  
CC secreted protein. The specification claims an isolated trypsinogen  
CC analogue comprising a protein having trypsin activity and a leader  
CC sequence having at least two amino acids which are not Lys or Arg. The  
CC trypsin derived from the recombinant trypsinogen is useful for the  
CC characterization of other proteins, and in the manufacture of other  
CC recombinant bioproducts, for example to cleave leader sequences from  
CC small recombinant proteins expressed initially as fusion proteins. The  
CC present method provides for expression of an inactive zymogen form that  
CC is soluble and properly folded yet is not activated until after  
CC purification from fermentation broth or cell extracts. This is  
CC accomplished through the expression of a single chain trypsinogen  
CC analogue where the leader sequence is modified such that it lacks a  
CC trypsin-like enzyme cleavage site. Specifically the trypsinogen analogues  
CC of the present invention lack a lysine or arginine in the N-terminal  
CC leader sequence of the protein to prevent auto-activation or activation  
CC by endogenous host cell enzymes  
XX  
SQ Sequence 699 BP; 139 A; 221 C; 178 G; 161 T; 0 U; 0 Other;  
Query Match 0.7%; Score 26.2; DB 1; Length 699;  
Best Local Similarity 53.4%; Pred. No. 8;  
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;  
Qy 821 TCCAGGCAACCAATTCATATACAGTATCCAAAGTCATGCCCCCAACAGTATGCTG 880  
Db 229 TCCAAAGTCCATCGTGCAACCGCTCTAGCACTCCCAACCTCTGAACATGACATCATGCTG 288  
Qy 881 AAGAAGCTGAAGTTGAACGGTCCCTATGAAGACCTTACAGACCT 923



Db 289 ATCAAGCTCAAGTCCGCGCATCCCTGAACTCCCGCTGGCCT 331

RESULT 16  
AAF81479  
ID AAF81479 standard; DNA; 699 BP.  
AC AAF81479;  
XX AAF81479;  
DT 06-JUN-2001 (first entry)  
XX  
DE Bovine met-phe-trypsinogen coding sequence.  
XX  
KW Trypsinogen; bovine; trypsin; serine protease; ds.  
XX  
OS Bos sp.  
XX  
FH Key Location/Qualifiers  
FT CDS 4..699  
FT /\*tag= a  
FT /product= "Trypsinogen"  
XX  
PN W0200119970-A2.  
XX  
XX 22-MAR-2001.  
XX  
PF 05-SEP-2000; 2000WO-US020813.  
XX  
PR 15-SEP-1999; 98US-0154019P.  
XX  
PA (ELIL ) LILLY & CO ELI.  
XX  
PI Hanquier JM, Hershberger CL, Larson JL, Rosteck PR;  
XX  
DR WPI; 2001-273425/28.  
DR P-PSDB; AAB80953.  
XX  
XX New chymotrypsin-free trypsin and trypsinogen useful for manufacturing  
recombinant protein pharmaceuticals and pure trypsin.  
XX  
PS Claim 20; Fig 1; 55pp; English.  
XX  
CC The present sequence is the coding sequence for bovine met-phe-  
trypsinogen. Trypsin is a serine protease which cleaves the peptide bond  
on the carboxy-terminus of basic amino acid residues. Trypsin is  
synthesized in a slightly longer catalytically inactive form:  
trypsinogen, which itself is cleaved (leader sequence removed) to give  
trypsin. The leader sequence of the protein encoded by the present  
sequence consists of ((Asp)4-Lys) and is present at the amino-terminus.  
The protein encoded by the present sequence has two additional residues  
at the amino terminus: Met and Phe. Bovine met-phe-trypsinogen is useful  
for the manufacture of recombinant protein pharmaceuticals. High purity  
trypsin products are produced by expressing trypsinogen inside a  
prokaryotic cell which is then isolated and activated to form trypsin  
XX  
SQ Sequence 699 BP; 139 A; 221 C; 178 G; 161 T; 0 U; 0 Other;

Query Match 0.7%; Score 26.2; DB 1; Length 699;  
Best Local Similarity 53.4%; Pred. No. 9;  
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 821 TCCAAGGCAACCAATTCATATCAAGTCTATGCGCCCAACCAAGTATGCTG 880  
Db 229 TCCAAGTCCATGTCGACCCGCTCTACAACTCCCAACTCTGAACAATGACATCATGCTG 288  
QY 881 AAGAGCTGAGTTCGAAGGTCCTATGAGACCTTACAAGACCT 923  
Db 289 ATCAAGCTCAAGTCCGCGCATCCCTGAACTCCCGCTGGCCT 331

RESULT 17  
AAQ63795

ID AAQ63795 standard; DNA; 701 BP.  
XX  
AC AAQ63795;  
XX  
DT 25-MAR-2003 (revised)  
DT 01-DEC-1994 (first entry)  
XX  
DE Bovine trypsinogen gene.  
XX  
XX Cattle; cow; trypsinogen; enzyme; protease; proinsulin; insulin; hormone;  
KW plasmid pRMG4; ss.  
XX  
OS Bos taurus.  
XX  
FH Key Location/Qualifiers  
FT CDS 4..694  
FT /\*tag= a  
XX  
PN EP597681-A1.  
XX  
PD 18-MAY-1994.  
XX  
PF 10-NOV-1993; 93EP-00308959.  
XX  
PR 13-NOV-1992; 92US-00977703.  
XX  
PA (ELIL ) LILLY & CO ELI.  
XX  
PI Greaney MG, Rosteck PR;  
XX  
XX WPI; 1994-160671/20.  
XX  
PT Expression vectors for bovine trypsin and bovine trypsinogen - for  
cleavage of zymogens into active drugs, e.g. pro-insulin conversion into  
insulin.  
XX  
PS Disclosure; Page 27; 35pp; English.  
XX  
CC This gene is expressed in a recombinant host, e.g. E. coli, using plasmid  
pRMG7. The encoded bovine trypsinogen gene may be expressed recombinantly  
and is able to cleave zymogens into active drugs, e.g. pro-insulin  
conversion into insulin. (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 701 BP; 141 A; 222 C; 180 G; 158 T; 0 U; 0 Other;

Query Match 0.7%; Score 26.2; DB 1; Length 701;  
Best Local Similarity 53.4%; Pred. No. 8;  
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 821 TCCAAGGCAACCAATTCATATCAAGTCTATGCGCCCAACCAAGTATGCTG 880  
Db 226 TCCAAGTCCATGTCGACCCGCTCTACAACTCCCAACTCTGAACAATGACATCATGCTG 285  
QY 881 AAGAGCTGAGTTCGAAGGTCCTATGAGACCTTACAAGACCT 923  
Db 286 ATCAAGCTCAAGTCCGCGCATCCCTGAACTCCCGCTGGCCT 328

RESULT 18  
AAQ63795  
ID AAQ63795 standard; DNA; 702 BP.  
XX  
AC AAQ63795;  
XX  
DT 19-JUL-2000 (first entry)  
XX  
DE DNA encoding a trypsinogen analogue.  
XX  
KW Trypsinogen analogue; mutated bovine trypsinogen; leader sequence;  
KW trypsin activity; recombinant protein production; inactive zymogen; ss.  
XX  
OS Synthetic.  
OS Bos taurus.

```

XX FH Key Location/Qualifiers
XX FT misc_RNA 1..12
XX FT /*tag= a
XX FT /note= "linker peptide"
XX FT sig_peptide 13..29
XX FT /*tag= b
XX FT /note= "leader sequence"
XX FT mat_peptide 30..599
XX FT /*tag= c
XX FT /product= "trypsin"
XX PN WO200017332-A1.
XX PN 30-MAR-2000.
XX PD
XX PF 15-SEP-1999; 99WO-US021047.
XX PR 21-SEP-1998; 98US-0101213P.
XX PA (ELIL ) LILLY & CO ELI.
XX PI Hanquier JM, Hershberger CL, Desplancq D, Larson JL, Rostock PR;
XX PI WPI; 2000-283565/24.
XX DR P-PSDB; AAY91925.
XX XX
XX PT New trypsinogen analog useful for the production of recombinant trypsin
XX PT has a modified leader sequence not cleavable by trypsin or trypsin-like
XX PT enzymes.
XX PS Claim 11; Page 45-47; 56pp; English.
XX XX
XX CC This sequence encodes a trypsinogen analogue. The wild type bovine
XX CC trypsinogen was mutated to destroy the trypsin cleavage site. The lys
XX CC residue present in the leader sequence of the native bovine trypsinogen
XX CC protein was mutated to an Asp residue. The vector was constructed such
XX CC that DNA encoding a (Glu-Ala)2 peptide was inserted between the C-
XX CC terminus of the alpha factor signal and the N-terminus of the trypsinogen
XX CC analogue leader sequence to improve the yield of the secreted protein.
XX CC The specification claims an isolated trypsinogen analogue comprising a
XX CC protein having trypsin activity and a leader sequence having at least two
XX CC amino acids which are not Lys or Arg. A recombinantly produced trypsin
XX CC (AAY91926) is also claimed. The trypsin derived from the recombinant
XX CC trypsinogen is useful for the characterization of other proteins, and in
XX CC the manufacture of other recombinant bioproducts, for example to cleave
XX CC leader sequences from small recombinant proteins expressed initially as
XX CC fusion proteins. The present method provides for expression of an
XX CC inactive zymogen form that is soluble and properly folded yet is not
XX CC activated until after purification from fermentation broth or cell
XX CC extracts. This is accomplished through the expression of a single chain
XX CC trypsinogen analogue where the leader sequence is modified such that it
XX CC lacks a trypsin-like enzyme cleavage site. Specifically the trypsinogen
XX CC analogues of the present invention lack a lysine or arginine in the N-
XX CC terminal leader sequence of the protein to prevent auto-activation or
XX CC activation by endogenous host cell enzymes
XX SQ Sequence 702 BP; 141 A; 221 C; 181 G; 159 T; 0 U; 0 Other;

Query Match 0.7%; Score 26.2; DB 1; Length 702;
Best Local Similarity 53.4%; Pred. No. 8;
Matches 55; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 821 TCCAGGCAACCATTCATATCAGTATCCAGTCTATGCCCAACCAAGTAATGCTG 880
Db |||||
Dy 232 TCCAGTCCATGTCGACCGCTCTTACAACTCCAACTCTGAACATGACATCATGCTG 291
QY 881 AAGAAGCTGAAGTTGAACGGCTCTATGAAGACCTTACAGACCT 923
Db |||||
Dy 292 ATCAAGCTCAAGTCCGCGGATCCTGAACTCCCGCGTGCCT 334

RESULT 19

```

```

AAA07168
ID AAA07168 standard; DNA; 828 BP.
XX AC AAA07168;
XX DT 16-JUN-2000 (first entry)
XX DE Pig lung protease coding sequence.
XX KW Protease; pig; virus activator; inhibitor identification; influenza;
XX KW viral infection; ss.
XX OS Sus scrofa.
XX PN WO200011193-A1.
XX PD 02-MAR-2000.
XX PF 23-AUG-1999; 99WO-JP004529.
XX PR 24-AUG-1998; 98JP-00237240.
XX PA (SANY ) SANKYO CO LTD.
XX PI Yamashita M, Iida K, Kido H;
XX DR WPI; 2000-224708/19.
XX DR P-PSDB; AAY81826.
XX PT New pig lung protease with virus activation activity is used for
XX PT screening potential inhibitors of virus infection, especially of
XX PT influenza virus.
XX PS Claim 9; Page 54-56; 65pp; Japanese.
XX CC This sequence encodes the protease of the invention, and was derived from
XX CC pig lung. The protease has virus activation activity. The protease can be
XX CC used for the identification of potential inhibitors of infection by
XX CC viruses such as influenza
XX SQ Sequence 828 BP; 147 A; 280 C; 266 G; 135 T; 0 U; 0 Other;

Query Match 0.7%; Score 26.2; DB 1; Length 828;
Best Local Similarity 49.6%; Pred. No. 8.4;
Matches 67; Conservative 0; Mismatches 68; Indels 0; Gaps 0;

QY 2534 TGCTAAAGCTGAACCTCCAGTACTTTGGCCACTGATCAGAGAGCTGACTCACTGGAA 2593
Db |||||
Dy 11 TGCTGGTGTCTGGCGTGCCTCTGTGAGCTGTCTCCACACGGCCCCCAGGCC 70
QY 2594 AGACCTGTATGCTGGGAGGATTTGGGGCAGGAGGAGAGGAGGAGGAGATGAGAT 2653
Db |||||
Dy 71 AGGCTCTGGAGCAGGAGGAGGATCTGTGGCGGAAAGAGCCCTGGGACACAGTGGCCT 130
QY 2654 GGCTGGATGGCATCA 2668
Db |||||
Dy 131 GGCAGGTGAGCCTGA 145

RESULT 20
AAD08286/c
ID AAD08286 standard; cDNA; 1151 BP.
XX AC AAD08286;
XX DT 08-AUG-2001 (first entry)
XX DE Human secreted protein-encoding gene 4 cDNA clone HWH1H10, SEQ ID NO: 14.
XX KW Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
XX KW fetal abnormality; developmental abnormality; haematopoietic disorder;
XX KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
XX KW

```

KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;  
KW inflammation; neurological disorder; Alzheimer's disease; food additive;  
KW angiotensin disorder; kidney disorder; gastrointestinal disorder; allergy;  
KW pregnancy-related disorder; endocrine disorder; infection; wound healing;  
KW cell culture; chemotaxis; vulnery; binding partner identification;  
KW gene therapy; ss.  
XX  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH 42. .914  
CDS /\*tag= a  
FT /product= "Human secreted protein precursor"  
FT sig\_peptide 42. .107  
FT /\*tag= b  
FT mat\_peptide 108. .911  
FT /\*tag= c  
FT /product= "Mature human secreted protein"  
XX  
XX WO200136440-A1.  
XX  
XX 25-MAY-2001.  
XX  
XX 15-NOV-2000; 2000WO-US031282.  
XX  
XX 19-NOV-1999; 99US-0166414P.  
XX 21-JUL-2000; 2000US-0219665P.  
XX  
XX (HUYA-) HUMAN GENOME SCI INC.  
XX  
XX Ruben SM, Komatsoulis GA, Birse CR, Moore PA;  
XX  
XX WPI; 2001-343795/36.  
XX P-PSDB; AAE03821.  
XX  
XX Isolated nucleic acid molecule encoding a human secreted protein is used  
XX in preventing, treating or ameliorating a medical condition.  
XX  
XX Claim 1; Page 440-441; 553pp; English.  
XX  
XX AAD08283-AAD08355 represent cDNAs corresponding to 23 human secreted  
XX protein genes, and AAE03818-AAE03870 represent the proteins they encode.  
XX AAE03871-AAE03896 represent human secreted protein fragments or variants.  
XX The secreted proteins and their genes are useful for preventing, treating  
XX or ameliorating medical conditions, e.g., by protein or gene therapy.  
XX Pathological conditions can be diagnosed by determining the amount of the  
XX new protein in a sample or by determining the presence of mutations in  
XX the new genes. Specific uses are described for each of the 23 genes,  
XX based on the tissues in which they are most highly expressed, and include  
XX developing products for the diagnosis or treatment of proliferative  
XX disorders, cancer, tumours, foetal and developmental abnormalities,  
XX haematopoietic disorders, diseases of the immune system, AIDS, autoimmune  
XX diseases (e.g., rheumatoid arthritis), inflammation, allergies,  
XX neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),  
XX cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,  
XX psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,  
XX angiotensin disorders, kidney disorders, gastrointestinal disorders,  
XX pregnancy-related disorders, endocrine disorders, and infections. The  
XX proteins can also be used to aid wound healing and epithelial cell  
XX proliferation, to prevent skin aging due to sunburn, to maintain organs  
XX before transplantation, for supporting cell culture of primary tissues,  
XX to regenerate tissues, to identify their cognate ligands or binding  
XX partners, and in chemotaxis, and can be used as a food additive or  
XX preservative to modify storage properties. Antibodies specific for a  
XX protein of the invention can be used in alleviating symptoms associated  
XX with the disorders mentioned above, and in diagnostic immunoassays e.g.,  
XX radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The  
XX present sequence represents a human secreted protein-encoding cDNA of the  
XX invention  
XX  
XX Sequence 1151 BP; 252 A; 370 C; 336 G; 193 T; 0 U; 0 Other;  
XX  
XX Query Match 0.7%; Score 36.2; DB 1; Length 1151;

Best Local Similarity 63.5%; Pred. No. 9.2;  
Matches 40; Conservative 0; Mismatches 23; Indels 0; Gaps 0;  
QY 3226 TCTATGGCTTTAATAAGTTTTTTTTTTTTTTTTTTTAAAGATGTCATCTCTGTG 3285  
Db 1146 TTTTITTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCACAGGCTGGTTTATTCG 1087  
QY 3286 AAG 3288  
Db 1086 GAG 1084  
RESULT 21  
ABV97824  
ID ABV97824 standard; cDNA; 497 BP.  
XX AC ABV97824;  
XX DT 14-JAN-2003 (first entry)  
XX Human pancreatic cancer expressed cDNA SEQ ID NO 3232.  
XX Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;  
XX cytosolic; tumour; gene; ss.  
XX Homo sapiens.  
XX WO200260317-A2.  
XX 08-AUG-2002.  
XX 30-JAN-2002; 2002WO-US002781.  
XX 30-JAN-2001; 2001US-0265305P.  
XX 31-JAN-2001; 2001US-0265682P.  
XX 09-FEB-2001; 2001US-0267568P.  
XX 21-MAR-2001; 2001US-0278651P.  
XX 28-APR-2001; 2001US-0287112P.  
XX 16-MAY-2001; 2001US-0291631P.  
XX 12-JUL-2001; 2001US-0305484P.  
XX 20-AUG-2001; 2001US-0313999P.  
XX 27-NOV-2001; 2001US-0333626P.  
XX (CORI-) CORIXA CORP.  
XX Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;  
XX WPI; 2002-627435/67.  
XX New isolated polynucleotide and pancreatic tumor polypeptides, useful for  
XX diagnosing, preventing and/or treating cancer, particularly pancreatic  
XX cancer.  
XX Claim 1; SEQ ID NO 3232; 300pp + Sequence Listing; English.  
XX The invention relates to an isolated polynucleotide (I) comprising: (a)  
XX any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)  
XX complements of (a); (c) sequences consisting of at least 20 contiguous  
XX residues of (a); (d) sequences that hybridize to (a), under moderately  
XX stringent conditions; (e) sequences having at least 75% or 90% identity  
XX to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-  
XX ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer  
XX in a patient and compositions comprising polypeptides, polynucleotides,  
XX antibodies, fusion proteins, T cell populations and antigen presenting  
XX cells expressing the polypeptide are useful in treating pancreatic cancer  
XX and stimulating an immune response. The polynucleotides can be used as  
XX probes or primers for nucleic acid hybridisation, in the design and  
XX preparation of ribozyme molecules for inhibiting expression of the tumour  
XX polypeptides and proteins in the tumour cells, in vaccines and for gene  
XX therapy. Note: The sequence data for this patent did not form part of the  
XX printed specification, but was obtained in electronic format directly  
XX from WIPO at ftp.wipo.int/pub/published\_pat\_sequences



RESULT 24

AAA61697  
ID AAA61697 standard; cDNA; 1036 BP.  
XX  
AC AAA61697;  
XX  
DT 23-OCT-2000 (first entry)  
XX  
DE cDNA encoding human serine protease BSSP4 (hBSSP4) SEQ ID NO:5.  
XX  
KW BSSP4; serine protease; human; hBSSP4; mouse; mBSSP4; brain;  
XX  
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;  
XX  
KW oedema; dropsy; cancer; inflammation; prostate; testis; bone; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200031277-A1.  
XX  
PD 02-JUN-2000.  
XX  
PF 19-NOV-1999; 99WO-JP006472.  
XX  
PR 20-NOV-1998; 98JP-00347813.  
XX  
PA (FUSO) FUSO PHARM IND LTD.  
XX  
PI Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;  
XX  
WPI: 2000-400084/34.  
XX  
P-PSDB; AAB11702.  
XX  
PT Serine protease BSSP4 and antibodies recognizing BSSP4 for assay and  
XX  
PT diagnosis of diseases in which BSSP4 expression is altered.  
XX  
PS Claim 6; Page 71-73; 111pp; Japanese.  
XX  
CC The invention relates to novel serine proteases designated BSSP4  
XX  
CC (AAB11700-B11709), and to nucleic acids encoding them (AAA61695-A61704,  
XX  
CC AAA61799). The invention also relates to vectors and transformants  
XX  
CC comprising BSSP4 nucleic acids; transgenic animals in which the  
XX  
CC expression level of BSSP4 can be varied; and an mBSSP4 knockout mouse.  
XX  
CC The invention additionally encompasses anti-BSSP4 antibodies and methods  
XX  
CC of production of such antibodies, methods of BSSP4 detection using the  
XX  
CC antibodies, and the use of BSSP4 proteins or fragments as diagnostic  
XX  
CC markers for certain medical conditions. Nucleotides encoding BSSP4 were  
XX  
CC initially isolated in a human brain cDNA library using degenerate PCR  
XX  
CC primers (AAA61714-A61715) based on conserved regions of serine proteases.  
XX  
CC The BSSP4 serine proteases and nucleotides encoding them are useful in  
XX  
CC detecting homologues, mutants and polymorphic variants in biological  
XX  
CC samples (e.g., blood, urine, brain, prostate gland and testis) as  
XX  
CC diagnostic markers for diseases associated with altered BSSP4 expression  
XX  
CC levels. Such diseases include Alzheimer's disease, oedema (dropsy),  
XX  
CC cancer or inflammation of brain, prostate, testis or bone. Sequences  
XX  
CC AAA61695-A61703 and AAA61799 represent cDNAs encoding human BSSP4  
XX  
CC variants (hBSSP4), and sequence AAA61704 represents cDNA encoding murine  
XX  
CC BSSP4 (mBSSP4)

RESULT 25

Query Match 0.7%; Score 25.4; DB 1; Length 1036;  
Best Local Similarity 53.5%; Pred. No. 15;  
Matches 53; Conservative 0; Mismatches 46; Indels 0; Gaps 0;  
QY 2983 TCTATTACTTAAATCCACTTATTTTATGATTTTCTTAATAAAATCCAGTCTCTT 3042  
DB 911 TTTTCTGATATAATGATGATTTTATAGTATTTTGAACCCGTCACATATCTT 970  
QY 3043 TTTTATAAAGACATTTAAATTTTATTTCTTTAG 3081  
DB 971 ATTATTCCTCAATTCATTAATTTATTTCTCCAG 1009

AAA61697/c

ID AAA61697 standard; cDNA; 1036 BP.  
XX  
AC AAA61697;  
XX  
DT 23-OCT-2000 (first entry)  
XX  
DE cDNA encoding human serine protease BSSP4 (hBSSP4) SEQ ID NO:5.  
XX  
KW BSSP4; serine protease; human; hBSSP4; mouse; mBSSP4; brain;  
XX  
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;  
XX  
KW oedema; dropsy; cancer; inflammation; prostate; testis; bone; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200031277-A1.  
XX  
PD 02-JUN-2000.  
XX  
PF 19-NOV-1999; 99WO-JP006472.  
XX  
PR 20-NOV-1998; 98JP-00347813.  
XX  
PA (FUSO) FUSO PHARM IND LTD.  
XX  
PI Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;  
XX  
WPI: 2000-400084/34.  
XX  
P-PSDB; AAB11702.  
XX  
PT Serine protease BSSP4 and antibodies recognizing BSSP4 for assay and  
XX  
PT diagnosis of diseases in which BSSP4 expression is altered.  
XX  
PS Claim 6; Page 71-73; 111pp; Japanese.  
XX  
CC The invention relates to novel serine proteases designated BSSP4  
XX  
CC (AAB11700-B11709), and to nucleic acids encoding them (AAA61695-A61704,  
XX  
CC AAA61799). The invention also relates to vectors and transformants  
XX  
CC comprising BSSP4 nucleic acids; transgenic animals in which the  
XX  
CC expression level of BSSP4 can be varied; and an mBSSP4 knockout mouse.  
XX  
CC The invention additionally encompasses anti-BSSP4 antibodies and methods  
XX  
CC of production of such antibodies, methods of BSSP4 detection using the  
XX  
CC antibodies, and the use of BSSP4 proteins or fragments as diagnostic  
XX  
CC markers for certain medical conditions. Nucleotides encoding BSSP4 were  
XX  
CC initially isolated in a human brain cDNA library using degenerate PCR  
XX  
CC primers (AAA61714-A61715) based on conserved regions of serine proteases.  
XX  
CC The BSSP4 serine proteases and nucleotides encoding them are useful in  
XX  
CC detecting homologues, mutants and polymorphic variants in biological  
XX  
CC samples (e.g., blood, urine, brain, prostate gland and testis) as  
XX  
CC diagnostic markers for diseases associated with altered BSSP4 expression  
XX  
CC levels. Such diseases include Alzheimer's disease, oedema (dropsy),  
XX  
CC cancer or inflammation of brain, prostate, testis or bone. Sequences  
XX  
CC AAA61695-A61703 and AAA61799 represent cDNAs encoding human BSSP4  
XX  
CC variants (hBSSP4), and sequence AAA61704 represents cDNA encoding murine  
XX  
CC BSSP4 (mBSSP4)

Query Match

Best Local Similarity 0.7%; Score 25.2; DB 1; Length 1036;  
Matches 33; Conservative 0; Mismatches 13; Indels 0; Gaps 0;  
QY 3245 TTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTT 3290  
DB 1028 TTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTT 983  
RESULT 26  
ABV97809  
ID ABV97809 standard; cDNA; 448 BP.  
XX  
AC ABV97809;  
XX











PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230433P.  
PR 06-SEP-2000; 2000US-0230433P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 08-SEP-2000; 2000US-0231414P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0233081P.  
PR 12-SEP-2000; 2000US-0233198P.  
PR 14-SEP-2000; 2000US-0233397P.  
PR 14-SEP-2000; 2000US-0233398P.  
PR 14-SEP-2000; 2000US-0233399P.  
PR 14-SEP-2000; 2000US-0234009P.  
PR 14-SEP-2000; 2000US-0234012P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0234844P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241755P.  
PR 20-OCT-2000; 2000US-0241788P.  
PR 20-OCT-2000; 2000US-0241789P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 17-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249246P.  
PR 17-NOV-2000; 2000US-0249265P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 17-NOV-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 01-DEC-2000; 2000US-0250391P.  
PR 05-DEC-2000; 2000US-0251030P.  
PR 05-DEC-2000; 2000US-0251988P.  
PR 05-DEC-2000; 2000US-0256719P.  
PR 06-DEC-2000; 2000US-0251479P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
PR 08-DEC-2000; 2000US-0251989P.  
PR 11-DEC-2000; 2000US-0251990P.  
PR 05-JAN-2001; 2001US-0259678P.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX PI Rosen CA, Barash SC, Ruben SM;  
XX  
XX WPI; 2001-476222/51.  
XX P-PSDB; RAU17037.  
XX  
XX Novel polypeptides and polynucleotides useful as diagnostic reagents to  
XX diagnose diseases or disorders associated with aberrant expression or  
XX activity of polypeptides, for treating blood clotting disorder,  
XX hemophilia.  
XX  
XX Claim 1; SEQ ID NO 134; 601pp; English.  
XX  
XX The invention relates to isolated nucleic acid molecules and their  
XX encoded secreted proteins. The nucleic acids and proteins are used to  
XX prevent, treat or ameliorate a medical condition in e.g. humans, mice,  
XX rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used  
XX in diagnosing a pathological condition or susceptibility to a  
XX pathological condition. Antibodies to the proteins can also be used in  
XX alleviating symptoms associated with the disorders and in diagnostic  
XX immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays  
XX (ELISA). Disorders which are diagnosed or treated include autoimmune  
XX diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.  
XX neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac  
XX arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,  
XX nervous system disorders e.g. Alzheimer's disease, infections caused by  
XX bacteria, viruses and fungi and ocular disorders e.g. corneal infection,  
XX and many other disorders listed in the specification. The polypeptides  
XX can also be used to aid wound healing and epithelial cell proliferation,  
XX to prevent skin aging due to sunburn, to maintain organs before  
XX transplantation, for supporting cell culture of primary tissues, to  
XX regenerate tissues and in chemotaxis. The polypeptides can also be used  
XX as a food additive or preservative to increase or decrease storage  
XX capabilities, fat content, lipid, protein, carbohydrate, vitamins,  
XX minerals, cofactors and other nutritional components. The present  
XX sequence encodes a novel secreted protein of the invention. Note: The  
XX  
XX Query Match 0.7%; Score 24.6; DB 1; Length 1352;  
XX Best Local Similarity 53.7%; Pred. NO. 26;  
XX Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTACTTTAAATGGACCTATTTTATTTGATTTCTTAATAAATCCAGTCCTTGT 3042  
Db 1241 TTTTGTATATAATGTTAAATGATTTTATAGGATTTTAACTCCCATATCTT 1300  
QY 3043 TTTTAAAAAGACTTTAAATTAATTTCTCT 3077

DB 1301 ATTATTCCTCCCAATTTCATAATAAATTATTTATTTCT 1335

RESULT 32

ID ABK72087

XX ABK72087 standard; cDNA; 1352 BP.

AC ABK72087;

XX

DT 13-AUG-2002 (first entry)

XX

DE Human cDNA encoding ovarian antigen #46.

XX

XX Human; ss; ovarian antigen; gene; ovary disorder; breast disorder;

XX neoplastic disorder; cancer; infectious disease; inflammatory disease;

XX reproductive system disorder; hyperproliferative disorder; hair loss;

XX blood-related disorder; autoimmune disorder; Alzheimer's disease;

XX urinary system disorder; cardiovascular disorder; arrhythmia;

XX respiratory disorder; musculoskeletal system disorder;

XX neural activity disorder; neurological disorder; endocrine disorder;

XX gastrointestinal disorder; liver disorder; pancreatic disorder;

XX gall bladder disorder; large intestine disorder; developmental disorder;

XX inherited disorder; wound healing; skin aging; food additive;

XX preservative.

XX

OS Homo sapiens.

XX

XX WO200155329-A2.

XX

XX 02-AUG-2001.

XX

XX 17-JAN-2001; 2001WO-US001360.

XX

XX 31-JAN-2000; 2000US-0179065P.

XX

XX 04-FEB-2000; 2000US-0180628P.

XX

XX 07-JUN-2000; 2000US-0209467P.

XX

XX 14-SEP-2000; 2000US-0232339P.

XX

XX 17-NOV-2000; 2000US-0249300P.

XX

XX 01-DEC-2000; 2000US-0250150P.

XX

XX 08-DEC-2000; 2000US-0251868P.

XX

XX 08-DEC-2000; 2000US-0251990P.

XX

FA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Rosen CA, Barash SC, Ruben SM;

XX

XX WPI; 2001-476195/51.

XX

DR P-PSDB; ABG60284.

XX

PT Novel isolated human ovarian related polypeptide useful for

PT diagnosis/treatment of disorders of ovary and breast such as neoplastic

PT disorders, infectious diseases, inflammatory diseases, and reproductive

PT disorders.

XX

XX Claim 1; SEQ ID NO 56; 524pp; English.

XX

XX The invention relates to isolated ovarian related polypeptide (ovarian

CC antigen) comprising a sequence at least 90% identical to a sequence

CC selected from a polypeptide fragment, domain, epitope or full length

CC protein of a sequence (S1) appearing as ABG60239-ABG60296 having

CC biological activity, or a variant, allelic variant or species homologue

CC of S1. Also included are the cDNA clones encoding the proteins of S1. S1,

CC an anti-S1 antibody and the cDNA are useful for diagnosing, preventing,

CC treating or ameliorating a medical condition in mammalian subject

CC especially diseases and/or disorders of the ovary and/or breast such as

CC neoplastic disorders (such as ovarian Krukenberg tumour and cancer),

CC infectious diseases (e.g., mastitis, oophoritis), inflammatory diseases

CC (e.g., abscesses), reproductive system disorders (Paget's disease),

CC autoimmune disorders (systemic lupus erythematosus, rheumatoid

CC arthritis), blood-related disorders (sickle cell anaemia),

CC hyperproliferative disorders, urinary system disorders

CC (glomerulonephritis), cardiovascular disorders (arrhythmias), respiratory

CC disorders, musculoskeletal system disorders, neural activity and

CC

CC neurological disorders (Alzheimer's disease and Parkinson's disease),

CC endocrine disorders (Addison's disease), gastrointestinal disorders

CC (inflammatory disorders), liver disorders (biliary liver cirrhosis),

CC pancreatic and gall bladder disorders, disorders of the large intestine,

CC developmental and inherited disorders, diseases at the cellular level,

CC and wound healing and epithelial cell proliferation. They are also useful

CC to prevent skin aging, for preventing hair loss, to maintain organs

CC before transplantation or for supporting cell culture of primary tissues,

CC to modulate mammalian characteristics such as body height, to modulate

CC mammalian metabolism, to change a mammal's mental or physical state, and

CC as food additive or preservative. The present sequence is a cDNA encoding

CC an S1 protein

XX

XX Sequence 1352 BP; 238 A; 445 C; 407 G; 261 T; 0 U; 0 Other;

XX

XX Query Match 0.7%; Score 24.6; DB 1; Length 1352;

XX Best Local Similarity 53.7%; Pred. No. 26;

XX Matches S1; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

XX

QY 2983 TCTATTTTACTTTAATGTCACCTATTTTATTCGATTTTCTAATAAATCCAGTCCTTGT 3042

Db 1241 TTTTGTGTATATAAAGTTAATGATTTTATAGGTATTTGTAACCTGCCACATATCTT 1300

QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077

Db 1301 ATTTATTCCTCCCAATTTCATAATAAATTATTTATTTCT 1335

RESULT 33

ABK91679

ID ABK91679 standard; cDNA; 1352 BP.

XX

AC ABK91679;

XX

XX 26-AUG-2002 (first entry)

XX

DE cDNA encoding novel ovarian related polypeptide #46.

XX

XX Ovarian related polypeptide; neoplastic disorder; tumour; ovarian cancer;

XX hyperproliferative disorder; adult acute lymphocytic leukaemia;

XX breast cancer; reproductive system disorder; tuberculosis; arthritis;

XX immune system disorder; Chediak-Higashi's syndrome; neonatal neutropenia;

XX autoimmune disorder; Hashimoto's thyroiditis; inflammatory disorder;

XX septic shock; multiple sclerosis; central nervous system disorder;

XX neurological disorder; allergy; Parkinson's disease; Alzheimer's disease;

XX cardiovascular disorder; atherosclerosis; blood related disorder;

XX respiratory disorder; urinary system disorder; musculoskeletal disorder;

XX osteoporosis; wound healing; endocrine disorder; infectious disease;

XX gastrointestinal disorder; transplantation; food additive; preservative;

XX gene; ss.

XX

OS Homo sapiens.

XX

XX US2002045230-A1.

XX

XX 18-APR-2002.

XX

XX 20-JUL-2001; 2001US-00908711.

XX

XX 31-JAN-2000; 2000US-0179065P.

XX

XX 04-FEB-2000; 2000US-0180628P.

XX

XX 24-FEB-2000; 2000US-0184664P.

XX

XX 02-MAR-2000; 2000US-0186350P.

XX

XX 16-MAR-2000; 2000US-0189874P.

XX

XX 17-MAR-2000; 2000US-0190076P.

XX

XX 18-APR-2000; 2000US-0198123P.

XX

XX 19-MAY-2000; 2000US-0205515P.

XX

XX 07-JUN-2000; 2000US-0209467P.

XX

XX 28-JUN-2000; 2000US-0214886P.

XX

XX 30-JUN-2000; 2000US-0215135P.

XX

XX 07-JUL-2000; 2000US-0216647P.

XX

XX 07-JUL-2000; 2000US-0216880P.

XX

XX 11-JUL-2000; 2000US-0217487P.

|   |              |                  |    |              |                   |
|---|--------------|------------------|----|--------------|-------------------|
| R | 11-JUL-2000; | 2000US-0217496P. | PR | 01-NOV-2000; | 2000US-02446117P. |
| R | 14-JUL-2000; | 2000US-0218290P. | PR | 08-NOV-2000; | 2000US-0246474P.  |
| R | 26-JUL-2000; | 2000US-0220963P. | PR | 08-NOV-2000; | 2000US-0246475P.  |
| R | 26-JUL-2000; | 2000US-0220964P. | PR | 08-NOV-2000; | 2000US-0246476P.  |
| R | 14-AUG-2000; | 2000US-0224518P. | PR | 08-NOV-2000; | 2000US-0246477P.  |
| R | 14-AUG-2000; | 2000US-0224519P. | PR | 08-NOV-2000; | 2000US-0246478P.  |
| R | 14-AUG-2000; | 2000US-0225211P. | PR | 08-NOV-2000; | 2000US-0246523P.  |
| R | 14-AUG-2000; | 2000US-0225214P. | PR | 08-NOV-2000; | 2000US-0246524P.  |
| R | 14-AUG-2000; | 2000US-0225266P. | PR | 08-NOV-2000; | 2000US-0246525P.  |
| R | 14-AUG-2000; | 2000US-0225267P. | PR | 08-NOV-2000; | 2000US-0246526P.  |
| R | 14-AUG-2000; | 2000US-0225268P. | PR | 08-NOV-2000; | 2000US-0246527P.  |
| R | 14-AUG-2000; | 2000US-0225270P. | PR | 08-NOV-2000; | 2000US-0246528P.  |
| R | 14-AUG-2000; | 2000US-0225447P. | PR | 08-NOV-2000; | 2000US-0246532P.  |
| R | 14-AUG-2000; | 2000US-0225475P. | PR | 08-NOV-2000; | 2000US-0246609P.  |
| R | 14-AUG-2000; | 2000US-0225758P. | PR | 08-NOV-2000; | 2000US-0246610P.  |
| R | 14-AUG-2000; | 2000US-0225759P. | PR | 08-NOV-2000; | 2000US-0246611P.  |
| R | 18-AUG-2000; | 2000US-0226279P. | PR | 08-NOV-2000; | 2000US-0246613P.  |
| R | 22-AUG-2000; | 2000US-0226681P. | PR | 17-NOV-2000; | 2000US-0249207P.  |
| R | 22-AUG-2000; | 2000US-0226686P. | PR | 17-NOV-2000; | 2000US-0249208P.  |
| R | 22-AUG-2000; | 2000US-0227182P. | PR | 17-NOV-2000; | 2000US-0249209P.  |
| R | 23-AUG-2000; | 2000US-0227009P. | PR | 17-NOV-2000; | 2000US-0249210P.  |
| R | 30-AUG-2000; | 2000US-0228924P. | PR | 17-NOV-2000; | 2000US-0249211P.  |
| R | 01-SEP-2000; | 2000US-0229343P. | PR | 17-NOV-2000; | 2000US-0249213P.  |
| R | 01-SEP-2000; | 2000US-0229344P. | PR | 17-NOV-2000; | 2000US-0249214P.  |
| R | 01-SEP-2000; | 2000US-0229345P. | PR | 17-NOV-2000; | 2000US-0249215P.  |
| R | 05-SEP-2000; | 2000US-0229509P. | PR | 17-NOV-2000; | 2000US-0249216P.  |
| R | 05-SEP-2000; | 2000US-0229513P. | PR | 17-NOV-2000; | 2000US-0249217P.  |
| R | 06-SEP-2000; | 2000US-0230437P. | PR | 17-NOV-2000; | 2000US-0249218P.  |
| R | 06-SEP-2000; | 2000US-0230438P. | PR | 17-NOV-2000; | 2000US-0249244P.  |
| R | 08-SEP-2000; | 2000US-0231242P. | PR | 17-NOV-2000; | 2000US-0249245P.  |
| R | 08-SEP-2000; | 2000US-0231243P. | PR | 17-NOV-2000; | 2000US-0249264P.  |
| R | 08-SEP-2000; | 2000US-0231244P. | PR | 17-NOV-2000; | 2000US-0249265P.  |
| R | 08-SEP-2000; | 2000US-0231413P. | PR | 17-NOV-2000; | 2000US-0249297P.  |
| R | 08-SEP-2000; | 2000US-0231414P. | PR | 17-NOV-2000; | 2000US-0249299P.  |
| R | 08-SEP-2000; | 2000US-0232080P. | PR | 17-NOV-2000; | 2000US-0249300P.  |
| R | 08-SEP-2000; | 2000US-0232081P. | PR | 01-DEC-2000; | 2000US-0250160P.  |
| R | 12-SEP-2000; | 2000US-0231968P. | PR | 01-DEC-2000; | 2000US-0250391P.  |
| R | 14-SEP-2000; | 2000US-0232397P. | PR | 05-DEC-2000; | 2000US-0251030P.  |
| R | 14-SEP-2000; | 2000US-0232398P. | PR | 05-DEC-2000; | 2000US-0251988P.  |
| R | 14-SEP-2000; | 2000US-0232399P. | PR | 06-DEC-2000; | 2000US-0256719P.  |
| R | 14-SEP-2000; | 2000US-0232400P. | PR | 08-DEC-2000; | 2000US-0251856P.  |
| R | 14-SEP-2000; | 2000US-0232401P. | PR | 08-DEC-2000; | 2000US-0251868P.  |
| R | 14-SEP-2000; | 2000US-0233063P. | PR | 08-DEC-2000; | 2000US-0251869P.  |
| R | 14-SEP-2000; | 2000US-0233064P. | PR | 08-DEC-2000; | 2000US-0251989P.  |
| R | 21-SEP-2000; | 2000US-0233065P. | PR | 08-DEC-2000; | 2000US-0251990P.  |
| R | 21-SEP-2000; | 2000US-0234223P. | PR | 11-DEC-2000; | 2000US-0254097P.  |
| R | 25-SEP-2000; | 2000US-0234274P. | PR | 05-JAN-2001; | 2000US-0259678P.  |
| R | 25-SEP-2000; | 2000US-0234997P. | PR | 17-JAN-2001; | 2000US-00764853.  |
| R | 26-SEP-2000; | 2000US-0234998P. | PR | 17-JAN-2001; | 2000US-00764853.  |
| R | 27-SEP-2000; | 2000US-0235484P. | PR | 17-JAN-2001; | 2000US-00764856.  |
| R |              |                  |    |              |                   |



```
PR 17-JAN-2001; 2001WO-US001340.
PR 17-JAN-2001; 2001WO-US001341.
PR 17-JAN-2001; 2001WO-US001344.
PR 17-JAN-2001; 2001WO-US001345.
PR 17-JAN-2001; 2001WO-US001347.
PR 17-JAN-2001; 2001WO-US001348.
PR 17-JAN-2001; 2001WO-US001360.
XX
XX (ROSE/) ROSEN C A.
PA (RUBI/) RUBIN S M.
PA (BARA/) BARASH S C.

Query Match 0.7%; Score 24.6; DB 1; Length 1352;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTTTACTTAATGCACTTATTTTATTCATTTTCTAATAAAATCCAGTCCTTGT 3042
DB 1241 TTTTGTATATAAAGTTAATGATTTTATAGGTATTTGTAACTGCCACATATCTT 1300

QY 3043 TTTTAAAAAGACTTTAAATTTAATTTCTCT 3077
DB 1301 ATTATTCCTCCCAATTTCAATAAATTTATTTCT 1335

RESULT 34
AAS41621
ID AAS41621 standard; cDNA; 1352 BP.
XX
AC AAS41621;
XX
DT 17-DEC-2001 (first entry)
XX
DE cDNA encoding novel human enzyme polypeptide #837.
XX
KW Human; oxidoreductase enzyme; transferase; hydrolase; lyase; isomerase;
KW ligase; hyperproliferative disorder; immunodeficiency disorder;
KW autoimmune disorder; neurological disorder; metabolic disorder;
KW inflammatory disorder; cardiovascular disorder; reproductive disorder;
KW blood-related disorder; infectious disorder; gene therapy; cytostatic;
KW anti arthritic; nephrotropic; anticoagulant; ss.
XX
OS Homo sapiens.
XX
XX WO200155301-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001239.
XX
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
XX 24-FEB-2000; 2000US-0184664P.
XX 02-MAR-2000; 2000US-0186350P.
XX 16-MAR-2000; 2000US-0189874P.
XX 17-MAR-2000; 2000US-0190076P.
XX 18-APR-2000; 2000US-0198123P.
XX 19-MAY-2000; 2000US-020515P.
XX 07-JUN-2000; 2000US-0209467P.
XX 28-JUN-2000; 2000US-0214886P.
XX 30-JUN-2000; 2000US-0215135P.
XX 07-JUL-2000; 2000US-0216647P.
XX 07-JUL-2000; 2000US-0216880P.
XX 11-JUL-2000; 2000US-0217487P.
XX 11-JUL-2000; 2000US-0217496P.
XX 14-JUL-2000; 2000US-0218290P.
XX 26-JUL-2000; 2000US-0220963P.
XX 26-JUL-2000; 2000US-0220964P.
XX 14-AUG-2000; 2000US-0224518P.
XX 14-AUG-2000; 2000US-0224519P.
XX 14-AUG-2000; 2000US-0225213P.
XX 14-AUG-2000; 2000US-0225214P.
XX 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0232632P.
PR 14-SEP-2000; 2000US-0232634P.
PR 14-SEP-2000; 2000US-0232635P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234977P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239355P.
PR 13-OCT-2000; 2000US-0239377P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
```

08-NOV-2000; 2000US-0246526P.  
08-NOV-2000; 2000US-0246527P.  
08-NOV-2000; 2000US-0246528P.  
08-NOV-2000; 2000US-0246532P.  
08-NOV-2000; 2000US-0246609P.  
08-NOV-2000; 2000US-0246610P.  
08-NOV-2000; 2000US-0246611P.  
08-NOV-2000; 2000US-0246613P.  
17-NOV-2000; 2000US-0249207P.  
17-NOV-2000; 2000US-0249208P.  
17-NOV-2000; 2000US-0249209P.  
17-NOV-2000; 2000US-0249210P.  
17-NOV-2000; 2000US-0249211P.  
17-NOV-2000; 2000US-0249212P.  
17-NOV-2000; 2000US-0249213P.  
17-NOV-2000; 2000US-0249214P.  
17-NOV-2000; 2000US-0249215P.  
17-NOV-2000; 2000US-0249216P.  
17-NOV-2000; 2000US-0249217P.  
17-NOV-2000; 2000US-0249218P.  
17-NOV-2000; 2000US-0249244P.  
17-NOV-2000; 2000US-0249245P.  
17-NOV-2000; 2000US-0249264P.  
17-NOV-2000; 2000US-0249265P.  
17-NOV-2000; 2000US-0249297P.  
17-NOV-2000; 2000US-0249299P.  
17-NOV-2000; 2000US-0249300P.  
01-DEC-2000; 2000US-0250160P.  
01-DEC-2000; 2000US-0250391P.  
03-DEC-2000; 2000US-0251030P.  
03-DEC-2000; 2000US-0251988P.  
06-DEC-2000; 2000US-0251719P.  
06-DEC-2000; 2000US-0251793P.  
08-DEC-2000; 2000US-0251856P.  
08-DEC-2000; 2000US-0251868P.  
08-DEC-2000; 2000US-0251869P.  
08-DEC-2000; 2000US-0251989P.  
08-DEC-2000; 2000US-0251990P.  
11-DEC-2000; 2000US-0254097P.  
05-JAN-2001; 2001US-0259678P.  
(HUMA-) HUMAN GENOME SCI INC.  
Rosen CA, Barash SC, Ruben SM;  
WPI; 2001-465566/50.  
P-PSDB; AAU23751.  
Novel polypeptides and polynucleotides useful for diagnosing, preventing, treating neural, immune system, muscular, reproductive, pulmonary, cardiovascular, renal, proliferative disorders and cancerous diseases.  
Claim 4; SEQ ID NO 847; 1180pp; English.  
The present invention relates to the isolation of novel human enzyme polypeptides (AAU22915-AAU3844), and the cDNA and genomic sequences encoding them. The enzyme polypeptides of the invention may comprise the functional classes of oxidoreductases, transferases, hydrolases, lyases, isomerases or ligases. The sequences of the invention are useful in the diagnosis, treatment, prevention and/or prognosis of a wide range of disorders including hyperproliferative disorders (e.g. cancer), immunodeficiency disorders (e.g. AIDS) autoimmune disorders (e.g. arthritis), neurological disorders (e.g. Alzheimer's disease), metabolic disorders (e.g. phenylketonuria), inflammatory disorders (e.g. asthma), cardiovascular disorders (e.g. atherosclerosis), blood-related disorders (e.g. haemophilia), reproductive disorders (e.g. infertility) and infectious disorders (e.g. influenza). The polynucleotides of the invention can also be used in gene therapy. AAU40785-AAU41694 represent cDNA sequences encoding for the novel human enzyme polypeptides of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

SQ Sequence 1352 BP; 237 A; 444 C; 408 G; 260 T; 0 U; 3 Other;  
Query Match 0.7%; Score 24.6; DB 1; Length 1352;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTTTACTTAAATGCACTTATTTTATGATTTTCTAAATAAATCCAGTCCTTGT 3042  
DB 1231 TTTTGTGATATAAATGTTAATGATTTTATAGTATTTTAAACCTGCCACATATCTT 1290  
QY 3043 TTTTATAAAGACCTTTAAATATTTATTTCTCT 3077  
DB 1291 ATTATTCCTCCAATTTCAATAAATTTATTTCT 1325  
RESULT 35  
AA26943  
ID AA26943 standard; cDNA; 1352 BP.  
XX  
AC AA26943;  
XX  
DT 07-NOV-2001 (first entry)  
XX  
DE Human cDNA encoding a novel secreted protein, SEQ ID 135.  
XX  
KW Human; immunosuppressive; antiarthritic; ss; antirheumatic; cytostatic;  
KW cardiant; vasotropic; cerebroprotective; nootropic; neuroprotective;  
KW antibacterial; virucide; fungicide; ophthalmological; vulnary;  
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;  
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;  
KW cerebral ischaemia; angiogenesis; nervous system disorder;  
KW Alzheimer's disease; infection; ocular disorder; corneal infection;  
KW wound healing; epithelial cell proliferation; skin ageing; food additive;  
KW preservative; antiproliferative.  
XX  
OS Homo sapiens.  
XX  
PN WO200155441-A2.  
XX  
PD 02-AUG-2001.  
XX  
PF 17-JAN-2001; 2001WO-US001320.  
XX  
PR 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 24-FEB-2000; 2000US-0184664P.  
PR 02-MAR-2000; 2000US-0186350P.  
PR 16-MAR-2000; 2000US-0189874P.  
PR 17-MAR-2000; 2000US-0190076P.  
PR 18-APR-2000; 2000US-0198123P.  
PR 19-MAY-2000; 2000US-0205515P.  
PR 07-JUN-2000; 2000US-0209467P.  
PR 28-JUN-2000; 2000US-0214986P.  
PR 30-JUN-2000; 2000US-0215135P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.  
PR 26-JUL-2000; 2000US-0220963P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225213P.  
PR 14-AUG-2000; 2000US-0225214P.  
PR 14-AUG-2000; 2000US-0225268P.  
PR 14-AUG-2000; 2000US-0225269P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225447P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 14-AUG-2000; 2000US-0225759P.

PR 18-AUG-2000; 2000US-0226279P.  
PR 22-AUG-2000; 2000US-0226681P.  
PR 22-AUG-2000; 2000US-0226686P.  
PR 22-AUG-2000; 2000US-0227182P.  
PR 23-AUG-2000; 2000US-0227009P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230437P.  
PR 06-SEP-2000; 2000US-0230438P.  
PR 08-SEP-2000; 2000US-0231242P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231143P.  
PR 08-SEP-2000; 2000US-0231144P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0232081P.  
PR 12-SEP-2000; 2000US-0231968P.  
PR 14-SEP-2000; 2000US-0232397P.  
PR 14-SEP-2000; 2000US-0232398P.  
PR 14-SEP-2000; 2000US-0232399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0235484P.  
PR 26-SEP-2000; 2000US-0235484P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0246179P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.

PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249264P.  
PR 17-NOV-2000; 2000US-0249265P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 17-NOV-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 01-DEC-2000; 2000US-0250391P.  
PR 05-DEC-2000; 2000US-0251030P.  
PR 05-DEC-2000; 2000US-0251988P.  
PR 06-DEC-2000; 2000US-0256719P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
PR 08-DEC-2000; 2000US-0251989P.  
PR 11-DEC-2000; 2000US-0251990P.  
PR 11-DEC-2000; 2000US-0254097P.  
PR 05-JAN-2001; 2001US-0259678P.

(HUMA-) HUMAN GENOME SCI INC.  
Rosen CA, Barash SC, Ruben SM;  
P-PSDB; AAU17038.  
WPI; 2001-476222/51.  
Novel polypeptides and polynucleotides useful as diagnostic reagents to  
diagnose diseases or disorders associated with aberrant expression or  
activity of polypeptides, for treating blood clotting disorder,  
hemophilia.  
Claim 1; SEQ ID NO 135; 601pp; English.  
The invention relates to isolated nucleic acid molecules and their  
encoded secreted proteins. The nucleic acids and proteins are used to  
prevent, treat or ameliorate a medical condition in e.g. humans, mice,  
rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used  
in diagnosing a pathological condition or susceptibility to a  
pathological condition. Antibodies to the proteins can also be used in  
alleviating symptoms associated with the disorders and in diagnostic  
immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays  
(ELISA). Disorders which are diagnosed or treated include autoimmune  
diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.  
neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac  
arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiodysplasia,  
nervous system disorders e.g. Alzheimer's disease, infections caused by  
bacteria, viruses and fungi and ocular disorders e.g. corneal infection,  
and many other disorders listed in the specification. The polypeptides  
can also be used to aid wound healing and epithelial cell proliferation,  
to prevent skin aging due to sunburn, to maintain organs before  
transplantation, for supporting cell culture of primary tissues, to  
regenerate tissues and in chemotaxis. The polypeptides can also be used  
as a food additive or preservative to increase or decrease storage  
capabilities, fat content, lipid, protein, carbohydrates, vitamins,  
minerals, cofactors and other nutritional components. The present  
sequence encodes a novel secreted protein of the invention. Note: The

Query Match 0.7%; Score 24.6; DB 1; Length 1352;

Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTACTTTAATGCACTTATTTTATTTTATTTTCTAATAAAATCCAGTCCTTGT 3042  
Db 1231 TTTGCTATATAAAGTTTAAGATTTTATAGTATTTGTAACCTGCCACATATCTT 1290  
QY 3043 TTTTAAAAAGACTTTAAATATTAATTTCTCT 3077  
Db 1291 ATTATTCCTCCAATTTCAATAAATTTATTTATCT 1325  
RESULT 36  
AA52259  
ID AAX87259 standard; cDNA; 1378 BP.  
XX AC AAX87259;  
XX XX  
XX 27-SEP-1999 (first entry)  
XX cDNA clone encoding human PRO343, amplified in tumour cells.  
XX PRO343; UNQ302; cancer; tumour; diagnosis; therapy; human; ss.  
XX Homo sapiens.  
XX Key Location/Qualifiers  
XX CDS 53..1006  
XX /tag= a  
XX sig\_peptide 53..148  
XX /tag= b  
XX mat\_peptide 149..1003  
XX /tag= c  
XX W09935170-A2.  
XX XX  
XX 15-JUL-1999.  
XX XX  
XX 05-JAN-1999; 99WO-US000106.  
XX XX  
XX 05-JAN-1998; 98US-0070440P.  
XX PR 29-APR-1998; 98US-0083500P.  
XX PR 22-MAY-1998; 98US-0086414P.  
XX PR 10-JUN-1998; 98US-0088742P.  
XX PR 10-NOV-1998; 98US-0107783P.  
XX PR 20-NOV-1998; 98US-0109304P.  
XX XX  
XX (GETH ) GENENTECH INC.  
XX XX  
XX Botstein D, Goddard A, Gurney AL, Hillan KJ, Lawrence DA, Roy MA,  
XX Wood WI;  
XX WPI: 1999-430385/36.  
XX P-PSDB; AAY06482.  
XX DR  
XX PT Antibody against proteins expressed in neoplastic cells, useful for tumor  
XX diagnosis and treatment.  
XX XX  
XX Example 1; Fig 11; 162pp; English.  
XX XX  
XX This is the nucleotide sequence of cDNA clone DNA43318 (ATCC 209481)  
XX coding for human PRO343 (UNQ302) (see AAY06482). The clone was isolated  
XX from a foetal lung library. Amplification of DNA43318 (chromosome 16) was  
XX observed in primary lung and primary colon tumours, suggesting an  
XX association with tumour formation or growth. Antagonists (e.g.  
XX antibodies) directed against PRO343 may have utility in cancer therapy.  
XX The invention identifies 14 genes (see AAX87254-57) that are amplified in  
XX the genome of tumour cells. Such amplification is expected to be  
XX associated with overexpression of the gene product and to contribute to  
XX tumorigenesis. The encoded proteins (see AAY06477-90) may be useful  
XX targets for the diagnosis and/or treatment (including prevention) of  
XX certain cancers, and may act as predictors of the prognosis of tumour  
XX treatment

XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTACTTTAATGCACTTATTTTATTTTATTTTCTAATAAAATCCAGTCCTTGT 3042  
Db 1272 TTTTGTATATAAAGTTTAAGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331  
QY 3043 TTTTAAAAAGACTTTAAATATTAATTTCTCT 3077  
Db 1332 ATTATTCCTCCAATTTCAATAAATTTATTTATCT 1366  
RESULT 37  
AA52262  
ID AAX52262 standard; DNA; 1378 BP.  
XX AC AAX52262;  
XX XX  
XX 25-JUN-1999 (first entry)  
XX DE Protein PRO343 cDNA clone DNA43318-1217.  
XX XX  
XX Secreted protein; transmembrane protein; human; enterocolitis;  
XX Zollinger-Ellison syndrome; gastrointestinal ulceration;  
XX congenital microvillus atrophy; skin disease; cell growth;  
XX abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
XX parkinson's disease; Alzheimer's disease; ALS; neuropathy; fibromodulin;  
XX dermal scarring; Usher Syndrome; Atrophia areata; anti-thrombotic;  
XX wound healing; tissue repair; ss.  
XX Homo sapiens.  
XX XX  
XX W09914328-A2.  
XX XX  
XX 25-MAR-1999.  
XX XX  
XX 16-SEP-1998; 98WO-US019330.  
XX PR 17-SEP-1997; 97US-0059113P.  
XX PR 17-SEP-1997; 97US-0059115P.  
XX PR 17-SEP-1997; 97US-0059117P.  
XX PR 17-SEP-1997; 97US-0059119P.  
XX PR 17-SEP-1997; 97US-0059121P.  
XX PR 17-SEP-1997; 97US-0059122P.  
XX PR 18-SEP-1997; 97US-0059184P.  
XX PR 18-SEP-1997; 97US-0059263P.  
XX PR 18-SEP-1997; 97US-0059266P.  
XX PR 15-OCT-1997; 97US-0062125P.  
XX PR 17-OCT-1997; 97US-0062285P.  
XX PR 17-OCT-1997; 97US-0062287P.  
XX PR 21-OCT-1997; 97US-0063486P.  
XX PR 24-OCT-1997; 97US-0062814P.  
XX PR 24-OCT-1997; 97US-0062816P.  
XX PR 24-OCT-1997; 97US-0063045P.  
XX PR 24-OCT-1997; 97US-0063120P.  
XX PR 24-OCT-1997; 97US-0063121P.  
XX PR 24-OCT-1997; 97US-0063127P.  
XX PR 24-OCT-1997; 97US-0063128P.  
XX PR 27-OCT-1997; 97US-0063327P.  
XX PR 27-OCT-1997; 97US-0063329P.  
XX PR 28-OCT-1997; 97US-0063541P.  
XX PR 28-OCT-1997; 97US-0063542P.  
XX PR 28-OCT-1997; 97US-0063544P.  
XX PR 28-OCT-1997; 97US-0063549P.  
XX PR 28-OCT-1997; 97US-0063550P.  
XX PR 28-OCT-1997; 97US-0063564P.  
XX PR 29-OCT-1997; 97US-0063435P.  
XX PR 29-OCT-1997; 97US-0063704P.  
XX PR 29-OCT-1997; 97US-0063732P.

PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 XX

(GETH ) GENENTECH INC.

PI Wood WI, Gurney AL, Goddard A, Pennica D, Chen J, Yuan J;

XX WFI; 1999-229533/19.

DR P-PSDB; AAY13391.

XX New isolated human genes and polypeptides used in, e.g. treatment of  
 PT gastrointestinal ulceration.

XX Claim 2; Fig 97; 320pp; English.

XX AAX52213-74 encode secreted and transmembrane human proteins, and are  
 CC obtained from cDNA libraries, prepared from fetal lung, fetal kidney,  
 CC fetal brain, fetal liver and fetal retina. The encoded polypeptides have  
 CC specific uses based on their homology to known polypeptides, e.g. PRO211  
 CC and PRO217 can be used for disorders associated with the preservation and  
 CC maintenance of gastrointestinal mucosa and the repair of acute and  
 CC chronic mucosal lesions (e.g. enterocolitis, Zollinger-Ellison syndrome,  
 CC gastrointestinal ulceration and congenital microvillus atrophy), skin  
 CC diseases associated with abnormal keratinocyte differentiation (e.g.  
 CC psoriasis, epithelial cancers such as lung squamous cell carcinoma of the  
 CC vulva and gliomas), potent effects on cell growth and development,  
 CC diseases related to growth or survival of nerve cells including  
 CC Parkinson's disease, Alzheimer's disease, ALS, neuropathies or cancer.  
 CC PRO265 can be used as for fibromodulin, e.g. for reducing dermal  
 CC scarring. PRO264 can be used as a target for anti-tumor drugs. PRO333 may  
 CC be used in the treatment of Usher Syndrome or Atrophia areata; PRO269 can  
 CC be used as an anti-thrombotic agent; PRO287 polypeptides and portions may  
 CC have therapeutic applications in wound healing and tissue repair; PRO317  
 CC can be used for treating problems of the kidney, uterus, endometrium,  
 CC blood vessels, or related tissue, e.g. in the heart of genital tract.  
 XX

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTTTACTTTAATTCGACCTTATTTTATGATTTTCTAATAAATCCAGTCTTGT 3042

Db 1272 TTTTGCTATATAAAGTGAATCAATTTTATAGGATTATTTGACCTGCCACATATCTT 1331

OY 3043 TTTTAAAAAGACTTTAAATTAATTTCTCT 3077

Db 1332 ATTTATCTCCCAATTCATAAATTAATTTCTCT 1366

RESULT 38

AAA46914

ID AAA46914 standard; cDNA; 1378 BP.

XX

AC AAA46914;

XX 03-OCT-2000 (first entry)  
 XX cDNA encoding novel polypeptide PRO343.

XX PRO201; PRO292; PRO327; PRO1265; PRO344; PRO343; PRO347; PRO357; PRO715;  
 XX PRO1017; PRO1112; PRO509; PRO853; PRO882; tumour cell; tumourigenesis;  
 XX cancer; neoplastic cell growth; cell proliferation; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 53..1007

XX /\*tag= a

XX WO200037640-A2.

XX 29-JUN-2000.

XX 16-DEC-1999; 99WO-US030095.

XX 22-DEC-1998; 98US-0113296P.

XX 08-MAR-1999; 99WO-US005028.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 15-SEP-1999; 99WO-US021090.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 02-DEC-1999; 99WO-US028565.

XX (GETH ) GENENTECH INC.

XX Botstein D, Goddard A, Gurney AL, Hillan K, Lawrence DA, Roy MA;  
 XX Wood WI;

XX WFI; 2000-452188/39.

XX P-PSDB; AAY93689.

XX New anti-polypeptide antibody useful in the treatment and diagnosis of  
 PT neoplastic cell growth and proliferation.

XX Claim 50; Fig 11; 220pp; English.

XX The present sequence encodes a novel human polypeptide. The specification  
 CC describes novel polypeptides designated PRO201, PRO292, PRO327, PRO1265,  
 CC PRO344, PRO343, PRO347, PRO357, PRO715, PRO1017, PRO112, PRO509, PRO853  
 CC and PRO882. These genes are amplified in the genome of tumour cells. The  
 CC polypeptides are believed to contribute to tumourigenesis. The  
 CC polypeptides are useful target for the identification of certain cancers,  
 CC and may act as predictors of the prognosis of tumour treatment.  
 CC Antibodies against these polypeptides are useful in the treatment and  
 CC diagnosis of neoplastic cell growth and proliferation in mammals

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTTTACTTTAATTCGACCTTATTTTATGATTTTCTAATAAATCCAGTCTTGT 3042

Db 1272 TTTTGCTATATAAAGTGAATCAATTTTATAGGATTATTTGACCTGCCACATATCTT 1331

OY 3043 TTTTAAAAAGACTTTAAATTAATTTCTCT 3077

Db 1332 ATTTATCTCCCAATTCATAAATTAATTTCTCT 1366

RESULT 39

ADC78574

ID ADC78574 standard; cDNA; 1378 BP.

XX

```

AC ADC78574;
XX 01-JAN-2004 (first entry)
XX Human PRO343 cDNA.
XX
XX antiinflammatory; antiulcer; cytostatic; antipsoriatic; antiparkinsonian;
XX neurotropic; neuroprotective; vasotropic; chemotactic; angiogenic;
XX neurotrophic; osteopathic; antiasthmatic; antiarthritic; antirheumatic;
XX antiarteriosclerotic; cardiatic; antididiabetic; cerebroprotective;
XX thrombolytic; immunomodulator; enterocolitis; Zollinger-Ellison syndrome;
XX gastrointestinal ulceration; psoriasis; cancer; Parkinson's disease;
XX Alzheimer's; ALS; neuropathy; dermal scarring; wound healing;
XX nerve repair; thrombosis; bone; cartilage formation; angiogenesis;
XX asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disorder;
XX atherosclerosis; cardiac injury; infertility; premature aging; AIDS;
XX diabetes; stroke; gene therapy; transgenic; PRO; human; ss; gene.
XX
OS Homo sapiens.
XX
XX WO200015796-A2.
XX
XX 23-MAR-2000.
XX
XX 15-SEP-1999; 99WO-US021090.
XX
XX 16-SEP-1998; 98WO-US019330.
XX
XX (GETH ) GENENTECH INC.
XX
XX Chen J, Goddard A, Gurney AL, Hillan K, Pennica D, Wood WI;
XX Yuan J;
XX
XX WPI; 2000-271434/23.
XX
XX P-PSDB; ADC78575.
XX
XX Novel nucleic acids encoding secreted and transmembrane polypeptides with
XX homology, e.g. to growth and cancer-associated antigens.
XX
XX Claim 2; SEQ ID NO 262; 355pp; English.
XX
XX The invention relates to a novel nucleic acid encoding a PRO polypeptide.
XX The polypeptides and polynucleotides of the invention may be useful as
XX research tools and as therapeutics for treating enterocolitis, Zollinger-
XX Ellison syndrome, gastrointestinal ulceration, psoriasis, cancer,
XX Parkinson's disease, Alzheimer's disease, ALS, neuropathies, dermal
XX scarring and wound healing, nerve repair, thrombosis, bone and/or
XX cartilage formation, angiogenesis, asthma, rheumatoid arthritis, multiple
XX sclerosis, inflammatory disorders, atherosclerosis, cardiac injury,
XX infertility, premature aging, AIDS, diabetes complications and stroke.
XX The molecules may also be utilised during gene therapy procedures and
XX transgenic animal production. The current sequence is that of the human
XX PRO cDNA of the invention.
XX
XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGACCTATTTTATGTATTTTCTAATAAATCCAGTCCTTGT 3042
DB 1272 TTTTGTGTATATAATGTTATGATTTTATAGGTTATTTGACCCGCCACATATCTT 1331
QY 3043 TTTTATAAAGACTTAAATTAATTTATTTCTCT 3077
DB 1332 ATTATTCCTCAATTTCAATAAATTTATTTATCT 1366
RESULT 40
AAF72420
ID AAF72420 standard; cDNA; 1378 BP.
XX

```

```

AC AAF72420;
XX 24-APR-2001 (first entry)
XX Human PRO343 cDNA.
XX
XX Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
XX antiparkinsonian neurotropic; neuroprotective; vulnery; cardiant;
XX angiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
XX antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
XX ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
XX ischaemia; inflammation; ss.
XX
OS Homo sapiens.
XX
XX WO200104311-A1.
XX
XX 18-JAN-2001.
XX
XX 22-FEB-2000; 2000WO-US004414.
XX
XX 07-JUL-1999; 99US-0143048P.
XX 26-JUL-1999; 99US-0145698P.
XX 28-JUL-1999; 99US-0146222P.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 05-JAN-2000; 2000WO-US000219.
XX
XX (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
XX Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
XX Godowski PJ, Grimaldi CU, Gurney AL, Hillan KJ, Kijavini IJ;
XX Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
XX Williams PM, Wood WI;
XX
XX WPI; 2001-081051/09.
XX P-PSDB; AAB80259.
XX
XX Sixty one nucleic acids encoding PRO polypeptides which are useful in the
XX treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous
XX cell carcinoma) and neurodegenerative diseases (e.g. Alzheimer's
XX disease).
XX
XX Claim 2; Fig 97; 393pp; English.
XX
XX The present sequence is one of sixty one nucleic acids encoding novel
XX secreted and transmembrane PRO polypeptides. The PRO polypeptides are
XX useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
XX squamous cell carcinoma), gastrointestinal disorders (e.g.
XX enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
XX Parkinson's disease), wound repair, cardiovascular disorders (e.g.
XX endometrial bleeding, angiogenesis, ischaemias such as coronary ischaemia,
XX atherosclerosis), inflammatory disorders (e.g. asthma, rheumatoid
XX arthritis, multiple sclerosis), infertility, AIDS and diabetes and
XX retinal disorders such as retinitis pigmentosa. The PRO nucleic acids
XX have applications in molecular biology, including use as hybridization
XX probes, and in chromosome and gene mapping.
XX
XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;

```





CC assays, biochemical screening assays, immunoassays and cell-based assays.  
 CC This sequence represents a human PRO polynucleotide of the invention  
 XX

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCATTTTACCTTAATGACCTTATTTTATTTGATTTTCTATAAATCCAGTCCTTCT 3042  
 DB 1272 TTTGTGTATATAAGTTTAATGATTTTATAGTATTTGTACCTGCCACATATCTT 1331  
 OY 3043 TTTTAAAGAGCTTTAAATTTATTAATTTCTCT 3077  
 DB 1332 ATTTATCTCCATTTCAATTAATTTATTTCT 1366

## RESULT 42

ACAS6507  
 ID ACAS6507 standard; cDNA; 1378 BP.

XX ACAS6507;

XX 10-JUN-2003 (first entry)

DT cDNA encoding human PRO polypeptide #48.

DE Human; secreted and transmembrane protein; PRO polypeptide; cancer;  
 KW Alzheimer's disease; ischaemia; cytostatic; neurotropic; vasotropic;  
 KW neuroprotective; gene; ss.

XX Homo sapiens.

XX US2002192659-A1.

XX 19-DEC-2002.

XX 10-JUL-2001; 2001US-00902853.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059123P.

XX 17-SEP-1997; 97US-0059184P.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 15-OCT-1997; 97US-0062125P.

XX 17-OCT-1997; 97US-0062285P.

XX 17-OCT-1997; 97US-0062287P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0063122P.

XX 24-OCT-1997; 97US-0063124P.

XX 24-OCT-1997; 97US-0063126P.

XX 24-OCT-1997; 97US-0063128P.

XX 27-OCT-1997; 97US-0063327P.

XX 27-OCT-1997; 97US-0063329P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063542P.

XX 28-OCT-1997; 97US-0063544P.

XX 28-OCT-1997; 97US-0063549P.

XX 28-OCT-1997; 97US-0063550P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063435P.

XX 29-OCT-1997; 97US-0063704P.

XX 29-OCT-1997; 97US-0063732P.

XX 29-OCT-1997; 97US-0063734P.

XX 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 16-DEC-1999; 99WO-US028565.  
 PR 20-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 30-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;  
 Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 Williams PM, Wood WI;

WPI; 2003-361832/34.  
 P-PSDB; ABU71492.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or  
 PRO1868, useful in molecular biology, chromosome and gene mapping, in  
 generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 97; 474pp; English.

The present invention relates to the isolation of novel human secreted  
 and transmembrane proteins (PRO polypeptides), and the polynucleotide  
 sequences encoding them. The polynucleotide sequences are useful in  
 molecular biology, as hybridisation probes, in chromosome and gene  
 mapping, in generating antisense RNA and DNA, and in gene therapy. The  
 polynucleotide sequences may also be used in preparing PRO polypeptides  
 by recombinant techniques, and in generating either transgenic animals or  
 knock-out animals which, in turn, are useful in the development and  
 screening of therapeutically useful reagents. The PRO polypeptides or

CC their antibodies are useful in preparing a medicament for treating a  
 CC condition responsive to the polypeptide or antibody, such as cancer,  
 CC Alzheimer's disease or ischaemia, and in various diagnostic assays. The  
 CC present sequence encodes a human PRO polypeptide of the invention  
 XX  
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.78; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.78; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTACTTAAATGCGACTTATTTTATGATTTTCTAATAAAATCCAGTCTGTG 3042  
 Db |||||  
 1272 TTTTGTGTATATAATGTTAATGATTTTATAGTATTATGTAACCTGCCACATATCTT 1331  
 QY 3043 TTTTAAAAGACTTTAAATTAATTAATTTCTCT 3077  
 Db |||||  
 1332 ATTATTCCTCCCAATTCATATAAATTTATTTCT 1366

## RESULT 43

ACA60214  
 ID ACA60214 standard; cDNA; 1378 BP.

AC ACA60214;

DT 12-JUN-2003 (first entry)

DE Human cDNA for secreted/transmembrane protein PRO343.

KW Human; ss; Gene; secreted protein; transmembrane protein; PRO;  
 KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003003530-A1.

XX 02-JAN-2003.

XX 11-JUL-2001; 2001US-00904011.

PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059124P.  
 PR 18-SEP-1997; 97US-0059283P.  
 PR 18-SEP-1997; 97US-0059286P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 29-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063722P.  
 PR 29-OCT-1997; 97US-0063734P.

PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065893P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavir IU;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;

WPI; 2003-329602/31.

P-PSDB; ABU71938.

New transmembrane polypeptides and nucleic acids encoding the  
 polypeptides, useful in gene therapy, in chromosome identification, as  
 chromosome markers, in generating probes and in tissue typing.

Claim 2; Fig 97; 484pp; English.

The invention relates to an isolated nucleic acid with at least 80%  
 nucleic acid sequence identity to a nucleotide sequence encoding one of  
 61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a  
 PRO protein extracellular domain. Also included are a vector comprising  
 the PRO nucleic acid, a host cell comprising the vector, producing a PRO  
 polypeptide (by culturing the host cell for the expression of the PRO  
 polypeptide, and recovering the PRO polypeptide from the cell culture),  
 an isolated PRO polypeptide (having at least 80% sequence identity to:



PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PW, Wood WI;  
XX WPI; 2003-370793/35.  
DR P-PSDB; ABC01821.  
XX  
XX New genes and secreted and transmembrane polypeptides (e.g. PRO245 or  
PT PRO335), useful for treating or diagnosing e.g. Alzheimer's disease,  
PT cancers, hemorrhage, rheumatoid arthritis, diabetes, cirrhosis, ischemia  
PT or strokes.  
XX  
XX Claim 2; Fig 97; 482pp; English.  
PS  
CC The invention describes a new isolated nucleic acid molecule comprising  
CC the full length coding sequence of the DNA deposited with the American  
CC Type Culture Collection (e.g. ATCC Deposit No. 209258), or a sequence  
CC with at least 80% identity to a DNA encoding a PRO polypeptide comprising  
CC any of 61 sequences having 164-1119 amino acids fully defined in the  
CC specification. The PRO polypeptides or polynucleotides are useful as  
CC pharmaceuticals, diagnostics, biosensors or bioreactors. These are  
CC particularly useful for detecting or treating e.g. Parkinson's disease,  
CC Alzheimer's disease, inflammations, nephritis, wound healing, nerve  
CC repair, collateral blood vessel formation, cancers (e.g. colorectal  
CC cancer), haemorrhage (or reduce risk for haemorrhage), rheumatoid  
CC arthritis, diabetes, cirrhosis of the liver, fibrosis of the lungs,  
CC restenosis, dermal fibrotic conditions (e.g. keloids or scarring),  
CC ischaemia, strokes, hypertension, heart attacks, atherosclerosis, or  
CC infertility in mammals (e.g. humans, dogs, cats, cattle, horses, sheep,  
CC pigs, goats, or rabbits). The PRO polypeptides are useful as targets for  
CC therapeutic intervention in these diseases, and diagnostic determination  
CC of the presence of these diseases. The PRO polypeptides are also useful  
CC as molecular weight markers, or for chromosome identification. The PRO  
CC genes are useful as hybridisation probes, or for screening libraries of  
CC human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene  
CC therapy, particularly for replacing a defective gene. This sequence  
CC encodes a novel human secreted and transmembrane PRO polypeptide  
XX  
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTCTTAAATGCACTTATTTTATTTTATTTTCTTAAATTAATCCAGTCCTTCT 3042  
Db 1272 TTTTGTGTATATAAAGTTTAAATGATTTTATAGGATTTGTAACTCCCTCCACATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
Db 1332 ATTTATTCCTCAATTTCAATAAATTAATTTATTTCT 1366

RESULT 45  
ABX71662  
ID ABX71662 standard; cDNA; 1378 BP.  
XX  
XX AC ABX71662;  
XX  
XX DT 10-MAR-2003 (first entry)  
XX  
XX DE Human cDNA encoding secreted/transmembrane protein PRO343.  
XX  
XX Human; PRO; secreted protein; transmembrane protein; enterocolitis;  
KW gastrointestinal ulceration; skin disease; ss; gene;  
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
KW squamous cell carcinoma; Alzheimer's disease; Parkinson's disease;  
KW amyotrophic lateral sclerosis; inflammatory disease;  
KW rheumatoid arthritis; asthma; multiple sclerosis; organ failure;  
KW atherosclerosis; cardiac injury; infertility; birth defect;  
KW premature aging; AIDS; acquired immunodeficiency syndrome; cancer;  
KW diabetic complication; wound repair.

XX Homo sapiens.  
OS US2002132240-A1.  
XX  
XX 19-SEP-2002.  
PD  
PF 18-JUL-2001; 2001US-00909320.  
XX  
XX 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066468P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 01-DEC-1998; 98WO-US025108.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028584.  
PR 02-DEC-1999; 99WO-US028585.

PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 06-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 28-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini LJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 WPI; 2003-147434/14.  
 DR P-PSDB; ABUS4394.  
 XX  
 PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing or  
 PT treating inflammatory diseases, organ failure, atherosclerosis, cardiac  
 PT injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's  
 PT disease.  
 XX  
 Claim 2; Fig 97; 473pp; English.  
 XX  
 The invention relates to an isolated PRO polypeptide having at least 80%  
 amino acid sequence identity to: (a) any one of 61 fully defined amino  
 acid sequences given in the specification (appearing as ABUS4347-  
 ABUS4407); (b) an amino acid sequence encoded by the nucleotide sequence  
 deposited under American Type Culture Collection (accession numbers  
 listed in the specification); (c) any one of the PRO sequences which  
 lacks its associated signal peptide; (d) an extracellular domain of the  
 PRO polypeptide with its associated signal peptide; or (e) an  
 extracellular domain of the PRO polypeptide which lacks its associated  
 signal peptide. Also include are the nucleic acids encoding the PRO  
 polypeptides, vectors, host cells and anti-PRO antibodies. The PRO  
 polypeptides and nucleic acids are useful in diagnosing or treating  
 enterocolitis, gastrointestinal ulceration, skin diseases associated with  
 abnormal keratinocyte differentiation, e.g. psoriasis or epithelial  
 cancers such as squamous cell carcinoma, Alzheimer's disease, Parkinson's  
 disease, amyotrophic lateral sclerosis, inflammatory diseases, e.g.  
 rheumatoid arthritis, asthma or multiple sclerosis, organ failure,  
 atherosclerosis, cardiac injury, infertility, birth defects, premature  
 aging, AIDS, cancer, diabetic complications, or mutations in general. The  
 polypeptides are also useful for wound repair and associated therapies  
 concerned with re-growth of tissue. The nucleotide sequences may be used  
 as hybridisation probes in chromosome and gene mapping, or in generating  
 antisense RNA and DNA. PRO nucleic acids are also useful in preparing PRO  
 polypeptides, in assays to identify other proteins or molecules involved  
 in binding reaction, to generate transgenic animals or knockout animals,  
 which in turn are useful in the development and screening of  
 therapeutically useful reagents, for chromosome identification, and  
 tissue typing. The PRO polypeptides and nucleic acid molecules are also  
 useful in gene therapy, and as molecular weight markers for protein  
 electrophoresis purposes. The anti-PRO antibodies may be used in  
 diagnostic assays for PRO, or for the affinity purification of PRO from  
 recombinant cell culture or natural sources. The present sequence encodes  
 a PRO polypeptide  
 XX  
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 5; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTTTACTTTAAATGCACTTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042  
 |||||  
 Db 1272 TTTTGTATATATAATGTTAAATGATTTTATAGTATTGTAACCTGCCACATATCTT 1331  
 |||||  
 QY 3043 TTTTAAAGACACTTAAATTAATTAATTTCTCT 3077  
 |||||  
 Db 1332 ATTATCTCTCAATTTCAATAAATTAATTTATTTCT 1366  
 |||||  
 RESULT 46  
 ACH06994  
 ID ACH06994 standard; cDNA; 1378 BP.  
 XX  
 AC ACH06994;  
 XX  
 DT 08-OCT-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane polypeptide PRO343 cDNA.  
 XX  
 KW Human; gene; ss; abnormal bleeding; gynaecological disease; asthma;  
 KW hysterectomy; angiogenesis; coronary ischaemic condition; skin disease;  
 KW gastrointestinal mucosa disorder; acute mucosal lesion; neuropathy; AIDS;  
 KW chronic mucosal lesion; abnormal keratinocyte differentiation; psoriasis;  
 KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;  
 KW uncontrolled cell growth; cancer; blood coagulation cascade; thrombosis;  
 KW haemorrhage; endometrial bleeding; angiogenesis; wound healing; tumour;  
 KW tissue repair; rheumatoid arthritis; multiple sclerosis; tissue typing.  
 XX  
 OS Homo sapiens.  
 XX  
 FN US2003044839-A1.  
 XX  
 PD 06-MAR-2003.  
 XX  
 PF 10-JUL-2001; 2001US-00902903.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 18-SEP-1997; 97US-0062125P.  
 PR 18-SEP-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.





```
PR 17-SEP-1997; 97US-0059119P.
PR 17-SEP-1997; 97US-0059121P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 15-OCT-1997; 97US-0062125P.
PR 17-OCT-1997; 97US-0062855P.
PR 17-OCT-1997; 97US-0062876P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063128P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063542P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063549P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063554P.
PR 29-OCT-1997; 97US-0063435P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063734P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 31-OCT-1997; 97US-0064215P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 18-NOV-1997; 97US-0065693P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 24-NOV-1997; 97US-0066772P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 01-DEC-1998; 98WO-US025108.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 01-DEC-1999; 98WO-US028301.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US004414.
PR 02-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00665350.
XX (GETH ) GENENTECH INC.
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kiljavin IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX WPI; 2003-288105/28.
DR P-PSDB; ABJ64546.
XX
XX New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245)
PT and genes encoding them, useful for detecting or treating e.g.
PT hyperplasia, endometriosis, cancers, ischemia, coronary arterial disease
PT or inflammations.
XX
XX Claim 2; Fig 97; 477pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC and the nucleic acid encoding them. The polypeptides can be used to raise
CC antibodies that specifically bind to the PRO polypeptide, for linking a
CC bioactive molecule to a cell expressing a PRO protein and for modulating
CC at least one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors, for detecting or treating e.g. hyperplasia,
CC endometriosis, cancers (e.g. those involving solid tumors), ischemia,
CC coronary arterial disease, polycystic kidney disease, chronic or acute
CC renal failure, or inflammatory responses (e.g. asthma, rheumatoid
CC arthritis, psoriasis or multiple sclerosis) in mammals. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. The sequences presented in ABX96017-ABX96378 are the genes
CC encoding, the primers amplifying and the probes detecting the PRO
CC polynucleotides of the invention
XX
XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 26;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2983 TCTATTTACTTTTATGTCACCTATTTTATGATTTTCTTAATAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTATATAAATGTTAATGATTTTATAGGATTTTGAACCTCCACATATCTT 1331
Qy 3043 TTTTAAAAAGACITTTAAATTTAATTTCTCT 3077
Db 1332 ATTTATCTCCCAATTTCAATTAATTTATTTCT 1366
RESULT 48
ACA05552
ID ACA05552 standard; cDNA; 1378 BP.
XX
XX ACA05552;
XX
XX 29-MAY-2003 (first entry)
XX
XX cDNA encoding human secreted protein PRO343.
XX
XX Human; gene therapy; mucosal lesion; ulcer; enterocolitis; skin disease;
KW psoriasis; cancer; lung cancer; colon cancer; nerve cell disease;
KW Alzheimer's disease; Parkinson's disease; Usher syndrome; angiogenesis;
KW atrophy areata; inflammatory disease; asthma; rheumatoid arthritis;
KW ischaemia; ss; gene.
XX
XX Homo sapiens.
XX
XX US2003023054-A1.
XX
```

## RESULT 49

ACD20219  
ID ACD20219 standard; cDNA; 1378 BP.  
XX  
AC ACD20219;  
XX  
DT 25-AUG-2003 (first entry)  
XX  
DE Human secreted / transmembrane polypeptide PRO343 cDNA.  
XX  
KW Human; ss; gene; gene therapy; tumour; tissue typing; obesity; diabetes;  
KW Hypoinsulinaemia; hyperinsulinaemia; vascular permeability;  
KW cardiac insufficiency disorder; immune response; regeneration; cartilage;  
KW auditory hair cell; hearing loss; bone disorder; sports injury;  
XX  
OS Homo sapiens.  
XX  
PN US2003036060-A1.  
XX  
PD 20-FEB-2003.  
XX  
PF 12-JUL-2001; 2001US-00904859.  
XX  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063543P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063733P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065196P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-009803P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 30-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00655350.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2003-417923/39.  
DR P-PSDB; ABO14912.  
XX  
XX Novel secreted and transmembrane polypeptide for modulating biological  
PT activity of cell expressing the polypeptide, identifying agonists or  
PT antagonists of polypeptide, and as molecular weight markers.  
XX  
XX Claim 2; Fig 97; 469pp; English.  
XX  
XX The invention relates to an isolated, secreted and transmembrane  
CC polypeptide, termed PRO polypeptide. The polypeptide is useful for  
CC identifying agonists or antagonists of the polypeptide, for preparing  
CC variants of the polypeptide, as molecular weight markers for protein  
CC electrophoresis purpose and the nucleic acid is useful for recombinantly  
CC expressing those markers. The polypeptide is also useful as therapeutic  
CC agent. PRO is useful in assays to identify other proteins or molecules  
CC involved in binding interaction. The nucleic acid is useful as  
CC hybridisation probes, in chromosome and gene mapping, in generation of  
CC antisense RNA and DNA, in the preparation of PRO polypeptide, for  
CC generating transgenic animals or knockout animals which in turn are  
CC useful in the development and screening of therapeutically useful  
CC reagents, to construct hybridisation probes for mapping the gene which  
CC encodes the PRO and for the genetic analysis of individuals with genetic

CC disorders, in gene therapy, for chromosome identification, as chromosome  
CC marker, and for generating probes for polymerase chain reaction (PCR),  
CC Northern analysis, Southern analysis and Western analysis. PRO antibody  
CC is useful in diagnostic assays for PRO, e.g. detecting its expression in  
CC specific cells, tissues or serum and for affinity purification of PRO  
CC from recombinant cell culture or natural sources. The polypeptide or its  
CC antibody is useful for the preparation of medicament for treating  
CC conditions which is responsive to the PRO polypeptide or anti-PRO  
CC antibody e.g. tumour. The polypeptide and the nucleic acid is useful for  
CC tissue typing. The polypeptide is useful for treating obesity, diabetes  
CC or hypo- or hyper-insulinaemia and cardiac insufficiency disorders, for  
CC inhibiting tumour growth, enhances vascular permeability and immune  
CC response, for inducing regeneration of auditory hair cells and for  
CC treating hearing loss in mammals and for treating bone and/or cartilage  
CC disorders such as sports injuries and arthritis. The present sequence  
CC represents cDNA encoding a human secreted and transmembrane PRO  
CC polypeptide  
XX  
XX

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.78; Score 24.6; DB 1; Length 1378;

Best Local Similarity 53.74; Fred. NO. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTAATGCACTTATTTTATTCATTTTCTAATAAAATCCAGTCTCTGT 3042

DB 1272 TTITGTCATATAAATGTTAATGATTTTATAGTATTTTGTACCCCTGCCACATATCTT 1331

QY 3043 TTTTAAAAGACTTTAAATTTAAATTTCTCT 3077

DB 1332 ATTATTCCTCCCAATTCATTAATTAATTTATTTCT 1366

RESULT 50

ACA55022

ID ACA55022 standard; cDNA; 1378 BP.

XX ACA55022;

XX 05-JUN-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO343 cDNA.

KW Human, secreted and transmembrane protein; gene therapy; psoriasis;  
KW enterocolitis; gastrointestinal ulceration; skin disease;  
KW keratinocyte differentiation; epithelial cancer; Alzheimer's disease;  
KW squamous cell carcinoma; Parkinson's disease; inflammatory disease;  
KW amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;  
KW multiple sclerosis; organ failure; atherosclerosis; cardiac injury;  
KW infertility; birth defect; premature aging; AIDS; cancer;  
KW diabetic complication; wound repair; tissue re-growth; gene; ss.

XX Homo sapiens.

XX US2003017463-A1.

XX 23-JAN-2003.

XX 11-JUL-2001; 2001US-00903640.

XX 17-SEP-1997; 97US-0059113P.

XX 17-SEP-1997; 97US-0059115P.

XX 17-SEP-1997; 97US-0059117P.

XX 17-SEP-1997; 97US-0059119P.

XX 17-SEP-1997; 97US-0059121P.

XX 17-SEP-1997; 97US-0059122P.

XX 17-SEP-1997; 97US-0059184P.

XX 18-SEP-1997; 97US-0059463P.

XX 18-SEP-1997; 97US-0059466P.

XX 15-OCT-1997; 97US-0062125P.

XX 17-OCT-1997; 97US-0062285P.

XX 17-OCT-1997; 97US-0062287P.

XX 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065893P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-008026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98US-00100262P.  
PR 14-SEP-1998; 98US-00101824.  
PR 14-SEP-1998; 98US-001019177.  
PR 16-SEP-1998; 98US-001019330.  
PR 17-SEP-1998; 98US-00100858P.  
PR 17-SEP-1998; 98US-001019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-001025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99US-0020594.  
PR 13-SEP-1999; 99US-0020944.  
PR 15-SEP-1999; 99US-0021547.  
PR 15-SEP-1999; 99US-0021547.  
PR 05-OCT-1999; 99US-0023089.  
PR 29-NOV-1999; 99US-0028214.  
PR 30-NOV-1999; 99US-0028313.  
PR 02-DEC-1999; 99US-0028301.  
PR 02-DEC-1999; 99US-0028564.  
PR 16-DEC-1999; 99US-0028565.  
PR 16-DEC-1999; 99US-0028565.  
PR 20-DEC-1999; 99US-0030911.  
PR 20-DEC-1999; 99US-0030999.  
PR 05-JAN-2000; 2000US-0000219.  
PR 11-FEB-2000; 2000US-0003565.  
PR 22-FEB-2000; 2000US-0004414.  
PR 02-MAR-2000; 2000US-0005004.  
PR 02-MAR-2000; 2000US-0005841.  
PR 20-MAR-2000; 2000US-0007377.  
PR 30-MAR-2000; 2000US-0008439.

PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI GoGowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin LJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX WPI; 2003-341586/32.  
 DR P-PSDB; ABU69669.  
 XX  
 XX New PRO polypeptides and nucleic acid molecules, useful in diagnosing or  
 PT treating inflammatory diseases, organ failure, atherosclerosis, cardiac  
 PT injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's  
 PT disease.  
 XX  
 XX Claim 2; Fig 97; 473pp; English.  
 XX  
 XX The invention describes sixty one nucleic acids encoding PRO polypeptides  
 CC (secreted and transmembrane). The PRO polypeptides and nucleic acids are  
 CC useful in diagnosing or treating enterocolitis, gastrointestinal  
 CC ulceration, skin diseases associated with abnormal keratinocyte  
 CC differentiation, e.g. psoriasis or epithelial cancers such as squamous  
 CC cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic  
 CC lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,  
 CC asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac  
 CC injury, infertility, birth defects, premature aging, AIDS, cancer,  
 CC diabetic complications, or mutations in general. The polypeptides are  
 CC also useful for wound repair and associated therapies concerned with re-  
 CC growth of tissue. The PRO polypeptides and nucleic acid molecules are  
 CC also useful in gene therapy, and as molecular weight markers for protein  
 CC electrophoresis purposes. The anti-PRO antibodies may be used in  
 CC diagnostic assays for PRO, or for the affinity purification of PRO from  
 CC recombinant cell culture or natural sources. This sequence encodes a  
 CC novel human PRO polypeptide  
 XX  
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2983 TCTATTACTTAAATGCACATATTTTATGATTTCTTAATAAATCCAGTCCTTGT 3042  
 DB 1272 TTTTGTGATATAAATGTAATGATTTTATAGGTATTTGAACCTCCACATATCTT 1331  
 QY 3043 TTTTATAAAGACATTAAATATATATTTCTCT 3077  
 DB 1332 ATTATCTCTCAATTTCAATAAATATTTATCT 1366  
 RESULT 51  
 ACD19857  
 ID ACD19857 standard; cDNA; 1378 BP.  
 XX  
 AC ACD19857;  
 XX  
 XX 22-AUG-2003 (first entry)  
 DT  
 XX Human secreted / transmembrane polypeptide PRO343 cDNA.  
 DE  
 XX Human; ss; gene; gene therapy; apoptosis; bleeding; tumour; ALS;  
 KW synaological disease; hysterectomy; angiogenesis; skin disease; cancer;  
 KW coronary ischaemic condition; gastrointestinal mucosa disorder; asthma;  
 KW mucosal lesion repair; keratinocyte differentiation; psoriasis;  
 KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;  
 KW neuropathy; blood coagulation cascade disorder; thrombosis; haemorrhage;

KW neurodegenerative disease; endometrial bleeding; wound healing;  
 KW tissue repair; rheumatoid arthritis; multiple sclerosis; tissue typing.  
 XX Homo sapiens.  
 OS US2003027143-A1.  
 PN XX  
 PD 06-FEB-2003.  
 XX

XX 16-JUL-2001; 2001US-00906838.  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059123P.  
 PR 17-SEP-1997; 97US-0059125P.  
 PR 17-SEP-1997; 97US-0059127P.  
 PR 17-SEP-1997; 97US-0059129P.  
 PR 17-SEP-1997; 97US-0059131P.  
 PR 17-SEP-1997; 97US-0059133P.  
 PR 17-SEP-1997; 97US-0059135P.  
 PR 17-SEP-1997; 97US-0059137P.  
 PR 17-SEP-1997; 97US-0059139P.  
 PR 17-SEP-1997; 97US-0059141P.  
 PR 17-SEP-1997; 97US-0059143P.  
 PR 17-SEP-1997; 97US-0059145P.  
 PR 17-SEP-1997; 97US-0059147P.  
 PR 17-SEP-1997; 97US-0059149P.  
 PR 17-SEP-1997; 97US-0059151P.  
 PR 17-SEP-1997; 97US-0059153P.  
 PR 17-SEP-1997; 97US-0059155P.  
 PR 17-SEP-1997; 97US-0059157P.  
 PR 17-SEP-1997; 97US-0059159P.  
 PR 17-SEP-1997; 97US-0059161P.  
 PR 17-SEP-1997; 97US-0059163P.  
 PR 17-SEP-1997; 97US-0059165P.  
 PR 17-SEP-1997; 97US-0059167P.  
 PR 17-SEP-1997; 97US-0059169P.  
 PR 17-SEP-1997; 97US-0059171P.  
 PR 17-SEP-1997; 97US-0059173P.  
 PR 17-SEP-1997; 97US-0059175P.  
 PR 17-SEP-1997; 97US-0059177P.  
 PR 17-SEP-1997; 97US-0059179P.  
 PR 17-SEP-1997; 97US-0059181P.  
 PR 17-SEP-1997; 97US-0059183P.  
 PR 17-SEP-1997; 97US-0059185P.  
 PR 17-SEP-1997; 97US-0059187P.  
 PR 17-SEP-1997; 97US-0059189P.  
 PR 17-SEP-1997; 97US-0059191P.  
 PR 17-SEP-1997; 97US-0059193P.  
 PR 17-SEP-1997; 97US-0059195P.  
 PR 17-SEP-1997; 97US-0059197P.  
 PR 17-SEP-1997; 97US-0059199P.  
 PR 17-SEP-1997; 97US-0059201P.  
 PR 17-SEP-1997; 97US-0059203P.  
 PR 17-SEP-1997; 97US-0059205P.  
 PR 17-SEP-1997; 97US-0059207P.  
 PR 17-SEP-1997; 97US-0059209P.  
 PR 17-SEP-1997; 97US-0059211P.  
 PR 17-SEP-1997; 97US-0059213P.  
 PR 17-SEP-1997; 97US-0059215P.  
 PR 17-SEP-1997; 97US-0059217P.  
 PR 17-SEP-1997; 97US-0059219P.  
 PR 17-SEP-1997; 97US-0059221P.  
 PR 17-SEP-1997; 97US-0059223P.  
 PR 17-SEP-1997; 97US-0059225P.  
 PR 17-SEP-1997; 97US-0059227P.  
 PR 17-SEP-1997; 97US-0059229P.  
 PR 17-SEP-1997; 97US-0059231P.  
 PR 17-SEP-1997; 97US-0059233P.  
 PR 17-SEP-1997; 97US-0059235P.  
 PR 17-SEP-1997; 97US-0059237P.  
 PR 17-SEP-1997; 97US-0059239P.  
 PR 17-SEP-1997; 97US-0059241P.  
 PR 17-SEP-1997; 97US-0059243P.  
 PR 17-SEP-1997; 97US-0059245P.  
 PR 17-SEP-1997; 97US-0059247P.  
 PR 17-SEP-1997; 97US-0059249P.  
 PR 17-SEP-1997; 97US-0059251P.  
 PR 17-SEP-1997; 97US-0059253P.  
 PR 17-SEP-1997; 97US-0059255P.  
 PR 17-SEP-1997; 97US-0059257P.  
 PR 17-SEP-1997; 97US-0059259P.  
 PR 17-SEP-1997; 97US-0059261P.  
 PR 17-SEP-1997; 97US-0059263P.  
 PR 17-SEP-1997; 97US-0059265P.  
 PR 17-SEP-1997; 97US-0059267P.  
 PR 17-SEP-1997; 97US-0059269P.  
 PR 17-SEP-1997; 97US-0059271P.  
 PR 17-SEP-1997; 97US-0059273P.  
 PR 17-SEP-1997; 97US-0059275P.  
 PR 17-SEP-1997; 97US-0059277P.  
 PR 17-SEP-1997; 97US-0059279P.  
 PR 17-SEP-1997; 97US-0059281P.  
 PR 17-SEP-1997; 97US-0059283P.  
 PR 17-SEP-1997; 97US-0059285P.  
 PR 17-SEP-1997; 97US-0059287P.  
 PR 17-SEP-1997; 97US-0059289P.  
 PR 17-SEP-1997; 97US-0059291P.  
 PR 17-SEP-1997; 97US-0059293P.  
 PR 17-SEP-1997; 97US-0059295P.  
 PR 17-SEP-1997; 97US-0059297P.  
 PR 17-SEP-1997; 97US-0059299P.  
 PR 17-SEP-1997; 97US-0059301P.  
 PR 17-SEP-1997; 97US-0059303P.  
 PR 17-SEP-1997; 97US-0059305P.  
 PR 17-SEP-1997; 97US-0059307P.  
 PR 17-SEP-1997; 97US-0059309P.  
 PR 17-SEP-1997; 97US-0059311P.  
 PR 17-SEP-1997; 97US-0059313P.  
 PR 17-SEP-1997; 97US-0059315P.  
 PR 17-SEP-1997; 97US-0059317P.  
 PR 17-SEP-1997; 97US-0059319P.  
 PR 17-SEP-1997; 97US-0059321P.  
 PR 17-SEP-1997; 97US-0059323P.  
 PR 17-SEP-1997; 97US-0059325P.  
 PR 17-SEP-1997; 97US-0059327P.  
 PR 17-SEP-1997; 97US-0059329P.  
 PR 17-SEP-1997; 97US-0059331P.  
 PR 17-SEP-1997; 97US-0059333P.  
 PR 17-SEP-1997; 97US-0059335P.  
 PR 17-SEP-1997; 97US-0059337P.  
 PR 17-SEP-1997; 97US-0059339P.  
 PR 17-SEP-1997; 97US-0059341P.  
 PR 17-SEP-1997; 97US-0059343P.  
 PR 17-SEP-1997; 97US-0059345P.  
 PR 17-SEP-1997; 97US-0059347P.  
 PR 17-SEP-1997; 97US-0059349P.  
 PR 17-SEP-1997; 97US-0059351P.  
 PR 17-SEP-1997; 97US-0059353P.  
 PR 17-SEP-1997; 97US-0059355P.  
 PR 17-SEP-1997; 97US-0059357P.  
 PR 17-SEP-1997; 97US-0059359P.  
 PR 17-SEP-1997; 97US-0059361P.  
 PR 17-SEP-1997; 97US-0059363P.  
 PR 17-SEP-1997; 97US-0059365P.  
 PR 17-SEP-1997; 97US-0059367P.  
 PR 17-SEP-1997; 97US-0059369P.  
 PR 17-SEP-1997; 97US-0059371P.  
 PR 17-SEP-1997; 97US-0059373P.  
 PR 17-SEP-1997; 97US-0059375P.  
 PR 17-SEP-1997; 97US-0059377P.  
 PR 17-SEP-1997; 97US-0059379P.  
 PR 17-SEP-1997; 97US-0059381P.  
 PR 17-SEP-1997; 97US-0059383P.  
 PR 17-SEP-1997; 97US-0059385P.  
 PR 17-SEP-1997; 97US-0059387P.  
 PR 17-SEP-1997; 97US-0059389P.  
 PR 17-SEP-1997; 97US-0059391P.  
 PR 17-SEP-1997; 97US-0059393P.  
 PR 17-SEP-1997; 97US-0059395P.  
 PR 17-SEP-1997; 97US-0059397P.  
 PR 17-SEP-1997; 97US-0059399P.  
 PR 17-SEP-1997; 97US-0059401P.  
 PR 17-SEP-1997; 97US-0059403P.  
 PR 17-SEP-1997; 97US-0059405P.  
 PR 17-SEP-1997; 97US-0059407P.  
 PR 17-SEP-1997; 97US-0059409P.  
 PR 17-SEP-1997; 97US-0059411P.  
 PR 17-SEP-1997; 97US-0059413P.  
 PR 17-SEP-1997; 97US-0059415P.  
 PR 17-SEP-1997; 97US-0059417P.  
 PR 17-SEP-1997; 97US-0059419P.  
 PR 17-SEP-1997; 97US-0059421P.  
 PR 17-SEP-1997; 97US-0059423P.  
 PR 17-SEP-1997; 97US-0059425P.  
 PR 17-SEP-1997; 97US-0059427P.  
 PR 17-SEP-1997; 97US-0059429P.  
 PR 17-SEP-1997; 97US-0059431P.  
 PR 17-SEP-1997; 97US-0059433P.  
 PR 17-SEP-1997; 97US-0059435P.  
 PR 17-SEP-1997; 97US-0059437P.  
 PR 17-SEP-1997; 97US-0059439P.  
 PR 17-SEP-1997; 97US-0059441P.  
 PR 17-SEP-1997; 97US-0059443P.  
 PR 17-SEP-1997; 97US-0059445P.  
 PR 17-SEP-1997; 97US-0059447P.  
 PR 17-SEP-1997; 97US-0059449P.  
 PR 17-SEP-1997; 97US-0059451P.  
 PR 17-SEP-1997; 97US-0059453P.  
 PR 17-SEP-1997; 97US-0059455P.  
 PR 17-SEP-1997; 97US-0059457P.  
 PR 17-SEP-1997; 97US-0059459P.  
 PR 17-SEP-1997; 97US-0059461P.  
 PR 17-SEP-1997; 97US-0059463P.  
 PR 17-SEP-1997; 97US-0059465P.  
 PR 17-SEP-1997; 97US-0059467P.  
 PR 17-SEP-1997; 97US-0059469P.  
 PR 17-SEP-1997; 97US-0059471P.  
 PR 17-SEP-1997; 97US-0059473P.  
 PR 17-SEP-1997; 97US-0059475P.  
 PR 17-SEP-1997; 97US-0059477P.  
 PR 17-SEP-1997; 97US-0059479P.  
 PR 17-SEP-1997; 97US-0059481P.  
 PR 17-SEP-1997; 97US-0059483P.  
 PR 17-SEP-1997; 97US-0059485P.  
 PR 17-SEP-1997; 97US-0059487P.  
 PR 17-SEP-1997; 97US-0059489P.  
 PR 17-SEP-1997; 97US-0059491P.  
 PR 17-SEP-1997; 97US-0059493P.  
 PR 17-SEP-1997; 97US-0059495P.  
 PR 17-SEP-1997; 97US-0059497P.  
 PR 17-SEP-1997; 97US-0059499P.  
 PR 17-SEP-1997; 97US-0059501P.  
 PR 17-SEP-1997; 97US-0059503P.  
 PR 17-SEP-1997; 97US-0059505P.  
 PR 17-SEP-1997; 97US-0059507P.  
 PR 17-SEP-1997; 97US-0059509P.  
 PR 17-SEP-1997; 97US-0059511P.  
 PR 17-SEP-1997; 97US-0059513P.  
 PR 17-SEP-1997; 97US-0059515P.  
 PR 17-SEP-1997; 97US-0059517P.  
 PR 17-SEP-1997; 97US-0059519P.  
 PR 17-SEP-1997; 97US-0059521P.  
 PR 17-SEP-1997; 97US-0059523P.  
 PR 17-SEP-1997; 97US-0059525P.  
 PR 17-SEP-1997; 97US-0059527P.  
 PR 17-SEP-1997; 97US-0059529P.  
 PR 17-SEP-1997; 97US-0059531P.  
 PR 17-SEP-1997; 97US-0059533P.  
 PR 17-SEP-1997; 97US-0059535P.  
 PR 17-SEP-1997; 97US-0059537P.  
 PR 17-SEP-1997; 97US-0059539P.  
 PR 17-SEP-1997; 97US-0059541P.  
 PR 17-SEP-1997; 97US-0059543P.  
 PR 17-SEP-1997; 97US-0059545P.  
 PR 17-SEP-1997; 97US-0059547P.  
 PR 17-SEP-1997; 97US-0059549P.  
 PR 17-SEP-1997; 97US-0059551P.  
 PR 17-SEP-1997; 97US-0059553P.  
 PR 17-SEP-1997; 97US-0059555P.  
 PR 17-SEP-1997; 97US-0059557P.  
 PR 17-SEP-1997; 97US-0059559P.  
 PR 17-SEP-1997; 97US-0059561P.  
 PR 17-SEP-1997; 97US-0059563P.  
 PR 17-SEP-1997; 97US-0059565P.  
 PR 17-SEP-1997; 97US-0059567P.  
 PR 17-SEP-1997; 97US-0059569P.  
 PR 17-SEP-1997; 97US-0059571P.  
 PR 17-SEP-1997; 97US-0059573P.  
 PR 17-SEP-1997; 97US-0059575P.  
 PR 17-SEP-1997; 97US-0059577P.  
 PR 17-SEP-1997; 97US-0059579P.  
 PR 17-SEP-1997; 97US-0059581P.  
 PR 17-SEP-1997; 97US-0059583P.  
 PR 17-SEP-1997; 97US-0059585P.  
 PR 17-SEP-1997; 97US-0059587P.  
 PR 17-SEP-1997; 97US-0059589P.  
 PR 17-SEP-1997; 97US-0059591P.  
 PR 17-SEP-1997; 97US-0059593P.  
 PR 17-SEP-1997; 97US-0059595P.  
 PR 17-SEP-1997; 97US-0059597P.  
 PR 17-SEP-1997; 97US-0059599P.  
 PR 17-SEP-1997; 97US-0059601P.  
 PR 17-SEP-1997; 97US-0059603P.  
 PR 17-SEP-1997; 97US-0059605P.  
 PR 17-SEP-1997; 97US-0059607P.  
 PR 17-SEP-1997; 97US-0059609P.  
 PR 17-SEP-1997; 97US-0059611P.  
 PR 17-SEP-1997; 97US-0059613P.  
 PR 17-SEP-1997; 97US-0059615P.  
 PR 17-SEP-1997; 97US-0059617P.  
 PR 17-SEP-1997; 97US-0059619P.  
 PR 17-SEP-1997; 97US-0059621P.  
 PR 17-SEP-1997; 97US-0059623P.  
 PR 17-SEP-1997; 97US-0059625P.  
 PR 17-SEP-1997; 97US-0059627P.  
 PR 17-SEP-1997; 97US-0059629P.  
 PR 17-SEP-1997; 97US-0059631P.  
 PR 17-SEP-1997; 97US-0059633P.  
 PR 17-SEP-1997; 97US-0059635P.  
 PR 17-SEP-1997; 97US-0059637P.  
 PR 17-SEP-1997; 97US-0059639P.  
 PR 17-SEP-1997; 97US-0059641P.  
 PR 17-SEP-1997; 97US-0059643P.  
 PR 17-SEP-1997; 97US-0059645P.  
 PR 17-SEP-1997; 97US-0059647P.  
 PR 17-SEP-1997; 97US-0059649P.  
 PR 17-SEP-1997; 97US-0059651P.  
 PR 17-SEP-1997; 97US-0059653P.  
 PR 17-SEP-1997; 97US-0059655P.  
 PR 17-SEP-1997; 97US-0059657P.  
 PR 17-SEP-1997; 97US-0059659P.  
 PR 17-SEP-1997; 97US-0059661P.  
 PR 17-SEP-1997; 97US-0059663P.  
 PR 17-SEP-1997; 97US-0059665P.  
 PR 17-SEP-1997; 97US-0059667P.  
 PR 17-SEP-1997; 97US-0059669P.  
 PR 17-SEP-1997; 97US-0059671P.  
 PR 17-SEP-1997; 97US-0059673P.  
 PR 17-SEP-1997; 97US-0059675P.  
 PR 17-SEP-1997; 97US-0059677P.  
 PR 17-SEP-1997; 97US-0059679P.  
 PR 17-SEP-1997; 97US-0059681P.  
 PR 17-SEP-1997; 97US-0059683P.  
 PR 17-SEP-1997; 97US-0059685P.  
 PR 17-SEP-1997; 97US-0059687P.  
 PR 17-SEP-1997; 97US-0059689P.  
 PR 17-SEP-1997; 97US-0059691P.  
 PR 17-SEP-1997; 97US-0059693P.  
 PR 17-SEP-1997; 97US-0059695P.  
 PR 17-SEP-1997; 97US-0059697P.  
 PR 17-SEP-1997; 97US-0059699P.  
 PR 17-SEP-1997; 97US-0059701P.  
 PR 17-SEP-1997; 97US-0059703P.  
 PR 17-SEP-1997; 97US-0059705P.  
 PR 17-SEP-1997; 97US-0059707P.  
 PR 17-SEP-1997; 97US-0059709P.  
 PR 17-SEP-1997; 97US-0059711P.  
 PR 17-SEP-1997; 97US-0059713P.  
 PR 17-SEP-1997; 97US-0059715P.  
 PR 17-SEP-1997; 97US-0059717P.  
 PR 17-SEP-1997; 97US-0059719P.  
 PR 17-SEP-1997; 97US-0059721P.  
 PR 17-SEP-1997; 97US-0059723P.  
 PR 17-SEP-1997; 97US-0059725P.  
 PR 17-SEP-1997; 97US-0059727P.  
 PR 17-SEP-1997; 97US-0059729P.  
 PR 17-SEP-1997; 97US-0059731P.  
 PR 17-SEP-1997; 97US-0059733P.  
 PR 17-SEP-1997; 97US-0059735P.  
 PR 17-SEP-1997; 97US-0059737P.  
 PR 17-SEP-1997; 97US-0059739P.  
 PR 17-SEP-1997; 97US-0059741P.  
 PR 17-SEP-1997; 97US-0059743P.  
 PR 17-SEP-1997; 97US-0059745P.  
 PR 17-SEP-1997; 97US-0059747P.  
 PR 17-SEP-1997; 97US-0059749P.  
 PR 17-SEP-1997; 97US-0059751P.  
 PR 17-SEP-1997; 97US-0059753P.  
 PR 17-SEP-1997; 97US-0059755P.  
 PR 17-SEP-1997; 97US-0059757P.  
 PR 17-SEP-1997; 97US-0059759P.  
 PR 17-SEP-1997; 97US-0059761P.  
 PR 17-SEP-1997; 97US-0059763P.  
 PR 17-SEP-1997; 97US-0059765P.  
 PR 17-SEP-1997; 97US-0059767P.  
 PR 17-SEP-1997; 97US-0059769P.  
 PR 17-SEP-1997; 97US-0059771P.  
 PR 17-SEP-1997; 97US-0059773P.  
 PR 17-SEP-1997; 97US-0059775P.  
 PR 17-SEP-1997; 97US-0059777P.  
 PR 17-SEP-1997; 97US-0059779P.  
 PR 17-SEP-1997; 97US-0059781P.  
 PR 17-SEP-1997; 97US-0059783P.  
 PR 17-SEP-1997; 97US-0059785P.  
 PR 17-SEP-1997; 97US-0059787P.  
 PR 17-SEP-1997; 97US-0059789P.  
 PR 17-SEP-1997; 97US-0059791P.  
 PR 17-SEP-1997; 97US-0059793P.  
 PR 17-SEP-1997; 97US-0059795P.  
 PR 17-SEP-1997; 97US-0059797P.  
 PR 17-SEP-1997; 97US-0059799P.  
 PR 17-SEP-1997; 97US-0059801P.  
 PR 17-SEP-1997; 97US-0059803P.  
 PR 17-SEP-1997; 97US-0059805P.  
 PR 17-SEP-1997; 97US-0059807P.  
 PR 17-SEP-1997; 97US-0059809P.  
 PR 17-SEP-1997; 97US-0059811P.  
 PR 17-SEP-1997; 97US-0059813P.  
 PR 17-SEP-1997; 97US-0059815P.  
 PR 17-SEP-1997; 97US-0059817P.  
 PR 17-SEP-1997; 97US-0059819P.  
 PR 17-SEP-1997; 97US-0059821P.  
 PR 17-SEP-1997; 97US-0059823P.  
 PR 17-SEP-1997; 97US-0059825P.  
 PR 17-SEP-1997; 97US-0059827P.  
 PR 17-SEP-1997; 97US-0059829P

PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0143698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US033565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX XX  
  
XX (GETH ) GENENTECH INC.  
XX PA  
XX PA  
XX Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME, Goddard A;  
PI Godowski PV, Grimaldi JC, Gurney AL, Hillan KJ, Klavin LJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart RA, Tumas D;  
PI Williams PM, Wood WI;  
XX XX  
XX WPI; 2003-417249/39.  
DR P-PSDB; ABO14951.  
XX XX  
XX PT Novel secreted and transmembrane polypeptides and polynucleotides  
XX encoding them useful for treating abnormal bleeding involved in  
XX gynecological diseases, skin diseases and neurodegenerative diseases.  
XX XX  
XX Claim 2; Fig 97; 467pp; English.  
XX XX  
XX The invention relates to an isolated secreted and transmembrane PRO  
XX polypeptide. The PRO polypeptides are useful for modulating biological  
XX activity of a cell, in diagnosing or treating abnormal bleeding involved  
XX in gynaecological diseases e.g. to avoid or lessen the need for  
XX hysterectomy, for treating angiogenesis, tumour, coronary ischaemic  
XX condition, disorders associated with the preservation and maintenance of  
XX gastrointestinal mucosa and the repair of acute and chronic mucosal  
XX lesions, skin diseases associated with abnormal keratinocyte  
XX differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
XX disease, amyotrophic lateral sclerosis (ALS), neuropathies, disease  
XX related to uncontrolled cell growth (e.g. cancer), blood coagulation  
XX cascade disorders, neurodegenerative disease, thrombosis, haemorrhage,  
XX endometrial bleeding, wound healing, tissue repair, asthma, rheumatoid  
XX arthritis, multiple sclerosis. Nucleic acid encoding PRO polypeptides are  
XX useful in molecular biology including uses as hybridisation probes and in  
XX the generation of antisense RNA and DNA, for preparing PRO polypeptides,  
XX for generating transgenic animals or knockout animals. The PRO  
XX polypeptides and their nucleic acids are useful for tissue typing. PRO  
XX antibodies are useful for immunohistochemical staining and/or assay of  
XX sample fluids. Anti-PRO antibodies are useful in diagnostic assays for  
XX PRO e.g. detecting its expression in specific cells, tissues or serum and  
XX for affinity purification of PRO from recombinant cell culture or natural  
XX sources. The present sequence represents cDNA encoding a human secreted  
XX and transmembrane PRO polypeptide  
XX XX  
XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other  
SQ

|  |   |
|--|---|
| Query Match  | 0.78; Score 24.6; DB 1; Length 1378;                                      |
| Best Local Similarity  | 53.7%; Pred. No. 26;  |
| Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0; |   |
| QY   | 2983 TCTATTCTACTTTAAATGCACTTATTTTATTGATTTCTTAATAAAATCCAGTCCTTGT 3042      |
| DB   | 1272 TTTTGTGATATAAAGTAAATGATTTTATAGGATTTTGTAACCTGCCACATATCTT 1331         |
| QY   | 3043 TTTTTTAAAAAGACTTTAAAAATTATTAAATTTCTCT 3077                           |
| DB   | 1332 ATTATTCTCCCAATTTCAATAAATTATTATTCT 1366                               |
| RESULT 52  |   |
| ADB29467   | ID ADB29467 standard; cDNA; 1378 BP.                                      |
| XX   | XX  |
| AC   | ADB29467;   |
| XX   | XX  |
| DT   | 20-NOV-2003 (first entry)   |
| XX   | XX  |
| DE   | Human secreted/transmembrane protein cDNA, #52.                           |
| XX   | XX  |
| KW   | Human; gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;   |
| KW   | mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;    |
| KW   | Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis; |
| KW   | ALS; neuropathy; cell growth; cancer; tumour; viral infection;            |
| KW   | neurodegenerative disease; antithrombotic agent; haemorrhage;             |
| KW   | endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic; |
| KW   | tissue typing; immunohistochemical staining; gene therapy; neurotropic;   |
| KW   | neuroprotective; cytoskeletal; virucide; anticoagulant.                   |

[illegible]

PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065653P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069455P.  
 PR 04-JUN-1998; 98US-0088026P.  
 PR 10-SEP-1998; 98US-0099803P.  
 PR 10-SEP-1998; 98US-0099824P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 16-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98US-0109304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 99US-0143048P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99US-0202094P.  
 PR 13-SEP-1999; 99US-0202094P.  
 PR 15-SEP-1999; 99US-0202109P.  
 PR 15-SEP-1999; 99US-0202154P.  
 PR 05-OCT-1999; 99US-0203089P.  
 PR 29-NOV-1999; 99US-0208214P.  
 PR 30-NOV-1999; 99US-0208313P.  
 PR 01-DEC-1999; 99US-0208301P.  
 PR 02-DEC-1999; 99US-0208364P.  
 PR 16-DEC-1999; 99US-0208365P.  
 PR 20-DEC-1999; 99US-0208365P.  
 PR 20-DEC-1999; 99US-0208365P.  
 PR 05-JAN-2000; 2000US-0000219P.  
 PR 11-FEB-2000; 2000US-0003565P.  
 PR 22-FEB-2000; 2000US-0004414P.  
 PR 22-FEB-2000; 2000US-0005044P.  
 PR 02-MAR-2000; 2000US-0005841P.  
 PR 30-MAR-2000; 2000US-0007377P.  
 PR 30-MAR-2000; 2000US-0008439P.  
 PR 22-MAY-2000; 2000US-0014042P.  
 PR 02-JUN-2000; 2000US-0015264P.  
 PR 28-JUL-2000; 2000US-0020710P.  
 PR 24-AUG-2000; 2000US-0023328P.  
 PR 18-SEP-2000; 2000US-00665350P.  
 PA (GETH) GENENTECH INC.  
 XX Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams FW, Wood WI;  
 XX WPI; 2003-765473/72.  
 DR P-ESDB; ADB29468.  
 XX Novel isolated native PRO polypeptide useful for treating Parkinson's  
 PT disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal

PT ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usher  
 PT syndrome.  
 PS Claim 2; Fig 97; 469pp; English.  
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
 and the nucleic acid encoding them. The polypeptides can be used to raise  
 antibodies that specifically bind to the PRO polypeptide, for linking a  
 bioactive molecule to a cell expressing a PRO protein and for modulating  
 at least one biological activity of a cell. PRO polypeptides are useful  
 for detecting other PRO polypeptides in a sample and for linking a  
 bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 polypeptide antibodies are useful for modulating the biological activity  
 of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
 for treating disorders associated with the preservation and maintenance  
 of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 lesions, skin diseases associated with abnormal keratinocyte  
 differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
 diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 PRO polypeptides also serve as tumour specific antigens which may be  
 exploited as therapeutic targets for anti-tumour drugs, and are also  
 employed therapeutically in vivo for lessening the effects of viral  
 infection. The PRO polypeptides can be also used in assays to determine  
 if it has a role in neurodegenerative diseases or their reversal, as an  
 antithrombotic agent with reduced risk for haemorrhage as compared with  
 heparin, in treating other PRO-associated disorders, in modulating  
 endometrial bleeding angiogenesis, and may also have an effect on kidney  
 tissue. PRO polypeptides and their portions affect the expression of  
 genes which have a role in apoptosis. The polynucleotides are useful in  
 molecular biology including uses as hybridisation probes for cDNA library  
 to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 for preparing PRO polypeptides, for generating transgenic animals or  
 knockout animals which are useful in the development and screening of  
 therapeutically useful reagents, as probes and for the genetic analysis  
 of individuals with genetic disorders as well as for recombinantly  
 expressing the protein and for chromosome identification. The proteins  
 are useful as molecular marker for protein electrophoresis purposes, as  
 therapeutic agents, for screening compounds to identify those that mimic  
 the PRO polypeptide (agonists) or prevent the effect of the PRO  
 polypeptide (antagonists). The polynucleotides and proteins are useful  
 for tissue typing. PRO antibodies are useful for immunohistochemical  
 staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 diagnostic assays for PRO e.g. detecting its expression in specific  
 cells, tissues or serum and for affinity purification of PRO from  
 recombinant cell culture or natural sources. The PRO genes may also be  
 used in gene therapy, particularly for replacing a defective gene. The  
 sequence presented is a gene encoding a PRO polynucleotide of the  
 invention.

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 Qy 2983 TCTATTTTCTTTAATGACACTATTTTATGATTTTCTTAATAAATCAGCTCTGT 3042  
 Db 1272 TTTTGTATATAATGTTAATGATTTTATGATTTTCTTAATAAATCAGCTCTGT 1331  
 Qy 3043 TTTTAAAAAGACITTTAAATTTATTTATTTCTCT 3077  
 Db 1332 ATTTATCTCCATTTCAATTAATTTATTTCT 1366  
 RESULT 53  
 ADAL8323  
 ID ADAL8323 standard; cDNA; 1378 BP.  
 XX  
 AC ADAL8323;  
 XX  
 DT 20-NOV-2003 (first entry)





CC employed therapeutically in vivo for lessening the effects of viral  
CC infection. The PRO polypeptides can be also used in assays to determine  
CC if it has a role in neurodegenerative diseases or their reversal, as an  
CC antithrombotic agent with reduced risk for haemorrhage as compared with  
CC heparin, in treating other PRO-associated disorders, in modulating  
CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
CC tissue. PRO polypeptides and their portions affect the expression of  
CC genes which have a role in apoptosis. The polynucleotides are useful in  
CC molecular biology including uses as hybridisation probes for cDNA library  
CC to isolate the full-length PRO cDNA or to isolate other cDNAs in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC for preparing PRO polypeptides, for generating transgenic animals or  
CC knockout animals which are useful in the development and screening of  
CC therapeutically useful reagents, as probes and for the genetic analysis  
CC of individuals with genetic disorders as well as for recombinantly  
CC expressing the protein and for chromosome identification. The proteins  
CC are useful as molecular marker for protein electrophoresis purposes, as  
CC therapeutic agents, for screening compounds to identify those that mimic  
CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
CC polypeptide (antagonists). The polynucleotides and proteins are useful  
CC for tissue typing. PRO antibodies are useful for immunohistochemical  
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
CC diagnostic assays for PRO e.g. detecting its expression in specific  
CC cells, tissues or serum and for affinity purification of PRO from  
CC recombinant cell culture or natural sources. The PRO genes may also be  
CC used in gene therapy, particularly for replacing a defective gene. The  
CC sequence presented is a gene encoding a PRO polynucleotide of the  
CC invention.

XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;

Best Local Similarity 53.7%; Pred. No. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTACTTTTAACTGACCTTATTTTATGTTTCTTATTAATAAATCCAGTCCTTCT 3042  
DB 1272 TTTTGTATATAAATGTAATGTTTATGATTTTATGATTTTGAACCTGCCCCACATATCT 1331  
OY 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077  
DB 1332 ATTATTCCTCAATTCATATAAATTTATTTCT 1366

RESULT 54

ACD67004 ID ACD67004 standard; cDNA; 1378 BP.

XX AC ACD67004;

XX DT 17-SEP-2003 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein PRO343.

XX KW Human; ss; gene; PRO; secreted and transmembrane protein; inflammation;  
XX KW rheumatoid arthritis; psoriasis; multiple sclerosis; atherosclerosis;  
XX KW infertility; birth defect; premature aging; malignancy; cancer; stroke;  
XX KW heart attack; hypertension; gastrointestinal ulceration;  
XX KW Parkinson's disease; Alzheimer's disease; AIDS; cholesterol uptake;  
XX KW wound healing; tissue repair; gene therapy.

XX OS Homo sapiens.

XX PN US2003045693-A1.

XX PD 06-MAR-2003.

XX PF 11-JUL-2001; 2001US-00593749.

XX PR 17-SEP-1997; 97US-0059113P.

XX PR 17-SEP-1997; 97US-0059115P.

XX PR 17-SEP-1997; 97US-0059117P.

XX PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063412P.  
PR 28-OCT-1997; 97US-006342P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063722P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 16-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 98US-0143048P.  
PR 26-JUL-1999; 98US-0145698P.  
PR 28-JUL-1999; 98US-0145222P.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 05-OCT-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 01-DEC-1999; 98WO-US028301.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030055.

[illegible]



27-OCT-1997; 97US-00633329P.  
28-OCT-1997; 97US-00633541P.  
28-OCT-1997; 97US-00635442P.  
28-OCT-1997; 97US-00635443P.  
28-OCT-1997; 97US-00635444P.  
28-OCT-1997; 97US-00635499P.  
28-OCT-1997; 97US-00635508P.  
28-OCT-1997; 97US-00635642P.  
29-OCT-1997; 97US-00634335P.  
29-OCT-1997; 97US-00637048P.  
29-OCT-1997; 97US-00637332P.  
29-OCT-1997; 97US-00637342P.  
29-OCT-1997; 97US-00637352P.  
29-OCT-1997; 97US-00637382P.  
29-OCT-1997; 97US-00642152P.  
31-OCT-1997; 97US-00638708P.  
31-OCT-1997; 97US-00641033P.  
31-OCT-1997; 97US-00642488P.  
03-NOV-1997; 97US-00644809P.  
12-NOV-1997; 97US-00651862P.  
17-NOV-1997; 97US-00658462P.  
18-NOV-1997; 97US-00656932P.  
21-NOV-1997; 97US-00661202P.  
21-NOV-1997; 97US-00663646P.  
24-NOV-1997; 97US-00664533P.  
24-NOV-1997; 97US-00664666P.  
24-NOV-1997; 97US-00665112P.  
24-NOV-1997; 97US-00667702P.  
24-NOV-1997; 97US-00668442P.  
25-NOV-1997; 97US-00684252P.  
04-JUN-1998; 98US-00880282P.  
10-SEP-1998; 98US-00998032P.  
10-SEP-1998; 98US-00998033P.  
14-SEP-1998; 98US-01002622P.  
14-SEP-1998; 98US-01019177P.  
16-SEP-1998; 98US-01019330P.  
17-SEP-1998; 98US-01068582P.  
17-SEP-1998; 98US-01094377P.  
13-OCT-1998; 98US-01040802P.  
20-NOV-1998; 98US-01093042P.  
01-DEC-1998; 98US-01132962P.  
22-DEC-1998; 98US-01132962P.  
07-JUL-1999; 99US-01430482P.  
26-JUL-1999; 99US-01456982P.  
28-JUL-1999; 99US-01462232P.  
08-SEP-1999; 99US-01462232P.  
13-SEP-1999; 99US-02020594P.  
13-SEP-1999; 99US-02020944P.  
15-SEP-1999; 99US-02021030P.  
15-SEP-1999; 99US-02021547P.  
05-OCT-1999; 99US-02030899P.  
29-NOV-1999; 99US-02082214P.  
30-NOV-1999; 99US-02082214P.  
01-DEC-1999; 99US-02083013P.  
02-DEC-1999; 99US-02083013P.  
02-DEC-1999; 99US-02083584P.  
02-DEC-1999; 99US-02083585P.  
16-DEC-1999; 99US-02083585P.  
20-DEC-1999; 99US-02083585P.  
20-DEC-1999; 99US-02083585P.  
05-JAN-2000; 2000US-0000219P.  
11-FEB-2000; 2000US-00003565P.  
22-FEB-2000; 2000US-00004414P.  
24-FEB-2000; 2000US-00005004P.  
02-MAR-2000; 2000US-00005841P.  
20-MAR-2000; 2000US-00007377P.  
30-MAR-2000; 2000US-00008439P.  
22-MAY-2000; 2000US-0014042P.  
02-JUN-2000; 2000US-0015264P.  
28-JUL-2000; 2000US-0020710P.  
24-AUG-2000; 2000US-0023328P.  
18-SEP-2000; 2000US-00665350P.  
  
(GETH ) GENENTECH INC.,  
XX  
PA  
XX

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Forg S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kiljavin IJ;  
PI Macher JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI; 2003-521801/49.  
DR P-PSDB; ADA16299.  
XX  
PT New genes encoding for secreted and transmembrane PRO polypeptides,  
PT useful for treating e.g. cardiac insufficiency disorders, wounds,  
PT cancer, obesity, diabetes, hyperinsulinemia, hypoinsulinemia, or  
PT arthritis.  
XX  
PS Claim 2; SEQ ID NO 262; 476pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing C-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinemia,  
CC hypopigmentation, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polynucleotide of the invention.  
XX  
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
  
QY 2983 TCTATTTTACTTTTAAATTCACCTTTATTTTATTTGATTTTCTTAAATAAATCAGCTCTTGT 3042  
Db 1272 TTTTGTGTATATAAATGTTATGATTTTATAGTATTTTGTACCTGCCCATATCTT 1331  
QY 3043 TTTTAAAAAGACTTTAAATTTATTTCTCT 3077  
Db 1332 ATTATTCTCTCAATTTCAATAAATTTATTTCT 1366



polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. PRO polypeptides are also useful for treating disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions, skin diseases associated with abnormal keratinocyte differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's diseases, amyotrophic lateral sclerosis (ALS), neuropathies and additionally, disease related to uncontrolled cell growth, e.g. cancer. PRO polypeptides also serve as tumour specific antigens which may be exploited as therapeutic targets for anti-tumour drugs, and are also employed therapeutically in vivo for lessening the effects of viral infection. The PRO polypeptides can be also used in assays to determine if it has a role in neurodegenerative diseases or their reversal, as an antithrombotic agent with reduced risk for haemorrhage as compared with heparin, in treating other PRO-associated disorders, in modulating endometrial bleeding angiogenesis, and may also have an effect on kidney tissue. PRO polypeptides and their portions affect the expression of genes which have a role in apoptosis. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a gene encoding a PRO polynucleotide of the invention.

Sequence 1378 BP; 235 A; 451 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTATTAATTCGACTTATTTTATTTGATTTTCTAATAAATCCAGTCCTTGT 3042  
DB 1272 TTTTGTATATAATGTTATGATTTTATAGGTATTTGACCTGCCCATATCTT 1331  
QY 3043 TTTTAAAGACTTTAAATTTATTTCTCT 3077  
DB 1332 ATTTATCTCCATTTCAATAAATTTATTTCT 1366

RESULT 58

ACD23343  
ID ACD23343 standard; cDNA; 1378 BP.

XX ACD23343;

XX 26-AUG-2003 (first entry)

XX Human PRO polynucleotide #48.

XX Human; PRO; gene; ss; Parkinson's disease; Alzheimer's disease; ALS;  
KW amyotrophic lateral sclerosis; neuropathy; cancer; viral infection; AIDS;  
KW Usher's syndrome; haemorrhage; enterocolitis; Zollinger-Ellison syndrome;  
KW gastrointestinal ulceration; congenital microvillus atrophy; psoriasis;  
KW skin disease; endometrial bleeding; angiogenesis; ischaemic condition;  
KW asthma; rheumatoid arthritis; multiple sclerosis; inflammatory disease;  
KW atherosclerosis; infertility; birth defect; premature aging; stroke;  
KW diabetic complication.

OS Homo sapiens.  
XX US2003064367-A1.  
XX 03-APR-2003.  
XX 13-JUL-2001; 2001US-00904485.  
XX 17-SEP-1997; 97US-0059113P.  
XX 17-SEP-1997; 97US-0059115P.  
XX 17-SEP-1997; 97US-0059117P.  
XX 17-SEP-1997; 97US-0059119P.  
XX 17-SEP-1997; 97US-0059121P.  
XX 17-SEP-1997; 97US-0059122P.  
XX 17-SEP-1997; 97US-0059184P.  
XX 18-SEP-1997; 97US-0059263P.  
XX 18-SEP-1997; 97US-0059266P.  
XX 15-OCT-1997; 97US-0062125P.  
XX 17-OCT-1997; 97US-0062285P.  
XX 17-OCT-1997; 97US-0062287P.  
XX 21-OCT-1997; 97US-0063486P.  
XX 24-OCT-1997; 97US-0062814P.  
XX 24-OCT-1997; 97US-0062816P.  
XX 24-OCT-1997; 97US-0063045P.  
XX 24-OCT-1997; 97US-0063120P.  
XX 24-OCT-1997; 97US-0063121P.  
XX 24-OCT-1997; 97US-0063127P.  
XX 24-OCT-1997; 97US-0063128P.  
XX 27-OCT-1997; 97US-0063327P.  
XX 27-OCT-1997; 97US-0063329P.  
XX 28-OCT-1997; 97US-0063541P.  
XX 28-OCT-1997; 97US-0063542P.  
XX 28-OCT-1997; 97US-0063544P.  
XX 28-OCT-1997; 97US-0063549P.  
XX 28-OCT-1997; 97US-0063550P.  
XX 28-OCT-1997; 97US-0063564P.  
XX 29-OCT-1997; 97US-0063435P.  
XX 29-OCT-1997; 97US-0063704P.  
XX 29-OCT-1997; 97US-0063732P.  
XX 29-OCT-1997; 97US-0063734P.  
XX 29-OCT-1997; 97US-0063735P.  
XX 29-OCT-1997; 97US-0063738P.  
XX 29-OCT-1997; 97US-0064215P.  
XX 31-OCT-1997; 97US-0063870P.  
XX 31-OCT-1997; 97US-0064103P.  
XX 03-NOV-1997; 97US-0064248P.  
XX 07-NOV-1997; 97US-0064809P.  
XX 12-NOV-1997; 97US-0065186P.  
XX 17-NOV-1997; 97US-0065346P.  
XX 18-NOV-1997; 97US-0065593P.  
XX 21-NOV-1997; 97US-0066120P.  
XX 21-NOV-1997; 97US-0066364P.  
XX 24-NOV-1997; 97US-0066453P.  
XX 24-NOV-1997; 97US-0066466P.  
XX 24-NOV-1997; 97US-0066511P.  
XX 24-NOV-1997; 97US-0066770P.  
XX 25-NOV-1997; 97US-0066840P.  
XX 12-DEC-1997; 97US-0069425P.  
XX 04-JUN-1998; 98US-0088026P.  
XX 10-SEP-1998; 98US-0099803P.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98US-0100262P.  
XX 16-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98US-0100598P.  
XX 17-SEP-1998; 98WO-US019437.  
XX 13-OCT-1998; 98US-0104080P.  
XX 20-NOV-1998; 98US-0109304P.  
XX 01-DEC-1998; 98WO-US025108.  
XX 22-DEC-1998; 98US-0113296P.  
XX 07-JUL-1999; 99US-0143048P.  
XX 26-JUL-1999; 99US-0145698P.









CC of individuals with genetic disorders as well as for recombinantly  
CC expressing the protein and for chromosome identification. The proteins  
CC are useful as molecular marker for protein electrophoresis purposes, as  
CC therapeutic agents, for screening compounds to identify those that mimic  
CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
CC polypeptide (antagonists). The polynucleotides and proteins are useful  
CC for tissue typing. PRO antibodies are useful for immunohistochemical  
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
CC diagnostic assays for PRO e.g. detecting its expression in specific  
CC cells, tissues or serum and for affinity purification of PRO from  
CC recombinant cell culture or natural sources. The PRO genes may also be  
CC used in gene therapy, particularly for replacing a defective gene. The  
CC sequence presented is a gene encoding a PRO polynucleotide of the  
CC invention.

XX  
SQ Sequence 1378 BP; 235 A; 451 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;

Best Local Similarity 53.7%; Pred. No. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTCACCTTAAATTCACCTTATTTTATTTGATTTTCTAATAAATCCAGTCTTCT 3042

Db 1272 TTTTGTGATATAAATGTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331

QY 3043 TTTTATAAAGACCTTAAATTTATTAATTTCTCT 3077

Db 1332 ATTATTCCTCAATTCATTAATAAATTTATTTCT 1366

#### RESULT 61

ADA42019

ID ADA42019 standard; cDNA; 1378 BP.

AC ADA42019;

DT 20-NOV-2003 (first entry)

DE Human secreted/transmembrane protein cDNA, #52.

KW Human; Gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;  
KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;  
KW Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis;  
KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;  
KW neurodegenerative disease; antithrombotic agent; haemorrhage;  
KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy; nootropic;  
KW neuroprotective; cyrostatic; virucide; anticoagulant.

OS Homo sapiens.

PN US2003082540-A1.

PD 01-MAY-2003.

PF 10-JUL-2001; 2001US-00902634.

PR 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 18-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 15-OCT-1997; 97US-0062185P.

PR 17-OCT-1997; 97US-0062285P.

PR 21-OCT-1997; 97US-0062287P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063341P.  
PR 28-OCT-1997; 97US-0063342P.  
PR 28-OCT-1997; 97US-0063344P.  
PR 28-OCT-1997; 97US-0063349P.  
PR 28-OCT-1997; 97US-0063500P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 16-SEP-1998; 98US-0100330P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100913P.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-0109304P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145588P.  
PR 08-SEP-1999; 99US-0146222P.  
PR 08-SEP-1999; 99US-0146222P.  
PR 13-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 05-OCT-1999; 99US-0146222P.  
PR 29-NOV-1999; 99US-0146222P.  
PR 30-NOV-1999; 99US-0146222P.  
PR 01-DEC-1999; 99US-0146222P.  
PR 02-DEC-1999; 99US-0146222P.  
PR 02-DEC-1999; 99US-0146222P.  
PR 16-DEC-1999; 99US-0146222P.  
PR 20-DEC-1999; 99US-0146222P.  
PR 05-JAN-2000; 2000US-0000219.  
PR 11-FEB-2000; 2000US-0000219.  
PR 22-FEB-2000; 2000US-0000219.  
PR 24-FEB-2000; 2000US-0000219.  
PR 02-MAR-2000; 2000US-0000219.  
PR 20-MAR-2000; 2000US-0000219.  
PR 30-MAR-2000; 2000US-0000219.  
PR 22-MAY-2000; 2000US-0000219.  
PR 02-JUN-2000; 2000US-0000219.  
PR 28-JUL-2000; 2000US-0000219.

PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX (GETH ) GENENTECH INC.  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Klijavin IG;  
PI Mather JP, Pan J, Paoni NF, Roy WA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI; 2003-755103/71.  
DR P-PSDB; ADA42020.  
XX  
XX New PRO polypeptides useful for treating Parkinson's disease,  
PT enterocolitis, Zollinger-Ellison syndrome gastrointestinal ulceration,  
PT Alzheimer's disease, amyotrophic lateral sclerosis and Usher syndrome.  
XX  
XX Claim 2; SEQ ID NO 262; 468pp; English.  
XX  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
CC for treating disorders associated with the preservation and maintenance  
CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
CC lesions, skin diseases associated with abnormal keratinocyte  
CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
CC PRO polypeptides also serve as tumour specific antigens which may be  
CC exploited as therapeutic targets for anti-tumour drugs, and are also  
CC employed therapeutically in vivo for lessening the effects of viral  
CC infection. The PRO polypeptides can be also used in assays to determine  
CC if it has a role in neurodegenerative diseases or their reversal, as an  
CC antithrombotic agent with reduced risk for haemorrhage as compared with  
CC heparin, in treating other PRO-associated disorders, in modulating  
CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
CC tissue. PRO polypeptides and their portions affect the expression of  
CC genes which have a role in apoptosis. The polynucleotides are useful in  
CC molecular biology including uses as hybridisation probes for cDNA library  
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC for preparing PRO polypeptides, for generating transgenic animals or  
CC knockout animals which are useful in the development and screening of  
CC therapeutically useful reagents, as probes and for the genetic analysis  
CC of individuals with genetic disorders as well as for recombinantly  
CC expressing the protein and for chromosome identification. The proteins  
CC are useful as molecular marker for protein electrophoresis purposes, as  
CC therapeutic agents, for screening compounds to identify those that mimic  
CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
CC polypeptide (antagonists). The polynucleotides and proteins are useful  
CC for tissue typing. PRO antibodies are useful for immunohistochemical  
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
CC diagnostic assays for PRO e.g. detecting its expression in specific  
CC cells, tissues or serum and for affinity purification of PRO from  
CC recombinant cell culture or natural sources. The PRO genes may also be  
CC used in gene therapy, particularly for replacing a defective gene. The  
CC sequence presented is a gene encoding a PRO polynucleotide of the  
CC invention.  
XX  
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

OY 2983 TCTATTTTACTTTAATTCGACCTATTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042

Db 1272 TTTTGTGTATATAAATGCTTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331  
OY 3043 TTTTAAAAAGACTTTAAAAATTTAAATTTCTCT 3077  
Db 1332 ATTATTTCTCCCAATTTCAATAAATTTATTTATCTT 1366  
RESULT 62  
ADAL7366  
ID ADAL7366 standard; cDNA; 1378 BP.  
XX AC ADAL7366;  
XX AC ADAL7366;  
XX 20-NOV-2003 (first entry)  
XX Human secreted/transmembrane protein cDNA, #52.  
XX Human; Gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;  
KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;  
KW Parkinson's disease; Alzheimer's diseases; amyotrophic lateral sclerosis;  
KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;  
KW neurodegenerative disease; antithrombotic agent; haemorrhage;  
KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy; neurotropic;  
KW neuroprotective; cytostatic; virucide; anticoagulant.  
XX Homo sapiens.  
XX US2003017498-A1.  
XX 23-JAN-2003.  
XX 17-JUL-2001; 2001US-00908093.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063341P.  
PR 28-OCT-1997; 97US-0063342P.  
PR 28-OCT-1997; 97US-0063344P.  
PR 28-OCT-1997; 97US-0063345P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063722P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.

PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065894P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066433P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088036P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98US-0100262P.  
PR 16-SEP-1998; 98US-0100262P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0105304P.  
PR 01-DEC-1998; 98US-0105304P.  
PR 22-DEC-1998; 98US-0113295P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99US-0146222P.  
PR 13-SEP-1999; 99US-0202094P.  
PR 15-SEP-1999; 99US-0202094P.  
PR 15-SEP-1999; 99US-0202094P.  
PR 15-SEP-1999; 99US-0202109P.  
PR 15-SEP-1999; 99US-0202154P.  
PR 05-OCT-1999; 99US-0202154P.  
PR 29-NOV-1999; 99US-0202814P.  
PR 30-NOV-1999; 99US-0202814P.  
PR 01-DEC-1999; 99US-0202830P.  
PR 01-DEC-1999; 99US-0202830P.  
PR 02-DEC-1999; 99US-0202856P.  
PR 16-DEC-1999; 99US-0202856P.  
PR 16-DEC-1999; 99US-0202856P.  
PR 20-DEC-1999; 99US-0203091P.  
PR 20-DEC-1999; 99US-0203091P.  
PR 05-JAN-2000; 2000US-030999P.  
PR 11-FEB-2000; 2000US-030999P.  
PR 22-FEB-2000; 2000US-030999P.  
PR 24-FEB-2000; 2000US-030999P.  
PR 20-MAR-2000; 2000US-030999P.  
PR 30-MAR-2000; 2000US-030999P.  
PR 22-MAY-2000; 2000US-030999P.  
PR 02-JUN-2000; 2000US-030999P.  
PR 28-JUL-2000; 2000US-030999P.  
PR 24-AUG-2000; 2000US-030999P.  
PR 18-SEP-2000; 2000US-030999P.  
XX (GETH) GENENTECH INC.  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WT;  
DR WPI; 2003-531434/50.  
DR P-PSDB; ADA17367.  
XX  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or  
PT PRO1868, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX  
XX Claim 2; SEQ ID NO 262; 475pp; English.  
PS The invention discloses isolated PRO secreted/transmembrane polypeptides  
XX and the nucleic acid encoding them. The polypeptides can be used to raise  
CC and the nucleic acid encoding them. The polypeptides can be used to raise

CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC biactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC biactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
CC for treating disorders associated with the preservation and maintenance  
CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
CC lesions, skin diseases associated with abnormal keratinocyte  
CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
CC additionally, disease related to uncontrolled cell growth, e.g. cancer.  
CC PRO polypeptides also serve as tumour specific antigens which may be  
CC exploited as therapeutic targets for anti-tumour drugs and are also  
CC employed therapeutically in vivo for lessening the effects of viral  
CC infection. The PRO polypeptides can be also used in assays to determine  
CC if it has a role in neurodegenerative diseases or their reversal, as an  
CC antithrombotic agent with reduced risk for haemorrhage as compared with  
CC heparin, in treating other PRO-associated disorders, in modulating  
CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
CC tissue. PRO polypeptides and their portions affect the expression of  
CC genes which have a role in apoptosis. The polynucleotides are useful in  
CC molecular biology including uses as hybridisation probes for cDNA library  
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC for preparing PRO polypeptides, for generating transgenic animals or  
CC knockout animals which are useful in the development and screening of  
CC therapeutically useful reagents, as probes and for the genetic analysis  
CC of individuals with genetic disorders as well as for recombinantly  
CC expressing the protein and for chromosome identification. The proteins  
CC are useful as molecular marker for protein electrophoresis purposes, as  
CC therapeutic agents, for screening compounds to identify those that mimic  
CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
CC polypeptide (antagonists). The polynucleotides and proteins are useful  
CC for tissue typing. PRO antibodies are useful for immunohistochemical  
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
CC diagnostic assays for PRO e.g. detecting its expression in specific  
CC cells, tissues or serum and for affinity purification of PRO from  
CC recombinant cell culture or natural sources. The PRO genes may also be  
CC used in gene therapy, particularly for replacing a defective gene. The  
CC sequence presented is a gene encoding a PRO polynucleotide of the  
XX invention.

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.78; Score 24.6; DB 1; Length 1378;

Best Local Similarity 53.78; Pred. No. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTTAAATGCGACTTTATTTTATTTGATTTTCTAATAAAATCCAGTCCTCT 3042

Db 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGGTTATTTGTAACCTGCCACATATCT 1331

QY 3043 TTTTAAAGACTTTAAATTTATTTATTTCTCT 3077

Db 1332 ATTATTCCTCAATTTCAATAAATTTATTTCT 1366

RESULT 63

ADA42869

ID ADA42869 standard; cDNA; 1378 BP.

XX ADA42869;

XX ADA42869;

XX 20-NOV-2003 (first entry)

XX Human secreted/transmembrane protein cDNA, #52.

XX Human; gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;  
KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;  
KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;  
KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;

neurodegenerative disease; antithrombotic agent; haemorrhage;  
endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;  
tissue typing; immunohistochemical staining; gene therapy; nootropic;  
neuroprotective; cytostatic; virucide; anticoagulant.

XX Homo sapiens.  
XX US2003054351-A1.  
XX 20-MAR-2003.

XX 13-JUL-2001; 2001US-00904462.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059123P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062288P.  
PR 17-OCT-1997; 97US-0062289P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062818P.  
PR 24-OCT-1997; 97US-0063040P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063545P.  
PR 28-OCT-1997; 97US-0063546P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066468P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0086026P.  
PR 10-SEP-1998; 98US-0098033P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100859P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.

PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005941.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

PI Askenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillen KJ, Kijavins IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI; 2003-755052/71.  
XX P-PSDB; ADA42870.

PT Novel isolated secreted and transmembrane PRO polypeptide, useful for  
PT tissue typing, treating Parkinson's disease, Alzheimer's disease, birth  
PT defects, cancer.

XX Claim 2; SEQ ID NO 262; 464pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
XX and the nucleic acid encoding them. The polypeptides can be used to raise  
XX antibodies that specifically bind to the PRO polypeptide, for linking a  
XX bioactive molecule to a cell expressing a PRO protein and for modulating  
XX at least one biological activity of a cell. PRO polypeptides are useful  
XX for detecting other PRO polypeptides in a sample and for linking a  
XX bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
XX polypeptide antibodies are useful for modulating the biological activity  
XX of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
XX for treating disorders associated with the preservation and maintenance  
XX of gastrointestinal mucosa and the repair of acute and chronic mucosal  
XX lesions, skin diseases associated with abnormal keratinocyte  
XX differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
XX diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
XX additionally, disease related to uncontrolled cell growth, e.g. cancer.  
XX PRO polypeptides also serve as tumour specific antigens which may be  
XX exploited as therapeutic targets for anti-tumour drugs, and are also  
XX employed therapeutically in vivo for lessening the effects of viral  
XX infection. The PRO polypeptides can be also used in assays to determine  
XX if it has a role in neurodegenerative diseases or their reversal, as an  
XX antithrombotic agent with reduced risk for haemorrhage as compared with  
XX heparin, in treating other PRO-associated disorders, in modulating  
XX endometrial bleeding angiogenesis, and may also have an effect on kidney  
XX tissue. PRO polypeptides and their portions affect the expression of



|              |                  |
|--------------|------------------|
| 24-OCT-1997; | 97US-0062811P;   |
| 24-OCT-1997; | 97US-0062816P;   |
| 24-OCT-1997; | 97US-0063045P;   |
| 24-OCT-1997; | 97US-0063120P;   |
| 24-OCT-1997; | 97US-0063121P;   |
| 24-OCT-1997; | 97US-0063127P;   |
| 24-OCT-1997; | 97US-0063128P;   |
| 24-OCT-1997; | 97US-0063327P;   |
| 24-OCT-1997; | 97US-0063541P;   |
| 24-OCT-1997; | 97US-0063542P;   |
| 24-OCT-1997; | 97US-0063544P;   |
| 24-OCT-1997; | 97US-0063549P;   |
| 24-OCT-1997; | 97US-0063550P;   |
| 24-OCT-1997; | 97US-0063564P;   |
| 24-OCT-1997; | 97US-0063435P;   |
| 24-OCT-1997; | 97US-0063704P;   |
| 24-OCT-1997; | 97US-0063732P;   |
| 24-OCT-1997; | 97US-0063734P;   |
| 24-OCT-1997; | 97US-0063735P;   |
| 24-OCT-1997; | 97US-0063738P;   |
| 24-OCT-1997; | 97US-0064215P;   |
| 24-OCT-1997; | 97US-0063870P;   |
| 24-OCT-1997; | 97US-0064103P;   |
| 24-OCT-1997; | 97US-0064248P;   |
| 24-OCT-1997; | 97US-0064809P;   |
| 24-OCT-1997; | 97US-0065186P;   |
| 24-OCT-1997; | 97US-0065846P;   |
| 24-OCT-1997; | 97US-0065693P;   |
| 24-OCT-1997; | 97US-0066120P;   |
| 24-OCT-1997; | 97US-0066347P;   |
| 24-OCT-1997; | 97US-0066453P;   |
| 24-OCT-1997; | 97US-0066466P;   |
| 24-OCT-1997; | 97US-0066511P;   |
| 24-OCT-1997; | 97US-0066772P;   |
| 24-OCT-1997; | 97US-0066840P;   |
| 24-OCT-1997; | 97US-0069425P;   |
| 24-OCT-1997; | 98US-0080262P;   |
| 24-OCT-1997; | 98US-0098003P;   |
| 24-OCT-1997; | 98US-0100262P;   |
| 24-OCT-1997; | 98WO-US019177;   |
| 24-OCT-1997; | 98WO-US019330;   |
| 24-OCT-1997; | 98US-0100858P;   |
| 24-OCT-1997; | 98WO-US019437;   |
| 24-OCT-1997; | 98US-0104080P;   |
| 24-OCT-1997; | 98US-0109304P;   |
| 24-OCT-1997; | 98WO-US0118824;  |
| 24-OCT-1997; | 98US-0113296P;   |
| 24-OCT-1997; | 98US-0143048P;   |
| 24-OCT-1997; | 99US-0145698P;   |
| 24-OCT-1997; | 99US-0146222P;   |
| 24-OCT-1997; | 99WO-US020594;   |
| 24-OCT-1997; | 99WO-US020944;   |
| 24-OCT-1997; | 99WO-US021030;   |
| 24-OCT-1997; | 99WO-US021547;   |
| 24-OCT-1997; | 99WO-US023089;   |
| 24-OCT-1997; | 99WO-US028214;   |
| 24-OCT-1997; | 99WO-US028313;   |
| 24-OCT-1997; | 99WO-US028301;   |
| 24-OCT-1997; | 99WO-US030959;   |
| 24-OCT-1997; | 99WO-US030999;   |
| 24-OCT-1997; | 2000WO-US000219; |
| 24-OCT-1997; | 2000WO-US003565; |
| 24-OCT-1997; | 2000WO-US004414; |
| 24-OCT-1997; | 2000WO-US005004; |
| 24-OCT-1997; | 2000WO-US005841; |
| 24-OCT-1997; | 2000WO-US007377; |
| 24-OCT-1997; | 2000WO-US008439; |

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0;

17-NOV-1997; 97US-0065693P.  
18-NOV-1997; 97US-0065693P.  
21-NOV-1997; 97US-0066120P.  
21-NOV-1997; 97US-0066364P.

224-NOV-1997; 97US-0066433E.  
224-NOV-1997; 97US-0066466P.  
224-NOV-1997; 97US-0066511P.  
224-NOV-1997; 97US-0066770P.

RESULT 64  
ACD23705  
ID ACD23705 standard; cDNA: 1378 BP.

26-AUG-2003 (first entry)

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; leukocyte homing; rheumatoid arthritis; psoriasis; multiple sclerosis; mucosal lesion; enterocolitis Zollinger Ellison syndrome; asthma; antitussive; antirheumatic; antiarthritic; neuroprotective.

XX  
PN  
US2003064923-A1.XX  
13-III-2001.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059122P.

PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.

PR 21-OCT-1997; 97US-0063486P.



CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
 CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
 CC for preparing PRO polypeptides, for generating transgenic animals or  
 CC knockout animals which are useful in the development and screening of  
 CC therapeutically useful reagents, as probes and for the genetic analysis  
 CC of individuals with genetic disorders as well as for the recombinant  
 CC expressing the protein and for chromosome identification. The proteins  
 CC are useful as molecular marker for protein electrophoresis purposes, as  
 CC therapeutic agents, for screening compounds to identify those that mimic  
 CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
 CC polypeptide (antagonists). The polynucleotides and proteins are useful  
 CC for tissue typing. PRO antibodies are useful for immunohistochemical  
 CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO from  
 CC recombinant cell culture or natural sources. The PRO genes may also be  
 CC used in gene therapy, particularly for replacing a defective gene. The  
 CC sequence presented is a gene encoding a PRO polynucleotide of the  
 CC invention.

XX  
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTTAATTCGCACCTATTTTATTTTCTATATAAATCCAGTCTTCT 3042  
 DB 1272 TTTTGTATATAAATGTTATGATTTTATAGGTATTTGACCTGCCCATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAATTTTAAATTTCTCT 3077  
 DB 1332 ATTTATCTCCATTTCAATAAATTTATTTCT 1366

RESULT 66  
 ADB74924  
 ID ADB74924 standard; cDNA; 1378 BP.  
 XX AC ADB74924;  
 XX DT 04-DEC-2003 (first entry)  
 XX DE Human secreted/transmembrane protein cDNA, #52.  
 XX Human; gene; ss; PRO; secreted; transmembrane; gastrointestinal mucosa;  
 KW mucosal lesion; skin disease; keratinocyte differentiation; psoriasis;  
 KW Parkinson's disease; Alzheimer's disease; amyotrophic lateral sclerosis;  
 KW ALS; neuropathy; cell growth; cancer; tumour; viral infection;  
 KW neurodegenerative disease; antithrombotic agent; haemorrhage;  
 KW endometrial bleeding angiogenesis; kidney tissue; apoptosis; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy; neurotropic;  
 KW neuroprotective; cytostatic; virucide; anticoagulant.  
 XX Homo sapiens.  
 XX OS  
 XX US2003082542-A1.  
 XX PN  
 XX 01-MAY-2003.  
 XX PD  
 XX 17-JUL-2001; 2001US-00907979.  
 XX PF  
 XX 17-SEP-1997; 97US-0059113P.  
 XX PR 17-SEP-1997; 97US-0059115P.  
 XX PR 17-SEP-1997; 97US-0059117P.  
 XX PR 17-SEP-1997; 97US-0059119P.  
 XX PR 17-SEP-1997; 97US-0059121P.  
 XX PR 17-SEP-1997; 97US-0059122P.  
 XX PR 17-SEP-1997; 97US-0059124P.  
 XX PR 18-SEP-1997; 97US-0059263P.  
 XX PR 15-OCT-1997; 97US-0059266P.  
 XX PR 15-OCT-1997; 97US-0062125P.  
 XX PR 17-OCT-1997; 97US-0062285P.

22-DEC-1998; 98US-0113296P.  
 07-JUL-1999; 99US-0143048P.  
 26-JUL-1999; 99US-0145628P.  
 28-JUL-1999; 99US-0146222P.  
 08-SEP-1999; 99US-0020594.  
 13-SEP-1999; 99US-0020944.  
 15-SEP-1999; 99US-0021090.  
 05-OCT-1999; 99US-0021547.  
 29-NOV-1999; 99US-0023089.  
 30-NOV-1999; 99US-0028313.  
 01-DEC-1999; 99US-0028301.  
 02-DEC-1999; 99US-0028564.  
 16-DEC-1999; 99US-0028565.  
 20-DEC-1999; 99US-0030095.  
 20-DEC-1999; 99US-0030911.  
 05-JAN-2000; 99US-0030999.  
 11-FEB-2000; 2000US-0000219.  
 22-FEB-2000; 2000US-0003585.  
 24-FEB-2000; 2000US-0004414.  
 02-MAR-2000; 2000US-0005004.  
 30-MAR-2000; 2000US-0005841.  
 30-MAR-2000; 2000US-0007377.  
 22-MAY-2000; 2000US-0008439.  
 26-JUL-2000; 2000US-0014042.  
 26-JUL-2000; 2000US-0015264.  
 24-AUG-2000; 2000US-0020710.  
 18-SEP-2000; 2000US-0023330.  
 2000US-00665350.

(GETH ) GENENTECH INC.

Ashkenazi A, Bolstein D, Desnoyers L, Eaton DL, Ferrara N;  
 Pilyavoff E, Pong S, Gao W, Garber H, Gerritsen ME, Goddard A;  
 Godowski PU, Grimaldi JC, Gurney AU, Hillan KJ, Kljavin IJ;  
 Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 Williams PN, Wood WI;  
 WPI; 2003-765399/72.  
 P-PSDB; ADB77789.

New isolated secreted and transmembrane polypeptide, useful for treating  
 diseases, e.g. Parkinson's disease, Alzheimer's disease, amyotrophic  
 lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.

Claim 2; Fig 97; 467pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides  
 and the nucleic acid encoding them. The polypeptides can be used to raise  
 antibodies that specifically bind to the PRO polypeptide, for linking a  
 bioactive molecule to a cell expressing a PRO protein and for modulating  
 at least one biological activity of a cell. PRO polypeptides are useful  
 for detecting other PRO polypeptides in a sample and for linking a  
 bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 polypeptide antibodies are useful for modulating the biological activity  
 of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
 for treating disorders associated with the preservation and maintenance  
 of gastrointestinal mucosa and the repair of acute and chronic mucosal  
 lesions, skin diseases associated with abnormal keratinocyte  
 differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
 diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
 additionally, disease related to uncontrolled cell growth, e.g. cancer.  
 PRO polypeptides also serve as tumour specific antigens which may be  
 exploited as therapeutic targets for anti-tumour drugs, and are also  
 employed therapeutically in vivo for lessening the effects of viral  
 infection. The PRO polypeptides can be also used in assays to determine  
 if it has a role in neurodegenerative diseases or their reversal, as an  
 antithrombotic agent with reduced risk for haemorrhage as compared with  
 heparin, in treating other PRO-associated disorders, in modulating  
 endometrial bleeding angiogenesis, and may also have an effect on kidney  
 tissue. PRO polypeptides and their portions affect the expression of  
 genes which have a role in apoptosis. The polynucleotides are useful in  
 molecular biology including uses as hybridisation probes for cDNA library

PR 17-OCT-1997; 97US-0063287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0063816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0065120P.  
PR 21-NOV-1997; 97US-0065364P.  
PR 24-NOV-1997; 97US-0065453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0068428P.  
PR 04-JUN-1998; 98US-0086026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98US-00100262P.  
PR 14-SEP-1998; 98US-00101917P.  
PR 16-SEP-1998; 98US-0019330P.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98US-0100859P.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-0109304P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99US-020594P.  
PR 13-SEP-1999; 99US-020594P.  
PR 15-SEP-1999; 99US-0201050P.  
PR 15-SEP-1999; 99US-0201547P.  
PR 05-OCT-1999; 99US-0203089P.  
PR 29-NOV-1999; 99US-0208214P.  
PR 30-NOV-1999; 99US-0208313P.  
PR 01-DEC-1999; 99US-0208301P.  
PR 02-DEC-1999; 99US-0208564P.  
PR 02-DEC-1999; 99US-0208565P.  
PR 16-DEC-1999; 99US-0208565P.  
PR 20-DEC-1999; 99US-0208565P.  
PR 20-DEC-1999; 99US-0208565P.  
PR 05-JAN-2000; 2000US-0000219P.  
PR 11-FEB-2000; 2000US-0000219P.  
PR 22-FEB-2000; 2000US-0000414P.  
PR 24-FEB-2000; 2000US-00005004P.  
PR 02-MAR-2000; 2000US-00005841P.  
PR 20-MAR-2000; 2000US-00005841P.  
PR 30-MAR-2000; 2000US-00005841P.  
PR 22-MAY-2000; 2000US-00008439P.  
PR 02-JUN-2000; 2000US-00015264P.  
PR 28-JUL-2000; 2000US-00020710P.  
PR 24-AUG-2000; 2000US-00023328P.  
PR 18-SEP-2000; 2000US-00065350P.  
PA (GETH ) GENENTECH INC.  
XX  
XX  
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
XX  
DR WPI: 2003-765412/72.  
DR P-PSDB; ADB74325.  
XX  
XX  
PT Novel isolated native PRO polypeptide useful for tissue typing,  
PT modulating biological activity of cell, as molecular weight markers in  
PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison  
PT syndrome.  
XX  
XX  
PS Claim 2; Fig 97; 475pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. PRO polypeptides are also useful  
CC for treating disorders associated with the preservation and maintenance  
CC of gastrointestinal mucosa and the repair of acute and chronic mucosal  
CC lesions, skin diseases associated with abnormal keratinocyte  
CC differentiation (e.g. psoriasis), Parkinson's disease, Alzheimer's  
CC diseases, amyotrophic lateral sclerosis (ALS), neuropathies and  
CC additionally, diseases related to uncontrolled cell growth, e.g. cancer.  
CC PRO polypeptides also serve as tumour specific antigens which may be  
CC exploited as therapeutic targets for anti-tumour drugs, and are also  
CC employed therapeutically in vivo for lessening the effects of viral  
CC infection. The PRO polypeptides can be also used in assays to determine  
CC if it has a role in neurodegenerative diseases or their reversal, as an  
CC antithrombotic agent with reduced risk for haemorrhage as compared with  
CC heparin, in treating other PRO-associated disorders, in modulating  
CC endometrial bleeding angiogenesis, and may also have an effect on kidney  
CC tissue. PRO polypeptides and their portions affect the expression of  
CC genes which have a role in apoptosis. The polynucleotides are useful in  
CC molecular biology including uses as hybridisation probes for cDNA library  
CC to isolate the full-length PRO cDNA or to isolate other cDNAs, in  
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,  
CC for preparing PRO polypeptides, for generating transgenic animals or  
CC knockout animals which are useful in the development and screening of  
CC therapeutically useful reagents, as probes and for the genetic analysis  
CC of individuals with genetic disorders as well as for recombinantly  
CC expressing the protein and for chromosome identification. The proteins  
CC are useful as molecular marker for protein electrophoresis purposes, as  
CC therapeutic agents, for screening compounds to identify those that mimic  
CC the PRO polypeptide (agonists) or prevent the effect of the PRO  
CC polypeptide (antagonists). The polynucleotides and proteins are useful  
CC for tissue typing. PRO antibodies are useful for immunohistochemical  
CC staining and/or assay of sample fluids. Anti-PRO antibodies are useful in  
CC diagnostic assays for PRO e.g. detecting its expression in specific  
CC cells, tissues or serum and for affinity purification of PRO from  
CC recombinant cell culture or natural sources. The PRO genes may also be  
CC used in gene therapy, particularly for replacing a defective gene. The  
CC sequence presented is a gene encoding a PRO polynucleotide of the  
CC invention.  
XX  
XX  
SO Sequence 1378 BP 235 A 461 C 412 G 270 T 0 M 0 CAA

| Query Match           | 0.7%           | Score 24.6   | DB 1     | Length 1378 |    |
|-----------------------|----------------|--|----------|-------------|----|
| Best local similarity | 53.7%          | Pred. No. 26   |          |             |    |
| Matches 51            | Conservative 0 | Mismatches 44  | Indels 0 | Gaps 0      |    |
| Qy                    | 2983           | TCATTTTACTTTAAATTCGACTTATTTTATTTGATTTTCTAATAAAATCCAGTCTTGT                 | 3042     |             |    |
| Db                    | 1272           | TTTGTGTATATAAATGTTTAATGATTTTATAGGTATTTGTAACCTGCCACATATCTT                  | 1331     |             |    |
| Qy                    | 3043           | TTTTTTTAAAGACTTTAAATATATATATTTCTCT   | 3077     |             |    |
| Db                    | 1332           | ATTATTCCTCCAATTCATTAATATATTTATCT   | 1366     |             |    |
| RESULT 67             |                |  |          |             |    |
| ADC28570              |                |  |          |             |    |
| ID                    | ADC28570       | standard; cdna; 1378 BP.   |          |             |    |
| XX                    | XX             | AG   | AG       | AG          | AG |
| XX                    | XX             | ADC28570;  |          |             |    |
| DT                    | 18-DEC-2003    | (first entry)  |          |             |    |
| XX                    | XX             | Human secreted/transmembrane protein cdna, #52.                            |          |             |    |
| XX                    | XX             | Human; gene; ss; PRO; secreted; transmembrane; therapeutic;                |          |             |    |
| KW                    | KW             | tissue typing; immunohistochemical staining; gene therapy;                 |          |             |    |
| KW                    | KW             | neonatal heart; vascular endothelial growth factor; VEGF; proliferation;   |          |             |    |
| KW                    | KW             | endothelial cell; stimulated T-lymphocyte; retinal neuron;                 |          |             |    |
| KW                    | KW             | rod photoreceptor cell; c-fos; glucose; FFA; tumorigen;                    |          |             |    |
| KW                    | KW             | cardiac insufficiency disorder; wound; cancer; hyperinsulinaemia;          |          |             |    |
| KW                    | KW             | retinitis pigmentosa; obesity; diabetes; cartilage disorder; sport injury; |          |             |    |
| KW                    | KW             | hypotension; bone disorder; cytostatic; ophthalmological;                  |          |             |    |
| KW                    | KW             | arthritis; cardiant; vulnary; cytostatic; ophthalmological;                |          |             |    |
| KW                    | KW             | osteopathic; antiarthritic; anorectic.                                     |          |             |    |
| OS                    | XX             | Homo sapiens.  |          |             |    |
| XX                    | XX             | US2003059772-A1.   |          |             |    |
| XX                    | XX             | 27-MAR-2003.   |          |             |    |
| XX                    | XX             | 18-JUL-2001; 2001US-00903064.  |          |             |    |
| PR                    | PR             | 17-SEP-1997; 97US-0059113P.  |          |             |    |
| PR                    | PR             | 17-SEP-1997; 97US-0059115P.  |          |             |    |
| PR                    | PR             | 17-SEP-1997; 97US-0059117P.  |          |             |    |
| PR                    | PR             | 17-SEP-1997; 97US-0059119P.  |          |             |    |
| PR                    | PR             | 17-SEP-1997; 97US-0059121P.  |          |             |    |
| PR                    | PR             | 17-SEP-1997; 97US-0059122P.  |          |             |    |
| PR                    | PR             | 17-SEP-1997; 97US-0059184P.  |          |             |    |
| PR                    | PR             | 18-SEP-1997; 97US-0059263P.  |          |             |    |
| PR                    | PR             | 18-SEP-1997; 97US-0059266P.  |          |             |    |
| PR                    | PR             | 18-SEP-1997; 97US-006125P.   |          |             |    |
| PR                    | PR             | 17-OCT-1997; 97US-0062285P.  |          |             |    |
| PR                    | PR             | 17-OCT-1997; 97US-0062287P.  |          |             |    |
| PR                    | PR             | 21-OCT-1997; 97US-0063486P.  |          |             |    |
| PR                    | PR             | 24-OCT-1997; 97US-0062814P.  |          |             |    |
| PR                    | PR             | 24-OCT-1997; 97US-0062816P.  |          |             |    |
| PR                    | PR             | 24-OCT-1997; 97US-0063045P.  |          |             |    |
| PR                    | PR             | 24-OCT-1997; 97US-0063120P.  |          |             |    |
| PR                    | PR             | 24-OCT-1997; 97US-0063121P.  |          |             |    |
| PR                    | PR             | 24-OCT-1997; 97US-0063127P.  |          |             |    |
| PR                    | PR             | 24-OCT-1997; 97US-0063128P.  |          |             |    |
| PR                    | PR             | 27-OCT-1997; 97US-0063327P.  |          |             |    |
| PR                    | PR             | 27-OCT-1997; 97US-0063329P.  |          |             |    |
| PR                    | PR             | 28-OCT-1997; 97US-0063541P.  |          |             |    |
| PR                    | PR             | 28-OCT-1997; 97US-0063542P.  |          |             |    |
| PR                    | PR             | 28-OCT-1997; 97US-0063544P.  |          |             |    |
| PR                    | PR             | 28-OCT-1997; 97US-0063549P.  |          |             |    |
| PR                    | PR             | 28-OCT-1997; 97US-0063550P.  |          |             |    |
| PR                    | PR             | 28-OCT-1997; 97US-0063564P.  |          |             |    |
| PR                    | PR             | 29-OCT-1997; 97US-0063435P.  |          |             |    |
| PR                    | PR             | 29-OCT-1997; 97US-0063704P.  |          |             |    |
| PR                    | PR             | 29-OCT-1997; 97US-0063732P.  |          |             |    |
| PR                    | PR             | 29-OCT-1997; 97US-0063734P.  |          |             |    |
| PR                    | PR             | 29-OCT-1997; 97US-0063735P.  |          |             |    |
| PR                    | PR             | 29-OCT-1997; 97US-0063738P.  |          |             |    |
| PR                    | PR             | 29-OCT-1997; 97US-0064215P.  |          |             |    |
| PR                    | PR             | 31-OCT-1997; 97US-0063870P.  |          |             |    |
| PR                    | PR             | 31-OCT-1997; 97US-0064103P.  |          |             |    |
| PR                    | PR             | 03-NOV-1997; 97US-0064248P.  |          |             |    |
| PR                    | PR             | 07-NOV-1997; 97US-0064809P.  |          |             |    |
| PR                    | PR             | 12-NOV-1997; 97US-0065186P.  |          |             |    |
| PR                    | PR             | 17-NOV-1997; 97US-0065846P.  |          |             |    |
| PR                    | PR             | 18-NOV-1997; 97US-0065933P.  |          |             |    |
| PR                    | PR             | 21-NOV-1997; 97US-0066120P.  |          |             |    |
| PR                    | PR             | 21-NOV-1997; 97US-0066364P.  |          |             |    |
| PR                    | PR             | 24-NOV-1997; 97US-0066453P.  |          |             |    |
| PR                    | PR             | 24-NOV-1997; 97US-0066511P.  |          |             |    |

PT Novel secreted and transmembrane polypeptides and polynucleotides  
 PT encoding them useful for treating skin, neurodegenerative diseases, as an  
 PT antithrombotic agent and for inducing endothelial cell apoptosis.

XX Claim 2; SEQ ID NO 262; 470pp; English.

CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re  
 CC -differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a gene encoding a PRO  
 CC polynucleotide of the invention.

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTTTACTTTAAATGCACTTATTTTATTTTCTTCTAATAAAATCCAGTCCTCT 3042  
 Db 1272 TTTTGCTATATAAGTTTAAATGATTTTATAGGTATTTGTAACCTGCCACATATCTT 1331  
 QY 3043 TTTTAAAAAGACTTTAAATTTTAAATTTCTCT 3077  
 Db 1332 ATTTATCCCTCCCAATTTCAATAAATTTATTTCT 1366

RESULT 68

ADC39770

ID ADC39770 standard; cDNA; 1378 BP.

XX AC

XX AC

XX AC

DT 18-DEC-2003 (first entry)

XX

DE

XX

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

KW

XX

OS

XX

PN

XX

XX

PD

XX

XX

PF

XX

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

Human secreted/transmembrane protein cDNA, #52.

Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
 tissue typing; immunohistochemical staining; gene therapy;  
 neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;  
 cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
 arthritis; cardiant; vulnerary; cytostatic; ophthalmological;  
 osteopathic; antiarthritic; anorectic.

Homo sapiens.

US2003059828-A1.

27-MAR-2003.

13-JUL-2001; 2001US-00904553.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059119P.

17-SEP-1997; 97US-0059121P.

17-SEP-1997; 97US-0059122P.

17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.

15-OCT-1997; 97US-0062125P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

21-OCT-1997; 97US-0063486P.

24-OCT-1997; 97US-0062814P.

24-OCT-1997; 97US-0062816P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063120P.

24-OCT-1997; 97US-0063121P.

24-OCT-1997; 97US-0063127P.

24-OCT-1997; 97US-0063128P.

27-OCT-1997; 97US-0063327P.

27-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063541P.

28-OCT-1997; 97US-0063542P.

28-OCT-1997; 97US-0063544P.

28-OCT-1997; 97US-0063549P.

28-OCT-1997; 97US-0063550P.

28-OCT-1997; 97US-0063564P.

29-OCT-1997; 97US-0063435P.

29-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063732P.

29-OCT-1997; 97US-0063734P.

29-OCT-1997; 97US-0063735P.

29-OCT-1997; 97US-0063738P.

29-OCT-1997; 97US-0064215P.

31-OCT-1997; 97US-0063870P.

31-OCT-1997; 97US-0064103P.

03-NOV-1997; 97US-0064248P.

07-NOV-1997; 97US-0064809P.

12-NOV-1997; 97US-0065186P.

17-NOV-1997; 97US-0065846P.

18-NOV-1997; 97US-0065933P.

21-NOV-1997; 97US-0066120P.

24-NOV-1997; 97US-0066364P.

24-NOV-1997; 97US-0066453P.

24-NOV-1997; 97US-0066466P.

24-NOV-1997; 97US-0066511P.

24-NOV-1997; 97US-0066770P.

25-NOV-1997; 97US-0066840P.

12-DEC-1997; 97US-0069425P.

04-JUN-1998; 98US-0088026P.

PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98WO-US0109304P.  
PR 01-DEC-1998; 98WO-US0251108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 28-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUN-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IG;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2003-540675/51.  
DR P-PSDB; ADC39771.  
XX  
XX Novel secreted and transmembrane polypeptides and polynucleotides  
PT encoding them useful for treating skin, neurodegenerative diseases, as an  
PT antithrombotic agent and for inducing endothelial cell apoptosis.  
XX  
XX Claim 2; SEQ ID NO 262; 477pp; English.  
XX  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re

-differentiation of chondrocytes. In particular, these are useful for  
detecting or treating cardiac insufficiency disorders, wounds, cancerous  
tumours, retinal disorders or injuries (e.g. loss of sight due to  
retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
arthritis) in mammals. PRO polypeptides and their portions affect the  
expression of genes which have a role in cell death. The polynucleotides  
are useful in molecular biology including uses as hybridisation probes  
for cDNA library to isolate the full-length PRO cDNA or to isolate other  
cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
and DNA, for preparing PRO polypeptides, for generating transgenic  
animals or knockout animals which are useful in the development and  
screening of therapeutically useful reagents, as probes and for the  
genetic analysis of individuals with genetic disorders as well as for  
recombinantly expressing the protein and for chromosome identification.  
The proteins are useful as molecular marker for protein electrophoresis  
purposes, as therapeutic agents, for screening compounds to identify  
those that mimic the PRO polypeptide (agonists) or prevent the effect of  
the PRO polypeptide (antagonists). The polynucleotides and proteins are  
useful for tissue typing. PRO antibodies are useful for  
immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
antibodies are useful in diagnostic assays for PRO e.g. detecting its  
expression in specific cells, tissues or serum and for affinity  
purification of PRO from recombinant cell culture or natural sources. The  
PRO genes may also be used in gene therapy, particularly for replacing a  
defective gene. The sequence presented is a gene encoding a PRO  
polypeptide of the invention.  
XX  
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTCTACTTAATTCACCTTATTTTATTTATTTCTTAATAAATCCAGTCCTTCT 3042  
DB 1272 TTTTGTATATAAATGTTAATGATTTTATAGGATTGTGAACCTGCCACATATCTT 1331  
QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
DB 1332 ATTATTCTCCAAATTCATAATTAATTTATTTCT 1366  
RESULT 69  
ADC40284  
ID ADC40284 standard; cDNA; 1378 BP.  
XX  
XX ADC40284;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX Human secreted/transmembrane protein cDNA, #52.  
DE  
XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
XX tissue typing; immunohistochemical staining; gene therapy;  
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;  
XX rod photoreceptor cell; c-fos; glucose; PFA; chondrocyte;  
XX cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
XX retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
XX hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
XX arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
XX osteopathic; antiarthritic; anorectic.  
XX  
XX Homo sapiens.  
OS  
XX US2003059829-A1.  
PN  
XX 27-MAR-2003.  
XX  
XX 13-JUL-2001; 2001US-00905381.  
PF  
XX 17-SEP-1997; 97US-0059113P.  
PR



PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 31-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 03-NOV-1997; 97US-0064103P.  
PR 07-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066164P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066456P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 97US-0068026P.  
PR 10-SEP-1998; 98US-0039803P.  
PR 10-SEP-1998; 98US-0039803P.  
PR 14-SEP-1998; 98US-0039803P.  
PR 14-SEP-1998; 98US-0039803P.  
PR 16-SEP-1998; 98US-0039803P.  
PR 17-SEP-1998; 98US-0039803P.  
PR 17-SEP-1998; 98US-0039803P.  
PR 13-OCT-1998; 98US-0039803P.  
PR 13-OCT-1998; 98US-0039803P.  
PR 01-DEC-1998; 98US-0039803P.  
PR 22-DEC-1998; 98US-0039803P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 26-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99US-0146222P.  
PR 13-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 05-OCT-1999; 99US-0146222P.  
PR 29-NOV-1999; 99US-0146222P.  
PR 30-NOV-1999; 99US-0146222P.  
PR 01-DEC-1999; 99US-0146222P.

PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 05-JAN-2000; 2000WO-US030999.  
PR 11-FEB-2000; 2000WO-US000219.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX  
XX (GETH ) GENENTECH INC.  
PA  
XX  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Garritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2003-540676/51.  
DR P-PSDB; ADC40285.  
DR  
XX  
XX Novel secreted and transmembrane polypeptides and polynucleotides  
PT encoding them useful for treating skin, neurodegenerative diseases, as an  
XX antithrombotic agent and for inducing endothelial cell apoptosis.  
XX  
PS Claim 2; SEQ ID NO 262; 473pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or PFA uptake, inducing proliferation and/or re  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its

CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polypeptide of the invention.

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;

Best Local Similarity 53.7%; Pred. No. 26;

Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTCCTTAAATGCACTTATTTTATTCCTTATTTTCTTAAATCCAGTCTCTTGT 3042

Db 1272 TTTTGTATATAAAGTTTAAATGTTTATAGTATTTGTACCTGCCACATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAATATTTATTTCTCT 3077

DB 1332 ATTATTCCTCAATTTCAATAAATTATTTATCT 1366

RESULT 70

ADCL19108

ID ADC19108 standard; cDNA; 1378 BP.

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

XX AC ADC19108;

PI Godowski FU, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI William PM, Wood WI;  
 XX WPI: 2003-615762/58.  
 DR P-PSDB; ABC19109.  
 XX Novel secreted and transmembrane polypeptide for modulating biological  
 PT activity of cell expressing the polypeptide, identifying agonists or  
 PT antagonists of polypeptide, and as molecular weight markers.  
 XX Claim 2; SEQ ID NO 262; 476pp; English.  
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoinulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a gene encoding a PRO  
 CC polynucleotide of the invention.  
 XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2983 TCTATTTTACCTTAAATGCACCTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042  
 DB 1272 TTTTGTGTATATAATGTTAATGATTTTATAGTATTTGTACCTGCCACATATCTT 1331  
 QY 3043 TTTTAAAGACTTTAAATATTTTAAATTTTCTCT 3077  
 DB 1332 ATTTATTCCTCCAAATTTCAATAAATTTATTTATCTT 1366  
 RESULT 71

ADC34408  
 ID ADC34408 standard; cDNA; 1378 BP.  
 XX  
 AC ADC34408,  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein cDNA, #52.  
 XX  
 KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy; proliferation;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; retinal neuron;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulnary; cycostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003036094-A1.  
 XX  
 PD 20-FEB-2003.  
 XX  
 XX 13-JUL-2001; 2001US-00904820.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 29-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 03-NOV-1997; 97US-0064248P.  
 PR 07-NOV-1997; 97US-0064809P.  
 PR 12-NOV-1997; 97US-0065186P.  
 PR 17-NOV-1997; 97US-0065846P.  
 PR 18-NOV-1997; 97US-0065693P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066364P.  
 PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0065466P.  
 PR 24-NOV-1997; 97US-0065511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 24-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 10-JUN-1998; 98US-008026P.  
 PR 10-SEP-1998; 98US-009803P.  
 PR 10-SEP-1998; 98WO-US01824.  
 PR 14-SEP-1998; 98US-0100262P.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98US-0100858P.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0109304P.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 22-DEC-1998; 98US-0113298P.  
 PR 27-JUL-1999; 99US-0143048P.  
 PR 06-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 30-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 28-JUL-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnovers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI: 2003-615763/58.  
 DR P-PSDB; ADC34409.  
 XX  
 PT Novel secreted and transmembrane polypeptides and polynucleotides  
 PT encoding them useful for treating cancers, asthma, rheumatoid arthritis,  
 PT neurological diseases, and skin diseases.  
 XX  
 PS Claim 2; SEQ ID NO 262; 478pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or

CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumors, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypothyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a gene encoding a PRO  
 CC polypeptide of the invention.  
 XX

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2983 TCTATTTTACTTTAAATGCGACTTATTTTATGATTTTCTATAAAATCCAGCTCTGT 3042  
 DB 1272 TTTTGTGTATATAATGTTAATGATTTTATAGTATTTGTAACCTGCCACATATCTT 1331  
 QY 3043 TTTTAAAGACTTTAAATTTATTAATTTCTCT 3077  
 DB 1332 ATTTATCTCTCAATTTCAATAATTTATTTCT 1366  
 RESULT 72  
 ADC29463  
 ID ADC29463 standard; cDNA; 1378 BP.  
 XX  
 AC ADC29463;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein cDNA, #52.  
 KW Human; Gene; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabete; hyperinsulinaemia;  
 KW hypothyroidism; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiant; vulnery; cytotatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX



CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polynucleotide of the invention.

XX Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCTATTTTACTTAAATGCACATATTTTATTTTCTAATAAATCCAGTCTTCT 3042  
DB 1272 TTTTGTATATAAATGTTAATGATTTTATAGTATTTTGAACCTGCCACATATCTT 1331  
QY 3043 TTTTAAAAAGACTTTAAATTTTAAATTTCTCT 3077  
DB 1332 ATTTATCTCCCAATTCATTAATTTATTTCT 1366

# RESULT 73

ADC28994

ID ADC28994 standard; cDNA; 1378 BP.

AC ADC28994;

XX ADC28994;

XX 18-DEC-2003 (first entry)

DE Human secreted/transmembrane protein cDNA, #52.

KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypotension; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulvar; cytostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.

OS Homo sapiens.

XX US2003049677-A1.

PN 13-MAR-2003.

XX 17-JUL-2001; 2001US-00907794.

XX 17-SEP-1997; 97US-0059113P.

PR 17-SEP-1997; 97US-0059115P.

PR 17-SEP-1997; 97US-0059117P.

PR 17-SEP-1997; 97US-0059119P.

PR 17-SEP-1997; 97US-0059121P.

PR 17-SEP-1997; 97US-0059122P.

PR 17-SEP-1997; 97US-0059184P.

PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 15-OCT-1997; 97US-0062125P.

PR 17-OCT-1997; 97US-0062285P.

PR 21-OCT-1997; 97US-0062287P.

PR 24-OCT-1997; 97US-0062486P.

PR 24-OCT-1997; 97US-0062814P.

PR 24-OCT-1997; 97US-0062816P.

PR 24-OCT-1997; 97US-0063045P.

PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065939P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088036P.  
PR 10-SEP-1998; 98US-009803P.  
PR 14-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 21-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0145222P.  
PR 08-SEP-1999; 99WO-US020534.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.

PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX (GETH) GENENTECH INC.  
XX  
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Grittens ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
DR WPI: 2003-615797/58.  
DR P-FSDB; ADC28995.  
XX  
PT Novel secreted and transmembrane polypeptides and polynucleotides  
PT encoding them useful for treating skin, neurodegenerative diseases, as an  
PT antithrombotic agent and for inducing endothelial cell apoptosis.  
XX  
PS Claim 2; SEQ ID NO 262; 470pp; English.  
XX  
CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypotension, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polynucleotide of the invention.  
XX  
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTTTACTTTTAAATGACCTTTATTTTATTTGATTTTCTAATAAAATCCAGTCTCTT 3042  
Db 1272 TTTTGTGTAATAAAGCTTAATGATTTTATAGTATTGTAACCTGCGCCACATATCTT 1331

QY 3043 TTTTAAAAAGACTTTAAATTTATTTATTTATTTCTCT 3077  
Db 1332 ATTATTCCTCCCAATTTCAATAAATTTATTTCTCT 1366

RESULT 74  
ADC40879  
ID ADC40879 standard; cDNA; 1378 BP.  
XX  
AC ADC40879;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human secreted/transmembrane protein cDNA, #52.  
XX  
KW Human; gene: ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypotension; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.  
XX  
OS Homo sapiens.  
XX  
PN US2003054400-A1.  
XX  
PD 20-MAR-2003.  
XX  
PF 10-JUL-2001; 2001US-00902692.  
XX  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059124P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062135P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 31-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 03-NOV-1997; 97US-0064248P.



PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0068120P.  
PR 24-NOV-1997; 97US-0068364P.  
PR 24-NOV-1997; 97US-0068453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98US-0018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 16-SEP-1998; 98US-0101917.  
PR 17-SEP-1998; 98US-0101930.  
PR 17-SEP-1998; 98US-0100858P.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98US-0109304P.  
PR 28-DEC-1998; 98US-011326P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 13-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0146222P.  
PR 15-SEP-1999; 99US-0202094.  
PR 15-SEP-1999; 99US-0202109.  
PR 15-SEP-1999; 99US-0202154.  
PR 08-OCT-1999; 99US-0202308.  
PR 28-NOV-1999; 99US-0202814.  
PR 30-NOV-1999; 99US-0202814.  
PR 01-DEC-1999; 99US-0202830.  
PR 01-DEC-1999; 99US-0202856.  
PR 02-DEC-1999; 99US-0202856.  
PR 08-DEC-1999; 99US-0202856.  
PR 18-DEC-1999; 99US-0202856.  
PR 20-DEC-1999; 99US-0202856.  
PR 20-DEC-1999; 99US-0202856.  
PR 05-JAN-2000; 2000US-0000219.  
PR 11-FEB-2000; 2000US-0000356.  
PR 24-FEB-2000; 2000US-0000414.  
PR 24-FEB-2000; 2000US-0000414.  
PR 02-MAR-2000; 2000US-0000581.  
PR 30-MAR-2000; 2000US-0000737.  
PR 30-MAR-2000; 2000US-0000843.  
PR 22-MAY-2000; 2000US-014042.  
PR 02-JUN-2000; 2000US-015264.  
PR 28-JUL-2000; 2000US-0202710.  
PR 24-AUG-2000; 2000US-0202328.  
PR 18-SEP-2000; 2000US-00685350.  
  
(GETH ) GENENTECH INC.  
  
XX Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N;  
XX Fliviaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
XX Godowski PU, Grimaldi JC, Gurney AL, Hillan KJ, Kllavin IJ;  
XX Mather JP, Pan J, Paoni NF, Roy NA, Stewart TA, Tumas D;  
XX Williams PM, Wood WJ;  
  
XX WPI; 2003-708343/67.  
XX P-PSDB; ADC40880.  
  
XX Novel PRO polypeptides useful for treating Parkinson's disease,  
XX Alzheimer's disease, enterocolitis, Zollinger-Ellison syndrome,  
XX psoriasis, epidermoid carcinoma of the vulva and gliomas, gynecological  
XX diseases.  
XX Claim 2; SEQ ID NO 262; 473pp; English.  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides

CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumors, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinemia,  
CC hypocalcemia, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridization probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polypeptide of the invention.

XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
  
QY 2983 TCTATTACTTAATTCGACTTATTTTATGATTTTCTTAATAAATCCAGTCTTGT 3042  
Db 1272 TTTTGTGTATATAAATGTTAATGATTTTATAGGTATTGTAACTCCACATATCTT 1331  
  
QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
Db 1332 ATTATTCCTCAATTCATTAATTAATTTCTCT 1366

RESULT 75  
ADC19536  
ID ADC19536 standard; cDNA; 1378 BP.  
XX  
XX ADC19536;  
XX  
XX 18-DEC-2003 (first entry)  
XX Human secreted/transmembrane protein cDNA, #52.  
XX Human; gene: ss; PRO; secreted; transmembrane; therapeutic;  
XX tissue typing; immunohistochemical staining; gene therapy;  
XX neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
XX endothelial cell; stimulated T-lymphocyte; retinal neuron;  
XX rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;

cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
arthritis; cardiac; vulvar; cytostatic; ophthalmological;  
osteopathic; antiarthritic; anorectic.

Homo sapiens.

US2003054441-A1.

20-MAR-2003.

12-JUL-2001; 2001US-00905056.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059119P.

17-SEP-1997; 97US-0059121P.

17-SEP-1997; 97US-0059123P.

17-SEP-1997; 97US-0059125P.

17-SEP-1997; 97US-0059127P.

17-SEP-1997; 97US-0059129P.

17-SEP-1997; 97US-0059131P.

17-SEP-1997; 97US-0059133P.

17-SEP-1997; 97US-0059135P.

17-SEP-1997; 97US-0059137P.

17-SEP-1997; 97US-0059139P.

17-SEP-1997; 97US-0059141P.

17-SEP-1997; 97US-0059143P.

17-SEP-1997; 97US-0059145P.

17-SEP-1997; 97US-0059147P.

17-SEP-1997; 97US-0059149P.

17-SEP-1997; 97US-0059151P.

17-SEP-1997; 97US-0059153P.

17-SEP-1997; 97US-0059155P.

17-SEP-1997; 97US-0059157P.

17-SEP-1997; 97US-0059159P.

17-SEP-1997; 97US-0059161P.

17-SEP-1997; 97US-0059163P.

17-SEP-1997; 97US-0059165P.

17-SEP-1997; 97US-0059167P.

17-SEP-1997; 97US-0059169P.

17-SEP-1997; 97US-0059171P.

17-SEP-1997; 97US-0059173P.

17-SEP-1997; 97US-0059175P.

17-SEP-1997; 97US-0059177P.

17-SEP-1997; 97US-0059179P.

17-SEP-1997; 97US-0059181P.

17-SEP-1997; 97US-0059183P.

17-SEP-1997; 97US-0059185P.

17-SEP-1997; 97US-0059187P.

17-SEP-1997; 97US-0059189P.

17-SEP-1997; 97US-0059191P.

17-SEP-1997; 97US-0059193P.

17-SEP-1997; 97US-0059195P.

17-SEP-1997; 97US-0059197P.

17-SEP-1997; 97US-0059199P.

17-SEP-1997; 97US-0059201P.

17-SEP-1997; 97US-0059203P.

17-SEP-1997; 97US-0059205P.

13-OCT-1998; 98US-0104080P.  
20-NOV-1998; 98US-0109304P.  
01-DEC-1998; 98WO-US025108.  
22-DEC-1998; 98US-0113296P.  
07-JUL-1999; 98US-0143048P.  
26-JUL-1999; 98US-0145698P.  
28-JUL-1999; 98US-0146222P.  
08-SEP-1999; 98WO-US020594.  
13-SEP-1999; 98WO-US020944.  
15-SEP-1999; 98WO-US021090.  
15-SEP-1999; 98WO-US021547.  
05-OCT-1999; 98WO-US023089.  
29-NOV-1999; 98WO-US028214.  
30-NOV-1999; 98WO-US028313.  
01-DEC-1999; 98WO-US028301.  
02-DEC-1999; 98WO-US028564.  
02-DEC-1999; 98WO-US028565.  
16-DEC-1999; 98WO-US030095.  
20-DEC-1999; 98WO-US030911.  
20-DEC-1999; 98WO-US030999.  
05-JAN-2000; 2000WO-US000219.  
11-FEB-2000; 2000WO-US003565.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US005004.  
02-MAR-2000; 2000WO-US005841.  
30-MAR-2000; 2000WO-US007377.  
30-MAR-2000; 2000WO-US008439.  
22-MAY-2000; 2000WO-US014042.  
02-JUN-2000; 2000WO-US015264.  
28-JUL-2000; 2000WO-US020710.  
24-AUG-2000; 2000WO-US023328.  
18-SEP-2000; 2000US-00665350.

(GETH ) GENENTECH INC.

Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME, Goddard A;  
Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tamas D;  
William PM, Wood WI;

WPI; 2003-695902/66.  
P-PSDB; ADC19537.

Novel isolated PRO polypeptide useful for treating Parkinson's disease,  
enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration,  
Alzheimer's disease, amyotrophic lateral sclerosis.

Claim 2; SEQ ID NO 262; 478pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides  
and the nucleic acid encoding them. The polypeptides can be used to raise  
antibodies that specifically bind to the PRO polypeptide, for linking a  
bioactive molecule to a cell expressing a PRO protein and for modulating  
at least one biological activity of a cell. PRO polypeptides are useful  
for detecting other PRO polypeptides in a sample and for linking a  
bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
polypeptide antibodies are useful for modulating the biological activity  
of a cell expressing PRO polypeptides. The PRO polypeptides or  
polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
bioreactors. These are useful for stimulating hypertrophy of neonatal  
heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
proliferation of endothelial cells, modulating the proliferation of  
stimulated T-lymphocytes, enhancing the survival or proliferation of  
retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
cells, modulating glucose or PFA uptake, inducing proliferation and/or re-  
differentiation of chondrocytes. In particular, these are useful for  
detecting or treating cardiac insufficiency disorders, wounds, cancerous  
tumours, retinal disorders or injuries (e.g. loss of sight due to  
retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
arthritis) in mammals. PRO polypeptides and their portions affect the  
expression of genes which have a role in cell death. The polynucleotides

CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polynucleotide of the invention.

SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTTTAAATGACACTTAAATTTTATTTTATTTTCTAATAAATCCAGTCTCTT 3042  
DB 1272 TTTTGTATATAAATGTAATGATTTTATAGTATTTGTACCTGCCACATATCTT 1331  
QY 3043 TTTTAAAAAGACTTAAATTTTAAATTTCTT 3077  
DB 1332 ATTATTCCTCAATTCATTAATTTATTTTCT 1366

RESULT 76  
ADC33984  
ID ADC33984 standard; cDNA; 1378 BP.  
XX AC ADC33984;  
XX AC ADC33984;  
XX AC ADC33984;  
DT 18-DEC-2003 (first entry)  
DE Human secreted/transmembrane protein cDNA, #52.  
XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypotension; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulvar; cystostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.

XX Homo sapiens.  
XX OS  
XX US2003073077-A1.  
XX 17-APR-2003.  
XX 12-JUL-2001; 2001US-00905088.  
XX 17-SEP-1997; 97US-0059113P.  
XX 17-SEP-1997; 97US-0059115P.  
XX 17-SEP-1997; 97US-0059117P.  
XX 17-SEP-1997; 97US-0059119P.  
XX 17-SEP-1997; 97US-0059121P.  
XX 17-SEP-1997; 97US-0059122P.  
XX 17-SEP-1997; 97US-0059184P.  
XX 18-SEP-1997; 97US-0059263P.

18-SEP-1997; 97US-0059266P.  
15-OCT-1997; 97US-0062125P.  
17-OCT-1997; 97US-0062285P.  
17-OCT-1997; 97US-0062287P.  
21-OCT-1997; 97US-0063486P.  
24-OCT-1997; 97US-0062814P.  
24-OCT-1997; 97US-0062816P.  
24-OCT-1997; 97US-0063045P.  
24-OCT-1997; 97US-0063120P.  
24-OCT-1997; 97US-0063121P.  
24-OCT-1997; 97US-0063127P.  
24-OCT-1997; 97US-0063128P.  
27-OCT-1997; 97US-0063327P.  
27-OCT-1997; 97US-0063329P.  
28-OCT-1997; 97US-0063541P.  
28-OCT-1997; 97US-0063542P.  
28-OCT-1997; 97US-0063544P.  
28-OCT-1997; 97US-0063549P.  
28-OCT-1997; 97US-0063550P.  
29-OCT-1997; 97US-0063564P.  
29-OCT-1997; 97US-0063435P.  
29-OCT-1997; 97US-0063704P.  
29-OCT-1997; 97US-0063732P.  
29-OCT-1997; 97US-0063734P.  
29-OCT-1997; 97US-0063735P.  
29-OCT-1997; 97US-0063738P.  
29-OCT-1997; 97US-0064215P.  
31-OCT-1997; 97US-0063870P.  
31-OCT-1997; 97US-0064103P.  
03-NOV-1997; 97US-0064248P.  
07-NOV-1997; 97US-0064809P.  
12-NOV-1997; 97US-0065186P.  
17-NOV-1997; 97US-0065846P.  
18-NOV-1997; 97US-0065693P.  
21-NOV-1997; 97US-0066120P.  
21-NOV-1997; 97US-0066364P.  
24-NOV-1997; 97US-0066453P.  
24-NOV-1997; 97US-0066456P.  
24-NOV-1997; 97US-0066511P.  
24-NOV-1997; 97US-0066770P.  
24-NOV-1997; 97US-0066772P.  
25-NOV-1997; 97US-0066840P.  
12-DEC-1997; 97US-0069425P.  
04-JUN-1998; 98US-0088026P.  
10-SEP-1998; 98US-009803P.  
10-SEP-1998; 98WO-US018824.  
14-SEP-1998; 98US-0100262P.  
14-SEP-1998; 98WO-US019177.  
16-SEP-1998; 98WO-US019330.  
17-SEP-1998; 98US-0100858P.  
17-SEP-1998; 98WO-US019437.  
13-OCT-1998; 98US-0104080P.  
20-NOV-1998; 98US-0109304P.  
01-DEC-1998; 98WO-US025108.  
22-DEC-1998; 98US-0113296P.  
07-JUL-1999; 99US-0143048P.  
26-JUL-1999; 99US-0145698P.  
28-JUL-1999; 99US-0146222P.  
08-SEP-1999; 99WO-US020534.  
13-SEP-1999; 99WO-US020944.  
15-SEP-1999; 99WO-US021090.  
15-SEP-1999; 99WO-US021547.  
05-OCT-1999; 99WO-US023089.  
20-NOV-1999; 99WO-US028214.  
30-NOV-1999; 99WO-US028313.  
01-DEC-1999; 99WO-US028301.  
02-DEC-1999; 99WO-US028554.  
02-DEC-1999; 99WO-US028565.  
16-DEC-1999; 99WO-US030095.  
20-DEC-1999; 99WO-US030911.  
20-DEC-1999; 99WO-US030999.  
05-JAN-2000; 2000WO-US000219.  
11-FEB-2000; 2000WO-US003565.

PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 30-MAR-2000; 2000WO-US007377.  
 PR 22-MAY-2000; 2000WO-US008439.  
 PR 02-JUN-2000; 2000WO-US014042.  
 PR 28-JUL-2000; 2000WO-US015264.  
 PR 24-AUG-2000; 2000WO-US020710.  
 PR 18-SEP-2000; 2000WO-US023328.  
 XX 18-SEP-2000; 2000US-00663350.  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IU;  
 PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart FA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX WPI; 2003-695953/66.  
 DR P-PSDB; ABC33985.  
 PR Novel isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for  
 PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic  
 PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.  
 XX  
 PS Claim 2; SEQ ID NO 262; 476pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for  
 CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a gene encoding a PRO  
 CC polypeptide of the invention.  
 XX  
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2983 TCTATTTTACTTAAATGACACTTATTTTATTTGATTTTCTAATAAATCCAGTCCTTGT 3042  
 Db 1272 TTTTGTGTATATAATGTTTAAATGATTTTATAGGTATTTGTAACCTGCCACATATCTT 1331  
 QY 3043 TTTTATAAAGACTTTTAAATTTATTAATTTCTCT 3077  
 Db 1332 ATTATTCCTCCATTTCAATAAATTTATTTCT 1366  
 RESULT 77  
 ADC13054  
 ID ADC13054 standard; cDNA; 1378 BP.  
 XX  
 AC ADC13054;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein cDNA, #52.  
 XX  
 KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypoparathyroidism; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiant; vulnary; cytostatic; ophthalmological;  
 XX osteopathic; antiarthritic; anorectic.  
 OS Homo sapiens.  
 XX  
 XX US2003073079-A1.  
 XX 17-APR-2003.  
 XX 17-JUL-2001; 2001US-00907575.  
 XX 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059283P.  
 PR 18-SEP-1997; 97US-0059286P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.



XX Human secreted/transmembrane protein cDNA, #52.  
DE Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
XX tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypoinulinaemia; bone disorder; cartilage disorder; sport injury;  
KW arthritis; candidant; vulnarary; cytostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.  
XX Homo sapiens.  
XX US2003082541-A1.  
XX 01-MAY-2003.  
XX 10-JUL-2001; 2001US-00902713.  
XX 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059124P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 25-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0086026P.  
PR 10-SEP-1998; 98US-009803P.  
PR 10-SEP-1998; 98WO-US01894.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 02-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020534.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003585.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX (GETH ) GENENTECH INC.  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goodard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IG;  
PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI. 2003-743881/70.  
DR P-PSDB; ADC12507.  
XX New secreted transmembrane PRO polypeptides and nucleic acids encoding  
PT the polypeptides, useful in gene therapy, in identifying chromosomes, as  
PT chromosome markers, in generating probes and in tissue typing.  
XX Claim 2; SEQ ID NO 262; 487pp; English.  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial





PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 03-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 11-FEB-2000; 2000WO-US000414.  
 PR 22-FEB-2000; 2000WO-US000504.  
 PR 24-FEB-2000; 2000WO-US005841.  
 PR 02-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 XX  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Fertara N;  
 PI Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart TA, Tumas D;  
 PI Williams FW, Wood WI;  
 XX  
 DR WPI; 2003-801231/75.  
 DR P-PSDB; ADD05062.  
 XX  
 DR Novel isolated native PRO polypeptide useful for tissue typing.  
 PT modulating biological activity of cell, as molecular weight markers in  
 PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison  
 PT syndrome.  
 XX  
 PS Claim 2; SEQ ID NO 262; 474pp; English.  
 PS  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC and the nucleic acid encoding them. The polypeptides can be used to raise  
 CC antibodies that specifically bind to the PRO polypeptide, for linking a  
 CC bioactive molecule to a cell expressing a PRO protein and for modulating  
 CC at least one biological activity of a cell. PRO polypeptides are useful  
 CC for detecting other PRO polypeptides in a sample and for linking a  
 CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 CC polypeptide antibodies are useful for modulating the biological activity  
 CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
 CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
 CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 CC proliferation of endothelial cells, modulating the proliferation of  
 CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
 CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re-  
 CC differentiation of chondrocytes. In particular, these are useful for  
 CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
 CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
 CC hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
 CC arthritis) in mammals. PRO polypeptides and their portions affect the  
 CC expression of genes which have a role in cell death. The polynucleotides  
 CC are useful in molecular biology including uses as hybridisation probes  
 CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 CC and DNA, for preparing PRO polypeptides, for generating transgenic  
 CC animals or knockout animals which are useful in the development and  
 CC screening of therapeutically useful reagents, as probes and for the  
 CC genetic analysis of individuals with genetic disorders as well as for  
 CC recombinantly expressing the protein and for chromosome identification.  
 CC The proteins are useful as molecular marker for protein electrophoresis  
 CC purposes, as therapeutic agents, for screening compounds to identify  
 CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 CC useful for tissue typing. PRO antibodies are useful for

CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 CC expression in specific cells, tissues or serum and for affinity  
 CC purification of PRO from recombinant cell culture or natural sources. The  
 CC PRO genes may also be used in gene therapy, particularly for replacing a  
 CC defective gene. The sequence presented is a gene encoding a PRO  
 CC polypeptide of the invention.  
 XX  
 SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2983 TCTATTCTTACTTTAATGCACCTATTATTATTTGATTCTCTAATAAATCCAGTCTTGT 3042  
 Db 1272 TTTTGTGATATAAATGTTAATGATTTTATAGGTATTGTAACCTGCCACATATCTT 1331  
 QY 3043 TTTTAAAAAGACCTTTAAATTTAATTTCTCT 3077  
 Db 1332 ATTATTCTCTCAATTTCAATAAATTTATTCT 1366  
 RESULT 80  
 ADD04067  
 ID ADD04067 standard; cDNA; 1378 BP.  
 XX  
 AC ADD04067;  
 XX  
 DT 01-JAN-2004 (first entry)  
 XX  
 DE Human secreted/transmembrane protein cDNA, #52.  
 KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
 KW tissue typing; immunohistochemical staining; gene therapy;  
 KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
 KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
 KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
 KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
 KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
 KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;  
 KW arthritis; cardiac; vulvular; cytostatic; ophthalmological;  
 KW osteopathic; antiarthritic; anorectic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003104381-A1.  
 XX  
 PD 05-JUN-2003.  
 XX  
 PP 11-JUL-2001; 2001US-00903823.  
 XX  
 PR 17-SEP-1997; 97US-0059113P.  
 PR 17-SEP-1997; 97US-0059115P.  
 PR 17-SEP-1997; 97US-0059117P.  
 PR 17-SEP-1997; 97US-0059119P.  
 PR 17-SEP-1997; 97US-0059121P.  
 PR 17-SEP-1997; 97US-0059122P.  
 PR 17-SEP-1997; 97US-0059184P.  
 PR 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 15-OCT-1997; 97US-0062125P.  
 PR 17-OCT-1997; 97US-0062285P.  
 PR 17-OCT-1997; 97US-0062287P.  
 PR 21-OCT-1997; 97US-0062486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.

|    |              |                  |    |   |
|----|--------------|------------------|----|---|
| PR | 27-OCT-1997; | 97US-0063339P.   | PI | Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;                |
| PR | 28-OCT-1997; | 97US-0063541P.   | PI | Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;            |
| PR | 28-OCT-1997; | 97US-0063542P.   | PI | Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IJ;               |
| PR | 28-OCT-1997; | 97US-0063544P.   | PI | Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;                  |
| PR | 28-OCT-1997; | 97US-0063549P.   | PI | Williams PM, Wood WI;   |
| PR | 28-OCT-1997; | 97US-0063550P.   | XX |   |
| PR | 28-OCT-1997; | 97US-0063564P.   | DR | WPI; 2003-801226/75.  |
| PR | 29-OCT-1997; | 97US-0063704P.   | DR | P-FSDB; ADD04068.   |
| PR | 29-OCT-1997; | 97US-0063732P.   | XX |   |
| PR | 29-OCT-1997; | 97US-0063734P.   | PT | Novel isolated native PRO polypeptide useful for treating Parkinson's     |
| PR | 29-OCT-1997; | 97US-0063735P.   | PT | disease, enterocolitis, Zollinger-Ellison syndrome gastrointestinal       |
| PR | 29-OCT-1997; | 97US-0063738P.   | PT | ulceration, Alzheimer's disease, amyotrophic lateral sclerosis, Usher     |
| PR | 29-OCT-1997; | 97US-0064215P.   | PT | syndrome.   |
| PR | 31-OCT-1997; | 97US-0063870P.   | XX |   |
| PR | 31-OCT-1997; | 97US-0064103P.   | XX | Claim 2; SEQ ID NO 262; 487pp; English.                                   |
| PR | 03-NOV-1997; | 97US-0064248P.   | CC | The invention discloses isolated PRO secreted/transmembrane polypeptides  |
| PR | 07-NOV-1997; | 97US-0064809P.   | CC | and the nucleic acid encoding them. The polypeptides can be used to raise |
| PR | 12-NOV-1997; | 97US-0065186P.   | CC | antibodies that specifically bind to the PRO polypeptide, for linking a   |
| PR | 17-NOV-1997; | 97US-0065846P.   | CC | bioactive molecule to a cell expressing a PRO protein and for modulating  |
| PR | 18-NOV-1997; | 97US-0065693P.   | CC | at least one biological activity of a cell. PRO polypeptides are useful   |
| PR | 21-NOV-1997; | 97US-0066120P.   | CC | for detecting other PRO polypeptides in a sample and for linking a        |
| PR | 21-NOV-1997; | 97US-0066364P.   | CC | bioactive molecule to a cell expressing a PRO polypeptide. The PRO        |
| PR | 24-NOV-1997; | 97US-0066453P.   | CC | polypeptide antibodies are useful for modulating the biological activity  |
| PR | 24-NOV-1997; | 97US-0066466P.   | CC | of a cell expressing PRO polypeptides. The PRO polypeptides or            |
| PR | 24-NOV-1997; | 97US-0066511P.   | CC | polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or |
| PR | 24-NOV-1997; | 97US-0066770P.   | CC | bioreactors. These are useful for stimulating hypertrophy of neonatal     |
| PR | 25-NOV-1997; | 97US-0066772P.   | CC | heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated    |
| PR | 25-NOV-1997; | 97US-0066840P.   | CC | proliferation of endothelial cells, modulating the proliferation of       |
| PR | 12-DEC-1997; | 97US-0069425P.   | CC | stimulated T-lymphocytes, enhancing the survival or proliferation of      |
| PR | 10-SEP-1998; | 98US-0098026P.   | CC | retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial |
| PR | 14-SEP-1998; | 98US-0098033P.   | CC | cells, modulating glucose or FFA uptake, inducing proliferation and/or re |
| PR | 16-SEP-1998; | 98US-0102623P.   | CC | -differentiation of chondrocytes. In particular, these are useful for     |
| PR | 17-SEP-1998; | 98WO-US019177.   | CC | detecting or treating cardiac insufficiency disorders, wounds, cancerous  |
| PR | 17-SEP-1998; | 98WO-US019330.   | CC | tumours, retinal disorders or injuries (e.g. loss of sight due to         |
| PR | 17-SEP-1998; | 98US-0100858P.   | CC | retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, or           |
| PR | 17-SEP-1998; | 98WO-US019437.   | CC | hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or |
| PR | 18-SEP-1998; | 98WO-US018824.   | CC | arthritis) in mammals. PRO polypeptides and their portions affect the     |
| PR | 13-OCT-1998; | 98US-0104080P.   | CC | expression of genes which have a role in cell death. The polynucleotides  |
| PR | 20-NOV-1998; | 98US-0103304P.   | CC | are useful in molecular biology including uses as hybridisation probes    |
| PR | 01-DEC-1998; | 98WO-US025108.   | CC | for cDNA library to isolate the full-length PRO cDNA or to isolate other  |
| PR | 22-DEC-1998; | 98US-0113296P.   | CC | cDNAs, in chromosome and gene mapping, in the generation of antisense RNA |
| PR | 07-JUL-1999; | 99US-0143048P.   | CC | and DNA, for preparing PRO polypeptides, for generating transgenic        |
| PR | 26-JUL-1999; | 99US-0145699P.   | CC | animals or knockout animals which are useful in the development and       |
| PR | 08-SEP-1999; | 99US-0146222P.   | CC | screening of therapeutically useful reagents, as probes and for the       |
| PR | 13-SEP-1999; | 99WO-US020594.   | CC | genetic analysis of individuals with genetic disorders as well as for     |
| PR | 15-SEP-1999; | 99WO-US021090.   | CC | recombinantly expressing the protein and for chromosome identification.   |
| PR | 15-SEP-1999; | 99WO-US021547.   | CC | The proteins are useful as molecular marker for protein electrophoresis   |
| PR | 29-OCT-1999; | 99WO-US023089.   | CC | purposes, as therapeutic agents, for screening compounds to identify      |
| PR | 30-NOV-1999; | 99WO-US028214.   | CC | those that mimic the PRO polypeptide (agonists) or prevent the effect of  |
| PR | 01-DEC-1999; | 99WO-US028313.   | CC | the PRO polypeptide (antagonists). The polynucleotides and proteins are   |
| PR | 02-DEC-1999; | 99WO-US028301.   | CC | useful for tissue typing. PRO antibodies are useful for                   |
| PR | 02-DEC-1999; | 99WO-US028564.   | CC | immunohistochemical staining and/or assay of sample fluids. Anti-PRO      |
| PR | 16-DEC-1999; | 99WO-US030095.   | CC | antibodies are useful in diagnostic assays for PRO e.g. detecting its     |
| PR | 20-DEC-1999; | 99WO-US030911.   | CC | expression in specific cells, tissues or serum and for affinity           |
| PR | 05-JAN-2000; | 2000WO-US030999. | CC | purification of PRO from recombinant cell culture or natural sources. The |
| PR | 11-FEB-2000; | 2000WO-US000219. | CC | PRO genes may also be used in gene therapy, particularly for replacing a  |
| PR | 22-FEB-2000; | 2000WO-US003565. | CC | defective gene. The sequence presented is a gene encoding a PRO           |
| PR | 24-FEB-2000; | 2000WO-US004414. | XX | polypeptide of the invention.   |
| PR | 02-MAR-2000; | 2000WO-US005004. | SQ | Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;               |
| PR | 20-MAR-2000; | 2000WO-US007377. |    | Query Match 0.7%; Score 24.6; DB 1; Length 1378;                          |
| PR | 30-MAR-2000; | 2000WO-US008439. |    | Best Local Similarity 53.7%; Pred. No. 26;                                |
| PR | 22-MAY-2000; | 2000WO-US014042. |    | Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;              |
| PR | 02-JUN-2000; | 2000WO-US015264. |    |   |
| PR | 28-JUL-2000; | 2000WO-US020710. | QY | 2983 TCTATTTTACTTTAAATGCACCTATTATTTTATTTATTTTCTTAATAAATCCAGTCCTTGT 3042   |
| PR | 24-AUG-2000; | 2000WO-US023328. | DB | 1272 TTGTGCTATATAAAGCTTAATGATTTTATAGTATTTCGACCTGCCACATATCTT 1331          |
| PR | 18-SEP-2000; | 2000US-00665350. | QY | 3043 TTTTAAAAAGACTTTTAAATTTTAAATTTATTTCTCT 3077                           |
| XX |              |                  | DB | 1332 ATTATTCCTCCCAATTTCAATAAATTTATTTATTTCT 1366                           |

(GETH ) GENENTECH INC.

14-2

RESULT 81  
ADD03643  
ID ADD03643 standard; cDNA; 1378 BP.  
XX AC ADD03643;  
XX DT 01-JAN-2004 (first entry)  
XX DE Human secreted/transmembrane protein cDNA, #52.  
XX KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumor; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypotension; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulvar; cytostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.  
XX OS Homo sapiens.  
XX PN US2003108983-A1.  
XX PD 12-JUN-2003.  
XX PF 10-JUL-2001; 2001US-00902572.  
XX PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059124P.  
PR 18-SEP-1997; 97US-0059283P.  
PR 18-SEP-1997; 97US-0059286P.  
PR 18-SEP-1997; 97US-0059286P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063341P.  
PR 28-OCT-1997; 97US-0063342P.  
PR 28-OCT-1997; 97US-0063344P.  
PR 28-OCT-1997; 97US-0063349P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063554P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063733P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065693P.  
XX PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066468P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 25-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 14-JUN-1998; 98US-0088025P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98US-0100262P.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113296P.  
PR 07-JUL-1999; 98US-0143048P.  
PR 26-JUL-1999; 98US-0145698P.  
PR 28-JUL-1999; 98US-0146222P.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 15-SEP-1999; 98WO-US021547.  
PR 05-OCT-1999; 98WO-US023089.  
PR 29-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 01-DEC-1999; 98WO-US028301.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015284.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX (GETH ) GENENTECH INC.  
XX PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin IG;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX WPI: 2003-801268/75.  
DR P-PSDB; ADD03644.  
XX Novel isolated native PRO polypeptide useful for tissue typing,  
PT modulating biological activity of cell, as molecular weight markers in  
PT protein electrophoresis, for treating enterocolitis, Zollinger-Ellison  
PT syndrome.  
XX Claim 2; SEQ ID NO 262; 472pp; English.  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful

for detecting other PRO polypeptides in a sample and for linking a bioactive molecule to a cell expressing a PRO polypeptide. The PRO polypeptide antibodies are useful for modulating the biological activity of a cell expressing PRO polypeptides. The PRO polypeptides or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These are useful for stimulating hypertrophy of neonatal heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated proliferation of endothelial cells, modulating the proliferation of stimulated T-lymphocytes, enhancing the survival or proliferation of retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial cells, modulating glucose or FFA uptake, inducing proliferation and/or re differentiation of chondrocytes. In particular, these are useful for detecting or treating cardiac insufficiency disorders, wounds, cancerous tumours, retinal disorders or injuries (e.g. loss of sight due to retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, hypopinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or arthritis) in mammals. PRO polypeptides and their portions affect the expression of genes which have a role in cell death. The polynucleotides are useful in molecular biology including uses as hybridisation probes for cDNA library to isolate the full-length PRO cDNA or to isolate other cDNAs, in chromosome and gene mapping, in the generation of antisense RNA and DNA, for preparing PRO polypeptides, for generating transgenic animals or knockout animals which are useful in the development and screening of therapeutically useful reagents, as probes and for the genetic analysis of individuals with genetic disorders as well as for recombinantly expressing the protein and for chromosome identification. The proteins are useful as molecular marker for protein electrophoresis purposes, as therapeutic agents, for screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). The polynucleotides and proteins are useful for tissue typing. PRO antibodies are useful for immunohistochemical staining and/or assay of sample fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g. detecting its expression in specific cells, tissues or serum and for affinity purification of PRO from recombinant cell culture or natural sources. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequence presented is a gene encoding a PRO polypeptide of the invention.

Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTTTACTTAAATGCACTTATTTTATTTGATTTTCTAATAAATCCAGTCCTTGT 3042  
Db 1272 TTTTGTGATATAAATGTTAATGATTTTATAGGTATTTGTAACCCGCCACATATCTT 1331  
QY 3043 TTTTATAAAGACATTAAATTTATTTCTCT 3077  
Db 1332 ATTATTCCTCCAATTCATAAATTTATTTCT 1366

RESULT 82

AD34895  
ID AD34895 standard; cDNA; 1378 BP.

XX  
AC AD34895;  
XX

DT 29-JAN-2004 (first entry)

XX Human secreted/transmembrane protein cDNA, #52.

XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypopinsulinaemia; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulnary; cytostatic; ophthalmological;

osteopathic; antiarthritic; anorectic.  
XX  
OS Homo sapiens.  
XX US2003077583-A1.  
XX 24-APR-2003.  
XX  
PF 13-JUL-2001; 2001US-00905075.  
XX  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059119P.  
PR 17-SEP-1997; 97US-0059121P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 15-OCT-1997; 97US-0062125P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 24-OCT-1997; 97US-0063128P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063542P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063549P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063435P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063732P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 29-OCT-1997; 97US-0064215P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 18-NOV-1997; 97US-0065893P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 26-NOV-1997; 97US-0066840P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-SEP-1998; 98US-0099803P.  
PR 14-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100858P.  
PR 17-SEP-1998; 98WO-US019437.  
PR 13-OCT-1998; 98US-0104080P.  
PR 20-NOV-1998; 98US-0109304P.  
PR 01-DEC-1998; 98WO-US025108.  
PR 22-DEC-1998; 98US-0113256P.

PR 07-JUL-1999; 99US-0143048P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 28-JUL-1999; 99US-0146222P.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US021089.  
PR 28-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00665350.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, KJ, Javin IJ;  
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2003-777194/73.  
DR P-PSDB; ADE34896.  
DR  
XX  
PT New isolated PRO polypeptides e.g. PRO245 and PRO1868, useful for  
PT treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic  
PT lateral sclerosis, cancer, neuropathies, diabetes and psoriasis.  
XX  
PS Claim 2; SEQ ID NO 262; 474pp; English.  
XX  
XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioreactors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic

CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polynucleotide of the invention.  
XX  
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
Qy 2983 TCTATTTTACTTTAATGCACTTATTTTATTTGATTTTCTAATAAAATCCAGTCCTTGT 3042  
Db 1272 TTTTGCTATATAATGTTAATGATTTTATAGGTATTTGTAACTCCCTGCCACATATCTT 1331  
Qy 3043 TTTTAAAGAGACTTTAAATATTATAATTTCTCT 3077  
Db 1332 ATTATTCCTCCAATTTCAATAAATTATTATTTCT 1366  
RESULT 83  
ADE79340  
ID ADE79340 standard; cDNA; 1378 BP.  
XX  
AC ADE79340;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human secreted/transmembrane protein cDNA, #52.  
XX  
KW Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulnary; cyrostatic; ophthalmological;  
KW osteopathic; antiarthritic; anorectic.  
XX  
XX Homo sapiens.  
XX  
XX US2003135025-A1.  
XX  
PD 17-JUL-2003.  
XX  
XX 12-JUL-2001; 2001US-00904992.  
XX  
XX 17-SEP-1997; 97US-0059113P.  
XX 17-SEP-1997; 97US-0059115P.  
XX 17-SEP-1997; 97US-0059117P.  
XX 17-SEP-1997; 97US-0059119P.  
XX 17-SEP-1997; 97US-0059121P.  
XX 17-SEP-1997; 97US-0059122P.  
XX 17-SEP-1997; 97US-0059184P.  
XX 18-SEP-1997; 97US-0059263P.  
XX 18-SEP-1997; 97US-0059266P.  
XX 15-OCT-1997; 97US-0062125P.  
XX 17-OCT-1997; 97US-0062285P.  
XX 17-OCT-1997; 97US-0062287P.

PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0062814P.  
 PR 24-OCT-1997; 97US-0062816P.  
 PR 24-OCT-1997; 97US-0063045P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 24-OCT-1997; 97US-0063127P.  
 PR 24-OCT-1997; 97US-0063128P.  
 PR 27-OCT-1997; 97US-0063327P.  
 PR 27-OCT-1997; 97US-0063329P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063542P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063549P.  
 PR 28-OCT-1997; 97US-0063550P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063435P.  
 PR 29-OCT-1997; 97US-0063704P.  
 PR 29-OCT-1997; 97US-0063732P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 29-OCT-1997; 97US-0063735P.  
 PR 29-OCT-1997; 97US-0063738P.  
 PR 31-OCT-1997; 97US-0064215P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 31-OCT-1997; 97US-0064249P.  
 PR 31-OCT-1997; 97US-0064809P.  
 PR 31-OCT-1997; 97US-0065186P.  
 PR 12-NOV-1997; 97US-0065848P.  
 PR 17-NOV-1997; 97US-0065693P.  
 PR 18-NOV-1997; 97US-0066120P.  
 PR 21-NOV-1997; 97US-0066136P.  
 PR 21-NOV-1997; 97US-0066453P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066511P.  
 PR 24-NOV-1997; 97US-0066770P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 25-NOV-1997; 97US-0066840P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 12-DEC-1997; 98US-008026P.  
 PR 10-SEP-1998; 98US-009803P.  
 PR 14-SEP-1998; 98US-009803P.  
 PR 14-SEP-1998; 98US-009803P.  
 PR 14-SEP-1998; 98US-009803P.  
 PR 16-SEP-1998; 98US-009803P.  
 PR 17-SEP-1998; 98US-009803P.  
 PR 17-SEP-1998; 98US-009803P.  
 PR 13-OCT-1998; 98US-0104080P.  
 PR 20-NOV-1998; 98US-0103304P.  
 PR 01-DEC-1998; 98US-0103304P.  
 PR 22-DEC-1998; 98US-0113296P.  
 PR 07-JUL-1999; 98US-0143048P.  
 PR 26-JUL-1999; 98US-0143222P.  
 PR 28-JUL-1999; 98US-0143222P.  
 PR 08-SEP-1999; 98US-0143222P.  
 PR 13-SEP-1999; 98US-0143222P.  
 PR 15-SEP-1999; 98US-0143222P.  
 PR 15-SEP-1999; 98US-0143222P.  
 PR 05-OCT-1999; 98US-0143222P.  
 PR 30-NOV-1999; 98US-0143222P.  
 PR 01-DEC-1999; 98US-0143222P.  
 PR 02-DEC-1999; 98US-0143222P.  
 PR 02-DEC-1999; 98US-0143222P.  
 PR 20-DEC-1999; 98US-0143222P.  
 PR 20-DEC-1999; 98US-0143222P.  
 PR 05-JAN-2000; 98US-0143222P.  
 PR 11-FEB-2000; 98US-0143222P.  
 PR 22-FEB-2000; 98US-0143222P.  
 PR 24-FEB-2000; 98US-0143222P.  
 PR 02-MAR-2000; 98US-0143222P.  
 PR 20-MAR-2000; 98US-0143222P.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00665350.  
 PR (GETH ) GENENTECH INC.  
 PR Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PR Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PR Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kiljavin IJ;  
 PR Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PR Williams PM, Wood WI;  
 PR WPI; 2004-031331/03.  
 PR P-PSDB; ADE79341.  
 PR New nucleic acid encoding a PRO polypeptide, for producing a recombinant  
 PR PRO polypeptide and for treating e.g. cancer, infertility, kidney  
 PR disorders, and cardiac disfunctions.  
 PR Claim 2; SEQ ID NO 262; 473pp; English.  
 PR The invention discloses isolated PRO secreted/transmembrane polypeptides  
 PR and the nucleic acid encoding them. The polypeptides can be used to raise  
 PR antibodies that specifically bind to the PRO polypeptide, for linking a  
 PR bioactive molecule to a cell expressing a PRO protein and for modulating  
 PR at least one biological activity of a cell. PRO polypeptides are useful  
 PR for detecting other PRO polypeptides in a sample and for linking a  
 PR bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
 PR polypeptide antibodies are useful for modulating the biological activity  
 PR of a cell expressing PRO polypeptides. The PRO polypeptides or  
 PR polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
 PR bioreactors. These are useful for stimulating hypertrophy of neonatal  
 PR heart inhibiting vascular endothelial growth factor (VEGF)-stimulated  
 PR proliferation of endothelial cells, modulating the proliferation of  
 PR stimulated T-lymphocytes, enhancing the survival or proliferation of  
 PR retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
 PR cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
 PR -differentiation of chondrocytes. In particular, these are useful for  
 PR detecting or treating cardiac insufficiency disorders, wounds, cancerous  
 PR tumours, retinal disorders or injuries (e.g. loss of sight due to  
 PR retinitis pigmentosa), obesity, diabetes, diabetes, hyperinsulinaemia,  
 PR hypoparathyroidism, or bone or cartilage disorders (e.g. sports injuries or  
 PR arthritis) in mammals. PRO polypeptides and their portions affect the  
 PR expression of genes which have a role in cell death. The polynucleotides  
 PR are useful in molecular biology including uses as hybridisation probes  
 PR for cDNA library to isolate the full-length PRO cDNA or to isolate other  
 PR cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
 PR and DNA, for preparing PRO polypeptides, for generating transgenic  
 PR animals or knockout animals which are useful in the development and  
 PR screening of therapeutically useful reagents, as probes and for the  
 PR genetic analysis of individuals with genetic disorders as well as for  
 PR recombinantly expressing the protein and for chromosome identification.  
 PR The proteins are useful as molecular marker for protein electrophoresis  
 PR purposes, as therapeutic agents for screening compounds to identify  
 PR those that mimic the PRO polypeptide (agonists) or prevent the effect of  
 PR the PRO polypeptide (antagonists). The polynucleotides and proteins are  
 PR useful for tissue typing. PRO antibodies are useful for  
 PR immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
 PR antibodies are useful in diagnostic assays for PRO e.g. detecting its  
 PR expression in specific cells, tissues or serum and for affinity  
 PR purification of PRO from recombinant cell culture or natural sources. The  
 PR PRO genes may also be used in gene therapy, particularly for replacing a  
 PR defective gene. The sequence presented is a gene encoding a PRO  
 PR polynucleotide of the invention.  
 PR SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred.No.26;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;





XX The invention discloses isolated PRO secreted/transmembrane polypeptides  
CC and the nucleic acid encoding them. The polypeptides can be used to raise  
CC antibodies that specifically bind to the PRO polypeptide, for linking a  
CC bioactive molecule to a cell expressing a PRO protein and for modulating  
CC at least one biological activity of a cell. PRO polypeptides are useful  
CC for detecting other PRO polypeptides in a sample and for linking a  
CC bioactive molecule to a cell expressing a PRO polypeptide. The PRO  
CC polypeptide antibodies are useful for modulating the biological activity  
CC of a cell expressing PRO polypeptides. The PRO polypeptides or  
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or  
CC bioeffectors. These are useful for stimulating hypertrophy of neonatal  
CC heart, inhibiting vascular endothelial growth factor (VEGF)-stimulated  
CC proliferation of endothelial cells, modulating the proliferation of  
CC stimulated T-lymphocytes, enhancing the survival or proliferation of  
CC retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial  
CC cells, modulating glucose or FFA uptake, inducing proliferation and/or re  
CC differentiation of chondrocytes. In particular, these are useful for  
CC detecting or treating cardiac insufficiency disorders, wounds, cancerous  
CC tumours, retinal disorders or injuries (e.g. loss of sight due to  
CC retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia,  
CC hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or  
CC arthritis) in mammals. PRO polypeptides and their portions affect the  
CC expression of genes which have a role in cell death. The polynucleotides  
CC are useful in molecular biology including uses as hybridisation probes  
CC for cDNA library to isolate the full-length PRO cDNA or to isolate other  
CC cDNAs, in chromosome and gene mapping, in the generation of antisense RNA  
CC and DNA, for preparing PRO polypeptides, for generating transgenic  
CC animals or knockout animals which are useful in the development and  
CC screening of therapeutically useful reagents, as probes and for the  
CC genetic analysis of individuals with genetic disorders as well as for  
CC recombinantly expressing the protein and for chromosome identification.  
CC The proteins are useful as molecular marker for protein electrophoresis  
CC purposes, as therapeutic agents, for screening compounds to identify  
CC those that mimic the PRO polypeptide (agonists) or prevent the effect of  
CC the PRO polypeptide (antagonists). The polynucleotides and proteins are  
CC useful for tissue typing. PRO antibodies are useful for  
CC immunohistochemical staining and/or assay of sample fluids. Anti-PRO  
CC antibodies are useful in diagnostic assays for PRO e.g. detecting its  
CC expression in specific cells, tissues or serum and for affinity  
CC purification of PRO from recombinant cell culture or natural sources. The  
CC PRO genes may also be used in gene therapy, particularly for replacing a  
CC defective gene. The sequence presented is a gene encoding a PRO  
CC polynucleotide of the invention.  
XX  
SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
  
QY 2983 TCTATTTTTAAATGCACTTATTTTATTGATTTTCTAATAAATCCAGTCTTGT 3042  
Db 1272 TTTTGTATATAATGTTAATGATTTTATAGTATTGTAACCTGCCACATATCTT 1331  
  
QY 3043 TTTTAAAGACCTTAAATTTAATTTCTCT 3077  
Db 1332 ATTATTCCTCCAATTCATAAATTTATTTCT 1366  
  
RESULT 85  
ADE73440  
ID ADE73440 standard; cDNA; 1378 BP.  
XX  
AC ADE73440;  
DT  
DT 29-JAN-2004 (first entry)  
XX Human secreted/transmembrane protein cDNA, #52.  
DE  
XX Human; gene; ss; PRO; secreted; transmembrane; therapeutic;  
KW tissue typing; immunohistochemical staining; gene therapy;  
KW neonatal heart; vascular endothelial growth factor; VEGF; proliferation;  
KW

KW endothelial cell; stimulated T-lymphocyte; retinal neuron;  
KW rod photoreceptor cell; c-fos; glucose; FFA; chondrocyte;  
KW cardiac insufficiency disorder; wound; cancer; tumour; retinal disorder;  
KW retinitis pigmentosa; obesity; diabetes; hyperinsulinaemia;  
KW hypoinsulinaemia; bone disorder; cartilage disorder; sport injury;  
KW arthritis; cardiac; vulnerability; cycostatic; ophthalmological;  
XX osteopathic; antiarthritic; anorectic.  
XX Homo sapiens.  
OS  
XX US2003129592-A1.  
PN  
XX 10-JUL-2003.  
PD  
XX 13-JUL-2001; 2001US-00905449.  
PF  
XX 17-SEP-1997; 97US-0059113P.  
XX 17-SEP-1997; 97US-0059115P.  
XX 17-SEP-1997; 97US-0059117P.  
XX 17-SEP-1997; 97US-0059119P.  
XX 17-SEP-1997; 97US-0059121P.  
XX 17-SEP-1997; 97US-0059122P.  
XX 17-SEP-1997; 97US-0059184P.  
XX 18-SEP-1997; 97US-0059263P.  
XX 18-SEP-1997; 97US-0059266P.  
XX 15-OCT-1997; 97US-0062125P.  
XX 17-OCT-1997; 97US-0062285P.  
XX 17-OCT-1997; 97US-0062287P.  
XX 21-OCT-1997; 97US-0063486P.  
XX 24-OCT-1997; 97US-0062814P.  
XX 24-OCT-1997; 97US-0062816P.  
XX 24-OCT-1997; 97US-0063045P.  
XX 24-OCT-1997; 97US-0063120P.  
XX 24-OCT-1997; 97US-0063121P.  
XX 24-OCT-1997; 97US-0063127P.  
XX 24-OCT-1997; 97US-0063128P.  
XX 27-OCT-1997; 97US-0063327P.  
XX 27-OCT-1997; 97US-0063329P.  
XX 28-OCT-1997; 97US-0063541P.  
XX 28-OCT-1997; 97US-0063542P.  
XX 28-OCT-1997; 97US-0063544P.  
XX 28-OCT-1997; 97US-0063549P.  
XX 28-OCT-1997; 97US-0063550P.  
XX 28-OCT-1997; 97US-0063564P.  
XX 29-OCT-1997; 97US-0063435P.  
XX 29-OCT-1997; 97US-0063704P.  
XX 29-OCT-1997; 97US-0063732P.  
XX 29-OCT-1997; 97US-0063734P.  
XX 29-OCT-1997; 97US-0063735P.  
XX 29-OCT-1997; 97US-0063738P.  
XX 29-OCT-1997; 97US-0064215P.  
XX 31-OCT-1997; 97US-0063870P.  
XX 31-OCT-1997; 97US-0064103P.  
XX 03-NOV-1997; 97US-0064248P.  
XX 07-NOV-1997; 97US-0064809P.  
XX 12-NOV-1997; 97US-0065186P.  
XX 17-NOV-1997; 97US-0065846P.  
XX 18-NOV-1997; 97US-0065693P.  
XX 21-NOV-1997; 97US-0065120P.  
XX 21-NOV-1997; 97US-0066364P.  
XX 24-NOV-1997; 97US-0066453P.  
XX 24-NOV-1997; 97US-0066466P.  
XX 24-NOV-1997; 97US-0066511P.  
XX 24-NOV-1997; 97US-0066770P.  
XX 24-NOV-1997; 97US-0066772P.  
XX 25-NOV-1997; 97US-0066840P.  
XX 12-DEC-1997; 97US-0069425P.  
XX 04-JUN-1998; 98US-0088026P.  
XX 10-SEP-1998; 98US-0099803P.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98US-0100262P.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.



|    |              |                |    |   |                  |
|----|--------------|----------------|----|---|------------------|
| PR | 17-SEP-1997; | 97US-0059184P. | PR | 05-JAN-2000;  | 2000WO-US000219. |
| PR | 18-SEP-1997; | 97US-0059263P. | PR | 11-FEB-2000;  | 2000WO-US003565. |
| PR | 18-SEP-1997; | 97US-0059266P. | PR | 22-FEB-2000;  | 2000WO-US004414. |
| PR | 15-OCT-1997; | 97US-0062125P. | PR | 24-FEB-2000;  | 2000WO-US005004. |
| PR | 17-OCT-1997; | 97US-0062285P. | PR | 02-MAR-2000;  | 2000WO-US005841. |
| PR | 17-OCT-1997; | 97US-0062287P. | PR | 20-MAR-2000;  | 2000WO-US007377. |
| PR | 21-OCT-1997; | 97US-0063486P. | PR | 30-MAR-2000;  | 2000WO-US008439. |
| PR | 24-OCT-1997; | 97US-0062814P. | PR | 22-MAY-2000;  | 2000WO-US014042. |
| PR | 24-OCT-1997; | 97US-0062816P. | PR | 02-JUN-2000;  | 2000WO-US015264. |
| PR | 24-OCT-1997; | 97US-0063045P. | PR | 28-JUL-2000;  | 2000WO-US020710. |
| PR | 24-OCT-1997; | 97US-0063120P. | PR | 24-AUG-2000;  | 2000WO-US023328. |
| PR | 24-OCT-1997; | 97US-0063127P. | PR | 18-SEP-2000;  | 2000US-00665350. |
| PR | 24-OCT-1997; | 97US-0063128P. | PA | (GETH )   | GENENTECH INC.   |
| PR | 27-OCT-1997; | 97US-0063327P. | XX |   |                  |
| PR | 27-OCT-1997; | 97US-0063329P. | XX |   |                  |
| PR | 28-OCT-1997; | 97US-0063541P. | PI | Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;                |                  |
| PR | 28-OCT-1997; | 97US-0063542P. | PI | Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;            |                  |
| PR | 28-OCT-1997; | 97US-0063543P. | PI | Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IU;              |                  |
| PR | 28-OCT-1997; | 97US-0063544P. | PI | Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;                  |                  |
| PR | 28-OCT-1997; | 97US-0063545P. | PI | Williams PM, Wood WI;   |                  |
| PR | 28-OCT-1997; | 97US-0063550P. | XX |   |                  |
| PR | 28-OCT-1997; | 97US-0063556P. | DR | WPI; 2004-020440/02.  |                  |
| PR | 29-OCT-1997; | 97US-0063435P. | DR | F-PSDB; ADE73976.   |                  |
| PR | 29-OCT-1997; | 97US-0063704P. | XX |   |                  |
| PR | 29-OCT-1997; | 97US-0063732P. | PT | Isolated secreted and transmembrane PRO nucleic acids and the proteins    |                  |
| PR | 29-OCT-1997; | 97US-0063734P. | PT | they encode, e.g. PRO245, PRO269 and PRO1868, useful for preventing,      |                  |
| PR | 29-OCT-1997; | 97US-0063735P. | PT | diagnosing and treating e.g. disorders relating to blood coagulation.     |                  |
| PR | 29-OCT-1997; | 97US-0063738P. | XX | Claim 2; SEQ ID NO 262; lpp; English.                                     |                  |
| PR | 31-OCT-1997; | 97US-0063870P. | XX |   |                  |
| PR | 31-OCT-1997; | 97US-0064103P. | CC | The invention discloses isolated PRO secreted/transmembrane polypeptides  |                  |
| PR | 03-NOV-1997; | 97US-0064248P. | CC | and the nucleic acid encoding them. The polypeptides can be used to raise |                  |
| PR | 07-NOV-1997; | 97US-0064809P. | CC | antibodies that specifically bind to the PRO polypeptide, for linking a   |                  |
| PR | 12-NOV-1997; | 97US-0065186P. | CC | bioactive molecule to a cell expressing a PRO protein and for modulating  |                  |
| PR | 17-NOV-1997; | 97US-0065846P. | CC | at least one biological activity of a cell. PRO polypeptides are useful   |                  |
| PR | 18-NOV-1997; | 97US-0065693P. | CC | for detecting other PRO polypeptides in a sample and for linking a        |                  |
| PR | 21-NOV-1997; | 97US-0066120P. | CC | bioactive molecule to a cell expressing a PRO polypeptide. The PRO        |                  |
| PR | 24-NOV-1997; | 97US-0066453P. | CC | polypeptide antibodies are useful for modulating the biological activity  |                  |
| PR | 24-NOV-1997; | 97US-0066466P. | CC | of a cell expressing PRO polypeptides. The PRO polypeptides or            |                  |
| PR | 24-NOV-1997; | 97US-0066511P. | CC | polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or |                  |
| PR | 24-NOV-1997; | 97US-0066770P. | CC | bioreactors. These are useful for stimulating hypertrophy of neonatal     |                  |
| PR | 24-NOV-1997; | 97US-0066772P. | CC | heart inhibiting vascular endothelial growth factor (VEGF)-stimulated     |                  |
| PR | 25-NOV-1997; | 97US-0066840P. | CC | proliferation of endothelial cells, modulating the proliferation of       |                  |
| PR | 12-DEC-1997; | 97US-0069425P. | CC | stimulated T-lymphocytes, enhancing the survival or proliferation of      |                  |
| PR | 04-JUN-1998; | 98US-0088026P. | CC | retinal neurons or rod photoreceptor cells, inducing c-fos in endothelial |                  |
| PR | 10-SEP-1998; | 98US-0098803P. | CC | cells, modulating glucose or FFA uptake, inducing proliferation and/or re |                  |
| PR | 10-SEP-1998; | 98WO-US018824. | CC | -differentiation of chondrocytes. In particular, these are useful for     |                  |
| PR | 14-SEP-1998; | 98US-0100262P. | CC | detecting or treating cardiac insufficiency disorders, wounds, cancerous  |                  |
| PR | 14-SEP-1998; | 98WO-US019177. | CC | tumours, retinal disorders or injuries (e.g. loss of sight due to         |                  |
| PR | 16-SEP-1998; | 98WO-US019330. | CC | retinitis pigmentosa), obesity, diabetes, hyperinsulinaemia, injuries or  |                  |
| PR | 17-SEP-1998; | 98US-0100859P. | CC | hypoinsulinaemia, or bone or cartilage disorders (e.g. sports injuries or |                  |
| PR | 17-SEP-1998; | 98WO-US019437. | CC | arthritis) in mammals. PRO polypeptides and their portions affect the     |                  |
| PR | 13-OCT-1998; | 98US-0104080P. | CC | expression of genes which have a role in cell death. The polynucleotides  |                  |
| PR | 20-NOV-1998; | 98US-0109304P. | CC | are useful in molecular biology including uses as hybridisation probes    |                  |
| PR | 01-DEC-1998; | 98WO-US025108. | CC | for cDNA library to isolate the full-length PRO cDNA or to isolate other  |                  |
| PR | 22-DEC-1998; | 98US-0113296P. | CC | CDNAs, in chromosome and gene mapping, in the generation of antisense RNA |                  |
| PR | 07-JUL-1999; | 99US-0143048P. | CC | cDNAs, for preparing PRO polypeptides, for generating transgenic          |                  |
| PR | 26-JUL-1999; | 99US-0145698P. | CC | animals or knockout animals which are useful in the development and       |                  |
| PR | 08-SEP-1     |                |    |   |                  |

XX SQ Sequence 1378 BP; 235 A; 461 C; 412 G; 270 T; 0 U; 0 Other;  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 26;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTCTTAAATGCACTTATTTTATGATTTTCTTAATAAATCCAGTCTCTGT 3042  
DB 1272 TTTTGTGATATAAATGTTAATGATTTTATAGTATTTGTAACTCCCTGCCACATATCT 1331  
QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
DB 1332 ATTATCTCCCAATTCATTAATTAATTTATCT 1366  
RESULT 87  
AAT27590  
ID AAT27590 standard; DNA; 132 BP.  
XX AC AAT27590;  
XX 25-MAR-2003 (revised)  
DT 06-AUG-1996 (first entry)  
XX DE Novel growth factor domain fragment B DNA.  
XX KW Tissue plasminogen activator; tPA; alpha2-plasmin inhibitor;  
KW fibrinolytic; thrombolytic; fibrin; thrombosis; blood clotting;  
KW protein engineering; growth factor domain; Factor IX; ds.  
XX OS Synthetic.  
XX PN US5504001-A.  
XX PD 02-APR-1996.  
XX PF 06-JUN-1994; 94US-00254485.  
XX PR 25-NOV-1987; 87US-00125629.  
XX PR 28-JAN-1992; 92US-00827587.  
XX PA (ZYMO ) ZYMOGENETICS INC.  
XX PI Foster DC;  
XX WPI; 1996-187699/19.  
XX P-PSDB; AAR96225.  
XX Hybrid plasminogen activator comprises human tPA activator and N-terminal  
PT crosslinking domain from alpha2-plasmin inhibitor - useful to treat  
PT thrombosis and image blood clots.  
XX Example 6; Fig 15; 35pp; English.  
XX Amino acid substitutions are designed in the growth factor domain of  
CC tissue plasminogen activator (tPA) with the goal of disrupting possible  
CC specific receptor interactions. Oligonucleotides (AAR27589-92) encoding  
CC the growth factor region replacement domains A-D (AAR96224-27) were  
CC generated from 14 different oligonucleotides. Fragment B results in  
CC replacement of tPA amino acids 52-91 with the entire growth factor region  
CC of human Factor IX. Mutant tPAs were expressed in BHK cells and  
CC characterised for plasma half life and fibrin binding properties.  
CC (Updated on 25-MAR-2003 to correct PF field.)  
XX SQ Sequence 132 BP; 39 A; 15 C; 28 G; 50 T; 0 U; 0 Other;  
Query Match 0.7%; Score 24.2; DB 1; Length 132;  
Best Local Similarity 53.8%; Pred. No. 17;  
Matches 50; Conservative 0; Mismatches 43; Indels 0; Gaps 0;  
QY 2915 TCTCTACTTATTATTTGGGATTTTAACTATTTCTTCAATGACTTGTATTCTAATAT 2974

DB 1 TCGGTACCTGTAAATCTTGTGAATCTAATCTTGCTTAATGAGGATCTTCTAAAGAT 60  
QY 2975 TTACTTATTTCTTACTTTTAAATTCACATAT 3007  
DB 61 GATATTAATTCATATGAATGTGTGTCTCTTTT 93  
RESULT 88  
AAA31550  
ID AAA31550 standard; DNA; 260 BP.  
XX AC AAA31550;  
XX 05-JUL-2000 (first entry)  
XX DE Plant microsatellite marker #511.  
XX KW Plant microsatellite sequence; core repeat sequence; detection; probe;  
KW DNA polymorphism; genome mapping; physical mapping; fingerprinting;  
KW variety identification; genetic variability evaluation; primer; ss.  
XX OS Eucalyptus grandis.  
XX PN WO9967421-A1.  
XX PD 29-DEC-1999.  
XX PF 25-JUN-1999; 99WO-NZ000092.  
XX PR 25-JUN-1998; 98US-00105307.  
XX PA (GENE-) GENESIS RES & DEV CORP LTD.  
XX PA (FLET-) FLETCHER CHALLENGE FOREST LTD.  
XX PI Havukkala IJ, Bloksberg LN, Glenn M;  
XX WPI; 2000-116958/10.  
XX New plant microsatellite markers and associated flanking species for the  
XX detection of polymorphic genetic markers.  
XX Claim 1; Page 227; 392pp; English.  
XX Sequences AAA31040-A32093 represent novel plant microsatellite sequences  
XX and associated flanking species. The sequences comprise a central core  
XX repeat sequence, especially selected from the sequences AAA32094-A32096  
XX with left and right flanking sequences. The polynucleotide sequences can  
XX be used in the detection of DNA polymorphisms, in genome mapping, in  
XX physical mapping, in positional cloning of genes, in variety  
XX identification and in evaluation of genetic variability within and  
XX between plant tissues, populations, cultivars, species and species  
XX groups. They may also be used to design hybridization probes for  
XX oligonucleotide fingerprinting and library screening and to design  
XX primers for microsatellite-primed PCR. Microsatellite markers are useful  
XX to locate specific economically useful genes in plant genomes  
XX SQ Sequence 260 BP; 51 A; 101 C; 64 G; 44 T; 0 U; 0 Other;  
Query Match 0.7%; Score 23.6; DB 1; Length 260;  
Best Local Similarity 61.3%; Pred. No. 30;  
Matches 36; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 868 ACCAGTAATGCTGAAGAAGTGAAGTTGAACGGTCTCTATGAAGACCTACAGACCTTTTA 927  
DB 78 AGCAGACATGGCGAGGGGCTGCCTGAAGGGGACATGAAGGCCACACGACATGCT 137  
QY 928 GA 929  
DB 138 GA 139  
RESULT 89  
ABX42370/c

|                       |   |
|-----------------------|---|
| ID                    | ABX42370 standard; cDNA; 361 BP.  |
| XX                    | XX  |
| AC                    | ABX42370;   |
| XX                    | XX  |
| DT                    | 20-FEB-2003 (first entry)   |
| XX                    | XX  |
| DE                    | Bovine EST associated with lactation/muscle/fat deposition #7535.         |
| XX                    | XX  |
| KW                    | Bovine; ss; EST; expressed sequence tag; lactation; LMFD;                 |
| KW                    | muscle deposition; fat deposition; genome mapping; gene identification;   |
| KW                    | gene analysis; cattle breeding.   |
| XX                    | XX  |
| OS                    | Bos Taurus.   |
| XX                    | XX  |
| PN                    | US2002137139-A1.  |
| PD                    | 26-SEP-2002.  |
| PP                    | 24-SEP-2001; 2001US-00960352.   |
| XX                    | XX  |
| PR                    | 12-JAN-1999; 99US-0115707P.   |
| PR                    | 11-JAN-2000; 2000US-00480902.   |
| XX                    | (BYAT/) BYATT J C.  |
| PA                    | (MATH/) MATHIALAGAN N.  |
| PA                    | (TAON/) TAO N.  |
| PA                    | (WARRE/) WARREN W C.  |
| XX                    | XX  |
| PI                    | Byatt JC, Mathialagan N, Tao N, Warren WC;                                |
| DR                    | WPI; 2003-110599/10.  |
| XX                    | XX  |
| PT                    | New nucleic acid associated with lactation, and muscle and fat            |
| PT                    | deposition, useful for genome mapping, gene identification and analysis,  |
| PT                    | cattle breeding, or for genetically improving cattle.                     |
| XX                    | XX  |
| PS                    | Claim 2; SEQ ID NO 7535; 245pp; English.                                  |
| XX                    | XX  |
| CC                    | The invention relates to a purified nucleic acid molecule associated with |
| CC                    | lactation or muscle and fat deposition (designated LMFD), derived from    |
| CC                    | cattle, and the LMFD nucleic acid can specifically hybridize to a second  |
| CC                    | nucleic acid molecule comprising any of 1512 nucleotide sequences,        |
| CC                    | appearing as ABX34836-ABX49947, or complements of them. Also included are |
| CC                    | ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic |
| CC                    | acid linked to a promoter and a 3' non-translated sequence that           |
| CC                    | functions in the cell to cause termination of transcription and addition  |
| CC                    | of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and   |
| CC                    | (2) determining a level or pattern of a molecule in a bovine cell or      |
| CC                    | tissue comprising: (a) incubating a marker nucleic acid (comprising any   |
| CC                    | of the 1512 nucleic acid sequences or its complement or fragment) with a  |
| CC                    | complementary nucleic acid molecule obtained from the bovine cell or      |
| CC                    | tissue, where hybridisation between the marker nucleic acid and the       |
| CC                    | complementary nucleic acid permits the detection of the molecule; and (b) |
| CC                    | detecting the level or pattern of the complementary nucleic acid, where   |
| CC                    | the detection of the complementary nucleic acid is predictive of the      |
| CC                    | level or pattern of the molecule. The LMFD nucleic acid is used for       |
| CC                    | determining a level or pattern of a molecule in a bovine cell or tissue.  |
| CC                    | It is useful for genome mapping, gene identification and analysis, cattle |
| CC                    | breeding, preparation of constructs for use in cattle gene expression, or |
| CC                    | for genetically improving cattle. The present sequence is one of the      |
| CC                    | 1512 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The    |
| CC                    | present sequence was not shown in the specification but was obtained in   |
| CC                    | electronic format from the USPTO web site:                                |
| CC                    | seqdata.uspto.gov/sequence.html?DocID=20020137139                         |
| XX                    | XX  |
| SQ                    | Sequence 361 BP; 117 A; 62 C; 83 G; 99 T; 0 U; 0 Other;                   |
| Query Match           | 0.7%; Score 23.6; DB 1; Length 361;                                       |
| Best Local Similarity | 54.7%; Pred. No. 33;  |
| Matches               | 47; Conservative 0; Mismatches 39; Indels 0; Gaps 0;                      |

2919 TACTTATTAAATTTGGCATTTTAACTATTTCCTCAATGATCTTATTCTTATTCTAATAATTAC 2978

GT



|    | CC blood disorders, AIDS, diabetes, obesity, asthma, IgA nephropathy, cirrhosis, arthritis, Alzheimer's disease, infections (e.g. bacterial, viral, parasitic), stroke, muscular dystrophy, epilepsy, and other wasting disorders associated with chronic diseases | XX   |
|----|--|------|
| SQ | Sequence 882 BP; 185 A; 303 C; 254 G; 160 T; 0 U; 0 Other;   |      |
|    | Query Match 0.7%; Score 23.4; DB 1; Length 882;  |      |
|    | Best Local Similarity 49.4%; Pred. No. 47;   |      |
|    | Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;   |      |
| Qy | 2560 GGCACCTGATCAGAAAGCTGACTACTCGAAGAGCCCTGATCTCTGGAGGAGATTGGG   | 2619 |
|    |  |      |
| Db | 450 GGCCACATGACCCACGACAGTGACAGTGGAGGCCGTGGGGAAGGAGGCGTTGGC   | 391  |
|    |  |      |
| Qy | 2620 GGCAGGAGGAGAAGGGACGACAGGATGAGATGGCTGGATGCATCATCTGACTCGATG   | 2679 |
|    |  |      |
| Db | 390 TGCAGGAGCGCAGATGGCCCGATGTAGCGGAGAAGGTGATGGTCTGCTGAGTTGGAG  | 331  |
|    |  |      |
| Qy | 2680 G-----ACGTGAGTCTGGGTGAACCTCTGGAGTTGTTGATGGACAGGGAGG   | 2725 |
|    |  |      |
| Db | 330 GAGTGCATGTGCGCCTGGAGCCCTCTCTGGAGGTAGCTGGGGTGGGGGATG  | 279  |

RESULT 93  
AAC87796/c  
ID AAC87796 standard; DNA; 1142 BP.  
XX AC AC  
XX AAC87796;  
XX DT DT  
XX 02-MAR-2001 (first entry)  
XX DE DE  
XX Activation construct CFEK2-6XHIS-TAG fusion gene vector SEQ ID NO:8.  
XX KW KW  
XX Activation construct; catalytic; fusion gene; expression vector;  
KW proteolysis; serine protease; zymogen precursor; characterisation;  
KW analysis; modulator; identification; ds.  
XX XX  
XX Homo sapiens.  
XX OS Synthetic.  
XX OS OS  
XX WO200066709-A2.  
XX PN PN  
XX PD PD  
XX 09-NOV-2000.  
XX PF PF  
XX 13-APR-2000; 200WO-US009973.  
XX PR PR  
XX 30-APR-1999; 9SUS-00303162.  
XX PA (ORTH ) ORTHO-MCNEIL PHARM RES INC.  
XX PI Darrow A, Qi J, Andrade-Gordon P;  
XX PI WPI; 2000-687533/67.  
XX DR DR  
XX PT Expression vector for producing recombinantly producing serine protease  
PT domains, comprising a presquence, a prosequence, and a cloning site for  
PT the insertion of catalytic domain cassette.  
XX PS Claim 7: Page 40-41: 89pp; English.

Claim 7; Page 40-41; 89pp; English.

The present invention describes an expression vector (I) comprising in frame and in order, a presquence, a prosequence, and a cloning site for the in frame insertion of catalytic domain cassette. (I) can be used as a modulator of proteins expressed from a zymogen activation construct. The recombinant catalytic domain of serine protease is useful for identifying compounds modulating the activity of proteases is expressed and activated from the zymogen activation construct. A method from the present invention comprises combining a modulator of the recombinant catalytic domain of a protease and measuring an effect of the modulator on the protein preferably inhibiting or enhancing its enzymatic activity or stimulation or inhibition of proteolysis mediated by the expressed catalytic domain. The present sequence represents a specifically claimed

|    |  |   |
|----|--|---|
| CC | fusion gene with a human serine protease catalytic domain from the |   |
| CC | present invention  |   |
| XX |  |   |
| XX | Sequence 1142 BP; 235 A; 360 C; 303 G; 244 T; 0 U; 0 Other;        |   |
| XX |  |   |
| XX | Query Match 0.7%; Score 23.4; DB 1; Length 1142;                   |   |
| XX | Best Local Similarity 49.4%; Pred. No. 50;                         |   |
| XX | Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;       |   |
| XX |  |   |
| QY | 2560   | GGCCACCTGATCAGAGAGCTGACTCACTGGAAAAAGACCCCTGATGCTGGAGGATGGG 2619           |
| Db | 537  | GGCCACATGACCCAGCCAGTCAGTGCGAGTGGAGCCCTTGGGGAAGAGGCGTTGCC 478              |
| QY | 2620   | GGCAGGAGGAGAGGGAGGACACAGAGGATGAGATGCTGGATGGCATCACTGACTCGATG 2679          |
| Db | 477  | TGCAGGAGGACGATGGCCGGATGTAGCCGGAGAGGTGATGGCTCTGCTGAGTTGGAG 418             |
| QY | 2680   | G-----ACGTGAGTCTGGTGAACTCCTGGAGTTGGTGATGCACAGGGAGG 2725                   |
| Db | 417  | GAGTGCATGTGCCCTTGGGAGCCCTCTGGAGGTAGTGGGGTGGGGGATG 366                     |
| XX |  |   |
| XX | RESULT 94  |   |
| XX | AAF55268/c   |   |
| XX | ID   | AAF55268 standard; DNA; 1142 BP.  |
| XX | AC   | AAF55268;   |
| XX | XX   |   |
| XX | DT   | 29-MAY-2001 (first entry)   |
| XX | XX   |   |
| XX | XX   | Nucleotide sequence of catalytic domain in CFEK2-6XHIS-TAG.               |
| XX | XX   | Expression vector; zymogen precursor; serine protease; prostatic;         |
| XX | XX   | protease; inflammation; reproduction; epidermal tissue; skin care;        |
| XX | XX   | neurological tissue; laundry detergent; stain-removing solution;          |
| XX | XX   | prolactin; protease EK; db.   |
| XX | XX   | Synthetic.  |
| XX | XX   |   |
| XX | Key  | Location/Qualifiers   |
| XX | CDS  | 13..972   |
| XX | FT   | /*tag= a  |
| XX | FT   | 13..78  |
| XX | FT   | /*tag= b  |
| XX | FT   | /note= "chymotrypsinogen presequence"                                     |
| XX | FT   | 162..951  |
| XX | FT   | /*tag= c  |
| XX | FT   | /note= "prostatic"  |
| XX | XX   |   |
| XX | PN   | WO200116289-A2.   |
| XX | XX   |   |
| XX | PD   | 08-MAR-2001.  |
| XX | XX   |   |
| XX | PF   | 14-AUG-2000; 2000WO-US022283.   |
| XX | XX   |   |
| XX | PR   | 31-AUG-1999; 99US-00386642.   |
| XX | XX   |   |
| XX | PA   | (ORTH ) ORTHO-MCNEIL PHARM INC.   |
| XX | PI   | Darrow A, Qi J, Andrade-Gordon P;   |
| XX | XX   |   |
| XX | XX   | WPI; 2001-218523/22.  |
| XX | DR   | P-FSDB; AAB67541.   |
| XX | XX   |   |
| XX | PT   | An expression vector for the expression of inactive zymogen proteases     |
| XX | PT   | useful for therapeutic or commercial products comprises a pre-sequence, a |
| XX | PT   | pro-sequence and a cloning site for in frame insertion of a catalytic     |
| XX | PT   | domain cassette.  |
| XX | XX   |   |
| XX | PS   | Claim 7; Fig 4A-D; 175pp; English.  |
| XX | XX   |   |
| XX | XX   | The specification describes an expression vector system that will permit, |
| XX | CC   | through limited proteolysis, the activation of expressed zymogen          |
| XX | CC   |   |





XX WO200116289-A2.  
PN XX  
XX PD  
XX PF  
PF 14-AUG-2000; 2000WO-US022283.  
XX 31-AUG-1999; 99US-00386642.  
XX (ORTH ) ORTHO-MCNEIL PHARM INC.  
XX Darrow A, Qi J, Andrade-Gordon P;  
XX WPI; 2001-218523/22.  
DR F-PDSB; AA567540.  
XX  
XX An expression vector for the expression of inactive zymogen proteases useful for therapeutic or commercial products comprises a pre-sequence, a pro-sequence and a cloning site for in frame insertion of a catalytic domain cassette.

XX Claim 7; Fig 3A-D; 175pp; English.

XX The specification describes an expression vector system that will permit, through limited proteolysis, the activation of expressed zymogen precursors of serine proteases (e.g. prostasin) in a highly controlled and reproducible fashion. The expression vector comprises, in frame and in order, a pre-sequence, a pro-sequence and a cloning site for in frame insertion of a catalytic domain cassette. The expression vectors of the invention are useful for the expression of heterologous inactive zymogen proteases that can subsequently be proteolytically processed to generate the active enzyme product. The active enzyme produce can be useful for directly treating diseases associated with inflammatory, reproductive, epidermal or neurological tissue or for identifying modulators of protease activity which can be used for treatment. The proteases can also be used in commercial products, e.g. laundry detergents, stain-removing solutions and skin care products. The present sequence represents the catalytic domain in an expression vector of the invention. The construct encodes a prostasin protease sequence

XX Sequence 1169 BP; 248 A; 358 C; 313 G; 250 T; 0 U; 0 Other;

Query Match 0.7%; Score 23.4; DB 1; Length 1169;  
Best Local Similarity 49.4%; Pred.No.51;  
Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;

QY 2560 GGCCACCTCATCAGAAAGAGTCACTCACATGGAAGAACCCTGTACTGGGAGGAGATTGGG 2619  
DB 564 GGCCACATGACCCACCCAGTCAGTCAGTGAGGCCCGTTGGGGAAGAGGCGTTGC 505  
QY 2620 GGCAAGAGAGAGAGGGAGCGACAGAGAGTAGATGGCTGGATGGCATCACTGACTCGATG 2679  
DB 504 TGCAGGAGGAGCGAGATGGGCGGATGTATGGCGGAGAAAGGTGATGGGTCTGCTGAGTTGGAG 445  
QY 2680 G-----ACGTGAGTCTGGTGAACCTCCCTGGAGTTCGTGATGACAGGGAGG 2725  
DB 444 GAGTGAATGTGCCCTTGGAGCCCTCTCTGGAGGTAGCTGGGGTGGGGGATG 393

RESULT 98  
AAA54031/c  
ID AAA54031 standard; DNA; 1507 BP.  
XX AC  
XX AAA54031;  
XX  
XX 08-FEB-2001 (first entry)  
XX Human factor X coding sequence.

XX Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric protein;  
KW fusion protein; coagulation factor; Factor X; Factor VII; Protein S;  
KW Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;  
KW ds.





XX WPI; 1999-167446/14.

XX Determination of HLA class I group type of a subject - using group

PT specific untranslated region primer pair.

XX Disclosure; Fig 13; 195pp; English.

XX The present invention describes a method using novel primers involving

CC the PCR-based determination of histocompatibility locus antigen B (HLA-B)

CC Class I group type. Determining the HLA-B Class I group type of a subject

CC comprises: (i) combining a group-specific untranslated region primer pair

CC with a target DNA sample from the subject under conditions such that

CC primer-based amplification of the target DNA may occur; and (ii)

CC determining whether a nucleic acid product is produced by the

CC amplification; where the ability of the primer pair to produce a nucleic

CC acid product is associated with a particular HLA group type. The method

CC can be used for HLA-B typing. In the method, the initial group specific

CC amplification allows a PCR based separation of haplotypes in 95% of

CC patient samples. It permits the resolution of cis/trans linkages of

CC heterozygote sequencing results which cannot be achieved with other

CC protocols. AAX37845 to AAX38286 represent DNA sequence used in the

CC exemplification of the present invention

XX Sequence 244 BP; 31 A; 91 C; 90 G; 32 T; 0 U; 0 Other;

Query Match 0.6%; Score 23; DB 1; Length 244;

Best Local Similarity 60.3%; Pred. No. 42;

Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 2691 GGCTGAACCTCTGCGAGTGGTGATGCACAGGAGGCGCTCTCTCGCGGATTCATGCGGT 2750

DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2751 CAC 2753

DB |||||

7 CAC 5

RESULT 103

AAT76438/C

ID AAT76438 standard; DNA; 250 BP.

AC AAT76438;

DT 16-SEP-1997 (first entry)

DE Substance P antisense oligonucleotide.

XX Asthma; airway epithelium; adenosine free; cystic fibrosis;

KW chronic obstructive pulmonary disease; bronchitis; ss.

XX Synthetic.

XX WO9640162-A1.

PN 19-DEC-1996.

PD 06-JUN-1996; 96WO-US009306.

PF 07-JUN-1995; 95US-00474497.

PR (UYEC-) UNIV EAST CAROLINA.

PA Nyce JW, Metzger WJ;

XX WPI; 1997-051871/05.

DR Treatment of airway diseases such as asthma - by topically applying

PT adenosine-free antisense oligonucleotide to airway epithelium of

XX subject.

PS Example 5; Page 39; 71pp; English.

XX A method for treating airway disease in a subject has been produced,

CC which involves the topical administration of an essentially adenosine

CC free antisense oligonucleotide (ON) to the airway epithelium of the

CC subject. The present sequence is an antisense oligonucleotide specific

CC for the substance P, targeted at the initiation codon. The method can be

CC used to treat airway diseases such as cystic fibrosis, asthma, chronic

CC obstructive pulmonary disease, bronchitis and other airway diseases

CC characterised by an inflammatory response. By eliminating adenosine from

CC the antisense ON, its liberation upon antisense degradation is prevented,

CC thereby preventing adenosine-induced bronchoconstriction in patients with

CC hyper-reactive airways

XX Sequence 250 BP; 1 A; 64 C; 70 G; 65 T; 0 U; 50 Other;

Query Match 0.6%; Score 23; DB 1; Length 250;

Best Local Similarity 38.5%; Pred. No. 43;

Matches 52; Conservative 26; Mismatches 57; Indels 0; Gaps 0;

QY 184 AACTAGTCAATCTAATCACACTAGGACCAAGAGCTGTCTTAACTCAATGAATAGCCCA 243

DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

238 AACACAGAGAACTCAGCACCCCGCGGAGCVGCGVCCAAAACCAACAVGAAAVCCV 179

QY 244 TGCCCGTGGGGCAACCAAGATGGGAGGTCATGCTGGAGAGATCTCAGAGATGTGGTC 303

DB ||: ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

178 CGVGGCCVGGCAGCVVVVVVVCVGVCCACVCGCVGVVGGCAGAAAVAGGAGC 119

QY 304 CACTGGAGAGGGAA 318

DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

118 CAAVGAAGVAVCGAA 104

RESULT 104

AAX54759/C

ID AAX54759 standard; DNA; 250 BP.

XX AAX54759;

AC AAX54759;

DT 05-JUL-1999 (first entry)

XX Substance P antisense oligonucleotide fragment.

DE Antisense oligonucleotide; multiple target; antisense treatment;

KW impaired respiration; inflammation; lung disease;

KW pulmonary vasoconstriction; inflammation; allergic rhinitis;

KW acute asthma; allergy; asthma; impeded respiration;

KW respiratory distress syndrome; pain; cystic fibrosis;

KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;

KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;

KW colon cancer; breast cancer; lung cancer; pancreatic cancer;

KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;

KW prostate cancer; ss.

XX Synthetic.

XX WO9913886-A1.

PN 25-MAR-1999.

PD 17-SEP-1998; 98WO-US019419.

PF 17-SEP-1997; 97US-0059160P.

PR 09-JUN-1998; 98US-00093972.

XX (UYEC-) UNIV EAST CAROLINA.

PA Nyce JW;

XX WPI; 1999-229400/19.

DR New antisense oligonucleotides used in treatment of, e.g. pulmonary

PT vasoconstriction.

XX







Db 238 AACACAGAGAACTCAGCAGCCCGGCGGACVGCVCAGAAAVCAACAVGAAAVCCV 179  
Cc  
Qy 244 TGCCCGTGGGCGCAACCAAGATGGCAGGTCATGTTGGAGAGATCTGACAGAAATGGTTC 303  
Cc  
Db 178 CGVGGCCVGGCAGCVVVVVVVCVVGVCVCCACVCGCVGVVVGACAGAAAVAGGACC 119  
Cc  
Qy 304 CACTGGAGAGGGNA 318  
Cc  
Db 118 CAAVGAAGVAVCGVGA 104  
Cc  
RESULT 108  
ABX46375  
ID ABX46375 standard; cDNA; 370 BP.  
XX  
AC ABX46375;  
XX  
XX 21-FEB-2003 (first entry)  
XX  
XX Bovine EST associated with lactation/muscle/fat deposition #11540.  
XX  
XX Bovine; ss; EST; expressed sequence tag; lactation; LMFD;  
XX muscle deposition; fat deposition; genome mapping; gene identification;  
XX gene analysis; cattle breeding.  
XX  
XX Bos Taurus.  
XX  
XX US2002137139-A1.  
XX  
XX 26-SEP-2002.  
XX  
XX 24-SEP-2001; 2001US-00960352.  
XX  
XX 12-JAN-1999; 99US-0115707P.  
XX  
XX 11-JAN-2000; 2000US-00480902.  
XX  
XX (BYAT/) BYATT J C.  
XX (NATH/) NATHIALAGAN N.  
XX (TAON/) TAO N.  
XX (WARR/) WARREN W C.  
XX  
XX Byatt JC, Nathialagan N, Tao N, Warren WC;  
XX WPI; 2003-110599/10.  
XX  
XX New nucleic acid associated with lactation, and muscle and fat  
XX deposition, useful for genome mapping, gene identification and analysis,  
XX cattle breeding, or for genetically improving cattle.  
XX  
XX Claim 2; SEQ ID NO 11540; 245pp; English.  
XX  
XX The invention relates to a purified nucleic acid molecule associated with  
XX lactation or muscle and fat deposition (designated LMFD), derived from  
XX cattle, and the LMFD nucleic acid can specifically hybridize to a second  
XX nucleic acid molecule comprising any of 15112 nucleotide sequences,  
XX appearing as ABX34836-ABX49947, or complements of them. Also included are  
XX ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic  
XX acid linked to a promoter and a 3' non-translated sequence that  
XX functions in the cell to cause termination of transcription and addition  
XX of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
XX (2) determining a level or pattern of a molecule in a bovine cell or  
XX tissue comprising: (a) incubating a marker nucleic acid (comprising any  
XX of the 15112 nucleic acid sequences or its complement or fragment) with a  
XX complementary nucleic acid molecule obtained from the bovine cell or  
XX tissue, where hybridisation between the marker nucleic acid and the  
XX complementary nucleic acid permits the detection of the molecule; and (b)  
XX detecting the level or pattern of the complementary nucleic acid, where  
XX the detection of the complementary nucleic acid is predictive of the  
XX level or pattern of the molecule. The LMFD nucleic acid is used for  
XX determining a level or pattern of a molecule in a bovine cell or tissue.  
XX It is useful for genome mapping, gene identification and analysis, cattle  
XX breeding, preparation of constructs for use in cattle gene expression, or  
XX for genetically improving cattle. The present sequence is one of the

Cc 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The  
Cc present sequence was not shown in the specification but was obtained in  
Cc electronic format from the USPTO web site:  
Cc seqdata.uspto.gov/sequence.html?DocID=20020137139  
Cc  
XX Sequence 370 BP; 126 A; 58 C; 77 G; 109 T; 0 U; 0 Other;  
Sg  
Query Match 0.6%; Score 23; DB 1; Length 370;  
Best Local Similarity 54.0%; Pred. NO. 47;  
Matches 47; Conservative 0; Mismatches 40; Indels 0; Gaps 0;  
Qy 1560 ATAAAGCATCTCAATGCAGAGTTCACAGAACTCCAGAGTTCAGCTGTTTAA 1619  
Db 78 ATGAAGGAAATATATGATATATACCAAGGTGTCCTCCGTTATGTCACACTGGA 137  
Qy 1620 AAGTCAGAGGACACAGAGACCAAAATG 1646  
Db 138 AAAACAAGCTCACATAAAGAAAATG 164  
RESULT 109  
ABV97874  
ID ABV97874 standard; cDNA; 381 BP.  
XX  
AC ABV97874;  
XX  
XX 14-JAN-2003 (first entry)  
XX  
XX Human pancreatic cancer expressed cDNA SEQ ID NO 3282.  
XX  
XX Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;  
XX cytostatic; tumour; gene; ss.  
XX  
XX Homo sapiens.  
XX  
XX W0200260317-A2.  
XX  
XX 08-AUG-2002.  
XX  
XX 30-JAN-2002; 2002WO-US002781.  
XX  
XX 30-JAN-2001; 2001US-0265305P.  
XX  
XX 31-JAN-2001; 2001US-0265682P.  
XX  
XX 09-FEB-2001; 2001US-0267568P.  
XX  
XX 21-MAR-2001; 2001US-0278651P.  
XX  
XX 28-APR-2001; 2001US-0287112P.  
XX  
XX 16-MAY-2001; 2001US-0291631P.  
XX  
XX 12-JUL-2001; 2001US-0305484P.  
XX  
XX 20-AUG-2001; 2001US-0313999P.  
XX  
XX 27-NOV-2001; 2001US-0333626P.  
XX  
XX (CORI-) CORIXA CORP.  
XX  
XX Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;  
XX WPI; 2002-627435/67.  
XX  
XX New isolated polynucleotide and pancreatic tumor polypeptides, useful for  
XX diagnosing, preventing and/or treating cancer, particularly pancreatic  
XX cancer.  
XX  
XX Claim 1; SEQ ID NO 3282; 300pp + Sequence Listing; English.  
XX  
XX The invention relates to an isolated polynucleotide (I) comprising: (a)  
XX any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)  
XX complements of (a); (c) sequences consisting of at least 20 contiguous  
XX residues of (a); (d) sequences that hybridize to (a) under moderately  
XX stringent conditions; (e) sequences having at least 75% or 90% identity  
XX to (a); or (f) degenerate variants of (a). Polypeptides (ABV68596-  
XX ABV6637) encoded by (I) and oligonucleotide can be used to detect cancer  
XX in a patient and compositions comprising polypeptides, polynucleotides,  
XX antibodies, fusion proteins, T cell populations and antigen presenting  
XX cells expressing the polypeptide are useful in treating pancreatic cancer

CC and stimulating an immune response. The polynucleotides can be used as probes or primers for nucleic acid hybridisation, in the design and preparation of ribozyme molecules for inhibiting expression of the tumour polypeptides and proteins in the tumour cells, in vaccines and for gene therapy. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

SQ Sequence 381 BP; 81 A; 97 C; 93 G; 104 T; 0 U; 6 Other;  
 Query Match 0.6%; Score 23; DB 1; Length 381;  
 Best Local Similarity 83.9%; Pred. No. 48;  
 Matches 26; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 3235 TTATAATAAGCTTTTTTTTTTTTTTTTTTTTTTTT 3265  
 DB 1 TTGTACAGCTTTTTTTTTTTTTTTTTTTTTTTT 31

RESULT 110  
 AAN60065  
 ID AAN60065 standard; DNA; 2438 BP.  
 AC AAN60065;  
 XX 25-MAR-2003 (revised)  
 DT 31-OCT-2002 (revised)  
 DT 23-MAY-1991 (first entry)  
 XX Factor IX/Factor VII cDNA fusion.  
 XX Factor VII; Factor IX; DNA construct.

XX Unidentified.  
 OS  
 FH Key Location/Qualifiers  
 FT CDS 7..1368  
 FT /\*tag= a  
 XX EF200421-A.  
 XX 10-DEC-1986.  
 XX 16-APR-1986; 86EP-00302855.  
 XX 17-APR-1985; 85US-00724311.  
 PR 16-DEC-1985; 85US-00810002.  
 XX (ZYMO ) ZYMOGENETICS INC.

PI Hagen FS, Murry MJ, Berkner KL, Insley MY, Woodbury RG, Gray CL;  
 XX WPI; 1986-326899/50.  
 DR P-PSDB; AAP60057.

XX DNA construct used to transfect hosts - to produce protein which  
 PT activates to give factor VIIa.

XX Disclosure; Fig 7; 55pp; English.

XX The cDNA is a fusion of Factor IX and Factor VII. It is used to express  
 CC Factor IX and Factor VII. cDNA encoding Factor VII can be used in DNA  
 CC construct which contains a nucleotide sequence encoding a protein which,  
 CC on activation, has the same biological activity for blood coagulation as  
 CC Factor VIIa. The nucleotide codes at least partially for Factor VII and  
 CC comprises a sequence encoding a calcium binding domain joined to a second  
 CC sequence downstream of this encoding a catalytic domain for the serine  
 CC protease activity of Factor VIIa. The calcium binding domain comprises a  
 CC gene encoding Factor VII, IX, X, Protein C, prothrombin or Protein S. The  
 CC construct is used to transfect host cells to produce the protein which,  
 CC on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing  
 CC OS field.) (Updated on 25-MAR-2003 to correct PA field.)

SQ Sequence 2438 BP; 658 A; 670 C; 666 G; 444 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 23; DB 1; Length 2438;  
 Best Local Similarity 50.5%; Pred. No. 77;  
 Matches 56; Conservative 0; Mismatches 55; Indels 0; Gaps 0;  
 QY 1661 ATCATGGAAGCAAGAGAGTTCAGAAAAACATCTATTTCTGCTTTATGACTATGCA 1720  
 DB 25 ATCATGGAGAATCACCAGGCTCATCACCATCTGCTTTTAGGATATCTACTCAGTGCT 84  
 QY 1721 AAGCCTTTGACTGTGGGGTCAACAATAAACTGTGAAAAATCTGAAAGG 1771  
 DB 85 GAAGTACAGTTTCTTTTGATCATGAAGACCCACAAAATTTCTGAATCGG 135

RESULT 111  
 AAC55669/c  
 ID AAC55669 standard; cDNA; 231 BP.

AC AAC55669;  
 XX 17-JAN-2001 (first entry)  
 DT Human differentially regulated gene from Fig 35.

XX Human; differentially regulated gene; macrophage development; diagnosis;  
 KW matrix metalloproteinase 19; MMP19; antiarthritis; antiinflammatory;  
 KW destructive macrophage development inhibitor; arthritis;  
 KW colorectal cancer; immune response; ss.

XX Homo sapiens.

XX WO200055373-A2.

XX 21-SEP-2000.

XX 15-MAR-2000; 2000WO-US006883.

XX 15-MAR-1999; 99US-0124530P.

XX (BOSB-) BOS BIOTECHNOLOGY INC.

XX Murray R;

XX WPI; 2000-628200/60.

XX Screening drug candidates comprises adding a drug to a cell expressing an  
 PT expression profile gene and determining the effect of the drug on the  
 PT expression of the expression profile gene.

XX Example 2; Fig 35; 99pp; English.

XX The present invention describes a method for screening drug candidates.  
 CC The method comprises adding a drug to a cell that expresses an expression  
 CC profile gene encoding a protein encoded by 5 sequences of defined base  
 CC pairs as given in C55638, C55642, C55643, C55644 and C55653 or a sequence  
 CC represented by Genbank accession number X92521, X62466, J04130, X62087  
 CC and X76534 (or a fragment) and determining the effect of the drug on the  
 CC expression of the expression profile gene. An inhibitor of matrix  
 CC metalloproteinase 19 (MMP-19), preferably an antibody, is useful for  
 CC treating destructive macrophage disorders (DMD) by inhibiting DM  
 CC development in a cell of an individual having arthritis. Antibodies to  
 CC MMP-19 are useful for localising a therapeutic moiety preferably  
 CC cytotoxic agent or a radioisotope to colorectal cancer tissue. A  
 CC composition comprising MMP-19 is useful for eliciting an immune response  
 CC in an individual. C55635 to C55710 represent human differentially  
 CC regulated genes of the invention

SQ Sequence 231 BP; 66 A; 65 C; 61 G; 39 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.8; DB 1; Length 231;  
 Best Local Similarity 79.4%; Pred. No. 47;  
 Matches 27; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

The invention relates to diagnosing (M1) a destructive macrophage disorder (DMD) or determining (M2) the prognosis of an individual with DMD, by determining the expression or level of matrix metalloproteinase (MMP)-19, (M1) involves comparing the expression of the gene encoding MMP-19 in a first tissue type of a first individual, with expression of the gene from second normal tissue from the individual. (M2) involves determining level of MMP-19 in sample, where high level of MMP-19 indicates poor prognosis. Also included are screening (M3) drug candidates (involves providing a cell that expresses an expression profile gene which encodes a protein encoded by any one of 5 expression profile genes which are nucleic acids differentially expressed in the development path of destructive macrophages (DMs), referred as DM sequences, and the sequence represented by accession number X32521, X62466, J04130, X62078 and X76534, or its fragment; adding a drug candidate to the cell, and determining the effect of the drug candidate on the expression of the expression profile gene), screening (M4) for a bioactive agent capable of binding to a destructive macrophage (DM) modulator protein or a bioactive agent capable of modulating the activity of a DM modulator protein (where the DM modulator protein is MMP-19 or its fragment), a biochip (comprising a nucleic acid segment encoding MMP-19, or its fragment, comprising fewer than 1000 nucleic acid probes), an anti MMP-19 antibody (I1) which specifically binds to MMP-19, or its fragment, screening for a bioactive agent capable of interfering with the binding of a DM modulator protein or its fragment and an antibody which binds to the DM modulator protein or its fragment and inhibiting DMD in a cell by administering antisense molecules to MMP 19. The antibody is useful for treating an individual for DMD by inhibiting MMP19. The DM

CC polyketide biosynthesis. The present sequence is S. amphibiosporus  
 CC lactimidomycin ORF2 DNA  
 XX  
 SQ Sequence 255 BP; 51 A; 75 C; 84 G; 45 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 22.8; DB 1; Length 255;  
 Best Local Similarity 56.8%; Pred. No. 49;  
 Matches 42; Conservative 0; Mismatches 32; Indels 0; Gaps 0;  
 QY 981 AGTAGGAGCAAGAACAACCTCGAGTACAGCAAAATTGGCTTGGAAATACGGAATGA 1040  
 DB 5 AGCAGGAACCTCAAGCAGTACATGGAAGACAGTTCATGTTTCGAGTTCGATTCGGAGATCA 64  
 QY 1041 AGCAGGCGCAAGAC 1054  
 DB 65 CCGAGGACCCGAC 78  
 RESULT 114  
 ABX36877/c  
 ID ABX36877 standard; cDNA; 356 BP.  
 XX  
 AC ABX36877;  
 XX  
 DT 20-FEB-2003 (first entry)  
 XX  
 DE Bovine EST associated with lactation/muscle/fat deposition #2042.  
 XX  
 KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;  
 KW muscle deposition; fat deposition; genome mapping; gene identification;  
 KW gene analysis; cattle breeding.  
 XX  
 OS Bos Taurus.  
 XX  
 PN US20021371139-A1.  
 XX  
 PD 26-SEP-2002.  
 XX  
 PF 24-SEP-2001; 2001US-00960352.  
 XX  
 PR 12-JAN-1999; 99US-0115707P.  
 PR 11-JAN-2000; 2000US-00480902.  
 XX  
 PA (BYAT/) BYATT J C.  
 PA (MATH/) MATHIALAGAN N.  
 PA (TAON/) TAO N.  
 PA (WARR/) WARREN W C.  
 XX  
 PI Byatt JC, Mathialagan N, Tao N, Warren WC;  
 XX  
 DR WPI; 2003-110599/10.  
 XX  
 PT New nucleic acid associated with lactation, and muscle and fat  
 PT deposition, useful for genome mapping, gene identification and analysis,  
 PT cattle breeding, or for genetically improving cattle.  
 XX  
 PS Claim 2; SEQ ID NO 2042; 245pp; English.

CC The invention relates to a purified nucleic acid molecule associated with  
 CC lactation or muscle and fat deposition (designated LMFD), derived from  
 CC cattle, and the LMFD nucleic acid can specifically hybridize to a second  
 CC nucleic acid molecule comprising any of 15112 nucleotide sequences,  
 CC appearing as ABX34836-ABX49947, or complements of them. Also included are  
 CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic  
 CC acid linked to a promoter and a 3' non-translated sequence that  
 CC functions in the cell to cause termination of transcription and addition  
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
 CC (2) determining a level or pattern of a molecule in a bovine cell or  
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any  
 CC of the 15112 nucleic acid sequences or its complement or fragment) with a  
 CC complementary nucleic acid molecule obtained from the bovine cell or  
 CC tissue, where hybridisation between the marker nucleic acid and the  
 CC complementary nucleic acid permits the detection of the molecule; and (b)

CC detecting the level or pattern of the complementary nucleic acid, where  
 CC the detection of the complementary nucleic acid is predictive of the  
 CC level or pattern of the molecule. The LMFD nucleic acid is used for  
 CC determining a level or pattern of a molecule in a bovine cell or tissue.  
 CC It is useful for genome mapping, gene identification and analysis, cattle  
 CC breeding, preparation of constructs for use in cattle gene expression, or  
 CC for genetically improving cattle. The present sequence is one of the  
 CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The  
 CC present sequence was not shown in the specification but was obtained in  
 CC electronic format from the USPTO web site:  
 CC seqdata.uspto.gov/sequence.html?docID=20020137139

SQ Sequence 356 BP; 76 A; 107 C; 106 G; 67 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.8; DB 1; Length 356;  
 Best Local Similarity 56.8%; Pred. No. 53;  
 Matches 42; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGCTGATCGATGACGTGAGTCTGGTGAACCTCTGGAGTTGG 2710  
 DB 150 GCTGGCTCTGGAGAACACATGAGTCAGGAGGAGCTGGTGTGCTGGAATTCGCCAGATGG 91  
 QY 2711 TGATGGACAGGAG 2724  
 DB 90 TCAGAACAGTAAG 77

RESULT 115

ABX35924/c

ID ABX35924 standard; cDNA; 399 BP.

XX

AC ABX35924;

XX

DT 20-FEB-2003 (first entry)

XX

DE Bovine EST associated with lactation/muscle/fat deposition #1089.

XX

KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;

KW muscle deposition; fat deposition; genome mapping; gene identification;

KW gene analysis; cattle breeding.

XX

OS Bos Taurus.

XX

PN US20021371139-A1.

XX

PD 26-SEP-2002.

XX

PF 24-SEP-2001; 2001US-00960352.

XX

PR 12-JAN-1999; 99US-0115707P.

PR

PR 11-JAN-2000; 2000US-00480902.

XX

PA (BYAT/) BYATT J C.

PA

PA (MATH/) MATHIALAGAN N.

PA

PA (TAON/) TAO N.

PA

PA (WARR/) WARREN W C.

XX

PI Byatt JC, Mathialagan N, Tao N, Warren WC;

XX

DR WPI; 2003-110599/10.

XX

PT New nucleic acid associated with lactation, and muscle and fat

PT deposition, useful for genome mapping, gene identification and analysis,

PT cattle breeding, or for genetically improving cattle.

XX

PS Claim 2; SEQ ID NO 1089; 245pp; English.

XX

CC The invention relates to a purified nucleic acid molecule associated with  
 CC lactation or muscle and fat deposition (designated LMFD), derived from  
 CC cattle, and the LMFD nucleic acid can specifically hybridize to a second  
 CC nucleic acid molecule comprising any of 15112 nucleotide sequences,  
 CC appearing as ABX34836-ABX49947, or complements of them. Also included are  
 CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic  
 CC acid linked to a promoter and a 3' non-translated sequence that  
 CC functions in the cell to cause termination of transcription and addition  
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
 CC (2) determining a level or pattern of a molecule in a bovine cell or  
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any  
 CC of the 15112 nucleic acid sequences or its complement or fragment) with a  
 CC complementary nucleic acid molecule obtained from the bovine cell or  
 CC tissue, where hybridisation between the marker nucleic acid and the  
 CC complementary nucleic acid permits the detection of the molecule; and (b)









XX DT 09-OCT-2001 (first entry)

XX XX Probe #1524 used to measure gene expression in human breast sample.

DE XX Probe; human; breast disease; breast cancer; development disorder; ss;

KW XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.

XX XX Homo sapiens.

XX XX WO200157270-A2.

XX XX 09-AUG-2001.

XX XX 29-JAN-2001; 2001WO-US000661.

XX PF 04-FEB-2000; 2000US-0180312P.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 30-JUN-2000; 2000US-00608408.

XX PR 03-AUG-2000; 2000US-00632366.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX XX (MOLE-) MOLECULAR DYNAMICS INC.

XX XX Penn SG, Hanzel DK, Chen W, Rank DR;

XX XX WPI; 2001-476286/51.

XX XX Novel single exon nucleic acid probe used to measuring gene expression in

XX XX a human breast.

XX XX Claim 25; SEQ ID NO 1524; 322bp; English.

XX CC The present invention relates to novel single exon nucleic acid probes.

XX CC measuring human gene expression in a human breast sample. The probes are useful for

XX CC hybridises at high stringency to a nucleic acid expressed in the human

XX CC breast. The probes are useful for predicting, diagnosing, grading,

XX CC staging, monitoring and prognosing diseases of the human breast,

XX CC particularly those diseases with polygenic aetiology. The diseases

XX CC include: breast cancer, disorders of development, inflammatory diseases

XX CC of the breast, fibrocystic changes, proliferative breast disease and non-

XX CC carcinoma tumours. Note: The sequence data for this patent did not form

XX CC part of the printed specification, but was obtained in electronic format

XX CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 468 BP; 122 A; 106 C; 129 G; 111 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.6; DB 1; Length 468;

Best Local Similarity 60.7%; Pred. No. 65;

Matches 37; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 2608 CGAGGGATTGGGCGAGGAGGAGGCGAGGAGGATGAGATGGCTGGATGCGATC 2667

DB 79 CGAGGGAGTGGGCGAGGAGGAGGCGAGGAGGATGAGATGGCTGGATGCGATC 138

QY 2668 A 2668

DB 139 A 139

RESULT 123

AA60063

ID AA60063 standard; cDNA; 2177 BP.

XX XX

XX AC AA60063;

XX XX 25-MAR-2003 (revised)

DT 31-OCT-2002 (revised)

DT 23-MAY-1991 (first entry)

XX XX

DE Partial Factor VII cDNA.

XX XX Factor VII; Factor VIIa; DNA construct.

XX XX Homo sapiens.

XX XX Key Location/Qualifiers

XX FT 13..1128

XX FT /\*tag= a

XX XX EP200421-A.

XX XX 10-DEC-1986.

XX XX 16-APR-1986; 86EP-00302855.

XX XX 17-APR-1985; 85US-00724311.

XX XX 16-DEC-1985; 85US-00810002.

XX XX (ZYMO) ZYMOGENETICS INC.

XX XX Hagen FS, Murry MJ, Berkner KL, Inasley MY, Woodbury RG, Gray CL;

XX XX WPI; 1986-326899/50.

XX XX P-PSDB; AAP60055.

XX XX DNA construct used to transfect hosts - to produce protein which

XX XX activates to give factor VIIa.

XX XX Disclosure; Fig 1A; 55pp; English.

XX CC The partial factor VII cDNA sequence is produced by joining portions of

XX CC cDNA clones lambda VII2115 and lambda VII1923. It is used in a DNA

XX CC construct which contains a nucleotide sequence encoding a protein which,

XX CC on activation, has the same biological activity for blood coagulation as

XX CC factor VIIa. The nucleotide codes at least partially for factor VII and

XX CC comprises a sequence encoding a calcium binding domain joined to a second

XX CC sequence downstream of this encoding a catalytic domain for the serine

XX CC protease activity of Factor VIIa. The calcium binding domain comprises a

XX CC gene encoding Factor VII, IX, X, Protein C, prothrombin or protein S. The

XX CC construct is used to transfect host cells to produce the protein which,

XX CC on activation, yields Factor VIIa. (Updated on 31-OCT-2002 to add missing

XX CC OS field.) (Updated on 25-MAR-2003 to correct PA field.)

XX SQ Sequence 2177 BP; 569 A; 624 C; 605 G; 379 T; 0 U; 0 Other;

Query Match 0.6%; Score 22.6; DB 1; Length 2177;

Best Local Similarity 48.8%; Pred. No. 94;

Matches 61; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

QY 2186 TCTCAGACTTATTTTGGGGGCTCCAAATCACTGCAGATGTGACTGCAGCATGA 2245

DB 2045 TTCTCCCTTCTGCTGGGTGGGGTGCACAGACTATTCCCACTGCTTCCAGCTTCA 2104

QY 2246 AATTAAGACACTTACCTCTGGAGAGAAAGTTAACCACTAGATGATATTGAAA 2305

DB 2105 CATTAACGGCTGCTCTCTCGCAAAAAA 2164

QY 2306 GCAGA 2310

DB 2165 AAAAA 2169

RESULT 124

ABN76724/c

ID ABN76724 standard; cDNA; 186 BP.

XX XX

XX AC ABN76724;

XX XX 08-JUL-2002 (first entry)

XX XX Human ORF1671 cDNA, SEQ ID NO:3341.

XX XX

Human; ORF; open reading frame; ORFX; drug screening; diagnosis; disease monitoring; cytokine; cell proliferation; cell differentiation; immune modulation; haematopoiesis regulation; tissue growth; angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic; thrombolytic; tumour inhibition; bodily characteristics; fertility; behaviour; cancer; proliferative disorder; neurological disorder; cardiovascular disease; immune system disorder; organ transplantation; tissue growth disorder; tissue regeneration disorder; diabetes mellitus; hypothyroidism; cholesterol ester storage disease; infection; vulnery; vasotropic; antipsoriatic; antidiabetic; cytostatic; nootropic; neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic; cardiant; hypotensive; antithyroid; antiinflammatory; immunomodulator; dermatological; analgesic; virucide; antibacterial; fungicide; gene; ss.

Homo sapiens.

WO200190366-A2.

29-NOV-2001.

24-MAY-2001; 2001WO-US017076.

24-MAY-2000; 2000US-0206690P.

(CURA-) CURAGEN CORP.

Leach MD, Shinkets RA;

WPI; 2002-106300/14.

P-PSDB; ABP32698.

Novel human polypeptides and polynucleotides useful for diagnosing, preventing and treating cardiovascular disease, neurodegenerative, hyperproliferative disorders and disorders related to organ transplantation.

Claim 1; Page 1094; 2508pp; English.

Sequences ABP31028-ABP35561 represent 4534 novel human proteins designated ORF (open reading frame) 1-4534, and sequences ABN75054-ABN79587 represent cDNAs encoding them. The invention also encompasses polypeptides at least 80% identical to the ORF1-ORF4534 (collectively referred to as ORFX) proteins, polynucleotides at least 85% identical to the ORFX nucleic acid sequences, vectors and host cells comprising ORFX polynucleotides, the recombinant production of ORFX proteins, antibodies specific for ORFX proteins, methods of detecting ORFX polynucleotides and polypeptides, methods of screening for modulators of ORFX expression or activity, and methods of screening individuals for a predisposition to an ORFX-associated disorder. The ORFX proteins of the invention have a wide range of biological activities, such as cytokine, cell proliferation, cell differentiation, immune modulation, haematopoiesis regulation, tissue growth, angiogenesis, activin or inhibin activity, chemotactic/chemokinetic activity, haemostatic activity, thrombolytic activity, receptor/ligand, antiinflammatory activity, tumour inhibition activity, and antifertility activity, and may also be involved in the determination of bodily characteristics, fertility and behaviour. ORFX proteins, nucleic acids and antibodies may be used in the treatment of cancers, other proliferative disorders such as psoriasis and benign tumours, neurological disorders such as epilepsy and Alzheimer's disease, cardiovascular diseases, immune system disorders, disorders related to organ transplantation, disorders of tissue growth and regeneration, diseases such as diabetes mellitus, hypothyroidism, and cholesterol storage disease, and infectious diseases caused by viral, bacterial, fungal and other pathogens. ORFX nucleic acids may also be used as a source of primers and probes, in the detection of ORFX genomic sequences or transcripts, in the identification and cloning of homologous sequences, in genetic diagnosis, and in forensic biology. The ORFX nucleic acids may additionally be used to produce transgenic animals which may be useful for studying the function and/or activity of ORFX protein, and in drug screening. The ORFX proteins may also be used as immunogens to generate specific antibodies, which are useful in the diagnosis, treatment and monitoring of ORFX-associated diseases

SQ Sequence 186 BP; 37 A; 66 C; 51 G; 32 T; 0 U; 0 Other;  
Query Match 0.6%; Score 22.4; DB 1; Length 186;  
Best Local Similarity 53.4%; Pred. No. 57;  
Matches 47; Conservative 0; Mismatches 41; Indels 0; Gaps 0;  
QY 2670 TGACTCGATGACGTCAGTCTGGGTGAACCTCCTGGAGTTGTGACGACGAGGAGCGCTG 2729  
Db 149 TGGCCCGGTTCAGGTGGCGGTAGATCAAGTTTCAGGCCCCGGGTGGTGGCCCCGAGTGC 89  
QY 2730 TCCTCGCGGATTCATGGGGTCACAAAG 2757  
Db 88 GCAGCGGGGCTTGTGCTCAGTAG 61

RESULT 125

ABV97959/c

ID ABV97959 standard; cDNA; 317 BP.

XX AC ABV97959;

XX DT 14-JAN-2003 (first entry)

XX DE Human pancreatic cancer expressed cDNA SEQ ID NO 3367.

XX KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;  
XX KW cytostatic; tumour; gene; ss.

XX OS Homo sapiens.

XX PN WO200260317-A2.

XX PD 08-AUG-2002.

XX PF 30-JAN-2002; 2002WO-US002781.

XX PR 30-JAN-2001; 2001US-0265305P.

XX PR 31-JAN-2001; 2001US-0265682P.

XX PR 09-FEB-2001; 2001US-0267568P.

XX PR 21-MAR-2001; 2001US-0278651P.

XX PR 28-APR-2001; 2001US-0287112P.

XX PR 16-MAY-2001; 2001US-0291631P.

XX PR 12-JUL-2001; 2001US-0305484P.

XX PR 20-AUG-2001; 2001US-0333999P.

XX PR 27-NOV-2001; 2001US-0333626P.

XX PA (CORI-) CORIXA CORP.

XX PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;

XX DR WPI; 2002-627435/67.

XX PT New isolated polynucleotide and pancreatic tumor polypeptides, useful for  
XX PT diagnosing, preventing and/or treating cancer, particularly pancreatic  
XX PT cancer.

XX PS Claim 1; SEQ ID NO 3367; 300pp + Sequence Listing; English.

XX CC The invention relates to an isolated polynucleotide (I) comprising: (a)  
XX CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)  
XX CC complements of (a); (c) sequences consisting of at least 20 contiguous  
XX CC residues of (a); (d) sequences that hybridize to (a), under moderately  
XX CC stringent conditions; (e) sequences having at least 75% or 90% identity  
XX CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-  
XX CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer  
XX CC in a patient and compositions comprising polypeptides, polynucleotides,  
XX CC antibodies, fusion proteins, T cell populations and antigen presenting  
XX CC cells expressing the polypeptide are useful in treating pancreatic cancer  
XX CC and stimulating an immune response. The polynucleotides can be used as  
XX CC probes or primers for nucleic acid hybridization, in the design and  
XX CC preparation of ribozyme molecules for inhibiting expression of the tumour  
XX CC polypeptides and proteins in the tumour cells, in vaccines and for gene  
XX CC therapy. Note: The sequence data for this patent did not form part of the





Db 310 TTGCGACATAATGATCTTAAAAAAGAAATGAAATACCAAAACCAAGATCTCTCTTAAAA 251  
 QY 1323 CCTAAATCCCAATCC 1336  
 Db 250 TGAATTTAATCC 237  
 RESULT 130  
 ABX49447/c  
 ID ABX49447 standard; cDNA; 432 BP.  
 XX  
 AC ABX49447;  
 DT 21-FEB-2003 (first entry)  
 XX  
 XX Bovine EST associated with lactation/muscle/fat deposition #14612.  
 XX  
 XX Bovine; ss: EST; expressed sequence tag; lactation; LMFD;  
 KW muscle deposition; fat deposition; genome mapping; gene identification;  
 KW gene analysis; cattle breeding.  
 XX  
 OS Bos Taurus.  
 XX  
 XX US2002137139-A1.  
 XX  
 XX 26-SEP-2002.  
 XX  
 XX 24-SEP-2001; 2001US-00960352.  
 XX  
 XX 12-JAN-1999; 99US-0115707P.  
 PR 11-JAN-2000; 2000US-00480902.  
 XX  
 XX (BYAT/) BYATT J C.  
 PA (MATH/) MATHIALAGAN N.  
 PA (TAON/) TAO N.  
 PA (WARR/) WARREN W C.  
 XX  
 XX Byatt JC, Mathialagan N, Tao N, Warren WC;  
 XX WPI; 2003-110599/10.  
 XX  
 XX New nucleic acid associated with lactation, and muscle and fat  
 PT deposition, useful for genome mapping; gene identification and analysis,  
 PT cattle breeding, or for genetically improving cattle.  
 XX  
 PS Claim 2; SEQ ID NO 14612; 245pp; English.  
 XX  
 CC The invention relates to a purified nucleic acid molecule associated with  
 CC lactation or muscle and fat deposition (designated LMFD), derived from  
 CC cattle, and the LMFD nucleic acid can specifically hybridize to a second  
 CC nucleic acid molecule comprising any of 15112 nucleotide sequences,  
 CC appearing as ABX34836-ABX49947, or complements of them. Also included are  
 CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic  
 CC acid linked to a promoter and a 3' non-translated sequence that  
 CC functions in the cell to cause termination of transcription and addition  
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
 CC (2) determining a level or pattern of a molecule in a bovine cell or  
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any  
 CC of the 15112 nucleic acid sequences or its complement or fragment) with a  
 CC complementary nucleic acid molecule obtained from the bovine cell or  
 CC tissue, where hybridisation between the marker nucleic acid and the  
 CC complementary nucleic acid permits the detection of the molecule; and (b)  
 CC detecting the level or pattern of the complementary nucleic acid, where  
 CC the detection of the complementary nucleic acid is predictive of the  
 CC level or pattern of the molecule. The LMFD nucleic acid is used for  
 CC determining a level or pattern of a molecule in a bovine cell or tissue.  
 CC It is useful for genome mapping, gene identification and analysis, cattle  
 CC breeding, preparation of constructs for use in cattle gene expression, or  
 CC for genetically improving cattle. The present sequence is one of the  
 CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The  
 CC present sequence was not shown in the specification but was obtained in  
 CC electronic format from the USPTO web site:

CC seqdata.uspto.gov/sequence.html?DocID=20020137139  
 XX  
 SQ Sequence 432 BP; 140 A; 69 C; 107 G; 116 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 22; DB 1; Length 432;  
 Best Local Similarity 53.5%; Pred. No. 91;  
 Matches 46; Conservative 0; Mismatches 40; Indels 0; Gaps 0;  
 QY 2919 TACTTATTAAATTTGGGATTTTAACTATTTCTTCAATGACTTCTATTTCTAATATTAC 2978  
 Db 267 TCGTTCCAAATTCAGTAGTTTCTCAGTGTTCCTCAAAAACCTTCGTCTCTCAAAA 208  
 QY 2979 TTATTCTATTTTACTTTTAAATTCGCACT 3004  
 Db 207 CTACATTTTCTCTTTACATTTCTCT 182  
 RESULT 131  
 ABX44157/c  
 ID ABX44157 standard; cDNA; 534 BP.  
 XX  
 AC ABX44157;  
 XX  
 DT 21-MAY-2002 (first entry)  
 XX  
 DE cDNA #97 encoding human pancreatic tumour protein.  
 XX  
 KW Human; pancreatic tumour protein; immune response; pancreatic cancer;  
 KW development of cancer; cancer progression; cytostatic; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200212331-A2.  
 XX  
 PD 14-FEB-2002.  
 XX  
 PF 06-AUG-2001; 2001WO-US024619.  
 XX  
 XX 07-AUG-2000; 2000US-0223130P.  
 PR 30-JAN-2001; 2001US-0265447P.  
 PR 15-MAY-2001; 2001US-0291201P.  
 XX  
 XX (CORI-) CORIXA CORP.  
 PA  
 PI Pyle RA, Xu J, Kalos MD;  
 XX  
 XX WPI; 2002-241741/29.  
 XX  
 XX Novel polynucleotide encoding pancreatic tumor polypeptides, useful in  
 PT pharmaceutical compositions, e.g. vaccines, for treating pancreatic  
 PT cancers.  
 XX  
 PS Claim 1; Page 144; 167pp; English.  
 XX  
 CC The present invention relates to the isolation of cDNA sequences encoding  
 CC human pancreatic tumour proteins. The polynucleotide sequences encoding  
 CC human pancreatic tumour proteins are useful for stimulating an immune  
 CC response in a patient and treating pancreatic cancer in a patient. A host  
 CC cell that expresses these polynucleotides is useful for determining the  
 CC presence of cancer in a patient. A composition comprising the  
 CC polynucleotide, its encoded protein, or an antibody that binds to the  
 CC protein may be used in the diagnosis, prevention and/or treatment of  
 CC diseases, particularly pancreatic cancer. The sequences of the invention  
 CC are also useful in pharmaceutical compositions, e.g. vaccines, for the  
 CC diagnosis and treatment of pancreatic cancer. Such compositions may be  
 CC useful for inhibiting the development of cancer in a patient, or as  
 CC markers for the progression of cancer. The polynucleotide sequences may  
 CC also be used as probes or primers for nucleic acid hybridisation assays.  
 CC ABX44061-ABX44209 represent cDNA sequences encoding for human pancreatic  
 CC tumour proteins  
 XX  
 SQ Sequence 534 BP; 110 A; 164 C; 137 G; 121 T; 0 U; 2 Other;

Query Match 0.6%; Score 22; DB 1; Length 534;  
Best Local Similarity 63.0%; Pred. No. 96;  
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTAGAACTAACCCCAAAAGATGTCCTTCTCATTATAGGGACTGGAA 974  
DB 64 CCTCAGAGTGTAGCCCAACGATCTTGTCATCATCAATCAAGGGGGCAGCAA 11

RESULT 132  
AAN81633/C  
ID AAN81633 standard; DNA; 741 BP.  
XX AAN81633;  
AC  
XX  
XX 25-MAR-2003 (revised)  
DT 07-NOV-1990 (first entry)  
DE Human spleen trypsin III (trypsinogen III).  
KW Human spleen plasminogen; trauma lesions; ss.  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH 1..741  
FT /\*tag= a  
FT /product= "human spleen plasminogen III."  
XX  
XX JP63160582-A.  
XX  
XX PD 04-JUL-1988.  
XX  
XX PF 25-DEC-1986; 86JP-00307770.  
XX  
XX PR 25-DEC-1986; 86JP-00307770.  
XX  
XX (SANY ) SANKYO CO LTD.  
XX  
XX WPI; 1988-224890/32.  
XX P-PSDB; AAP81243.  
XX Human spleen trypsin - used to treat lesions or trauma, without  
PT hypersensitive allergic side effects.  
XX Claim 8+9; Page 3; 9pp; Japanese.  
XX  
XX Expression vectors E.coli LE 392 and YA 21 are preferable for mass  
CC production, and animal cells or B.subtilis are suitable for the  
CC production of an enzyme of similar activity to that of natural human  
CC spleen trypsinogen. Culturing the recombinant cells produced the desired  
CC trypsin as insoluble protein in inclusion bodies and the trypsin can be  
CC isolated by lysing the cells by a suitable method. The trypsin was then  
CC isolated and purified. The product is used in the treatment of lesions or  
CC trauma, eg burns, gangrene, abscesses, injury etc. (Updated on 25-MAR-  
XX 2003 to correct PA field.)  
XX  
XX Sequence 741 BP; 160 A; 214 C; 200 G; 167 T; 0 U; 0 Other;  
Query Match 0.6%; Score 22; DB 1; Length 741;  
Best Local Similarity 63.0%; Pred. No. 1e+02;  
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTAGAACTAACCCCAAAAGATGTCCTTCTCATTATAGGGACTGGAA 974  
DB 94 CCTCAGAGTGTAGCCCAACGATCTTGTCATCATCAATCAAGGGGGCAGCAA 41

RESULT 133  
AAT04001/C  
ID AAT04001 standard; cDNA to mRNA; 744 BP.  
XX  
XX AAT04001;

XX 25-MAR-2003 (revised)  
DT 19-MAR-1996 (first entry)  
XX  
XX Human pancreatic trypsin III cDNA.  
DE Pancreatic trypsin III; trypsinogen; human; hydrolysis; ds.  
KW Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH 1..744  
FT /\*tag= a  
FT /product= "pancreatic\_trypsin\_III"  
XX  
XX JP07184655-A.  
XX  
XX PD 25-JUL-1995.  
XX  
XX PF 25-DEC-1986; 94JP-00311512.  
XX  
XX PR 25-DEC-1986; 86JP-00307770.  
XX  
XX (SANY ) SANKYO CO LTD.  
XX  
XX WPI; 1995-287966/38.  
XX Novel human pancreatic trypsin III - can be easily produced by  
PT recombinant methods.  
XX Claim 4; Page 9; 11pp; Japanese.  
XX  
XX AAT03999-T04001 are all human cDNA sequences which code for pancreatic  
CC trypsin III (AAR87203), the sequences differ only in their stop codons.  
CC The cDNA molecules can be used in the recombinant production of trypsin  
CC which can be used as a drug to treat diseases wherein trypsin production  
CC is impaired. (Updated on 25-MAR-2003 to correct PF field.)  
XX  
XX Sequence 744 BP; 161 A; 214 C; 201 G; 168 T; 0 U; 0 Other;  
SQ  
Query Match 0.6%; Score 22; DB 1; Length 744;  
Best Local Similarity 63.0%; Pred. No. 1e+02;  
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTAGAACTAACCCCAAAAGATGTCCTTCTCATTATAGGGACTGGAA 974  
DB 94 CCTCAGAGTGTAGCCCAACGATCTTGTCATCATCAATCTTGTCTCATCTGCAAGGGGGCAGCAA 41

RESULT 134  
AAT04000/C  
ID AAT04000 standard; cDNA to mRNA; 744 BP.  
XX  
XX AAT04000;  
AC  
XX  
XX 25-MAR-2003 (revised)  
DT 19-MAR-1996 (first entry)  
XX  
XX Human pancreatic trypsin III cDNA.  
DE Pancreatic trypsin III; trypsinogen; human; hydrolysis; ds.  
KW Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH 1..744  
FT /\*tag= a  
FT /product= "pancreatic\_trypsin\_III"  
XX  
XX JP07184655-A.  
XX  
XX PD 25-JUL-1995.  
XX

PF 25-DEC-1986; 94JP-00311512.  
 XX 25-DEC-1986; 86JP-00307770.  
 XX (SANY ) SANKYO CO LTD.  
 PA WPI; 1995-287966/38.  
 DR P-PSDB; AAR82703.  
 XX Novel human pancreatic trypsin III - can be easily produced by  
 PT recombinant methods.  
 XX Claim 3; Page 7-8; ilpp; Japanese.  
 XX AAT03999-T04001 are all human cDNA sequences which code for pancreatic  
 CC trypsin III (AAR87203), the sequences differ only in their stop codons.  
 CC The cDNA molecules can be used in the recombinant production of trypsin  
 CC which can be used as a drug to treat diseases wherein trypsin production  
 CC is impaired. (Updated on 25-MAR-2003 to correct PF field.)  
 XX Sequence 744 BP; 161 A; 214 C; 201 G; 168 T; 0 U; 0 Other;  
 SQ Query Match 0.6%; Score 22; DB 1; Length 744;  
 Best Local Similarity 63.0%; Pred. No. 1e+02;  
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;  
 QY 921 CCTTTAGAACTAACACCCCAAAAGATGTCCTTCTCATTATAGGGGACTGGAA 974  
 DB 94 CCTCAGGTGTAGCCCCCAACAATCTTGTCTCATCTGTCACAAAGGGGACAGCAA 41  
 RESULT 135  
 AAT03999/c  
 ID AAT03999 standard; cDNA to mRNA; 744 BP.  
 AC AAT03999;  
 XX 25-MAR-2003 (revised)  
 DT 19-MAR-1996 (first entry)  
 XX Human pancreatic trypsin III cDNA.  
 XX Pancreatic trypsin III; trypsinogen; human; hydrolysis; ds.  
 OS Homo sapiens.  
 XX Key Location/Qualifiers  
 FH 1..744  
 FT CDS /\*tag= a  
 FT /product= "pancreatic\_trypsin\_III"  
 XX JP07184655-A.  
 XX 25-JUL-1995.  
 PF 25-DEC-1986; 94JP-00311512.  
 XX 25-DEC-1986; 86JP-00307770.  
 XX (SANY ) SANKYO CO LTD.  
 PA WPI; 1995-287966/38.  
 DR P-PSDB; AAR87203.  
 XX Novel human pancreatic trypsin III - can be easily produced by  
 PT recombinant methods.  
 XX Claim 2; Page 6-7; ilpp; Japanese.  
 XX AAT03999-T04001 are all human cDNA sequences which code for pancreatic  
 CC trypsin III (AAR87203), the sequences differ only in their stop codons.  
 CC The cDNA molecules can be used in the recombinant production of trypsin  
 CC which can be used as a drug to treat diseases wherein trypsin production

CC is impaired. (Updated on 25-MAR-2003 to correct PF field.)  
 XX Sequence 744 BP; 162 A; 214 C; 200 G; 168 T; 0 U; 0 Other;  
 SQ Query Match 0.6%; Score 22; DB 1; Length 744;  
 Best Local Similarity 63.0%; Pred. No. 1e+02;  
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;  
 QY 921 CCTTTAGAACTAACACCCCAAAAGATGTCCTTCTCATTATAGGGGACTGGAA 974  
 DB 94 CCTCAGGTGTAGCCCCCAACAATCTTGTCTCATCTGTCACAAAGGGGACAGCAA 41  
 RESULT 136  
 AAV24548/c  
 ID AAV24548 standard; cDNA; 790 BP.  
 AC AAV24548;  
 XX 16-SEP-1998 (first entry)  
 DT Trypsinogen-like protein coding sequence.  
 DE Trypsinogen-like protein coding sequence.  
 XX Trypsinogen-like protein; human; ds.  
 OS Homo sapiens.  
 XX Key Location/Qualifiers  
 FH 1..723  
 FT CDS /\*tag= a  
 FT /product= "trypsinogen-like protein"  
 XX JP10099080-A.  
 XX 21-APR-1998.  
 PF 26-SEP-1996; 96JP-00273923.  
 XX 26-SEP-1996; 96JP-00273923.  
 XX (SHIS ) SHISEIDO CO LTD.  
 XX WPI; 1998-289873/26.  
 DR P-PSDB; AAW57740.  
 XX DNA encoding trypsinogen-like protein - used for recombinant production  
 PT of the protein.  
 XX Claim 1; Page 4-5; 7pp; Japanese.  
 CC This sequence represents the gene of the invention, and encodes a human  
 CC trypsinogen-like protein  
 XX Sequence 790 BP; 183 A; 234 C; 205 G; 168 T; 0 U; 0 Other;  
 SQ Query Match 0.6%; Score 22; DB 1; Length 790;  
 Best Local Similarity 63.0%; Pred. No. 1e+02;  
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;  
 QY 921 CCTTTAGAACTAACACCCCAAAAGATGTCCTTCTCATTATAGGGGACTGGAA 974  
 DB 73 CCTCAGGTGTAGCCCCCAACAATCTTGTCTCATCTGTCACAAAGGGGACAGCAA 20  
 RESULT 137  
 ABZ35087/c  
 ID ABZ35087 standard; cDNA; 853 BP.  
 AC ABZ35087;  
 XX 05-FEB-2003 (first entry)  
 DT Human gene expression profile polynucleotide SEQ ID NO 199.  
 DE



XX Human; artery; endothelium; umbilical; vein; aorta; pulmonary artery;  
KW bronchial epithelium; prostate; muscle; lung fibroblast; osteoblast;  
KW tumour; microarray; genome mapping; antibiotic; antiviral; antifungal;  
KW gene expression; gene; ss.  
XX Homo sapiens.  
XX WO200274979-A2.  
XX 26-SEP-2002.  
XX 20-MAR-2002; 2002WO-US008456.  
XX 20-MAR-2001; 2001US-0276947P.  
XX (ORTH ) ORTHO CLINICAL DIAGNOSTICS INC.  
XX Wan J, Wang Y;  
XX WPI, 2002-740862/80.  
XX New gene expression profile generated from primary, endothelial,  
PT epithelial, and muscle cell types, useful for identifying disease  
PT pathologies involving alterations of gene expression, e.g. cancer.  
XX Claim 5; Page 405; 850pp; English.  
XX The invention relates to a gene expression profile comprising one or more  
CC genes (AB234889-AB235692) and generated from a cell type. The cell type  
CC is a coronary artery endothelium, umbilical artery or vein endothelium,  
CC aortic endothelium, dermal microvascular endothelium, pulmonary artery  
CC endothelium, myometrium microvascular endothelium, keratinocyte  
CC epithelium, bronchial epithelium, mammary epithelium, prostate  
CC epithelium, renal cortical epithelium, renal proximal tubule epithelium,  
CC small airway epithelium, renal epithelium, umbilical artery smooth  
CC muscle, neonatal dermal fibroblast, pulmonary artery smooth muscle,  
CC dermal fibroblast, neural progenitor cells, skeletal muscle, astrocytes,  
CC aortic smooth muscle, mesangial cells, coronary artery smooth muscle,  
CC bronchial smooth muscle, uterine smooth muscle, lung fibroblast,  
CC osteoblasts or prostate stromal cell. The gene expression profile is used  
CC for determining the level of RNA expression for a sample, determining the  
CC phenotype of a cell and distinguishing cell types. The gene or a protein  
CC expression profile is useful in identifying disease pathologies involving  
CC alterations of gene expression. The assessment of expression profiles may  
CC provide meaningful information with respect to tumour type and stage,  
CC treatment methods, and prognosis. The gene or protein expression profile  
CC may also be used for creating microarrays. The microarray is useful for  
CC genetic and physical mapping of genomes, DNA sequencing, genetic or  
CC medical diagnosis, genotyping of organisms, confirming cell or tissue  
CC identifications and in identifying promising antibiotics, antiviral or  
CC antifungal agents  
XX SQ Sequence 853 BP; 192 A; 253 C; 231 G; 177 T; 0 U; 0 Other;  
Query Match 0.6%; Score 22; DB 1; Length 853;  
Best Local Similarity 63.0%; Pred. No. 1.1e-02;  
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;  
QY 921 CCTTTAGACTTACACCCAAAAGATGCTCTTCTATTATAGGGGACTGGAA 974  
Db 137 CCTCACAGGTGTAGCCCCCAACAACTTCTGTCATCTCCTCAAGGGGACAGCA 84  
RESULT 138  
ABA79599/C  
ID ABA79599 standard; DNA; 121 BP.  
XX ABA79599;  
XX ABA79599;  
XX 24-JAN-2002 (first entry)  
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2445.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
KW Alzheimer's disease; cytosolic; antitickling; antianaemic; haemostatic;  
KW antileptic; ss.  
XX Homo sapiens.  
XX WO200173002-A2.  
XX 04-OCT-2001.  
XX 27-MAR-2001; 2001WO-US009761.  
XX 27-MAR-2000; 2000US-0192176P.  
XX 27-MAR-2000; 2000US-0192179P.  
XX 01-JUN-2000; 2000US-0208538P.  
XX 30-OCT-2000; 2000US-0244989P.  
XX (UYDE ) UNIV DELAWARE.  
XX Kmiec EB, Gamper HB, Rice MC;  
XX WPI, 2001-639230/73.  
XX Oligonucleotide for targeted alterations of genetic sequences and for  
PT treating cystic fibrosis, comprises at least one mismatch and chemical  
PT modification.  
XX Claim 7; Page 183; 294pp; English.  
XX The present invention provides single-stranded oligonucleotides which can  
CC be used for the targeted alteration of genomic sequences, where the  
CC oligonucleotide has at least one mismatch compared with the genomic  
CC sequence to be altered. In particular, these sequences are directed at  
CC the following genes: adenosine deaminase, p53, beta-globin,  
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus  
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and  
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
CC various syndromes. The present sequence is one of the gene correcting  
CC oligonucleotides of the invention  
XX SQ Sequence 121 BP; 29 A; 28 C; 16 G; 48 T; 0 U; 0 Other;  
Query Match 0.6%; Score 21.8; DB 1; Length 121;  
Best Local Similarity 58.5%; Pred. No. 72;  
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
QY 785 CGAGTCTCAAAACGACAGATGATCTCTGTTTTCACAGGCAACCAATTCATCA 844  
Db 72 GAAGTTTITGAAAACACTGAAGAACAGTGAAGTATTTCCACATAATACCTTCAGATGCA 13  
QY 845 CAGTA 849  
Db 12 GAGCA 8  
RESULT 139  
ABA79602  
ID ABA79602 standard; DNA; 121 BP.  
XX

AC ABA79602;  
 XX  
 DT 24-JAN-2002 (first entry)  
 XX  
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2448..  
 XX  
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese;  
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
 KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;  
 XX antileptic; ss.  
 OS Homo sapiens.  
 XX  
 XX WO200173002-A2.  
 XX  
 PD 04-OCT-2001.  
 XX  
 XX 27-MAR-2001; 2001WO-US009761.  
 XX  
 XX 27-MAR-2000; 2000US-0192176P.  
 PR  
 PR 27-MAR-2000; 2000US-0192176P.  
 PR  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX  
 XX (UYDE ) UNIV DELAWARE.  
 PA  
 XX Kmiec EB, Gamper HB, Rice MC;  
 PI  
 XX WPI; 2001-639230/73.  
 XX  
 XX Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX  
 PS Claim 7; Page 183; 294pp; English.  
 XX  
 CC The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin,  
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX  
 SQ Sequence 121 BP; 49 A; 16 C; 28 G; 28 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 21.8; DB 1; Length 121;  
 Best Local Similarity 58.5%; Pred. No. 72;  
 Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTCTTTGTTTCCAGGCAACCATTCATCA 844  
 DB 52 GAAGTTTTCGAACACTGAAAGACAGTGTATTTCCATATACCTTCAGATGCA 111  
 QY 845 CAGTA 849  
 DB 112 GAGCA 116

RESULT 140  
 ABA79603/C  
 ID ABA79603 standard; DNA; 121 BP.  
 XX  
 AC ABA79603;  
 XX  
 DT 24-JAN-2002 (first entry)  
 XX  
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2449.  
 XX  
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisenese;  
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
 KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;  
 XX antileptic; ss.  
 OS Homo sapiens.  
 XX  
 XX WO200173002-A2.  
 XX  
 PD 04-OCT-2001.  
 XX  
 XX 27-MAR-2001; 2001WO-US009761.  
 XX  
 XX 27-MAR-2000; 2000US-0192176P.  
 PR  
 PR 27-MAR-2000; 2000US-0192176P.  
 PR  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX  
 XX (UYDE ) UNIV DELAWARE.  
 PA  
 XX Kmiec EB, Gamper HB, Rice MC;  
 PI  
 XX WPI; 2001-639230/73.  
 XX  
 XX Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX  
 PS Claim 7; Page 183; 294pp; English.  
 XX  
 CC The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin,  
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX  
 SQ Sequence 121 BP; 28 A; 28 C; 16 G; 49 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 21.8; DB 1; Length 121;  
 Best Local Similarity 58.5%; Pred. No. 72;  
 Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTCTTTGTTTCCAGGCAACCATTCATCA 844  
 DB 70 GAAGTTTTCGAACACTGAAAGACAGTGTATTTCCATATACCTTCAGATGCA 111













DE XX cDNA #91 encoding human pancreatic tumour protein.  
KW Human; pancreatic tumour protein; immune response; pancreatic cancer;  
KW development of cancer; cancer progression; cytostatic; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200212331-A2.  
XX  
PD 14-FEB-2002.  
XX  
PF 06-AUG-2001; 2001WO-US024619.  
XX  
PR 07-AUG-2000; 2000US-0223130P.  
PR 30-JAN-2001; 2001US-0265447P.  
PR 15-MAY-2001; 2001US-0291201P.  
XX  
PA (CORI-) CORIXA CORP.  
XX  
PI Pyle RA, Xu J, Kalos MD;  
XX  
DR WPI; 2002-241741/29.  
XX  
PT Novel polynucleotide encoding pancreatic tumor polypeptides, useful in  
PT pharmaceutical compositions, e.g. vaccines, for treating pancreatic  
PT cancers.  
XX  
XX Claim 1; Page 142; 167pp; English.  
XX  
XX The present invention relates to the isolation of cDNA sequences encoding  
CC human pancreatic tumour proteins. The polynucleotide sequences encoding  
CC human pancreatic tumour proteins are useful for stimulating an immune  
CC response in a patient and treating pancreatic cancer in a patient. A host  
CC cell that expresses these polynucleotides is useful for determining the  
CC presence of cancer in a patient. A composition comprising the  
CC polynucleotide, its encoded protein, or an antibody that binds to the  
CC protein may be used in the diagnosis, prevention and/or treatment of  
CC diseases, particularly pancreatic cancer. The sequences of the invention  
CC are also useful in pharmaceutical compositions, e.g. vaccines, for the  
CC diagnosis and treatment of pancreatic cancer. Such compositions may be  
CC useful for inhibiting the development of cancer in a patient, or as  
CC markers for the progression of cancer. The polynucleotide sequences may  
CC also be used as probes or primers for nucleic acid hybridisation assays.  
CC ABK44061-ABK44209 represent cDNA sequences encoding for human pancreatic  
CC tumour proteins  
XX  
SQ Sequence 522 BP; 110 A; 162 C; 132 G; 116 T; 0 U; 2 Other;  
  
Query Match 0.6%; Score 21.8; DB 1; Length 522;  
Best Local Similarity 62.7%; Pred. No. 1.1e+02;  
-Matches 32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;  
  
QY 921 CCTTTAGACTTAACACCCAAAAGATGCTCTCTATTATAGGGGACTG 971  
DB 52 CCTCAGATGATAGCCCCCAGACGATCTTGTATCATCATCAAAAGGGGNCNG 2  
  
RESULT 152  
AAL48492  
ID AAL48492 standard; DNA; 711 BP.  
XX  
AC AAL48492;  
XX  
XX 11-OCT-2002 (first entry)  
DT  
DE Human serine protease MP493 related coding sequence.  
XX  
XX Human; serine protease; MP493; cancer; kidney disease; lung disease;  
KW protein coordinate data; cytostatic; antiasthmatic; anti-allergic;  
KW anti-inflammatory; virucide; immunomodulator; gene; ds.  
XX  
OS Homo sapiens.  
XX  
PF 15-DEC-1992; 92EP-00311446.

FH Key Location/Qualifiers  
FT CDS 1..711  
FT /\*tag= a  
FT /product= "unknown protein"  
FT /partial  
FT /note= "no start or stop codon"  
XX  
XX WO200259295-A1.  
XX  
XX 01-AUG-2002.  
XX  
XX 23-JAN-2002; 2002WO-JP000465.  
XX  
XX 23-JAN-2001; 2001JP-00014963.  
XX  
XX (MOCH ) MOCHIDA PHARM CO LTD.  
XX  
XX Nakamura Y, Sugano S, Matsusue T, Okamoto A, Okawa K;  
XX  
XX WPI; 2002-566849/60.  
XX  
XX P-PSDB; AAO18403.  
XX  
XX Transmembrane serine protease MP493 for diagnosis of and developing drugs  
XX for cancer, kidney diseases and lung diseases e.g. asthma, allergy,  
XX bronchitis, pneumonectasis, pancreatitis and nephritis.  
XX  
XX Claim 2; Page 158; 163pp; Japanese.  
XX  
XX The present invention provides the protein and coding sequences of a  
CC human serine protease designated MP493. The sequences can be used in the  
CC diagnosis of and development of drugs for treating cancer, kidney and  
CC lung diseases, for example asthma, allergy, bronchitis, pneumonectasis,  
CC viral diseases, shock, multiple organ failure, pancreatitis and  
CC nephritis. The present sequence is a coding sequence shown in the  
CC exemplification of the invention  
XX  
SQ Sequence 711 BP; 149 A; 205 C; 212 G; 145 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 21.8; DB 1; Length 711;  
Best Local Similarity 56.2%; Pred. No. 1.2e+02;  
Matches 41; Conservative 0; Mismatches 32; Indels 0; Gaps 0;  
  
QY 185 ACTAGTCAATCTAATCACAACACAGGACGCTTGTCTAATCAATGAAGTAAAGCCAT 244  
DB 188 ACATATCCAGCCCATCCACTTGGTGAGAGATGTTCTACACACCAAGTACAGCCAA 247  
  
QY 245 GCCCGTGGGGCAA 257  
DB 248 AGAGGCTGGGCAA 260  
  
RESULT 153  
AAQ43935/c  
ID AAQ43935 standard; DNA; 268 BP.  
XX  
AC AAQ43935;  
XX  
XX 25-MAR-2003 (revised)  
DT  
XX 22-OCT-1993 (first entry)  
DT  
DE MetTyr human proinsulin.  
XX  
XX Deletion; cistron; expression; human insulin; interferon; interleukin;  
KW tissue plasminogen activator; growth hormone releasing factor;  
KW translational activating sequence; HPI; human proinsulin; ds.  
XX  
XX Synthetic.  
XX  
XX EP547873-A2.  
XX  
XX 23-JUN-1993.  
XX  
XX 15-DEC-1992; 92EP-00311446.



Best Local Similarity 53.6%; Pred. No. 1e+02;  
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 2550 CCAGTACTTTGGCCACCTGATGATCAAGAAGAGCTCACTGCGAAAGACCCCTGATGCTGGG 2609  
166 CCTGCACCCGGGCCACGCCAGCTCCACCTGACCCACTTGCAGGTCTCTGCTCAGG 107

QY 2610 AGGATTGGGGGCAGGAGGAAG 2633  
106 CGGTCTTCGGGGTCTAGAAG 83

RESULT 156  
ACA03539  
ID ACA03539 standard; DNA; 360 BP.  
XX ACA03539;  
XX  
XX 22-MAY-2003 (first entry)  
XX  
XX Synthetic DNA encoding immunogenic HIV peptide #22.  
XX  
XX Immunogenic HIV polypeptide; human immunodeficiency virus; HIV; vaccine;  
XX gene therapy; packaging cell line; humoral immune response;  
XX cellular immune response; gene delivery vector; DNA immunisation; ds.  
XX Synthetic.  
XX  
XX WO2003004657-A1.  
XX  
XX 16-JAN-2003.  
XX  
XX 05-JUL-2002; 2002WO-US021421.  
XX  
XX 05-JUL-2001; 2001US-0303192P.  
XX 31-AUG-2001; 2001US-0316860P.  
XX 16-JAN-2002; 2002US-0349728P.  
XX 16-JAN-2002; 2002US-0349739P.  
XX 16-JAN-2002; 2002US-0349871P.  
XX  
XX (CHIR ) CHIRON CORP.  
XX  
XX Zur Megede J, Barnett SW, Lian Y;  
XX  
XX WPI; 2003-221602/21.  
XX  
XX New synthetic polynucleotides encoding antigenic HIV type B and/or type C  
XX polypeptides, useful as immunogenic compositions or vaccines for  
XX generating humoral or cellular immune responses against HIV in a subject,  
XX especially humans.  
XX  
XX Example 1; Fig 27; 262pp; English.  
XX  
XX The invention describes a synthetic polynucleotide encoding 2 or more  
XX immunogenic HIV polypeptides, where at least 2 of the polypeptides are  
XX derived from different HIV subtypes. The polynucleotide is useful for  
XX immunisation, generation of packaging cell lines, or production of HIV  
XX polypeptides. The polynucleotide and its encoding proteins are useful as  
XX immunogenic compositions or vaccines for generating humoral or cellular  
XX immune responses against HIV in a subject, or for inducing neutralising  
XX antibodies against HIV. The gene delivery vector comprising the  
XX polynucleotide is also useful for DNA immunisation of, or for generating  
XX an immune response (e.g. a humoral or cellular immune response) in, a  
XX subject such as a mammal, particularly a human. This sequence encodes a  
XX human immunodeficiency virus immunogenic peptide  
XX  
XX Sequence 360 BP; 84 A; 113 C; 125 G; 38 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.6; DB 1; Length 360;  
Best Local Similarity 50.0%; Pred. No. 1.1e+02;  
Matches 54; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

OY 2602 ATGCTGGGAGGATTTGGGGCAGGAGGAGGAGACGAGGATGAGATGGCTGGAT 2661

XX AC ABX37095;  
XX DT 20-FEB-2003 (first entry)  
XX DE Bovine EST associated with lactation/muscle/fat deposition #2260.  
XX KW Bovine, ss; EST; expressed sequence tag; lactation; LMFD;  
XX KW muscle deposition; fat deposition; genome mapping; gene identification;  
XX KW gene analysis; cattle breeding.  
XX OS Bos Taurus.  
XX PN US2002137139-A1.  
XX PD 26-SEP-2002.  
XX PF 24-SEP-2001; 2001US-00960352.  
XX PR 12-JAN-1999; 98US-0115707P.  
XX PR 11-JAN-2000; 2000US-00480902.  
XX XX (BYAT/) BYATT J C.  
XX FA (MATH/) MATHIALAGAN N.  
XX PA (TAON/) TAO N.  
XX PA (WARR/) WARREN W C.  
XX PI Byatt JC, Mathialagan N, Tao N, Warren WC;  
XX DR WPI; 2003-110599/10.  
XX PT New nucleic acid associated with lactation, and muscle and fat  
XX PT deposition, useful for genome mapping, gene identification and analysis,  
XX PT cattle breeding, or for genetically improving cattle.  
XX PS Claim 2; SEQ ID NO 2260; 245pp; English.  
XX XX The invention relates to a purified nucleic acid molecule associated with  
XX CC lactation or muscle and fat deposition (designated LMFD), derived from  
XX CC cattle, and the LMFD nucleic acid can specifically hybridize to a second  
XX CC nucleic acid molecule comprising any of 15112 nucleotide sequences,  
XX CC appearing as ABX34836-ABX4947, or complements of them. Also included are  
XX CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic  
XX CC acid linked to a promoter and a 3' non-translated sequence that  
XX CC functions in the cell to cause termination of transcription and addition  
XX CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
XX CC (2) determining a level or pattern of a molecule in a bovine cell or  
XX CC tissue comprising: (a) incubating a marker nucleic acid (comprising any  
XX CC of the 15112 nucleic acid sequences or its complement or fragment) with a  
XX CC complementary nucleic acid molecule obtained from the bovine cell or  
XX CC tissue, where hybridisation between the marker nucleic acid and the  
XX CC complementary nucleic acid permits the detection of the molecule; and (b)  
XX CC detecting the level or pattern of the complementary nucleic acid, where  
XX CC the detection of the complementary nucleic acid is predictive of the  
XX CC level or pattern of the molecule. The LMFD nucleic acid is used for  
XX CC determining a level or pattern of a molecule in a bovine cell or tissue.  
XX CC It is useful for genome mapping, gene identification and analysis, cattle  
XX CC breeding, preparation of constructs for use in cattle gene expression, or  
XX CC for genetically improving cattle. The present sequence is one of the  
XX CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The  
XX CC present sequence was not shown in the specification but was obtained in  
XX CC electronic format from the USPIO web site:  
XX CC seqdata.uspto.gov/sequence.html?DocId=20020137139  
XX SQ Sequence 372 BP; 113 A; 73 C; 87 G; 99 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.6; DB 1; Length 372;  
Best Local Similarity 53.6%; Pred. No. 1.1e+02;  
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;  
XX 2957 GACTTTGTTCTTCTAATTACTTATTCCTTAATTTACTTTAATTCGACTATTATTGGA 3016  
XX 269 GACTATTTTTCATACGAATGATAAAATCTTCGTGGCTGAAATATTTGGGATAA 328

QY 3017 TTTTCTTATATAAATCCAGTCCTT 3040  
DB 329 CGTCACTCAAGCAACCAATCAAT 352  
RESULT 159  
AAK53749  
ID AAK53749 standard; cDNA; 427 BP.  
XX AC AAK53749;  
XX DT 16-NOV-2001 (first entry)  
XX DE Murine transport and binding associated protein encoding cDNA SEQ ID 314.  
XX KW Murine; liver; gene library; amino acid synthesis; binding protein;  
XX KW cell metabolism; energy metabolism; fatty acid metabolism; synthesis;  
XX KW phospholipid metabolism; purine; pyrimidine; nucleoside; nucleotide;  
XX KW replication; transcription; translation; transport protein; ss.  
XX OS Mus musculus.  
XX PN DE20103510-UI.  
XX PD 07-JUN-2001.  
XX PF 28-FEB-2001; 2001DE-02003510.  
XX PR 28-FEB-2001; 2001DE-02003510.  
XX XX (LION-) LION BIOSCIENCE AG.  
XX DR WPI; 2001-368570/39.  
XX PT Gene library containing sequences with specific 3'-ends and no polyA  
XX PT tail, encoding proteins involved in a wide range of cellular processes.  
XX PS Claim 15; Page 106; 251pp; German.  
XX CC This invention describes a novel gene library (A) comprises a gene  
XX CC sequence (or its part) encoding a protein involved in amino acid  
XX CC synthesis, cellular/energy metabolism, metabolism of fatty  
XX CC acids/phospholipids, synthesis or breakdown of  
XX CC purines/pyrimidines/nucleosides/nucleotides, DNA  
XX CC replication/transcription/translation, or is a transport/binding protein.  
XX CC (A) are produced that correspond to the 3'-end of mRNA but without the  
XX CC polyA tail. They can be prepared more efficiently and with less effort  
XX CC than conventional libraries. AAK53436-AAK54275 represent fragments of the  
XX CC gene library described in the method of the invention  
XX SQ Sequence 427 BP; 95 A; 126 C; 101 G; 105 T; 0 U; 0 Other;  
Query Match 0.6%; Score 21.6; DB 1; Length 427;  
Best Local Similarity 53.6%; Pred. No. 1.2e+02;  
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;  
QY 3457 TGGCTTTAAAGTAATTTGCTGCTATTACATGATTAAGTCTTATTGACTATAGTG 3516  
DB 326 TGGCTGCACACAGATGTTCTCCGAGACCAATCTTCATGACCTCCACCATCATTTC 385  
QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540  
DB 386 GAGCAACCAAGGGATCGGATGA 409  
RESULT 160  
ABX14193  
ID ABX14193 standard; DNA; 6098 BP.  
XX AC ABX14193;  
XX DT 11-MAR-2003 (first entry)

XX DE Plasmid pLN174 for expressing human coagulation Factor VII.  
 XX KW Human; coagulation; Factor VII; Factor VIIa; blood coagulation;  
 XX KW fibrin clot; haemostatic; tissue factor; zymogen; Factor IX; Factor X;  
 XX KW prothrombin; thrombin; Factor V; Factor VIII; fibrinogen; fibrin;  
 XX KW plasma factor; bleeding episode; haemophilia A; haemophilia B; thrombus;  
 XX KW intimal hyperplasia; restenosis; cardiogenic embolism; stroke;  
 XX KW platelet deposition; percutaneous transluminal coronary angioplasty; PTCA;  
 XX KW cancer; tumour; angiogenesis; ischaemia; reperfusion; thrombolysis;  
 XX KW rheumatoid arthritis; arteriosclerosis; inflammation; septic shock;  
 XX KW hypotension; adult respiratory distress syndrome; ARDS;  
 XX KW myocardial infarction; vasotropic; cerebroprotective; antibacterial;  
 XX KW immunosuppressive; cardiac; gene therapy; ds; pLN174.  
 OS OS Homo sapiens.  
 OS OS Unidentified.  
 OS OS Synthetic.  
 XX FH Key Location/Qualifiers  
 XX FT CDS 285..1505  
 XX FT /\*tag= a  
 XX FT /product= "Coagulation Factor VII"  
 XX FT /partial  
 XX FT /transl\_except= (pos:300..305,aa:Xaa-Xaa)  
 XX FT /transl\_except= (pos:324..326,aa:Xaa)  
 XX FT /transl\_except= (pos:330..332,aa:Xaa)  
 XX FT /transl\_except= (pos:339..344,aa:Xaa-Xaa)  
 XX FT /transl\_except= (pos:357..362,aa:Xaa-Xaa)  
 XX FT /transl\_except= (pos:369..371,aa:Xaa)  
 XX FT /transl\_except= (pos:387..389,aa:Xaa)  
 XX FT /note= "No start codon shown. Xaa = gamma carboxylated  
 glutamic acid"  
 XX FT  
 XX PN WO200277218-A1.  
 XX XX  
 XX PD 03-OCT-2002.  
 XX XX  
 XX PF 21-MAR-2002; 2002WO-00000189.  
 XX XX  
 XX PR 22-MAR-2001; 2001DK-00000477.  
 XX XX  
 XX PA (NOVO ) NOVO NORDISK AS.  
 XX XX  
 XX PI Persson E;  
 XX XX  
 XX DR WPI; 2003-058374/05.  
 XX DR P-PSDB; ABG73119.  
 XX XX  
 XX PT Novel factor VII polypeptide, its derivatives useful for preparing  
 XX PT medicament for treating bleeding episodes, or for enhancing normal  
 XX PT hemostatic system, especially for treating hemophilia.  
 XX PS Disclosure; Page 82-85; 96pp; English.  
 XX CC  
 XX CC The invention discloses a human factor VII polypeptide, or a variant or  
 XX CC derivative of it, where an amino acid has been modified. This change  
 XX CC results in a polypeptide with the same or an increased activity when  
 XX CC compared to recombinant wild type human factor VIIa. Blood coagulation  
 XX CC consists of a complex interaction of various blood components that  
 XX CC eventually give rise to a fibrin clot. Initiation of the haemostatic  
 XX CC process is mediated by the formation of a complex between tissue factor  
 XX CC and Factor VIIa (the active form of the Factor VII zymogen). This complex  
 XX CC activates Factors IX and X, converting prothrombin to thrombin, which  
 XX CC thrombin converts fibrinogen to fibrin resulting in formation of a fibrin  
 XX CC clot. The Factor VII zymogen, or its derivative, can be modified in its  
 XX CC catalytic centre to inhibit the ability of the Factor VII polypeptide to  
 XX CC activate plasma factor X or IX. The factor VII derivative is useful for  
 XX CC preparing a medicament for the treatment of bleeding episodes, for the  
 XX CC enhancement of the normal haemostatic system, especially for the  
 XX CC treatment of haemophilia A or B and for inhibiting thrombus formation.  
 XX CC The inactivated factor VII derivatives are useful for treating intimal  
 CC hyperplasia, restenosis, cardiogenic emboli, platelet deposition  
 CC disorders, percutaneous transluminal coronary angioplasty (PTCA), stroke,  
 CC cancer, tumour metastasis, angiogenesis, ischaemia/reperfusion,  
 CC rheumatoid arthritis, thrombolysis, arteriosclerosis, acute and chronic  
 CC indications, such as inflammation, septic shock, hypotension, adult  
 CC respiratory distress syndrome (ARDS) and myocardial infarction. The  
 CC sequence presented is the plasmid, pLN174, which expresses the  
 CC inactivated human coagulation Factor VII polypeptide  
 XX Sequence 6098 BP; 1413 A; 1597 C; 1623 G; 1475 T; 0 U; 0 Other;  
 SQ Query Match 0.6%; Score 21.6; DB 1; Length 6098;  
 Best Local Similarity 55.3%; Pred. No. 1.6e+02;  
 Matches 42; Conservative 0; Mismatches 34; Indels 0; Gaps 0;  
 Qy 3000 GCACCTATTTTATTCATTTTCTTAATAAAATCCAGTCCTGTTTTTAAAAAGACTTTT 3059  
 Db 2690 GAACCCCTATTTGTTTATTTTCTTAATAATACATTCAAAATATGTCGCTCATGAGACAAT 2749  
 Qy 3060 AAAATATTATTAATTTCT 3075  
 Db 2750 AACCTGATTAATGCT 2765  
 RESULT 161  
 ADB81477/C  
 ID ADB81477 standard; DNA; 144 BP.  
 XX AC ADB81477;  
 XX DT 04-DEC-2003 (first entry)  
 XX DE Human oestrogen receptor alpha splice variant 7 (ESR-alpha VII) DNA.  
 XX KW human; ds; oestrogen receptor alpha; ESR-alpha VII; oestrogen receptor 1;  
 KW ESR1; NR3A1; bone maintenance; cardiovascular system; cancer;  
 KW gene therapy; hyperproliferative disease; inflammation; tumour formation;  
 KW infection; cytostatic; antiinflammatory; antimicrobial.  
 XX OS Homo sapiens.  
 XX PN WO2003052072-A2.  
 XX XX  
 XX PD 26-JUN-2003.  
 XX PF 13-DEC-2002; 2002WO-US040083.  
 XX PR 18-DEC-2001; 2001US-00027983.  
 XX XX  
 XX PA (ISIS-) ISIS PHARM INC.  
 XX PI Dobie KW, Roach MP;  
 XX DR WPI; 2003-577322/54.  
 XX PT New antisense compound targeted to nucleic acid encoding estrogen  
 XX PT receptor alpha and inhibiting expression of estrogen receptor alpha,  
 XX PT useful for treating a disease or condition e.g. a hyperproliferative  
 XX PT disease.  
 XX PS Claim 20; Page 232; 232pp; English.  
 XX CC This invention relates to human oestrogen receptor alpha (ESR-alpha), and  
 XX CC the novel antisense oligonucleotides that modulate its expression. The  
 XX CC oestrogen receptor alpha protein is also known as oestrogen receptor 1,  
 XX CC ESR1, and NR3A1. Oestrogen, the steroid hormone ligand of ESR-alpha, is  
 XX CC important for bone maintenance and plays a protective role in the  
 XX CC cardiovascular system, as well as being required for normal sexual  
 XX CC maturation through promoting growth and differentiation. Splice variants  
 XX CC of ESR-alpha, however, have been associated with various cancers  
 XX CC including the breast and pituitary. Accordingly, antisense  
 XX CC oligonucleotides that inhibit the expression of ESR-alpha in cells or  
 XX CC tissues can be used in gene therapy to treat conditions such as

1993

1993











|    |  |
|----|--|
| PT | New peptide useful as a marker for the diagnosis of breast cancer.     |
| XX |  |
| PS | Claim 1; Page 2657-2658; 3695pp; English.                              |
| XX |  |
| CC | The invention relates to human breast cancer expressed polynucleotides |
| CC | (AAL07544-AAL26789) and methods of assessing whether a patient is      |
| CC | afflicted with breast cancer by examining the correlation between the  |
| CC | expression of certain markers and the cancerous state of breast cells. |
| CC | The polynucleotides and encoded polypeptides are potential markers for |
| CC | detecting, diagnosing, monitoring, characterising treating and         |
| CC | potentially preventing breast cancer. The polynucleotides and encoded  |
| CC | polypeptides are also useful for isolating compounds with cytostatic   |
| CC | activity   |
| XX |  |
| SQ | Sequence 280 BP; 69 A; 70 C; 74 G; 67 T; 0 U; 0 Other;                 |
|    |  |
|    | Query Match            0.6%; Score 21.2; DB 1; Length 280;             |
|    | Best Local Similarity 53.7%; Pred. NO. 1.3e+02;                        |
|    | Matches 44; Conservative 0; Mismatches 38; Indels 0; Gaps 0;           |
|    |  |
| QY | 2764 ACACGAGCTCAGCAACTGAACCTGAACCTGACTCGAAACCTTAGTATTATTA              |
|    | CTCTTTTCTTGAT 169  |
| Db | 110 AGACCACCTGGACAATCAGAAGAGAGAAATTCCTGGTCACAGACAGACTCTCTTGAT 169      |
|    |  |
| QY | 2824 CAGAAAATAGTAATTTTCATATG 2845                                      |
|    |  |
| Db | 170 CTGCAAAATACGACTTCATCATG 191  |
|    |  |
|    | RESULT 174   |
|    | ABK30273   |
| ID | ABK30273 standard; cDNA; 505 BP.                                       |
| XX |  |
| AC | ABK30273;  |
| XX |  |
| DT | 23-APR-2002 (first entry)  |
| XX |  |

|    |  |
|----|--|
| XX | Human; ss; gene; G-protein-coupled protease; gene therapy; transgenic;       |
| XX | protease mediated disorder; proliferative disorder;                          |
| KW | differentiative disorder; developmental disorder;                            |
| KW | haematopoietic disorder.   |
| XX |  |
| XX | Homo sapiens.  |
| OS |  |
| XX | US6331427-B1.  |
| PN |  |
| XX | 18-DEC-2001.   |
| PD |  |
| XX | XX   |
| XX | 26-MAR-1999; 99US-00280116.  |
| PF |  |
| XX | XX   |
| PR | 26-MAR-1999; 99US-00280116.  |
| XX |  |
| XX | (WILL-) MILLENNIUM PHARM INC.  |
| PA |  |
| XX | XX   |
| PI | Robison KE;  |
| XX |  |
| XX | WPI; 2002-129545/17.   |
| DR |  |
| XX |  |
| PT | New polynucleotides encoding protease homologs of the G-protein-coupled      |
| PT | protease family, useful in identifying agonists and antagonists for          |
| PT | diagnosis and treatment of protease mediated disorders.                      |
| PT |  |
| PS | Disclosure; Col 95-98; 246pp; English.                                       |
| XX |  |
| XX | .. The invention relates to an isolated human protease nucleic acid molecule |
| CC | comprising a nucleotide sequence of 546 base pairs, one of 268 fully         |
| CC | defined in the specification. Also disclosed are production of an            |
| CC | isolated polypeptide encoded by the nucleic acid, comprising introducing     |
| CC | the nucleic acid into a host cell and culturing under conditions to          |
| CC | express the protein from the nucleic acid, use of an antibody to detect      |
| CC | the encoded protein in a sample and to modulate its in vivo activity.        |

CC identifying agents that bind to the protein and identification of a  
CC polynucleotide agent that modulates the expression of the nucleic acid or  
CC its complement (i.e. gene therapy). The nucleic acid can be used to  
CC identify an agent that modulates the expression or activity of the  
CC nucleic acid, and can be used to isolate the protein. The nucleic acid  
CC can be used in diagnostic assays for determining nucleic acid expression  
CC as well as activity in the context of a biological sample (e.g., blood,  
CC serum, cells, tissue) to determine whether an individual has a disease or  
CC disorder, or is at risk of developing a disease or disorder, associated  
CC with aberrant expression or activity of the nucleic acid. The nucleic  
CC acid can be used to detect mutations in protease genes and gene  
CC expression products such as mRNA. The nucleic acid can be used as  
CC hybridisation probes to detect naturally-occurring genetic mutations in a  
CC protease gene. The nucleic acid can be used in drug screening methods to  
CC identify agonists and antagonists that can be used to diagnose and treat  
CC such protease mediated disorders e.g., proliferative, differentiative,  
CC developmental or haematopoietic disorders. The nucleic acid can be used  
CC as probes, primers, in biological assays, to determine patterns of gene  
CC expression, to design ribozymes and to construct transgenic animals. The  
CC present sequence represents one of the 268 disclosed human G-protein-  
CC coupled protease cDNA sequences

XX  
SQ Sequence 505 BP; 95 A; 135 C; 170 G; 105 T; 0 U; 0 Other;  
Query Match 0.6%; Score 21.2; DB 1; Length 505;  
Best Local Similarity 69.0%; Pred. No. 1.5e+02;  
Matches 29; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 3253 TTTTCTTTTAAAGATGTCATCTTTCTGGAAGTTTGA 3294  
|||||  
Db 1 TTTTCTTTTCTAAACAGATGCATTTAAATGGGAATCTTAA 42

RESULT 175  
ADA50533  
ID ADA50533 standard; DNA; 609 BP.  
XX  
AC ADA50533;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Human protease gene SEQ ID NO:37.  
XX  
KW ds; enzyme; gene; human; protease.  
XX  
OS Homo sapiens.  
XX  
XN WO20003040393-A2.  
XX  
PD 15-MAY-2003.  
XX  
PF 04-NOV-2002; 2002WO-1B004615.  
XX  
PR 06-NOV-2001; 2001US-0332633P.  
XX  
PA (DECO-) DECODE GENETICS EHF.  
XX  
PI Martinez RAM, Sigurdsson GT;  
XX  
DR WPI: 2003-441582/41.  
DR P-PSDB; ADA50486.  
XX

PS Novel isolated protease polypeptide and polynucleotide encoding the  
PT polypeptide useful for diagnosing and treating diseases or conditions  
PT associated with a protease.  
XX  
PS Claim 4; Page 80-81; 16pp; English.  
XX  
CC The invention relates to a novel isolated polypeptide comprising an amino  
CC acid sequence that has greater than 95 % identity to any one of 47 150-  
CC 350 residue protease polypeptide sequences, given in the specification.  
CC The nucleic acids, probes, primers, polypeptides and antibodies of the  
CC invention can be used in methods of diagnosis of a susceptibility to a

CC disease or condition associated with a protease. The present sequence  
CC represents a protease gene of the invention.  
XX  
SQ Sequence 609 BP; 139 A; 153 C; 156 G; 161 T; 0 U; 0 Other;  
Query Match 0.6%; Score 21.2; DB 1; Length 609;  
Best Local Similarity 47.1%; Pred. No. 1.6e+02;  
Matches 65; Conservative 0; Mismatches 73; Indels 0; Gaps 0;  
Qy 2908 TGATTTTCTCTACTTATTAAATTTGGGATTTTAACTATTCTTCAATGACTGTATTT 2967  
|||||  
Db 143 TTTATTTGCCATATATTAGATCATGCTGTGGCCCTTTTGTGTTTGGAAATTTCTTCCATTT 202  
Qy 2968 CTAATATTACTTATTCTATTATTACTTTAAATGACATTTATTATTGATTTTCTAATA 3027  
|||||  
Db 203 GGAATGGGAACATTTACCAATACCTTACTTGCAATTTGTTTCTACAGATGTAGTA 262  
Qy 3028 AAATCCAGTCCTTTT 3045  
Db 263 TTTGTAGGATCATGTGT 280

RESULT 176  
ABK31769  
ID ABK31769 standard; DNA; 888 BP.  
XX  
AC ABK31769;  
XX  
DT 23-APR-2002 (first entry)  
XX  
DE DNA encoding novel human protease #26.  
XX  
KW Human; protease; cancer; immune-related disorder; cardiovascular disease;  
KW neuronal-associated disease; metabolic disorder; inflammatory disorder;  
KW nervous system disorder; sexual dysfunction; pain; mood disorder;  
KW hypertension; psychotic disorder; neurological disorder; dyskinesia;  
KW viral infection; human immunodeficiency virus; HIV; non-viral infection;  
KW ocular disease; cytostatic; gene; ds.  
XX  
OS Homo sapiens.  
XX  
XN WO200200860-A2.  
XX  
PD 03-JAN-2002.  
XX  
PF 26-JUN-2001; 2001WO-US020171.  
XX  
PR 26-JUN-2000; 2000US-0214047P.  
XX  
PA (SUGB-) SUGEN INC.  
XX  
PI Plowman G, Whyte D, Sudarsanam S, Manning G, Caenepeel S;  
PI Charyczak G;  
XX  
DR WPI: 2002-139913/18.  
DR P-PSDB; AAU82727.  
XX  
XX Nucleic acids encoding novel human proteases, useful for useful for  
PT treating diseases and disorders such as cancers, immune-related diseases  
PT and disorders, cardiovascular disease (e.g. restenosis) and inflammatory  
PT disorders.  
XX  
PS Claim 26; Fig 1AA-BB; 313pp; English.  
XX  
CC The present invention relates to the isolation of novel human proteases,  
CC and the nucleic acids encoding them. The sequences of the invention are  
CC useful for treating diseases and disorders such as cancers (e.g. breast,  
CC colon, lung), immune-related diseases and disorders (e.g. inflammatory  
CC diseases and asthma), cardiovascular diseases (e.g. restenosis and  
CC coronary thrombosis), brain or neuronal-associated diseases, metabolic  
CC disorders (e.g. diabetes, obesity), inflammatory disorders (e.g.  
CC rheumatoid arthritis and psoriasis), central or peripheral nervous system  
CC diseases, migraines, pain, sexual dysfunction, mood disorders, attention

CC disorders, cognition disorders, hypotension, hypertension, psychotic  
 CC disorders, neurological disorders (e.g. Alzheimer's disease, Parkinson's  
 CC disease) and dyskinesias. The nucleic acids and polypeptides are also  
 CC useful for treating viral infections caused by human immunodeficiency  
 CC virus (HIV), and non-viral infections such as ocular disease (e.g.  
 CC glaucoma) and macular degeneration. ABK31744-ABK31802 represent DNA  
 CC sequences encoding for the novel human proteases of the invention  
 XX  
 SQ Sequence 888 BP; 163 A; 268 C; 269 G; 188 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.2; DB 1; Length 888;  
 Best Local Similarity 52.2%; Pred. No. 1.8e+02;  
 Matches 47; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 2683 GTGAGTCTGGTGAACCTCTGGAGTTGGTGTGATGGACAGGAGGCTCTCGCGCGATT 2742  
 DB 620 GGGATTCATGTTTCTGCTGCTGCTGAGGATGGCAGTGTAGACACCTGCAAGGTGACT 679  
 QY 2743 CATGGGTGACAAAGAGTTGGACACGACTG 2772  
 DB 680 CAGGTGGACCTTGGTCTGTGACAAAGGATG 709

## RESULT 177

AAI67198

ID AAI67198 standard; DNA; 918 BP.

XX

AC AAI67198;

XX

DT 11-FEB-2002 (first entry)

XX

DE Nucleotide sequence of GSK gene ID 15037.

XX

KW Peptide hormone; antidiabetic; anorectic; antianorectic; antiaesthetic;  
 KW antidepressant; nootropic; neuroprotectant; hypotensive; hypertensive;  
 KW cytostatic; cerebroprotective; vasotropic; human; ds.

XX

OS Homo sapiens.

XX

PN WO200172961-A2.

XX

PD 04-OCT-2001.

XX

PF 22-MAR-2001; 2001WO-US009226.

XX

PR 24-MAR-2000; 2000US-0192158P.

XX

PR 28-MAR-2000; 2000US-0192668P.

XX

PR 27-APR-2000; 2000US-0200166P.

XX

PA (SMIK ) SMITHKLINE BEECHAM CORP.

XX

PA (SMIK ) SMITHKLINE BEECHAM PLC.

XX

PI Agarwal P, Murdock PR, Rizvi SK, Smith RP, Xiang Z, Kabnick KS;

XX

PI Lai Y;

XX

DR WPI; 2001-639223/73.

XX

DR P-PSDB; AAG65908.

XX

PS Isolated polypeptides, which may be peptide hormones, which are

XX

PT identified by high throughput genome-based biology which identifies genes  
 PT and gene products as therapeutic targets for treatment of diseases such  
 PT as diabetes and cancer.

XX

PS Claim 2; Page 52; 99pp; English.

XX

CC The invention provides polypeptides (AAG65886-65918) which may be peptide  
 CC hormones (including insulin, growth hormones, chemokines, cytokines,  
 CC neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic  
 CC hormones, neuropeptin, pituitary hormones, pleiotropins, prostaglandins,  
 CC secretogranins, selectins, thromboglobulins, thymosins) identified by  
 CC high throughput genome-based biology and polynucleotides (AAI67176-67208)  
 CC encoding them. The polypeptides can be expressed by standard recombinant  
 CC methodology. The polypeptides are useful in the treatment of disease such

CC as diabetes, breast-, prostate-, colon cancer and other malignant tumors,  
 CC hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities,  
 CC asthma, manic depression, dementia, delirium, mental retardation,  
 CC Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental  
 CC or sexual development disorders, and dysfunctions of the blood cascade  
 CC system including those leading to stroke. The polynucleotides may be used  
 CC as diagnostic reagents through detecting mutations in the associated gene  
 CC and for chromosome localization and for tissue expression studies. The  
 CC polypeptides and polynucleotides may also be used as vaccines

XX

SQ Sequence 918 BP; 170 A; 272 C; 282 G; 194 T; 0 U; 0 Other;

Query Match 0.6%; Score 21.2; DB 1; Length 918;

Best Local Similarity 52.2%; Pred. No. 1.8e+02;

Matches 47; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 2683 GTGAGTCTGGTGAACCTCTGGAGTTGGTGTGATGGACAGGAGGCTCTCGCGCGATT 2742

DB 647 GGGATTCATGTTTCTGCTGCTGCTGAGGATGGCAGTGTAGACACCTGCAAGGTGACT 706

QY 2743 CATGGGTGACAAAGAGTTGGACACGACTG 2772

DB 707 CAGGTGGACCTTGGTCTGTGACAAAGGATG 736

RESULT 178

AAAF77000/C

ID AAF77000 standard; cDNA; 1130 BP.

XX

AC AAF77000;

XX

DT 29-MAY-2001 (first entry)

XX

DE Fusion gene of protease T in a zymogen activation vector.

XX

KW Human; protease T; serine protease; dermatological; desquamation;

XX

KW skin care; laundry; detergent; shampoo; skin flaking; fusion;

XX

KW zymogen activation vector; ss.

XX

OS Homo sapiens.

XX

OS Synthetic.

XX

PN WO200116293-A2.

XX

PD 08-MAR-2001.

XX

XX 30-AUG-2000; 2000WO-US023823.

XX

XX 31-AUG-1999; 99US-00386653.

XX

XX (ORTH ) ORTHO-MCNEIL PHARM INC.

XX

XX Barrow AL, Qi J, Andrade-Gordon P;

XX

XX WPI; 2001-265889/27.

XX

XX P-PSDB; AAB73946.

XX

XX New serine protease termed protease T, useful for treating and preventing

XX

XX skin flaking or imbalance of desquamation.

XX

XX Claim 2; Fig 4; 83pp; English.

XX

XX The present sequence encodes a protease T fusion protein. Protease T is

XX

XX useful for treating a condition mediated by protease T. It is useful for

XX

XX treating an imbalance of desquamation, by topical application of a

XX

XX pharmaceutical composition containing the protease. The composition is

XX

XX useful as a topical skin care composition. It is useful as a laundry

XX

XX detergent, shampoo, hard surface cleaning composition, and dish care

XX

XX cleaning composition. Protease T protein is useful for treating and

XX

XX preventing skin flaking. It is less immunogenic to sensitive individuals

XX

XX and it provides efficient proteolytic activity in a non-natural

XX environment

XX

SQ Sequence 1130 BP; 249 A; 329 C; 327 G; 225 T; 0 U; 0 Other;  
Query Match 0.6%; Score 21.2; DB 1; Length 1130;  
Best Local Similarity 50.0%; Pred. No. 1.8e+02;  
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;  
QY 2860 TCATATGTTGGTTAAGATATTAAGATTTTCAAAATTCATTTTATCTTTGATTTTCTCT 2919  
Db 1110 TTATAATGGTTACAAATTAAGCAATAGCATCACAAATTTCAAAATAAAGCATTTTTC 1051  
QY 2920 ACTTATTAATTTGGGATTTTAACTATTTCTTCAATGACTTGTAT 2965  
Db 1050 ACTGCATTCATGTTGGTTGTTCCAACTCAATGATATCTAT 1005  
RESULT 179  
AAD02991/C  
ID AAD02991 standard; DNA; 1166 BP.  
XX AC AAD02991;  
XX 11-SEP-2003 (revised)  
DT 31-MAY-2001 (first entry)  
XX Zymogen activation construct, PFEK2-C-E-HIS ERI-HCII DNA.  
XX Human; serine protease; protease C-E; therapy; desquamation; skin care;  
KW laundry detergent; shampoo; cleaning agent; hair care; skin flaking;  
KW neurodegenerative disorder; dermatological; immunogenic; proteolytic;  
KW bovine; zymogen activation construct; PFEK2-C-E-HIS ERI-HCII;  
KW fusion protein; chromosome 16p13.3; ds.  
XX OS Bos sp.  
OS Homo sapiens.  
OS Chimeric.  
XX Key Location/Qualifiers  
FH CDS 13..996  
FT /\*tag= a  
FT /product= "PFEK-C-E-HIS fusion protein"  
XX WO200116288-A2.  
XX 08-MAR-2001.  
PD 14-AUG-2000; 2000WO-US022117.  
PF 31-AUG-1999; 99US-00386629.  
XX (ORTH ) ORTHO-MCNEIL PHARM INC.  
XX Darrow A, Qi J, Andrade-Gordon P;  
PI WPI; 2001-226681/23.  
DR P-PSDB; AAY72891.  
XX Novel serine protease termed protease C-E, useful for treating and  
PT preventing skin flaking or imbalance of desquamation.  
XX Claim 2; Fig 4; 78pp; English.  
XX The present sequence is a zymogen activation construct, PFEK2-C-E-HIS ERI  
CC -HCII DNA. It comprises bovine preprolactin signal sequence fused in-  
CC frame with MoAbM2 anti-FLAG antibody epitope for the purpose of secretion  
CC and antibody detection (PF), enterokinase cleavage site from human  
CC trypsinogen I (EK), catalytic domain of protease C-E and six histidine  
CC codons (6XHS). Protease C-E gene located on chromosome 16p13.3 is a  
CC member of the S1 serine protease family and is expressed in pancreas,  
CC placenta, prostate, small intestine, stomach, spleen, fibroblasts,  
CC epidermis, cerebellum, cerebral cortex, pituitary and hippocampus.  
CC Protease C-E is useful for treating an imbalance of desquamation, by  
CC topical application. A non-pharmaceutical composition comprising the  
CC protein may be formulated as a laundry detergent, shampoo, hard surface

CC cleaning composition, dish care cleaning composition, skin care  
CC composition and hair care composition. Protease C-E is useful for  
CC treating and preventing skin flaking, neurodegenerative disorders and  
CC dermatological pathologies. It is less immunogenic to sensitive  
CC individuals and it provides efficient proteolytic activity in a non-  
CC natural environment. (Updated on 11-SEP-2003 to standardise CS field)  
XX SQ Sequence 1166 BP; 232 A; 335 C; 349 G; 250 T; 0 U; 0 Other;  
Query Match 0.6%; Score 21.2; DB 1; Length 1166;  
Best Local Similarity 50.0%; Pred. No. 1.9e+02;  
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;  
QY 2860 TCATATGTTGGTTAAGATATTAAGATTTTCAAAATTCATTTTATCTTTGATTTTCTCT 2919  
Db 1146 TTATAATGGTTACAAATTAAGCAATAGCATCACAAATTTCAAAATAAAGCATTTTTC 1087  
QY 2920 ACTTATTAATTTGGGATTTTAACTATTTCTTCAATGACTTGTAT 2965  
Db 1086 ACTGCATTCATGTTGGTTGTTCCAACTCATCAATGATATCTTAT 1041  
RESULT 180  
AAQ12680  
ID AAQ12680 standard; DNA; 1529 BP.  
XX AC AAQ12680;  
XX 25-MAR-2003 (revised)  
DT 30-SEP-1991 (first entry)  
XX PAP-I-protein C fusion construct.  
XX Phospholipid; binding protein; lipocortin; domain; vitamin K; PBP;  
KW gla-domain; VKDP; ss.  
XX Homo sapiens.  
XX Key Location/Qualifiers  
FH CDS 1..408  
FT /\*tag= a  
FT /label= PAP-I  
FT /note= "amino acids 1-136"  
FT CDS 409..1529  
FT /\*tag= b  
FT /label= protein\_C  
FT /note= "amino acids 46-136"  
XX WO9105953-A.  
XX 11-JUL-1991.  
XX 29-DEC-1989; 89US-00459082.  
XX 29-DEC-1989; 89US-00459082.  
XX (ZYMO ) ZYMOGENETICS INC.  
XX Foster DC;  
XX WPI; 1991-222905/30.  
XX P-PSDB; AARI3083.  
XX Recombinant prodn. of hybrid phospholipid-binding proteins - comprising  
PT lipocortin phospholipid-binding domain and vitamin-K-dependent protein.  
XX Claim 19; Page 41; 57pp; English.  
XX The fusion was constructed using site-directed mutagenesis to fuse PAP-I  
CC encoding amino acid 1-136 with a protein C DNA sequence at the codon for  
CC amino acid 46. A plasmid contg. this construct was transfected into BHK  
CC cells which were then cultured to produce PAP-I-protein C fusions which  
CC were activated to a form fully active in both amidolytic and





```
XX (PEKE ) PE CORP NY.
PA
XX Venter JC, Adams M, Li PWD, Myers EW;
PI
XX WPI; 2001-656860/75.
DR
XX
XX New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signaling and cell-cell
PT interactions.
PT
XX Claim 1; SEQ ID NO 35806; 21pp + Sequence Listing; English.
PS
XX The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signaling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC ABB72072). The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 237 BP; 66 A; 75 C; 20 G; 76 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 21; DB 1; Length 237;
Best Local Similarity 46.3%; Pred. No. 1.4e+02;
Matches 69; Conservative 0; Mismatches 80; Indels 0; Gaps 0;
QY 907 GAAGACCTACAGACCTTTTAGAAGTAAACACCCAAAAAGATGCTCTTCATTATAGGG 966
Db 219 GTAGGAGTAGTAGTAGTACGAGGAGTAGTAGGAGTAGTAGTAGTAGTAGTAGTAGTA 160
QY 967 GACTGGAATGCAAAAGTAGGAGCAAGAAACACCTGGAGTACAGGCAATTGGCCCTT 1026
Db 159 GGAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGTAGT 100
QY 1027 GGAATACGGAATGAAGCAGGCAAGACT 1055
Db 99 GTAGTACGAGTAGTAGTAGGCGGAGGAT 71
RESULT 183
ABZ72491
ID ABZ72491 standard; DNA; 291 BP.
XX
XX ABZ72491;
XX
XX 09-APR-2003 (first entry)
XX
XX Sorghum chalcone synthase CHS5 DNA sequence.SEQ ID NO:43.
XX
XX DNA construct; transgenic plant; antibacterial; fungicide; virucide;
XX insecticide; gene therapy; genetic trait; gene; ds.
XX
XX Sorghum bicolor.
XX
XX WO200286146-A2.
XX
XX 31-OCT-2002.
XX
XX 24-APR-2002; 2002WO-US013377.
XX
XX 24-APR-2001; 2001US-0286075P.
XX
XX (CORR ) CORNELL RES FOUND INC.
XX
XX Consalves D, Fermin-Munoz GA;
XX
XX WPI; 2003-093-46/08.
XX
XX New DNA construct comprising a modified nucleic acid molecule having at
```

```
PT least 80% homology to a desired trait DNA, useful for imparting
PT resistance to plants against a variety of pathogens, e.g. viruses,
PT bacteria, fungi or viroids.
PS
XX Example 16; Fig 15; 191pp; English.
XX
XX The present invention describes a DNA construct (I) comprising a modified
CC nucleic acid molecule having a nucleotide sequence which is at least 80%,
CC but less than 100%, homologous to two or more desired trait DNA molecules
CC and which imparts the desired trait to plants transformed with the DNA
CC construct. Each of the desired trait DNA molecules relative to the
CC modified nucleic acid molecule have a nucleotide sequence similarity
CC value which differs by no more than 3 percentage points. Also described:
CC (1) a DNA expression vector comprising the DNA construct above; (2) a
CC host cell transformed with the DNA construct above; (3) a transgenic
CC plant comprising a plant with a DNA construct above; (4) imparting a trait to
CC plants comprising transforming a plant with a DNA construct above, or by
CC planting a transgenic plant seed and propagating a plant from the planted
CC transgenic plant seed; (5) preparing a modified nucleic acid molecule
CC suitable to impart multiple traits to a plant; and (6) determining
CC whether multiple desired traits can be imparted to plants by a single
CC modified nucleic acid molecule. (I) can have antibacterial, fungicide, the
CC virucide and insecticide activities, and can be used in gene therapy. The
CC DNA construct is useful for imparting resistance to plants against a wide
CC variety of pathogens including viruses, bacteria, fungi, viroids,
CC phytoplasmas, nematodes and insects. The DNA construct may also be used
CC to impart a desired genetic trait to the plant, such as desired colour,
CC enzyme production (or cessation of enzyme production), and plant
CC hormones. ABZ72364 to ABZ72598 represent nucleotide sequences used in the
CC exemplification of the present invention
XX
XX Sequence 291 BP; 69 A; 87 C; 93 G; 42 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 21; DB 1; Length 291;
Best Local Similarity 48.0%; Pred. No. 1.5e+02;
Matches 60; Conservative 0; Mismatches 65; Indels 0; Gaps 0;
QY 2695 GAATCTCTGGAGTTGGTATGGACAGGAGCGCTGCTCTCGCGGATTCATGGGTGACA 2754
Db 134 GACATCGTGGTGGAGGTGCCAAGCTAGGCAAGCGCGGCATAGGCGATCAAG 193
QY 2755 AAGAGTTGGACAGCACTGACCAACTGAACTGAACTGAACTGAACTGAACTGAACTG 2814
Db 194 GAGTGGGGGAGCGCGGAAATCCAAAGATCACTCACTCGTCTTCTGCAACCACTCGGCGTC 253
QY 2815 TATAT 2819
Db 254 GACAT 258
RESULT 184
AAH57326/c
ID AAH57326 standard; cDNA; 292 BP.
XX
XX AAH57326;
XX
XX 10-SEP-2001 (first entry)
XX
XX Human pancreas specific cDNA sequence SEQ ID NO:166.
XX
XX Human; tissue specific; diagnosis; brain; heart; skeletal muscle; lung;
XX liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss;
XX metabolic disease; developmental disease; cytosstatic; immunomodulatory;
XX neuroprotective; gene therapy; cancer; immunopathology; neuropathology.
XX
XX Homo sapiens.
XX
XX WO200132927-A2.
XX
XX 10-MAY-2001.
XX
XX 02-NOV-2000; 2000WO-US030396.
XX
XX
```

```
PR 04-NOV-1999; 99US-0163508P.
XX (INCY-) INCYTE GENOMICS INC.
PA Sornasse T, Seilhamer JU, Watson GA;
XX WPI; 2001-291057/30.
XX
XX New cell and tissue specific polynucleotides useful for diagnosis,
PT prognosis or monitoring of treatments for disorders where the gene is
PT associated with a cancer, immunopathology or neuropathology.
XX
XX Claim 1; Page 127; 327pp; English.
XX
XX AAH57161 to AAH57576 represent cell and tissue specific polynucleotide
CC sequences (I). (I) can have cytostatic, immunomodulatory and
CC neuroprotective activities, and can be used in gene therapy. (I) and
CC proteins (II) encoded by then are used in high throughput screening
CC assays to select DNA molecules, RNA molecules, peptide nucleic acids,
CC mimetics, peptides, proteins, agonists, antagonists, antibodies or their
CC fragments, immunoglobulins, inhibitors, drug compounds and pharmaceutical
CC agents. Expression of (I) in a sample indicates the differentiation of
CC embryonic stem cells into a tissue selected from brain, heart, kidney,
CC liver, lung, skeletal muscle or pancreatic tissues. (I) and (II) are used
CC to produce an expression profile that defines a metabolic or
CC developmental process, treatment, condition, disease or disorder. The
CC gene profile can be used for diagnosis, prognosis or monitoring of
CC treatments and for investigating a predisposition to a disorder where the
CC gene is associated with a cancer, immunopathology or neuropathology
XX
XX Sequence 292 BP; 56 A; 76 C; 75 G; 58 T; 0 U; 17 Other;
SQ
Query Match 0.6%; Score 21; DB 1; Length 292;
Best Local Similarity 62.3%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 922 CTTTGAACCTACACCCCAAAAGATGCTTCTCATATAGGGGACTGGAA 974
DB 81 CTCACAGGTGATGCCCAACCAATCTTGTCATCATCGTCAAAAGGGGACAGCAA 29
RESULT 185
ACC46452
ID ACC46452 standard; cDNA; 631 BP.
XX
XX ACC46452;
XX
XX 02-JUN-2003 (first entry)
XX
XX Human dithp protein modification/maintenance protein-encoding cDNA.
XX
XX Human; dithp; diagnostic and therapeutic polynucleotide; diagnosis;
XX cancer; cell proliferative disorder; autoimmune disorder;
XX inflammatory disorder; infection; hormonal disorder; metabolic disorder;
XX neurological disorder; gastrointestinal disorder; transport disorder;
XX connective tissue disorder; drug screening; proteome analysis;
XX gene therapy; antisense therapy; genotyping; transgenic animal; knock in;
XX disease model; toxicological testing; transcript imaging;
XX protein modification; protein maintenance; gene; ss.
XX
XX Homo sapiens.
XX
XX WO200297031-A2.
XX
XX 05-DEC-2002.
XX
XX 27-MAR-2002; 2002WO-US010056.
XX
XX 28-MAR-2001; 2001US-0279619P.
XX 29-MAR-2001; 2001US-0280067P.
XX 29-MAR-2001; 2001US-0280068P.
XX 16-MAY-2001; 2001US-0291280P.
XX 17-MAY-2001; 2001US-0291829P.
```

```
PR 17-MAY-2001; 2001US-0291849P.
PR 19-JUN-2001; 2001US-0299428P.
PR 20-JUN-2001; 2001US-0299776P.
PR 20-JUN-2001; 2001US-0300001P.
XX (INCY-) INCYTE GENOMICS INC.
PA Daffo A, Jones AL, Tran AB, Dahl CR, Gietzen D, Chinn J;
XX Dufour GE, Hillman JL, Yu JY, Tuason O, Yap PE, Anshay SR;
PI Daugherty SC, Dam TC, Liu TF, Nguyen DA, Kleefeld Y, Gerstin EH;
PI Peralta CH, David MH, Lewis SA, Chen AJ, Panzer SR, Harris B;
PI Flores V, Marwaha R, Lo A, Lan RY, Urashka ME;
XX WPI; 2003-129518/12.
XX P-PSDB; ABR41514.
XX
XX Novel human diagnostic and therapeutic polypeptide useful for identifying
PT test compound which specifically binds to a polypeptide encoded by human
PT diagnostic and therapeutic polynucleotide, and to induce antibodies.
XX
XX Claim 2; SEQ ID NO 373; 591pp; English.
XX
XX The invention relates to novel human diagnostic and therapeutic
CC polynucleotides designated dithp (ACC46080-ACC46749) and to their encoded
CC proteins (DITHP; ABR41136-ABR41812). The invention also relates to
CC polynucleotide sequences at least 90% identical to the dithp cDNA
CC sequences of the invention; recombinant vectors, host cells and
CC transgenic organisms comprising a dithp nucleic acid sequence; the
CC recombinant production of DITHP proteins; antibodies specific for DITHP
CC proteins; microarrays comprising dithp nucleic acid sequences; methods of
CC detecting dithp nucleotide and protein sequences; methods of screening
CC for compounds which specifically bind a DITHP protein; and methods of
CC assessing the toxicity of test compounds using a dithp hybridisation
CC probe. Dithp nucleic acid sequences and DITHP proteins may be used in the
CC diagnosis of a wide variety of conditions including cancer and other cell
CC proliferative disorders; autoimmune or inflammatory disorders; bacterial,
CC viral, fungal or parasitic infections; hormonal disorders; metabolic
CC disorders; neurological disorders; gastrointestinal disorders; transport
CC disorders; and connective tissue disorders. They may also be used to
CC screen for modulators of protein activity or gene expression. DITHP
CC proteins can additionally be used in analysis of the proteome of a tissue
CC or cell type and to induce antibodies. The dithp nucleic acids are
CC additionally useful in somatic or germline gene therapy of the disorders
CC mentioned above, as a source of antisense sequences, as a source of
CC probes and primers, in genotyping and identification of individuals, in
CC the generation of transgenic animal models of human disease or knock in
CC humanised animals, in toxicological testing, and in transcript imaging.
XX The present sequence represents a dithp cDNA encoding a DITHP protein
XX which is involved in protein modification and/or maintenance. Note: The
XX sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 631 BP; 121 A; 179 C; 192 G; 139 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 21; DB 1; Length 631;
Best Local Similarity 54.5%; Pred. No. 1.8e+02;
Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 813 TGTGTTTTCAGGCAACCACTTCAATATACAGTAATCCAGTCTATCCCCCAACCAG 872
DB 435 TGTCTGGGGCCGCCAGGTGCCAGGATCCCACTCAGCACCTCCAGTCCACCAC 494
QY 873 TAATGCTGAAGAAGCTG 889
DB 495 TGCTGCTGCTTGAGCTG 511
RESULT 186
ABL65438/c
ID ABL65438 standard; DNA; 850 BP.
XX
XX ABL65438;
AC
```

XX DT 15-MAY-2002 (first entry)  
XX DE Lung cancer related gene sequence SEQ ID NO:3775.  
XX KW Human; cancer; colon; breast; ovary; oesophagus; kidney; thyroid;  
XX KW stomach; lung; prostate; pancreas; carcinoma; antitumour; cancerous;  
XX KW cytostatic; gene therapy; antineoplastic; Wilm's tumour; adenocarcinoma;  
XX KW gene; ds.  
XX OS Homo sapiens.  
XX PN WO200194629-A2.  
XX PD 13-DEC-2001.  
XX PF 30-MAY-2001; 2001WO-US010838.  
XX PR 05-JUN-2000; 2000US-0209473P.  
XX PR 05-JUN-2000; 2000US-0209531P.  
XX PR 18-SEP-2000; 2000US-0233133P.  
XX PR 18-SEP-2000; 2000US-0233617P.  
XX PR 20-SEP-2000; 2000US-0234009P.  
XX PR 20-SEP-2000; 2000US-0234034P.  
XX PR 20-SEP-2000; 2000US-0234052P.  
XX PR 22-SEP-2000; 2000US-0234509P.  
XX PR 22-SEP-2000; 2000US-0234567P.  
XX PR 25-SEP-2000; 2000US-0234923P.  
XX PR 25-SEP-2000; 2000US-0234924P.  
XX PR 25-SEP-2000; 2000US-0235077P.  
XX PR 25-SEP-2000; 2000US-0235082P.  
XX PR 25-SEP-2000; 2000US-0235134P.  
XX PR 25-SEP-2000; 2000US-0235280P.  
XX PR 25-SEP-2000; 2000US-0235637P.  
XX PR 26-SEP-2000; 2000US-0235638P.  
XX PR 27-SEP-2000; 2000US-0235711P.  
XX PR 27-SEP-2000; 2000US-0235720P.  
XX PR 27-SEP-2000; 2000US-0235840P.  
XX PR 27-SEP-2000; 2000US-0235863P.  
XX PR 28-SEP-2000; 2000US-0236028P.  
XX PR 28-SEP-2000; 2000US-0236032P.  
XX PR 28-SEP-2000; 2000US-0236033P.  
XX PR 28-SEP-2000; 2000US-0236034P.  
XX PR 28-SEP-2000; 2000US-0236109P.  
XX PR 28-SEP-2000; 2000US-0236111P.  
XX PR 29-SEP-2000; 2000US-0236842P.  
XX PR 29-SEP-2000; 2000US-0236891P.  
XX PR 29-SEP-2000; 2000US-0237172P.  
XX PR 02-OCT-2000; 2000US-0237173P.  
XX PR 02-OCT-2000; 2000US-0237278P.  
XX PR 02-OCT-2000; 2000US-0237294P.  
XX PR 02-OCT-2000; 2000US-0237295P.  
XX PR 02-OCT-2000; 2000US-0237316P.  
XX PR 03-OCT-2000; 2000US-0237425P.  
XX PR 03-OCT-2000; 2000US-0237598P.  
XX PR 03-OCT-2000; 2000US-0237604P.  
XX PR 03-OCT-2000; 2000US-0237606P.  
XX PR 03-OCT-2000; 2000US-0237608P.  
XX PR 01-NOV-2000; 2000US-0244867P.  
XX PR 01-NOV-2000; 2000US-0245084P.  
XX PA (AVAL-) AVALON PHARM.  
XX PI Young PE, Augustus M, Carter KC, Ebner R, Endress G, Horrigan S;  
XX PI Soppet DR, Weaver Z;  
XX WIPI; 2002-188264/24.  
XX PT Screening for anti-neoplastic agent involves exposing cells to a chemical  
XX PT agent to be tested for anti-neoplastic activity, and determining a change  
XX PT in expression of a gene of a signature gene set.  
XX Claim 1; SEQ ID NO 3775; 44pp; English.

XX CC The present invention describes a method (M1) for screening for an anti-  
CC neoplastic agent. The method involves exposing cells to a chemical agent  
CC to be tested for anti-neoplastic activity, determining a change in  
CC expression of at least one gene (I) of a signature gene set, where (I)  
CC comprises a sequence (S) selected from 8447 sequences (given in ABL61664  
CC to ABL70110), or is at least 95% identical to (S), where a change in  
CC expression is indicative of anti-neoplastic activity. (I) has cytostatic  
CC activity and can be used in gene therapy. M1 can be used for screening an  
CC anti-neoplastic agent, and can be used for producing a product which is  
CC the data collected with respect to the anti-neoplastic agent as a result  
CC of M1, and the data is sufficient to convey the chemical structure and/or  
CC properties of the agent. M1 can be used in the treatment of cancer such  
CC as colon, breast, stomach, lung, thyroid, oesophageal, ovarian, kidney,  
CC prostate or pancreatic cancer, adenocarcinoma, carcinoma, clear cell  
CC cancer, infiltrating ductal cancer, infiltrating lobular cancer, squamous  
CC cell carcinoma, neuroendocrine carcinoma, papillary carcinoma and Wilm's  
CC tumour

XX SQ Sequence 850 BP; 191 A; 253 C; 229 G; 177 T; 0 U; 0 Other;  
XX  
XX Query Match 0.6%; Score 21; DB 1; Length 850;  
XX Best Local Similarity 62.3%; Pred. No. 1.9e+02;  
XX Matches 33; Conservative 0; Mismatches 20; Indels 0; Gaps 0;  
CY 922 CTTTGAACCTAACACCCCAAAAGATGCTCTTCTCATTTATAGGGGACTGGAA 974  
DB 136 CTCACAGGTGTAGCCCCCAACAATCTTGTCTCATCTCGTCAAGGGGACAGCA 84

RESULT 187  
AAV59135  
ID AAV59135 standard; DNA; 933 BP.  
AC AAV59135;  
XX  
XX 07-JAN-1999 (first entry)  
XX  
XX Nucleotide sequence of SP002LA, a homologue of HELA2.  
XX Serine protease; regulation; cell activity; viability; HELA2; ATC2;  
XX BCMO; testisin; fertility; suppressor; testicular germ cell cancer;  
XX seminoma; testis-specific expression; antitumour; sperm development;  
XX infertility; human; chromosome 16p13.3; ss.  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
XX CDS 3..872  
XX /tag= a  
XX /product= "SP002LA"  
XX  
XX WO9836054-A1.  
XX  
XX 20-AUG-1998.  
XX  
XX 13-FEB-1998; 98WO-AU0000085.  
XX  
XX 13-FEB-1997; 97AU-00005101.  
XX 18-NOV-1997; 97AU-00000422.  
XX  
XX (AMRA-) AMRAD OPERATIONS PTY LTD.  
XX  
XX  
XX Antalis TM, Hooper JD;  
XX WIPI; 1998-480768/41.  
XX P-PSDB; AAW77303.  
XX  
XX New serine protease(s) and kinase involved in regulating cell activity  
XX and viability - particularly the testis-specific protease HELA2 used for  
XX modulation of fertility and as tumour suppressor.  
XX  
XX Example 15; Fig 20B; 167pp; English.

XX CC AAV59134-36 represent HELA2 homologues. The genes are found in a cluster  
 CC on chromosome 16p13.3. HELA2 was isolated from HeLa cells, and has  
 CC homology to serine proteases. The protein is involved in or associated  
 CC with regulation of cell activity and/or viability. Administration of  
 CC recombinant HELA2 (also called testisin) is used to increase fertility.  
 CC Downregulation of HELA2 reduces fertility. HELA2 is also a suppressor of  
 CC testicular germ cell cancers (seminoma) and is also expressed in some non  
 CC testicular cancers (of colon, pancreas, prostate and ovary), so is a  
 CC marker/potential therapeutic target for cancer. The promoter, from the  
 CC HELA2 gene is useful for testis-specific expression of other genes, e.g.  
 CC for gene therapy or modulation of fertility. Drugs that block activity of  
 CC HELA2 should have antitumour activity (other than in testis) while in  
 CC testis recombinant HELA2 should stop growth of tumours and normalise  
 CC sperm development (eliminating the need for orchidectomy). Identification  
 CC of mutant forms of HELA2 can be used to diagnose infertility  
 XX CC  
 SQ Sequence 933 BP; 166 A; 294 C; 284 G; 189 T; 0 U; 0 Other;

Query Match 0.6%; Score 21; DB 1; Length 933;  
 Best Local Similarity 54.5%; Pred. No. 2e+02;  
 Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 813 TGTGTTGTTTCCAGGCAACCAATTCATATATCAGTAATCCAGTCTATGCCCAACGAG 872  
 |||||  
 Db 766 TGCTGGGGCCCGCCAGGTGCCCGAGATCCCATCAGGCACCTCCAGATCCCAACGAG 825  
 |||||  
 Qy 873 TAATGCTGAAGAAGCTG 889  
 |||||  
 Db 826 TGCTGCTGCTTGAGCTG 842  
 |||||

## RESULT 188

ADA05757

ID ADA05757 standard; cDNA; 951 BP.

XX AC ADA05757;

XX DT 06-NOV-2003 (first entry)

XX DE Human NOV25a encoding cDNA SEQ ID NO:117.

XX KW human; NOVX; antidiabetic; anorectic; antibacterial; virucide;  
 KW immunomodulator; cytostatic; nootropic; neuroprotective;  
 KW antiparkinsonian; antilipaeamic; gene therapy; human disease;  
 KW metabolic disorder; diabetes; obesity; infection; cachexia; cancer;  
 KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;  
 KW immune disorder; haematopoietic disorder; dyslipidaemia; gene; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers  
 XX CDS 1..951  
 FT /\*tag= a  
 FT /product= "NOV25a"

XX PN WO2003029424-A2.

XX PD 10-APR-2003.

XX PF 02-OCT-2002; 2002WO-US031373.

XX PR 02-OCT-2001; 2001US-0326483P.

XX PR 05-OCT-2001; 2001US-0327435P.

XX PR 09-OCT-2001; 2001US-0327449P.

XX PR 09-OCT-2001; 2001US-0327517P.

XX PR 09-OCT-2001; 2001US-0328029P.

XX PR 09-OCT-2001; 2001US-0328044P.

XX PR 12-OCT-2001; 2001US-0328056P.

XX PR 15-OCT-2001; 2001US-0329414P.

XX PR 17-OCT-2001; 2001US-0330142P.

XX PR 18-OCT-2001; 2001US-0330309P.

PR 22-OCT-2001; 2001US-0341058P.  
 PR 24-OCT-2001; 2001US-0339268P.  
 PR 24-OCT-2001; 2001US-0343629P.  
 PR 29-OCT-2001; 2001US-0349575P.  
 PR 01-NOV-2001; 2001US-0346357P.  
 PR 17-APR-2002; 2002US-0373260P.  
 PR 19-APR-2002; 2002US-0373813P.  
 PR 19-APR-2002; 2002US-0373817P.  
 PR 19-APR-2002; 2002US-0373826P.  
 PR 19-APR-2002; 2002US-0373884P.  
 PR 22-APR-2002; 2002US-0374977P.  
 PR 16-MAY-2002; 2002US-0381037P.  
 PR 16-MAY-2002; 2002US-0381038P.  
 PR 16-MAY-2002; 2002US-0381042P.  
 PR 17-MAY-2002; 2002US-0381642P.  
 PR 28-MAY-2002; 2002US-0383656P.  
 PR 29-MAY-2002; 2002US-0383831P.  
 PR 25-JUN-2002; 2002US-0391335P.  
 PR 01-OCT-2002; 2002US-00262511.

(CURA-) CURAGEN CORP.

XX Smithson G, Millet I, Peyman JA, Kekuda R, Ju J, Li L, Guo X;  
 XX Patturajan M, Spytek KA, Edinger SR, Ellerman K, Malyankar UM;  
 XX Ort T, Gorman L, Zerhusen BD, Anderson DW, Zhong M, Cartterton E;  
 XX Ji W, Miller CE, Rastelli L, Stone DJ, Pena CEA, Shenoy SG;  
 XX Shimkets RA, Rothenberg ME, Leach MD, Agee ML, Bergus C, Dipippo VA;  
 XX Eisen AJ, Gangolli EA, Rieger DK, Spaderna SK;  
 XX WPI; 2003-381626/36.

DR P-PSDB; ADA05758.  
 DR P-PSDB; ADA05758.

PT New NOVX polypeptides and nucleic acids, useful for diagnosing,  
 PT preventing or treating NOVX-associated disorders, e.g. diabetes, obesity,  
 PT cancer or dyslipidaemia, and in chromosome mapping, tissue typing or  
 PT pharmacogenomics.

Claim 20; Page 191; 586pp; English.

XX The present invention describes NOVX proteins, where X can be 1 to 55  
 CC (e.g. NOV1). Also described: (1) a composition comprising a polypeptide  
 CC described above and a carrier; (2) a kit comprising, in one or more  
 CC containers, the composition described above; (3) an isolated nucleic acid  
 CC molecule which encodes a NOVX protein of the invention; (4) a vector  
 CC comprising the nucleic acid molecule described above; (5) a cell  
 CC comprising the above vector; (6) an antibody that immunospecifically  
 CC binds to the polypeptide described above; (7) methods for determining the  
 CC presence or amount of the above polypeptide or nucleic acid molecule in a  
 CC sample; (8) methods for determining the presence of or predisposition to  
 CC a disease associated with altered levels of expression of the above  
 CC polypeptide or nucleic acid molecule in a first mammalian subject; (9) a  
 CC method of identifying an agent that binds to the polypeptide described  
 CC above; (10) a method for identifying a potential therapeutic agent for  
 CC use in treating a pathology that is related to an aberrant expression or  
 CC aberrant physiological interactions of the polypeptide; (11) a method of  
 CC screening for a modulator of activity or of latency or predisposition to  
 CC a pathology associated with the polypeptide; (12) a method for modulating  
 CC the activity of the polypeptide described above; (13) methods of treating  
 CC or preventing a pathology associated with the above polypeptide in a  
 CC mammal; and (14) a method for producing the above polypeptide. NOVX  
 CC sequences have antidiabetic, anorectic, antibacterial, virucide,  
 CC immunomodulator, cytostatic, nootropic, neuroprotective, antiparkinsonian  
 CC and antilipaeamic activities, and can be used in gene therapy. The  
 CC polypeptide is useful in manufacturing a medicament for treating a  
 CC syndrome associated with a human disease. The polypeptide or the nucleic  
 CC acid molecule may be used to diagnose, treat or prevent metabolic  
 CC disorders such as diabetes or obesity, infections, cachexia, cancer,  
 CC neurodegenerative disorders such as Alzheimer's disease or Parkinson's  
 CC disease, immune disorders, haematopoietic disorders and various  
 CC dyslipidaemias. The nucleic acids can also be used as hybridisation  
 CC probes, in chromosome mapping, tissue typing, preventive medicine and  
 CC pharmacogenomics. The present sequence encodes a human NOVX protein from  
 CC the present invention.

|            |   |
|------------|---|
| XX         | Sequence 951 BP; 156 A; 310 C; 292 G; 193 T; 0 U; 0 Other;                |
| SQ         | Query Match 0.6%; Score 21; DB 1; Length 951;                             |
|            | Best Local Similarity 54.5%; Pred. No. 2e-02;                             |
|            | Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;              |
| QY         | 813 TGTGTTGTTCCAGGCAACCACTTCAATATACAGTAGTAATCCAGTGTATGCCGCCAACGAG 872     |
| DB         | 845 TGTCTGGGGCGCGCCAGGTGCCCGGAGTCCCACTCAGGCACCTCCAGATCCCAACGAG 904        |
| QY         | 873 TAATGCTGAAGAAGCTG 889   |
| DB         | 905 TCTCTGCTGCTTGCAGTGTG 921  |
| RESULT 189 |   |
| AA06059    | ID AAS06059 standard; DNA; 1551 BP.                                       |
| XX         | AA06059;  |
| AC         | 12-SEP-2001 (first entry)   |
| XX         | Angiotensin converting enzyme (ACEV) splice variant DNA #59.              |
| DE         | XX  |
| XX         | Angiotensin converting enzyme splice variant; ACEV; interleukin 6;        |
| KW         | granulocyte colony stimulating factor receptor; glucagon; hypertrophy;    |
| KW         | platelet-derived endothelial cell growth factor; cardiovascular disease;  |
| KW         | cellular tumour antigen P53; cyclin-dependent kinase inhibitor 1C; ds;    |
| KW         | vasoactive intestinal polypeptide receptor 2; arteriosclerosis; cancer;   |
| KW         | myocardial infarction; coronary arterial thrombosis; renal disease;       |
| KW         | diabetic nephropathy; muscular disease; immune disorder; sarcoidosis;     |
| KW         | multiple sclerosis; immune complex nephritis; deep vein thrombosis;       |
| KW         | noncardioidic pulmonary granulomatous disease; endothelial abnormality;   |
| KW         | vascular disorder; asbestosis.  |
| XX         | XX  |
| OS         | Mus sp.   |
| XX         | W0200136632-A2.   |
| PN         | 25-MAY-2001.  |
| XX         | 17-NOV-2000; 2000WO-IL0000766.  |
| PF         | 17-NOV-1999; 99IL-00132978.   |
| PR         | 10-DEC-1999; 99IL-00133455.   |
| PR         | (COMP-) COMPUEN LTD.  |
| XX         | Levine Z, David A, Azar I, Khosravi R, Bernstein J;                       |
| XX         | WPI; 2001-336004/35.  |
| XX         | P-PSDB; AAU02959.   |
| DR         | Novel alternative splicing variants e.g. variant of angiotensin           |
| DR         | converting enzyme (ACEV), useful in identifying candidate compounds       |
| XX         | capable of binding to the variant and to detect anti-variant antibodies.  |
| XX         | Claim 1; Page 358; 519pp; English.  |
| PS         | The sequence represents a DNA encoding an angiotensin converting enzyme   |
| CC         | splice variant (ACEV) polypeptide. The polypeptides of the invention      |
| CC         | include variants of granulocyte colony stimulating factor receptor.       |
| CC         | glucagon, interleukin 6, platelet-derived endothelial cell growth factor, |
| CC         | cyclin-dependent kinase inhibitor 1C, cellular tumour antigen P53, and    |
| CC         | vasoactive intestinal polypeptide receptor 2. The polypeptides and their  |
| CC         | associated nucleic acids are useful for identification of variant         |
| CC         | sequences and detection of candidate compounds capable of binding the     |
| CC         | molecules. the sequences of the invention can be used in the treatment    |
| CC         | and diagnosis of various disorders including cardiovascular diseases such |
| CC         | as arteriosclerosis, myocardial infarction and coronary arterial          |
| CC         | thrombosis, renal diseases such as diabetic nephropathy, muscular         |





CC The present invention describes novel human proteins, designated NOVX  
CC proteins. The NOVX sequences have cardiant, antiarteriosclerotic,  
CC hypotensive, vasotropic, dermatological, anorectic, immunosuppressive,



CC functions in the cell to cause termination of transcription and addition  
 CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
 CC (2) determining a level or pattern of a molecule in a bovine cell or  
 CC tissue comprising: (a) incubating a marker nucleic acid (comprising any  
 CC of the 1512 nucleic acid sequences or its complement or fragment) with a  
 CC complementary nucleic acid molecule obtained from the bovine cell or  
 CC tissue, where hybridisation between the marker nucleic acid and the  
 CC complementary nucleic acid permits the detection of the molecule; and (b)  
 CC detecting the level or pattern of the complementary nucleic acid, where  
 CC the detection of the complementary nucleic acid is predictive of the  
 CC level or pattern of the molecule. The LMPD nucleic acid is used for  
 CC determining a level or pattern of a molecule in a bovine cell or tissue.  
 CC It is useful for genome mapping, gene identification and analysis, cattle  
 CC breeding, preparation of constructs for use in cattle gene expression, or  
 CC for genetically improving cattle. The present sequence is one of the  
 CC 1512 bovine LMPD EST (expressed sequence tag) nucleic acids. Note: The  
 CC present sequence was not shown in the specification but was obtained in  
 CC electronic format from the USPTO web site:  
 CC seqdata.uspto.gov/sequence.html?DocID=20020137139  
 XX  
 SQ Sequence 432 BP; 140 A; 69 C; 107 G; 116 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.9; DB 1; Length 432;  
 Best Local Similarity 46.3%; Pred. No. 1.8e+02;  
 Matches 101; Conservative 0; Mismatches 116; Indels 1; Gaps 1;

QY 2800 GAAACCTTAGTATTATATTAATCTAGAAATAGTAATTTTATATGTTTC-AAAATTTAT 2858  
 DB 171 GGAACCTTCAGAGAGAGAGTAAAGAGAAATAGTTTGAAGACGACGAGAGTTT 230  
 QY 2859 TTCATAATGTTGGTTAAGATAATAGATTTTCAAAATGATTTTATCTTGATTTTCTC 2918  
 DB 231 TTGAAACACTGAGAAACTACTGAATTTTGAAGCAATATGTTGATGGAGATCAGTGTG 290  
 QY 2919 TACTTATTATTTTGGGATTTTAACTATTTCTTCAATGACCTTGATTTCTAATATTAC 2978  
 DB 291 AATCCATCCATGTTTAAATGCGGCGATGTGCAAGATGACATTAATTCCTATGTAATTT 350  
 QY 2979 TTATTTCTATTTTACCTTAAATTCGACTTATTTTATTTATTTGA 3016  
 DB 351 GGTGTCAAGCTGGATTTGAAGGAGCACTGTGAATTA 388

RESULT 197  
 ABV97483  
 ID ABV97483 standard; cDNA; 197 BP.  
 XX  
 AC ABV97483;  
 XX  
 DT 14-JAN-2003 (first entry)  
 XX  
 DE Human pancreatic cancer expressed cDNA SEQ ID NO 2891.  
 XX  
 KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;  
 KW cytostatic; tumour; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200260317-A2.  
 XX  
 PD 08-AUG-2002.  
 XX  
 PF 30-JAN-2002; 2002WO-US002781.  
 XX  
 PR 30-JAN-2001; 2001US-0265305P.  
 PR 31-JAN-2001; 2001US-0265682P.  
 PR 09-FEB-2001; 2001US-0267568P.  
 PR 21-MAR-2001; 2001US-0278651P.  
 PR 28-APR-2001; 2001US-0287112P.  
 PR 16-MAY-2001; 2001US-0291631P.  
 PR 12-JUL-2001; 2001US-0305484P.  
 PR 20-AUG-2001; 2001US-0313999P.  
 PR 27-NOV-2001; 2001US-0333626P.

XX  
 PA (CORI-) CORIXA CORP.  
 XX  
 FI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;  
 XX  
 DR WPI; 2002-627435/67.  
 XX  
 PT New isolated polynucleotide and pancreatic tumor polypeptides, useful for  
 PT diagnosing, preventing and/or treating cancer, particularly pancreatic  
 PT cancer.  
 XX  
 FS Claim 1; SEQ ID NO 2891; 300pp + Sequence Listing; English.  
 XX  
 CC The invention relates to an isolated polynucleotide (I) comprising: (a)  
 CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)  
 CC complements of (a); (c) sequences consisting of at least 20 contiguous  
 CC residues of (a); (d) sequences that hybridize to (a), under moderately  
 CC stringent conditions; (e) sequences having at least 75% or 90% identity  
 CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-  
 CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer  
 CC in a patient and compositions comprising polypeptides, polynucleotides,  
 CC antibodies, fusion proteins, T cell populations and antigen presenting  
 CC cells expressing the polypeptide are useful in treating pancreatic cancer  
 CC and stimulating an immune response. The polynucleotides can be used as  
 CC probes or primers for nucleic acid hybridisation, in the design and  
 CC preparation of ribozyme molecules for inhibiting expression of the tumour  
 CC polypeptides and proteins in the tumour cells, in vaccines and for gene  
 CC therapy. Note: The sequence data for this patent did not form part of the  
 CC printed specification, but was obtained in electronic format directly  
 CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 197 BP; 59 A; 43 C; 65 G; 30 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.8; DB 1; Length 197;  
 Best Local Similarity 78.1%; Pred. No. 1.5e+02;  
 Matches 25; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1943 GAAACCTTGGCTGGAGAGACACACAGCTCGA 1974  
 DB 93 GAGACTCTGGCCAGGAGAGCTGAAGCTCGA 124

RESULT 198  
 ABN18436/C  
 ID ABN18436 standard; cDNA; 252 BP.  
 XX  
 AC ABN18436;  
 XX  
 DT 24-JUN-2002 (first entry)  
 XX  
 DE Human ORFX polynucleotide sequence SEQ ID NO:5349.  
 XX  
 KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;  
 KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;  
 KW degenerative disorder; osteoarthritis; neurodegenerative disorder;  
 KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;  
 KW hypertension; hypothyroidism; cholesterol ester storage disease;  
 KW immune deficiency; immune disorder; infectious disease;  
 KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;  
 KW myasthenia gravis; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192523-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 29-MAY-2001; 2001WO-US010836.  
 XX  
 PR 30-MAY-2000; 2000US-0206132P.  
 PR 29-AUG-2000; 2000US-0228716P.  
 XX  
 PA (CURA-) CURAGEN CORP.



XX PN WO9906550-A2.  
XX PD 11-FEB-1999.  
XX PF 31-JUL-1998; 98WO-1B001232.  
XX PR 01-AUG-1997; 97US-00905144.  
XX PA (GEST ) GENSET.  
XX PI Dumas Milne Edwards J, Duclert A, Lacroix B;  
XX DR WPI; 1999-153780/13.  
XX DR P-PSDB; AA111719.  
XX PT New isolated prostate-derived nucleic acids - used to develop products  
XX PT which may have cytokine, immune regulatory, haematopoiesis regulating,  
XX PT anti-inflammatory or tumour inhibition activity.  
XX PS Claim 1; Page 174-175; 675pp; English.  
XX CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for  
CC human secreted proteins expressed in prostate, and encode the proteins  
CC given in AA11716 to AA11993 respectively. The proteins given represent  
CC the signal peptide and an N-terminal fragment of a secreted protein. The  
CC nucleic acid sequences can be used for producing secreted human gene  
CC products. They can also be used to develop products for diagnosis and  
CC therapy. The proteins obtained may have cytokine activity, cell  
CC proliferation and differentiation activity, haematopoiesis regulating  
CC activity, tissue growth regulating activity, reproductive hormone  
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and  
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory  
CC activity, tumour inhibition activity or other activities. The products  
CC can be used in forensic, gene therapy and chromosome mapping procedures.  
CC The sequences can also be used for obtaining corresponding promoter  
CC sequences. The nucleic acids encoding the signal peptides can be used for  
CC directing extracellular secretion of a polypeptide or the insertion of a  
CC polypeptide into a membrane, or importing a polypeptide into a cell  
XX SQ Sequence 323 BP; 59 A; 119 C; 89 G; 52 T; 0 U; 4 Other;

Query Match 0.6%; Score 20.8; DB 1; Length 323;  
Best Local Similarity 46.5%; Pred. No. 1.7e-02;  
Matches 67; Conservative 0; Mismatches 77; Indels 0; Gaps 0;  
QY 249 GTGGGCAACCAAGATGGGAGGTTCATGGTGAGAGATCTGACAGATGGTCCACTG 308  
DB 267 GGTGCGCCCAAGAGATAGCCCGTCTTCGAAACAGGCTCCCTGCCAGGCTGGAGT 208  
QY 309 GAGAAGGGAATGCAACCACTTCAGTATTTCTTTCCTTGAGAACCCCATCAACAGTATGAA 368  
DB 207 GAGGCTTGCACTCGAACCCCTTGATGATCTCTCTCCCTACAGCCCTGTGCA 148  
QY 369 AAGGCAATGATAGTACTGAA 392  
DB 147 GAGCAGCAGGATTAACTGCAGAA 124

RESULT 201  
AAS59116/c  
ID AAS59116 standard; cDNA; 380 BP.  
XX AC AAS59116;  
XX AC AAS59116;  
XX DT 16-JAN-2002 (first entry)  
XX DE Human cancer related cDNA sequence #234.  
XX KW Human; ss; lung cancer; adenocarcinoma; breast cancer; colon cancer;  
XX KW prostate cancer; benign prostatic hypertrophy; BHP; cytostatic.  
XX OS Homo sapiens.

XX PN WO200172781-A2.  
XX PD 04-OCT-2001.  
XX PF 27-MAR-2001; 2001WO-US009952.  
XX PR 28-MAR-2000; 2000US-0192583P.  
XX PA (CHIR ) CHIRON CORP.  
XX PA (HYSE-) HYSEQ INC.  
XX PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;  
PI Reinhard C, He Z, Randazzo F, Kennedy GC, Pot D, Kassam A;  
PI Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;  
PI Leshkowitz D, Kita D, Garcia V, Jones LW, Stache-Crain B;  
XX DR WPI; 2001-626251/72.  
XX PT New human polynucleotides useful for the treatment and diagnosis of  
XX PT cancer.  
XX PS Claim 1; Page 216-217; 240pp; English.  
XX CC The invention relates to an isolated polynucleotide comprising a  
CC nucleotide sequence which hybridises to a sequence selected from one of  
CC 316 fully defined sequences given in the specification, antisense  
CC molecules complementary to the sequences, the polypeptides encoded by the  
CC sequences and antibodies raised against the proteins. The nucleic acids  
CC are useful for detecting differentially expressed genes which correlate  
CC with a cancerous state of a mammalian cell i.e. diagnosing cancer  
CC (especially lung cancer, colon cancer, breast cancer, prostate cancer and  
CC adenocarcinoma). Modifying the gene products of the nucleic acids  
CC results in inhibition of tumour growth. The nucleic acids are also useful  
CC in gene mapping and tissue profiling. The present sequence is one of the  
XX SQ 316 cancer related cDNA sequences

Query Match 0.6%; Score 20.8; DB 1; Length 380;  
Best Local Similarity 44.3%; Pred. No. 1.8e+02;  
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;  
QY 3129 ATCTTTTCTCAAGTTTGAATTTGGTACGTAACTCATTTATCTTTATTTTGAATTA 3188  
DB 259 AGCTCTCAAGAGAAATATCATAGTCATGATGGTGTGTGTTTTCATGACAAATT 200  
QY 3189 GCTCTTTAAATTCATTTATTTCTTTGATACAGCTTCAGTTCTATGGCTTTAATAAGTTT 3248  
DB 199 ATTCTCCGGAGACCCCGTTTCATTTTGAAGGTTTATTGTTACTCCAAAGGAGCAGTC 140  
QY 3249 TTTTCTTTTCTTTTAAAGAAATGTCATTTCTTTGTAAGTTTTCACAAATGCTTTGAGCA 3308  
DB 139 CACTCGCAGGGTCTTATATGTTGTAACAGTGAGCAGCACTCACAGCCATGTGCA 80  
QY 3309 ATAATTTAGGAT 3320  
DB 79 TTAATTAAGGTT 68

RESULT 202  
ABX44887/c  
ID ABX44887 standard; cDNA; 396 BP.  
XX AC ABX44887;  
XX AC ABX44887;  
XX DT 21-FEB-2003 (first entry)  
XX DE Bovine EST associated with lactation/muscle/fat deposition #10052.  
XX KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;  
XX KW muscle deposition; fat deposition; genome mapping; gene identification;  
XX KW gene analysis; cattle breeding.

```
XX OS Bos Taurus.
XX PN US2002137139-A1.
XX PD 26-SEP-2002.
XX PF 24-SEP-2001; 2001US-00960352.
XX PR 12-JAN-1999; 99US-0115707P.
XX PN 11-JAN-2000; 2000US-00480902.
XX PA (BYAT/) BYATT J C.
XX PA (MATH/) MATHIALAGAN N.
XX PA (TAON/) TAO N.
XX PA (WARREN/) WARREN W C.
XX PI Byatt JC, Mathialagan N, Tao N, Warren WC;
XX DR WPI; 2003-110599/10.
XX PT New nucleic acid associated with lactation, and muscle and fat
XX PT deposition, useful for genome mapping. Gene identification and analysis,
XX PT cattle breeding, or for genetically improving cattle.
XX PS Claim 2; SEQ ID NO 10052; 245pp; English.
XX CC The invention relates to a purified nucleic acid molecule associated with
XX CC lactation or muscle and fat deposition (designated LMFD), derived from
XX CC cattle, and the LMFD nucleic acid can specifically hybridise to a second
XX CC nucleic acid molecule comprising any of 15112 nucleotide sequences,
XX CC appearing as AX34836-ABX4947, or complements of them. Also included are
XX CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic
XX CC acid linked to a promoter and a 3' non-translated sequence that
XX CC functions in the cell to cause termination of transcription and addition
XX CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and
XX CC (2) determining a level or pattern of a molecule in a bovine cell or
XX CC tissue comprising: (a) incubating a marker nucleic acid (comprising any
XX CC of the 15112 nucleic acid sequences or its complement or fragment) with a
XX CC complementary nucleic acid molecule obtained from the bovine cell or
XX CC tissue, where hybridisation between the marker nucleic acid and the
XX CC complementary nucleic acid permits the detection of the molecule; and (b)
XX CC detecting the level or pattern of the complementary nucleic acid, where
XX CC the detection of the complementary nucleic acid is predictive of the
XX CC level or pattern of the molecule. The LMFD nucleic acid is used for
XX CC determining a level or pattern of a molecule in a bovine cell or tissue.
XX CC It is useful for genome mapping, gene identification and analysis, cattle
XX CC breeding, preparation of constructs for use in cattle gene expression, or
XX CC for genetically improving cattle. The present sequence is one of the
XX CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The
XX CC present sequence was not shown in the specification but was obtained in
XX CC electronic format from the USPTO web site:
XX CC seqdata.uspto.gov/sequence.html?docID=20020137139
XX SQ Sequence 396 BP; 109 A; 83 C; 95 G; 109 T; 0 U; 0 Other;
Query Match 0.6%; Score 20.8; DB 1; Length 396;
Best Local Similarity 57.8%; Pred. No. 1.8e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
QY 1048 CAAGAAGCTATAGAGTTTGGCCAGAAATGCTGGTCTATAGCAACACCTCTTCCAA 1107
Db 92 CACAGAATGAGCAATTTTCCCATGCAAAAGGACCTGCCAAGGGAATTGACCTCTTTCAG 33
QY 1108 CAAC 1111
Db 32 CATC 29
RESULT 203
AAS59112/c
ID AAS59112 standard; cDNA; 400 BP.
XX
```

```
AC AAS59112;
XX 16-JAN-2002 (first entry)
XX DE Human cancer related cDNA sequence #230.
XX KW Human; ss; lung cancer; adenocarcinoma; breast cancer; colon cancer;
XX KW prostate cancer; benign prostatic hypertrophy; BHP; cytostatic.
XX OS Homo sapiens.
XX PN WO200172781-A2.
XX PD 04-OCT-2001.
XX PF 27-MAR-2001; 2001WO-US009952.
XX PR 28-MAR-2000; 2000US-0192583P.
XX PA (CHIR ) CHIRON CORP.
XX PA (HYSE-) HYSEQ INC.
XX PI Williams LT, Escobedo J, Innis MA, Garcia PD, Sudduth-Klinger J;
XX PI Reinhard C, He Z, Randazzo F, Kennedy GC, Pot D, Kassam A;
XX PI Lamson G, Drmanac R, Crkvenjakov R, Dickson M, Drmanac S, Labat I;
XX PI Leshkowitz D, Kita D, Garcia V, Jones LW, Stache-Crain B;
XX DR WPI; 2001-626251/72.
XX PT New human polynucleotides useful for the treatment and diagnosis of
XX PT cancer.
XX PS Claim 1; Page 215-216; 240pp; English.
XX CC The invention relates to an isolated polynucleotide comprising a
XX CC nucleotide sequence which hybridises to a sequence selected from one of
XX CC 316 fully defined sequences given in the specification, antisense
XX CC molecules complementary to the sequences, the polypeptides encoded by the
XX CC sequences and antibodies raised against the proteins. The nucleic acids
XX CC are useful for detecting differentially expressed genes which correlate
XX CC with a cancerous state of a mammalian cell i.e. diagnosing cancer
XX CC (especially lung cancer, colon cancer, breast cancer, prostate cancer and
XX CC adenocarcinoma). Modifying the gene products of the nucleic acids
XX CC results in inhibition of tumour growth. The nucleic acids are also useful
XX CC in gene mapping and tissue profiling. The present sequence is one of the
XX CC 316 cancer related cDNA sequences
XX SQ Sequence 400 BP; 113 A; 83 C; 100 G; 104 T; 0 U; 0 Other;
Query Match 0.6%; Score 20.8; DB 1; Length 400;
Best Local Similarity 44.3%; Pred. No. 1.8e+02;
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
QY 3129 ATCTTTCTCAAGTTTGAATTCGCTACGTAACCTATCTTATCTTTTCTTAATTA 3188
Db 276 AGCTCTGCAGAGAAATATCATAGTCATGTGGGTGTTGTTATTTTCAUGCAATT 217
QY 3189 GCTCTTTAAATTCATATTTCTTTGATAACAGCTTCAGTTTATGGGTTTAATAAGTTTT 3248
Db 216 ATTCCTCGGAGACCCCGTTTCATTTTCGAAGGTTTATTGTTACTCCAAAGGAAGCAGTC 157
QY 3249 TTTTCTTTTCTTTTAAAGATGTCATCTTTTGTGAAGTTTGTGACATGCTTTCAGCA 3308
Db 156 CATCTGCGAGGGTCTTTATATGTTGTTAAACAGTGACGACACTCAAGCCCATGTGGCA 97
QY 3309 ATAATTTAGGAT 3320
Db 96 TTAATTAAGGT 85
RESULT 204
ABA67855/c
ID ABA67855 standard; DNA; 545 BP.
XX
```

```
XX AC ABA67855;
XX DT 01-FEB-2002 (first entry)
XX DE Human foetal liver single exon nucleic acid probe #16160.
XX KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.
XX OS Homo sapiens.
XX PN WO200157277-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000669.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX DR WPI; 2001-483447/52.
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human fetal liver.
XX PS Claim 4; SEQ ID NO 16160; 639pp + Sequence Listing; English.
XX CC The invention relates to a single exon nucleic acid probe for measuring
XX CC human gene expression in a sample derived from human foetal liver. The
XX CC single exon nucleic acid probes may be used for predicting, measuring and
XX CC displaying gene expression in samples derived from human fetal liver. The
XX CC present sequence is a single exon nucleic acid probe of the invention.
XX CC Note: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 545 BP; 175 A; 108 C; 122 G; 140 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.8; DB 1; Length 545;
Best Local Similarity 51.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 49; Conservative 0; Mismatches 47;
QY 2827 AAAATAGTAATTCATATGTAATTCAAAATTAATTCATATGTTGGTTAAGATAAAGAT 2886
Db 118 AGAAGGCAATGCTCATGTTGTAATTAATAGCTGCAATGTTGGTTGAGGAATA 59
QY 2887 TTTCAAATGATTTTATCTTTGATTTTCTACT 2922
Db 58 ATTCGAATCACATTTGCTTTTGTCTGTATGTTCT 23

RESULT 205
ABS41612/c
ID ABS41612 standard; DNA; 545 BP.
XX AC ABS41612;
XX DT 25-FEB-2003 (first entry)
XX DE Human liver single exon probe, SEQ ID NO 16602.
XX KW Human; single exon nucleic acid probe; liver; cirrhosis;
XX KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX KW coronary heart disease; ss.

XX OS Homo sapiens.
XX PN WO200157273-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX DR WPI; 2001-488898/53.
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human adult liver.
XX PS Claim 4; SEQ ID NO 16602; 658pp; English.
XX CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
XX CC measuring human gene expression in a sample derived from human adult
XX CC liver, comprising one of 13109 defined nucleotide sequences given in the
XX CC specification (or complements/ fragments). The probe hybridises at high
XX CC stringency to a nucleic acid molecule expressed in the human adult liver.
XX CC (I) may be used for predicting, measuring and displaying gene expression
XX CC in samples derived from human adult liver. The genes identified may be
XX CC involved in genetic liver diseases such as cirrhosis,
XX CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
XX CC associated with coronary heart disease. ABS25011-ABS51005 represent human
XX CC liver single exon nucleic acid probes of the invention. Note: The
XX CC sequence information for this patent does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 545 BP; 175 A; 108 C; 122 G; 140 T; 0 U; 0 Other;

Query Match 0.8%; Score 20.8; DB 1; Length 545;
Best Local Similarity 51.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 49; Conservative 0; Mismatches 47;
QY 2827 AAAATAGTAATTCATATGTAATTCAAAATTAATTCATATGTTGGTTAAGATAAAGAT 2886
Db 118 AGAAGGCAATGCTCATGTTGTAATTAATAGCTGCAATGTTGGTTGAGGAATA 59
QY 2887 TTTCAAATGATTTTATCTTTGATTTTCTACT 2922
Db 58 ATTCGAATCACATTTGCTTTTGTCTGTATGTTCT 23

RESULT 206
AAI99982
ID AAI99982 standard; cDNA; 1338 BP.
XX AC AAI99982;
XX DT 07-FEB-2002 (first entry)
XX DE Human FVII encoding cDNA SEQ ID NO 2.
XX KW Factor VII; FVII; Factor VIIa; haemostatic; thrombolytic;
XX KW cardiant; hepatotrophic; cerebroprotective; haemophilic; liver disease;
XX KW myocardial infarction; thrombotic stroke; deep-vein thrombosis;
XX KW chromosome 13q35-9; ss.
```



```
OS Homo sapiens.
XX Key Location/Qualifiers
PH CDS 115..1335
FT /*tag= a
FT /product= "FVII"
FT /partial
FT /note= "CDS lacks an initiation codon"
XX
XX WO20015935-A2.
XX
XX 16-AUG-2001.
XX
XX 12-FEB-2001; 2001WO-DK000094.
XX
XX 11-FEB-2000; 2000DK-00000218.
XX 18-OCT-2000; 2000DK-00001558.
XX
XX (MAXY-) MAXYGEN AFS.
XX
XX Andersen KV, Pedersen AH, Bornaes C;
XX
XX WPI; 2001-581807/65.
XX P-FSDB; AAM52171.
XX
XX New conjugate, useful for treating Factor VIIa related diseases or
XX disorders such as haemophilia, liver disease, myocardial infarction and
XX deep-vein thrombosis, comprises non-polypeptide group covalently attached
XX to polypeptide group.
XX
XX Example 2; Page 83-85; 89pp; English.
XX
XX The invention relates to novel Factor VII (FVII) or Factor VIIa (FVIIa)
XX polypeptide conjugates, comprising at least one non-polypeptide group
XX covalently attached to a polypeptide, where the amino acid sequence of
XX polypeptide differs from that of the wildtype FVIIa (AAM52171) in that at
XX least one amino acid residue containing an attachment group for the non-
XX polypeptide group has been introduced or removed. The FVIIa conjugates
XX have haemostatic, thrombolytic, cardiant, hepatotrophic and
XX cerebroprotective activity and are useful for treating FVIIa/TF-related
XX diseases or disorders such as haemophilia, liver disease, myocardial
XX infarction, thrombotic stroke and deep-vein thrombosis. The conjugates
XX have increased bioavailability in vivo half life and/or increased plasma half
XX life, increased bioavailability and/or reduced sensitivity to proteolytic
XX degradation. Consequently medical treatment using the conjugates has a
XX number of advantages over currently available such as longer duration
XX between injections
XX
XX Sequence 1338 BP; 245 A; 427 C; 410 G; 256 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.8; DB 1; Length 1338;
XX Best Local Similarity 57.8%; Pred. No. 2.4e-02;
XX Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
XX
XX QY 1443 AGGGATCGAGACATCCCATGCAAGAAAGCAAAAGCAAAATGGCTGTCTGGGA 1502
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 132 AGAGTCCGCCCTGGCTCCCTGGACGGGATGCAAGAGGACAGTGCAGCTTTGAGGA 191
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX
XX QY 1503 GCCC 1506
XX |||||
XX Db 192 AGCC 195
XX
XX RESULT 207
XX AAS41085/C
XX ID AAS41085 standard; cDNA; 1352 BP.
XX
XX AC AAS41085;
XX
XX 17-DEC-2001 (first entry)
XX
XX cDNA encoding novel human enzyme polypeptide #301.
XX
```

Human; oxidoreductase enzyme; transferase; hydrolase; lyase; isomerase;  
ligase; hyperproliferative disorder; immunodeficiency disorder;  
autoimmune disorder; neurological disorder; metabolic disorder;  
inflammatory disorder; cardiovascular disorder; reproductive disorder;  
blood-related disorder; infectious disorder; gene therapy; cytostatic;  
anti arthritic; nephrotropic; anticoagulant; ss.

Human sapiens.

WO200155301-A2.

02-AUG-2001.

17-JAN-2001; 2001WO-US001239.

31-JAN-2000; 2000US-0179065P.

04-FEB-2000; 2000US-0180628P.

24-FEB-2000; 2000US-0184664P.

02-MAR-2000; 2000US-0186350P.

16-MAR-2000; 2000US-0189874P.

17-MAR-2000; 2000US-0190076P.

18-APR-2000; 2000US-0198123P.

19-MAY-2000; 2000US-0205515P.

07-JUN-2000; 2000US-0209467P.

28-JUN-2000; 2000US-0214886P.

30-JUN-2000; 2000US-0215135P.

07-JUL-2000; 2000US-0216647P.

07-JUL-2000; 2000US-0216880P.

11-JUL-2000; 2000US-0217487P.

11-JUL-2000; 2000US-0217496P.

14-JUL-2000; 2000US-0218290P.

26-JUL-2000; 2000US-0220963P.

26-JUL-2000; 2000US-0220964P.

14-AUG-2000; 2000US-0224518P.

14-AUG-2000; 2000US-0224519P.

14-AUG-2000; 2000US-0225133P.

14-AUG-2000; 2000US-0225214P.

14-AUG-2000; 2000US-0225266P.

14-AUG-2000; 2000US-0225267P.

14-AUG-2000; 2000US-0225268P.

14-AUG-2000; 2000US-0225270P.

14-AUG-2000; 2000US-0225447P.

14-AUG-2000; 2000US-0225757P.

14-AUG-2000; 2000US-0225758P.

14-AUG-2000; 2000US-0225759P.

18-AUG-2000; 2000US-0226279P.

22-AUG-2000; 2000US-0226681P.

22-AUG-2000; 2000US-0226686P.

22-AUG-2000; 2000US-0227182P.

23-AUG-2000; 2000US-0227009P.

30-AUG-2000; 2000US-0228924P.

01-SEP-2000; 2000US-0229287P.

01-SEP-2000; 2000US-0229343P.

01-SEP-2000; 2000US-0229344P.

01-SEP-2000; 2000US-0229345P.

02-SEP-2000; 2000US-0229509P.

03-SEP-2000; 2000US-0229513P.

06-SEP-2000; 2000US-0230437P.

06-SEP-2000; 2000US-0230438P.

08-SEP-2000; 2000US-0231242P.

08-SEP-2000; 2000US-0231243P.

08-SEP-2000; 2000US-0231244P.

08-SEP-2000; 2000US-0231413P.

08-SEP-2000; 2000US-0231414P.

08-SEP-2000; 2000US-0232080P.

08-SEP-2000; 2000US-0232081P.

12-SEP-2000; 2000US-0231968P.

14-SEP-2000; 2000US-0232397P.

14-SEP-2000; 2000US-0232398P.

14-SEP-2000; 2000US-0232399P.

14-SEP-2000; 2000US-0232400P.

14-SEP-2000; 2000US-0232401P.

14-SEP-2000; 2000US-0233063P.





```

RESULT 210
ABK91679/c
ID ABK91679 standard; cDNA; 1352 BP.
XX
XX
AC ABK91679;
XX
XX
26-AUG-2002 (first entry)
DT
XX
DE
DE
XX
XX
cDNA encoding novel ovarian related polypeptide #46.

```

XX Homo sapiens.  
OS  
XX  
XX WO200155329-A2.  
XX  
XX  
XX  
XX 02-AUG-2001.  
XX  
XX  
XX 17-JAN-2001; 2001WO-US001360.  
XX  
XX  
XX 31-JAN-2000; 2000US-0179065P.  
XX  
XX  
XX





|    |              |                  |    |      |  |
|----|--------------|------------------|----|------|--|
| PR | 27-SEP-2000; | 2000US-0235834P. | XX | PI   | Rosen CA, Barash SC, Ruben SM;   |
| PR | 27-SEP-2000; | 2000US-0235835P. | XX | XX   |  |
| PR | 29-SEP-2000; | 2000US-0236327P. | DR | DR   | WPI; 2001-465566/50.   |
| PR | 29-SEP-2000; | 2000US-0236367P. | DR | DR   | P-PSDB; AAU23751.  |
| PR | 29-SEP-2000; | 2000US-0236368P. | XX | XX   | Novel polypeptides and polynucleotides useful for diagnosing, preventing,                |
| PR | 29-SEP-2000; | 2000US-0236369P. | PT | PT   | treating neural, immune system, muscular, reproductive, pulmonary,                       |
| PR | 29-SEP-2000; | 2000US-0236370P. | PT | PT   | cardiovascular, renal, proliferative disorders and cancerous diseases.                   |
| PR | 02-OCT-2000; | 2000US-0236802P. | XX | XX   |  |
| PR | 02-OCT-2000; | 2000US-0237037P. | XX | XX   | Claim 4; SEQ ID NO 847; 1180pp; English.   |
| PR | 02-OCT-2000; | 2000US-0237038P. | XX | XX   |  |
| PR | 02-OCT-2000; | 2000US-0237039P. | XX | XX   |  |
| PR | 02-OCT-2000; | 2000US-0237040P. | XX | XX   | The present invention relates to the isolation of novel human enzyme                     |
| PR | 13-OCT-2000; | 2000US-0239335P. | CC | CC   | polypeptides (AAU2915-AAU23814), and the cDNA and genomic sequences                      |
| PR | 13-OCT-2000; | 2000US-0239337P. | CC | CC   | encoding them. The enzyme polypeptides of the invention may comprise the                 |
| PR | 20-OCT-2000; | 2000US-0240560P. | CC | CC   | functional classes of oxidoreductases, transferases, hydrolases, lyases,                 |
| PR | 20-OCT-2000; | 2000US-0241221P. | CC | CC   | isomerases or ligases. The sequences of the invention are useful in the                  |
| PR | 20-OCT-2000; | 2000US-0241785P. | CC | CC   | diagnosis, treatment, prevention and/or prognosis of a wide range of                     |
| PR | 20-OCT-2000; | 2000US-0241786P. | CC | CC   | disorders, including hyperproliferative disorders (e.g. cancer),                         |
| PR | 20-OCT-2000; | 2000US-0241787P. | CC | CC   | disorders, including hyperproliferative disorders (e.g. AIDS) autoimmune disorders (e.g. |
| PR | 20-OCT-2000; | 2000US-0241808P. | CC | CC   | immunodeficiency disorders (e.g. Alzheimer's disease), metabolic                         |
| PR | 20-OCT-2000; | 2000US-0241809P. | CC | CC   | arthrititis) (e.g. phenylketonuria), inflammatory disorders (e.g. asthma),               |
| PR | 20-OCT-2000; | 2000US-0241826P. | CC | CC   | disorders (e.g. atherosclerosis), blood-related disorders                                |
| PR | 01-NOV-2000; | 2000US-0244617P. | CC | CC   | cardiovascular disorders (e.g. atherosclerosis), blood-related disorders                 |
| PR | 08-NOV-2000; | 2000US-0246474P. | CC | CC   | (e.g. haemophilia), reproductive disorders (e.g. infertility) and                        |
| PR | 08-NOV-2000; | 2000US-0246475P. | CC | CC   | infectious disorders (e.g. influenza). The polynucleotides of the                        |
| PR | 08-NOV-2000; | 2000US-0246476P. | CC | CC   | invention can also be used in gene therapy. AAS40785-AAS41684 represent                  |
| PR | 08-NOV-2000; | 2000US-0246477P. | CC | CC   | cDNA sequences encoding for the novel human enzyme polypeptides of the                   |
| PR | 08-NOV-2000; | 2000US-0246478P. | CC | CC   | cDNA sequences encoding for the novel human enzyme polypeptides of the                   |
| PR | 08-NOV-2000; | 2000US-0246523P. | CC | CC   | invention. Note: The sequence data for this patent did not form part of                  |
| PR | 08-NOV-2000; | 2000US-0246524P. | CC | CC   | the printed specification, but was obtained in electronic format directly                |
| PR | 08-NOV-2000; | 2000US-0246525P. | CC | CC   | from WIPO at ftp.wipo.int/pub/published_sequences  |
| PR | 08-NOV-2000; | 2000US-0246526P. | XX | XX   |  |
| PR | 08-NOV-2000; | 2000US-0246527P. | XX | XX   | Sequence 1352 BP; 237 A; 444 C; 408 G; 260 T; 0 U; 3 Other;                              |
| PR | 08-NOV-2000; | 2000US-0246528P. | XX | XX   |  |
| PR | 08-NOV-2000; | 2000US-0246532P. | XX | XX   |  |
| PR | 08-NOV-2000; | 2000US-0246609P. | XX | XX   |  |
| PR | 08-NOV-2000; | 2000US-0246610P. | XX | XX   |  |
| PR | 08-NOV-2000; | 2000US-0246611P. | XX | XX   |  |
| PR | 17-NOV-2000; | 2000US-0249207P. | QY | 3251 | TTTTTTTTTTTTTTAAAGATGTCATCTTCTTGGAAGTT 3290  |
| PR | 17-NOV-2000; | 2000US-0249208P. | Db | 1342 | TTTTTTTTTTTTTTGGAGATAAATAATTATTGAAATT 1303   |
| PR | 17-NOV-2000; | 2000US-0249209P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249210P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249211P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249212P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249213P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249214P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249215P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249216P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249217P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249218P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249244P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249245P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249264P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249265P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249297P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249399P. |    |      |  |
| PR | 17-NOV-2000; | 2000US-0249300P. |    |      |  |
| PR | 01-DEC-2000; | 2000US-0250160P. |    |      |  |
| PR | 01-DEC-2000; | 2000US-0250391P. |    |      |  |
| PR | 05-DEC-2000; | 2000US-0251030P. |    |      |  |
| PR | 05-DEC-2000; | 2000US-0251988P. |    |      |  |
| PR | 05-DEC-2000; | 2000US-0256719P. |    |      |  |
| PR | 08-DEC-2000; | 2000US-0251856P. |    |      |  |
| PR | 08-DEC-2000; | 2000US-0251868P. |    |      |  |
| PR | 08-DEC-2000; | 2000US-0251869P. |    |      |  |
| PR | 08-DEC-2000; | 2000US-0251989P. |    |      |  |
| PR | 11-DEC-2000; | 2000US-0251990P. |    |      |  |
| PR | 05-JAN-2001; | 2001US-0254097P. |    |      |  |
| XX |              |                  |    |      |  |
| PA |              |                  |    |      | (HUMA-) HUMAN GENOME SCI INC.  |

Query Match 0.6%; Score 20.8; DB 1; Length 1352;  
Best Local Similarity 70.0%; Pred. No. 2.4e+02;  
Matches 28; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

RESULT 212  
AAS26943/C  
ID AAS26943 standard; cDNA; 1352 BP.  
XX AC AAS26943;  
XX DT 07-NOV-2001 (first entry)  
XX DE Human cDNA encoding a novel secreted protein, SEQ ID 135.  
XX Human; immunosuppressive; antiarthritic; ss; antirheumatic; cytostatic;  
XX cardiant; vasotropic; cerebroprotective; neurotropic; neuroprotective;  
XX antibacterial; virucide; fungicide; opthalmological; vulnary;  
XX secreted protein; rheumatoid arthritis; hyperproliferative disorder;  
XX cardiovascular disorder; cardiac arrest; cerebrovascular disorder;  
XX cerebral ischaemia; angiogenesis; nervous system disorder;  
XX Alzheimer's disease; infection; ocular disorder; corneal infection;  
XX wound healing; epithelial cell proliferation; skin ageing; food additive;  
XX preservative; antiproliferative.  
XX Homo sapiens.  
XX WO200155441-A2.  
XX PN 02-AUG-2001.  
XX PD 17-JAN-2001; 2001WO-US001320.  
XX PF 31-JAN-2000; 2000US-0179065P.  
XX PR 04-FEB-2000; 2000US-0180628P.  
XX PR 24-FEB-2000; 2000US-0184664P.





XX New conjugate, useful for treating Factor VIIa related diseases or  
PT disorders such as haemophilia, liver disease, myocardial infarction and  
PT deep-vein thrombosis, comprises non-polypeptide group covalently attached  
PT to polypeptide group.  
XX  
PS Example 2; Page 63-64; 89pp; English.  
XX  
CC The invention relates to novel Factor VII (FVII) or Factor VIIa (FVIIa)  
CC polypeptide conjugates, comprising at least one non-polypeptide group  
CC covalently attached to a polypeptide, where the amino acid sequence of  
CC polypeptide differs from that of the wildtype FVIIa (AAM52171) in that at  
CC least one amino acid residue containing an attachment group for the non-  
CC polypeptide group has been introduced or removed. The FVIIa conjugates  
CC have haemostatic, thrombolytic, cardiac, hepatotropic and  
CC cerebroprotective activity and are useful for treating FVIIa/TF-related  
CC diseases or disorders such as haemophilia, liver disease, myocardial  
CC infarction, thrombotic stroke and deep-vein thrombosis. The conjugates  
CC have increased functional in vivo half life and/or increased plasma half  
CC life, increased bioavailability and or reduced sensitivity to proteolytic  
CC degradation. Consequently medical treatment using the conjugates has a  
CC number of advantages over currently available such as longer duration  
CC between injections. The present sequence is that of a human FVII  
CC expression cassette, encompassing the short form of the full length cDNA  
CC encoding FVII, for expression of human FVII in mammalian cells  
XX  
SQ Sequence 1357 BP; 249 A; 435 C; 414 G; 259 T; 0 U; 0 Other;

XX Query Match 0.6%; Score 20.8; DB 1; Length 1357;  
PT Best Local Similarity 57.8%; Pred. No. 2.4e+02;  
PT Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
XX  
QY 1443 AGGATCGAGACCATCCCATGGAAGAAGAAATCCAAAAGCAAATGCTGTCTGGGA 1502  
DB 145 AGAGTCCGGCTGGCTCCCTCGAAGCGGAATGCAAGAGAACAGTGCAGCTTTGAGGA 204  
QY 1503 GGCC 1506  
DB 205 AGCC 208  
RESULT 214  
AA199983  
ID AA199983 standard; cDNA; 1357 BP.  
AC AA199983;  
XX  
XX 07-FEB-2002 (first entry)  
DT  
DE Human FVII expression cassette SEQ ID NO 4.  
XX  
XX Factor VII; FVII; Factor VIIa; haemostatic; thrombolytic;  
XX cardiant; hepatotropic; cerebroprotective; haemophilia; liver disease;  
XX myocardial infarction; thrombotic stroke; deep-vein thrombosis; ss.  
XX  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
XX CDS 128..1348  
XX /\*tag= a  
XX /\*product= "FVII"  
XX /\*partial  
XX /\*note= "CDS lacks an initiation codon"  
XX  
XX WO200158935-A2.  
XX  
XX 16-AUG-2001.  
XX  
XX 12-FEB-2001; 2001WO-DK000094.  
XX  
XX 11-FEB-2000; 2000DK-00000218.  
XX 18-OCT-2000; 2000DK-00001558.  
XX  
XX (MAXY-) MAXYGEN APS.  
XX  
XX Andersen KV, Pedersen AH, Bornaes C;  
XX  
XX WPI; 2001-581807/65.  
XX P-PSDB; AAM52172.  
XX  
XX

```
XX PS Claim 1; Fig 12; 134pp; English.
XX CC AAZ32159 to AAZ32194 represent reference alleles for specifically claimed
XX CC nucleic acid sequences from the present invention which comprise
XX CC polymorphic sites as given in a table in the specification, selected from
XX CC 92 single nucleotide polymorphisms in which the nucleotide at the
XX CC polymorphic site is different from a nucleotide at the same site in a
XX CC reference allele. The nucleic acids, and primers and probes, are used to
XX CC identify polymorphisms, which may predispose an individual to disease,
XX CC especially a vascular disease. They can also be used in phenotype
XX CC correlations, forensics, paternity testing, medicine or genetic analysis.
XX CC AA49550 to AA49573 represent the proteins which correspond to some of
XX CC the reference alleles
XX SQ Sequence 1366 BP; 302 A; 388 C; 425 G; 251 T; 0 U; 0 Other;

Query Match      0.6%; Score 20.8; DB 1; Length 1366;
Best Local Similarity 57.8%; Pred. No. 2.4e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 453 CTCGAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
      |||||
Db 1191 CTCGAGAGGCCCAAGAGAGGATGGAGGACAGACAGACAGAGCGGTGCTGTGTTAC 1132

QY 513 TGGT 516
      ||
Db 1131 ATGT 1128

RESULT 215
AAQ13357/c
ID AAQ13357 standard; cDNA; 1754 BP.
XX AC AAQ13357;
XX DT 25-MAR-2003 (revised)
XX DT 04-NOV-1991 (first entry)
XX DE Human protein C gene.
XX KW HPC; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT CDS 69..1454
FT sig_peptide /*tag= a
FT mat_peptide /*tag= b
FT misc_RNA /*tag= c
FT /*tag= d
FT /*tag= e
FT /*tag= "Light chain"
FT /*tag= "heavy chain"
XX WO9112320-A.
XX PD 22-AUG-1991.
XX PF 09-FEB-1990; 90US-00478084.
XX PR 09-FEB-1990; 90US-00478084.
XX PA (ZYMO ) ZYMOGENETICS INC.
XX PA (TEIJ ) TEIJIN LTD.
XX PI Miyagi F, Sumi Y, Wakabayash K, Foster DC;
XX WPI; 1991-267132/36.

DR P-PSDB; AAR13622.
XX FT Activated human protein C with truncated light chain - used in therapy
XX FT and prophylaxis to enhance anticoagulant and fibrinolytic capabilities.
XX PS Example; Fig 1; 49pp; English.
XX CC The cDNA sequence encodes human protein C (HPC). It can be obtd. from a
XX CC lambda-gt11 cDNA library prepd. from human liver mRNA by standard
XX CC methods. The activated protein can comprise one of 3 different truncated
XX CC light chains, 195 to 644, 647 or 650. The activated HPC, with a truncated
XX CC light chain is more stable during storage. It can be administered for
XX CC prophylactic and/or therapeutic treatments of disease states or injuries
XX CC to enhance the patient's own anticoagulative or fibrinolytic
XX CC capabilities. See also WO9109951 (AAQ12649). (Updated on 25-MAR-2003 to
XX CC correct PA field.)
XX SQ Sequence 1754 BP; 378 A; 506 C; 540 G; 330 T; 0 U; 0 Other;

Query Match      0.6%; Score 20.8; DB 1; Length 1754;
Best Local Similarity 57.8%; Pred. No. 2.4e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 453 CTCGAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
      |||||
Db 1573 CTCGAGAGGCCCAAGAGAGGATGGAGGACAGACAGACAGCGCGGTGCTGTGTTAC 1514

QY 513 TGGT 516
      ||
Db 1513 ATGT 1510

RESULT 216
AAQ12649/c
ID AAQ12649 standard; cDNA; 1754 BP.
XX AC AAQ12649;
XX DT 25-MAR-2003 (revised)
XX DT 02-OCT-1991 (first entry)
XX DE Protein C precursor gene.
XX KW Anticoagulant; fibrinolysis; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT sig_peptide 72..110
FT /*tag= a
FT mat_peptide /label= prepro peptide
FT /*tag= b
XX WO9109951-A.
XX PD 11-JUL-1991.
XX PF 22-DEC-1989; 89US-00456092.
XX PR 22-DEC-1989; 89US-00456092.
XX PA (ZYMO ) ZYMOGENETICS INC.
XX PA (TEIJ ) TEIJIN LTD.
XX PI Foster DC, Holly RD, Suzuki M, Wakabayash K, Kumar AA;
XX WPI; 1991-222903/30.
XX DR P-PSDB; AAR13074.
XX PT Recombinant protein C with truncated light chain - for use as an
XX PT anticoagulant.
```

10664775-2.rng

Mon Aug 9 17:46:53 2004

PT Recombinant prodn. of hybrid phospholipid-binding proteins - comprising  
PT lipocortin phospholipid-binding domain and vitamin-K-dependent protein.  
XX  
XX Disclosure; Fig 2; 57pp; English.  
XX This sequence, or a fragment of it, is used in the construction of DNA  
CC sequences encoding hybrid phospholipid-binding proteins (PBP) having the  
CC same biological activity as human protein C or human activated protein C.  
CC The hybrid sequence would comprise at least one lipocortin phospholipid  
CC binding domain (PBP), e.g. of PAP-I, joined to a gla-domainless protein C  
CC or activated protein C. See AAQ12678-81 for such examples. A lambda gt11  
CC cDNA library was prep'd. from human liver mRNA by conventional methods in  
CC order to obtain this cDNA. See also AAQ12678-81. (Updated on 25-MAR-2003  
CC to correct PA field.)  
XX  
SQ Sequence 1755 BP; 378 A; 506 C; 541 G; 330 T; 0 U; 0 Other;  
Query Match 0.6%; Score 20.8; DB 1; Length 1755;  
Best Local Similarity 57.8%; Pred. No. 2.4e+02; Indels 0; Gaps 0;  
Matches 37; Conservative 0; Mismatches 27;  
QY 453 CTCGAGAAAGATGAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512  
DB 1574 CTCGAGAGAGCCCAAGAGAGGATGGAGGACAGACAGACAGCGCGGTGCTGTGTAC 1515  
QY 513 TGGT 516  
DB 1514 ATGT 1511  
RESULT 218  
AAT32795/C  
ID AAT32795 standard; cDNA; 1755 BP.  
XX  
XX AAT32795;  
XX  
XX 25-MAR-2003 (revised)  
XX 05-NOV-1996 (first entry)  
XX Human protein C cDNA.  
XX Activated protein C; serine protease; thrombosis; thrombolytic;  
XX fibrinolytic; antithrombotic; blood clotting; therapy; ss.  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
XX FH 70..1455  
XX CDS /tag= a  
XX /product= "protein C prepro-protein"  
XX FT 70..195  
XX FT /tag= b  
XX FT /function= "prepro-peptide"  
XX FT mat\_peptide 196..1452  
XX FT /tag= c  
XX FT polyA\_signal 1502..1507  
XX FT /tag= d  
XX FT polyA\_signal 1721..1726  
XX FT /tag= e  
XX  
XX US5516650-A.  
XX  
XX 14-MAY-1996.  
XX  
XX 08-APR-1994; 94US-00225253.  
XX  
XX 27-JUN-1985; 85US-00749600.  
XX 29-OCT-1986; 86US-00924462.  
XX 08-DEC-1987; 87US-00130370.  
XX 28-FEB-1989; 89US-00317205.  
XX 10-SEP-1990; 90US-00582131.  
XX 04-DEC-1992; 92US-00987532.  
XX

PS The sequence was determined from a clone isolated from a cDNA library  
XX prep'd. from mRNA from Hep G2 cells. It encodes a protein C precursor,  
CC including light and heavy chains, which is cleaved to produce activated  
CC protein C (see protein file for details). The sequence can be manipulated  
CC by genetic engineering techniques to express a protein comprising residues  
CC activated) a heavy chain and a truncated light chain comprising residues  
CC 1-149, 1-150, 1-151 or 1-152 of the natural sequence. The protein pref.  
CC comprises the precursor of formula: Pre-pro-L-X-H Pre-pro = pre-pro  
CC peptide of protein C with all/part replaced by the corresponding peptide  
CC of either protein S, factors VII, IX or X, or prothrombin; L = AAs 1-149,  
CC 150, 151 or 152 of light chain; X = 3-10 Lys/arg residues; and H = heavy  
CC chain. Cells transformed with expression vectors contg. the modified DNA  
CC sequences produce the new proteins which can be used to regulate  
CC anticoagulant and fibrinolytic systems. See also W09112320 (AAQ13357).  
XX  
XX (Updated on 25-MAR-2003 to correct PA field.)  
XX  
SQ Sequence 1754 BP; 378 A; 505 C; 540 G; 331 T; 0 U; 0 Other;  
Query Match 0.6%; Score 20.8; DB 1; Length 1754;  
Best Local Similarity 57.8%; Pred. No. 2.4e+02; Indels 0; Gaps 0;  
Matches 37; Conservative 0; Mismatches 27;  
QY 453 CTCGAGAAAGATGAGAGATGGAGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512  
DB 1573 CTCGAGAGAGCCCAAGAGAGGATGGAGGACAGACAGACAGCGCGGTGCTGTGTAC 1514  
QY 513 TGGT 516  
DB 1513 ATGT 1510  
RESULT 217  
AAQ12678/C  
ID AAQ12678 standard; cDNA; 1755 BP.  
XX  
XX AAQ12678;  
XX  
XX 25-MAR-2003 (revised)  
XX 30-SEP-1991 (first entry)  
XX Human protein C.  
XX Phospholipid; binding protein; lipocortin; domain; vitamin K; PBP;  
XX gla-domain; VKDP; ss.  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
XX FH 70..1452  
XX CDS /tag= a  
XX /product= "protein\_C"  
XX FT 70..195  
XX FT /tag= b  
XX FT mat\_peptide 196..1452  
XX FT /tag= c  
XX  
XX W09109953-A.  
XX  
XX 11-JUL-1991.  
XX  
XX 29-DEC-1989; 89US-00459082.  
XX  
XX 29-DEC-1989; 89US-00459082.  
XX (ZYMO ) ZYMOGENETICS INC.  
XX Foster DC;  
XX WPI; 1991-222905/30.  
XX P-PSDB; AAR13081.  
XX



CC obtained, the full 5' UTR is rarely included. 5' ESTs are derived from  
 CC mRNAs with intact 5' ends and can therefore be used to obtain full length  
 CC cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,  
 CC gene therapy and chromosome mapping procedures. They are used to obtain  
 CC upstream regulatory sequences and to design expression and secretion  
 CC vectors

SQ Sequence 228 BP; 51 A; 54 C; 37 G; 71 T; 0 U; 15 Other;

Query Match 0.6%; Score 20.6; DB 1; Length 228;

Best Local Similarity 47.8%; Pred. No. 1.8e+02;

Matches 33; Conservative 8; Mismatches 28; Indels 0; Gaps 0;

QY 773 CAGTACTTGAGTCAGTCTCAAAACGACAGAAATGATCTCTGTTTGTTCAGGCAAC 832

Db 188 CAAATCTKACAGCTGACACATTGATAGATACAGATCTGAGWTTKCTWAKKAAG 129

QY 833 CATTCAATA 841

Db 128 CWKAAATD 120

RESULT 221

AAN93747/C

ID AAN93747 standard; DNA; 271 BP.

AC AAN93747;

DT 25-MAR-2003 (revised)

DT 04-JUN-1990 (first entry)

XX Leader sequence of Factor X and Gla domain of Factor IX.

XX Fusion protein; Factor X; Factor IX; anticoagulant; protein-C; ss.

XX Synthetic.

PH Key Location/Qualifiers

FT Signal\_peptide 14..133

FT /\*tag= a

FT /product= "leader sequence of Factor X"

FT CDS 134..262

FT /\*tag= b

FT /product= "AAs 1-43 of Factor IX"

FT CDS 263..271

FT /\*tag= c

FT /product= "AAs 44-46 of protein C"

XX EP296413-A.

XX 28-DEC-1988.

XX 09-JUN-1988; 88EP-00109186.

XX 12-JUN-1987; 87JP-00145293.

XX 09-JUN-1988; 88JP-00140558.

XX (FARH ) HOECHST JAPAN LTD.

XX Iwasaki W, Takahashi M, Hashimoto T;

XX WPI; 1989-000910/01.

XX Hybrid protein of protein C with replaced Gla domain - using human

XX vitamin-K dependent proteins, e.g. factor X, to give improved

XX anticoagulation activity.

XX Table 5; Page 14; 23pp; English.

XX The nucleotide sequence of synthetic DNA encodes the amino acid sequence

XX including the Gla domain of Factor-XI. See also AAN93063 and AAN93746-49.

XX (Updated on 25-MAR-2003 to correct PF field.) (Updated on 25-MAR-2003 to

XX correct PR field.)

XX

SQ Sequence 271 BP; 77 A; 57 C; 77 G; 60 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.6; DB 1; Length 271;

Best Local Similarity 53.0%; Pred. No. 1.9e+02;

Matches 44; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 3056 CTTTAAATTAATTAATTCCTTTAGTGTTCCTTACCAGTCTCTTCAGGCTACTCTTTTGA 3115

Db 262 CTTCCAAATTCAGTGTCTCTTTTCACTGTTCCTTCAAAACTTCTCGTGTCTTCAAACT 203

QY 3116 TTTATTGGTCCCTATCTTTCTC 3138

Db 202 ACATTTTCTCCATATCTC 180

RESULT 222

ADA49305/C

ID ADA49305 standard; DNA; 312 BP.

XX ADA49305;

XX 20-NOV-2003 (first entry)

XX DT 20-NOV-2003 (first entry)

XX DE Maize gene conferring disease resistance in plants.

XX KW disease resistance; pathogen tolerance; plant pathogen; ds; gene; plant;

XX KW maize.

XX OS Zea mays.

XX PN WO2003000906-A2.

XX PD 03-JAN-2003.

XX PF 21-JUN-2002; 2002WO-IB002453.

XX 22-JUN-2001; 2001US-0300112P.

XX 26-SEP-2001; 2001US-0352277P.

XX 22-MAR-2002; 2002US-0366535P.

XX (SYGN ) SYNGENTA PARTICIPATIONS AG.

XX Glazebrook J, Briggs S, Cooper B, Goff SA, Moughamer T;

XX Katagiri F, Kreps J, Provart N, Rickel D, Zhu T;

XX WPI; 2003-184052/18.

XX New polynucleotide comprising a plant nucleotide sequence having an open

XX reading frame that encodes a polypeptide associated with disease

XX resistance, useful for conferring resistance or tolerance to a plant

XX pathogen.

XX Disclosure; SEQ ID NO 1375; 299pp; English.

XX The invention relates to a novel isolated polynucleotide comprising a

XX plant nucleotide sequence having an open reading frame that encodes a

XX polypeptide associated with disease resistance or its fragment having

XX substantially the same activity as the full-length polypeptide. The

XX polynucleotide of the invention is useful for conferring resistance or

XX tolerance to a plant pathogen. The present sequence represents a gene

XX conferring disease resistance used in the invention.

XX SQ Sequence 312 BP; 69 A; 92 C; 95 G; 56 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.6; DB 1; Length 312;

Best Local Similarity 54.7%; Pred. No. 1.9e+02;

Matches 41; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 1654 CCTCTGTATCATGCAAAAAGAGAGAGTTCAGAAAACATCTATTCTGCTTTATTGA 1713

Db 183 CATCTGTATCATGCAAACTGGTCTGAAAGTCCCTCGTGCACGAGGA 124

QY 1714 CTATGCAAAAGCCTT 1728  
Db 123 GTCGACCGGCGCTT 109

RESULT 223  
ABX44887  
ID ABX44887 standard; cDNA; 396 BP.  
XX  
AC ABX44887;  
XX  
DT 21-FEB-2003 (first entry)  
XX  
DE Bovine EST associated with lactation/muscle/fat deposition #10052.  
XX  
KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;  
KW muscle deposition; fat deposition; genome mapping; gene identification;  
KW gene analysis; cattle breeding.  
XX  
OS Bos Taurus.  
XX  
FN US2002137139-A1.  
XX  
PD 26-SEP-2002.  
XX  
PF 24-SEP-2001; 2001US-00960352.  
XX  
PR 12-JAN-1999; 99US-0115707P.  
PR 11-JAN-2000; 2000US-00480902.  
XX  
PA (BYAT/) BYATT J C.  
PA (MATH/) MATHIALAGAN N.  
PA (TAON/) TAO N.  
PA (WAER/) WARREN W C.  
XX  
PI Byatt JC, Mathialagan N, Tao N, Warren WC;  
XX WPI; 2003-110599/10.  
XX  
PT New nucleic acid associated with lactation, and muscle and fat  
PT deposition, useful for genome mapping, gene identification and analysis,  
PT cattle breeding, or for genetically improving cattle.  
XX  
PS Claim 2; SEQ ID NO 10052; 245pp; English.  
XX

The invention relates to a purified nucleic acid molecule associated with  
lactation or muscle and fat deposition (designated LMFD), derived from  
cattle, and the LMFD nucleic acid can specifically hybridize to a second  
nucleic acid molecule comprising any of 15112 nucleotide sequences,  
appearing as ABX34836-ABX4947, or complements of them. Also included are  
; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic  
acid linked to a promoter and a 3' non- translated sequence that  
functions in the cell to cause termination of transcription and addition  
of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
(2) determining a level or pattern of a molecule in a bovine cell or  
tissue comprising: (a) incubating a marker nucleic acid (comprising any  
of the 15112 nucleic acid sequences or its complement or fragment) with a  
complementary nucleic acid molecule obtained from the bovine cell or  
tissue, where hybridisation between the marker nucleic acid and the  
complementary nucleic acid permits the detection of the molecule; and (b)  
detecting the level or pattern of the complementary nucleic acid, where  
the detection of the complementary nucleic acid is predictive of the  
level or pattern of the molecule. The LMFD nucleic acid is used for  
determining a level or pattern of a molecule in a bovine cell or tissue.  
It is useful for genome mapping, gene identification and analysis, cattle  
breeding, preparation of constructs for use in cattle gene expression, or  
for genetically improving cattle. The present sequence is one of the  
15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The  
present sequence was not shown in the USPTO web site:  
electronic format from the USPTO web site:  
seqdata.uspto.gov/sequence.html?DocID=20020137139  
Sequence 396 BP; 109 A; 83 C; 95 G; 109 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.6; DB 1; Length 396;  
Best Local Similarity 54.7%; Pred. No. 2.1e+02;  
Matches 41; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 429 TACTGGAGATCAGTGGAGAAATACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAA 488  
Db 160 TACTGTTGTTGTCAGGTGAGCATAACACCCGAGAGCCAGAACCTTACAGAGCAAAAGCGAAA 219  
QY 489 AGAATACCCAGCTGT 503  
Db 220 TGTGATCCGTGCTAT 234

RESULT 224  
AAC71346/C  
ID AAC71346 standard; DNA; 717 BP.  
XX  
AC AAC71346;  
XX  
DT 09-FEB-2001 (first entry)  
XX  
DE Single nucleotide polymorphism containing sequence #392.  
XX  
KW Single nucleotide polymorphism: SNP; human; genetic disease;  
KW disease susceptibility; cardiovascular system; endocrine system;  
KW neurological system; forensic testing; paternity testing; ds.  
XX  
OS Homo sapiens.  
XX  
FN WC2000058519-A2.  
XX  
PD 05-OCT-2000.  
XX  
PF 30-MAR-2000; 2000MO-US008440.  
XX  
PR 31-MAR-1999; 99US-0127248P.  
XX  
PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.  
PA (AFFY-) AFFYMETRIX INC.  
XX  
PI Altschuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;  
PI Lipshutz RJ, Patil N, Sklar P;  
XX WPI; 2000-611722/58.  
XX  
PT Nucleic acid selected from one of 106 genes comprising single nucleotide  
PT polymorphisms, allele-specific oligonucleotides to the genes are useful  
PT for phenotypic correlations, forensics, paternity testing, medicine and  
PT genetic analysis.  
XX  
PS Claim 1; Fig 5; 214pp; English.  
XX

The present invention is concerned with a number of human single  
nucleotide polymorphisms (SNPs) which the inventors identified in human  
genes. These SNPs can be used in disease diagnosis and prediction of an  
individual's susceptibility to disease, in forensic and paternity testing  
and in genetic mapping. In particular, the SNPs of the invention can be  
used to diagnose susceptibility to diseases of the cardiovascular,  
endocrine and neurological systems, such as coronary artery disease,  
schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's  
diseases. Note: The degenerate codon within the sequence represents the  
position of an SNP, for example the letter S represents a polymorphism  
where the nucleotide may be C or G

QY Sequence 717 BP; 231 A; 133 C; 151 G; 201 T; 0 U; 1 Other;  
Query Match 0.6%; Score 20.6; DB 1; Length 717;  
Best Local Similarity 54.7%; Pred. No. 2.4e+02;  
Matches 41; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 3139 AGCTTTTGAATGGCTACGTAACCTATTATCTTTATTTTGTAAATGCTCTTTAAA 3198





|    |   |
|----|---|
| CC | for this patent did not form part of the printed specification, but was |
| CC | obtained in electronic format directly from WIPO at                     |
| CC | ftp.wipo.int/pub/published_pct_sequences                                |
| XX |   |
| SQ | Sequence 1843 BP; 417 A; 530 C; 564 G; 332 T; 0 U; 0 Other;             |
|    | Query Match 0.6%; Score 20.6; DB 1; Length 1843;                        |
|    | Best Local Similarity 59.3%; Pred. No. 2.7e+02;                         |
|    | Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;            |
| QY | 1507 TTACAAATAGCTGTGTAAGAGAGAGAGTGTGTAAGCAAGCAAGCAAGTAAAA 1565          |
| Db | 1748 TTATGAAAAGAAATATAAAAAACACACACGCAAAAAAATAAAAAAATAAAAAA 1806         |

RESULT 228  
ADE79050/c  
ID ADE79050 standard; DNA; 1982 BP.  
XX  
XX AC ADE79050;  
XX  
XX  
DT 29-JAN-2004 (first entry)

protein modification and maintenance molecule; PMMW;  
protein modification; protein maintenance; protein function;  
protein conformation; protein stabilisation; protein degradation; kinase;  
phosphatase; protease; protease inhibitor; isomerase; transferase;  
molecular chaperone; anti-HIV; anti-allergic; antiinflammatory;  
antihaemic; antiparkinsonian; nootropic; anticonvulsant;  
antiarteriosclerotic; antiasthmatic; immunosuppressive; antithyroid;  
cytostatic; hepatotropic; dermatological; antidiabetic; nephrotropic;  
antigout; thymimetic; neuroprotective; osteopathic; aniahrthritic;  
antiparasitic; antihelminic; antipsoriatic; uropathic; ophthalmological;  
antirheumatic; haemostatic; antibacterial; virucide; protozoacide;  
fungicide; gene therapy; cell proliferative disorder; arteriosclerosis;  
hepatitis; polycythaemia vera; psoriasis; primary thrombocytopaenia;  
cancer; developmental disorder; anaemia; mental retardation;  
neurological disorder; Alzheimer's disease; Parkinson's disease;  
epilepsy; autoimmune disorder; inflammatory disorder; AIDS; allergies;  
asthma; autoimmune thyroiditis; Crohn's disease; diabetes mellitus;  
glomerulonephritis; Goodpasture's syndrome; multiple sclerosis;  
arthritis; osteoporosis; pancreaticitis; Sjogren's syndrome;  
microbial infection; human; gene; ds.

|     |  |
|-----|--|
| KW  | cancer; developmental disorder; anaemia; mental retardation;           |
| KW  | neurological disorder; Alzheimer's disease; Parkinson's disease;       |
| KW  | epilepsy; autoimmune disorder; inflammatory disorder; AIDS; allergies; |
| KW  | asthma; autoimmune thyroiditis; Crohn's disease; diabetes mellitus;    |
| KW  | glomerulonephritis; Goodpasture's syndrome; multiple sclerosis;        |
| KW  | arthritis; osteoporosis; pancreatitis; Sjogren's syndrome;             |
| KW  | microbial infection; human; gene; ds.                                  |
| XX  |  |
| OS  | Homo sapiens.  |
| XX  |  |
| XX  |  |
| Key | Location/Qualifiers  |
| FFH | replace(108,A)   |
| FT  | /*tag= a   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |
| FFH | replace(109,G)   |
| FT  | /*tag= b   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |
| FFH | replace(193,C)   |
| FT  | /*tag= c   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |
| FFH | replace(195,T)   |
| FT  | /*tag= d   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |
| FFH | replace(196,C)   |
| FT  | /*tag= e   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |
| FFH | replace(197,T)   |
| FT  | /*tag= f   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |
| FFH | replace(419,G)   |
| FT  | /*tag= g   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |
| FFH | replace(420,A)   |
| FT  | /*tag= h   |
| FT  | /standard_name= "Single nucleotide polymorphism"                       |

|    |           |   |  |
|----|-----------|---|--|
| FT | variation | /standard_name="Single nucleotide polymorphism" |  |
| FT |           | replace(196,C)                                  |  |
| FT |           | /*tag= e  |  |
| FT | variation | /standard_name="Single nucleotide polymorphism" |  |
| FT |           | replace(197,T)                                  |  |
| FT |           | /*tag= f  |  |
| FT | variation | /standard_name="Single nucleotide polymorphism" |  |
| FT |           | replace(419,G)                                  |  |
| FT |           | /*tag= g  |  |
| FT | variation | /standard_name="Single nucleotide polymorphism" |  |
| FT |           | replace(420,A)                                  |  |
| FT |           | /*tag= h  |  |
| FT | variation | /standard_name="Single nucleotide polymorphism" |  |



```

PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 181; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 31 A; 29 C; 15 G; 46 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.7e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAGGCAACCATTC A 838
Db 54 GAAGTTTTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCTTCA 1

RESULT 230
ABA79566
ID ABA79566 standard; DNA; 121 BP.
XX
XX ABA79566;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2412.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.

```

```

XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192179P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 181; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 46 A; 15 C; 29 G; 31 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.7e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAGGCAACCATTC A 838
Db 68 GAAGTTTTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCTTCA 121

RESULT 231
ABA79583/C
ID ABA79583 standard; DNA; 121 BP.
XX
XX ABA79583;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2429.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX

```

```

PF 27-MAR-2001; 2001WO-US009761.
XX
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
XX
PA (UYDE ) UNIV DELAWARE.
XX
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
XX
DR WPI; 2001-639230/73.
XX
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX
PS Claim 7; Page 182; 294pp; English.
XX
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX
SQ Sequence 121 BP; 31 A; 29 C; 16 G; 45 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.7e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTTCAGGCAACCAATTC 838
DB 59 GAAGTTTTCGAAACACTGAAAGACAGTGCAGTATTTCCACATATACCTTCA 6

RESULT 232
ABA79595/C
ID ABA79595 standard; DNA; 121 BP.
XX
XX
AC ABA79595;
XX
XX
DT 24-JAN-2002 (first entry)
XX
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2441.
XX
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200173002-A2.
XX
XX
PD 04-OCT-2001.

```

```

XX
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
XX
PA (UYDE ) UNIV DELAWARE.
XX
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
XX
DR WPI; 2001-639230/73.
XX
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX
PS Claim 7; Page 182; 294pp; English.
XX
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
XX
SQ Sequence 121 BP; 29 A; 30 C; 16 G; 46 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.7e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTTCAGGCAACCAATTC 838
DB 61 GAAGTTTTCGAAACACTGAAAGACAGTGCAGTATTTCCACATATACCTTCA 8

RESULT 233
ABA79591/C
ID ABA79591 standard; DNA; 121 BP.
XX
XX
AC ABA79591;
XX
XX
DT 24-JAN-2002 (first entry)
XX
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2437.
XX
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200173002-A2.
XX
XX

```

PD 04-OCT-2001.  
 XX 27-MAR-2001; 2001WO-US009761.  
 PF XX  
 XX 27-MAR-2000; 2000US-0192176P.  
 PR XX  
 PR 27-MAR-2000; 2000US-0192179P.  
 PR XX  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR XX  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX XX  
 PA (UYDE ) UNIV DELAWARE.  
 XX XX  
 XX Kmiec EB, Gamper HB, Rice MC;  
 PI WPI; 2001-639230/73.  
 DR XX  
 XX Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX XX  
 PS Claim 7; Page 182; 294pp; English.  
 XX CC  
 CC The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin,  
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX XX  
 SQ Sequence 121 BP; 29 A; 30 C; 16 G; 46 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 20.4; DB 1; Length 121;  
 Best Local Similarity 61.1%; Pred. NO. 1.7e+02;  
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAACCATTC A 838  
 DB 61 GAAGTTTTCAGAACACTGAAGACAGTGAATTTCCACATATACCTTCA 8

RESULT 234  
 ABA79578  
 ID ABA79578 standard; DNA; 121 BP.  
 XX AC ABA79578;  
 XX XX  
 DT 24-JAN-2002 (first entry)  
 XX DE  
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2424.  
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;  
 KW antilipemic; ss.  
 XX OS Homo sapiens.  
 XX WO200173002-A2.  
 PN

XX 04-OCT-2001.  
 XX 27-MAR-2001; 2001WO-US009761.  
 XX XX  
 XX 27-MAR-2000; 2000US-0192176P.  
 PR XX  
 PR 27-MAR-2000; 2000US-0192179P.  
 PR XX  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR XX  
 PR 30-OCT-2000; 2000US-0244989P.  
 XX XX  
 PA (UYDE ) UNIV DELAWARE.  
 XX XX  
 XX Kmiec EB, Gamper HB, Rice MC;  
 PI WPI; 2001-639230/73.  
 DR XX  
 XX Oligonucleotide for targeted alterations of genetic sequences and for  
 PT treating cystic fibrosis, comprises at least one mismatch and chemical  
 PT modification.  
 XX XX  
 PS Claim 7; Page 182; 294pp; English.  
 XX CC  
 CC The present invention provides single-stranded oligonucleotides which can  
 CC be used for the targeted alteration of genomic sequences, where the  
 CC oligonucleotide has at least one mismatch compared with the genomic  
 CC sequence to be altered. In particular, these sequences are directed at  
 CC the following genes: adenosine deaminase, p53, beta-globin,  
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A  
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus  
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,  
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase  
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and  
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases  
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,  
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,  
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and  
 CC various syndromes. The present sequence is one of the gene correcting  
 CC oligonucleotides of the invention  
 XX XX  
 SQ Sequence 121 BP; 45 A; 16 C; 29 G; 31 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 20.4; DB 1; Length 121;  
 Best Local Similarity 61.1%; Pred. NO. 1.7e+02;  
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAACCATTC A 838  
 DB 63 GAAGTTTTCAGAACACTGAAGACAGTGAATTTCCACATATACCTTCA 116

RESULT 235  
 ABA79590  
 ID ABA79590 standard; DNA; 121 BP.  
 XX AC ABA79590;  
 XX XX  
 DT 24-JAN-2002 (first entry)  
 XX DE  
 DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2436.  
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;  
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;  
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;  
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;  
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;  
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;  
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;  
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;  
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;  
 KW antilipemic; ss.  
 XX OS Homo sapiens.  
 XX

```

PN WO200173002-A2.
XX 04-OCT-2001.
XX 27-MAR-2001; 2001WO-US009761.
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192176P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX (UYDE ) UNIV DELAWARE.
XX Kniec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX Claim 7; Page 182; 294pp; English.
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX Sequence 121 BP; 46 A; 16 C; 30 G; 29 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.4; DB 1; Length 121;
XX Best Local Similarity 61.1%; Pred. No. 1.7e+02;
XX Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
XX
QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACGCAACCATTTCA 838
Db 61 GAAGTTTGTGAAACACTGAAAGACAGTGAGTATTTCCACATATACCCCTTCA 114

RESULT 236
ABA79579/c
ID ABA79579 standard; DNA; 121 BP.
XX
XX ABA79579;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2425.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytosstatic; antickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX Homo sapiens.

```

```

XX WO200173002-A2.
XX 04-OCT-2001.
XX 27-MAR-2001; 2001WO-US009761.
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192176P.
XX 01-JUN-2000; 2000US-0208538P.
XX 30-OCT-2000; 2000US-0244989P.
XX (UYDE ) UNIV DELAWARE.
XX Kniec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX Claim 7; Page 182; 294pp; English.
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX Sequence 121 BP; 31 A; 29 C; 16 G; 45 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.4; DB 1; Length 121;
XX Best Local Similarity 61.1%; Pred. No. 1.7e+02;
XX Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
XX
QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACGCAACCATTTCA 838
Db 59 GAAGTTTGTGAAACACTGAAAGACAGTGAGTATTTCCACATATACCCCTTCA 6

RESULT 237
ABA79582
ID ABA79582 standard; DNA; 121 BP.
XX
XX ABA79582;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2428.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytosstatic; antickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX

```



```

OS Homo sapiens.
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 182; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 45 A; 16 C; 29 G; 31 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.4; DB 1; Length 121;
XX Best Local Similarity 61.1%; Pred. No. 1.7e+02;
XX Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
XX
XX 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTC 838
XX
XX 63 GAAGTTTTCAAAACACTGAAGAAGACAGTGAGTATTTCCACATATACCCCTCA 116
XX
XX RESULT 238
XX ABA79586
XX ID ABA79586 standard; DNA; 121 BP.
XX
XX AC ABA79586;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2432.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antileptic; ss.

```

```

XX Homo sapiens.
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 182; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX Sequence 121 BP; 45 A; 15 C; 29 G; 32 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 20.4; DB 1; Length 121;
XX Best Local Similarity 61.1%; Pred. No. 1.7e+02;
XX Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
XX
XX 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTC 838
XX
XX 64 GAAGTTTTCAAAACACTGAAGAAGACAGTGAGTATTTCCACATATACCCCTCA 117
XX
XX RESULT 239
XX ABA79594
XX ID ABA79594 standard; DNA; 121 BP.
XX
XX AC ABA79594;
XX
XX 24-JAN-2002 (first entry)
XX
XX Factor IX mutation correcting oligonucleotide SEQ ID NO: 2440.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antileptic; ss.

```



XX PD 05-OCT-2000.  
XX PF 30-MAR-2000; 2000WO-US008440.  
XX PR 31-MAR-1999; 99US-0127248P.  
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.  
XX PA (AFHY-) AFFYMETRIX INC.  
XX PI Alshuler D, Cargill M, Daley GG, Ireland JS, Lander ES;  
XX PI Lipshutz RJ, Patil N, Sklar P;  
XX DR WPI; 2000-611722/58.  
XX PT Nucleic acid selected from one of 106 genes comprising single nucleotide  
XX PT polymorphisms, allele-specific oligonucleotides to the genes are useful  
XX PT for phenotypic correlations, forensics, paternity testing, medicine and  
XX PT genetic analysis.  
XX PS Claim 1; Fig 5; 214pp; English.  
XX CC The present invention is concerned with a number of human single  
XX CC nucleotide polymorphisms (SNPs) which the inventors identified in human  
XX CC genes. These SNPs can be used in disease diagnosis and prediction of an  
XX CC individual's susceptibility to disease, in forensic and paternity testing  
XX CC and in genetic mapping. In particular, the SNPs of the invention can be  
XX CC used to diagnose susceptibility to diseases of the cardiovascular,  
XX CC endocrine and neurological systems, such as coronary artery disease,  
XX CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's  
XX CC diseases. Note: the degenerate codon within the sequence represents the  
XX CC position of an SNP, for example the letter S represents a polymorphism  
XX CC where the nucleotide may be C or G  
XX SQ Sequence 268 BP; 51 A; 89 C; 65 G; 62 T; 0 U; 1 Other;  
  
Query Match 0.6%; Score 20.4; DB 1; Length 268;  
Best Local Similarity 62.5%; Pred. No. 2.1e+02;  
Matches 30; Conservative 1; Mismatches 17; Indels 0; Gaps 0;  
  
QY 1643 APTGCCACATCTCTGTATCTGGAAGAAAGCAGAGAGTTCCAGAA 1690  
DB 170 ACTGGGCRCTGCTCTTCTCTATCCAGAGCAAGTGGTCTCATA 123  
  
RESULT 242  
ADA49152/c  
ID ADA49152 standard; DNA; 270 BP.  
XX AC ADA49152;  
XX DT 20-NOV-2003 (first entry)  
XX DE Maize gene conferring disease resistance in plants.  
XX KW disease resistance; pathogen tolerance; plant pathogen; ds; gene; plant;  
XX KW maize.  
XX OS Zea mays.  
XX PN WO2003000906-A2.  
XX PD 03-JAN-2003.  
XX PF 21-JUN-2002; 2002WO-IB002453.  
XX PR 22-JUN-2001; 2001US-0300112P.  
XX PR 26-SEP-2001; 2001US-0352277P.  
XX PR 22-MAR-2002; 2002US-0366535P.  
XX PA (SYGN ) SYNGENTA PARTICIPATIONS AG.  
XX PI Glazebrook J, Briggs S, Cooper B, Goff SA, Moughamer T;

PI Katagiri F, Kreps J, Provart N, Ricke D, Zhu T;  
XX WPI; 2003-184052/18.  
XX PT New polynucleotide comprising a plant nucleotide sequence having an open  
XX PT reading frame that encodes a polypeptide associated with disease  
XX PT resistance, useful for conferring resistance or tolerance to a plant  
XX PT pathogen.  
XX PS Disclosure; SEQ ID NO 1222; 299pp; English.  
XX CC The invention relates to a novel isolated polynucleotide comprising a  
XX CC plant nucleotide sequence having an open reading frame that encodes a  
XX CC polypeptide associated with disease resistance or its fragment having  
XX CC substantially the same activity as the full-length polypeptide. The  
XX CC polynucleotide of the invention is useful for conferring resistance or  
XX CC tolerance to a plant pathogen. The present sequence represents a gene  
XX CC conferring disease resistance used in the invention.  
XX SQ Sequence 270 BP; 45 A; 74 C; 106 G; 45 T; 0 U; 0 Other;  
  
Query Match 0.6%; Score 20.4; DB 1; Length 270;  
Best Local Similarity 61.1%; Pred. No. 2.1e+02;  
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
  
QY 708 CTGCGGCGAGCATCTCTGAGAGAAATGAGTAGCATCATGGTCAACAAAG 761  
DB 183 CGGCGGCTTCGAGGACTTCAGAGCCAGCGATGGCTGCTGCCAAGAG 130  
  
RESULT 243  
AAH57325/c  
ID AAH57325 standard; cDNA; 285 BP.  
XX AC AAH57325;  
XX DT 10-SEP-2001 (first entry)  
XX DE Human pancreas specific cDNA sequence SEQ ID NO:165.  
XX KW Human; tissue specific; diagnosis; brain; heart; skeletal muscle; lung;  
XX KW liver; uterus; ovary; stomach; intestine; kidney; pancreas; ss;  
XX KW metabolic disease; developmental disease; cytostatic; immunomodulatory;  
XX KW neuroprotective; gene therapy; cancer; immunopathology; neuropathology.  
XX OS Homo sapiens.  
XX PN WO200132927-A2.  
XX PD 10-MAY-2001.  
XX PF 02-NOV-2000; 2000WO-US030396.  
XX PR 04-NOV-1999; 99US-0163508P.  
XX PA (INCY-) INCYTE GENOMICS INC.  
XX PI Sornasse T, Seilhamer JJ, Watson GA;  
XX DR WPI; 2001-291057/30.  
XX PT New cell and tissue specific polynucleotides useful for diagnosis,  
XX PT prognosis or monitoring of treatments for disorders where the gene is  
XX PT associated with a cancer, immunopathology or neuropathology.  
XX PS Claim 1; Page 127; 327pp; English.  
XX CC AAH57161 to AAH57576 represent cell and tissue specific polynucleotide  
XX CC sequences (I). (I) can have cytostatic, immunomodulatory and  
XX CC neuroprotective activities, and can be used in gene therapy. (I) and  
XX CC proteins (II) encoded by then are used in high throughput screening  
XX CC assays to select DNA molecules, RNA molecules, peptide nucleic acids,  
XX CC mimetics, peptides, proteins, agonists, antagonists, antibodies or their

CC fragments, immunoglobulins, inhibitors, drug compounds and pharmaceutical  
CC agents. Expression of (I) in a sample indicates the differentiation of  
CC embryonic stem cells into a tissue selected from brain, heart, kidney,  
CC liver, lung, skeletal muscle or pancreatic tissues. (I) and (II) are used  
CC to produce an expression profile that defines a metabolic or  
CC developmental process, treatment, condition, disease or disorder. The  
CC gene profile can be used for diagnosis, prognosis or monitoring of  
CC treatments and for investigating a predisposition to a disorder where the  
CC gene is associated with a cancer, immunopathology or neuropathology  
XX  
SQ Sequence 285 BP: 66 A; 78 C; 73 G; 68 T; 0 U; 0 Other;

Sequence 285 BP; 66 A; 78 C; 73 G; 68 T; 0 U; 0 Other;

Query Match 0.6%: Score 20.4: DB 1: Length 285:

Query Match 0.0%; Score 20.4; DB 1; length 283  
Best Local Similarity 61.1%; Pred. No. 2.1e+02;  
Matches 33; Conservative 0; Mismatches 21; Indels

machines 33; conservative 31; mismatches 21; indices 0; gaps 0;

QY 921 CCTTTAGAACTAACACCCAAAAGATGTCTCTCATTTATAGGGGACTGGAA 974

Db CCTCAGTTGTAGCCCCCAACGATCTTGTTCATCATCATCAAGGGGGCAGCAA 44

RESIN.T 244

ABL71211/C

ID ABL71211 standard; cDNA: 290 BP.

XX

AC ABL71211;

XX

DT 14-MAY-2002 (first entry)

Best Local Similarity 71.1%; Pred. No. 2.2e+02;  
Matches 27; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1960 GAAGCACAAAGCTGGGAATCAAGATTGCCGGGAGAAATAG 1997  
|||||  
DB 272 GCATCACAAAGCTGGGGTGAAGGCTGCGGCCAGAAAGAG 235  
|||||

RESULT 246  
AAV69281/C  
ID AAV69281 standard; cDNA; 334 BP.  
XX  
XX AAV69281;  
AC  
XX  
XX  
DT 15-FEB-1999 (first entry)  
XX  
DE EST clone CG175.  
XX  
XX Human; secreted protein; expressed sequence tag; EST; haematopoiesis;  
KW tissue growth; activin; inhibitor; chemotaxis; chemokinesis; haemostatic;  
KW receptor; ligand; thrombolytic; anti-inflammatory; cadherin; anti-tumour;  
KW gene therapy; ss.  
XX  
XX Homo sapiens.  
OS  
XX W09845436-A2.  
PN  
XX  
XX 15-OCT-1998.  
PD  
XX  
XX 10-APR-1998; 98WO-US006955.  
PF  
XX  
XX 10-APR-1997; 97US-00838821.  
PR  
XX  
XX (GEMY ) GENETICS INST INC.  
PA  
XX  
XX Jacobs K, McCoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;  
PI Spaulding V, Agostino MJ;  
PI  
XX  
XX WPI; 1999-070077/06.  
DR  
XX  
XX New polynucleotides encoding human secreted proteins - derived from e.g.  
PT human blood, kidney, foetal lung, placenta, testes, brain, ovary,  
PT pituitary, retina and colon cDNA libraries.  
PT  
XX  
XX Claim 1; Page 168; 618pp; English.  
PS  
XX  
XX The present sequence represents a human expressed sequence tag (EST). The  
CC polynucleotide, which is a secreted EST, and the encoded protein are  
CC predicted to have useful biological activities which would make them  
CC suitable for treating, preventing or ameliorating medical conditions in  
CC humans and animals, although no supporting data is given. Suggested  
CC activities include nutritional activity, immune stimulating, or  
CC suppressing activity, haematopoiesis regulating activity, tissue growth  
CC activity, activin/inhibin activity, chemotactic/chemokinetic activity,  
CC haemostatic and thrombolytic activity, receptor/ligand activity, anti-  
CC inflammatory activity, cadherin/tumour invasion suppressor activity,  
CC tumour inhibition activity. The polynucleotide may also be useful for  
CC gene therapy  
XX  
XX  
SQ Sequence 334 BP; 78 A; 95 C; 85 G; 76 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 334;  
Best Local Similarity 61.1%; Pred. No. 2.2e+02;  
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 921 CTTTATGAACCTAACACCCAAAAGATGTCCTTCTCATATAGGGGACTGGAA 974  
|||||  
DB 116 CTCACAGTGTAGCCCCCACCAGATCTGTGCATCATCAACAGGGGGCAGCAA 63  
|||||

RESULT 247  
AAD58761/C  
ID AAD58761 standard; DNA; 394 BP.

PF 19-NOV-1999; 99WO-JP006475.  
 PR 20-NOV-1998; 98JP-00347785.  
 XX (FUSO) FUSO PHARM IND LTD.  
 PI Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;  
 DR WPI; 2000-400082/34.  
 DR P-PSDB; AAB11695.  
 XX Serine protease BSSP2, useful in detecting homologs, mutants and  
 PT polymorphic variants as markers for diagnosis of e.g. Alzheimer's  
 PT disease, cancer, inflammation and prostate hypertrophy, using blood,  
 PT urine or other tissues.  
 XX  
 PS Claim 2; Page 55-57; 92pp; Japanese.  
 XX  
 CC The invention relates to novel serine proteases designated BSSP2  
 CC (AAB11695-B11699), and to nucleic acids encoding them (AAA61659-A61663).  
 CC The invention also relates to vectors and transformants comprising BSSP2  
 CC nucleic acids; transgenic animals in which the expression level of BSSP2  
 CC can be varied; and an mBSSP2 knockout mouse. The invention additionally  
 CC encompasses anti-BSSP2 antibodies and methods of production of such  
 CC antibodies, methods of BSSP2 detection using the antibodies, and the use  
 CC of BSSP2 proteins or fragments as diagnostic markers for certain medical  
 CC conditions. Nucleotides encoding BSSP2 were initially isolated in a mouse  
 CC brain cDNA library using degenerate PCR primers (AAA61673-AAA61674)  
 CC based on conserved regions of serine proteases. The BSSP2 serine  
 CC proteases and nucleotides encoding them are useful in detecting  
 CC homologues, mutants and polymorphic variants in biological samples (e.g.,  
 CC blood, urine, brain, prostate gland and testis) as diagnostic markers for  
 CC conditions such as Alzheimer's disease, epilepsy, cancer, inflammation,  
 CC infertility and prostatic hypertrophy. Sequences AAA61659-A61662  
 CC represent cDNAs encoding murine BSSP2 variants (mBSSP2), and sequence  
 CC AAA61663 represents cDNA encoding human BSSP2 (hBSSP2)  
 XX  
 SQ Sequence 717 BP; 138 A; 204 C; 221 G; 154 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 20.4; DB 1; Length 717;  
 Best Local Similarity 61.1%; Pred. No. 2.7e+02;  
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
 QY 1200 CTCATACAGTACGCAAAACACAGGAGCTTACTGTGCTCGAGATCATGA 1253  
 DB 242 CTTGTACAGTGCACAGACCATGACTATGATGTGGCTCTGCTGAGCTCCGGA 295  
 RESULT 249  
 ABK86038/c  
 ID ABK86038 standard; DNA; 1383 BP.  
 AC ABK86038;  
 XX  
 DT 23-AUG-2002 (first entry)  
 DE Synthetic DNA encoding protein C precursor protein.  
 KW Human; Protein C; precursor protein; ds; Gene; N-glycosylation;  
 KW serum half-life; chromosome 2q13-q14; stroke; myocardial infarction;  
 KW after venous thrombosis; disseminated intravascular coagulation; DIC;  
 KW sepsis; septic shock; embolism; pulmonary embolism; burn; pregnancy;  
 KW bone marrow transplantation; major surgery; trauma; ARDS; coagulant;  
 KW adult respiratory distress syndrome; alpha-1 antitrypsin; APC;  
 KW activated protein C.  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PH Key Location/Qualifiers  
 FT CDS 1..1383  
 FT /\*tag= a  
 FT /product= "Precursor protein C"

/partial  
 /note= "No stop codon shown"  
 1..126  
 /\*tag= b  
 127..1383  
 /\*tag= c  
 /product= "Mature protein C"  
 WO200232461-A2.  
 XX  
 PN 25-APR-2002.  
 XX  
 PD 15-OCT-2001; 2001WO-DK000679.  
 XX  
 PF 18-OCT-2000; 2000DK-00001560.  
 XX  
 PR 18-OCT-2000; 2000US-0242268P.  
 PR 21-JUN-2001; 2001DK-00000970.  
 PR 21-JUN-2001; 2001US-0300154P.  
 XX  
 XX (MAXY-) MAXYGEN APS.  
 XX (MAXY-) MAXYGEN HOLDINGS LTD.  
 PA  
 PA Andersen KV, Pedersen AH, Frestgaard PO;  
 PI  
 PI WPI; 2002-489875/52.  
 XX P-PSDB; AAU99001.  
 DR  
 DR Novel conjugate useful for treating or preventing septic shock, stroke  
 PT and myocardial infarction, comprises non-polypeptide group covalently  
 PT attached to protein C polypeptide comprising an attachment group.  
 PT  
 PS Example 4; Page 74-76; 92pp; English.  
 XX  
 CC The invention relates to a conjugate (I) comprising at least one non-  
 CC polypeptide moiety (II) (e.g. an N-glycosyl group) covalently attached to  
 CC a protein C polypeptide comprising an amino acid sequence which differs  
 CC from that of a parent protein C polypeptide (III) in at least one  
 CC introduced and/or at least one removed amino acid residue comprising an  
 CC attachment group for the non-polypeptide group (e.g. an N-glycosylation  
 CC site). Also included are (1) a variant (IV) of (III) comprising a  
 CC substitution in a position (P) where (P) is an amino acid with at least  
 CC 25% of its side group exposed to the surface, with the proviso that the  
 CC substitution is not Thr245Ser/Ala/His/Lys/Arg/Asn/Asp/Glu/Gly/Gln,  
 CC Tyr302Ser/Ala/Thr/His/Lys/Arg/Asn/Asp/Glu/Gly/Gln or Phe316Ser/Ala/Thr/  
 CC His/Lys/Arg/Asn/Asp/Glu/Gly/Gln; (2) a nucleotide sequence (V) encoding  
 CC (IV); (3) an expression vector (VI) comprising (V); (4) a host cell (VII)  
 CC comprising (V) or (VI); (5) increasing (M2) the functional in vivo half-  
 CC life or the serum half-life of a parent protein C polypeptide. The  
 CC conjugates, variants and protein C proteins are useful as medicaments,  
 CC and in the manufacture of medicaments for the treatment (and  
 CC diagnosis/prevention) of stroke, myocardial infarction, after venous  
 CC thrombosis, disseminated intravascular coagulation (DIC), sepsis, septic  
 CC shock, emboli e.g. pulmonary emboli, transplantation such as bone marrow  
 CC transplantation, burns, pregnancy, major surgery/trauma or adult  
 CC respiratory distress syndrome (ARDS). The variant protein C has an  
 CC increased resistance to activation by e.g. human plasma and alpha-1  
 CC antitrypsin. The conjugates have an increased in vivo half-life,  
 CC increased serum half-life, increased resistance to inhibitors, reduced  
 CC renal clearance, reduced immunogenicity and/or increased bioavailability.  
 CC The conjugate offers a number of advantages over the currently available  
 CC APC products, including longer duration between injections,  
 CC administration of less protein, and fewer side effects. Moreover, a  
 CC reduced anticoagulant activity is beneficial to reduce the risk of  
 CC bleeding while maintaining the antiinflammatory activity of APC  
 CC (activated protein C) conjugates. This must be especially important when  
 CC the conjugate has an extended plasma life. The gene for protein C is  
 CC located on chromosome 2q13-q14. The present sequence encodes precursor  
 CC protein C  
 XX  
 SQ Sequence 1383 BP; 286 A; 418 C; 440 G; 239 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 20.4; DB 1; Length 1383;  
 Best Local Similarity 55.7%; Pred. No. 2.9e+02;

Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCGATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCGGGAATTCGCCAGGTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25

## RESULT 250

AAN90024/c  
ID AAN90024 standard; DNA; 1386 BP.

XX AC AAN90024;

XX 25-MAR-2003 (revised)

DT 01-NOV-1989 (first entry)

XX Nascent human protein C DNA.

XX Human protein C; anti-coagulant; myocardial infarction;  
KW deep vein thrombosis.

XX Homo sapiens.

XX Key Location/Qualifiers

FT CDS 1..1383

FT /\*tag= a

FT sig\_peptide

FT /\*tag= b

FT misc\_feature

FT 126..589

FT /\*tag= c

FT misc\_feature

FT 587..592

FT /\*tag= d

FT misc\_feature

FT 598..631

FT /\*tag= e

FT misc\_feature

FT 634..1380

FT /\*tag= f

XX EP319312-A.

XX 07-JUN-1989.

XX 02-DEC-1988; 88EP-00311421.

XX 04-DEC-1987; 87US-00129027.

XX (ELIL ) LILLY & CO ELI.

XX Bang NU, Ehrlich HJ, Grinnell BW, Jaskunas SR;

XX WFI; 1989-167318/23.

XX New DNA cpds. and vectors - used for direct expression of activated human protein C.

XX Disclosure; Page 4; 48pp; English.

XX Nascent human protein C produces inactive protein C. It is used as an

XX anti-coagulant in myocardial infarction and deep vein thrombosis. The

XX patent discloses a recombinant way of making activated protein C.

XX Nucleotides 1-125 encode the signal peptide and propeptide; 126-589

XX constitute the light chain of both the zymogen and activated forms; 589-

XX 592 residues are believed to be removed to form 2-chain protein C; 598-

XX 631 are the activation peptides removed from the zymogen to form

XX activated protein C; 634-1380 constitute the activated heavy chain after

XX post-translational modification. (Updated on 25-MAR-2003 to correct PD

XX field.) (Updated on 25-MAR-2003 to correct PR field.) (Updated on 25-MAR-

XX 2003 to correct PA field.)

XX Sequence 1386 BP; 287 A; 419 C; 440 G; 240 T; 0 U; 0 Other;

Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.9e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCGATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCGGGAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720

Db 34 CCACGAACAG 25

Search completed: August 9, 2004, 16:32:31  
Job time : 1400 secs



This Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:34:29 ; Search time 17 Seconds  
(without alignments)  
3.877 Million cell updates/sec

Title: us-10-664-775-2  
Perfect score: 3572  
Sequence: 1 GTCAGGAAGGCGGCGAGTGA.....GCAACAACAGCAGAAAGCTT 3572

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 20 seqs, 9225 residues

Total number of hits satisfying chosen parameters: 40

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries

Database : ruidb:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

| Result No. | Query | Score | Match | Length | DB               | ID | Description       |
|------------|-------|-------|-------|--------|------------------|----|-------------------|
| 1          | 18.4  | 0.5   | 1440  | 1      | US-07-882-202A-3 |    | Sequence 3, Appli |
| 2          | 18.4  | 0.5   | 1440  | 1      | US-08-021-615A-3 |    | Sequence 3, Appli |
| 3          | 18.4  | 0.5   | 1440  | 1      | US-08-321-777-3  |    | Sequence 3, Appli |
| 4          | 18.4  | 0.5   | 1440  | 1      | US-09-009-217-13 |    | Sequence 13, Appl |
| 5          | 18.4  | 0.5   | 1440  | 1      | US-09-009-656-13 |    | Sequence 13, Appl |
| 6          | 18.4  | 0.5   | 1440  | 1      | PCT-US93-04493-3 |    | Sequence 3, Appli |
| 7          | 17.4  | 0.5   | 1440  | 1      | US-07-882-202A-3 |    | Sequence 3, Appli |
| 8          | 17.4  | 0.5   | 1440  | 1      | US-08-021-615A-3 |    | Sequence 3, Appli |
| 9          | 17.4  | 0.5   | 1440  | 1      | US-08-321-777-3  |    | Sequence 3, Appli |
| 10         | 17.4  | 0.5   | 1440  | 1      | US-09-009-217-13 |    | Sequence 13, Appl |
| 11         | 17.4  | 0.5   | 1440  | 1      | PCT-US93-04493-3 |    | Sequence 3, Appli |
| 12         | 17.4  | 0.5   | 1440  | 1      | US-08-849-248-6  |    | Sequence 6, Appli |
| 13         | 14.6  | 0.4   | 141   | 1      | US-08-849-248-6  |    | Sequence 6, Appli |
| 14         | 13    | 0.4   | 141   | 1      | US-08-849-248-6  |    | Sequence 6, Appli |
| 15         | 12.4  | 0.3   | 42    | 1      | US-08-955-635-8  |    | Sequence 8, Appli |
| 16         | 12.2  | 0.3   | 27    | 1      | US-08-293-778-16 |    | Sequence 16, Appl |
| 17         | 12.2  | 0.3   | 45    | 1      | US-08-756-506-13 |    | Sequence 13, Appl |
| 18         | 11.8  | 0.3   | 42    | 1      | US-08-955-635-8  |    | Sequence 8, Appli |
| 19         | 11.4  | 0.3   | 35    | 1      | US-07-998-972A-7 |    | Sequence 7, Appli |
| 20         | 11.4  | 0.3   | 35    | 1      | US-08-463-953-7  |    | Sequence 7, Appli |
| 21         | 11.4  | 0.3   | 35    | 1      | US-08-462-261-7  |    | Sequence 7, Appli |
| 22         | 11.4  | 0.3   | 35    | 1      | PCT-US92-11357-7 |    | Sequence 7, Appli |
| 23         | 11.4  | 0.3   | 36    | 1      | US-08-955-635-9  |    | Sequence 9, Appli |
| 24         | 11.4  | 0.3   | 36    | 1      | US-08-955-635-10 |    | Sequence 10, Appl |
| 25         | 11    | 0.3   | 36    | 1      | US-08-955-635-9  |    | Sequence 9, Appli |
| 26         | 11    | 0.3   | 36    | 1      | US-08-955-635-10 |    | Sequence 10, Appl |
| 27         | 10.8  | 0.3   | 38    | 1      | US-09-558-027-4  |    | Sequence 4, Appli |
| 28         | 10.4  | 0.3   | 45    | 1      | US-08-756-506-13 |    | Sequence 13, Appl |
| 29         | 10    | 0.3   | 35    | 1      | US-07-998-972A-7 |    | Sequence 7, Appli |
| 30         | 10    | 0.3   | 35    | 1      | US-08-463-953-7  |    | Sequence 7, Appli |
| 31         | 10    | 0.3   | 35    | 1      | US-08-462-261-7  |    | Sequence 7, Appli |
| 32         | 10    | 0.3   | 35    | 1      | PCT-US92-11357-7 |    | Sequence 7, Appli |
| 33         | 9.8   | 0.3   | 27    | 1      | US-08-293-778-17 |    | Sequence 17, Appl |

Sequence 4, Appli  
Sequence 22, Appli  
Sequence 20, Appli  
Sequence 17, Appli  
Sequence 16, Appli  
Sequence 22, Appli  
Sequence 20, Appli

#### ALIGNMENTS

##### RESULT 1

US-07-882-202A-3  
; Sequence 3, Application US/07882202A  
; Patent No. 5374617  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified  
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/882,202A  
; FILING DATE: 13-MAY-1992  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRF B34290  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; factor VII cDNA"

US-07-882-202A-3  
Query Match 0.5%; Score 18.4; DB 1; Length 1440;  
Best Local Similarity 56.7%; Pred. No. 2.7;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
Qy 1445 GGATCGAGACATCCCATCGAAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504  
Db 621 GGAATAATCTATTCTTAGAAAGAAATGCGACGACCAACCCAGCCCAATTTGGGG 680

```
RESULT 2
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-021-615A-3
Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1445 GGATCGAGACCATCCCATCGAAAGAAATGCAAAAGCAAAATGGCTGTCTGTGGGGAGG 1504
Db 621 GGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGGG 680
RESULT 3
US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-021-615A-3
Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1445 GGATCGAGACCATCCCATCGAAAGAAATGCAAAAGCAAAATGGCTGTCTGTGGGGAGG 1504
Db 621 GGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGGG 680
RESULT 4
US-09-009-217-13
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
```

```
/ COUNTRY: USA
/ ZIP: 77210
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/009,217
/ FILING DATE: Concurrently Herewith
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/042,427
/ FILING DATE: 27-MAR-1997
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/036,205
/ FILING DATE: 27-JAN-1997
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/035,920
/ FILING DATE: 22-JAN-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Hibler, David W.
/ REGISTRATION NUMBER: 41,071
/ REFERENCE/DOCKET NUMBER: UTSD:536
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 512/418-3000
/ TELEFAX: 512/474-7577
/ INFORMATION FOR SEQ ID NO: 13:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 1440 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-009-217-13

Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504
DB 621 GGAATAATACCTTACTTAGAAAAAGAAATGCCAGAACCCCAAGCGCGAATTGTGGG 680

RESULT 5
US-09-009-656-13
/ Sequence 13, Application US/09009656
/ Patent No. 6132730
/ GENERAL INFORMATION:
/ APPLICANT: Thorpe, Philip E.
/ APPLICANT: King, Steven W.
/ APPLICANT: Gao, Boning
/ TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIA
/ TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
/ NUMBER OF SEQUENCES: 27
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Arnold, White & Durkee
/ STREET: P.O. Box 4433
/ CITY: Houston
/ STATE: Texas
/ COUNTRY: USA
/ ZIP: 77210
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/009,656
/ FILING DATE: Concurrently Herewith
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
```

```
/ APPLICATION NUMBER: US 60/042,427
/ FILING DATE: 27-MAR-1997
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/036,205
/ FILING DATE: 27-JAN-1997
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/035,920
/ FILING DATE: 22-JAN-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Hibler, David W.
/ REGISTRATION NUMBER: 41,071
/ REFERENCE/DOCKET NUMBER: UTSD:537
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 512/418-3000
/ TELEFAX: 512/474-7577
/ INFORMATION FOR SEQ ID NO: 13:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 1440 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-009-656-13

Query Match 0.5%; Score 18.4; DB 1; Length 1440;
Best Local Similarity 56.7%; Pred. No. 2.7;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504
DB 621 GGAATAATACCTTACTTAGAAAAAGAAATGCCAGAACCCCAAGCGCGAATTGTGGG 680

RESULT 6
PCT-US93-04493-3
/ Sequence 3, Application PC/TUS9304493
/ GENERAL INFORMATION:
/ APPLICANT: Morrissey, James H.
/ APPLICANT: Comp, Philip C.
/ TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
/ TITLE OF INVENTION: FVII Activator for Blood Coagulation
/ NUMBER OF SEQUENCES: 4
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Richards, Medlock & Andrews
/ STREET: 1201 Elm Street, Suite 4500
/ CITY: Dallas
/ STATE: Texas
/ COUNTRY: US
/ ZIP: 75270-2197
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US93/04493
/ FILING DATE: 19930512
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/882202
/ FILING DATE: 13-MAY-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/021615
/ FILING DATE: 19-FEB-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Trujillo, Doreen Y.
/ REGISTRATION NUMBER: 35,719
/ REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 214-939-4500
/ TELEFAX: 214-939-4600
/ INFORMATION FOR SEQ ID NO: 3:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 1440 base pairs
```



Query Match 0.5%; Score 17.4; DB 1; Length 1440;  
Best Local Similarity 53.7%; Pred. No. 8.3;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTCTATGAAGACCTCAAGACCTTTTAGAA 930  
Db 344 AGAATCCAGAACAGCTTCGTCTCTCCGGCTCTTGAAGATCTCCCGGGCTCTCTCGAA 285

Qy 931 CTAACAC 937  
Db 284 GGAGCAC 278

RESULT 9  
US-08-321-777-3/c  
; Sequence 3, Application US/08321777  
; Patent No. 5504067  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified  
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: IBM PC compatible  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/321,777  
; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/882202  
; FILING DATE: 13-MAY-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRF B34290C  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; factor VII cDNA"  
US-08-321-777-3

Query Match 0.5%; Score 17.4; DB 1; Length 1440;  
Best Local Similarity 53.7%; Pred. No. 8.3;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTCTATGAAGACCTCAAGACCTTTTAGAA 930  
Db 344 AGAATCCAGAACAGCTTCGTCTCTCCGGCTCTTGAAGATCTCCCGGGCTCTCTCGAA 285

Qy 931 CTAACAC 937  
Db 284 GGAGCAC 278

RESULT 10  
US-09-009-217-13/c  
; Sequence 13, Application US/09009217  
; Patent No. 6132729  
; GENERAL INFORMATION:  
; APPLICANT: Thorpe, Philip E.  
; APPLICANT: King, Steven W.  
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND  
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Arnold, White & Durkee  
; STREET: P.O. Box 4433  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: USA  
; ZIP: 77210  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; OPERATING SYSTEM: IBM PC compatible  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/009,217  
; FILING DATE: Concurrently Herewith  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/042,427  
; FILING DATE: 27-MAR-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/036,205  
; FILING DATE: 27-JAN-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/035,920  
; FILING DATE: 22-JAN-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hidler, David W.  
; REGISTRATION NUMBER: 41,071  
; REFERENCE/DOCKET NUMBER: UTSD:536  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 512/418-3000  
; TELEFAX: 512/474-7577  
; INFORMATION FOR SEQ ID NO: 13:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-09-009-217-13

Query Match 0.5%; Score 17.4; DB 1; Length 1440;  
Best Local Similarity 53.7%; Pred. No. 8.3;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTCTATGAAGACCTCAAGACCTTTTAGAA 930  
Db 344 AGAATCCAGAACAGCTTCGTCTCTCCGGCTCTTGAAGATCTCCCGGGCTCTCTCGAA 285

Qy 931 CTAACAC 937  
Db 284 GGAGCAC 278

RESULT 11  
US-09-009-656-13/c  
; Sequence 13, Application US/09009656  
; Patent No. 6132730  
; GENERAL INFORMATION:  
; APPLICANT: Thorpe, Philip E.  
; APPLICANT: King, Steven W.  
; APPLICANT: Gao, Boning  
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR  
; TITLE OF INVENTION: TREATMENT  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Arnold, White & Durkee  
; STREET: P.O. Box 4433  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: USA  
; ZIP: 77210  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; FILING DATE: 27-JAN-1997  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/042,427  
; FILING DATE: 27-MAR-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/036,205  
; FILING DATE: 27-JAN-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/035,920  
; FILING DATE: 22-JAN-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hibler, David W.  
; REGISTRATION NUMBER: 41,071  
; REFERENCE/DOCKET NUMBER: UTSD:537  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 512/418-3000  
; TELEFAX: 512/474-7577  
; INFORMATION FOR SEQ ID NO: 13:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-09-009-656-13  
Query Match 0.5%; Score 17.4; DB 1; Length 1440;  
Best Local Similarity 53.7%; Pred. No. 8.3;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 871 AGTATGCTGAGAGAGCTGAAGTTGAACGGTCTCTATGAAGACCTTACAGACCTTTTAA 930  
Db 344 AGAATCCAGACAGCTTCTCGTCTCTTGAAGATCTCCCGGCGCTCTCTCGAA 285  
QY 931 CTAACAC 937  
Db 284 GGAGCAC 278  
RESULT 12  
PCT-US93-04493-3/c  
; Sequence 3, Application PC/TUS9304493  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp. Philip C.  
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or

; TITLE OF INVENTION: FVII Activator for Blood Coagulation  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US93/04493  
; FILING DATE: 19930512  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/882202  
; FILING DATE: 13-MAY-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/021615  
; FILING DATE: 19-FEB-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Trujillo, Doreen Y.  
; REGISTRATION NUMBER: 35,719  
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: NUCLEIC ACID  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: CDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /product= "Tissue Factor"  
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"  
; OTHER INFORMATION: /citation= {(1)}  
PCT-US93-04493-3  
Query Match 0.5%; Score 17.4; DB 1; Length 1440;  
Best Local Similarity 53.7%; Pred. No. 8.3;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 871 AGTATGCTGAGAGAGCTGAAGTTGAACGGTCTCTATGAAGACCTTACAGACCTTTTAA 930  
Db 344 AGAATCCAGACAGCTTCTCGTCTCTTGAAGATCTCCCGGCGCTCTCTCGAA 285  
QY 931 CTAACAC 937  
Db 284 GGAGCAC 278  
RESULT 13  
US-08-849-248-6  
; Sequence 6, Application US/08849248  
; Patent No. 5948759  
; GENERAL INFORMATION:  
; APPLICANT: Husbun, Mette  
; APPLICANT: Fischer, Peter  
; APPLICANT: Orning, Lars  
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use



```

1 TITLE OF INVENTION:  in blood clotting disorders
2
3 NUMBER OF SEQUENCES:  6
4
5 CORRESPONDENCE ADDRESS:
6
7 ADDRESSEE:  Bacon and Thomas
8
9 STREET:  625 Slaters Lane, 4th Floor
10
11 CITY:  Alexandria
12
13 STATE:  Virginia
14
15 COUNTRY:  USA
16
17 ZIP:  22314
18
19 COMPUTER READABLE FORM:
20
21 MEDIUM TYPE:  Floppy disk
22
23 COMPUTER:  IBM PC compatible
24
25 OPERATING SYSTEM:  PC-DOS/MS-DOS
26
27 SOFTWARE:  PatentIn Release #1.0, Version #1.30 (EPO)
28
29 CURRENT APPLICATION DATA:
30
31 APPLICATION NUMBER:  US/08/849,248
32
33 FILING DATE:  27 Aug 1997
34
35 INFORMATION FOR SEQ ID NO:  6:
36
37 SEQUENCE CHARACTERISTICS:
38
39 LENGTH:  141 base pairs
40
41 TYPE:  nucleic acid
42
43 STRANDEDNESS:  single
44
45 TOPOLOGY:  linear
46
47 MOLECULE TYPE:  other nucleic acid
48
49 DESCRIPTION:  /desc = "recombinant DNA"
50
51 US-08-849-248-6

```

Query Match 0.4%; Score 14.6; DB 1; Length 141;  
Best Local Similarity 69.0%; Pred. No. 9.1;  
Matches 20: Conservative 0; Mismatches 9; Indels

Qy 2757 GAGTTGGACGACGACTGAGCAACTGAAC TG 2785  
||| ||| | ||| ||| ||| ||| |||  
Db 1 GAGACGCACAAGGATGACCAGCTGATCTG 29

RESULT 14  
IIS-08-849-248-6/C

US-08-849-248-8/C  
 ; Sequence 6, Application US/08849248  
 ; Patent No. 5948759  
 ;  
 ; GENERAL INFORMATION:  
 ;  
 ; APPLICANT: Husbyn, Mette  
 ; APPLICANT: Fischer, Peter  
 ; APPLICANT: Orning, Lars  
 ; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use  
 ; TITLE OF INVENTION: in blood clotting disorders  
 ;  
 ; NUMBER OF SEQUENCES: 6  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Bacon and Thomas  
 ; STREET: 625 Slatters Lane, 4th Floor  
 ; CITY: Alexandria  
 ; STATE: Virginia  
 ; COUNTRY: USA  
 ; ZIP: 22314

```

ZIF: 42314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatenIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/849,248
FILING DATE: 27 Aug 1997
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 141 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6

```

Query Match 0.4%; Score 13; DB 1; Length 141;

|    |                       |   |              |     |            |     |
|----|-----------------------|---|--------------|-----|------------|-----|
|    | Best Local Similarity | 48.1%;  | Pred. No.    | 71; | Gaps       | 0;  |
|    | Matches               | 37;   | Conservative | 0;  | Mismatches | 40; |
|    | Indels                | 40;   |              |     |            |     |
| QY | 2481                  | CAACAGATCCATTCTGAAGGAGATCAGCCCTGGGATTTCTTTCGAAGGAATGATGTAAA | 2540         |     |            |     |
| Dd | 132                   | CACCCCGTGTGCCAGAGAGTAGTACCCTCGTGCCACGACGAGCGCTTGGTGCCCGT    | 73           |     |            |     |
| QY | 2541                  | GCTGAACCTCCAGTACT   | 2557         |     |            |     |
| Dd | 72                    | GTGGTCAC'TGCAGTACT  | 56           |     |            |     |

## RESULT 15

```

US-08-955-636-8
Sequence 8, Application US/08955636A
Patent No. 6017882
GENERAL INFORMATION:
APPLICANT: Nelstuen, Gary
TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
FILE REFERENCE: 09531/002001
CURRENT APPLICATION NUMBER: US/08/955,636A
CURRENT FILING DATE: 1997-10-23
NUMBER OF SEQ ID NOS: 35
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 42
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
US-08-955-636-8

```

Query Match 0.3%; Score 12.4; DB 1; Length 42;  
Best Local Similarity 63.3%; Pred. No. 23;  
Matches 19; Conservative 0; Mismatches 11; Indels

QY 2597 CCTGATCTGGAGGGATTGGGGCAGGA 2626  
|| || || || || || || || || ||  
nb 12 CACGGCTGTGGACGAGCTCCTCCAGGA 41

RESULT, T 16

RESULT 16  
 US-08-293-778-16  
 ; Sequence 16, Application US/08293778  
 ; Patent No. 5580560  
 ;  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Nicolaisen, Else M.  
 ; APPLICANT: Bjorn, Soren E.  
 ; APPLICANT: Wiberg, Finn C.  
 ; APPLICANT: Woodbury, Richard  
 ; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
 ; NUMBER OF SEQUENCES: 26  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: NC. 55805600 No. 5580560disk of No. 5580560th America, Inc.  
 ; STREET: 405 Lexington Avenue, 62nd Floor  
 ; CITY: New York  
 ; STATE: New York  
 ; COUNTRY: United States of America  
 ; ZIP: 10174-6201  
 ;  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ;  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/293,778  
 ; FILING DATE:  
 ; CLASSIFICATION: 435  
 ;  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/104,509  
 ; FILING DATE:  
 ; APPLICATION NUMBER: DK 3235/87



```

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-447-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
US-07-998-972A-7

```

Query Match . 0.3%; Score 11.4; DB 1; Length 35;  
Best Local Similarity 71.4%; Pred. No. 69;  
Matches 15; Conservative 0; Mismatches 6; Indels

QY 2484 CCAGTCCATTCCTGAAGGAGAT 2504  
| | | | | | | | | | | | | | | |  
Dδ 15 CAACTCCTTCTCTGGAGGAGCT 35

RESULT 20  
 US-08-463-953-7  
 ; Sequence 7, Application US/08463953  
 ; Patent No. 5502034  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Holly, Richard D.  
 ; APPLICANT: Foster, Donald C.  
 ; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
 ; NUMBER OF SEQUENCES: 48  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Townsend and Townsend  
 ; STREET: One Market Plaza, Stewart Street Tower,  
 ; STREET: Twentieth Floor  
 ; CITY: San Francisco  
 ; STATE: CA  
 ; COUNTRY: USA  
 ; ZIP: 94105  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/463.953  
 ; FILING DATE:  
 ; CLASSIFICATION: 514  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/860,701  
 ; FILING DATE: 31-MAR-1992  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/816,281  
 ; FILING DATE: 31-DEC-1991  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Parmelee, Steven W  
 ; REGISTRATION NUMBER: 31,990  
 ; REFERENCE/DOCKET NUMBER: 13952-12-2  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 206-467-9600  
 ; TELEFAX: 415-543-5043  
 ; INFORMATION FOR SEQ ID NO: 7:

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-463-953-7

```

Query Match 0.3%; Score 11.4; DB 1; Length 35;  
Best Local Similarity 71.4%; Pred. No. 69;  
Matches 15; Conservative 0; Mismatches 6; Indels

QY  
db

2484 CCAGTCCATTCTGAAGGAGAT 2504  
          |      |      |      |      |  
15 CAACTCCTTCCTGGAGGAGCT 35

```

RESULT 21
US-08-462-261-7
; Sequence 7, Application US/08462261
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-462-261-7

```

Query Match 0.3%; Score 11.4; DB 1; Length 35;  
Best Local Similarity 71.4%; Pred. No. 69;  
Matches 15; Conservative 0; Mismatches 6; Indels

TELEPHONE: 415-543-5043  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0



QY 40 TCACAGTAAAGGACGAGTACTGCGCT 66  
|||||  
Db 5 TCACAGTTCGGTGGCGACGCTCTCT 31

## RESULT 26

US-08-955-636-10/c  
; Sequence 10, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelsetuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 10  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-10

Query Match 0.3%; Score 11; DB 1; Length 36;  
Best Local Similarity 63.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 40 TCACAGTAAAGGACGAGTACTGCGCT 66  
|||||  
Db 32 TCACAGTTCGGTGGCGACGCTCTCT 5

## RESULT 27

US-09-558-027-4  
; Sequence 4, Application US/09558027  
; Patent No. 6329176  
; GENERAL INFORMATION:  
; APPLICANT: Woldike, Helle  
; APPLICANT: Wiberg, Finn  
; APPLICANT: Nielsen, Lars  
; TITLE OF INVENTION: Method for the Production of FVII  
; FILE REFERENCE: S65-204-US  
; CURRENT APPLICATION NUMBER: US/09/558,027  
; CURRENT FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 60/108,065  
; PRIOR FILING DATE: 1998-11-12  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Saccharomyces cerevisiae  
US-09-558-027-4

Query Match 0.3%; Score 10.8; DB 1; Length 38;  
Best Local Similarity 60.0%; Pred. No. 1.7e+02;  
Matches 18; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 1716 ATGCAAAAGCCTTGACTGCGGGTCACA 1745  
|||||  
Db 6 ATTCAGTCTAGGGAATGGGGCTCGCA 35

## RESULT 28

US-08-756-506-13  
; Sequence 13, Application US/08756506  
; Patent No. 5905185  
; GENERAL INFORMATION:  
; APPLICANT: Garner, Ian

; APPLICANT: Cottingham, Ian R.  
; APPLICANT: Temperley, Simon M.  
; APPLICANT: Foster, Donald C.  
; APPLICANT: Sprecher, Cindy A.  
; APPLICANT: Prunkard, Donna E.  
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC  
; TITLE OF INVENTION: ANIMALS  
; NUMBER OF SEQUENCES: 25  
; CORRESPONDENCE ADDRESS:  
; ADDRESSER: ZymoGenetics, Inc.  
; STREET: 1201 Eastlake Avenue East  
; CITY: Seattle  
; STATE: WA  
; COUNTRY: USA  
; ZIP: 98102  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/756,506  
; FILING DATE:  
; CLASSIFICATION: 800  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Sawislak, Deborah A  
; REGISTRATION NUMBER: 37,438  
; REFERENCE/DOCKET NUMBER: 95-28  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-442-6672  
; TELEFAX: 206-442-6678  
; INFORMATION FOR SEQ ID NO: 13:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 45 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; CLONE: ZC6337  
US-08-756-506-13

Query Match 0.3%; Score 10.4; DB 1; Length 45;  
Best Local Similarity 70.0%; Pred. No. 3e+02;  
Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 48 AAGGAGCAGTAGTCGCGCTT 67  
|||||  
Db 2 AGGAGGAGTTCGCGCGCTT 21

## RESULT 29

US-07-998-972A-7/c  
; Sequence 7, Application US/07998972A  
; Patent No. 5476777  
; GENERAL INFORMATION:  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Foster, Donald C.  
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend  
; STREET: One Market Plaza, Stewart Street Tower,  
; CITY: San Francisco  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/998,972A  
FILING DATE: 19921230  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324

US-07-998-972A-7

Query Match 0.3%; Score 10; DB 1; Length 35;  
Best Local Similarity 72.2%; Pred. No. 3.6e+02;  
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGCTGACTCACTCGA 2591  
Db 22 AGGATTGGCTCGCCGA 5

RESULT 30  
US-08-463-953-7/c  
Sequence 7, Application US/08463953  
Patent No. 5502034  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/463,953  
FILING DATE:  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600

TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-08-463-953-7

Query Match 0.3%; Score 10; DB 1; Length 35;  
Best Local Similarity 72.2%; Pred. No. 3.6e+02;  
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGCTGACTCACTCGA 2591  
Db 22 AGGATTGGCTCGCCGA 5

RESULT 31  
US-08-462-261-7/c  
Sequence 7, Application US/08462261  
Patent No. 5527692  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/462,261  
FILING DATE: 05-JUN-1995  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/998,972  
FILING DATE: 30-DEC-1992  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-08-462-261-7

Query Match 0.3%; Score 10; DB 1; Length 35;  
Best Local Similarity 72.2%; Pred. No. 3.6e+02;

Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGCTGACTCTACTGGA 2591  
| | | | | | | | | | | | | |  
Db 22 AGGAGTTGGCTCGCCGGA 5

## RESULT 32

PCT-US92-11357-7/c  
; Sequence 7, Application PC/TUS9211357  
; GENERAL INFORMATION:  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Foster, Donald C.  
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend  
; STREET: One Market Plaza, Stewart Street Tower,  
; STREET: Twentieth Floor  
; CITY: San Francisco  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US92/11357  
; FILING DATE: 19921230  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/860,701  
; FILING DATE: 31-MAR-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/816,281  
; FILING DATE: 31-DEC-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Parmelee, Steven W  
; REGISTRATION NUMBER: 31,990  
; REFERENCE/DOCKET NUMBER: 13952-12-2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-467-9600  
; TELEFAX: 415-543-5043  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 base pairs  
; TYPE: NUCLEIC ACID  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; CLONE: ZC1324  
PCT-US92-11357-7

Query Match 0.3%; Score 10; DB 1; Length 35;  
Best Local Similarity 72.2%; Pred. No. 3.6e+02;  
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2574 AAGAGCTGACTCTACTGGA 2591  
| | | | | | | | | | | | | |  
Db 22 AGGAGTTGGCTCGCCGGA 5

## RESULT 33

US-08-293-778-17  
; Sequence 17, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren B.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard

; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agiris, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129.224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 17:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: CDNA  
US-08-293-778-17

Query Match 0.3%; Score 9.8; DB 1; Length 27;  
Best Local Similarity 66.7%; Pred. No. 3.5e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 281 GAGAGATCTGACAGATGTGG 301  
| | | | | | | | | | | | | |  
Db 5 GGGAAATCTTCAGGACGGG 25

## RESULT 34

US-09-558-027-4/c  
; Sequence 4, Application US/09558027  
; Patent No. 6329176  
; GENERAL INFORMATION:  
; APPLICANT: Woldike, Helle  
; APPLICANT: Wiberg, Finn  
; APPLICANT: Nielsen, Lars  
; TITLE OF INVENTION: Method for the Production of FVII  
; FILE REFERENCE: 5565.204-US  
; CURRENT APPLICATION NUMBER: US/09/558,027  
; CURRENT FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 60/108,065  
; PRIOR FILING DATE: 1998-11-12  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: FastSeq for Windows version 4.0



```
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

Query Match
; Best Local Similarity 62.5%; Pred. No. 4.5e+02; Length 38;
Matches 15; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 706 TACTGGGGGAGGAATCCCTCAGA 729
Db 38 TCCTGGAGGCCCATTCCTCAGA 15

RESULT 35
US-08-293-778-22
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; FILING DATE: 25-JUN-1987
; APPLICATION NUMBER: DK 3235/87
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-22

Query Match
; Best Local Similarity 62.5%; Pred. No. 4.5e+02; Length 38;
Matches 15; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 706 TACTGGGGGAGGAATCCCTCAGA 729
Db 38 TCCTGGAGGCCCATTCCTCAGA 15

Best Local Similarity 68.4%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2749 GTCACAAAGAGTTGGACAC 2767
Db 7 GTCACGGAAGTCGGAGAC 25

RESULT 36
US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; FILING DATE: 25-JUN-1987
; APPLICATION NUMBER: DK 3235/87
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match
; Best Local Similarity 68.4%; Pred. No. 4.9e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2709 GCTGATGGACAGGGAGGCC 2727
Db 1 GCTGCTGGACCTGGGGGCC 19
```

RESULT 37  
US-08-293-778-17/c  
; Sequence 17, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560o No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agtis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129.224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 17:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cdna  
; US-08-293-778-17  
Query Match 0.3%; Score 9; DB 1; Length 27;  
Best Local Similarity 70.8%; Pred. No. 6.2e+02;  
Matches 12; Conservative 0; Mismatches 5; Indels 0; Gaps 0;  
QY 1655 CTCTGATCATCGAAGA 1671  
Db 27 CTCGCGCTCTGGAAGA 11  
RESULT 38  
US-08-293-778-16/c  
; Sequence 16, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.

; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560o No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agtis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129.224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cdna  
; US-08-293-778-16  
Query Match 0.2%; Score 8.8; DB 1; Length 27;  
Best Local Similarity 65.0%; Pred. No. 6.5e+02;  
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;  
QY 913 CTACAAGACCTTTTAGAACT 932  
Db 27 CTCGCGCTCTGGAATCT 8  
RESULT 39  
US-08-293-778-22/c  
; Sequence 22, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560o No. 5580560disk of No. 5580560th America, Inc.

STREET: 405 Lexington Avenue, 62nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/293,778

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/104,509

FILING DATE:

APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/434,149

FILING DATE: 13-NOV-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/DK88/00103

FILING DATE: 24-JUN-1988

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/898,248

FILING DATE: 12-JUN-1992

ATTORNEY/AGENT INFORMATION:

NAME: Agis, Cheryl H.

REGISTRATION NUMBER: 34,086

REFERENCE/DOCKET NUMBER: 3129.224-US

TELEPHONE: 212-867-0123

TELEFAX: 212-867-0298

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 26 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cdna

US-08-293-778-22

Query Match 0.2%; Score 8.6; DB 1; Length 26;

Best Local Similarity 73.3%; Pred. No. 6.9e+02;

Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1786 CCACCTGACCTGACT 1800

Db 20 CGACCTTCCTGACT 6

RESULT 40

US-08-293-778-20/c

Sequence 20, Application US/08293778

Patent No. 5580560

GENERAL INFORMATION:

APPLICANT: Nicolaisen, Else M.

APPLICANT: Bjorn, Soren E.

APPLICANT: Wiberg, Finn C.

APPLICANT: Woodbury, Richard

TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:

ADDRESSEE: No. 5580560 of No. 5580560th America, Inc.

STREET: 405 Lexington Avenue, 62nd Floor

CITY: New York

STATE: New York

COUNTRY: United States of America

ZIP: 10174-6201

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/293,778

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/104,509

FILING DATE:

APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/434,149

FILING DATE: 13-NOV-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/DK88/00103

FILING DATE: 24-JUN-1988

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/898,248

FILING DATE: 12-JUN-1992

ATTORNEY/AGENT INFORMATION:

NAME: Agis, Cheryl H.

REGISTRATION NUMBER: 34,086

REFERENCE/DOCKET NUMBER: 3129.224-US

TELEPHONE: 212-867-0123

TELEFAX: 212-867-0298

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 27 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cdna

US-08-293-778-20

Query Match 0.2%; Score 8.4; DB 1; Length 27;

Best Local Similarity 66.7%; Pred. No. 6.8e+02;

Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 62 GCGCTTTGCTGAGCAGC 79

Db 18 GCGCCAGGTCAGCAGC 1

Search completed: August 9, 2004, 16:34:47

Job time: 18 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:35:17 ; Search time 48 seconds  
(without alignments)

3.742 Million cell updates/sec

Title: us-10-664-775-2

Perfect score: 3572

Sequence: 1 gtcagaaaggcgcagtgta.....gcacacagcagaagctt 3572

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 61 seqs, 25143 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rnpbdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description        |
|------------|-------|-------------|--------|-------|--------------------|
| 1          | 20.8  | 0.6         | 1338   | 1     | US-09-782-587B-2   |
| 2          | 20.8  | 0.6         | 1357   | 1     | US-09-782-587B-4   |
| 3          | 19.8  | 0.6         | 1338   | 1     | US-09-782-587B-2   |
| 4          | 19.8  | 0.6         | 1357   | 1     | US-09-782-587B-4   |
| 5          | 18.6  | 0.5         | 1361   | 1     | US-10-382-248-35   |
| 6          | 18.4  | 0.5         | 1332   | 1     | US-10-411-037-7    |
| 7          | 18.4  | 0.5         | 1332   | 1     | US-10-411-026-7    |
| 8          | 18.4  | 0.5         | 1332   | 1     | US-10-410-962-7    |
| 9          | 18.4  | 0.5         | 1332   | 1     | US-10-411-049-7    |
| 10         | 18.4  | 0.5         | 1332   | 1     | US-10-410-930-7    |
| 11         | 18.4  | 0.5         | 1332   | 1     | US-10-410-997-7    |
| 12         | 18.4  | 0.5         | 1332   | 1     | US-10-411-012-7    |
| 13         | 18.4  | 0.5         | 1332   | 1     | US-10-287-994-7    |
| 14         | 18.4  | 0.5         | 1332   | 1     | US-10-410-913-7    |
| 15         | 18.4  | 0.5         | 1440   | 1     | US-10-375-741-13   |
| 16         | 18.4  | 0.5         | 2040   | 1     | US-10-617-619-12   |
| 17         | 18.4  | 0.5         | 2106   | 1     | US-10-617-619-9    |
| 18         | 18.1  | 0.5         | 555    | 1     | US-10-029-386-9623 |
| 19         | 18.1  | 0.5         | 1361   | 1     | US-10-382-248-35   |
| 20         | 17.4  | 0.5         | 1332   | 1     | US-10-411-037-7    |
| 21         | 17.4  | 0.5         | 1332   | 1     | US-10-411-026-7    |
| 22         | 17.4  | 0.5         | 1332   | 1     | US-10-410-962-7    |
| 23         | 17.4  | 0.5         | 1332   | 1     | US-10-411-049-7    |
| 24         | 17.4  | 0.5         | 1332   | 1     | US-10-410-930-7    |
| 25         | 17.4  | 0.5         | 1332   | 1     | US-10-410-997-7    |
| 26         | 17.4  | 0.5         | 1332   | 1     | US-10-411-012-7    |
| 27         | 17.4  | 0.5         | 1332   | 1     | US-10-287-994-7    |
| 28         | 17.4  | 0.5         | 1332   | 1     | US-10-410-913-7    |
| 29         | 17.4  | 0.5         | 1440   | 1     | US-10-375-741-13   |
| 30         | 17.4  | 0.5         | 2040   | 1     | US-10-617-619-12   |
| 31         | 17.4  | 0.5         | 2106   | 1     | US-10-617-619-9    |
| 32         | 17.1  | 0.5         | 222    | 1     | US-10-029-386-9623 |
| 33         | 17    | 0.5         | 483    | 1     | US-09-918-995-8429 |

|     |   |                     |      |                   |
|-----|---|---------------------|------|-------------------|
| 555 | 1 | US-10-029-386-9623  | 17   | Sequence 9623, Ap |
| 483 | 1 | US-09-918-995-8429  | 16.6 | Sequence 8429, Ap |
| 100 | 1 | US-10-272-665-107   | 14.8 | Sequence 107, App |
| 100 | 1 | US-10-273-321-107   | 14.8 | Sequence 107, App |
| 100 | 1 | US-10-272-756-107   | 14.8 | Sequence 107, App |
| 100 | 1 | US-10-273-228-107   | 14.8 | Sequence 107, App |
| 100 | 1 | US-10-272-665-106   | 14.4 | Sequence 106, App |
| 100 | 1 | US-10-273-321-106   | 14.4 | Sequence 106, App |
| 100 | 1 | US-10-272-756-106   | 14.4 | Sequence 106, App |
| 100 | 1 | US-10-273-228-106   | 14.4 | Sequence 106, App |
| 38  | 1 | US-10-398-4228-20   | 14.2 | Sequence 20, Appl |
| 38  | 1 | US-09-959-357-2     | 14.2 | Sequence 2, Appl  |
| 38  | 1 | US-10-254-394-2     | 14.2 | Sequence 2, Appl  |
| 60  | 1 | US-10-272-665-22    | 13.2 | Sequence 22, Appl |
| 60  | 1 | US-10-273-321-22    | 13.2 | Sequence 22, Appl |
| 60  | 1 | US-10-272-756-22    | 13.2 | Sequence 22, Appl |
| 60  | 1 | US-10-273-228-22    | 13.2 | Sequence 22, Appl |
| 100 | 1 | US-10-272-665-106   | 13.2 | Sequence 106, App |
| 100 | 1 | US-10-273-321-106   | 13.2 | Sequence 106, App |
| 100 | 1 | US-10-272-756-106   | 13.2 | Sequence 106, App |
| 100 | 1 | US-10-273-228-106   | 13.2 | Sequence 106, App |
| 60  | 1 | US-10-272-665-22    | 13   | Sequence 22, Appl |
| 60  | 1 | US-10-273-321-22    | 13   | Sequence 22, Appl |
| 60  | 1 | US-10-272-756-22    | 13   | Sequence 22, Appl |
| 60  | 1 | US-10-273-228-22    | 13   | Sequence 22, Appl |
| 100 | 1 | US-10-272-665-107   | 12.8 | Sequence 107, App |
| 100 | 1 | US-10-273-321-107   | 12.8 | Sequence 107, App |
| 100 | 1 | US-10-272-756-107   | 12.8 | Sequence 107, App |
| 100 | 1 | US-10-273-228-107   | 12.8 | Sequence 107, App |
| 31  | 1 | US-10-017-122-4     | 12.6 | Sequence 4, Appl  |
| 38  | 1 | US-10-358-4228-20   | 12.6 | Sequence 20, Appl |
| 38  | 1 | US-09-969-357-2     | 12.6 | Sequence 2, Appl  |
| 38  | 1 | US-10-254-394-2     | 12.6 | Sequence 2, Appl  |
| 42  | 1 | US-09-803-810-8     | 12.4 | Sequence 8, Appl  |
| 42  | 1 | US-10-298-330-8     | 12.4 | Sequence 8, Appl  |
| 60  | 1 | US-10-272-665-23    | 12.4 | Sequence 23, Appl |
| 60  | 1 | US-10-273-321-23    | 12.4 | Sequence 23, Appl |
| 60  | 1 | US-10-272-756-23    | 12.4 | Sequence 23, Appl |
| 60  | 1 | US-10-273-228-23    | 12.4 | Sequence 23, Appl |
| 222 | 1 | US-10-029-386-23323 | 12.2 | Sequence 23323, A |
| 36  | 1 | US-09-951-121A-8    | 11.8 | Sequence 9, Appl  |
| 36  | 1 | US-10-255-032-8     | 11.8 | Sequence 9, Appl  |
| 36  | 1 | US-10-255-032-9     | 11.8 | Sequence 9, Appl  |
| 36  | 1 | US-10-295-682-8     | 11.8 | Sequence 9, Appl  |
| 36  | 1 | US-10-295-682-9     | 11.8 | Sequence 9, Appl  |
| 42  | 1 | US-09-803-810-8     | 11.8 | Sequence 8, Appl  |
| 42  | 1 | US-10-238-330-8     | 11.8 | Sequence 8, Appl  |
| 33  | 1 | US-09-951-121A-14   | 11.6 | Sequence 14, Appl |
| 33  | 1 | US-10-295-682-14    | 11.6 | Sequence 14, Appl |
| 33  | 1 | US-10-295-682-15    | 11.6 | Sequence 15, Appl |
| 33  | 1 | US-09-951-121A-14   | 11.4 | Sequence 14, Appl |
| 33  | 1 | US-10-295-682-14    | 11.4 | Sequence 14, Appl |
| 33  | 1 | US-10-295-682-15    | 11.4 | Sequence 15, Appl |
| 54  | 1 | US-10-349-858-8     | 11.4 | Sequence 8, Appl  |
| 32  | 1 | US-10-281-727-6     | 11.2 | Sequence 6, Appl  |
| 32  | 1 | US-10-281-727-7     | 11.2 | Sequence 7, Appl  |
| 35  | 1 | US-10-109-498-5     | 11   | Sequence 5, Appl  |
| 35  | 1 | US-10-109-498-6     | 11   | Sequence 6, Appl  |
| 60  | 1 | US-10-272-665-23    | 11   | Sequence 23, Appl |
| 60  | 1 | US-10-273-321-23    | 11   | Sequence 23, Appl |
| 60  | 1 | US-10-272-756-23    | 11   | Sequence 23, Appl |
| 60  | 1 | US-10-273-228-23    | 11   | Sequence 23, Appl |
| 54  | 1 | US-10-349-858-8     | 10.6 | Sequence 8, Appl  |
| 36  | 1 | US-09-951-121A-8    | 10.4 | Sequence 9, Appl  |
| 36  | 1 | US-10-255-032-8     | 10.4 | Sequence 8, Appl  |
| 36  | 1 | US-10-255-032-9     | 10.4 | Sequence 9, Appl  |
| 36  | 1 | US-10-295-682-8     | 10.4 | Sequence 8, Appl  |
| 36  | 1 | US-10-295-682-9     | 10.4 | Sequence 9, Appl  |
| 36  | 1 | US-10-281-727-2     | 10.4 | Sequence 2, Appl  |

C 107 10.4 0.3 36 1 US-10-281-727-2 Sequence 2, Appli  
C 108 10.4 0.3 36 1 US-10-281-727-3 Sequence 3, Appli  
C 109 10.4 0.3 36 1 US-10-281-727-3 Sequence 3, Appli  
C 110 10 0.3 35 1 US-10-109-498-5 Sequence 5, Appli  
C 111 10 0.3 35 1 US-10-109-498-6 Sequence 6, Appli  
C 112 9.8 0.3 34 1 US-09-951-121A-2 Sequence 2, Appli  
C 113 9.8 0.3 34 1 US-09-951-121A-3 Sequence 3, Appli  
C 114 9.8 0.3 34 1 US-10-295-682-2 Sequence 2, Appli  
C 115 9.8 0.3 34 1 US-10-295-682-3 Sequence 3, Appli  
C 116 9.2 0.3 31 1 US-10-017-122-4 Sequence 4, Appli  
C 117 8.8 0.2 32 1 US-10-281-727-6 Sequence 6, Appli  
C 118 8.8 0.2 32 1 US-10-281-727-7 Sequence 7, Appli  
C 119 8.6 0.2 34 1 US-09-951-121A-2 Sequence 2, Appli  
C 120 8.6 0.2 34 1 US-09-951-121A-3 Sequence 3, Appli  
C 121 8.6 0.2 34 1 US-10-295-682-2 Sequence 2, Appli  
C 122 8.6 0.2 34 1 US-10-295-682-3 Sequence 3, Appli

## ALIGNMENTS

## RESULT 1

US-09-782-587B-2  
; Sequence 2, Application US/09782587B  
; Publication No. US20030096338A1  
; GENERAL INFORMATION:  
; APPLICANT: PEDERSEN, ANDERS H.  
; APPLICANT: ANDERSON, KIM V.  
; APPLICANT: BORNAES, CLAUD  
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
; FILE REFERENCE: 31-001100US  
; CURRENT APPLICATION NUMBER: US/09/782,587B  
; CURRENT FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: PA 2000 00218  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: 60/184,036  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: 60/241,916  
; PRIOR FILING DATE: 2000-10-18  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 1338  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: (115)..(1332)  
US-09-782-587B-2

Query Match 0.6%; Score 20.8; DB 1; Length 1338;  
Best Local Similarity 57.8%; Pred. No. 0.76; 27; Indels 0; Gaps 0;  
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
QY 1443 AGGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGGCTGTCTGGGA 1502  
DB 132 AGAGCTCCGCCCTGGCTCCCTGGAACGCAATGCAAGAGGAACAGTGCAGCTTTGAGGA 191  
QY 1503 GGCC 1506  
DB 192 AGCC 195

## RESULT 2

US-09-782-587B-4  
; Sequence 4, Application US/09782587B  
; Publication No. US20030096338A1  
; GENERAL INFORMATION:  
; APPLICANT: PEDERSEN, ANDERS H.  
; APPLICANT: ANDERSON, KIM V.  
; APPLICANT: BORNAES, CLAUD  
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
; FILE REFERENCE: 31-001100US

; CURRENT APPLICATION NUMBER: US/09/782,587B  
; CURRENT FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: PA 2000 00218  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: 60/184,036  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: 60/241,916  
; PRIOR FILING DATE: 2000-10-18  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 1357  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Expression  
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells  
US-09-782-587B-4

Query Match 0.6%; Score 20.8; DB 1; Length 1357;  
Best Local Similarity 57.8%; Pred. No. 0.77; 27; Indels 0; Gaps 0;  
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
QY 1443 AGGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGGCTGTCTGGGA 1502  
DB 145 AGAGCTCCGCCCTGGCTCCCTGGAACGCAATGCAAGAGGAACAGTGCAGCTTTGAGGA 204  
QY 1503 GGCC 1506  
DB 205 AGCC 208

## RESULT 3

US-09-782-587B-2/c  
; Sequence 2, Application US/09782587B  
; Publication No. US20030096338A1  
; GENERAL INFORMATION:  
; APPLICANT: PEDERSEN, ANDERS H.  
; APPLICANT: ANDERSON, KIM V.  
; APPLICANT: BORNAES, CLAUD  
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
; FILE REFERENCE: 31-001100US  
; CURRENT APPLICATION NUMBER: US/09/782,587B  
; CURRENT FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: PA 2000 00218  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: 60/184,036  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: 60/241,916  
; PRIOR FILING DATE: 2000-10-18  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 1338  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: (115)..(1332)  
US-09-782-587B-2

Query Match 0.6%; Score 19.8; DB 1; Length 1338;  
Best Local Similarity 69.2%; Pred. No. 2.5; 12; Indels 0; Gaps 0;  
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;  
QY 44 AGSTAAGGAGCAGTAGCTGGCTTTGTGCGAGCGCT 82  
DB 322 AGATATAGCTCTGCAGCTGGTCTTTGCGAGGAGCGCCCGT 284

## RESULT 4

US-09-782-587B-4/c  
; Sequence 4, Application US/09782587B

Publication No. US20030096338A1  
GENERAL INFORMATION:  
APPLICANT: PEDERSEN, ANDERS H.  
APPLICANT: ANDERSON, KIM V.  
APPLICANT: BORNAES, CLAUS  
TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
FILE REFERENCE: 31-001100US  
CURRENT APPLICATION NUMBER: US/09/782,587B  
CURRENT FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: PA 2000 00218  
PRIOR FILING DATE: 2000-02-11  
PRIOR APPLICATION NUMBER: 60/184,036  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: 60/241,916  
PRIOR FILING DATE: 2000-10-18  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 4  
LENGTH: 1357  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Expression  
OTHER INFORMATION: cassette for expression of FVII in mammalian cells  
US-09-782-587B-4  
Query Match 0.6%; Score 19.8; DB 1; Length 1357;  
Best Local Similarity 69.2%; Pred. No. 2.6; Mismatches 0; Indels 0; Gaps 0;  
Matches 27; Conservative 0;  
QY 44 AGGTAAGGAGCAGTAGCTGGCGTTTGTGGAGCAGCCGT 82  
DB 335 AGATAGCTCGAGCTGGTCTTTGCAGGAGCCCGCT 297  
RESULT 5  
US-10-382-248-35  
Sequence 35, Application US/10382248  
Publication No. US20040059347A1  
GENERAL INFORMATION:  
APPLICANT: Alsbrook, et al.  
TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME  
FILE REFERENCE: 21402-568C  
CURRENT APPLICATION NUMBER: US/10/382,248  
CURRENT FILING DATE: 2003-03-05  
PRIOR APPLICATION NUMBER: 60/366,928  
PRIOR FILING DATE: 2002-03-22  
PRIOR APPLICATION NUMBER: 60/361,974  
PRIOR FILING DATE: 2002-03-06  
PRIOR APPLICATION NUMBER: 60/365,477  
PRIOR FILING DATE: 2002-03-19  
PRIOR APPLICATION NUMBER: 60/401,661  
PRIOR FILING DATE: 2002-08-06  
NUMBER OF SEQ ID NOS: 82  
SOFTWARE: CuraseqList version 0.1  
SEQ ID NO 35  
LENGTH: 1361  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: CDS  
LOCATION: (45)...(1301)  
US-10-382-248-35  
Query Match 0.5%; Score 18.6; DB 1; Length 1361;  
Best Local Similarity 49.5%; Pred. No. 10; Mismatches 49; Indels 0; Gaps 0;  
Matches 48; Conservative 0;  
QY 1408 CTATGGCAGAGGTTTCATGACATTTACAGGAGCAGGATCGAGACCATCCCATGGAA 1457  
DB 452 CGAGGCGCGGAACTGTGAGAGCGTTGAATATCCATGTGCAAAATACCTATTCTAGAAA 511  
QY 1468 AAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504

DB 512 AAGAAATCCAGCAACCCCAAGCCGAATTTGGGG 548  
RESULT 6  
US-10-411-037-7  
Sequence 7, Application US/10411037  
Publication No. US20040043446A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: Defrees, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
APPLICANT: Bowe, Caryn  
TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA  
TITLE OF INVENTION: GALACTOSIDASE A  
FILE REFERENCE: 040853-01-5082  
CURRENT APPLICATION NUMBER: US/10/411,037  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527  
PRIOR FILING DATE: 2002-08-28  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-411-037-7  
Query Match 0.5%; Score 18.4; DB 1; Length 1332;  
Best Local Similarity 56.7%; Pred. No. 12; Mismatches 26; Indels 0; Gaps 0;  
Matches 34; Conservative 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAATAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGCCGAATTTGGGG 579  
RESULT 7  
US-10-411-026-7  
Sequence 7, Application US/10411026  
Publication No. US20040063911A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: Defrees, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PEPTIDES PRODUCED BY THE  
TITLE OF INVENTION: METHODS  
FILE REFERENCE: 040853-01-5053  
CURRENT APPLICATION NUMBER: US/10/411,026  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527  
PRIOR FILING DATE: 2002-08-28  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-411-026-7

Query Match 0.5%; Score 18.4; DB 1; Length 1332;  
Best Local Similarity 56.7%; Pred. No. 12;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579

## RESULT 8

US-10-410-962-7  
Sequence 7, Application US/10410962  
Publication No. US2004007836A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: DeFrees, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
APPLICANT: Bowe, Caryn  
TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND  
FILE OF INVENTION: GLYCOCONJUGATION OF G-CSF  
FILE REFERENCE: 040853-01-5054  
CURRENT APPLICATION NUMBER: US/10/410,962  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-410-962-7

Query Match 0.5%; Score 18.4; DB 1; Length 1332;  
Best Local Similarity 56.7%; Pred. No. 12;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579

RESULT 9  
US-10-411-049-7  
Sequence 7, Application US/10411049  
Publication No. US20040082026A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: DeFrees, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
APPLICANT: Bowe, Caryn  
TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON  
FILE REFERENCE: 040853-01-5055  
CURRENT APPLICATION NUMBER: US/10/411,049  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-411-049-7

Query Match 0.5%; Score 18.4; DB 1; Length 1332;  
Best Local Similarity 56.7%; Pred. No. 12;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579

## RESULT 10

US-10-410-930-7  
Sequence 7, Application US/10410930  
Publication No. US20040115168A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: DeFrees, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
APPLICANT: Bowe, Caryn  
TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON  
FILE REFERENCE: 040853-01-5056  
CURRENT APPLICATION NUMBER: US/10/410,930  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-410-930-7

Query Match 0.5%; Score 18.4; DB 1; Length 1332;  
Best Local Similarity 56.7%; Pred. No. 12;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579



```

; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCGGAGAAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579

RESULT 11
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCGGAGAAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579

RESULT 12
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCGGAGAAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579

RESULT 13
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
```

```

US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match
Best Local Similarity 0.5%; Score 18.4; DB 1; Length 1332;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCGGAGAAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504
Db 520 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGG 579

RESULT 13
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
```

; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 62  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-287-994-7

Query Match 0.5%; Score 18.4; DB 1; Length 1332;  
Best Local Similarity 56.7%; Pred. No. 12;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGGG 579

RESULT 14  
US-10-410-913-7  
; Sequence 7, Application US/10410913  
; Publication No. US20040142856A1  
; GENERAL INFORMATION:  
; APPLICANT: Necse Technologies, Inc.  
; APPLICANT: DeFrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bowe, Caryn  
; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
; FILE OF INVENTION: METHODS  
; FILE REFERENCE: 040853-01-5081  
; CURRENT APPLICATION NUMBER: US/10/410,913  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-410-913-7

Query Match 0.5%; Score 18.4; DB 1; Length 1332;  
Best Local Similarity 56.7%; Pred. No. 12;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGGG 579

RESULT 15  
US-10-375-741-13  
; Sequence 13, Application US/10375741  
; Publication No. US20030232753A1

; GENERAL INFORMATION:  
; APPLICANT: Thorpe, Philip E  
; APPLICANT: King, Steven W  
; APPLICANT: Gao, Boning  
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR  
; FILE OF INVENTION: TREATMENT  
; FILE REFERENCE: 4001-001999  
; CURRENT APPLICATION NUMBER: US/10/375,741  
; CURRENT FILING DATE: 2003-02-27  
; PRIOR APPLICATION NUMBER: 09/573,835  
; PRIOR FILING DATE: 2000-05-18  
; PRIOR APPLICATION NUMBER: 6,156,321  
; PRIOR FILING DATE: 1998-01-20  
; PRIOR APPLICATION NUMBER: 60/042,427  
; PRIOR FILING DATE: 1997-03-27  
; PRIOR APPLICATION NUMBER: 60/036,205  
; PRIOR FILING DATE: 1997-01-27  
; PRIOR APPLICATION NUMBER: 60/035,920  
; PRIOR FILING DATE: 1997-01-22  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 13  
; LENGTH: 1440  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-375-741-13

Query Match 0.5%; Score 18.4; DB 1; Length 1440;  
Best Local Similarity 56.7%; Pred. No. 13;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 621 GGAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGGG 680

RESULT 16  
US-10-617-619-12  
; Sequence 12, Application US/10617619  
; Publication No. US20040110929A1  
; GENERAL INFORMATION:  
; APPLICANT: Bjorn, Soren E  
; APPLICANT: Nicolaisen, Else M  
; APPLICANT: Jorgensen, Anker S  
; TITLE OF INVENTION: TF Binding Compound  
; FILE REFERENCE: 6455.200-US  
; CURRENT APPLICATION NUMBER: US/10/617,619  
; CURRENT FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099  
; PRIOR FILING DATE: 2002-07-12  
; PRIOR APPLICATION NUMBER: US 60/404,568  
; PRIOR FILING DATE: 2002-08-19  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 12  
; LENGTH: 2040  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-617-619-12

Query Match 0.5%; Score 18.4; DB 1; Length 2040;  
Best Local Similarity 56.7%; Pred. No. 16;  
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
QY 1445 GGATCGAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGG 1504  
DB 520 GGAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCCAAGGCCGAATTGTGGGG 579

RESULT 17  
US-10-617-619-9

```
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaissen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-10-617-619-9

Query Match 0.5%; Score 18.4; DB 1; Length 2106;
Best Local Similarity 56.7%; Pred. No. 16;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GATCAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504
DB 586 GGAAATACCTATTCTAGAAAAGAAATGCCAAACCCCAAGGCCGAATTGTGGGG 645

RESULT 18
US-10-029-386-9623
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annotax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
; US-10-029-386-9623

Query Match 0.5%; Score 18.1; DB 1; Length 555;
Best Local Similarity 47.0%; Pred. No. 7;
Matches 86; Conservative 0; Mismatches 94; Indels 3; Gaps 1;

QY 2 TCAGGAGGGCGGCGATGAGGAGGTACCTACCTCGTCCAGGTAAAGGACGATGACT 61
DB 29 TCCGTGACTGCTCGAGCGCATCTCGGTGTCATCAGCGGGGCGACGTTGAGGACCATGAGCT 88

; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaissen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-10-617-619-9

Query Match 0.5%; Score 18.1; DB 1; Length 2106;
Best Local Similarity 56.7%; Pred. No. 16;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GATCAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504
DB 586 GGAAATACCTATTCTAGAAAAGAAATGCCAAACCCCAAGGCCGAATTGTGGGG 645

RESULT 19
US-10-382-248-35/c
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
; US-10-382-248-35

Query Match 0.5%; Score 18.1; DB 1; Length 1361;
Best Local Similarity 47.0%; Pred. No. 16;
Matches 86; Conservative 0; Mismatches 94; Indels 3; Gaps 1;

QY 2 TCAGGAGGGCGGCGATGAGGAGGTACCTACCTCGTCCAGGTAAAGGACGATGACT 61
DB 1029 TCCGTGACTGCTGCAGGCGAGTCCTGGGTCTATCAGCCGGGGCAGCTTGAGGACCATGAGCT 970

; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaissen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-10-617-619-9

Query Match 0.5%; Score 18.1; DB 1; Length 2106;
Best Local Similarity 56.7%; Pred. No. 16;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GATCAGACCATCCCATGGAAGAAATGCAAAAGCAAAATGCTGTCTGGGAGG 1504
DB 586 GGAAATACCTATTCTAGAAAAGAAATGCCAAACCCCAAGGCCGAATTGTGGGG 645

RESULT 20
US-10-411-037-7/c
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
```

```
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; TITLE OF INVENTION: GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match      0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAAGCTGAAGTGAACGGTCTTATGAAGACCTTACAAGACCTTTTAGAA 930
Db 243 AGAAATCCAGAACACAGCTTCGTCCTCTCCGCGTCTTGAAGATCTCCCGGGCTCTCGAA 184

QY 931 CTAACAC 937
Db 183 GGAGCAC 177

RESULT 21
US-10-411-026-7/c
; Sequence 7, Application US/10411026
; Publication No. US20040063911A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match      0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAAGCTGAAGTGAACGGTCTTATGAAGACCTTACAAGACCTTTTAGAA 930
Db 243 AGAAATCCAGAACACAGCTTCGTCCTCTCCGCGTCTTGAAGATCTCCCGGGCTCTCGAA 184

QY 931 CTAACAC 937
Db 183 GGAGCAC 177

RESULT 22
US-10-410-962-7/c
; Sequence 7, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-962-7
```

RESULT 23



QY 871 AGTAATGCTGAAGAAGCTGAAGTTGAACGGTCTATGAAGACCTTACAAGACCTTTTAGAA 930  
Db 243 AGAATCCAGACAGCTTCGTCTCTCCGGTCTTGAAGATCTCCCGGCTCTCTCGAA 184

QY 931 CTAACAC 937  
Db 183 GGAGCAC 177

## RESULT 26

US-10-411-012-7/c  
; Sequence 7, Application US/10411012  
; Publication No. US20040132640A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bove, Caryn  
; TITLE OF INVENTION: GLYCOPREGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
; FILE REFERENCE: 040853-01-5051  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/411,012  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-411-012-7

Query Match 0.5%; Score 17.4; DB 1; Length 1332;  
Best Local Similarity 53.7%; Pred. No. 28;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 871 AGTAATGCTGAAGAAGCTGAAGTTGAACGGTCTATGAAGACCTTACAAGACCTTTTAGAA 930  
Db 243 AGAATCCAGACAGCTTCGTCTCTCCGGTCTTGAAGATCTCCCGGCTCTCTCGAA 184  
QY 931 CTAACAC 937  
Db 183 GGAGCAC 177

## RESULT 27

US-10-287-994-7/c  
; Sequence 7, Application US/10287994  
; Publication No. US20040137557A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Bove, Caryn  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi

Query Match 0.5%; Score 17.4; DB 1; Length 1332;  
Best Local Similarity 53.7%; Pred. No. 28;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 871 AGTAATGCTGAAGAAGCTGAAGTTGAACGGTCTATGAAGACCTTACAAGACCTTTTAGAA 930  
Db 243 AGAATCCAGACAGCTTCGTCTCTCCGGTCTTGAAGATCTCCCGGCTCTCTCGAA 184  
QY 931 CTAACAC 937  
Db 183 GGAGCAC 177

US-10-410-913-7/c  
; Sequence 7, Application US/10410913  
; Publication No. US20040142856A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bove, Caryn  
; TITLE OF INVENTION: GLYCOCOCNUJGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
; FILE REFERENCE: 040853-01-5081  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7

; TITLE OF INVENTION: REMODELING AND GLYCOCOCNUJGATION OF PEPTIDES  
; FILE REFERENCE: 040853-01-5052-00  
; CURRENT FILING DATE: 2002-11-05  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 62  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-287-994-7

Query Match 0.5%; Score 17.4; DB 1; Length 1332;  
Best Local Similarity 53.7%; Pred. No. 28;  
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 871 AGTAATGCTGAAGAAGCTGAAGTTGAACGGTCTATGAAGACCTTACAAGACCTTTTAGAA 930  
Db 243 AGAATCCAGACAGCTTCGTCTCTCCGGTCTTGAAGATCTCCCGGCTCTCTCGAA 184  
QY 931 CTAACAC 937  
Db 183 GGAGCAC 177

## RESULT 28

US-10-410-913-7/c  
; Sequence 7, Application US/10410913  
; Publication No. US20040142856A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bove, Caryn  
; TITLE OF INVENTION: GLYCOCOCNUJGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
; FILE REFERENCE: 040853-01-5081  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7

```
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match          0.5%; Score 17.4; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    |||||
Db 243 AGAAATCCAGAACAGCTTCGTCTCTCCGGTCTCTTGAAGATCTCCCGGGCTCTCTCGAA 184
    |||||

QY 931 CTAACAC 937
    |||||
Db 183 GGAGCAC 177

RESULT 29
US-10-375-741-13/c
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match          0.5%; Score 17.4; DB 1; Length 1440;
Best Local Similarity 53.7%; Pred. No. 28;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    |||||
Db 344 AGAAATCCAGAACAGCTTCGTCTCTCCGGTCTCTTGAAGATCTCCCGGGCTCTCTCGAA 285
    |||||

QY 931 CTAACAC 937
    |||||
Db 284 GGAGCAC 278

RESULT 30
US-10-617-619-12/c
; Sequence 12, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
```

```
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match          0.5%; Score 17.4; DB 1; Length 2040;
Best Local Similarity 53.7%; Pred. No. 24;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    |||||
Db 243 AGAAATCCAGAACAGCTTCGTCTCTCCGGTCTCTTGAAGATCTCCCGGGCTCTCTCGAA 184
    |||||

QY 931 CTAACAC 937
    |||||
Db 183 GGAGCAC 177

RESULT 31
US-10-617-619-9/c
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match          0.5%; Score 17.4; DB 1; Length 2106;
Best Local Similarity 53.7%; Pred. No. 23;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTAATGCTGAAGAGCTGAAGTTGAACGGTCTTATGAAGACCTTACAGACCTTTTAGAA 930
    |||||
Db 309 AGAAATCCAGAACAGCTTCGTCTCTCCGGTCTCTTGAAGATCTCCCGGGCTCTCTCGAA 250
    |||||

QY 931 CTAACAC 937
    |||||
Db 249 GGAGCAC 243

RESULT 32
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
```



```

; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annonmax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match 0.5%; Score 17.1; DB 1; Length 222;
Best Local Similarity 47.1%; Pred. No. 8;
Matches 82; Conservative 0; Mismatches 89; Indels 3; Gaps 1;

QY 11 GCGGAGTGGAGGAGTACCTCGTCCAGGTAAGGACAGTAGCT---GCGCTT 67
Db 2 GCTGAGGAGTCCCTGGTTCATCAGCCGGGGCAGCTTGAGGACCATGAGCTCCAGGGCG 61

QY 68 TGTGTGAGCAGCGCGTAAAGAGATACCCACGCGCCCAAGTAAAGAAACCCCAAGTAAGATG 127
Db 62 TGGCGCCAGCGTCCAGCAGCTGCGCCCGCCAGCGCTGACCAATGAGAAGCGCAGAGGCCA 121

QY 128 GTAGGTGTTGTGAGGGGATCAGAGGGGAGGAGGAGCATCTGAAACCATACACCGAG 181
Db 122 GCGTCTCTCAGAGAACTCCGTTCCGGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 175

RESULT 33
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)---(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match 0.5%; Score 17; DB 1; Length 483;
Best Local Similarity 59.2%; Pred. No. 21;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1458 CCCCATGGAAGAAGATGCAAAAAGCAAAATGCTGTCTCGGGAGGCC 1506
```

```

Db 246 CTCCTCGAGGAGGAGTGCAGGAGGAGGAGGAGTCTCTCTTCGAGGAGGCC 294

RESULT 34
US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annonmax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

Query Match 0.5%; Score 17; DB 1; Length 555;
Best Local Similarity 44.1%; Pred. No. 24;
Matches 71; Conservative 0; Mismatches 90; Indels 0; Gaps 0;

QY 20 AGGAGGAGTACCTACCTCGTCCAGGTAAGGAGGAGGAGTACGCTGCGCTTTGCTGGAGCAG 79
Db 434 AGAAATGGCCACAGCCCATCCCATCCACAGGGGTGAGGTGGCAGGTGGTGGAAAGG 375

QY 80 CGTAAAGAGATACCCACGCGCCCAAGGTAAGAGAAACCCCAAGTAAGATGTTAGTGTGTG 139
Db 374 CTTGAGGGGGGCTTCTTCCTCCAGGCGAGCAGACCTCAGGAGCAGCAGCGGGATGAG 315

QY 140 AGAGGGCATCAGAGGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 180
Db 314 CAGAGCGCGGGGTGGCGGAGGTATCATATCCCGAGCAGCGTA 274

RESULT 35
US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
```

; NAME/KEY: misc feature  
; LOCATION: (1)- (483)  
; OTHER INFORMATION: n = A,T,C or G  
US-09-918-995-8429

Query Match 0.5%; Score 16.6; DB 1; Length 483;  
Best Local Similarity 64.1%; Pred. No. 32;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 44 AGGTAGGAGGAGTGGCTTGGTGGAGGAGCCGT 82  
DB 421 AGATATAGGAGTGGCTTGGTGGAGGAGCCCAT 383

## RESULT 36

US-10-272-665-107  
; Sequence 107, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P

; FILE REFERENCE: 24736-2033E

; CURRENT APPLICATION NUMBER: US/10/272,665

; CURRENT FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 09/663,968

; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 107

; LENGTH: 100

; TYPE: DNA

; ORGANISM: Homo sapien

US-10-272-665-107

Query Match 0.4%; Score 14.8; DB 1; Length 100;  
Best Local Similarity 59.5%; Pred. No. 49;  
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGATGTGTCTCCACTGGAGAGGGAATGCAACCACTTCAG 333  
DB 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCACTACCG 53

## RESULT 37

US-10-273-321-107  
; Sequence 107, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P

; FILE REFERENCE: 24736-2033B

; CURRENT APPLICATION NUMBER: US/10/273,321

; CURRENT FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 09/663,968

; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 107  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-107

Query Match 0.4%; Score 14.8; DB 1; Length 100;  
Best Local Similarity 59.5%; Pred. No. 49;  
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGATGTGTCTCCACTGGAGAGGGAATGCAACCACTTCAG 333  
DB 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCACTACCG 53

## RESULT 38

US-10-272-756-107

; Sequence 107, Application US/10272756

; Publication No. US20030190644A1

; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P

; FILE REFERENCE: 24736-2033C

; CURRENT APPLICATION NUMBER: US/10/272,756

; CURRENT FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 09/663,968

; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 107

; LENGTH: 100

; TYPE: DNA

; ORGANISM: Homo sapien

US-10-272-756-107

Query Match 0.4%; Score 14.8; DB 1; Length 100;  
Best Local Similarity 59.5%; Pred. No. 49;  
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGATGTGTCTCCACTGGAGAGGGAATGCAACCACTTCAG 333  
DB 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCACTACCG 53

## RESULT 39

US-10-273-228-107

; Sequence 107, Application US/10273228

; Publication No. US20030207297A1

; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P

; FILE REFERENCE: 24736-2033D

; CURRENT APPLICATION NUMBER: US/10/273,228

; CURRENT FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

```
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match
Best Local Similarity 0.4%; Score 14.8; DB 1; Length 100;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 292 CAGAAATGTCCTGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTACG 53

RESULT 40
US-10-272-665-106
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 100;
Matches 24; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 292 CAGAAATGTCCTGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTAC 51

RESULT 41
US-10-273-321-106
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
```

```
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 100;
Matches 24; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 292 CAGAAATGTCCTGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTAC 51

RESULT 42
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match
Best Local Similarity 0.4%; Score 14.4; DB 1; Length 100;
Matches 24; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 292 CAGAAATGTCCTGAGAGGGAATGCAAACTTC 331
Db 12 CTGCAAGGGGACAGTGGAGGCCACATGCCACCTAC 51

RESULT 43
US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
```

; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-106

Query Match 0.4%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 60.0%; Pred. No. 78;  
Matches 24; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 292 CAGAATGTGTCCTCACTGGAGGGAATGCAACCACTTC 331  
DB 12 CTCGAGGGGACAGTGGAGGCCCATGCCCACCACTAC 51

## RESULT 44

US-10-398-422A-20  
; Sequence 20, Application US/10398422A  
; Publication No. US20040058413A1  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else Marie  
; APPLICANT: Nielsen, Lars Soegaard  
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins  
; FILE REFERENCE: 6270.204-US  
; CURRENT FILING DATE: 2003-09-02

; PRIOR APPLICATION NUMBER: US/10/398,422A  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456  
; PRIOR FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262  
; PRIOR FILING DATE: 2001-02-16  
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430  
; PRIOR FILING DATE: 2001-03-14  
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751  
; PRIOR FILING DATE: 2001-05-14  
; PRIOR APPLICATION NUMBER: US 60/238,944  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/271,581  
; PRIOR FILING DATE: 2001-02-26  
; PRIOR APPLICATION NUMBER: US 60/276,322  
; PRIOR FILING DATE: 2001-03-16  
; PRIOR APPLICATION NUMBER: PCT/DK01/00635  
; PRIOR FILING DATE: 2001-10-02  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 20  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: synthetic  
US-10-398-422A-20

Query Match 0.4%; Score 14.2; DB 1; Length 38;  
Best Local Similarity 84.2%; Pred. No. 33;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 63 CGCTTTGCTGGAGCAGCG 81  
DB 15 CGCTTCTCTGGAGAGCTG 33

## RESULT 45

US-09-969-357-2  
; Sequence 2, Application US/09969357  
; Publication No. US20020137673A1  
; GENERAL INFORMATION:  
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.  
; APPLICANT: Pingel, Hans K  
; APPLICANT: Klausen, Niels K  
; TITLE OF INVENTION: Factor VII Glycoforms  
; FILE REFERENCE: 6207.510-US  
; CURRENT FILING DATE: 2002-10-02

; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456  
; PRIOR FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262  
; PRIOR FILING DATE: 2001-02-16  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430  
; PRIOR FILING DATE: 2001-03-14  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751  
; PRIOR FILING DATE: 2001-05-14  
; PRIOR APPLICATION NUMBER: US 60/238,944  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/271,581  
; PRIOR FILING DATE: 2001-02-26  
; PRIOR APPLICATION NUMBER: US 60/276,322  
; PRIOR FILING DATE: 2001-03-16  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 2  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-969-357-2

Query Match 0.4%; Score 14.2; DB 1; Length 38;  
Best Local Similarity 84.2%; Pred. No. 33;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 63 CGCTTTGCTGGAGCAGCG 81  
DB 15 CGCTTCTCTGGAGAGCTG 33

## RESULT 46

US-10-254-394-2  
; Sequence 2, Application US/10254394  
; Publication No. US20030096368A1  
; GENERAL INFORMATION:  
; APPLICANT: Knudsen, Ida Molgaard  
; TITLE OF INVENTION: Method for Production of Recombinant  
; FILE REFERENCE: 6480.500-US  
; CURRENT FILING DATE: 2002-09-25  
; PRIOR APPLICATION NUMBER: PCT/DK01/00632  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PCT/DK01/00634  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PA 2002 00460  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: 60/374,855  
; PRIOR FILING DATE: 2002-10-04  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-254-394-2

Query Match 0.4%; Score 14.2; DB 1; Length 38;  
Best Local Similarity 84.3%; Pred. No. 33;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 63 CGCTTTGCTGGAGCAGCCG 81  
Db 15 CGCTTTCTGGAGGAGCTG 33

## RESULT 47

US-10-272-665-22  
; Sequence 22, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-272-665-22

Query Match 0.4%; Score 13.2; DB 1; Length 60;  
Best Local Similarity 83.3%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675  
Db 14 GGATGGCAGCAAGGACTC 31

## RESULT 48

US-10-273-321-22  
; Sequence 22, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22

; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-273-321-22

Query Match 0.4%; Score 13.2; DB 1; Length 60;  
Best Local Similarity 83.3%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675  
Db 14 GGATGGCAGCAAGGACTC 31

## RESULT 49

US-10-272-756-22  
; Sequence 22, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-272-756-22

Query Match 0.4%; Score 13.2; DB 1; Length 60;  
Best Local Similarity 83.3%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675  
Db 14 GGATGGCAGCAAGGACTC 31

## RESULT 50

US-10-273-228-22  
; Sequence 22, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033D  
; CURRENT APPLICATION NUMBER: US/10/273,228  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-273-228-22

Query Match 0.4%; Score 13.2; DB 1; Length 60;  
Best Local Similarity 83.3%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2658 GGATGGCATCTGACTC 2675  
|||||  
Db 14 GGATGGCAGCAAGACTC 31

## RESULT 51

US-10-272-665-106/c  
; Sequence 106, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-665-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;  
Best Local Similarity 69.2%; Pred. No. 2.6e+02;  
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2597 CCTGTGCTGGGAGGATGGGCC 2622  
|||||  
Db 56 CCTGTGTAGTGGTGGCATGTGGCC 31

## RESULT 52

US-10-273-321-106/c  
; Sequence 106, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;  
Best Local Similarity 69.2%; Pred. No. 2.6e+02;  
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2597 CCTGTGCTGGGAGGATGGGCC 2622  
|||||  
Db 56 CCTGTGTAGTGGTGGCATGTGGCC 31

## RESULT 53

US-10-272-756-106/c  
; Sequence 106, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-756-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;  
Best Local Similarity 69.2%; Pred. No. 2.6e+02;  
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2597 CCTGTGCTGGGAGGATGGGCC 2622  
|||||  
Db 56 CCTGTGTAGTGGTGGCATGTGGCC 31

## RESULT 54

US-10-273-228-106/c  
; Sequence 106, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P  
; FILE REFERENCE: 24736-2033D

; CURRENT APPLICATION NUMBER: US/10/273,228  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-106

Query Match 0.4%; Score 13.2; DB 1; Length 100;  
Best Local Similarity 59.2%; Pred. No. 2.6e-02;  
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2597 CCTGATGCTGGGAGGATGGGGC 2622  
Db 56 CCTGTGAGGGGTGCGATGGGGC 31

RESULT 55  
US-10-272-665-22/c  
; Sequence 22, Application US/10/272,665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO

; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-272-665-22

Query Match 0.4%; Score 13; DB 1; Length 60;  
Best Local Similarity 59.5%; Pred. No. 2.2e+02;  
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 1954 CTGGAAGAACACAAAGCTGGAATCAAGATTGCCGGA 1990  
Db 38 CTTCAGAGTCTTCTGCTCCATCCGAGTAGCGGCA 2

RESULT 56  
US-10-273-321-22/c  
; Sequence 22, Application US/10/273,321  
; Publication No. US20030180749A1

; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-273-321-22

Query Match 0.4%; Score 13; DB 1; Length 60;  
Best Local Similarity 59.5%; Pred. No. 2.2e+02;  
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 1954 CTGGAAGAACACAAAGCTGGAATCAAGATTGCCGGA 1990  
Db 38 CTTCAGAGTCTTCTGCTCCATCCGAGTAGCGGCA 2

RESULT 57  
US-10-272-756-22/c  
; Sequence 22, Application US/10/272,756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-272-756-22

Query Match 0.4%; Score 13; DB 1; Length 60;  
Best Local Similarity 59.5%; Pred. No. 2.2e+02;  
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 1954 CTGGAAGAACACAAAGCTGGAATCAAGATTGCCGGA 1990  
Db 38 CTTCAGAGTCTTCTGCTCCATCCGAGTAGCGGCA 2



Db 38 CTTCGAGGAGTCTTCTGCTCCATCCAGTAGCGCGCA 2

## RESULT 58

US-10-273-228-22/c

; Sequence 22, Application US/10273228

; Publication No. US20030207297A1

; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

; FILE REFERENCE: 24736-2033D

; CURRENT APPLICATION NUMBER: US/10/273,228

; PRIOR FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 09/663,968

; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 22

; LENGTH: 60

; TYPE: DNA

; ORGANISM: Homo sapien

; FEATURE:

; OTHER INFORMATION: Probe

US-10-273-228-22

Query Match 0.4%; Score 13; DB 1; Length 60;

Best Local Similarity 59.5%; Pred. No. 2.2e+02;

Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 1954 CTGAGAGACCAAGCTGATCAAGATTGCGGGA 1990

Db 38 CTTCGAGGAGTCTTCTGCTCCATCCAGTAGCGCGCA 2

## RESULT 59

US-10-272-665-107/c

; Sequence 107, Application US/10272665

; Publication No. US20030180748A1

; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

; FILE REFERENCE: 24736-2033E

; CURRENT APPLICATION NUMBER: US/10/272,665

; PRIOR FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 09/663,968

; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 107

; LENGTH: 100

; TYPE: DNA

; ORGANISM: Homo sapien

US-10-272-665-107

Query Match 0.4%; Score 12.8; DB 1; Length 100;

Best Local Similarity 48.6%; Pred. No. 3.5e+02;  
Matches 35; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2680 GACGTGAGTCTGGGTGAACCTCTGGAGTTGGTATGGACAGGAGGCTCTCTCTCGCGCG 2739

Db 76 GATGCCCGTCAGGTACCAACGTGCCCGGTAGTGGTGGCATGTGGGCTCTCCACTGTCCCC 19

QY 2740 ATTATGGGGTC 2751

Db 18 CTTCGAGGAGTC 7

## RESULT 60

US-10-273-321-107/c

; Sequence 107, Application US/10273321

; Publication No. US20030180749A1

; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P

; FILE REFERENCE: 24736-2033B

; CURRENT APPLICATION NUMBER: US/10/273,321

; PRIOR FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 09/663,968

; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 107

; LENGTH: 100

; TYPE: DNA

; ORGANISM: Homo sapien

US-10-273-321-107

Query Match 0.4%; Score 12.8; DB 1; Length 100;

Best Local Similarity 48.6%; Pred. No. 3.5e+02;

Matches 35; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2680 GACGTGAGTCTGGGTGAACCTCTGGAGTTGGTATGGACAGGAGGCTCTCTCTCGCGCG 2739

Db 76 GATGCCCGTCAGGTACCAACGTGCCCGGTAGTGGTGGCATGTGGGCTCTCCACTGTCCCC 19

QY 2740 ATTATGGGGTC 2751

Db 18 CTTCGAGGAGTC 7

## RESULT 61

US-10-272-756-107/c

; Sequence 107, Application US/10272756

; Publication No. US20030190644A1

; GENERAL INFORMATION:

; APPLICANT: Braun et al.

; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P

; FILE REFERENCE: 24736-2033C

; CURRENT APPLICATION NUMBER: US/10/272,756

; PRIOR FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 09/687,483

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658

; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13

; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10

```
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match      0.4%; Score 12.8; DB 1; Length 100;
Best Local Similarity 48.6%; Pred. No. 3.5e+02;
Matches 35; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2680 GACGTGAGTCTGGTGAACCTCTGGAGTTGGTGATGGACAGGAGCCCTGCTCGGGG 2739
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 78 GATGCCCGTCAGTACCACGTGCCCCGGTAGTGGGTGGCATGTGGGCTCCACTGTCCCC 19

QY 2740 ATTCATGGGGTC 2751
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 18 CTTGCAGGAGTC 7

RESULT 62
US-10-273-228-107/c
; Sequence 107, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.4%; Score 12.8; DB 1; Length 100;
Best Local Similarity 48.6%; Pred. No. 3.5e+02;
Matches 35; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2680 GACGTGAGTCTGGTGAACCTCTGGAGTTGGTGATGGACAGGAGCCCTGCTCGGGG 2739
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 78 GATGCCCGTCAGTACCACGTGCCCCGGTAGTGGGTGGCATGTGGGCTCCACTGTCCCC 19

QY 2740 ATTCATGGGGTC 2751
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 18 CTTGCAGGAGTC 7

RESULT 63
US-10-017-122-4/c
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: NMI-007
```

```
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match      0.4%; Score 12.6; DB 1; Length 31;
Best Local Similarity 66.7%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 737 GAGTAGCCATCATGGTCAACAAAGAG 763
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 27 GAGTACCCCTCATGGCACCAGGAG 1

RESULT 64
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match      0.4%; Score 12.6; DB 1; Length 38;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2331 GCCCATCTAGTCAAGGCTATGTTT 2357
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 37 GCCGAGCTCTCCAGGAAGCGTTT 11

RESULT 65
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
```

```

; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-969-357-2
;
Query Match 0.4%; Score 12.6; DB 1; Length 38;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2331 GCCCATCTAGTCAAGGCTATGGTTT 2357
DB 37 GCCGAGCTCTCTCCAGGAAGCGTTT 11

RESULT 66
US-10-254-394-2/c
; Sequence 2, Application US/10254394
; Publication No. US20030096366A1
; GENERAL INFORMATION:
; APPLICANT: Krudsen, Ida Mølgård
; TITLE OF INVENTION: Method for Production of Recombinant
; FILE REFERENCE: 6480.500-US
; CURRENT APPLICATION NUMBER: US/10/254,394
; CURRENT FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: PCT/DK01/00632
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PCT/DK01/00634
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PA 2002 00460
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: 60/374,855
; PRIOR FILING DATE: 2002-10-04
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-254-394-2
;
Query Match 0.4%; Score 12.6; DB 1; Length 38;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 18; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2331 GCCCATCTAGTCAAGGCTATGGTTT 2357
DB 37 GCCGAGCTCTCTCCAGGAAGCGTTT 11

RESULT 67
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8
;
Query Match 0.3%; Score 12.4; DB 1; Length 42;
Best Local Similarity 63.3%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2597 CCTGATCTCGGAGGATTGGGGCAGGA 2626
DB 12 CCAGGCTCTGGGACGGAGCTCCTCCAGGA 41

RESULT 68
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8
;
Query Match 0.3%; Score 12.4; DB 1; Length 42;
Best Local Similarity 63.3%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2597 CCTGATCTCGGAGGATTGGGGCAGGA 2626
DB 12 CCAGGCTCTGGGACGGAGCTCCTCCAGGA 41

RESULT 69
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Sequence 23, Application US/10272665
```

```
Publication No. US20030180748A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
FILE REFERENCE: 24736-2033E
CURRENT APPLICATION NUMBER: US/10/272,665
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 09/663,968
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 23
LENGTH: 60
TYPE: DNA
ORGANISM: Homo sapien
US-10-272-665-23

Query Match
Best Local Similarity 0.3%; Score 12.4; DB 1; Length 60;
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 2675 CGATGGAGTGTCTGGTGAACCTCTGGAGTTGGTG 2712
DB 39 CGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2

RESULT 70
US-10-273-321-23/c
Sequence 23, Application US/10273321
Publication No. US20030180749A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
FILE REFERENCE: 24736-2033B
CURRENT APPLICATION NUMBER: US/10/273,321
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 23
LENGTH: 60
TYPE: DNA
ORGANISM: Homo sapien
US-10-273-321-23

Query Match
Best Local Similarity 0.3%; Score 12.4; DB 1; Length 60;
Matches 22; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2675 CGATGGAGTGTCTGGTGAACCTCTGGAGTTGGTG 2712
DB 39 CGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2

Publication No. US20030180748A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
FILE REFERENCE: 24736-2033E
CURRENT APPLICATION NUMBER: US/10/272,665
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 09/663,968
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 23
LENGTH: 60
TYPE: DNA
ORGANISM: Homo sapien
US-10-272-665-23

Query Match
Best Local Similarity 0.3%; Score 12.4; DB 1; Length 60;
Matches 22; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 2675 CGATGGAGTGTCTGGTGAACCTCTGGAGTTGGTG 2712
DB 39 CGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2

RESULT 70
US-10-273-321-23/c
Sequence 23, Application US/10273321
Publication No. US20030180749A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
FILE REFERENCE: 24736-2033B
CURRENT APPLICATION NUMBER: US/10/273,321
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 23
LENGTH: 60
TYPE: DNA
ORGANISM: Homo sapien
US-10-273-321-23

Query Match
Best Local Similarity 0.3%; Score 12.4; DB 1; Length 60;
Matches 22; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2675 CGATGGAGTGTCTGGTGAACCTCTGGAGTTGGTG 2712
DB 39 CGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2
```

```
US-10-272-756-23/c
Sequence 23, Application US/10272756
Publication No. US20030190644A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
FILE REFERENCE: 24736-2033C
CURRENT APPLICATION NUMBER: US/10/272,756
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 09/663,968
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 23
LENGTH: 60
TYPE: DNA
ORGANISM: Homo sapien
US-10-272-756-23

Query Match
Best Local Similarity 0.3%; Score 12.4; DB 1; Length 60;
Matches 22; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2675 CGATGGAGTGTCTGGTGAACCTCTGGAGTTGGTG 2712
DB 39 CGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2

RESULT 72
US-10-273-228-23/c
Sequence 23, Application US/10273228
Publication No. US20030207297A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
FILE REFERENCE: 24736-2033D
CURRENT APPLICATION NUMBER: US/10/273,228
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: 09/687,483
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/217,658
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 60/159,176
PRIOR FILING DATE: 1999-10-13
PRIOR APPLICATION NUMBER: 60/217,251
PRIOR FILING DATE: 2000-07-10
PRIOR APPLICATION NUMBER: 09/663,968
PRIOR FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 23
LENGTH: 60
TYPE: DNA
ORGANISM: Homo sapien
US-10-273-228-23

Query Match
Best Local Similarity 0.3%; Score 12.4; DB 1; Length 60;
Matches 22; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2675 CGATGGAGTGTCTGGTGAACCTCTGGAGTTGGTG 2712
DB 39 CGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2
```

Db 39 CGATGCCGTCAGGTACACAGTGCCTGGTGGTG 2

RESULT 73  
US-10-029-386-23323/c  
; Sequence 23323, Application US/10029386  
; Publication No. US20030194704A1  
; GENERAL INFORMATION:  
; APPLICANT: Penn, Sharon G.  
; APPLICANT: Rank, David R.  
; APPLICANT: Hanzel, David K.  
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G  
; FILE REFERENCE: ABOMICA-X-2  
; CURRENT APPLICATION NUMBER: US/10/029,386  
; CURRENT FILING DATE: 2001-12-20  
; NUMBER OF SEQ ID NOS: 34288  
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1  
; SEQ ID NO 23323  
; LENGTH: 222  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: MAP TO CHR13.3  
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7  
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1  
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46  
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2  
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95  
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3  
; OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122  
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26  
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37  
US-10-029-386-23323

Query Match 0.3%; Score 12.2; DB 1; Length 222;  
Best Local Similarity 50.9%; Pred. No. 2.3e-02;  
Matches 29; Conservative 28; Mismatches 28; Indels 0; Gaps 0;

OY 2649 GAGATGGCTGGATGTCATCAGTCGATGCTGGTGAATCTCTGGA 2705  
Db 129 GAGGACGCTGGCTTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGGA 73

RESULT 74  
US-09-951-121A-8/c  
; Sequence 8, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 8  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-8

Query Match 0.3%; Score 11.8; DB 1; Length 36;  
Best Local Similarity 86.7%; Pred. No. 4.8e-02;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 999 ACCTGGAGTAAACAGG 1013  
Db 23 ACCTGGAGCACCAGG 9

RESULT 75  
US-09-951-121A-9  
; Sequence 9, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 9  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-9

Query Match 0.3%; Score 11.8; DB 1; Length 36;  
Best Local Similarity 86.7%; Pred. No. 4.8e-02;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 999 ACCTGGAGTAAACAGG 1013  
Db 23 ACCTGGAGCACCAGG 9

RESULT 76  
US-10-255-032-8/c  
; Sequence 8, Application US/10255032  
; Publication No. US20030100075A1  
; GENERAL INFORMATION:  
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S  
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES  
; FILE REFERENCE: 6357-WO  
; CURRENT APPLICATION NUMBER: US/10/255,032  
; CURRENT FILING DATE: 2002-09-24  
; PRIOR APPLICATION NUMBER: DK PA 2001 01413  
; PRIOR FILING DATE: 2001-09-27  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 8  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII  
US-10-255-032-8

Query Match 0.3%; Score 11.8; DB 1; Length 36;  
Best Local Similarity 86.7%; Pred. No. 4.8e-02;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 999 ACCTGGAGTAAACAGG 1013  
Db 23 ACCTGGAGCACCAGG 9

RESULT 77  
US-10-255-032-9  
; Sequence 9, Application US/10255032

; Publication No. US20030100075A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: NO. US20030100075A1c No. US20030100075A1disk A/S  
 ; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES  
 ; FILE REFERENCE: 6357-WO  
 ; CURRENT APPLICATION NUMBER: US/10/255,032  
 ; CURRENT FILING DATE: 2002-09-24  
 ; PRIOR APPLICATION NUMBER: DK PA 2001 01413  
 ; PRIOR FILING DATE: 2001-09-27  
 ; NUMBER OF SEQ ID NOS: 9  
 ; SOFTWARE: Patent in version 3.1  
 ; SEQ ID NO 9  
 ; LENGTH: 36  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic  
 ; US-10-295-682-9

Query Match 0.3%; Score 11.8; DB 1; Length 36;  
 Best Local Similarity 86.7%; Pred. No. 4.8e+02;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013  
 Db 14 ACCTGGAGCACCAGG 28

## RESULT 78

US-10-295-682-8/c  
 ; Sequence 8, Application US/10295682  
 ; Publication No. US20030100740A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Persson, Egon  
 ; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
 ; FILE REFERENCE: 6224.200-US  
 ; CURRENT APPLICATION NUMBER: US/10/295,682  
 ; CURRENT FILING DATE: 2002-11-15  
 ; PRIOR APPLICATION NUMBER: PA 2000 01361  
 ; PRIOR FILING DATE: 2000-09-13  
 ; PRIOR APPLICATION NUMBER: 60/236,455  
 ; PRIOR FILING DATE: 2000-09-29  
 ; NUMBER OF SEQ ID NOS: 17  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 8  
 ; LENGTH: 36  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic  
 ; US-10-295-682-8

Query Match 0.3%; Score 11.8; DB 1; Length 36;  
 Best Local Similarity 86.7%; Pred. No. 4.8e+02;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013  
 Db 23 ACCTGGAGCACCAGG 9

## RESULT 79

US-10-295-682-9  
 ; Sequence 9, Application US/10295682  
 ; Publication No. US20030100740A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Persson, Egon  
 ; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
 ; FILE REFERENCE: 6224.200-US  
 ; CURRENT APPLICATION NUMBER: US/10/295,682  
 ; CURRENT FILING DATE: 2002-11-15

; PRIOR APPLICATION NUMBER: PA 2000 01361  
 ; PRIOR FILING DATE: 2000-09-13  
 ; PRIOR APPLICATION NUMBER: 60/236,455  
 ; PRIOR FILING DATE: 2000-09-29  
 ; NUMBER OF SEQ ID NOS: 17  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 9  
 ; LENGTH: 36  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic  
 ; US-10-295-682-9

Query Match 0.3%; Score 11.8; DB 1; Length 36;  
 Best Local Similarity 86.7%; Pred. No. 4.8e+02;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 ACCTGGAGTAAACAGG 1013  
 Db 14 ACCTGGAGCACCAGG 28

## RESULT 80

US-09-803-810-8/c  
 ; Sequence 8, Application US/09803810  
 ; Publication No. US20010018414A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Nelsestuen, Gary L.  
 ; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
 ; FILE REFERENCE: 09531/002001  
 ; CURRENT APPLICATION NUMBER: US/09/803,810  
 ; CURRENT FILING DATE: 2001-03-12  
 ; NUMBER OF SEQ ID NOS: 18  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 8  
 ; LENGTH: 42  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
 ; US-09-803-810-8

Query Match 0.3%; Score 11.8; DB 1; Length 42;  
 Best Local Similarity 69.6%; Pred. No. 5.4e+02;  
 Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1192 TGGAGAGCTCTATACAGTCAGC 1214  
 Db 38 TGGAGAGCTCCGTCCCGCAGCAGC 16

## RESULT 81

US-10-298-330-8/c  
 ; Sequence 8, Application US/10298330  
 ; Publication No. US20030100506A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Nelsestuen, Gary L.  
 ; TITLE OF INVENTION: Modified Vitamin K-Dependent  
 ; FILE REFERENCE: 09531-127001  
 ; CURRENT APPLICATION NUMBER: US/10/298,330  
 ; CURRENT FILING DATE: 2002-11-18  
 ; PRIOR APPLICATION NUMBER: 09/497,591  
 ; PRIOR FILING DATE: 2000-02-03  
 ; PRIOR APPLICATION NUMBER: 09/302,239  
 ; PRIOR FILING DATE: 1999-04-29  
 ; PRIOR APPLICATION NUMBER: 08/955,636  
 ; PRIOR FILING DATE: 1997-10-23  
 ; NUMBER OF SEQ ID NOS: 27  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 8

```
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-951-121A-15
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 25 GGATGGCGGCAAGGACTC 8

RESULT 84
US-10-295-682-14
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 9 GGATGGCGGCAAGGACTC 26

RESULT 85
US-10-295-682-15/c
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 9 GGATGGCGGCAAGGACTC 26

RESULT 83
US-09-951-121A-15/c
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14
Query Match 0.3%; Score 11.6; DB 1; Length 33;
Best Local Similarity 77.8%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2658 GGATGGCATCACTGACTC 2675
Db 9 GGATGGCGGCAAGGACTC 26

RESULT 82
US-09-951-121A-14
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14
Query Match 0.3%; Score 11.8; DB 1; Length 42;
Best Local Similarity 69.6%; Pred. No. 5.4e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1192 TGGAGAGCTCTATACAGTCAGC 1214
Db 38 TGGAGGAGCTCCGTCCAGCAGC 16
```

```
QY 2658 GGATGGCCTCACTGACTC 2675
Db 25 GGATGGCGCAAGGACTC 8

RESULT 86
US-09-951-121A-14/c
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGCACAGAGTGAATGTCACATCTTAGGA 645
Db 32 TTGCAGAGTCTTGGCCCATCCGAGTA 4

RESULT 87
US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGCACAGAGTGAATGTCACATCTTAGGA 645
Db 2 TTGCAGAGTCTTGGCCCATCCGAGTA 30

RESULT 88
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGCACAGAGTGAATGTCACATCTTAGGA 645
Db 32 TTGCAGAGTCTTGGCCCATCCGAGTA 4

RESULT 89
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match 0.3%; Score 11.4; DB 1; Length 33;
Best Local Similarity 62.1%; Pred. No. 6.7e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 617 TGCACAGAGTGAATGTCACATCTTAGGA 645
Db 2 TTGCAGAGTCTTGGCCCATCCGAGTA 30

RESULT 90
US-10-349-858-8/c
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
```





; PRIOR FILING DATE: 2001-04-03  
; PRIOR APPLICATION NUMBER: PA 2001 00477  
; PRIOR FILING DATE: 2001-03-22  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 6  
; LENGTH: 35  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Nucleotide Primer  
US-10-109-498-6

Query Match 0.3%; Score 11; DB 1; Length 35;  
Best Local Similarity 53.0%; Pred. No. 9.4e+02;  
Matches 17; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 2625 GAGGAGAAGGGGACGACGAGGATGAG 2651  
|||||  
Db 8 GAGCACCACGGGACAGTGCAGGCGGAG 34  
|||||

## RESULT 95

US-10-272-665-23  
; Sequence 23, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

; TITLE OF INVENTION: GENETIC MARKERS  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien

US-10-272-665-23

Query Match 0.3%; Score 11; DB 1; Length 60;  
Best Local Similarity 53.5%; Pred. No. 8.1e+02;  
Matches 23; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 116 CCAAGTAAGATGTTGTTGTGAGAGGGCATCAGAGGGCAG 158  
|||||  
Db 11 CCGGGGCACGTGTTACCTGACGGGCATCTGCTGCTGGGGCCAG 53  
|||||

## RESULT 96

US-10-273-321-23  
; Sequence 23, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

; TITLE OF INVENTION: GENETIC MARKERS  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-23

Query Match 0.3%; Score 11; DB 1; Length 60;  
Best Local Similarity 53.5%; Pred. No. 8.1e+02;  
Matches 23; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 116 CCAAGTAAGATGTTGTTGTGAGAGGGCATCAGAGGGCAG 158  
|||||  
Db 11 CCGGGGCACGTGTTACCTGACGGGCATCTGCTGCTGGGGCCAG 53  
|||||

## RESULT 97

US-10-272-756-23  
; Sequence 23, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

; TITLE OF INVENTION: GENETIC MARKERS  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien

US-10-272-756-23

Query Match 0.3%; Score 11; DB 1; Length 60;  
Best Local Similarity 53.5%; Pred. No. 8.1e+02;  
Matches 23; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 116 CCAAGTAAGATGTTGTTGTGAGAGGGCATCAGAGGGCAG 158  
|||||  
Db 11 CCGGGGCACGTGTTACCTGACGGGCATCTGCTGCTGGGGCCAG 53  
|||||

## RESULT 98

US-10-273-228-23  
; Sequence 23, Application US/10273228  
; Publication No. US2003020297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC

; TITLE OF INVENTION: GENETIC MARKERS  
; FILE REFERENCE: 24736-2033D  
; CURRENT APPLICATION NUMBER: US/10/273,228

```
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23

Query Match          0.3%; Score 11; DB 1; Length 60;
Best Local Similarity 53.5%; Pred. No. 8.1e+02; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 116 CCAAGTAAGATGAGGTGTTGTGAGAGGGCATCAGAGGGCAG 158
Db 11 CCGGGCAGGTGTTACCTGACGGCATCGTCAGCTGGGGCCAG 53

RESULT 99
US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US2003020247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; PRIOR FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1998-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.3%; Score 10.6; DB 1; Length 54;
Best Local Similarity 64.0%; Pred. No. 9.2e+02; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 1172 ATATCTTTGCAGCCCAAGATGAG 1196
Db 1 AGAGTCTTCGTACCCAGGAGGAG 25

RESULT 100
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US

; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match          0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 2341 GTCAAGGCTATGTTTTCAGTGGTCA 2368
Db 36 GCCACGGCCCTGGTGTCTCCAGGTCTCA 9

RESULT 102
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DX PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patent in version 3.1
```

```
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGGTTTTCACAGTGGTCA 2368
Db      1 GCCACGGCCCTGGTCTCCAGGTCCTCA 28

RESULT 103
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGGTTTTCACAGTGGTCA 2368
Db      1 GCCACGGCCCTGGTCTCCAGGTCCTCA 28

RESULT 104
US-10-295-682-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGGTTTTCACAGTGGTCA 2368
Db      36 GCCACGGCCCTGGTCTCCAGGTCCTCA 9

RESULT 105
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2341 GTCACGGCTATGGTTTTCACAGTGGTCA 2368
Db      36 GCCACGGCCCTGGTCTCCAGGTCCTCA 9

RESULT 106
US-10-281-727-2
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match      0.3%; Score 10.4; DB 1; Length 36;
Best Local Similarity 55.6%; Pred. No. 1.3e+03;
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
```

QY 60 CTGCGCTTTGCTGGAGCAGCGCTAAAGAGATACCCC 95  
DB 1 CTGCGCTGACAGGACGACGCTGGGAGACTCCCC 36

## RESULT 107

US-10-281-727-2/c  
; Sequence 2, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE OF INVENTION: Polypeptides  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII

US-10-281-727-2

Query Match 0.3%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 55.6%; Pred. No. 1.3e+03;  
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2576 GAGCTGACTCATCGAAAGACCCCTGATGCTGGGAG 2611  
DB 36 GGGGAGCTCTCCACGTCGCGCTTCTCTGCTGCAGGCAG 1

## RESULT 108

US-10-281-727-3  
; Sequence 3, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE OF INVENTION: Polypeptides  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII

US-10-281-727-3

Query Match 0.3%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 55.6%; Pred. No. 1.3e+03;  
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2576 GAGCTGACTCATCGAAAGACCCCTGATGCTGGGAG 2611  
DB 1 GGGGAGCTCTCCACGTCGCGCTTCTCTGCTGCAGGCAG 36

## RESULT 109

US-10-281-727-3/c  
; Sequence 3, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE OF INVENTION: Polypeptides  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII

US-10-281-727-3

Query Match 0.3%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 55.6%; Pred. No. 1.3e+03;  
Matches 20; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 60 CTGCGCTTTGCTGGAGCAGCGCTAAAGAGATACCCC 95  
DB 36 CTGCGCTGACAGGACGACGCTGGGAGACTCCCC 1

## RESULT 110

US-10-109-498-5  
; Sequence 5, Application US/10109498  
; Publication No. US20030044908A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Coagulation Factor VII Derivatives  
; FILE REFERENCE: 6286.200-US  
; CURRENT APPLICATION NUMBER: US/10/109,498  
; CURRENT FILING DATE: 2002-03-22  
; PRIOR APPLICATION NUMBER: 60/281,261  
; PRIOR FILING DATE: 2001-04-03  
; PRIOR APPLICATION NUMBER: PA 2001 00477  
; PRIOR FILING DATE: 2001-03-22  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 5  
; LENGTH: 35  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Nucleotide Primer

US-10-109-498-5

Query Match 0.3%; Score 10; DB 1; Length 35;  
Best Local Similarity 61.5%; Pred. No. 1.4e+03;  
Matches 16; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 2451 CTGAGAGTCCCTTGGACTGCAAGGA 2476  
DB 8 CTGCACTGTCCCGTGTCTCTCACTGA 33

## RESULT 111

US-10-109-498-6/c  
; Sequence 6, Application US/10109498



; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-3

Query Match 0.3%; Score 9.8; DB 1; Length 34;  
Best Local Similarity 84.6%; Pred. No. 1.5e+03;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2200 TTTTGGGGGGCTC 2212  
||| |||||  
Db 29 TTGTGGGGGGCGC 17

RESULT 116  
US-10-017-122-4  
; Sequence 4, Application US/10017122  
; Publication No. US20030087244A1  
; GENERAL INFORMATION:  
; APPLICANT: McCarthy, Jeanette  
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE  
; FILE REFERENCE: WMI-007  
; CURRENT APPLICATION NUMBER: US/10/017,122  
; CURRENT FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: 60/327,487  
; PRIOR FILING DATE: 2001-10-09  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: Patent in Ver. 2.0  
; SEQ ID NO 4  
; LENGTH: 31  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-017-122-4

Query Match 0.3%; Score 9.2; DB 1; Length 31;  
Best Local Similarity 78.6%; Pred. No. 1.6e+03;  
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 570 TGTGAGTCCATGA 593  
||| |||||  
Db 5 TGTGAGTCCATGA 18

RESULT 117  
US-10-281-727-6/c  
; Sequence 6, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 6  
; LENGTH: 32  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII

US-10-281-727-6

Query Match 0.2%; Score 8.8; DB 1; Length 32;  
Best Local Similarity 83.3%; Pred. No. 1.6e+03;  
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3217 CAGCTTCAGTTC 3228  
||| |||||  
Db 23 CACCTTCGGTTC 12

RESULT 118  
US-10-281-727-7  
; Sequence 7, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 7  
; LENGTH: 32  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII  
US-10-281-727-7

Query Match 0.2%; Score 8.8; DB 1; Length 32;  
Best Local Similarity 83.3%; Pred. No. 1.6e+03;  
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3217 CAGCTTCAGTTC 3228  
||| |||||  
Db 10 CACCTTCGGTTC 21

RESULT 119  
US-09-951-121A-2/c  
; Sequence 2, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-2

Query Match 0.2%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 73.3%; Pred. No. 1.5e+03;

Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 246 CCGTGGGGCAACCC 260  
Db 33 CCTTGGGGCACACC 19

## RESULT 120

US-09-951-121A-3  
; Sequence 3, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-3

Query Match 0.2%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 73.3%; Pred. No. 1.5e+03;  
Matches 11; Conservative 0; Mismatches 4; Indels 0;

QY 246 CCGTGGGGCAACCC 260  
Db 2 CCTTGGGGCACACC 16

## RESULT 121

US-10-295-682-2/c  
; Sequence 2, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-2

Query Match 0.2%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 73.3%; Pred. No. 1.5e+03;  
Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 246 CCGTGGGGCAACCC 260  
Db 33 CCTTGGGGCACACC 19

## RESULT 122

US-10-295-682-3  
; Sequence 3, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-3

Query Match 0.2%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 73.3%; Pred. No. 1.5e+03;  
Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 246 CCGTGGGGCAACCC 260  
Db 2 CCTTGGGGCACACC 16

Search completed: August 9, 2004, 16:36:07  
Job time : 50 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:36:28 ; Search time 5 Seconds  
(without alignments)

3.936 Million cell updates/sec

Title: us-10-664-775-2  
Perfect score: 3572  
Sequence: 1 gtcaggagggcgccagtg.....gcaacacagcagaagctt 3572

Scoring table: IDENTITY NUC  
Gapop 10.0, Gapext 0.5

Searched: 4 segs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries

Database: rstdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description                 |
|------------|-------|-------------|--------|-------|-----------------------------|
| C 1        | 23.2  | 0.6         | 1201   | 1     | AL531727 ACCESSION:AL531727 |
| 2          | 21    | 0.6         | 609    | 1     | AI099321 ACCESSION:AI099321 |
| 3          | 21    | 0.6         | 645    | 1     | AI116939 ACCESSION:AI116939 |
| C 4        | 18.4  | 0.5         | 609    | 1     | AI099321 ACCESSION:AI099321 |
| 5          | 18.4  | 0.5         | 1201   | 1     | AL531727 ACCESSION:AL531727 |
| C 6        | 17.4  | 0.5         | 300    | 1     | AU099140 ACCESSION:AU099140 |
| C 7        | 17.2  | 0.5         | 645    | 1     | AI116939 ACCESSION:AI116939 |
| 8          | 17    | 0.5         | 300    | 1     | AU099140 ACCESSION:AU099140 |

#### ALIGNMENTS

RESULT 1  
AL531727/c 1201 bp mRNA linear EST 23-MAY-2003  
LOCUS  
DEFINITION  
AL531727 Homo sapiens FETAL LIVER EST 23-MAY-2003  
CSODM003Y101 5-PRIME, mRNA sequence.

ACCESSION  
AL531727  
VERSION  
AL531727.2 GI:31069559

KEYWORDS  
EST.

SOURCE  
Homo sapiens (human)

ORGANISM  
Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1. (bases 1 to 1201)

Li, W.B., Gruber, C., Jesse, J. and Polayes, D.

Full-length cDNA libraries and normalization

Unpublished (2001)

On Feb 13, 2001 this sequence version replaced gi:12795220.

Contact: Genoscope

Genoscope - Centre National de Sequencage

BP 191 91006 EVRY cedex - France

Email: segref@genoscope.cns.fr, Web : www.genoscope.cns.fr  
Library was constructed by Life Technologies, a division of  
Invitrogen. This sequence belongs to sequence cluster 7252.f For  
more information about this cluster, see

http://www.genoscope.cns.fr/  
cgi-bin/cluster.cgi?seq=CSODM003AE01QPI&cluster=7252.f. Contact :  
Feng Liang Email : fliang@lifetech.com URL :  
http://fulllength.invitrogen.com/Invitrogen Corporation 1600  
Paradise Avenue Genoscope sequence ID : CSODM003AE01QPI.

#### FEATURES

source

1..1201

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/clone="CSODM003Y101"

/tissue\_type="FETAL LIVER"

/dev\_stage="fetal"

/clone\_lib="Homo sapiens FETAL LIVER"

/note="Organ: liver; Vector: pCMVSPORT\_6; 1st strand cDNA  
was primed with a NotI-oligo(dT) primer. Five prime end  
enriched, double-strand cDNA was digested with Not I and  
cloned into the Not I and EcoRV sites of the pCMVSPORT 6  
vector. Library was not normalized."

Query Match 0.6%; Score 23.2; DB 1; Length 1201;

Best Local Similarity 40.0%; Pred. No. 0.17;

Matches 36; Conservative 17; Mismatches 37; Indels 0; Gaps 0;

QY 3192 CUTTAATTCATTCTTTGATAACAGCTTCAGTCTCTATGCTTTATAAAGTTTTTTT 3251

DB 1201 CCTTARRWYCTTTCCWTCRAWACCGMAAAATTTTCCTDWTGGATTCC 1142

QY 3252 TTTTCTTTTAAAGATGCTATTCTT 3281

DB 1141 CCTTCTTATTTGAGGADTCTGKTAT 1112

#### RESULT 2

AI099321

LOCUS

DEFINITION

AI099321

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (1996)

Contact: Marra M/Mouse EST Project

Washington University School

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: mouseest@watson.wustl.edu

This clone is available royalty-free through LNL ; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.

MGI:930865

Seq primer: custom primer used

High quality sequence stop: 289.

Location/Qualifiers

1..609

/organism="Mus musculus"

```

/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
(note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTTTTTTTTTTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTCG and 3' end
primer CGACTCGAGCTCGAGCACA."
Query Match 0.6%; Score 21; DB 1; Length 609;
Best Local Similarity 48.7%; Pred. No. 1.1;
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1390 GACAGAGTACCTATGAACATATGGACAGAGTTTCATGACATGTACAGGACAGGATC 1449
DB 73 GAGGAAGCACATGGTGTCTTACACAGGCAAGGCGTGCACACTCCTCTGGAGAGCTT 132
QY 1450 GAGACATCCCATCGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGGAGGCC 1506
DB 133 TGGCCCGCTCTCTGGAGAGAGTGCAATGAGGAACAGTGTCTCTTTGAGGAGGCC 189

RESULT 3
LOCUS A1116939 645 bp mRNA linear EST 02-SEP-1998
DEFINITION ue29g08.y1 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1481822 5', similar to gb:MI3232 COAGULATION FACTOR VII
PRECURSOR (HUMAN); mRNA sequence.
ACCESSION A1116939
VERSION A1116939.1 GI:3517263
KEYWORDS Mus musculus (house mouse)
SOURCE EST.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.
TITLE The WashU-HMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930178
Seq primer: custom primer used
High quality sequence stop: 483.
Location/Qualifiers
1..645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"

```

```

/db_xref="taxon:10090"
/clone="IMAGE:1481822"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
(note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTTTTTTTTTTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTCG and 3' end
primer CGACTCGAGCTCGAGCACA."
Query Match 0.6%; Score 21; DB 1; Length 645;
Best Local Similarity 48.7%; Pred. No. 1.1;
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1390 GACAGAGTACCTATGAACATATGGACAGAGTTTCATGACATGTACAGGACAGGATC 1449
DB 108 GAGGAAGCACATGGTGTCTTACACAGGCAAGGCGTGCACACTCCTCTGGAGAGCTT 167
QY 1450 GAGACATCCCATCGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGGAGGCC 1506
DB 168 TGGCCCGCTCTCTGGAGAGAGTGCAATGAGGAACAGTGTCTCTTTGAGGAGGCC 224

RESULT 4
LOCUS A1099321/c 609 bp mRNA linear EST 20-AUG-1998
DEFINITION ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1482509 5', similar to gb:MI3232 COAGULATION FACTOR VII
PRECURSOR (HUMAN); mRNA sequence.
ACCESSION A1099321
VERSION A1099321.1 GI:3448846
KEYWORDS Mus musculus (house mouse)
SOURCE EST.
ORGANISM Mus musculus
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.
TITLE The WashU-HMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.
Location/Qualifiers
1..609
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/clone="IMAGE:1482509"

```

```

/sex="female"
/dev_stages="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
(note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGG); Site 2: DraIII (CACCATGTG); 1st Strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTATTTTATTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [GTGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTTGTGCTCTAAAGCTGCG and 3' end
primer CGACCTCAGCTCGAGCA."
Query Match 0.5%; Score 18.4; DB 1; Length 609;
Best Local Similarity 49.0%; Pred. No. 4;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 799 GACGAGATGATCTCTGTTGTTTCCAGGCAACATTCATATCAAGTAATCAAGTC 858
DB 405 GTCACAGTCACCATTTTCATTTCACAGATCACTGTTTCATTCTGCTTCTCACAGTT 346

QY 859 TATGCCCAACAGTAATGCTGAAGAGCTGAAGTTGAAC 898
DB 345 CCGACCTCAAGTCTAGGAGCGAGACGACGTAAGAC 306

RESULT 5
AL531727 1201 bp mRNA linear EST 23-MAY-2003
LOCUS AL531727 Homo sapiens FETAL LIVER Homo sapiens cDNA clone
DEFINITION CS0DM003YI01 5-PRIME, mRNA sequence.
ACCESSION AL531727.2 GI:31069559
VERSION AL531727.2
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1201)
AUTHORS Li, W.B., Gruber, C., Jesses, J., and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On Feb 13, 2001 this sequence version replaced gi:12795220.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 7252.f For
more information about this cluster, see
http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CS0DM003AE01QPI&cluster=7252.f. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DM003AE01QPI.
FEATURES
Location/Qualifiers
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DM003YI01"
/tissue_type="FETAL LIVER"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/notes="Organ: liver; Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6

```

```

vector. Library was not normalized."
Query Match 0.5%; Score 18.4; DB 1; Length 1201;
Best Local Similarity 56.7%; Pred. No. 2;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1445 GGATCGAGACCATCCCATCGGAAAGAAATGCAAAAGCAAAATCGCTGTCTGGGAGG 1504
DB 610 CGAAAAATACCTATTCTAGAAAAAGAAATGCCAGCAACCCACAGGCCGAATTGTGGGG 669

RESULT 6
AU099140/c 300 bp mRNA linear EST 05-APR-2001
LOCUS AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HVII12463, mRNA sequence.
ACCESSION AU099140
VERSION AU099140.1 GI:13550269
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 300)
AUTHORS Suzuki, Y., Tsunoda, T., Taira, H., Mizushima-Sugano, J., Sese, J.,
Hata, H., Oka, T., Isogai, T., Tanaka, T., Nakamura, Y., Morishita, S.,
Okubo, K., Suyama, A. and Sugano, S.
TITLE In silico mapping of the 5'-ends of human mRNAs using full-length
enriched and 5'-end enriched cDNA libraries constructed by
Oligo-capping method
JOURNAL Unpublished (2001)
COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ims.u-tokyo.ac.jp
Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and
Sugano, S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
FEATURES
Location/Qualifiers
1..300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP20983"
/clone_lib="Sugano Homo sapiens cDNA library"

Query Match 0.5%; Score 17.4; DB 1; Length 300;
Best Local Similarity 53.7%; Pred. No. 12;
Matches 36; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 871 AGTATGCTGAGAGAGCTGAAGTTCGAGCGTCTTGAAGACCTTACAGACCTTTTAGAA 930
DB 277 AGAAATCCAGACAGCTTGTCTCTCGCGCTCTTGAAGATCTCCCGGCGCTCTCGAA 218

QY 931 CTAACAC 937
DB 217 CGAGCAC 211

RESULT 7
AU116939/c 645 bp mRNA linear EST 02-SEP-1998
LOCUS AU116939 ue29g08.v1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:1481822.5, similar to gb:U13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN);, mRNA sequence.
ACCESSION AU116939
VERSION AU116939.1 GI:3517263
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

```

10664775-2.rst

Mon Aug 9 17:46:54 2004

**TITLE** In silico mapping of the 5'-ends of human mRNAs using full-length enriched and 5'-end enriched cDNA libraries constructed by oligo-capping method  
**JOURNAL** Unpublished (2001)  
**COMMENT** Contact: Yutaka Suzuki  
 Department of Medical Science, University of Tokyo  
 Institute of Medical Science, University of Tokyo  
 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
 Email: ysuzuki@ims.u-tokyo.ac.jp  
 Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and Sugano, S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).

**FEATURES** Location/Qualifiers  
 source 1..300  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="HEP20983"  
 /clone\_lib="Sugano Homo sapiens cDNA library"

Query Match 0.5%; Score 17; DB 1; Length 300;  
 Best Local Similarity 59.2%; Pred. No. 13;  
 Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1458 CCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGGCC 1506  
 DB 181 CTCCTGGAGAGGAGTGCACAGGAGGAGCAGTGTCTCTCGAGGAGGCC 229

Search completed: August 9, 2004, 16:36:34  
 Job time: 6 secs

**REFERENCE**  
**AUTHORS** Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 645)  
 Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Stepien, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.  
**TITLE** The WashU-HHMI Mouse EST Project  
**JOURNAL** Unpublished (1996)  
**COMMENT** Contact: Marra M/Mouse EST Project  
 Washington University School of Medicine  
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
 Tel: 314 286 1800  
 Fax: 314 286 1810  
 Email: mouseest@watson.wustl.edu  
 This clone is available royalty-free through LLNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.  
 MGI:930178  
 Seq primer: custom primer used  
 High quality sequence stop: 483.

**FEATURES** Location/Qualifiers  
 source 1..645  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /strain="C57BL"  
 /db\_xref="taxon:10090"  
 /clone="IMAGE:1481822"  
 /sex="female"  
 /dev\_stage="adult"  
 /lab\_host="DH10B"  
 /clone\_lib="Sugano mouse liver mlia"  
 /note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII (CACTGTGTG); Site 2: DraIII (CACTGTGTG); 1st strand cDNA was primed with an oligo(dT) primer (ATGTGGCTTTTCTTTTCTTTT); Double-stranded cDNA was ligated to a DraIII adaptor (NGTGGCTACTGG), digested and cloned into distinct DraIII sites of the pME18S-FL3 vector (5' site CACTGTGTG, 3' site CACTGTGTG). XhoI should be used to isolate the cDNA insert. Size selection was performed to exclude fragments <1.5kb. Library constructed by Dr. Sumio Sugano (University of Tokyo Institute of Medical Science). Custom primers for sequencing: 5' end primer CTTCGTCTTAAAGCTCG and 3' end primer CGACTGCAGCTCGACACA."

Query Match 0.5%; Score 17.2; DB 1; Length 645;  
 Best Local Similarity 60.9%; Pred. No. 5.9;  
 Matches 28; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 1233 TTACTGTGCTCAGATCATGACTCTTATTCGCCAAATTCAGACTT 1278  
 DB 426 TTTCATTGCACAGATCAGCTCTCTCTCTCTCTCTCTCTCTCTCTCT 381

**RESULT 8**  
**LOCUS** AU099140  
**DEFINITION** AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone HEP20983 similar to Human factor VII serine protease precursor mRNA clone lambda-HV112463, mRNA sequence.  
**ACCESSION** AU099140  
**VERSION** AU099140.1 GI:13550269  
**KEYWORDS** EST.  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 300)  
**REFERENCE** Suzuki, Y., Tsunoda, T., Taira, H., Mizushima-Sugano, J., Sese, J., Hata, H., Ota, T., Isogai, T., Tanaka, T., Nakamura, Y., Morishita, S., Okubo, K., Suyama, A. and Sugano, S.

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.  
OM nucleic - nucleic search, using sw model  
Run on: August 9, 2004, 15:28:50 ; Search time 13 Seconds  
(without alignments)  
3.853 Million cell updates/sec  
Title: us-10-664-775-1  
Perfect score: 2715  
Sequence: 1 ctgaggaagagcgacagg.....ttgtaattctaggtgtgat 2715  
Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5  
Searched: 20 seqs, 9225 residues  
Total number of hits satisfying chosen parameters: 40  
Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries  
Database : ruidb:\*  
Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

ALIGNMENTS

RESULT 1  
US-07-882-202A-3/c  
; Sequence 3, Application US/07882202A  
; Patent No. 5374617  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified  
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA: US/07882,202A  
; APPLICATION NUMBER: US/07882,202A  
; FILING DATE: 13-MAY-1992  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRF B34290  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4500  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; OTHER INFORMATION: factor VII cDNA"  
US-07-882-202A-3  
Query Match 0.8%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 3.3;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 876 TTCATGTCCTTTTATCTGTCGACACTGCTTCCTTTTGAATATGATTCATTTGG 934  
DB 659 TTGCTGCACTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACCTGIG 601

SUMMARIES

| Result No. | Score | Match | Length | DB | ID               | Description       |
|------------|-------|-------|--------|----|------------------|-------------------|
| C 1        | 20.6  | 0.8   | 1440   | 1  | US-07-882-202A-3 | Sequence 3, Appli |
| C 2        | 20.6  | 0.8   | 1440   | 1  | US-08-021-615A-3 | Sequence 3, Appli |
| C 3        | 20.6  | 0.8   | 1440   | 1  | US-08-321-777-3  | Sequence 3, Appli |
| C 4        | 20.6  | 0.8   | 1440   | 1  | US-09-009-217-13 | Sequence 13, Appl |
| C 5        | 20.6  | 0.8   | 1440   | 1  | US-09-009-656-13 | Sequence 13, Appl |
| C 6        | 20.6  | 0.8   | 1440   | 1  | PCT-US93-04493-3 | Sequence 3, Appli |
| C 7        | 20.4  | 0.8   | 1440   | 1  | US-07-882-202A-3 | Sequence 3, Appli |
| C 8        | 20.4  | 0.8   | 1440   | 1  | US-08-021-615A-3 | Sequence 3, Appli |
| C 9        | 20.4  | 0.8   | 1440   | 1  | US-08-321-777-3  | Sequence 13, Appl |
| C 10       | 20.4  | 0.8   | 1440   | 1  | US-09-009-217-13 | Sequence 13, Appl |
| C 11       | 20.4  | 0.8   | 1440   | 1  | US-09-009-656-13 | Sequence 13, Appl |
| C 12       | 20.4  | 0.8   | 1440   | 1  | PCT-US93-04493-3 | Sequence 3, Appli |
| C 13       | 14.2  | 0.5   | 38     | 1  | US-09-558-027-4  | Sequence 4, Appli |
| C 14       | 12.8  | 0.5   | 141    | 1  | US-08-849-248-6  | Sequence 6, Appli |
| C 15       | 12.8  | 0.5   | 141    | 1  | US-08-849-248-6  | Sequence 6, Appli |
| C 16       | 12    | 0.4   | 38     | 1  | US-09-558-027-4  | Sequence 4, Appli |
| C 17       | 11.8  | 0.4   | 26     | 1  | US-08-293-778-22 | Sequence 22, Appl |
| C 18       | 11.8  | 0.4   | 45     | 1  | US-08-756-506-13 | Sequence 13, Appl |
| C 19       | 11.2  | 0.4   | 27     | 1  | US-08-293-778-17 | Sequence 17, Appl |
| C 20       | 11.2  | 0.4   | 42     | 1  | US-08-955-636-8  | Sequence 8, Appli |
| C 21       | 11    | 0.4   | 27     | 1  | US-08-293-778-16 | Sequence 16, Appl |
| C 22       | 11    | 0.4   | 35     | 1  | US-07-998-972A-7 | Sequence 7, Appli |
| C 23       | 11    | 0.4   | 35     | 1  | US-08-463-953-7  | Sequence 7, Appli |
| C 24       | 11    | 0.4   | 35     | 1  | US-08-462-261-7  | Sequence 7, Appli |
| C 25       | 11    | 0.4   | 35     | 1  | PCT-US92-11357-7 | Sequence 20, Appl |
| C 26       | 10.6  | 0.4   | 27     | 1  | US-08-293-778-20 | Sequence 20, Appl |
| C 27       | 10.4  | 0.4   | 45     | 1  | US-08-756-506-13 | Sequence 13, Appl |
| C 28       | 10    | 0.4   | 36     | 1  | US-08-955-636-9  | Sequence 9, Appli |
| C 29       | 10    | 0.4   | 36     | 1  | US-08-955-636-10 | Sequence 10, Appl |
| C 30       | 9.8   | 0.4   | 27     | 1  | US-08-293-778-16 | Sequence 16, Appl |
| C 31       | 9.6   | 0.4   | 26     | 1  | US-08-293-778-22 | Sequence 22, Appl |
| C 32       | 9.6   | 0.4   | 27     | 1  | US-08-293-778-20 | Sequence 20, Appl |
| C 33       | 9.6   | 0.4   | 35     | 1  | US-07-998-972A-7 | Sequence 7, Appli |

RESULT 2  
US-08-021-615A-3/c  
; Sequence 3, Application US/08021615A  
; Patent No. 5504064  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified  
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of  
; TITLE OF INVENTION: FVII  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/021,615A  
; FILING DATE: 19-FEB-1993  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/892,202  
; FILING DATE: 13-MAY-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; factor VII cDNA"  
US-08-021-615A-3

Query Match 0.8%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 3.3;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 876 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAATATGTTTCAATTGG 934  
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGTATTTTCCACATGATATCACTGG 601  
RESULT 3  
US-08-321-777-3/c  
; Sequence 3, Application US/08321777  
; Patent No. 5504067  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.

; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/321,777  
; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/892202  
; FILING DATE: 13-MAY-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRF B34290C  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; factor VII cDNA"  
US-08-321-777-3

Query Match 0.8%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 3.3;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 876 TTCAATTGCTTTTATCTGCGAGACTTGCTTTGTTTGAATATGTTTCAATTGG 934  
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGTATTTTCCACATGATATCACTGG 601

RESULT 4  
US-09-009-217-13/c  
; Sequence 13, Application US/09009217  
; Patent No. 6132729  
; GENERAL INFORMATION:  
; APPLICANT: Thorpe, Philip E.  
; APPLICANT: King, Steven W.  
; APPLICANT: Gao, Boming  
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND  
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION  
; TITLE OF INVENTION: AND TUMOR TREATMENT  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Arnold, White & Durkee  
; STREET: P.O. Box 4433

COUNTRY: USA  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/009,217  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/042,427  
FILING DATE: 27-MAR-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/036,205  
FILING DATE: 27-JAN-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/035,920  
FILING DATE: 22-JAN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hibler, David W.  
REGISTRATION NUMBER: 41,071  
REFERENCE/DOCKET NUMBER: UTSD:536  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-009-217-13

Query Match 0.8%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 3.3;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 876 TTCAATTGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTCATTTGG 934  
DB 659 TTGCTGCGCAATTCCTTTTCTAGATAGGTATTTTCCACATGATATTCACGTGG 601

RESULT 5  
US-09-009-656-13/c  
Sequence 13, Application US/09009656  
Patent No. 6132730  
GENERAL INFORMATION:  
APPLICANT: Thorpe, Philip E.  
APPLICANT: King, Steven W.  
APPLICANT: Gao, Boming  
TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR  
TITLE OF INVENTION: TREATMENT  
NUMBER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Arnold, White & Durkee  
STREET: P. O. Box 4433  
CITY: Houston  
STATE: Texas  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/009,656  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/042,427  
FILING DATE: 27-MAR-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/036,205  
FILING DATE: 27-JAN-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/035,920  
FILING DATE: 22-JAN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hibler, David W.  
REGISTRATION NUMBER: 41,071  
REFERENCE/DOCKET NUMBER: UTSD:537  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-009-656-13

Query Match 0.8%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 3.3;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 876 TTCAATTGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTCATTTGG 934  
DB 659 TTGCTGCGCAATTCCTTTTCTAGATAGGTATTTTCCACATGATATTCACGTGG 601

RESULT 6  
PCT-US93-04493-3/c  
Sequence 3, Application PC/TUS9304493  
GENERAL INFORMATION:  
APPLICANT: Morrissey, James H.  
APPLICANT: Comp, Philip C.  
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or  
TITLE OF INVENTION: FVII Activator for Blood Coagulation  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Richards, Medlock & Andrews  
STREET: 1201 Elm Street, Suite 4500  
CITY: Dallas  
STATE: Texas  
COUNTRY: US  
ZIP: 75270-2197  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US93/04493  
FILING DATE: 19930512  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/882202  
FILING DATE: 13-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/021615  
FILING DATE: 19-FEB-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Trujillo, Doreen Y.  
REGISTRATION NUMBER: 35,719  
REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 214-939-4500  
TELEFAX: 214-939-4600  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs

```
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ ORIGINAL SOURCE:
/ ORGANISM: Homo sapiens
/ TISSUE TYPE: Blood
/ FEATURE:
/ NAME/KEY: CDS
/ LOCATION: 36..1433
/ OTHER INFORMATION: /product= "Tissue Factor"
/ OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
/ OTHER INFORMATION: /citation= ([1])
PCT-US93-04493-3

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3; Mismatches 0; Gaps 0;
Matches 35; Conservative 0; Indels 24;

Qy 876 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATTCATTTGG 934
Db 659 TTTCCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGG 601

RESULT 7
US-07-882-202A-3
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: factor VIII cDNA"

Query Match 0.8%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 3.3; Mismatches 0; Gaps 0;
Matches 35; Conservative 0; Indels 24;

Qy 876 TTCAATTGCTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATTCATTTGG 934
Db 659 TTTCCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGG 601

RESULT 8
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504654
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"

US-08-021-615A-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
```

```
/ LOCATION: 36..1433
/ OTHER INFORMATION: /note= "Coding portion of human
/ OTHER INFORMATION: factor VII cDNA"
US-07-882-202A-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 374 ACAGCATGGCCATGGCTCCAGAGATTGCCCTTCCAGGTGCAGGC 419
Db 4 ACAGCAGGGCAGCAGCATGCAGAGATTTCATCATGTTCCCGGC 49

RESULT 8
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504654
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"

US-08-021-615A-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
```



```
QY 374 ACAGGCATGGCCATGGCTCCAGAGATTGCCTCTTCCAGGTGCAGGC 419
Db 4 ACAGGCGGGGCGAGCACTGCAGAGATTTTCATCATGGTCTCCAGGC 49

RESULT 9
US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FvIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-321-777-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCCATGGCTCCAGAGATTGCCTCTTCCAGGTGCAGGC 419
Db 4 ACAGGCGGGGCGAGCACTGCAGAGATTTTCATCATGGTCTCCAGGC 49

RESULT 10
US-09-009-217-13
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 4.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCCATGGCTCCAGAGATTGCCTCTTCCAGGTGCAGGC 419
Db 4 ACAGGCGGGGCGAGCACTGCAGAGATTTTCATCATGGTCTCCAGGC 49

RESULT 11
US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
```

CITY: Houston  
STATE: Texas  
COUNTRY: USA  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/042,427  
FILING DATE: 27-MAR-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/036,205  
FILING DATE: 27-JAN-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/035,920  
FILING DATE: 22-JAN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hibler, David W.  
REGISTRATION NUMBER: 41,071  
REFERENCE/DOCKET NUMBER: UTS:537  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

PCT-US93-04493-13

Query Match 0.8%; Score 20.4; DB 1; Length 1440;  
Best Local Similarity 65.2%; Pred. No. 4.3;  
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCGCATGCTCCAGAGATTGCCCTTCACAGGTGCAGGC 419  
|||||  
Db 4 ACAGGCAGGGCGAGCACTGCAGAGATTTCATCATGCTCTCCAGGC 49

RESULT 12  
PCT-US93-04493-3  
Sequence 3, Application PC/TUS9304493  
GENERAL INFORMATION:  
APPLICANT: Morrissey, James H.  
APPLICANT: Comp, Philip C.  
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or  
TITLE OF INVENTION: FVII Activator for Blood Coagulation  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Richards, Medlock & Andrews  
STREET: 1201 Elm Street, Suite 4500  
CITY: Dallas  
STATE: Texas  
COUNTRY: US  
ZIP: 75270-2197  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: IBM PC compatible  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US93/04493  
FILING DATE: 19930512  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/882202

FILING DATE: 13-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/021615  
FILING DATE: 19-FEB-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Irujillo, Doreen Y.  
REGISTRATION NUMBER: 35,719  
REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 214-939-4500  
TELEFAX: 214-939-4600  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
TISSUE TYPE: Blood  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1433 /product= "Tissue Factor"  
OTHER INFORMATION: /note= "Coding portion of human factor VIII CDNA"  
OTHER INFORMATION: /citation= {[1]}  
PCT-US93-04493-3

Query Match 0.8%; Score 20.4; DB 1; Length 1440;  
Best Local Similarity 65.2%; Pred. No. 4.3; 16; Indels 0; Gaps 0;  
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 374 ACAGGCATGGCGCATGCTCCAGAGATTGCCCTTCACAGGTGCAGGC 419  
|||||  
Db 4 ACAGGCAGGGCGAGCACTGCAGAGATTTCATCATGCTCTCCAGGC 49

RESULT 13  
US-09-558-027-4  
Sequence 4, Application US/09558027  
Patent No. 6329176  
GENERAL INFORMATION:  
APPLICANT: Wolldike, Helle  
APPLICANT: Wiberg, Finn  
APPLICANT: Nielsen, Lars  
TITLE OF INVENTION: Method for the Production of FVIII  
FILE REFERENCE: 5565.204-US  
CURRENT APPLICATION NUMBER: US/09/558,027  
CURRENT FILING DATE: 2000-04-25  
PRIOR APPLICATION NUMBER: 60/108,065  
PRIOR FILING DATE: 1998-11-12  
NUMBER OF SEQ ID NOS: 4  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 4  
LENGTH: 38  
TYPE: DNA  
ORGANISM: Saccharomyces cerevisiae  
US-09-558-027-4

Query Match 0.5%; Score 14.2; DB 1; Length 38;  
Best Local Similarity 70.4%; Pred. No. 1.1;  
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 434 GGATGATCACTCTCTTAGTGAAAGTTGGG 460  
|||||  
Db 3 GGAATTCACCTAGTCTAGGGAATGGGG 29

RESULT 14  
US-08-849-248-6

```

; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6

```

```

Query Match 0.5%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```

```

QY 82 GCACGTGGGATGTCAGATGTCAG 105
DB 6 GCACAGAGTACACGCTGATCTG 29

```

```

RESULT 15
US-08-849-248-6/c
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6
Query Match 0.5%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 583 TCTGCTGGCATACTTCTGGGGCT 606
DB 25 TCAGCTGGTCATCTTGTGGCTCT 2
RESULT 16
US-09-558-027-4/c
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565,204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

```

```

Query Match 0.4%; Score 12; DB 1; Length 38;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```

```

QY 1329 AGGGCCATTTCCTTAGAATA 1348
DB 31 AGCCCCATTTCCTTAGACTA 12

```

```

RESULT 17
US-08-293-778-22
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435

```

PRIOR APPLICATION DATA: US/08/104,509  
FILING DATE: 25-JUN-1987  
APPLICATION NUMBER: DK 3235/87  
FILING DATE: 25-JUN-1987  
APPLICATION DATA: US 07/434,149  
FILING DATE: 13-NOV-1989  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988  
APPLICATION DATA: US 07/898,248  
FILING DATE: 12-JUN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Agis, Cheryl H.  
REGISTRATION NUMBER: 34,086  
REFERENCE/DOCKET NUMBER: 3129.224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0298  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 22:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 26 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cdna  
US-08-293-778-22

Query Match 0.4%; Score 11.8; DB 1; Length 26;  
Best Local Similarity 86.7%; Pred. No. 15;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 294 GAGCAGCAGCGGAAG 308  
| | | | | | | | | |  
Db 2 GAGCAGTCACGGAAG 16

RESULT 18  
US-08-756-506-13/c  
Sequence 13, Application US/08756506  
Patent No. 5905185  
GENERAL INFORMATION:  
APPLICANT: Garner, Ian  
APPLICANT: Cottingham, Ian R.  
APPLICANT: Temperley, Simon M.  
APPLICANT: Foster, Donald C.  
APPLICANT: Sprecher, Cindy A.  
APPLICANT: Prunkard, Donna E.  
TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC  
ANIMALS  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: ZymoGenetics, Inc.  
STREET: 1201 Eastlake Avenue East  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98102  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/756,506  
FILING DATE:  
CLASSIFICATION: 800  
ATTORNEY/AGENT INFORMATION:  
NAME: Sawislak, Deborah A.  
REGISTRATION NUMBER: 37,438  
REFERENCE/DOCKET NUMBER: 95-28

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-442-6672  
TELEFAX: 206-442-6678  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 45 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC6337  
US-08-756-506-13  
Query Match 0.4%; Score 11.8; DB 1; Length 45;  
Best Local Similarity 56.4%; Pred. No. 76;  
Matches 22; Conservative 0; Mismatches 17; Indels 0; Gaps 0;  
QY 408 CCAGGTGCGAGCGGCATGCTCTGTGATCACTCT 446  
| | | | | | | | | | | | | | | | | | | | | |  
Db 40 CCAGGTGCTGCAACGCGCAAGCGCGCAACTCTCTCT 2  
| | | | | | | | | | | | | | | | | | | | | |  
RESULT 19  
US-08-293-778-17/c  
Sequence 17, Application US/08293778  
Patent No. 5580560  
GENERAL INFORMATION:  
APPLICANT: Nicolaisen, Else M.  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Wiberg, Finn C.  
APPLICANT: Woodbury, Richard  
TITLE OF INVENTION: MODIFIED FACTOR VII/VIII  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.  
STREET: 405 Lexington Avenue, 52nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/293,778  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87  
FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/898,248  
FILING DATE: 12-JUN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Agis, Cheryl H.  
REGISTRATION NUMBER: 34,086  
REFERENCE/DOCKET NUMBER: 3129.224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0298  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 17:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 27 base pairs

TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-293-778-17

Query Match 0.4%; Score 11.2; DB 1; Length 27;  
Best Local Similarity 81.2%; Pred. No. 42;  
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2224 GCTTCTGGATGTTT 2239  
||| ||||| |||||  
DB 23 GCGTCTGGAAGATT 8

RESULT 20  
US-08-955-636-8  
Sequence 8, Application US/08955636A  
Patent No. 6017882  
GENERAL INFORMATION:  
APPLICANT: Nelsestuen, Gary  
TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
FILE REFERENCE: 09531/002001  
CURRENT APPLICATION NUMBER: US/08/955,636A  
CURRENT FILING DATE: 1997-10-23  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 8  
LENGTH: 42  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-8

Query Match 0.4%; Score 11.2; DB 1; Length 42;  
Best Local Similarity 59.4%; Pred. No. 1.4e+02;  
Matches 19; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 283 CACTCTCCAGGAGCGAGGAGAGGAGGCTC 314  
||||| ||||| ||||| |||||  
DB 2 CACTCCCGCTCCAGGCTGCTGGAGGAGCTC 33

RESULT 21  
US-08-293-778-16  
Sequence 16, Application US/08293778  
Patent No. 5580560  
GENERAL INFORMATION:  
APPLICANT: Nicolson, Else M.  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Wiberg, Finn C.  
APPLICANT: Woodbury, Richard  
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.  
STREET: 405 Lexington Avenue, 62nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/293,778  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87  
FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA: US 07/434,149  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
PRIOR APPLICATION DATA: PCT/DK88/00103  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988  
PRIOR APPLICATION DATA: US 07/898,248  
APPLICATION NUMBER: US 07/898,248  
FILING DATE: 12-JUN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Agis, Cheryl H.  
REGISTRATION NUMBER: 34,086  
REFERENCE/DOCKET NUMBER: 3129,224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0123  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 27 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-293-778-16

Query Match 0.4%; Score 11; DB 1; Length 27;  
Best Local Similarity 100.0%; Pred. No. 57;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2523 TCTTCAAGGAC 2533  
||||| |||||  
DB 11 TCTTCAAGGAC 21

RESULT 22  
US-07-998-972A-7/C  
Sequence 7, Application US/07998972A  
Patent No. 5476777  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
STREET: Twentieth Floor  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/998,972A  
FILING DATE: 19921230  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-VAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990

REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-07-998-972A-7

Query Match 0.4%; Score 11; DB 1; Length 35;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 285 CTCCTCCAGGA 295  
Db 33 CTCCTCCAGGA 23

RESULT 23  
US-08-463-953-7/c  
Sequence 7, Application US/08463953  
Patent No. 5502034  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
STREET: Twentieth Floor  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/463,953  
FILING DATE:  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-08-463-953-7

Query Match 0.4%; Score 11; DB 1; Length 35;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 285 CTCCTCCAGGA 295  
Db 33 CTCCTCCAGGA 23

RESULT 24  
US-08-462-261-7/c  
Sequence 7, Application US/084622361  
Patent No. 5527492  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
STREET: Twentieth Floor  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/462,261  
FILING DATE: 05-JUN-1995  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/998,972  
FILING DATE: 30-DEC-1992  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-08-462-261-7

Query Match 0.4%; Score 11; DB 1; Length 35;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 285 CTCCTCCAGGA 295  
Db 33 CTCCTCCAGGA 23

RESULT 25  
PCT-US92-11357-7/c  
Sequence 7, Application PC/TUS9211357  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D

APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US92/11357  
FILING DATE: 19921230  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
PCT-US92-11357-7

Query Match 0.4%; Score 11; DB 1; Length 35;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCCTCCAGGA 295  
Db 33 CTCCTCCAGGA 23

RESULT 26  
US-08-293-778-20/c  
Sequence 20, Application US/08293778  
Patent No. 5580560  
GENERAL INFORMATION:  
APPLICANT: Nicolaisen, Else M.  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Wiberg, Finn C.  
APPLICANT: Woodbury, Richard  
TITLE OF INVENTION: MODIFIED FACTOR VII/VIII  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.  
STREET: 405 Lexington Avenue, 62nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/293,778  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87  
FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/898,248  
FILING DATE: 12-JUN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Agtis, Cheryl H.  
REGISTRATION NUMBER: 34,086  
REFERENCE/DOCKET NUMBER: 3129.224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0123  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 20:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 27 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-293-778-20

Query Match 0.4%; Score 10.6; DB 1; Length 27;  
Best Local Similarity 64.0%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 6 GGAGAGCGCAGCGGCGCAGCGGC 30  
Db 25 GGCGTGGCGCCCGAGTCCAGCAGC 1

RESULT 27  
US-08-756-506-13  
Sequence 13, Application US/08756506  
Patent No. 5905185  
GENERAL INFORMATION:  
APPLICANT: Garner, Ian R.  
APPLICANT: Cottingham, Ian R.  
APPLICANT: Temperley, Simon M.  
APPLICANT: Foster, Donald C.  
APPLICANT: Sprecher, Cindy A.  
APPLICANT: Prunkard, Donna E.  
TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: ZymoGenetics, Inc.  
STREET: 1201 Eastlake Avenue East  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98102  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/756,506

```
; FILING DATE:
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Sawislak, Deborah A
; REGISTRATION NUMBER: 37,438
; REFERENCE/DOCKET NUMBER: 95-28
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6672
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC6337
; US-08-756-506-13

Query Match 0.4%; Score 10.4; DB 1; Length 45;
Best Local Similarity 60.7%; Pred. No. 3.5e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1078 GTTGGAGAGAAATGGGGTATTGAAGTAGC 1105
      ||||| ||||| ||||| ||||| |||||
Db 10 GTTGGCGCGCTTGGCGGTTGCAGACC 37

RESULT 28
US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-9

Query Match 0.4%; Score 10; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 323 GCTCCTCTAG 332
      ||||| |||||
Db 24 GCTCCTCTAG 33

RESULT 29
US-08-955-636-10/c
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.4%; Score 10; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 323 GCTCCTCTAG 332
      ||||| |||||
Db 13 GCTCCTCTAG 4

RESULT 30
US-08-293-778-16/c
; Sequence 16, Application US/08293778
; Patent No. 5580360
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESS: No. 5580560 No. 5580560 disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-16

Query Match 0.4%; Score 9.8; DB 1; Length 27;
```



```
Best Local Similarity 66.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 999 GTCGTAAATATCTAGGTC 1009
Db 21 GTCCTTGAAGATCCCGGC 1

RESULT 31
US-08-293-778-22/c
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-22

Query Match 0.4%; Score 9.6; DB 1; Length 26;
Best Local Similarity 75.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 311 CCTCAGGTGATGCTC 326
Db 17 CCTTCGTGACTGCTC 2

Best Local Similarity 66.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 999 GTCGTAAATATCTAGGTC 1009
Db 21 GTCCTTGAAGATCCCGGC 1

RESULT 32
US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match 0.4%; Score 9.6; DB 1; Length 27;
Best Local Similarity 62.5%; Pred. No. 3.8e+02;
Matches 15; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 252 TGATGCAATTGGAGGCTATGGCTC 275
Db 3 TGCTGGACCTGGCGCCACGGCCC 26

RESULT 33
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
```

APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/998,972A  
FILING DATE: 19921230  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-07-998-972A-7

Query Match 0.4%; Score 9.6; DB 1; Length 35;  
Best Local Similarity 75.0%; Pred. No. 4.8e+02;  
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 282 TCACTCTCCAGGAGC 297  
Db 19 TCCTTCTCGAGGAGC 34

RESULT 34  
US-08-463-953-7  
Sequence 7, Application US/08463953  
Patent No. 5502034  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/463,953  
FILING DATE:  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-08-463-953-7  
Query Match 0.4%; Score 9.6; DB 1; Length 35;  
Best Local Similarity 75.0%; Pred. No. 4.8e+02;  
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 282 TCACTCTCCAGGAGC 297  
Db 19 TCCTTCTCGAGGAGC 34

RESULT 35  
US-08-462-261-7  
Sequence 7, Application US/08462261  
Patent No. 5527692  
GENERAL INFORMATION:  
APPLICANT: Holly, Richard D.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend  
STREET: One Market Plaza, Stewart Street Tower,  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94105  
COMPUTER READABLE FORM: disk  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/462,261  
FILING DATE: 05-JUN-1995  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/998,972  
FILING DATE: 30-DEC-1992  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W

Best Local Similarity 75.0%; Pred. No. 4.8e+02;  
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 282 TCACCTCTCCAGGAC 297  
Db 19 TCCTCTCGAGGAC 34

RESULT 37

US-08-293-778-17  
; Sequence 17, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-8201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129.224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 17:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
US-08-293-778-17

Query Match 0.3%; Score 9.4; DB 1; Length 27;  
Best Local Similarity 90.9%; Pred. No. 4.6e+02;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2523 TCTTCAAGGAC 2533  
Db 11 TCTTCAAGGAC 21

REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
US-08-462-261-7

Query Match 0.4%; Score 9.6; DB 1; Length 35;  
Best Local Similarity 75.0%; Pred. No. 4.8e+02;  
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 282 TCACCTCTCCAGGAC 297  
Db 19 TCCTCTCGAGGAC 34

RESULT 36  
PCT-US92-11357-7  
; Sequence 7, Application PC/TUS9211357  
; GENERAL INFORMATION:  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Foster, Donald C.  
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend  
; STREET: One Market Plaza, Stewart Street Tower,  
; CITY: San Francisco  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US92/11357  
; FILING DATE: 19921230  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/860,701  
; FILING DATE: 31-MAR-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/816,281  
; FILING DATE: 31-DEC-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Parmelee, Steven W  
; REGISTRATION NUMBER: 31,990  
; REFERENCE/DOCKET NUMBER: 13952-12-2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-467-9600  
; TELEFAX: 415-543-5043  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 base pairs  
; TYPE: NUCLEIC ACID  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; CLONE: ZC1324  
PCT-US92-11357-7

Query Match 0.4%; Score 9.6; DB 1; Length 35;

RESULT 38  
US-08-955-636-9/c  
; Sequence 9, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelstuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 9  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-9

Query Match 0.3%; Score 9.2; DB 1; Length 36;  
Best Local Similarity 78.6%; Pred. No. 5.1e+02;  
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 286 TCCTCCAGGAGCAG 299  
DB 35 TCCTAGAGGAGCTG 22

RESULT 39  
US-08-955-636-10  
; Sequence 10, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelstuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 10  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-10

Query Match 0.3%; Score 9.2; DB 1; Length 36;  
Best Local Similarity 78.6%; Pred. No. 5.1e+02;  
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 286 TCCTCCAGGAGCAG 299  
DB 2 TCCTAGAGGAGCTG 15

RESULT 40  
US-08-955-636-8/c  
; Sequence 8, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelstuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35

; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-8  
  
Query Match 0.3%; Score 8.8; DB 1; Length 42;  
Best Local Similarity 57.1%; Pred. No. 4.4e+02;  
Matches 16; Conservative 0; Mismatches 12; Indels 0; Gaps 0;  
  
QY 286 TCCTCCAGGAGCAGGCGAGAGCCT 313  
DB 41 TCCTGGAGGAGCTCCGTCGCCAGCAGCCT 14  
  
Search completed: August 9, 2004, 15:29:04  
Job time : 14 secs

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 15:30:00 ; Search time 34 Seconds  
(without alignments)  
4.015 Million cell updates/sec

US-10-272-665-107  
US-10-273-321-107  
US-10-272-756-107

Title: us-10-664-775-1  
 Perfect score: 2715  
 Sequence: 1 ctgcaggaaaggagacagg.....ttgtaattctagggtgctgat 2715

US-09-951-121A-8  
US-09-951-121A-9  
US-10-255-032-8

US-10-255-032-9  
US-10-295-682-8  
US-10-295-682-9  
US-10-295-682-9

US-10-295-682-9  
US-10-281-727-2  
US-10-281-727-3

US-10-281-727-3  
US-10-281-727-6  
US-10-281-727-7  
US-10-281-727-8

US-10-349-858-8  
US-10-281-727-6  
US-10-281-727-7

US-10-281-727-7  
US-10-398-422A-20  
US-09-969-357-2  
US-10-354-304-3

US-09-969-357-2  
US-10-254-394-2  
US-10-272-665-22  
US-10-272-321-22

US-10-272-665-22  
US-10-273-321-22  
US-10-272-756-22

## US-10-272-665-107

US-10-212-258-107  
US-10-273-228-107  
US-10-212-258-106  
US-10-273-665-106  
US-10-272-651-106  
US-10-273-321-106  
US-10-272-756-106  
US-10-273-228-106  
US-10-273-228-106  
US-09-951-121A-14  
US-09-951-121A-15  
US-10-295-682-14  
US-10-295-682-15  
US-10-295-682-15  
US-10-109-498-5  
US-10-109-498-6  
US-10-109-498-6  
US-09-803-810-8  
US-10-298-330-8  
US-10-338-442A-20  
US-09-969-337-2  
US-10-254-394-2  
US-10-017-132-4  
US-09-951-121A-14  
US-09-951-121A-15  
US-10-295-682-14  
US-10-295-682-15  
US-09-951-131A-8  
US-09-951-131A-9  
US-09-951-131A-9  
US-10-255-032-8  
US-10-255-032-9  
US-10-295-682-8  
US-10-295-682-9  
US-10-272-665-23  
US-10-272-665-23  
US-10-273-321-23  
US-10-273-321-23  
US-10-273-756-23  
US-10-273-756-23  
US-10-273-228-23  
US-10-273-228-23  
US-10-273-228-23

```

107 10.4 0.4 36 1 US-10-281-727-2 Sequence 2, Appli
108 10.4 0.4 36 1 US-10-281-727-3 Sequence 3, Appli
109 10.2 0.4 35 1 US-10-109-498-5 Sequence 5, Appli
110 10.2 0.4 35 1 US-10-109-498-6 Sequence 6, Appli
111 10 0.4 54 1 US-10-349-858-8 Sequence 8, Appli
112 9.4 0.3 31 1 US-10-017-122-4 Sequence 4, Appli
113 9.2 0.3 34 1 US-09-951-121A-2 Sequence 2, Appli
114 9.2 0.3 34 1 US-09-951-121A-3 Sequence 3, Appli
115 9.2 0.3 34 1 US-10-295-682-2 Sequence 2, Appli
116 9.2 0.3 34 1 US-10-295-682-3 Sequence 3, Appli
117 8.8 0.3 42 1 US-09-803-810-8 Sequence 8, Appli
118 8.8 0.3 42 1 US-10-298-330-8 Sequence 8, Appli
119 8.6 0.3 34 1 US-09-951-121A-2 Sequence 2, Appli
120 8.6 0.3 34 1 US-09-951-121A-3 Sequence 3, Appli
121 8.6 0.3 34 1 US-10-295-682-2 Sequence 2, Appli
122 8.6 0.3 34 1 US-10-295-682-3 Sequence 3, Appli

```

## ALIGNMENTS

## RESULT 1

```

US-10-382-248-35
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-588C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

```

```

Query Match 0.9%; Score 24.6; DB 1; Length 1361;
Best Local Similarity 50.4%; Pred. No. 0.17;
Matches 60; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 401 GCTCTTCAGGTGACGAGGCGCATGCTCTGTGATCACTCTCTAGTGAAGTGG 460
DB 400 GTCTCTGACGACACGCTCCAGTCTCTATATCTGCTCTCTCTCTCGAGGCC 459
QY 461 GGGTCTGAGGCTCCATGCTTGTGATGTTGAGTATCTCATACAGAGGATGCACT 519
DB 460 GGAAGTGTGAGACGCTTGAATATCCATGTGGAATAATACCTATTCTAGAAAAGAAAT 518

```

## RESULT 2

```

US-10-411-037-7/c
; Sequence 7, Application US/10411037
; Publication No. US2004004346A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert

```

```

; APPLICANT: Chen, Xi
; APPLICANT: Bows, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match 0.8%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 4.9;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATCAATTTGG 934
DB 558 TTTCGTCGCAATTTCTTTTCTAGAATAGTATTTTCCACATGGATATTTCAACTGTGG 500

```

## RESULT 3

```

US-10-411-026-7/c
; Sequence 7, Application US/10411026
; Publication No. US2004006391A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi

```

```

; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332

```







Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 876 TTCATTGCTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTTGG 934  
558 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 500

Db

RESULT 10

US-10-410-913-7/c

Sequence 7, Application US/10410913

Publication No. US20040142856A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: DeFrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bowe, Caryn

TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE

TITLE OF INVENTION: METHODS

FILE REFERENCE: 040853-01-5081

CURRENT APPLICATION NUMBER: US/10/410,913

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-410-913-7

Query Match 0.8%; Score 20.6; DB 1; Length 1332;

Best Local Similarity 59.3%; Pred. No. 4.9;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 876 TTCATTGCTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTTGG 934  
558 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 500

Db

RESULT 11

US-10-375-741-13/c

Sequence 13, Application US/10375741

Publication No. US20030232753A1

GENERAL INFORMATION:

APPLICANT: Thorpe, Philip E

APPLICANT: King, Steven W

APPLICANT: Gao, Boming

TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR

TITLE OF INVENTION: TREATMENT

FILE REFERENCE: 4001.001999

CURRENT APPLICATION NUMBER: US/10/375,741

CURRENT FILING DATE: 2003-02-27

PRIOR APPLICATION NUMBER: 09/573,835

PRIOR FILING DATE: 2000-05-18

PRIOR APPLICATION NUMBER: 6,156,321

PRIOR FILING DATE: 1998-01-20

PRIOR APPLICATION NUMBER: 60/042,427

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 876 TTCATTGCTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTTGG 934  
558 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 601

Db

Query Match 0.8%; Score 20.6; DB 1; Length 1440;

Best Local Similarity 59.3%; Pred. No. 5.2;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 876 TTCATTGCTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTTGG 934  
558 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 601

Db

RESULT 12

US-10-617-619-12/c

Sequence 12, Application US/10617619

Publication No. US20040110929A1

GENERAL INFORMATION:

APPLICANT: Bjorn, Soren E

APPLICANT: Nicolaissen, Else M

APPLICANT: Jorgensen, Anker S

TITLE OF INVENTION: TF Binding Compound

FILE REFERENCE: 6455-200-US

CURRENT APPLICATION NUMBER: US/10/617,619

CURRENT FILING DATE: 2003-07-11

PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099

PRIOR FILING DATE: 2002-07-12

PRIOR APPLICATION NUMBER: US 60/404,568

PRIOR FILING DATE: 2002-08-19

NUMBER OF SEQ ID NOS: 13

SOFTWARE: PatentIn version 3.2

SEQ ID NO 12

LENGTH: 2040

TYPE: DNA

ORGANISM: Artificial

FEATURE:

OTHER INFORMATION: Synthetic

US-10-617-619-12

Query Match 0.8%; Score 20.6; DB 1; Length 2040;

Best Local Similarity 59.3%; Pred. No. 6.8;

Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 876 TTCATTGCTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTTGG 934  
558 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 500

Db

RESULT 13

US-10-617-619-9/c

Sequence 9, Application US/10617619

Publication No. US20040110929A1

GENERAL INFORMATION:

APPLICANT: Bjorn, Soren E

APPLICANT: Nicolaissen, Else M

APPLICANT: Jorgensen, Anker S

TITLE OF INVENTION: TF Binding Compound

FILE REFERENCE: 6455-200-US

CURRENT APPLICATION NUMBER: US/10/617,619

CURRENT FILING DATE: 2003-07-11

PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099

PRIOR FILING DATE: 2002-07-12

PRIOR APPLICATION NUMBER: US 60/404,568

PRIOR FILING DATE: 2002-08-19

```
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      0.8%; Score 20.6; DB 1; Length 2106;
Best Local Similarity 59.3%; Pred. No. 7;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATTGCTTTTAATCTGTCGAGACTGCTTTGTTTGAATATGATTCATTTGG 934
Db 624 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATTCAACTGTGG 566

RESULT 14
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match      0.8%; Score 20.4; DB 1; Length 483;
Best Local Similarity 65.2%; Pred. No. 2.3;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGCCATGCTCCAGATGCTCTTCCAGGTGCAGGC 419
Db 68 ACAGGAGGGGAGCAGCTGAGAGATTCATCATGTTCTCCAGGC 113

RESULT 15
US-10-375-741-13
; Sequence 13, Application US/10375741
; Publication No. US2003023753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
```

```
; PRIOR FILING DATE: 1997-01-27
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match      0.8%; Score 20.4; DB 1; Length 1440;
Best Local Similarity 65.2%; Pred. No. 6.1;
Matches 30; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 374 ACAGGCATGCCATGCTCCAGATGCTCTTCCAGGTGCAGGC 419
Db 4 ACAGGAGGGGAGCAGCTGAGAGATTCATCATGTTCTCCAGGC 49

RESULT 16
US-10-382-248-35/c
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-588C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)...(1301)
US-10-382-248-35

Query Match      0.7%; Score 19.4; DB 1; Length 1361;
Best Local Similarity 55.1%; Pred. No. 12;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2596 CTCAGGCGCTATTGTAATAGGGTTTTCAGGAGGACATATTGCTGTTGTTATTCTG 2655
Db 1312 CTGCTGGCTAGGAAATGGGCTCCAGGAGGACTCTCTGGGCGTCTGAGCCATG 1253

QY 2656 TGTTTTTC 2664
Db 1252 AGCTTTTC 1244

RESULT 17
US-09-782-587B-2/c
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001000S
; CURRENT APPLICATION NUMBER: US/09/782,587B
```

```

; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match
Best Local Similarity 0.7%; Score 19.2; DB 1; Length 1338;
Matches 48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 371 GGTACAGGATGGCCATGGCTCCAGAGATTGCCTTCCAGGTGCAGGCAGGGCCATGGC 430
DB 619 GGACCTGGCAGGGGACTCCCTTAGGCAGACCTTCCGCCGACGATCCGGCCCTGGG 560
QY 431 TCTGGTGATCACTCCTCTAGTGAAGGTGGGGTCT 466
DB 559 GTTGTAGCGTTCCGCTTTTCTAGATGGGAATCT 524

RESULT 18
US-09-782-587B-4/c
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match
Best Local Similarity 0.7%; Score 19.2; DB 1; Length 1357;
Matches 48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 371 GGTACAGGATGGCCATGGCTCCAGAGATTGCCTTCCAGGTGCAGGCAGGGCCATGGC 430
DB 632 GGACCTGGCAGGGGACTCCCTTAGGCAGACCTTCCGCCGACGATCCGGCCCTGGG 573
QY 431 TCTGGTGATCACTCCTCTAGTGAAGGTGGGGTCT 466
DB 572 GTTGTAGCGTTCCGCTTTTCTAGATGGGAATCT 537

RESULT 19
US-10-411-037-7
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; TITLE OF INVENTION: GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match
Best Local Similarity 0.7%; Score 18; DB 1; Length 1332;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGTGTCAGTCCCTCGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
DB 560 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGTGTCCATGGCAGGTCC 619
QY 404 TCTTCAGGTGCAGGCAGGGCCATGGCTCTGGTGATCACTCTCTCTAGTGAAGGTGGGG 463
DB 620 TGTGTTGGTGAATGGAGCTCAGTTGTGGGGGGACCCCTGATCAACACCATCTGGGTGG 679
QY 464 TCTGAGGCTCCAATGGTT 481
DB 680 TCTCCGGCGCCCACTGTT 697

RESULT 20
US-10-411-026-7
; Sequence 7, Application US/10411026
; Publication No. US20040063911A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR APPLICATION NUMBER: US 60/328,523

```

```
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-026-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db      |||||
QY 560 CCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGGAGTGTCCATGGCAGGTCC 619
Db      |||||
QY 404 TCTTCAGGTGCGAGGCGGCCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db      |||||
QY 620 TGTGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGGACCTGTGATCAACACCATCTGGGTGG 679
Db      |||||
QY 464 TCTGAGGCTCCAATGGTT 481
Db      |||||
QY 680 TCTCCGCGGCCCACTGTT 697
Db      |||||

RESULT 21
US-10-410-962-7
; Sequence 7, Application US/10410962
; Publication No. US2004007836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; FILE REFERENCE: 040853-01-5054
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US/10/410,962
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-962-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db      |||||
QY 560 CCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGGAGTGTCCATGGCAGGTCC 619
Db      |||||
QY 404 TCTTCAGGTGCGAGGCGGCCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db      |||||
QY 620 TGTGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGGACCTGTGATCAACACCATCTGGGTGG 679
Db      |||||
QY 464 TCTGAGGCTCCAATGGTT 481
Db      |||||
QY 680 TCTCCGCGGCCCACTGTT 697
Db      |||||

RESULT 22
US-10-411-049-7
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US/10/411,049
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-049-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db      |||||
QY 560 CCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGGAGTGTCCATGGCAGGTCC 619
Db      |||||
QY 404 TCTTCAGGTGCGAGGCGGCCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db      |||||
QY 620 TGTGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGGACCTGTGATCAACACCATCTGGGTGG 679
Db      |||||
QY 464 TCTGAGGCTCCAATGGTT 481
Db      |||||
QY 680 TCTCCGCGGCCCACTGTT 697
Db      |||||
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-962-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db      |||||
QY 560 CCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGGAGTGTCCATGGCAGGTCC 619
Db      |||||
QY 404 TCTTCAGGTGCGAGGCGGCCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db      |||||
QY 620 TGTGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGGACCTGTGATCAACACCATCTGGGTGG 679
Db      |||||
QY 464 TCTGAGGCTCCAATGGTT 481
Db      |||||
QY 680 TCTCCGCGGCCCACTGTT 697
Db      |||||

RESULT 22
US-10-411-049-7
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US/10/411,049
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-049-7

Query Match      0.7%; Score 18; DB 1; Length 1332;
Best Local Similarity 45.7%; Pred. No. 28;
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403
Db      |||||
QY 560 CCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGGAGTGTCCATGGCAGGTCC 619
Db      |||||
QY 404 TCTTCAGGTGCGAGGCGGCCCATGGCTCTGGGTGATCACTCTCTAGTGAAGGTGGGG 463
Db      |||||
QY 620 TGTGTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGGACCTGTGATCAACACCATCTGGGTGG 679
Db      |||||
QY 464 TCTGAGGCTCCAATGGTT 481
Db      |||||
QY 680 TCTCCGCGGCCCACTGTT 697
Db      |||||
```

Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 23

US-10-410-930-7

Sequence 7, Application US/10410930

Publication No. US20040115168A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON

TITLE OF INVENTION: BETA

FILE REFERENCE: 040853-01-5056

CURRENT APPLICATION NUMBER: US/10/410,930

PRIOR FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-410-930-7

Query Match 0.7%; Score 18; DB 1; Length 1332;

Best Local Similarity 45.7%; Pred. No. 28;

Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403

Db 560 CCCAAGCGCGAATTGTGGGGGCGCAAGTGTGCCCAAAGGGAGTGTCCATGGCAGGTCC 619

QY 404 TCTTCCAGGTGACAGGCGGCATGGCTCTGTGTATCACTCTCTAGTGAAGGTGGGG 463

Db 620 TGTGTTGGTGAATGAGCTCAGTTGTGTGGGGGGACCCCTGATCAACACCATCTGGGTGG 679

QY 464 TCTGAGGCTCCAATGTT 481

Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 25

US-10-411-012-7

Sequence 7, Application US/10411012

Publication No. US20040132640A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: GLYCOPGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE

TITLE OF INVENTION: METHODS

FILE REFERENCE: 040853-01-5051

CURRENT APPLICATION NUMBER: US/10/411,012

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 24

US-10-410-997-7

Sequence 7, Application US/10410997

Publication No. US20040126838A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF

TITLE OF INVENTION: BETA

FILE REFERENCE: 040853-01-5056

CURRENT APPLICATION NUMBER: US/10/410,930

PRIOR FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-410-930-7

Query Match 0.7%; Score 18; DB 1; Length 1332;

Best Local Similarity 45.7%; Pred. No. 28;

Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403

Db 560 CCCAAGCGCGAATTGTGGGGGCGCAAGTGTGCCCAAAGGGAGTGTCCATGGCAGGTCC 619

QY 404 TCTTCCAGGTGACAGGCGGCATGGCTCTGTGTATCACTCTCTAGTGAAGGTGGGG 463

Db 620 TGTGTTGGTGAATGAGCTCAGTTGTGTGGGGGGACCCCTGATCAACACCATCTGGGTGG 679

QY 464 TCTGAGGCTCCAATGTT 481

Db 680 TCTCCGGCGCCCACTGTT 697

RESULT 25

US-10-411-012-7

Sequence 7, Application US/10411012

Publication No. US20040132640A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: GLYCOPGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE

TITLE OF INVENTION: METHODS

FILE REFERENCE: 040853-01-5051

CURRENT APPLICATION NUMBER: US/10/411,012

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-411-012-7

Query Match 0.7%; Score 18; DB 1; Length 1332;  
Best Local Similarity 45.7%; Pred. No. 28;  
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTCGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403  
DB 560 CCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCATGGCAGGTCC 619  
QY 404 TCTTCCAGTGCAGGCAGGCCCATGGCTCTGTGTGATCACTCTCTAGTCAAAAGGTGGGGG 463  
DB 620 TGTGTGTGTGATGAGCTCAGTGTGTGGGGGGACCCCTGATCAACACCATCTCGGTGG 679  
QY 464 TCTGAGGCTCCAATGTT 481  
DB 680 TCTCCGGCGCCCACTGTT 697

## RESULT 26

US-10-287-994-7  
; Sequence 7, Application US/10287994  
; Publication No. US20040137857A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Bower, Caryn  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES  
; FILE REFERENCE: 040853-01-5052-00  
; CURRENT APPLICATION NUMBER: US/10/287,994  
; CURRENT FILING DATE: 2002-11-05  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 62  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-287-994-7

Query Match 0.7%; Score 18; DB 1; Length 1332;  
Best Local Similarity 45.7%; Pred. No. 28;  
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTCGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403  
DB 560 CCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCATGGCAGGTCC 619  
QY 404 TCTTCCAGTGCAGGCAGGCCCATGGCTCTGTGTGATCACTCTCTAGTCAAAAGGTGGGGG 463

DB 620 TGTGTGTGTGTAATGGAGCTCAGTTGTGTGGGGGGACCCCTGATCAACACCATCTGGGTGG 679  
QY 464 TCTGAGGCTCCAATGTT 481  
DB 680 TCTCCGGCGCCCACTGTT 697

## RESULT 27

US-10-410-913-7  
; Sequence 7, Application US/10410913  
; Publication No. US20040142856A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bower, Caryn  
; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
; FILE REFERENCE: 040853-01-5081  
; CURRENT APPLICATION NUMBER: US/10/410,913  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-410-913-7

Query Match 0.7%; Score 18; DB 1; Length 1332;  
Best Local Similarity 45.7%; Pred. No. 28;  
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGCTCAGTCCCTCGGTACAGGCATGCCCATGGCTCCAGAGATTGCC 403  
DB 560 CCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCAAGGGAGGTGTCCATGGCAGGTCC 619  
QY 404 TCTTCCAGTGCAGGCAGGCCCATGGCTCTGTGTGATCACTCTCTAGTCAAAAGGTGGGGG 463  
DB 620 TGTGTGTGTGTAATGGAGCTCAGTTGTGTGGGGGGACCCCTGATCAACACCATCTGGGTGG 679  
QY 464 TCTGAGGCTCCAATGTT 481  
DB 680 TCTCCGGCGCCCACTGTT 697

## RESULT 28

US-10-617-619-12  
; Sequence 12, Application US/10617619  
; Publication No. US20040110929A1  
; GENERAL INFORMATION:  
; APPLICANT: Bjorn, Soren E  
; APPLICANT: Nicolaisen, Else M  
; APPLICANT: Jorgensen, Anker S  
; TITLE OF INVENTION: TF Binding Compound

FILE REFERENCE: 6455.200-US  
; CURRENT APPLICATION NUMBER: US/10/617,619  
; CURRENT FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099  
; PRIOR FILING DATE: 2002-07-12  
; PRIOR APPLICATION NUMBER: US 60/404,568  
; PRIOR FILING DATE: 2002-08-19  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 12  
; LENGTH: 2040  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-617-619-12

Query Match 0.7%; Score 18; DB 1; Length 2040;  
Best Local Similarity 45.7%; Pred. No. 23;  
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGGTCCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403  
DB 560 CCCAAGGCCGAATTGTGGGGGCAAGGTGTCCCAAGGGAGTGTCCATGGCAGGTCC 619  
QY 404 TCTTCCAGTGCAGCAGGGCCATGGCTCTGTGATCACTCTCTAGTAGAAGTGGGG 463  
DB 620 TGTGTGTGTAATGGAGCTCAGTTGTGTGGGGGACCCCTGATCAACACCATCTGGGTGG 679  
QY 464 TCTGAGGCTCCAATGTT 481  
DB 680 TCTCCGGCGCCCACTGTT 697

RESULT 29  
US-10-617-619-9  
; Sequence 9, Application US/10617619  
; Publication No. US20040110929A1  
; GENERAL INFORMATION:  
; APPLICANT: Bjoern, Soren E  
; APPLICANT: Nicolaisen, Else M  
; APPLICANT: Jorgensen, Anker S  
; TITLE OF INVENTION: TF Binding Compound  
; FILE REFERENCE: 6455.200-US  
; CURRENT APPLICATION NUMBER: US/10/617,619  
; CURRENT FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099  
; PRIOR FILING DATE: 2002-07-12  
; PRIOR APPLICATION NUMBER: US 60/404,568  
; PRIOR FILING DATE: 2002-08-19  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 9  
; LENGTH: 2106  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-617-619-9

Query Match 0.7%; Score 18; DB 1; Length 2106;  
Best Local Similarity 45.7%; Pred. No. 23;  
Matches 63; Conservative 0; Mismatches 75; Indels 0; Gaps 0;

QY 344 CCCAATGATCATGTGGTCCAGTCCCTGGGTACAGGCATGGCCATGGCTCCAGAGATTGCC 403  
DB 626 CCCAAGGCCGAATTGTGGGGGCAAGGTGTGCCCAAGGGAGTGTCCATGGCAGGTCC 685  
QY 404 TCTTCCAGTGCAGCAGGGCCATGGCTCTGTGTGATCACTCTCTAGTAGAAGTGGGG 463  
DB 686 TGTGTGTGTAATGAGCTCAGTTGTGTGGGGGACCCCTGATCAACACCATCTGGGTGG 745  
QY 464 TCTGAGGCTCCAATGTT 481

Db 746 TCTCCGGCGGCCCACTGTT 763

RESULT 30  
US-09-782-587B-4  
; Sequence 4, Application US/09782587B  
; Publication No. US20030096338A1  
; GENERAL INFORMATION:  
; APPLICANT: PEDERSEN, ANDERS H.  
; APPLICANT: ANDERSON, KIM V.  
; APPLICANT: BORNAES, CLAUS  
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
; FILE REFERENCE: 31-001100US  
; CURRENT APPLICATION NUMBER: US/09/782,587B  
; CURRENT FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: PA 2000 00218  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: 60/184,036  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: 60/241,916  
; PRIOR FILING DATE: 2000-10-18  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 1357  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Expression  
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells  
US-09-782-587B-4

Query Match 0.6%; Score 17.1; DB 1; Length 1357;  
Best Local Similarity 62.7%; Pred. No. 35;  
Matches 42; Conservative 0; Mismatches 24; Indels 1; Gaps 1;

QY 280 GATCACTCTCTCCAGGAGCAGGCGAGG-GAAGAGCCTCAGGTGATTGCTCTTAGATGCTG 338  
DB 2 GATCCCGCCACCATGTGTCAGCAGGCCCTCCGCTCTGCTGCTCTCTCTGGGCTGCAG 61  
QY 339 GCAGGCC 345  
DB 62 GGCTGCC 68

RESULT 31  
US-09-782-587B-2  
; Sequence 2, Application US/09782587B  
; Publication No. US20030096338A1  
; GENERAL INFORMATION:  
; APPLICANT: PEDERSEN, ANDERS H.  
; APPLICANT: ANDERSON, KIM V.  
; APPLICANT: BORNAES, CLAUS  
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
; FILE REFERENCE: 31-001100US  
; CURRENT APPLICATION NUMBER: US/09/782,587B  
; CURRENT FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: PA 2000 00218  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: 60/184,036  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: 60/241,916  
; PRIOR FILING DATE: 2000-10-18  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 1338  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: (115)..(1332)





```
;
;
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUATE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUATE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUATE 5.00e-76
;
US-10-029-386-3623
Query Match 0.5%; Score 14.8; DB 1; Length 555;
Best Local Similarity 53.4%; Pred. No. 88;
Matches 31; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

Qy 415 CAGCAGGGCATGGCTCTGGTGATCACTCTCTAGTGAAGTGGGGTCTGAGGCT 472
Db 169 CTGAGAGACGCTGGCTCTGGTGGCTTCTTCTTGGTCAAGGCTGGGGCAGTGGCT 112

RESULT 36
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g114783796, EVALUATE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUATE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUATE 3.00e-37
;
US-10-029-386-23323
Query Match 0.5%; Score 14.4; DB 1; Length 222;
Best Local Similarity 65.6%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 393 CAGCATTCCTCTTCCAGTCCAGGCAGGGC 424
Db 173 CAGTGAGGACACCGGCTGGTGCAGGCGAGC 204

RESULT 37
US-10-029-386-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
```

```
;
;
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
;
US-10-272-665-22
Query Match 0.5%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCCTTCTTCCCTTCTCTTCTTCTTCTTCTTCTT 2201
Db 58 TGTGGGCTCCACTGTCTCCCTTGCAGGAGTCCTT 24

RESULT 38
US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
;
US-10-273-321-22
Query Match 0.5%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCCTTCTTCCCTTCTCTTCTTCTTCTTCTTCTT 2201
Db 58 TGTGGGCTCCACTGTCTCCCTTGCAGGAGTCCTT 24

RESULT 39
US-10-272-756-22/c
; Sequence 22, Application US/10272756
```

```

; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

Query Match 0.5%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTGACCTGCTTCTTCCCTTCTCTCTCTCTCTT 2201
DB 58 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 40
US-10-273-228-22/c
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

Query Match 0.5%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTGACCTGCTTCTTCCCTTCTCTCTCTCTT 2201
DB 58 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 40
US-10-273-228-22/c
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

Query Match 0.5%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTGACCTGCTTCTTCCCTTCTCTCTCTCTT 2201
DB 58 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 24
```

```

DB 58 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 41
US-10-272-665-107/c
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

Query Match 0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTGACCTGCTTCTTCCCTTCTCTCTCTT 2201
DB 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 42
US-10-273-321-107/c
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-107

Query Match 0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
```

Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201  
| | | | | | | | | | | | | | | | | | | | | |  
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 43

US-10-272-756-107/c  
; Sequence 107, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 107  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-756-107

Query Match 0.5%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 62.9%; Pred. No. 91;  
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201  
| | | | | | | | | | | | | | | | | | | | | |  
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 44

US-10-273-228-107/c  
; Sequence 107, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033D  
; CURRENT APPLICATION NUMBER: US/10/273,228  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 107  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-107

Query Match 0.5%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 62.9%; Pred. No. 91;  
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201  
| | | | | | | | | | | | | | | | | | | | | |  
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 45

US-10-272-665-106/c  
; Sequence 106, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-665-106

Query Match 0.5%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 62.9%; Pred. No. 91;  
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 2167 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 2201  
| | | | | | | | | | | | | | | | | | | | | |  
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 46

US-10-273-321-106/c  
; Sequence 106, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-106

```
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match      0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTTGACCTGCTTCTTCCCTTCTCTTATTCCTT 2201
      |||||
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 47
US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match      0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTTGACCTGCTTCTTCCCTTCTCTTATTCCTT 2201
      |||||
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 48
US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match      0.5%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 91;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 2167 TTTTGACCTGCTTCTTCCCTTCTCTTATTCCTT 2201
      |||||
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 49
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 423 GCCATGGCTCTGCTGATC 440
      |||||
Db 1 GCCACGGCCCTGCTGCTC 18

RESULT 50
US-09-951-121A-9/c
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```

```
US-09-951-121A-9
Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 19

RESULT 51
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-8

Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 18

RESULT 52
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 19

RESULT 53
US-10-295-682-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 1 GCCACGGCCCTGGTGCTC 18

RESULT 54
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.5%; Score 13.2; DB 1; Length 36;
Best Local Similarity 83.3%; Pred. No. 83;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 423 GCCATGGCTCTGGTGATC 440
Db 36 GCCACGGCCCTGGTGCTC 19

RESULT 55
US-10-281-727-2/c
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
```

```

: APPLICANT: Persson, Egon
: APPLICANT: Olsen, Ole Hvilsted
: TITLE OF INVENTION: Human Coagulation Factor VII
: TITLE OF INVENTION: Polypeptides
: FILE REFERENCE: 6410.200-US
: CURRENT APPLICATION NUMBER: US/10/281,727
: CURRENT FILING DATE: 2002-10-28
: PRIOR APPLICATION NUMBER: PA 2001 01627
: PRIOR FILING DATE: 2001-11-02
: PRIOR APPLICATION NUMBER: 60/335,383
: PRIOR FILING DATE: 2001-11-15
: NUMBER OF SEQ ID NOS: 7
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 2
: LENGTH: 36
: TYPE: DNA
: ORGANISM: Unknown
: FEATURE:

```

OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII  
US-10-281-727-2

```

RESULT 56
US/10-281-727-3
/ Sequence 3, Application US/10281727
/ Publication No. US20030130191A1
/ GENERAL INFORMATION:
/ APPLICANT: Persson, Egon
/ APPLICANT: Olsen, Ole Hvilsted
/ TITLE OF INVENTION: Human Coagulation
/ TITLE OF INVENTION: Polypeptides
/ FILE REFERENCE: 6410.200-US
/ CURRENT APPLICATION NUMBER: US/10/272
/ CURRENT FILING DATE: 2002-10-28
/ PRIOR APPLICATION NUMBER: PA 2001 C
/ PRIOR FILING DATE: 2001-11-02
/ PRIOR APPLICATION NUMBER: 60/335,38
/ PRIOR FILING DATE: 2001-11-15
/ NUMBER OF SEQ ID NOS: 7
/ SOFTWARE: FastSeq for Windows Ver8.1
/ SEQ ID NO 3
/ LENGTH: 36
/ TYPE: DNA
/ ORGANISM: Unknown
/ FEATURE:

```

```

; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3
QUERY MATCH
Score 12.8; DB 1; Length 36;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 TTCAGGTGCAGGCGAC 421
||| ||| ||| ||| |||
Db 21 TTCTGTGTGCAGGCGAC 36

```

RESULT 57  
US-10-281-727-6  
; Sequence 6, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulat

```

? TITLE OF INVENTION: Polypeptides
? FILE REFERENCE: 6410.200-US
? CURRENT APPLICATION NUMBER: US/10/281,727
? CURRENT FILING DATE: 2002-10-28
? PRIOR APPLICATION NUMBER: PA 2001 01627
? PRIOR FILING DATE: 2001-11-02
? PRIOR APPLICATION NUMBER: 60/335,383
? PRIOR FILING DATE: 2001-11-15
? NUMBER OF SEQ ID NOS: 7
? SOFTWARE: FastSeq for Windows Version 4.0
? SEQ ID NO 6
? LENGTH: 32
? TYPE: DNA
? ORGANISM: Unknown
? FEATURE:
? OTHER INFORMATION: DNA primer for preparation
? US-10-281-727-6

```

```

Query Match      0.5%; Score 12.6; DB 1; Length 32;
Best Local Similarity 79.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      290 CCAGGAGCAGGCAGGGAAG 308
          |||||
Db       2 CCTGCAGCAGGAACGGGAAG 20

```

```

RESULT 58
US/10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US2003013019A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsson, Ole Hvilstedt
; TITLE OF INVENTION: Human Ceasgulat
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,3
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Vers
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; -OTHER INFORMATION: DNA primer for
US-10-281-727-7

```

```

Query Match      0.5%; Score 12.6; DB 1; Length 32;
Best Local Similarity 78.9%; Prid.No.1.2e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 250 CCAGGAGCAGGCAGGGAAG 308
      |||||
Db 31 CCTCGACGAGAACGGAAG 13

```

RESULT 59  
US-10-349-858-8/c  
; Sequence 8, Application US/10349858  
; Publication No. US20030220247A1  
; GENERAL INFORMATION:  
; APPLICANT: The Children's Hospital of Philadelphia  
; APPLICANT: HIGH, KATHERINE A.  
; APPLICANT: CAMIRE, RODNEY M.  
; APPLICANT: LARSON, PETER J.  
; APPLICANT: STAFFORD, BARREL W.  
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF

```
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match      0.4%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.6%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 2361 TGAGGTTCTCTGTTGGGTTCTTAA 2383
Db 29 TGGGCTTCTCTCTGGGTTACGAA 7

RESULT 60
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match      0.4%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 2.8e-02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2435 TTCCACTTTCAGGTCCTG 2452
Db 26 TCCACCTTCCGTTCTCTG 9

RESULT 61
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
```

```
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match      0.4%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 2.8e-02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2435 TTCCACTTTCAGGTCCTG 2452
Db 7 TCCACCTTCCGTTCTCTG 24

RESULT 62
US-10-398-422A-20
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Lars Sogaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match      0.4%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 3.7e-02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 563 TAATATATTTTCTGAAGCCTCTGCTGC 591
Db 10 TAAACGCTTCTCTGGAGAGCTCGGCC 38

RESULT 63
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
```

; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.  
; APPLICANT: Pingel, Hans K  
; APPLICANT: Klausen, Niels K  
; TITLE OF INVENTION: Factor VII Glycoforms  
; FILE REFERENCE: 6207.510-US  
; CURRENT FILING DATE: 2002-10-02  
; PRIOR APPLICATION NUMBER: US/09/969,357  
; PRIOR FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456  
; PRIOR FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262  
; PRIOR FILING DATE: 2001-02-16  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430  
; PRIOR FILING DATE: 2001-03-14  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751  
; PRIOR FILING DATE: 2001-05-14  
; PRIOR APPLICATION NUMBER: US 60/238,944  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/271,581  
; PRIOR FILING DATE: 2001-02-26  
; PRIOR APPLICATION NUMBER: US 60/276,322  
; PRIOR FILING DATE: 2001-03-16  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: Patent in version 3.2  
; SEQ ID NO 2  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-969-357-2

Query Match 0.4%; Score 11.4; DB 1; Length 38;  
Best Local Similarity 62.1%; Pred. No. 3.7e+02;  
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 563 TAATATATTTTCTGAAGCCTCTGCTGCG 591  
Db 10 TAAACGCTTCTCTGAGGAGTGCGGCC 38

RESULT 64  
US-10-254-394-2  
; Sequence 2, Application US/10254394  
; Publication No. US20030096366A1  
; GENERAL INFORMATION:  
; APPLICANT: Knudsen, Ida Molgaard  
; TITLE OF INVENTION: Method for Production of Recombinant  
; FILE REFERENCE: 6480.500-US  
; CURRENT APPLICATION NUMBER: US/10/254,394  
; CURRENT FILING DATE: 2002-09-25  
; PRIOR APPLICATION NUMBER: PCT/DR01/00632  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PCT/DR01/00634  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PA 2002 00460  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: 60/374,855  
; PRIOR FILING DATE: 2002-10-04  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-254-394-2

Query Match 0.4%; Score 11.4; DB 1; Length 38;  
Best Local Similarity 62.1%; Pred. No. 3.7e+02;  
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 563 TAATATATTTTCTGAAGCCTCTGCTGCG 591  
Db 10 TAAACGCTTCTCTGAGGAGTGCGGCC 38

RESULT 65  
US-10-272-665-22  
; Sequence 22, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POL  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-272-665-22

Query Match 0.4%; Score 11.4; DB 1; Length 60;  
Best Local Similarity 56.8%; Pred. No. 4.6e+02;  
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGCGCTATTGTAATAGGTTTACGAGGACATAT 2634  
Db 23 CAAGGACTCTGCAAGGGGACAGTGAGGCCACAT 59

RESULT 66  
US-10-273-321-22  
; Sequence 22, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POL  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
; FEATURE:



OTHER INFORMATION: Probe  
US-10-273-321-22  
Query Match 0.4%; Score 11.4; DB 1; Length 60;  
Best Local Similarity 56.8%; Pred. No. 4.6e+02;  
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2634  
Db 23 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 59  
RESULT 67  
US-10-272-756-22  
Sequence 22, Application US/10272756  
Publication No. US20030190644A1  
GENERAL INFORMATION:  
APPLICANT: Braun et al.  
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
FILE REFERENCE: 24736-2033C  
CURRENT APPLICATION NUMBER: US/10/272,756  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: 09/687,483  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 60/217,658  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 60/159,176  
PRIOR FILING DATE: 1999-10-13  
PRIOR APPLICATION NUMBER: 60/217,251  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 09/663,968  
PRIOR FILING DATE: 2000-09-19  
NUMBER OF SEQ ID NOS: 118  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 22  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Homo Sapien  
FEATURE:  
OTHER INFORMATION: Probe  
US-10-272-756-22  
Query Match 0.4%; Score 11.4; DB 1; Length 60;  
Best Local Similarity 56.8%; Pred. No. 4.6e+02;  
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2634  
Db 23 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 59  
RESULT 68  
US-10-273-321-22  
Sequence 22, Application US/10273228  
Publication No. US20030207297A1  
GENERAL INFORMATION:  
APPLICANT: Braun et al.  
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
FILE REFERENCE: 24736-2033D  
CURRENT APPLICATION NUMBER: US/10/273,321  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: 09/687,483  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 60/217,658  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 60/159,176  
PRIOR FILING DATE: 1999-10-13  
PRIOR APPLICATION NUMBER: 60/217,251  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 09/663,968  
PRIOR FILING DATE: 2000-09-19

NUMBER OF SEQ ID NOS: 118  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 22  
LENGTH: 60  
TYPE: DNA  
ORGANISM: Homo Sapien  
FEATURE:  
OTHER INFORMATION: Probe  
US-10-273-228-22  
Query Match 0.4%; Score 11.4; DB 1; Length 60;  
Best Local Similarity 56.8%; Pred. No. 4.6e+02;  
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2634  
Db 23 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 59  
RESULT 69  
US-10-272-665-107  
Sequence 107, Application US/10272665  
Publication No. US20030180748A1  
GENERAL INFORMATION:  
APPLICANT: Braun et al.  
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
FILE REFERENCE: 24736-2033E  
CURRENT APPLICATION NUMBER: US/10/272,665  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: 09/687,483  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 60/217,658  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 60/159,176  
PRIOR FILING DATE: 1999-10-13  
PRIOR APPLICATION NUMBER: 60/217,251  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 09/663,968  
PRIOR FILING DATE: 2000-09-19  
NUMBER OF SEQ ID NOS: 118  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 107  
LENGTH: 100  
TYPE: DNA  
ORGANISM: Homo sapien  
FEATURE:  
OTHER INFORMATION: Probe  
US-10-272-665-107  
Query Match 0.4%; Score 11.4; DB 1; Length 100;  
Best Local Similarity 56.8%; Pred. No. 4.5e+02;  
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
Qy 2598 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2634  
Db 3 CAAGGACTCTGCAAGGGGGACAGTGGAGGCCACAT 39  
RESULT 70  
US-10-273-321-107  
Sequence 107, Application US/10273321  
Publication No. US20030180749A1  
GENERAL INFORMATION:  
APPLICANT: Braun et al.  
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
FILE REFERENCE: 24736-2033B  
CURRENT APPLICATION NUMBER: US/10/273,321  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: 09/687,483  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 60/217,658  
PRIOR FILING DATE: 2000-07-10  
PRIOR APPLICATION NUMBER: 09/663,968  
PRIOR FILING DATE: 2000-09-19



```
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
; US-10-273-321-106

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGCGCTATTGTAATAGGTTTACGAGGACATAT 2634
DB 3 CAAGGACTCTCTCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 75
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
; US-10-272-756-106

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGCGCTATTGTAATAGGTTTACGAGGACATAT 2634
DB 3 CAAGGACTCTCTCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 76
US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
; US-10-273-228-106

Query Match      0.4%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2598 CAGGCGCTATTGTAATAGGTTTACGAGGACATAT 2634
DB 3 CAAGGACTCTCTCAAGGGGGACAGTGGAGGCCACAT 39

RESULT 77
US-09-951-121A-14/c
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-09-951-121A-14

Query Match      0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1837 TGCAGTAGTCTGGCCTGACATCTG 1860
DB 31 TGCAGGAGTCTTGGCCGCAATCCG 8

RESULT 78
US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
```

```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      3 TGCAGGAGTCCTTGGCGCCATCCG 26

RESULT 79
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      31 TGCAGGAGTCCTTGGCGCCATCCG 8

RESULT 80
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
```

```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match          0.4%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1837 TGCAGTAGTCTGGCTGACATCTG 1860
Db      3 TGCAGGAGTCCTTGGCGCCATCCG 26

RESULT 79
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.4%; Score 11.2; DB 1; Length 35;
Best Local Similarity 59.4%; Pred. No. 4e+02;
Matches 19; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 393 CAGAGATTCCTCTTCCAGGTGCGAGCGGC 424
Db      32 CACTGAGGACCAACGGGACAGTCAGCGCGGAGC 1

RESULT 82
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
```



```
/ PRIOR APPLICATION NUMBER: US 60/238,944
/ PRIOR FILING DATE: 2000-10-10
/ PRIOR APPLICATION NUMBER: US 60/271,581
/ PRIOR FILING DATE: 2001-02-26
/ PRIOR APPLICATION NUMBER: US 60/276,322
/ PRIOR FILING DATE: 2001-03-16
/ NUMBER OF SEQ ID NOS: 2
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 2
/ LENGTH: 38
/ TYPE: DNA
/ ORGANISM: Artificial
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match      0.4%; Score 11; DB 1; Length 38;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCCTCCAGGA 295
Db 30 CTCCTCCAGGA 20

RESULT 87
US-10-254-394-2/c
/ Sequence 2, Application US/10254394
/ Publication No. US20030096366A1
/ GENERAL INFORMATION:
/ APPLICANT: Knudsen, Ida Molgaard
/ TITLE OF INVENTION: Method for Production of Recombinant
/ TITLE OF INVENTION: Proteins in Eukaryote Cells
/ FILE REFERENCE: 6480.500-US
/ CURRENT APPLICATION NUMBER: US/10/254,394
/ CURRENT FILING DATE: 2002-09-25
/ PRIOR APPLICATION NUMBER: PCT/DK01/00632
/ PRIOR FILING DATE: 2001-10-02
/ PRIOR APPLICATION NUMBER: PCT/DK01/00634
/ PRIOR FILING DATE: 2001-10-02
/ PRIOR APPLICATION NUMBER: PA 2002 00460
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: 60/374,855
/ PRIOR FILING DATE: 2002-10-04
/ NUMBER OF SEQ ID NOS: 2
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 2
/ LENGTH: 38
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-10-254-394-2

Query Match      0.4%; Score 11; DB 1; Length 38;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 CTCCTCCAGGA 295
Db 30 CTCCTCCAGGA 20

RESULT 88
US-10-017-122-4/c
/ Sequence 4, Application US/10017122
/ Publication No. US20030087244A1
/ GENERAL INFORMATION:
/ APPLICANT: McCarthy, Jeanette
/ TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
/ FILE REFERENCE: MMI-007
/ CURRENT APPLICATION NUMBER: US/10/017,122
/ CURRENT FILING DATE: 2001-12-14

/ PRIOR APPLICATION NUMBER: 60/327,487
/ PRIOR FILING DATE: 2001-10-09
/ NUMBER OF SEQ ID NOS: 4
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 4
/ LENGTH: 31
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-017-122-4

Query Match      0.4%; Score 10.6; DB 1; Length 31;
Best Local Similarity 64.0%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 280 GATCACTCTCTCCAGGACGACGAGG 304
Db 27 GAGTACCCCTCATGCGACGACGAGG 3

RESULT 89
US-09-951-121A-14
/ Sequence 14, Application US/09951121A
/ Publication No. US20030104978A1
/ GENERAL INFORMATION:
/ APPLICANT: Persson, Egon
/ TITLE OF INVENTION: Human Coagulation Factor VII Variants
/ FILE REFERENCE: 6224.200-US
/ CURRENT APPLICATION NUMBER: US/09/951,121A
/ CURRENT FILING DATE: 2001-09-13
/ PRIOR APPLICATION NUMBER: PA 2000 01361
/ PRIOR FILING DATE: 2000-09-13
/ PRIOR APPLICATION NUMBER: 60/236,455
/ PRIOR FILING DATE: 2000-09-29
/ NUMBER OF SEQ ID NOS: 17
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 14
/ LENGTH: 33
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match      0.4%; Score 10.6; DB 1; Length 33;
Best Local Similarity 76.5%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 261 TGGAGGCTATGGCTCTCT 277
Db 12 TGGCGGCAAGGACTCTCT 28

RESULT 90
US-09-951-121A-15/c
/ Sequence 15, Application US/09951121A
/ Publication No. US20030104978A1
/ GENERAL INFORMATION:
/ APPLICANT: Persson, Egon
/ TITLE OF INVENTION: Human Coagulation Factor VII Variants
/ FILE REFERENCE: 6224.200-US
/ CURRENT APPLICATION NUMBER: US/09/951,121A
/ CURRENT FILING DATE: 2001-09-13
/ PRIOR APPLICATION NUMBER: PA 2000 01361
/ PRIOR FILING DATE: 2000-09-13
/ PRIOR APPLICATION NUMBER: 60/236,455
/ PRIOR FILING DATE: 2000-09-29
/ NUMBER OF SEQ ID NOS: 17
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 15
/ LENGTH: 33
/ TYPE: DNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match      0.4%; Score 10.6; DB 1; Length 33;
Best Local Similarity 76.5%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Query 261 TGGAGGCTATGGCTCCT 277
      ||| ||| ||| ||| |||
Db 22 TGGCGGCAAGGACTCCT 6

RESULT 91
US-10-295-682-14
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-29
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match      0.4%; Score 10.6; DB 1; Length 33;
Best Local Similarity 76.5%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Query 261 TGGAGGCTATGGCTCCT 277
      ||| ||| ||| ||| |||
Db 12 TGGCGGCAAGGACTCCT 28

RESULT 92
US-10-295-682-15/c
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-29
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match      0.4%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Query 2438 CACGTTGAGGACTCGAA 2454
      ||| ||| ||| ||| |||
Db 33 CACGTTGAGGACTCGA 17

RESULT 94
US-09-951-121A-9
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match      0.4%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Query 2438 CACGTTGAGGACTCGAA 2454
      ||| ||| ||| ||| |||
Db 33 CACGTTGAGGACTCGA 17

```

Db 4 CACGTTGAGGACCTGGA 20  
|||||

RESULT 95  
US-10-255-032-8/c  
; Sequence 8, Application US/10255032  
; Publication No. US20030100075A1  
; GENERAL INFORMATION:  
; APPLICANT: NO. US20030100075A10 No. US20030100075A1disk A/S  
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES  
; FILE REFERENCE: 6357-WO  
; CURRENT APPLICATION NUMBER: US/10/255,032  
; PRIOR FILING DATE: 2002-09-24  
; PRIOR APPLICATION NUMBER: DK PA 2001 01413  
; PRIOR FILING DATE: 2001-09-27  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 8  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII  
US-10-255-032-8

Query Match 0.4%; Score 10.6; DB 1; Length 36;  
Best Local Similarity 76.5%; Pred. No. 6.1e+02;  
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454  
|||||

Db 33 CACGTTGAGGACCTGGA 17  
|||||

RESULT 96  
US-10-255-032-9  
; Sequence 9, Application US/10255032  
; Publication No. US20030100075A1  
; GENERAL INFORMATION:  
; APPLICANT: NO. US20030100075A10 No. US20030100075A1disk A/S  
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES  
; FILE REFERENCE: 6357-WO  
; CURRENT APPLICATION NUMBER: US/10/255,032  
; PRIOR FILING DATE: 2002-09-24  
; PRIOR APPLICATION NUMBER: DK PA 2001 01413  
; PRIOR FILING DATE: 2001-09-27  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 9  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII  
US-10-255-032-9

Query Match 0.4%; Score 10.6; DB 1; Length 36;  
Best Local Similarity 76.5%; Pred. No. 6.1e+02;  
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454  
|||||

Db 4 CACGTTGAGGACCTGGA 20  
|||||

RESULT 97  
US-10-295-682-8/c  
; Sequence 8, Application US/10295682  
; Publication No. US200301000740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 8  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-8

Query Match 0.4%; Score 10.6; DB 1; Length 36;  
Best Local Similarity 76.5%; Pred. No. 6.1e+02;  
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454  
|||||

Db 33 CACGTTGAGGACCTGGA 17  
|||||

RESULT 98  
US-10-295-682-9  
; Sequence 9, Application US/10295682  
; Publication No. US200301000740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 9  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-9

Query Match 0.4%; Score 10.6; DB 1; Length 36;  
Best Local Similarity 76.5%; Pred. No. 6.1e+02;  
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2438 CACTTTCAGGTCCTGAA 2454  
|||||

Db 4 CACGTTGAGGACCTGGA 20  
|||||

RESULT 99  
US-10-272-665-23  
; Sequence 23, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POL  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483



```

; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 415 CAGCGAGGGCCATGGCT 431
Db 41 CAGCTGGGGCCAGGGCT 57

RESULT 100
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
Db 42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 101
US-10-273-321-23
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
Db 42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 102
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
Db 42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 103
US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; FILE REFERENCE: 24736-2033B
```

```

; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 415 CAGCGAGGGCCATGGCT 431
Db 41 CAGCTGGGGCCAGGGCT 57

RESULT 102
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match      0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1521 TTGGATTCTTGTATCTTGCACCTGTGAGTGTGTGTGTG 1561
Db 42 TGACGATGCCCGTCAGGTACCGTCCCGGTAGTGGTG 2

RESULT 103
US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
```

```
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 415 CAGCGAGGCCGCGGCT 431
DB 41 CAGCTGGGGCCAGGGCT 57
```

## RESULT 104

```
US-10-272-756-23/c
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
```

```
QY 1521 TGTGATCTTTGTTATCTTGCACTGTGCAAGTGTGTGTG 1561
DB 42 TGACGATGCCGTCAGGTACCAAGTGTGTGTGTG 2
```

## RESULT 105

```
US-10-273-228-23
; Sequence 23, Application US/10273228
```

```
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 76.5%; Pred. No. 6.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 415 CAGCGAGGCCGCGGCT 431
DB 41 CAGCTGGGGCCAGGGCT 57
```

## RESULT 106

```
US-10-273-228-23/c
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23
```

```
Query Match 0.4%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 6.7e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
```

```
QY 1521 TGTGATCTTTGTTATCTTGCACTGTGCAAGTGTGTGTG 1561
DB 42 TGACGATGCCGTCAGGTACCAAGTGTGTGTGTG 2
```

```
RESULT 107
US-10-281-727-2
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match 0.4%; Score 10.2; DB 1; Length 35;
Best Local Similarity 80.0%; Pred. No. 7.7e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 73 GCTTCATCTGCACTG 87
DB 1 GCTCCGCTGCACTG 15

RESULT 110
US-10-109-498-6/c
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6

Query Match 0.4%; Score 10.2; DB 1; Length 35;
Best Local Similarity 80.0%; Pred. No. 7.7e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 73 GCTTCATCTGCACTG 87
DB 35 GCTCCGCTGCACTG 21

RESULT 111
US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US2003020247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
```

US-10-281-727-2 DNA primer for preparation of S314E/K316H-FVII

Query Match 0.4%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 70.0%; Pred. No. 7e+02;  
Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 405 CTTCCAGGTGCGAGCGGC 424  
DB 1 CTGCTGCGAGGAAACGC 20

US-10-281-727-3/c

; Sequence 3, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII  
US-10-281-727-3

Query Match 0.4%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 70.0%; Pred. No. 7e+02;  
Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 405 CTTCCAGGTGCGAGCGGC 424  
DB 36 CTGCTGCGAGGAAACGC 17

RESULT 109  
US-10-109-498-5  
; Sequence 5, Application US/10109498

```
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match      0.4%; Score 10; DB 1; Length 54;
Best Local Similarity 61.5%; Pred. No. 8.3e+02;
Matches 16; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 394 AGAGTTGCTCTTCAGTGCAGGC 419
Db 1 AGAGTCTTCTTAACCCAGGAGGAGC 26

RESULT 112
US-10-017-122-4
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match      0.3%; Score 9.4; DB 1; Length 31;
Best Local Similarity 68.4%; Pred. No. 1.1e+03;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 131 TTCTGCTGTGTCATATG 149
Db 2 TCCTGCTGTCATATG 20

RESULT 113
US-09-951-121A-2
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match      0.3%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.8%; Pred. No. 1.2e+03;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1548 GAAAGTGTGTGTGTGTGTGTG 1569
Db 32 GAATTGTGGGGCGCGGTGTG 11

RESULT 114
US-09-951-121A-3/c
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match      0.3%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.8%; Pred. No. 1.2e+03;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1548 GAAAGTGTGTGTGTGTGTGTG 1569
Db 32 GAATTGTGGGGCGCGGTGTG 11

RESULT 115
US-10-295-682-2
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2
```

## US-10-295-682-2

Query Match 0.3%; Score 9.2; DB 1; Length 34;  
Best Local Similarity 63.6%; Pred. No. 1.2e+03;  
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1548 GAAGTGTGTGTGTGTGTGTG 1569  
Db 3 GAATTGTGGGGCGCGGTGTG 24  
|||||

## RESULT 116

US-10-295-682-3/c  
; Sequence 3, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Nelsson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295.682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-3

Query Match 0.3%; Score 9.2; DB 1; Length 34;  
Best Local Similarity 63.6%; Pred. No. 1.2e+03;  
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1548 GAAGTGTGTGTGTGTGTGTG 1569  
Db 32 GAATTGTGGGGCGCGGTGTG 11  
|||||

## RESULT 117

US-09-803-810-8/c  
; Sequence 8, Application US/09803810  
; Publication No. US20010018414A1  
; GENERAL INFORMATION:  
; APPLICANT: Nelsson, Gary L.  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/09/803,810  
; CURRENT FILING DATE: 2001-03-12  
; NUMBER OF SEQ ID NOS: 18  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-09-803-810-8

Query Match 0.3%; Score 8.8; DB 1; Length 42;  
Best Local Similarity 57.1%; Pred. No. 1.2e+03;  
Matches 16; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 286 TCCTCCAGGAGCGGAGAGCGCT 313  
Db 41 TCCTGAGGAGCTCCGTCCAGCAGCT 14  
|||||

## RESULT 118

US-10-298-330-8/c  
; Sequence 8, Application US/10298330  
; Publication No. US20030100506A1  
; GENERAL INFORMATION:  
; APPLICANT: Nelsson, Gary L.  
; TITLE OF INVENTION: Modified Vitamin K-Dependent  
; FILE REFERENCE: 09531-127001  
; CURRENT APPLICATION NUMBER: US/10/298,330  
; CURRENT FILING DATE: 2002-11-18  
; PRIOR APPLICATION NUMBER: 09/497,591  
; PRIOR FILING DATE: 2000-02-03  
; PRIOR APPLICATION NUMBER: 09/302,239  
; PRIOR FILING DATE: 1999-04-29  
; PRIOR APPLICATION NUMBER: 08/955,636  
; PRIOR FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-298-330-8

Query Match 0.3%; Score 8.8; DB 1; Length 42;  
Best Local Similarity 57.1%; Pred. No. 1.2e+03;  
Matches 16; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 286 TCCTCCAGGAGCGGAGAGCGCT 313  
Db 41 TCCTGAGGAGCTCCGTCCAGCAGCT 14  
|||||

## RESULT 119

US-09-951-121A-2/c  
; Sequence 2, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-2

Query Match 0.3%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 54.8%; Pred. No. 1.4e+03;  
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 177 CACTGTGTGTACCAATCTCTCTCCCAATT 207  
Db 34 CCCTTGGGCACACCGCGCCCCCAATT 4  
|||||

## RESULT 120

US-09-951-121A-3  
; Sequence 3, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-3

Query Match 0.3%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 54.8%; Pred. No. 1.4e+03;  
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 177 CACTGTGTTTACCCATCTCTTCTCCCAATT 207  
Db 1 CCTTTGGGGCACACCGCGCCCCCACAATT 31

## RESULT 121

US-10-295-682-2/c  
; Sequence 2, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-2

Query Match 0.3%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 54.8%; Pred. No. 1.4e+03;  
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 177 CACTGTGTTTACCCATCTCTTCTCCCAATT 207  
Db 34 CCTTTGGGGCACACCGCGCCCCCACAATT 4

## RESULT 122

US-10-295-682-3  
; Sequence 3, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-3

Query Match 0.3%; Score 8.6; DB 1; Length 34;  
Best Local Similarity 54.8%; Pred. No. 1.4e+03;  
Matches 17; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 177 CACTGTGTTTACCCATCTCTTCTCCCAATT 207  
Db 1 CCTTTGGGGCACACCGCGCCCCCACAATT 31

Search completed: August 9, 2004, 15:30:37  
Job time : 36 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 15:31:08 ; Search time 4 seconds  
(without alignments)  
3.740 Million cell updates/sec

Title: us-10-664-775-1  
Perfect score: 2715  
Sequence: 1 ctgcaggagagggacagg.....ttgtaattctaggtgctgat 2715

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 4 seqs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries

Database : rstdb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----|-------------|
| C 1        | 20.6  | 0.8         | 1201   | 1  | AL531727    |
| C 2        | 19.8  | 0.7         | 645    | 1  | AL116939    |
| C 3        | 18    | 0.7         | 1201   | 1  | AL531727    |
| C 4        | 17.2  | 0.6         | 609    | 1  | AL099321    |
| C 5        | 17.2  | 0.6         | 645    | 1  | AL116939    |
| C 6        | 17    | 0.6         | 300    | 1  | AU099140    |
| C 7        | 16.3  | 0.6         | 609    | 1  | AL099321    |
| C 8        | 14    | 0.5         | 300    | 1  | AU099140    |

ALIGNMENTS

RESULT 1  
AL531727/c 1201 bp mRNA linear EST 23-MAY-2003  
LOCUS  
DEFINITION  
AL531727 Homo sapiens PITAL LIVER Homo sapiens cDNA clone  
CS0DM003Y101 5-PRIME, mRNA sequence.

ACCESSION  
AL531727  
VERSION  
AL531727.2 GI:31069559  
KEYWORDS  
EST.  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens

REFERENCE  
1. (bases 1 to 1201)  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS  
Li, W.B., Gruber, C., Jesse, J. and Polayes, D.  
TITLE  
Full-length cDNA libraries and normalization  
JOURNAL  
Unpublished (2001)  
COMMENT  
On Feb 13, 2001 this sequence version replaced gi:12795220.

Contact: Genoscope  
Genoscope - Centre National de Sequencage  
BP 191 91006 EVRY cedex - France

Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr  
Library was constructed by Life Technologies, a division of  
Invitrogen. This sequence belongs to sequence cluster 7252.f For  
more information about this cluster, see  
http://www.genoscope.cns.fr/  
cgi-bin/cluster.cgi?seq=CS0DM003AE01QP1&cluster=7252.f. Contact :  
Feng Liang Email : fliang@lifetech.com URL :  
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600  
Faraday Avenue Genoscope sequence ID : CS0DM003AE01QP1.

FEATURES  
source

1. 1201  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CS0DM003Y101"  
/tissue\_type="FETAL LIVER"  
/dev\_stage="fetal"  
/clone\_lib="Homo sapiens FETAL LIVER"  
/notes="Organ: liver; Vector: pCMVSPORT 6; 1st strand cDNA  
was primed with a NotI-oligo(dT) primer. Five prime end  
enriched, double-strand cDNA was digested with Not I and  
cloned into the Not I and EcoRV sites of the pCMVSPORT 6  
vector. Library was not normalized."

Query Match 0.8%; Score 20.6; DB 1; Length 1201;  
Best Local Similarity 59.3%; Pred. No. 0.31;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 876 TTCAATTGCTTTTATCTGCGAGACTTGGTTTGTGAAATATGATTCATTTGG 934  
DB 648 TTGCTGCGCATTTCTTTTCTAGATAGTATTTTCCATGATATCACTGG 590

RESULT 2  
AL116939/c

LOCUS  
DEFINITION

AL116939 645 bp mRNA linear EST 02-SEP-1998  
ue29g08.v1 Sugano mouse liver mlia Mus musculus cDNA clone  
IMAGE:1481822 5', similar to gb:M13232 CORRELATION FACTOR VII  
PRECURSOR (HUMAN) ;, mRNA sequence.

ACCESSION  
AL116939

VERSION  
AL116939.1 GI:3517263

KEYWORDS  
EST.

SOURCE  
Mus musculus (house mouse)

ORGANISM  
Mus musculus

REFERENCE  
1 (bases 1 to 645)

AUTHORS  
Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T.,  
Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M.,  
Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B.,  
Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and  
Waterston, R.

TITLE  
The WashU-HMI Mouse EST Project

JOURNAL  
Unpublished (1996)

COMMENT  
Contact: Maxra M/Mouse EST Project  
WashU-HMI Mouse EST Project  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu  
This clone is available royalty-free through LNL ; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.

MGI:930178

Seq primer: custom primer used  
High quality sequence stop: 483.

Location/Qualifiers  
1. 645

/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"

/db\_xref="taxon:10090"  
/clone="IMAGE:1481822"

FEATURES  
source





Email: [mousestewatson.wustl.edu](mailto:mousestewatson.wustl.edu)  
 This clone is available royalty-free through LNL ; contact the  
 IMAGE Consortium ([info@image.lnl.gov](mailto:info@image.lnl.gov)) for further information.  
 MGI:930865  
 Fax: 314 286 1810

Seq primer: custom primer used  
High quality sequence stop: 289.

## FEATURES

## source

1..609  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1482509"  
/sex="female"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/clone\_lib="Sugano mouse liver mlia"  
/note="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII (CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA was primed with an oligo(dT) primer [ATGTGGCTTTTCTTTTCTTTT]; double-stranded cDNA was ligated to a DraIII adaptor [TCGTGGCCTACTGG], digested and cloned into distinct DraIII sites of the pME18S-FL3 vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should be used to isolate the cDNA insert. Size selection was performed to exclude fragments <1.5kb. Library constructed by Dr. Sumio Sugano (University of Tokyo Institute of Medical Science). Custom primers for sequencing: 5' end primer CTCTGCTCTAAAGCTGG and 3' end primer CGACCTGAGCTCGAGACA."

Query Match. 0.6%; Score 16.3; DB 1; Length 609;  
Best Local Similarity 63.5%; Pred. No. 6.5;  
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;  
QY 602 GGGCTGCTCCCTTCTCCCTGCTGATCTCCTAGGCTGAGGTTAC-CACTGCTCTCTCTC 660  
Db 209 GGGCTTCTGAAGATCTCCGGGCTCTCCTCAAGAGGACACTGTTCTCTATTGCATCTCTC 150  
QY 661 TCC 663  
Db 149 TCC 147

## RESULT 8

## AU099140/c

## LOCUS

DEFINITION AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
HEP20983 similar to Human factor VII serine protease precursor mRNA  
clone lambda-HV112463, mRNA sequence.

## ACCESSION

AU099140

VERSION AU099140.1 GI:13550269

## KEYWORDS

EST.

## SOURCE

ORGANISM

Homo sapiens (human)

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 300)

Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J.,

Hata,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S.,

Okubo,K., Suyama,A. and Sugano,S.

In silico mapping of the 5'-ends of human mRNAs using full-length

enriched and 5'-end enriched cDNA libraries constructed by

Oligo-capping method

Unpublished (2001)

Contact: Yutaka Suzuki

Department of Virology

Institute of Medical Science, University of Tokyo

4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan

Email: ysuzuki@ims.u-tokyo.ac.jp

Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and

Sugano,S. Construction and characterization of a full

length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),

149-156 (1997).

## FEATURES

## source

1..300  
/organism="Homo sapiens"

/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="HEP20983"  
/clone\_lib="Sugano Homo sapiens cDNA library"

Query Match 0.5%; Score 14; DB 1; Length 300;  
Best Local Similarity 50.0%; Pred. No. 18;  
Matches 35; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 324 CTCCTCTAGATGCTGGCAGGCCCAATGATCATGTGTCAGTCCCTGGGTACAGGCATGG 383  
Db 235 CTCGGGGCTCTCGAAGGAGCACTGCTCTCTTGCCTCTCTCCAGGAGCCCG 176  
QY 384 CCATGGCTCC 393  
Db 175 CCGCAGCTCC 166

Search completed: August 9, 2004, 15:31:12  
Job time : 4 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 15:32:59 ; Search time 1102 Seconds  
(without alignments)  
3.915 Million cell updates/sec

Title: us-10-664-775-2

Perfect score: 3572

Sequence: 1 gtcaggagggcgagtgga.....gcaacaacagcagaagctt 3572

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rgedb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description        |
|------------|-------|-------------|--------|----|--------------------|
| 1          | 39.4  | 1.1         | 289    | 1  | ACCESSION:AR162089 |
| 2          | 39.4  | 1.1         | 289    | 1  | ACCESSION:AR166614 |
| 3          | 37.6  | 1.1         | 1573   | 1  | ACCESSION:BC040125 |
| 4          | 33.4  | 0.9         | 1671   | 1  | ACCESSION:AY040345 |
| 5          | 30.8  | 0.9         | 1671   | 1  | ACCESSION:AY040345 |
| 6          | 30.2  | 0.8         | 289    | 1  | ACCESSION:AR162089 |
| 7          | 30.2  | 0.8         | 289    | 1  | ACCESSION:AR166614 |
| 8          | 29.6  | 0.8         | 1792   | 1  | ACCESSION:BC034377 |
| 9          | 28.8  | 0.8         | 1403   | 1  | ACCESSION:BC009726 |
| 10         | 27.7  | 0.8         | 1843   | 1  | ACCESSION:AR390799 |
| 11         | 27.7  | 0.8         | 1843   | 1  | ACCESSION:AR411026 |
| 12         | 27.2  | 0.8         | 387    | 1  | ACCESSION:AR263863 |
| 13         | 26.6  | 0.7         | 364    | 1  | ACCESSION:AR425705 |
| 14         | 26.6  | 0.7         | 364    | 1  | ACCESSION:BD121258 |
| 15         | 26.6  | 0.7         | 364    | 1  | ACCESSION:BD121258 |
| 16         | 26.2  | 0.7         | 230    | 1  | ACCESSION:AY022485 |
| 17         | 26.2  | 0.7         | 828    | 1  | ACCESSION:E40571   |
| 18         | 25.8  | 0.7         | 829    | 1  | ACCESSION:BC061135 |
| 19         | 25.6  | 0.7         | 2438   | 1  | ACCESSION:107991   |
| 20         | 25.2  | 0.7         | 1869   | 1  | ACCESSION:BC061149 |
| 21         | 25    | 0.7         | 882    | 1  | ACCESSION:AX675583 |
| 22         | 24.9  | 0.7         | 364    | 1  | ACCESSION:AR425705 |
| 23         | 24.9  | 0.7         | 364    | 1  | ACCESSION:BD121258 |
| 24         | 24.8  | 0.7         | 227    | 1  | ACCESSION:AY022941 |
| 25         | 24.8  | 0.7         | 251    | 1  | ACCESSION:AY028953 |
| 26         | 24.8  | 0.7         | 873    | 1  | ACCESSION:M35672   |
| 27         | 24.8  | 0.7         | 2177   | 1  | ACCESSION:E01075   |
| 28         | 24.6  | 0.7         | 352    | 1  | ACCESSION:M57841   |
| 29         | 24.6  | 0.7         | 1332   | 1  | ACCESSION:AF321182 |
| 30         | 24.6  | 0.7         | 1378   | 1  | ACCESSION:AR410811 |
| 31         | 24.6  | 0.7         | 1378   | 1  | ACCESSION:AX697671 |
| 32         | 24.6  | 0.7         | 1378   | 1  | ACCESSION:BD075581 |
| 33         | 24.6  | 0.7         | 1378   | 1  | ACCESSION:BD172441 |

|     |      |     |      |   |          |
|-----|------|-----|------|---|----------|
| 34  | 24.6 | 0.7 | 1378 | 1 | BD172760 |
| 35  | 24.6 | 0.7 | 1378 | 1 | BD173079 |
| 36  | 24.6 | 0.7 | 1378 | 1 | BD173398 |
| 37  | 24.6 | 0.7 | 1378 | 1 | BD175432 |
| 38  | 24.6 | 0.7 | 1378 | 1 | AY358396 |
| 39  | 24.6 | 0.7 | 1403 | 1 | BC009726 |
| 40  | 24.2 | 0.7 | 1573 | 1 | BC040125 |
| 41  | 23.8 | 0.7 | 813  | 1 | PIGFXA   |
| 42  | 23.6 | 0.7 | 1580 | 1 | AF318182 |
| 43  | 23.4 | 0.7 | 596  | 1 | AX193364 |
| 44  | 23.4 | 0.7 | 1142 | 1 | AR219285 |
| 45  | 23.4 | 0.7 | 1161 | 1 | AX675581 |
| 46  | 23.4 | 0.7 | 1169 | 1 | AR219284 |
| 47  | 23.4 | 0.7 | 1507 | 1 | AX774765 |
| 48  | 23.4 | 0.7 | 1507 | 1 | HUMFACX  |
| 49  | 23.4 | 0.7 | 1541 | 1 | BC046125 |
| 50  | 23.2 | 0.6 | 429  | 1 | BC034377 |
| 51  | 23.2 | 0.6 | 823  | 1 | SHPFIXA  |
| 52  | 23.2 | 0.6 | 823  | 1 | SHPFIXA  |
| 53  | 23   | 0.6 | 224  | 1 | AY023240 |
| 54  | 23   | 0.6 | 244  | 1 | HSB4901  |
| 55  | 23   | 0.6 | 873  | 1 | HUMCFIX  |
| 56  | 23   | 0.6 | 1293 | 1 | AF465275 |
| 57  | 23   | 0.6 | 2438 | 1 | 107991   |
| 58  | 22.8 | 0.6 | 264  | 1 | BD180174 |
| 59  | 22.8 | 0.6 | 1373 | 1 | BOVPBC   |
| 60  | 22.6 | 0.6 | 535  | 1 | DLA6882  |
| 61  | 22.6 | 0.6 | 1416 | 1 | AF465269 |
| 62  | 22.6 | 0.6 | 1722 | 1 | AF515269 |
| 63  | 22.6 | 0.6 | 2177 | 1 | E01075   |
| 64  | 22.4 | 0.6 | 186  | 1 | AX310356 |
| 65  | 22.4 | 0.6 | 1302 | 1 | AF465270 |
| 66  | 22.2 | 0.6 | 832  | 1 | AF011900 |
| 67  | 22   | 0.6 | 534  | 1 | AX527570 |
| 68  | 22   | 0.6 | 741  | 1 | HUMMA    |
| 69  | 22   | 0.6 | 741  | 1 | E01617   |
| 70  | 22   | 0.6 | 744  | 1 | E09633   |
| 71  | 22   | 0.6 | 790  | 1 | E15808   |
| 72  | 22   | 0.6 | 821  | 1 | BC030238 |
| 73  | 22   | 0.6 | 853  | 1 | HSTRPIV  |
| 74  | 21.8 | 0.6 | 121  | 1 | AX265053 |
| 75  | 21.8 | 0.6 | 121  | 1 | AX265054 |
| 76  | 21.8 | 0.6 | 121  | 1 | AX265057 |
| 77  | 21.8 | 0.6 | 121  | 1 | AX265058 |
| 78  | 21.8 | 0.6 | 170  | 1 | HSMTOB3  |
| 79  | 21.8 | 0.6 | 227  | 1 | AY023453 |
| 80  | 21.8 | 0.6 | 522  | 1 | AX527554 |
| 81  | 21.8 | 0.6 | 603  | 1 | BTTHRO   |
| 82  | 21.8 | 0.6 | 711  | 1 | BD173590 |
| 83  | 21.8 | 0.6 | 1759 | 1 | E01189   |
| 84  | 21.6 | 0.6 | 251  | 1 | AY083553 |
| 85  | 21.6 | 0.6 | 375  | 1 | AY179347 |
| 86  | 21.6 | 0.6 | 427  | 1 | AX524284 |
| 87  | 21.6 | 0.6 | 427  | 1 | AX553022 |
| 88  | 21.6 | 0.6 | 483  | 1 | MUSBALB6 |
| 89  | 21.6 | 0.6 | 596  | 1 | BV094002 |
| 90  | 21.6 | 0.6 | 1499 | 1 | MUSCP    |
| 91  | 21.6 | 0.6 | 1603 | 1 | BC013896 |
| 92  | 21.6 | 0.6 | 1722 | 1 | AF515269 |
| 93  | 21.6 | 0.6 | 6098 | 1 | AX565990 |
| 94  | 21.4 | 0.6 | 172  | 1 | AX814615 |
| 95  | 21.4 | 0.6 | 243  | 1 | AR430737 |
| 96  | 21.4 | 0.6 | 243  | 1 | AX028553 |
| 97  | 21.4 | 0.6 | 291  | 1 | AF336229 |
| 98  | 21.4 | 0.6 | 352  | 1 | HUMPS02  |
| 99  | 21.4 | 0.6 | 861  | 1 | AF011352 |
| 100 | 21.4 | 0.6 | 1329 | 1 | AF465274 |
| 101 | 21.4 | 0.6 | 1341 | 1 | AF532184 |
| 102 | 21.2 | 0.6 | 505  | 1 | AR263865 |
| 103 | 21.2 | 0.6 | 609  | 1 | AX763043 |
| 104 | 21.2 | 0.6 | 888  | 1 | AX360070 |
| 105 | 21.2 | 0.6 | 1130 | 1 | AR234337 |
| 106 | 21.2 | 0.6 | 1166 | 1 | AR221273 |

|       |      |     |      |   |           |                    |       |      |     |      |   |          |                    |
|-------|------|-----|------|---|-----------|--------------------|-------|------|-----|------|---|----------|--------------------|
| C 107 | 21.2 | 0.6 | 6098 | 1 | AX565590  | ACCESSION:AX565590 | C 180 | 20.4 | 0.6 | 1386 | 1 | I08112   | ACCESSION:I08112   |
| C 108 | 21   | 0.6 | 252  | 1 | HSU29334  | ACCESSION:U929334  | C 181 | 20.4 | 0.6 | 1386 | 1 | AR404692 | ACCESSION:AR404692 |
| C 109 | 21   | 0.6 | 255  | 1 | HSU59442  | ACCESSION:U99442   | C 182 | 20.4 | 0.6 | 1386 | 1 | AR404695 | ACCESSION:AR404695 |
| C 110 | 21   | 0.6 | 260  | 1 | HUMHCD21A | ACCESSION:M94617   | C 183 | 20.4 | 0.6 | 1386 | 1 | AR404696 | ACCESSION:AR404696 |
| C 111 | 21   | 0.6 | 285  | 1 | HUMDP111  | ACCESSION:L00599   | C 184 | 20.4 | 0.6 | 1386 | 1 | AX044042 | ACCESSION:AX044042 |
| C 112 | 21   | 0.6 | 535  | 1 | PWA344566 | ACCESSION:AF011901 | C 185 | 20.4 | 0.6 | 1386 | 1 | AX149640 | ACCESSION:AX149640 |
| C 113 | 21   | 0.6 | 836  | 1 | AF011901  | ACCESSION:AF011901 | C 186 | 20.4 | 0.6 | 1386 | 1 | AX149641 | ACCESSION:AX149641 |
| C 114 | 21   | 0.6 | 850  | 1 | AX333326  | ACCESSION:AX333326 | C 187 | 20.4 | 0.6 | 1386 | 1 | AX149643 | ACCESSION:AX149643 |
| C 115 | 21   | 0.6 | 850  | 1 | HSTRY1VB  | ACCESSION:X11345   | C 188 | 20.4 | 0.6 | 1386 | 1 | AX149646 | ACCESSION:AX149646 |
| C 116 | 21   | 0.6 | 933  | 1 | AR253972  | ACCESSION:AR253972 | C 189 | 20.4 | 0.6 | 1386 | 1 | AX077784 | ACCESSION:AX077784 |
| C 117 | 21   | 0.6 | 1416 | 1 | AF465269  | ACCESSION:AF465269 | C 190 | 20.4 | 0.6 | 1386 | 1 | AX212331 | ACCESSION:AX212331 |
| C 118 | 21   | 0.6 | 1551 | 1 | AX147505  | ACCESSION:AX147505 | C 191 | 20.4 | 0.6 | 1386 | 1 | AR070468 | ACCESSION:AR070468 |
| C 119 | 21   | 0.6 | 1850 | 1 | MMU44795  | ACCESSION:U44795   | C 192 | 20.4 | 0.6 | 1386 | 1 | BD246884 | ACCESSION:BD246884 |
| C 120 | 21   | 0.6 | 1869 | 1 | BC061149  | ACCESSION:BC061149 | C 193 | 20.4 | 0.6 | 1386 | 1 | AR404693 | ACCESSION:AR404693 |
| C 121 | 21   | 0.6 | 2078 | 1 | AF272773  | ACCESSION:AF272773 | C 194 | 20.4 | 0.6 | 1386 | 1 | AX044043 | ACCESSION:AX044043 |
| C 122 | 21   | 0.6 | 2422 | 1 | AR030786  | ACCESSION:AR030786 | C 195 | 20.4 | 0.6 | 1386 | 1 | AX149642 | ACCESSION:AX149642 |
| C 123 | 21   | 0.6 | 2422 | 1 | AR045090  | ACCESSION:AR045090 | C 196 | 20.4 | 0.6 | 1386 | 1 | AX149645 | ACCESSION:AX149645 |
| C 124 | 21   | 0.6 | 2422 | 1 | AR052946  | ACCESSION:AR052946 | C 197 | 20.4 | 0.6 | 1386 | 1 | AX207785 | ACCESSION:AX207785 |
| C 125 | 21   | 0.6 | 2422 | 1 | AR122899  | ACCESSION:AR122899 | C 198 | 20.4 | 0.6 | 1386 | 1 | AX207787 | ACCESSION:AX207787 |
| C 126 | 21   | 0.6 | 2422 | 1 | AR127821  | ACCESSION:AR127821 | C 199 | 20.4 | 0.6 | 1386 | 1 | AX212332 | ACCESSION:AX212332 |
| C 127 | 21   | 0.6 | 2483 | 1 | E01076    | ACCESSION:E01076   | C 200 | 20.4 | 0.6 | 1386 | 1 | BD246885 | ACCESSION:BD246885 |
| C 128 | 21   | 0.6 | 2483 | 1 | I07990    | ACCESSION:I07990   | C 201 | 20.4 | 0.6 | 1386 | 1 | AR404694 | ACCESSION:AR404694 |
| C 129 | 20.9 | 0.6 | 394  | 1 | AX839180  | ACCESSION:AX839180 | C 202 | 20.4 | 0.6 | 1386 | 1 | AX044044 | ACCESSION:AX044044 |
| C 130 | 20.8 | 0.6 | 252  | 1 | I28675    | ACCESSION:I28675   | C 203 | 20.4 | 0.6 | 1386 | 1 | AX207786 | ACCESSION:AX207786 |
| C 131 | 20.8 | 0.6 | 290  | 1 | S55227    | ACCESSION:S55227   | C 204 | 20.4 | 0.6 | 1386 | 1 | AX207788 | ACCESSION:AX207788 |
| C 132 | 20.8 | 0.6 | 323  | 1 | BD076788  | ACCESSION:BD076788 | C 205 | 20.4 | 0.6 | 1386 | 1 | AX212333 | ACCESSION:AX212333 |
| C 133 | 20.8 | 0.6 | 380  | 1 | AX262154  | ACCESSION:AX262154 | C 206 | 20.4 | 0.6 | 1386 | 1 | BD246886 | ACCESSION:BD246886 |
| C 134 | 20.8 | 0.6 | 400  | 1 | AX262150  | ACCESSION:AX262150 | C 207 | 20.4 | 0.6 | 1386 | 1 | AX044045 | ACCESSION:AX044045 |
| C 135 | 20.8 | 0.6 | 823  | 1 | SHFPIXA   | ACCESSION:M62233   | C 208 | 20.4 | 0.6 | 1386 | 1 | AX212334 | ACCESSION:AX212334 |
| C 136 | 20.8 | 0.6 | 860  | 1 | AF011898  | ACCESSION:AF011898 | C 209 | 20.4 | 0.6 | 1387 | 1 | AR364387 | ACCESSION:AR364387 |
| C 137 | 20.8 | 0.6 | 1259 | 1 | HUMPRC7   | ACCESSION:MI2712   | C 210 | 20.4 | 0.6 | 2422 | 1 | AR030786 | ACCESSION:AR030786 |
| C 138 | 20.8 | 0.6 | 1338 | 1 | AX211659  | ACCESSION:AX211659 | C 211 | 20.4 | 0.6 | 2422 | 1 | AR045090 | ACCESSION:AR045090 |
| C 139 | 20.8 | 0.6 | 1357 | 1 | AX211661  | ACCESSION:AX211661 | C 212 | 20.4 | 0.6 | 2422 | 1 | AR052946 | ACCESSION:AR052946 |
| C 140 | 20.8 | 0.6 | 1366 | 1 | HUMPRC    | ACCESSION:K02059   | C 213 | 20.4 | 0.6 | 2422 | 1 | AR122899 | ACCESSION:AR122899 |
| C 141 | 20.8 | 0.6 | 1755 | 1 | AR363767  | ACCESSION:AR363767 | C 214 | 20.4 | 0.6 | 2422 | 1 | AR127821 | ACCESSION:AR127821 |
| C 142 | 20.8 | 0.6 | 1756 | 1 | I05477    | ACCESSION:I05477   | C 215 | 20.4 | 0.6 | 2462 | 1 | AR095304 | ACCESSION:AR095304 |
| C 143 | 20.6 | 0.6 | 228  | 1 | AX886683  | ACCESSION:AX886683 | C 216 | 20.4 | 0.6 | 2462 | 1 | AR103988 | ACCESSION:AR103988 |
| C 144 | 20.6 | 0.6 | 228  | 1 | BD026293  | ACCESSION:BD026293 | C 217 | 20.4 | 0.6 | 2462 | 1 | AX335083 | ACCESSION:AX335083 |
| C 145 | 20.6 | 0.6 | 312  | 1 | AX661018  | ACCESSION:AX661018 | C 218 | 20.4 | 0.6 | 2462 | 1 | AX049604 | ACCESSION:AX049604 |
| C 146 | 20.6 | 0.6 | 854  | 1 | PVTRYP5IN | ACCESSION:X86369   | C 219 | 20.4 | 0.6 | 2462 | 1 | HUMFVII  | ACCESSION:M13232   |
| C 147 | 20.6 | 0.6 | 867  | 1 | CMRECT    | ACCESSION:X78490   | C 220 | 20.4 | 0.6 | 2483 | 1 | E01076   | ACCESSION:E01076   |
| C 148 | 20.6 | 0.6 | 1514 | 1 | AF191307  | ACCESSION:AF191307 | C 221 | 20.4 | 0.6 | 2483 | 1 | I07990   | ACCESSION:I07990   |
| C 149 | 20.6 | 0.6 | 1843 | 1 | AR390799  | ACCESSION:AR390799 | C 222 | 20.2 | 0.6 | 240  | 1 | HS88A12R | ACCESSION:Z63615   |
| C 150 | 20.6 | 0.6 | 1843 | 1 | AX411026  | ACCESSION:AX411026 | C 223 | 20.2 | 0.6 | 241  | 1 | HS88A12P | ACCESSION:Z63614   |
| C 151 | 20.6 | 0.6 | 1843 | 1 | HSRPTC    | ACCESSION:X02750   | C 224 | 20.2 | 0.6 | 243  | 1 | MACNAFAE | ACCESSION:L76725   |
| C 152 | 20.4 | 0.6 | 121  | 1 | AX265021  | ACCESSION:AX265021 | C 225 | 20.2 | 0.6 | 378  | 1 | AB108823 | ACCESSION:AB108823 |
| C 153 | 20.4 | 0.6 | 121  | 1 | AX265022  | ACCESSION:AX265022 | C 226 | 20.2 | 0.6 | 582  | 1 | AY348554 | ACCESSION:AY348554 |
| C 154 | 20.4 | 0.6 | 121  | 1 | AX265033  | ACCESSION:AX265033 | C 227 | 20.2 | 0.6 | 582  | 1 | AY348553 | ACCESSION:AY348553 |
| C 155 | 20.4 | 0.6 | 121  | 1 | AX265034  | ACCESSION:AX265034 | C 228 | 20.2 | 0.6 | 694  | 1 | AB083690 | ACCESSION:AB083690 |
| C 156 | 20.4 | 0.6 | 121  | 1 | AX265037  | ACCESSION:AX265037 | C 229 | 20.2 | 0.6 | 696  | 1 | AB086852 | ACCESSION:AB086852 |
| C 157 | 20.4 | 0.6 | 121  | 1 | AX265038  | ACCESSION:AX265038 | C 230 | 20.2 | 0.6 | 696  | 1 | AB083693 | ACCESSION:AB083693 |
| C 158 | 20.4 | 0.6 | 121  | 1 | AX265041  | ACCESSION:AX265041 | C 231 | 20.2 | 0.6 | 696  | 1 | AB083695 | ACCESSION:AB083695 |
| C 159 | 20.4 | 0.6 | 121  | 1 | AX265042  | ACCESSION:AX265042 | C 232 | 20.2 | 0.6 | 696  | 1 | AB083696 | ACCESSION:AB083696 |
| C 160 | 20.4 | 0.6 | 121  | 1 | AX265045  | ACCESSION:AX265045 | C 233 | 20.2 | 0.6 | 697  | 1 | AB083694 | ACCESSION:AB083694 |
| C 161 | 20.4 | 0.6 | 121  | 1 | AX265046  | ACCESSION:AX265046 | C 234 | 20.2 | 0.6 | 747  | 1 | AY454079 | ACCESSION:AY454079 |
| C 162 | 20.4 | 0.6 | 121  | 1 | AX265049  | ACCESSION:AX265049 | C 235 | 20.2 | 0.6 | 1341 | 1 | AF532184 | ACCESSION:AF532184 |
| C 163 | 20.4 | 0.6 | 121  | 1 | AX265050  | ACCESSION:AX265050 | C 236 | 20.2 | 0.6 | 1505 | 1 | AX523898 | ACCESSION:AX523898 |
| C 164 | 20.4 | 0.6 | 160  | 1 | AY254094  | ACCESSION:AX265050 | C 237 | 20.2 | 0.6 | 2462 | 1 | AR095304 | ACCESSION:AR095304 |
| C 165 | 20.4 | 0.6 | 160  | 1 | AY307359  | ACCESSION:AX265042 | C 238 | 20.2 | 0.6 | 2462 | 1 | AR103988 | ACCESSION:AR103988 |
| C 166 | 20.4 | 0.6 | 160  | 1 | AY307360  | ACCESSION:AX265045 | C 239 | 20.2 | 0.6 | 2462 | 1 | AX335083 | ACCESSION:AX335083 |
| C 167 | 20.4 | 0.6 | 162  | 1 | AX254095  | ACCESSION:AX265049 | C 240 | 20.2 | 0.6 | 2462 | 1 | AX049604 | ACCESSION:AX049604 |
| C 168 | 20.4 | 0.6 | 196  | 1 | HS2338514 | ACCESSION:AX265046 | C 241 | 20.2 | 0.6 | 2462 | 1 | HUMFVII  | ACCESSION:M13232   |
| C 169 | 20.4 | 0.6 | 196  | 1 | S68634    | ACCESSION:AX238514 | C 242 | 20   | 0.6 | 199  | 1 | AX555170 | ACCESSION:AX555170 |
| C 170 | 20.4 | 0.6 | 315  | 1 | AX040017  | ACCESSION:AX040017 | C 243 | 20   | 0.6 | 256  | 1 | AF542508 | ACCESSION:AF542508 |
| C 171 | 20.4 | 0.6 | 334  | 1 | BD071430  | ACCESSION:BD071430 | C 244 | 20   | 0.6 | 276  | 1 | AF005089 | ACCESSION:AF005089 |
| C 172 | 20.4 | 0.6 | 394  | 1 | AX814618  | ACCESSION:AX814618 | C 245 | 20   | 0.6 | 300  | 1 | AR242808 | ACCESSION:AR242808 |
| C 173 | 20.4 | 0.6 | 414  | 1 | SSU51135  | ACCESSION:U51135   | C 246 | 20   | 0.6 | 478  | 1 | BD120361 | ACCESSION:BD120361 |
| C 174 | 20.4 | 0.6 | 855  | 1 | AF011899  | ACCESSION:AF011899 | C 247 | 20   | 0.6 | 483  | 1 | DOCFVII  | ACCESSION:D21213   |
| C 175 | 20.4 | 0.6 | 1326 | 1 | AF465273  | ACCESSION:AF465273 | C 248 | 20   | 0.6 | 488  | 1 | MUSBALB6 | ACCESSION:D43755   |
| C 176 | 20.4 | 0.6 | 1383 | 1 | AX427734  | ACCESSION:AX427734 | C 249 | 20   | 0.6 | 488  | 1 | AX263931 | ACCESSION:AX263931 |
| C 177 | 20.4 | 0.6 | 1386 | 1 | AX149644  | ACCESSION:AX149644 | C 250 | 20   | 0.6 | 1129 | 1 | AX464088 | ACCESSION:AX464088 |
| C 178 | 20.4 | 0.6 | 1386 | 1 | BD246883  | ACCESSION:BD246883 |       |      |     |      |   |          |                    |
| C 179 | 20.4 | 0.6 | 1386 | 1 | I06643    | ACCESSION:I06643   |       |      |     |      |   |          |                    |

## ALIGNMENTS

|                       |  |  |                 |             |         |                 |
|-----------------------|--|--|-----------------|-------------|---------|-----------------|
| RESULT 1              | AR162089   | Sequence 17 from patent US 6258558.                          | 289 bp          | DNA         | linear  | PAT 17-OCT-2001 |
| LOCUS                 | AR162089   |  |                 |             |         |                 |
| DEFINITION            | AR162089   |  |                 |             |         |                 |
| ACCESSION             | AR162089   |  |                 |             |         |                 |
| VERSION               | AR162089.1   | GI:16229155  |                 |             |         |                 |
| KEYWORDS              | Unknown.   |  |                 |             |         |                 |
| SOURCE                | Unknown.   |  |                 |             |         |                 |
| ORGANISM              | Unknown.   |  |                 |             |         |                 |
| REFERENCE             | 1 (bases 1 to 289)   |  |                 |             |         |                 |
| AUTHORS               | Szostak, J.W., Roberts, R.W. and Liu, R.                   |  |                 |             |         |                 |
| TITLE                 | Method for selection of proteins using RNA-protein fusions |  |                 |             |         |                 |
| JOURNAL               | Patent: US 6258558-A 17 10-JUL-2001;                       |  |                 |             |         |                 |
| FEATURES              | Location/Qualifiers  |  |                 |             |         |                 |
| source                | 1..289   |  |                 |             |         |                 |
|                       | /organism="unknown"  |  |                 |             |         |                 |
|                       | /mol_type="unassigned DNA"                                 |  |                 |             |         |                 |
| Query Match           | 1.1%;  | Score 39.4;  | DB 1;           | Length 289; |         |                 |
| Best Local Similarity | 12.9%;   | Pred. No. 0.0023;  |                 |             |         |                 |
| Matches               | 37;  | Conservative 100;  | Mismatches 150; | Indels 0;   | Gaps 0; |                 |
| Qy                    | 1356   | AGTGAGAAATAGATTAAAGCGCCCTAGATCTGATACAGAGTACCTAATGAACCTATGGAC | 1415            |             |         |                 |
| Db                    | 1  | RGGRGRCARARATRTAARCTRTAATTTTTRACRCARATRTTRACRCARATRTGGRNRN   | 60              |             |         |                 |
| Qy                    | 1416   | AGAGTTTCATGACATTTACAGGAGACAGGATCGAGACCATCCCATGGAAAGAAATG     | 1475            |             |         |                 |
| Db                    | 61   | RSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRN      | 120             |             |         |                 |
| Qy                    | 1476   | CAAAAAAGCAAAATCGCTGTCTGGGGAGCCCTTACAAATAGCTGTGAAAAGAGAGAACT  | 1535            |             |         |                 |
| Db                    | 121  | RSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRN      | 180             |             |         |                 |
| Qy                    | 1536   | GAAGAAGCAAGCAAAAGGAAAGATAAAGCATCTGAATGCAGAGTTCCAAAGAACTTC    | 1595            |             |         |                 |
| Db                    | 181  | RSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRNRSNRN      | 240             |             |         |                 |
| Qy                    | 1596   | CAGTTGTTCAAGCTGGTTTTAGAAAAAGTCAGAGGAACACAGAGACAA             | 1642            |             |         |                 |
| Db                    | 241  | RCRTTCRTTRGRCRCRTTAAAAAATAAAAAAATAAAAAAATAAAAAA              | 287             |             |         |                 |
| RESULT 2              | AR166614   | Sequence 17 from patent US 6281344.                          | 289 bp          | DNA         | linear  | PAT 17-OCT-2001 |
| LOCUS                 | AR166614   |  |                 |             |         |                 |
| DEFINITION            | AR166614   |  |                 |             |         |                 |
| ACCESSION             | AR166614   |  |                 |             |         |                 |
| VERSION               | AR166614.1   | GI:16242009  |                 |             |         |                 |
| KEYWORDS              | Unknown.   |  |                 |             |         |                 |
| SOURCE                | Unknown.   |  |                 |             |         |                 |
| ORGANISM              | Unknown.   |  |                 |             |         |                 |
| REFERENCE             | 1 (bases 1 to 289)   |  |                 |             |         |                 |
| AUTHORS               | Szostak, J.W., Roberts, R.W. and Liu, R.                   |  |                 |             |         |                 |
| TITLE                 | Nucleic acid-protein fusion molecules and libraries        |  |                 |             |         |                 |
| JOURNAL               | Patent: US 6281344-A 17 28-AUG-2001;                       |  |                 |             |         |                 |
| FEATURES              | Location/Qualifiers  |  |                 |             |         |                 |
| source                | 1..289   |  |                 |             |         |                 |
|                       | /organism="unknown"  |  |                 |             |         |                 |
|                       | /mol_type="unassigned DNA"                                 |  |                 |             |         |                 |
| Query Match           | 1.1%;  | Score 39.4;  | DB 1;           | Length 289; |         |                 |
| Best Local Similarity | 12.9%;   | Pred. No. 0.0023;  |                 |             |         |                 |
| Matches               | 37;  | Conservative 100;  | Mismatches 150; | Indels 0;   | Gaps 0; |                 |
| Qy                    | 1356   | AGTGAGAAATAGATTAAAGCGCCCTAGATCTGATACAGAGTACCTAATGAACCTATGGAC | 1415            |             |         |                 |
| Db                    | 1  | RGGRGRCARARATRTAARCTRTAATTTTTRACRCARATRTTRACRCARATRTGGRNRN   | 60              |             |         |                 |







```

/tissue_type="Colon, Kidney, Stomach, adult, whole pooled"
/clone_lib="NIH MGC_116"
/lab_host="DH10B"
/notes="Vector: PCMV-SPORT6"
1. .1792
/gene="PROC"
/db_xref="LocusID:5624"
/db_xref="MIM:176860"
56. .1441
/codon_start=1
/product="protein C (inactivator of coagulation factors Va
and VIIIa)"
/protein_id="AAH34377.1"
/db_xref="GI:2170771"
/db_xref="LocusID:5624"
/translation="MWQLTSLLLFVATWGISTGPAPLDSVSSSRAHOVLRIKRRAN
SFLELRHSSLERECIEICDPEEAKELFQNVDDTLAFWSKHVDGDOCLVLPHPCA
SLCCGGYCIDGIFSDCDSRGWRCQREVSLNCSLNGSGCTHYCLEVGNRRRC
SCAPGKGGDDLLQCHPAVPCGPRWMEKRRSHLRKDTEDQEDQVDPRLDGKMT
RRGDSFQVVLDDSKKACGAVLHPSPWLTAAHCDMSKLLARVGEYDLRWKRW
ELDLIKGVFVHPNYSKSTTDNDIALHQAQFATLSQITVPCIPDSGLAEELNQAQ
QETLVGWYHSRSREKRNRTFVNFITKIPVPHNCESEVMNVMSENMLCAGILG
DRQACEDGSGGPMVASFHGTWFLVLVSGEGGGLLHNYGVYTKVSKRYLDWIHGIR
DKEAPQKSWAP"
misc_feature
125. .316
/notes="Gla; Region: Domain containing Gla
(gamma-carboxyglutamate) residues"
/db_xref="CDD:smart00069"
353. .451
/notes="EGF CA; Region: Calcium-binding EGF-like domain,
present in a large number of membrane-bound and
extracellular (mostly animal) proteins. Many of these
proteins require calcium for their biological function and
calcium-binding sites have been found to be located at the
N-terminus of particular EGF-like domains"
/db_xref="CDD:cd00054"
692. .1399
/misc_feature
/notes="Tryp SPc; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 0.8%; Score 29.6; DB 1; Length 1792;
Best Local Similarity 57.6%; Pred. No. 1.2;
Matches 53; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 2939 TTTAACTATTTCTCAATGACTTGTATTCATAATTTACTATCTATTTACTTTAAAT 2998
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1792 TTTTITTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCGT 1733

QY 2999 TGCACATTTATTTATGATTTCTCTATAAATAA 3030
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1732 GGTGTGTTTTTTTATCTCTTTTCATAAACAGA 1701

RESULT 9
BC009726/c 1403 bp mRNA linear PRI 12-NOV-2003
LOCUS Homo sapiens protease, serine, 22, mRNA (cDNA clone MGC:9599
DEFINITION IMAGE:3899480), complete cds.
ACCESSION BC009726
VERSION BC009726.1 GI:16307274
KEYWORDS MGC.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1403)
Strausberg, R.B., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Klausner, R.D., Zeeberg, B.S., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Scheetz, T.E., Brownstein, M.J., Ustin, T.B., Toshiyuki, S.,

```

```

Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
Abramson, R.D., Mullaby, S.J., Bosak, S.A., McEwan, P.J.,
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Fahney, J., Helton, E., Kettman, M., Madan, A., Rodrigues, S.,
Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smal, D.E.,
Schnerch, A., Schein, J.E., Jones, S.J., and Marra, W.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)

JOURNAL MEDLINE
PUBMED 12477932
REFERENCE 2 (bases 1 to 1403)
AUTHORS Strausberg, R.
TITLE Direct Submission
JOURNAL Submitted (29-JUN-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabs-remail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.
cDNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www-shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAC Plate: 14 Row: 1 Column: 15
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 21614535.

FEATURES
Location/Qualifiers
1. .1403
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:9599 IMAGE:3899480"
/issue_type="Pancreas, epithelioid carcinoma"
/clone_lib="NIH MGC_70"
/lab_host="DH10B"
/notes="Vector: PCMV-SPORT6"
1. .1403
/gene="PRSS22"
/notes="synonyms: BSSP-4, MGC9599, SP001LA, hBSSP-4"
/db_xref="LocusID:64063"
39. .992
/codon_start=1
/product="protease, serine, 22"
/protein_id="AAH09726.1"
/db_xref="GI:16307275"
/db_xref="LocusID:64063"
/translation="MVVSGAPPALGGCLGTTSLLLASTAILNAARIPVPPACGKRP
QQLNRVVGEGDSTSEWPIVSIQKNGTHGACASLLTSRWITAHCFKDLNKPFLP
SVLLGAWOLGNPSSQKQVAVWEPHPVYWGKACADIALRLERIQSFSLVPI
CLPDASILHPNTHCWI SWGSIQGVPLPHPTQIKLVPIIDSEVCSHLYWRGAGO
GPIEDMLCAPENTHGERDACLDSGGPLMCCVDGAWLLAGIISWGEGCAERNRPQVYI
SLGASHRSWVEKIVQSVQLRGRAQGGALRAFSGSGAARS"
misc_feature
186. .902
/notes="Tryp SPc; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 0.8%; Score 28.8; DB 1; Length 1403;
Best Local Similarity 69.6%; Pred. No. 1.8;

```







QY 370 AGGCAAAATGATAGGATAGTGAAGAGGAACTCCCGAGTTCAGTAGGTGCCCCATATGCT 429  
 Db 254 CAKWCCTVSWYWRASMKSKYCAWSRGSKCMYSRGSKSCYCCWGGSCCCGCCAGCA 313  
 QY 430 ACTGG 434  
 Db 314 GCAGG 318

RESULT 16  
 AY022485  
 LOCUS Oryza sativa microsatellite MRG4810 containing (AGG)X10, genomic  
 DEFINITION sequence.  
 ACCESSION AY022485  
 VERSION AY022485.1 GI:12705701  
 KEYWORDS Oryza sativa  
 ORGANISM Oryza sativa

REFERENCE  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
 Ehrhartoideae; Oryzeae; Oryza.  
 1 (bases 1 to 230)  
 Tao,N., Barbazuk,W.B., Liu,J., Wu,K. and Barry,G.F.  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 230)  
 Tao,N., Barbazuk,W.B., Liu,J., Wu,K. and Barry,G.F.  
 JOURNAL Direct Submission  
 TITLE Submitted (10-JAN-2001) Genomics, Monsanto, 800 North Lindbergh  
 Blvd., Creve Coeur, MO 63167, USA  
 COMMENT Derived from rice genomic sequences generated from the Monsanto  
 Rice Genome Sequencing project. Please see  
 http://www.rice-research.org for more information. The sequence  
 data were produced primarily in the laboratories of Dr. Leroy Hood  
 at the University of Washington in Seattle.

FEATURES  
 source  
 1..230  
 /organism="Oryza sativa"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:4530"

repeat\_region 1..230  
 /note="microsatellite MRG4810"  
 /rpt\_type=tandem  
 /rpt\_unit="agg"

Query Match 0.7%; Score 26.2; DB 1; Length 230;  
 Best Local Similarity 60.6%; Pred. No. 5.4;  
 Matches 43; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 2588 TGGAAAAGACCTGTATGCTGGAGGAGATTTGGGGCAGGAGGAGAGAGGGAGGACACAGGGA 2647  
 Db 63 TGGCCAGCGCGCGGAGAGGAGGAGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 122  
 QY 2648 TCAGATGGCTG 2658  
 Db 123 GGAGGAGGATG 133

RESULT 17  
 E40571  
 LOCUS Novel protease and DNA encoding said protease.  
 DEFINITION E40571  
 ACCESSION E40571.1 GI:18625105  
 VERSION JP 2000135094-A/1.  
 KEYWORDS Sus scrofa (pig)  
 SOURCE Sus scrofa  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
 1 (bases 1 to 828)  
 Yamashita,M., Iida,K. and Kido,H.  
 REFERENCE Novel protease and DNA encoding said protease  
 AUTHORS  
 TITLE

JOURNAL Patent: JP 2000135094-A 1 16-MAY-2000;  
 SANKYO CO LTD  
 OS Sus scrofa (pig)  
 PN JP 2000135094-A/1  
 PD 16-MAY-2000  
 PF 24-AUG-1999 JP 1999236296  
 PR  
 PI MAXOTO YAMASHITA, KENJI IIDA, HIROSHI KIDO  
 PC C12N15/09,C07K16/40,C12N1/21,C12N9/64,C12Q1/70,G01N33/15, PC  
 G01N33/50//  
 PC C12P21/08,(C12N15/09,C12R1:91),(C12N1/21,C12R1:19),(C12N9/64,  
 C12R1:19),  
 PC C12N15/00,(C12N15/00,C12R1:91)  
 CC  
 FH Key Location/Qualifiers  
 FT CDS (1)..(825)  
 FT sig\_peptide (1)..(90)  
 FT mat\_peptide (91)..(825).  
 FEATURES  
 source  
 1..828  
 /organism="Sus scrofa"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9823"

Query Match 0.7%; Score 26.2; DB 1; Length 828;  
 Best Local Similarity 49.6%; Pred. No. 7.5;  
 Matches 67; Conservative 0; Mismatches 68; Indels 0; Gaps 0;

QY 2534 TGCTAAGCTGAACTCCAGTACTTTGGCCACCTGATCAGAGAGCTGACTCACTGAAA 2593  
 Db 11 TGCTGTGCTGGCGTGCCTCTCTGTGAGCTGTGTCACACGCGCCGCCAGGCC 70  
 QY 2594 AGACCTCTGATGCTGGGAGGATTGGGGCAGGAGGAGAGGGGACACAGAGGATGAGAT 2653  
 Db 71 AGCCCTGGAGCGAGCAGGCGATCTGTGGCGGAAAGAGCCCTGGGACACAGTGGCCCT 130  
 QY 2654 GGCTGATGTCATCA 2668  
 Db 131 GGCAGGTGAGCCTGA 145

RESULT 18  
 BC061135/c  
 LOCUS Mus musculus trypsin 4, mRNA (cDNA clone MGC:74265 IMAGE:30306436),  
 DEFINITION complete cds.  
 ACCESSION BC061135  
 VERSION BC061135.1 GI:38511692  
 KEYWORDS MGC.  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 829)  
 Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,  
 Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,  
 Altschul,S.F., Zeeberg,B., Suetow,K.H., Schaefer,C.F., Bhat,N.K.,  
 Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,  
 Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,  
 Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,  
 Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,  
 Carninci,P., Prange,C., Raha,S.S., Locuelli,N.A., Peters,G.J.,  
 Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,  
 McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,  
 Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,  
 Viallon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,  
 Faye,J., Helton,E., Kettman,M., Madan,A., Rodriguez,S.,  
 Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,  
 Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,  
 Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,  
 Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalusz,D.E.,  
 Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.  
 REFERENCE Generation and initial analysis of more than 15,000 full-length  
 AUTHORS  
 TITLE



COMMENT Contact: MGC help desk  
Email: cgapbs-r@mail.nih.gov  
Tissue Procurement: Dr. Michael Brownstein  
cDNA Library Preparation: Michael Brownstein / Ted Usdin  
Laboratory  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNL)  
DNA Sequencing by: Sequencing Group at the Stanford Human Genome  
Center, Stanford University School of Medicine, Stanford, CA 94305  
Web site: http://www-shgc.stanford.edu  
Contact: (Dickson, Mark) mcdex@mail.stanford.edu  
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,  
R. M.

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/ILNL at: http://image.llnl.gov  
Series: IPAL Plate: 53 Row: n Column: 1  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 6753805.  
Location/Qualifiers  
1. 1869  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10090"  
/clone="MGC:74281 IMAGE:30305571"  
/tissue\_type="Liver, mouse"  
/clone\_lib="NIH MGC\_177"  
/lab\_host="DH10B"  
/note="Vector: pDNR-LIB"  
1. 1869  
/gene="F7"  
/note="Synonyms: FVII, mfVII"  
/db\_xref="LocusID:14068"  
/db\_xref="MGI:109325"  
10. 1350  
/product="coagulation factor VII"  
/protein\_id="AAH61149.1"  
/db\_xref="GI:38511702"  
/db\_xref="LocusID:14068"  
/translation="MVFQAGLLLLCFLLQLQGLPFAVITQEEAHGVILHRRRANS  
LLESLTPGSIERECNEQCFEEAREIFKPERTKQFIVISDQDCQPCQNGTGC  
OHLKSVFCFLDFEGRCEKSKNEOLICANENGDCDQYCRDHVGTFRKSCHEHYT  
LOPEVCKPKVEYPCGRIPVVEKRNSSRQGRIVGVNCPKGCPCAVLKINGLL  
CGVLLDARWITAAHCFEDNIRYMGNTVMGEHDFSEKGDQVRVTVQVMPDKYI  
RGKINHDLALRLHRPVTFTDYVPLCLPEKSFENTLARIKRSVSGWGLLDRGAT  
ALELMSIEVPLMTQDCLHAKHSNTPKTEFNFCAGYMDGDKACKGSGGPHATH  
YHGTWYLTGVVSWGEGCAAIIGHIVYTRVSQYIDWLVRHMDSKLQGVFRLPLI"  
79. 264  
/note="Gla; Region: Domain containing Gla  
(gamma-carboxyglutamate) residues"  
/db\_xref="CDD:smart00069"  
268. 378  
/note="EGF\_CA; Region: Calcium-binding EGF-like domain,  
present in a large number of membrane-bound and  
extracellular (mostly animal) proteins. Many of these  
proteins require calcium for their biological function and  
calcium-binding sites have been found to be located at the  
N-terminus of particular EGF-like domains"  
/db\_xref="CDD:cd00054"  
589. 1302  
/note="Tryp\_SPC; Region: Trypsin-like serine protease"  
/db\_xref="CDD:cd00190"

Query Match 0.7%; Score 25.2; DB 1; Length 1869;  
Best Local Similarity 78.9%; Pred. No. 16;  
Matches 30; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3245 TTTTITTTTTTTTTTTTTTTTTTAAAGATGGTCATCTTT 3282  
DB 1861 TTTTITTTTTTTTTTTTTTTTGACATGTTCTCAIT 1824

RESULT 21

AX675583/c  
LOCUS AX675583 882 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 33 from Patent WO02055704.  
ACCESSION AX675583  
VERSION AX675583.1 GI:29333568  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,  
Spytek, K.A., Zhong, M., Gangoli, E.A., Burgess, C.E., Patturajan, M.,  
Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,  
Boldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,  
Edingermark, S., Rothenberg, M.E., Ellerman, K., Macdougall, J.,  
Malyanar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and  
Stone, D.J.  
TITLE Proteins, polynucleotides encoding them and methods of using the  
same  
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;  
Curagen Corporation (US)  
FEATURES  
source  
1. 882  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 25; DB 1; Length 882;  
Best Local Similarity 50.0%; Pred. No. 15;  
Matches 86; Conservative 0; Mismatches 80; Indels 6; Gaps 1;

QY 2560 GGCCACCTGATCAGAAAGAGCTGACTCCTGGAAGAACCTGATGCTGGAGGATGGG 2619  
DB 450 GGCCACATGACCCAGCCAGTGCAGTGCAGTGGAGCGCTGGGAGAGCGCTGGC 391  
QY 2620 GCAGAGGAGAGGGGACGACAGAGGATGAGTGCCTGATGGCATCTGCTCGATG 2679  
DB 390 TGCAGGAGGACGATGGCGGATGATGAGGAGGAGGTGATGGTCTGCTGATGGAG 331  
QY 2680 G-----AGTCAGTCTGGGTGAACCTCTCGAGTGGTGTGATGACAGAGGAGG 2725  
DB 330 GAGTGAATGTCCCTCTGGAGCCCTCTCTGAGGTAGCTGGGTGGGGGATG 279

RESULT 22  
LOCUS AR425705/c  
DEFINITION Sequence 17202 from patent US 6639063.  
ACCESSION AR425705  
VERSION AR425705.1 GI:40180815  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 364)  
AUTHORS Edwards, J.-B.D.M., Jobert, S. and Giordano, J.-Y.  
TITLE EST's and encoded human proteins  
JOURNAL Patent: US 6639063-A 17202 28-OCT-2003;  
FEATURES  
source  
1. 364  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 24.9; DB 1; Length 364;  
Best Local Similarity 12.4%; Pred. No. 13;  
Matches 32; Conservative 117; Mismatches 108; Indels 5; Gaps 1;

QY 2490 CATTCGAAGGAGATCAGCCCTGGGATTTCTTTGAAGGAATGATCTAAAGCTGAACT 2549  
DB 258 SWNTGYRYSKMWYTGTRCTSKKXKKGSTSSKYASTSGKSKYKSTCRKSKKRYSA 199  
QY 2550 CCAGTACTTTGGCCACTGATCAGAAAGAGCTGACTCAGTGGAAAGAGCCCTGATGCTGGG 2609

[illegible]

```

FEATURES
  source
    Location/Qualifiers
      1..251
        /organism="Macaca mulatta"
        /mol_type="genomic DNA"
        /db_xref="taxon:9544"
      <1..>251
        /gene="GAP43"
      <1..>251
        /gene="GAP43"
      /product="growth associated protein 43"
      <1..>251
        /gene="GAP43"

  3' UTR
    Query Match
      Best Local Similarity 0.7%; Score 24.8; DB 1; Length 251;
      Matches 68; Conservative 0; Mismatches 72; Indels 0; Gaps 0;

  QY 3172 TTAATTTTGTAAATAGCTCTTTAAATTCATTATCTTGTGATACAGCTTCAGTTCTAT 3231
  Db 190 TCATCAITACCAAACTGCGCATACACACCAAGAAACAAAATGTTAAGCCACAC 131

  QY 3232 GGCTTTAATAAGTTTTTTTTTTTTTTTTTTTTTTTAAAGATGTCATCTTTGTGAAGTTT 3291
  Db 130 TGTGTGACTTGGGATCTTCCTGCTTTTTTTTTTTTCTTTTCTTTTTTTTTTTTAAAAATGT 71

  QY 3292 TGACATGCTTTGACATA 3311
  Db 70 TTGCCACACAGAGAGATA 51

RESULT 26
HUMCFIX
LOCUS HUMCFIX 873 bp mRNA linear PRI 01-NOV-1994
DEFINITION Human coagulation factor IX mRNA, partial cds.
ACCESSION M35672
VERSION M35672.1 GI:180287
KEYWORDS coagulation factor IX; serine protease.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
  1 (bases 1 to 873)
  Jagadeeswaran,P., Lavelle,D.E., Kaul,R., Mohandas,T. and
  Warren,S.T.
  Isolation and characterization of human factor IX cDNA:
  identification of Tag I polymorphism and regional assignment
  Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)
  84300526
  6089357
COMMENT Original source text: Human adult liver, cDNA to mRNA.
FEATURES
  source
    Location/Qualifiers
      1..873
        /organism="Homo sapiens"
        /mol_type="mRNA"
        /db_xref="taxon:9606"
      1..873
        /map="Xq26.3-q27.1"
      <1..>873
        /gene="P9"
      /gene="P9"
      /note="coagulation factor IX"
      /codon_start=1
      /protein_id="AAA51981.1"
      /db_xref="GI:180288"
      /db_xref="GDB:G00-119-900"
      /translation="NANKILNPKRYNSKLEEFVQGNLRRECMEKCSFEAREVPE
      NTERETPEWKYVGDQCESNPGCLNGSKDDINSYECMCPGPGEGKNCGLDVTCLIK
      NRCGFQCKNSADKNKVCSTEGTGRLAENQKSCPEAPVFPFCGRVSVSQTSLTRAETV
      PFDVDYINTEATILDNITQSFNDFTRVVGDEDAKPGQFPWQVLNGKVDATCG
      GSIVNEKWIIVTAACHCVETGKVTIVVAGEHNLEETEHTEQRENVRIRIIPHHYNAANK
      YNHDIALLELDEPLV"

  gene
    CDS
      Query Match
        Best Local Similarity 0.7%; Score 24.8; DB 1; Length 873;
        Matches 87; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

FEATURES
  source
    Location/Qualifiers
      1..251
        /organism="Macaca mulatta"
        /mol_type="genomic DNA"
        /db_xref="taxon:9544"
      <1..>251
        /gene="GAP43"
      <1..>251
        /gene="GAP43"
      /product="growth associated protein 43"
      <1..>251
        /gene="GAP43"

  3' UTR
    Query Match
      Best Local Similarity 0.7%; Score 24.8; DB 1; Length 251;
      Matches 68; Conservative 0; Mismatches 72; Indels 0; Gaps 0;

  QY 3172 TTAATTTTGTAAATAGCTCTTTAAATTCATTATCTTGTGATACAGCTTCAGTTCTAT 3231
  Db 190 TCATCAITACCAAACTGCGCATACACACCAAGAAACAAAATGTTAAGCCACAC 131

  QY 3232 GGCTTTAATAAGTTTTTTTTTTTTTTTTTTTTTTTAAAGATGTCATCTTTGTGAAGTTT 3291
  Db 130 TGTGTGACTTGGGATCTTCCTGCTTTTTTTTTTTTCTTTTCTTTTTTTTTTTTAAAAATGT 71

  QY 3292 TGACATGCTTTGACATA 3311
  Db 70 TTGCCACACAGAGAGATA 51

RESULT 27
E01075/c
LOCUS E01075 2177 bp RNA linear PAT 29-SEP-1997
DEFINITION cDNA sequence of factor VII fragment.
ACCESSION E01075
VERSION E01075.1 GI:2169334
KEYWORDS JP 1987000283-A/1.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 2177)
AUTHORS Furederitsuku,E.H., Maaku,J.M., Shiyaroon,J.B., Kiyasuriin,E.B.,
Maagaresuto,W.I., Richiyaado,J.U. and Chiyaaruzu,E.G.
DNA ENCODING FACTOR VII
Patent: JP 1987000283-A 1 06-JAN-1987;
HEMOIENETITSUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD,
TOYO SODA MFG CO LTD
OS Human (Homo sapiens)
PN JP 1987000283-A/1
PD 06-JAN-1987
PF 16-APR-1986 JP 1986087861
PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI
FUREDERITSUKU,ESU HAAGEN, MAAKU JIEI MARII,
PI SHIYAARON JIEI BAZUBII,
PI KIYASURIIN ERU BAKUNAA, MAAGARETSUTO WAI INSUREE, PI
RICHIAAADO JII UTSUDOBERRII, CHIYAARUZU ERU GUREI PC
C12N15/00,A61K37/465,C12N5/00,C12N9/50,(C12N9/50,C12R1:91); CC
strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: tissue type=liver;
CC *source: library=cDNA library, lambdaegt11 cDNA library; CC
*source: clone=lambdaVII 2115, lambdaVII 1923; FH Key
Location/Qualifiers
FH
FT CDS
  13..1128
  /product='factor VII peptide' FT
  polyA signal 2106..2111
  FT exon
  FT 3'UTR
    Location/Qualifiers
      1..2177
        /organism="unidentified"
        /mol_type="genomic RNA"
        /db_xref="taxon:32644"

FEATURES
  source
    Location/Qualifiers
      1..2177
        /organism="unidentified"
        /mol_type="genomic RNA"
        /db_xref="taxon:32644"

  Query Match
    Best Local Similarity 0.7%; Score 24.8; DB 1; Length 2177;
    Matches 32; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

  QY 3245 TTTTCTTAATAAAATCCAGTCCTT 3040
  Db 534 CATCACTCAAGCACCAATCATT 557

RESULT 28
HUMPS02/c
LOCUS HUMPS02 352 bp DNA linear PRI 10-JAN-1995
DEFINITION Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION M57841 J02917

```

```

VERSION M57841.1 GI:190535
KEYWORDS S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT 2 of 14
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 352)
AUTHORS Schmidl,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
TITLE Organization of the human protein S genes
JOURNAL Biochemistry 29 (34), 7845-7852 (1990)
MEDLINE 9109444
PUBMED 2148110
COMMENT Original source text: Human liver DNA.
FEATURES
    source
        1..352
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /map="3p11-q11.2"
            /tissue_type="liver"
            join(M57840.1:837..912,135..181)
            /gene="PS-alpha"
            order(M57840.1:913..1014,1..134)
            /gene="PROS1"
            /number=1
            135..252
            /gene="PROS1"
            /note="G00-120-721"
            /number=2

    sig_peptide
        join(M57840.1:837..912,135..181)
            /gene="PS-alpha"
            order(M57840.1:913..1014,1..134)
            /gene="PROS1"
            /number=1
            135..252
            /gene="PROS1"
            /note="G00-120-721"
            /number=2

    intron
        135..252
        /gene="PROS1"
        /note="G00-120-721"
        /number=2

    exon
        135..252
        /gene="PROS1"
        /note="G00-120-721"
        /number=2

Query Match 0.7%; Score 24.6; DB 1; Length 352;
Best Local Similarity 51.4%; Pred. No. 16;
Matches 57; Conservative 0; Mismatches 54; Indels 0; Gaps 0;

QY 2991 ACTTAAATGCACTATTATTATGCACTTTTCTAATAAAATCCAGTCCTCTTTTAA 3050
Db 125 ACAATCAGTTTATATGCAATTAATCAATTTTCCATGTAATATATTTGTTTAAACAA 66
QY 3051 AAAGACTTAAATATTATTCTTTAGTGGTTTACCAGTCTTTCAG 3101
Db 65 TAAGAGTTAAATCAATTTTCCATGTAATATGTAATCAATTAATCAAG 15

RESULT 29
AF321182
LOCUS AF321182
DEFINITION Homo sapiens serine protease PRSS22 mRNA, complete cds.
ACCESSION AF321182
VERSION AF321182.1 GI:11386012
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1332)
AUTHORS Wong,G.W., Yasuda,S., Madhusudan,M.S., Li,L., Yang,Y.,
Krilis,S.A., Sali,A. and Stevens,R.L.
TITLE Human trypsin epsilon (PRSS22), a new member of the chromosome
16p13.3 family of human serine proteases expressed in airway
epithelial cells
JOURNAL J. Biol. Chem. 276 (52), 49169-49182 (2001)
MEDLINE 21623609
PUBMED 11602603
REFERENCE 2 (bases 1 to 1332)
AUTHORS Wong,G.W.
TITLE Direct Submission
JOURNAL Submitted (14-NOV-2000) Rheumatology, Immunology and Allergy,
Brigham and Women's Hospital, Harvard Medical School, 1 Jimmy Fund
Way, Boston, MA 02115, USA
FEATURES
    source
        1..1332
            /organism="Homo sapiens"

```

```

/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosomes="16"
/map="16p13.3"
/tissue_type="pancreas"
18..971
/codon_start=1
/product="serine protease PRSS22"
/protein_id="AAG35070.1"
/db_xref="GI:11386013"
/translation="MVVSGAPPALGGGCLGTFSLLLASTAILNAARIPVPPACCKP
QQLNRVGGEDSTDSEMPWISQKNGTHHCAGSLTTSRWVTAACFKDNLNKPYLF
SVLLGAKQLGNPSRSQKVGVAWPHVPVYSHKEGACADIALVRLERSIQFSRVLPI
CUPDASIHUPPNHCHMSQSGSIQDGVPLPHQPTLQKLVPIIDSEVSGSHLYWRGAGQ
GPITDMLCAGYLEGRDACLGGSLMCGVDGAWLLAGLISWEGGCAERNRPGVYI
SLSHRSWVEKIVQVQLRGAQGGALRAPSGSGGAARS"

Query Match 0.7%; Score 24.6; DB 1; Length 1332;
Best Local Similarity 53.7%; Pred. No. 21;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTATTACTTAAATGCACTATTATTATGCACTTTTCTAATAAAATCCAGTCCTTGT 3042
Db 1237 TTTTGTGTATATAAATGTAATGATTTTATAGGATTTGTAAACCTGCCACATATCTT 1296
QY 3043 TTTTAAAAAGACTTTTAAATTTATTAATTTCTCT 3077
Db 1297 ATTATCTCTCAATTTCAATAATTTATTTATCT 1331

RESULT 30
AF410811
LOCUS AF410811
DEFINITION Sequence 262 from patent US 6635468.
ACCESSION AF410811
VERSION AF410811.1 GI:40162311
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1378)
AUTHORS Ashkenazi,A., Botstein,D., Desnoyers,L., Eaton,D.L., Ferrara,N.,
Filvaroff,E., Fong,S., Gao,W.-Q., Gexber,H., Gerritsen,M.E.,
Goddard,A., Godowski,P.J., Grimaldi,J.C., Gurney,A.L., Hillan,K.J.,
Kljavin,I.J., Mather,J.P., Pan,J., Paoni,N.F., Roy,M.A.,
Stewart,T.A., Tumas,D., Williams,P.M. and Wood,W.I.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: US 6635468-A 262 21-OCT-2003;
FEATURES
    source
        Location/Qualifiers
        1..1378
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2983 TCATTATTACTTAAATGCACTATTATTATGCACTTTTCTAATAAAATCCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAAATGTAATGATTTTATAGGATTTGTAAACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTTAAATTTATTAATTTCTCT 3077
Db 1332 ATTATCTCTCAATTTCAATAATTTATTTATCT 1366

RESULT 31
AX697671
LOCUS AX697671
DEFINITION Sequence 262 from Patent WO0104311.
ACCESSION AX697671
VERSION AX697671.1 GI:29498757

```



```

KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS       Ashkenazi,A.J., Botstein,D., Desnovers,L., Eaton,D.L., Ferrara,N.,
              Filvaroff,E., Fong,S., Gao,W.Q., Gerber,H., Gerritsen,M.E.,
              Goddard,A., Godowski,P.J., Grimaldi,C.J., Gurney,A.L., Hillan,K.J.,
              Kijavrin,I.J., Mather,J.P., Pan,J., Paoni,N.F., Roy,M.A.,
              Stewart,I.A., Tumas,D., Williams,P.M. and Wood,W.I.
TITLE         Secreted and transmembrane polypeptides and nucleic acids encoding
              the same
JOURNAL       Patent: WO 0104311-A 262 18-JAN-2001;
              Genentech Inc. (US)
FEATURES     1..1378
              Location/Qualifiers
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
              0.7%; Score 24.6; DB 1; Length 1378;
              Best Local Similarity 53.7%; Pred. No. 22;
              Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTAATAAAATCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAATGTTAATGATTTTATAGCTATTTGTACCCGCCACATATCTT 1331
Qy 3043 TTTTAAAAAGACTTTAAATTTAATTTCTCT 3077
Db 1332 ATTATTCCTCAATTTCAATAAATTTATTTCT 1366

RESULT 32
BD075581
LOCUS        BD075581.1 GI:22621184
DEFINITION   Secretory and transmembrane polypeptide and nucleic acid encoding
              the same.
ACCESSION   BD075581
VERSION     BD075581.1
KEYWORDS    JP 2001516580-A/214.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 1378)
AUTHORS     Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Chen,J. and Yuan,J.
TITLE       Secretory and transmembrane polypeptide and nucleic acid encoding
              the 'same'
JOURNAL     Patent: JP 2001516580-A 214 02-OCT-2001;
            GENENTECH INC.
COMMENT     OS Homo sapiens (human)
            PN JP 2001516580-A/214
            PD 02-OCT-2001
            PF 16-SEP-1998 JP 2000511867
            PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
            17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
            17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
            18-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
            18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
            17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
            21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
            24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
            24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
            24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
            27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
            28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
            28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
            28-OCT-1997 US 60/063564,28-OCT-1997 US 60/063564 PR
            29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
            29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
            29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR

```

```

29-OCT-1997 US 60/064103,31-OCT-1997 US 60/063870 PR
03-NOV-1997 US 60/064248,07-NOV-1997 US 60/064809 PR
12-NOV-1997 US 60/065186,17-NOV-1997 US 60/065846 PR
18-NOV-1997 US 60/065693,21-NOV-1997 US 60/066120 PR
21-NOV-1997 US 60/066364,24-NOV-1997 US 60/066772 PR
24-NOV-1997 US 60/066466,24-NOV-1997 US 60/066770 PR
24-NOV-1997 US 60/066511,24-NOV-1997 US 60/066453 PR
25-NOV-1997 US 60/066840
PI WILLIAM I WOOD,AUSTIN L GURNEY,AUDLEY GODDARD,DIANE PENICA, PI
JEAN CHEN
PI JEAN YUAN
PC C12N15/09, C07K14/47, C07K14/705, C07K16/18, C07K16/28, C07K19/00,
PC C12N1/19,
PC C12N1/21, C12N5/10, C12P21/02, C12P21/08, C12Q1/02, C12P21/08, PC
C12R1/91,
PC C12N15/00, C12N5/00
CC Secretory and transmembrane polypeptide and nucleic acid CC
PH Key encoding the same
FT source 1..1378
FT /organism="Homo sapiens (human)"
FEATURES     1..1378
              Location/Qualifiers
              /organism="Homo sapiens"
              /mol_type="genomic DNA"
              /db_xref="taxon:9606"
              0.7%; Score 24.6; DB 1; Length 1378;
              Best Local Similarity 53.7%; Pred. No. 22;
              Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTAATAAAATCAGTCCTTGT 3042
Db 1272 TTTTGTGTATATAATGTTAATGATTTTATAGCTATTTGTACCCGCCACATATCTT 1331
Qy 3043 TTTTAAAAAGACTTTAAATTTAATTTCTCT 3077
Db 1332 ATTATTCCTCAATTTCAATAAATTTATTTCT 1366

RESULT 33
BD172441
LOCUS        BD172441.1 GI:28413741
DEFINITION   Secreted and transmembrane polypeptides and nucleic acids encoding
              the same.
ACCESSION   BD172441
VERSION     BD172441.1
KEYWORDS    JP 200223786-A/214.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 1378)
AUTHORS     Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
            Yuan,J.
TITLE       Secreted and transmembrane polypeptides and nucleic acids encoding
              the same
JOURNAL     Patent: JP 200223786-A 214 13-AUG-2002;
            GENENTECH INC.
COMMENT     OS Homo sapiens (human)
            PN JP 200223786-A/214
            PD 13-AUG-2002
            PF 18-DEC-2001 JP 2001385135
            PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
            17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
            17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR
            18-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
            18-SEP-1997 US 60/059266,15-OCT-1997 US 60/062125 PR
            17-OCT-1997 US 60/062287,17-OCT-1997 US 60/062285 PR
            21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
            24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
            24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
            24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR

```

```

27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
17-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065844,18-NOV-1997 US 60/065634 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
C12P21/02/C12P21/08,(C12P21/02,C12R1:19),(C12P21/02,C12R1:91), PC
(C12P21/02,C12R1:645),C12N15/00,C12N5/00
CC Secreted and transmembrane polypeptides and nucleic CC acids
encoding the same
FH Key Location/Qualifiers
FT source 1..1378
/organism="Homo sapiens (human)".
FEATURES
source
Location/Qualifiers
1..1378
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTTAATAAATCCAGCTTGT 3042
Db 1272 TTTTGTATATAATGTTAATGATTTTATAGGATTTGTACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAAAATTATTAATTTCTCT 3077
Db 1332 ATTATTCCTCCAATTCATAAATATTATTCT 1366
RESULT 34
BD172760
LOCUS
DEFINITION
Secreted and transmembrane polypeptides and nucleic acids encoding
the same.
ACCESSION
BD172760
VERSION
BD172760.1 GI:28414064
KEYWORDS
JP 2002238586-A/214.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1378)
AUTHORS
Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J
TITLE
Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL
GENENTECH INC
Patent: JP 2002238586-A 214 27-AUG-2002;
COMMENT
OS Homo sapiens (human)
PN JP 2002238586-A/214
PD 27-AUG-2002
PF 18-DEC-2001 JP 2001385205
PR 17-SEP-1997 US 60/059115,17-SEP-1997 US 60/059184 PR
17-SEP-1997 US 60/059122,17-SEP-1997 US 60/059117 PR
17-SEP-1997 US 60/059113,17-SEP-1997 US 60/059121 PR

```

```

17-SEP-1997 US 60/059119,18-SEP-1997 US 60/059263 PR
18-SEP-1997 US 60/052666,15-OCT-1997 US 60/062125 PR
17-OCT-1997 US 60/062887,17-OCT-1997 US 60/062285 PR
21-OCT-1997 US 60/063486,24-OCT-1997 US 60/062816 PR
24-OCT-1997 US 60/062814,24-OCT-1997 US 60/063127 PR
24-OCT-1997 US 60/063120,24-OCT-1997 US 60/063121 PR
24-OCT-1997 US 60/063045,24-OCT-1997 US 60/063128 PR
27-OCT-1997 US 60/063329,27-OCT-1997 US 60/063327 PR
28-OCT-1997 US 60/063549,28-OCT-1997 US 60/063541 PR
28-OCT-1997 US 60/063550,28-OCT-1997 US 60/063542 PR
28-OCT-1997 US 60/063544,28-OCT-1997 US 60/063564 PR
29-OCT-1997 US 60/063734,29-OCT-1997 US 60/063738 PR
29-OCT-1997 US 60/063704,29-OCT-1997 US 60/063435 PR
29-OCT-1997 US 60/064215,29-OCT-1997 US 60/063735 PR
29-OCT-1997 US 60/063732,31-OCT-1997 US 60/064103 PR
31-OCT-1997 US 60/063870,03-NOV-1997 US 60/064248 PR
17-NOV-1997 US 60/064809,12-NOV-1997 US 60/065186 PR
17-NOV-1997 US 60/065846,18-NOV-1997 US 60/065693 PR
21-NOV-1997 US 60/066120,21-NOV-1997 US 60/066364 PR
24-NOV-1997 US 60/066772,24-NOV-1997 US 60/066466 PR
24-NOV-1997 US 60/066770,24-NOV-1997 US 60/066511 PR
24-NOV-1997 US 60/066453,25-NOV-1997 US 60/066840 PI
WILLIAM I WOOD,AUSTIN L GURNEY,AUDREY GODDARD,DIANE PENNICA, PI
JIAN ZHENG,
PI JEAN YUAN
PC C12N15/09,C07K14/47,C07K16/18,C07K19/00,C12N1/19,C12N1/21, PC
C12N5/10,
C12P21/02/C12P21/08,(C12N1/19,C12R1:645),(C12N1/21,C12R1:19),
PC
(C12N5/10,C12R1:91),(C12P21/02,C12R1:91),(C12P21/02,C12R1:645), PC
(C12P21/02,C12R1:19),(C12P21/08,C12R1:91),C12N15/00,C12N5/00, PC
(C12N5/00,C12R1:91)
CC Secreted and transmembrane polypeptides and nucleic CC acids
encoding the same
FH Key Location/Qualifiers
FT source 1..1378
/organism="Homo sapiens (human)".
FEATURES
source
Location/Qualifiers
1..1378
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 24.6; DB 1; Length 1378;
Best Local Similarity 53.7%; Pred. No. 22;
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2983 TCTATTTTACTTTAATGCACTTATTTTATGATTTTCTTAATAAATCCAGCTTGT 3042
Db 1272 TTTTGTATATAATGTTAATGATTTTATAGGATTTGTACCTGCCACATATCTT 1331
QY 3043 TTTTAAAAAGACTTTAAAAATTATTAATTTCTCT 3077
Db 1332 ATTATTCCTCCAATTCATAAATATTATTCT 1366
RESULT 35
BD173079
LOCUS
DEFINITION
Secreted and transmembrane polypeptides and nucleic acids encoding
the same.
ACCESSION
BD173079
VERSION
BD173079.1 GI:28414388
KEYWORDS
JP 2002238587-A/214.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1378)
AUTHORS
Wood,W.I., Gurney,A.L., Goddard,A., Pennica,D., Zheng,J. and
Yuan,J
TITLE
Secreted and transmembrane polypeptides and nucleic acids encoding
the same

```

JOURNAL Patent: JP 2002238587-A 214 27-AUG-2002;  
GENENTECH INC  
OS Homo sapiens (human)  
PN JP 2002238587-A/214  
PD 27-AUG-2002  
PF 18-DEC-2001 JP 2001385248  
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR  
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR  
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR  
17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR  
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR  
18-SEP-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR  
21-OCT-1997 US 60/062386, 24-OCT-1997 US 60/062815 PR  
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR  
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR  
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR  
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR  
28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR  
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR  
28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR  
29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR  
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR  
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064103 PR  
29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064248 PR  
31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR  
07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR  
17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR  
21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR  
24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066511 PR  
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR  
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI  
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI  
JIAN ZHENG,  
PI JEAN YUAN  
PC C12N15/09, C07K14/47, C07K16/18, C12N1/19, C12N1/21, C12N5/10, PC  
C12N15/02,  
C12P21/02, C12P21/08, C12P21/02, C12R1:91, C12P21/02, C12R1:19, PC  
C12P21/02, C12R1:645, C12N15/00, C12N5/00, C12N15/00 CC Secreted  
and transmembrane polypeptides and nucleic CC acids encoding the  
same  
FH Key Location/Qualifiers  
FT source 1..1378  
/organism="Homo sapiens (human)";  
/mol\_type="genomic DNA";  
/db\_xref="taxon:9606"  
FEATURES  
source  
1..1378  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 22;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTTTACTTAAATGCACCTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042  
DB 1272 TTTTGTGATATAAATGTAAGTATTTTATAGGATTTGTAACTCCGCCACATATCTT 1331  
QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
DB 1332 ATTTATCTCCCAATTCATAAATTAATTTATCT 1366  
RESULT 36  
BD173398  
LOCUS Secreted and transmembrane polypeptides and nucleic acids encoding  
the same.  
DEFINITION BD173398 1378 bp DNA linear PAT 18-FEB-2003  
ACCESSION BD173398  
VERSION BD173398.1 GI:28414709  
KEYWORDS JP 2002238588-A/214.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 1378)  
Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and  
Yuan, J.  
Secreted and transmembrane polypeptides and nucleic acids encoding  
the same  
Patent: JP 2002238588-A 214 27-AUG-2002;  
GENENTECH INC  
OS Homo sapiens (human)  
PN JP 2002238588-A/214  
PD 27-AUG-2002  
PF 18-DEC-2001 JP 2001385315  
PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR  
17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR  
17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR  
18-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR  
18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR  
17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR  
21-OCT-1997 US 60/062386, 24-OCT-1997 US 60/062816 PR  
24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR  
24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR  
24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR  
27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR  
28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR  
28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR  
28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR  
29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR  
29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063735 PR  
29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/064103 PR  
29-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064248 PR  
31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR  
07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR  
17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR  
21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR  
24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066511 PR  
24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR  
24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI  
WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI  
JIAN ZHENG,  
PI JEAN YUAN  
PC C12N15/09, C07K14/435, C07K16/18, C07K19/00, C12N1/19, C12N1/21, PC  
C12N5/10,  
C12P21/02, C12P21/08, C12N1/19, C12R1:645, C12N1/21, C12R1:19, PC  
C12N5/10, C12R1:91, C12N15/00, C12N5/00, C12N5/00, C12R1:91) CC  
Secreted and transmembrane polypeptides and nucleic CC acids  
encoding the same  
FH Key Location/Qualifiers  
FT source 1..1378  
/organism="Homo sapiens (human)";  
/mol\_type="genomic DNA";  
/db\_xref="taxon:9606"  
FEATURES  
source  
1..1378  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
Best Local Similarity 53.7%; Pred. No. 22;  
Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2983 TCTATTTTACTTAAATGCACCTATTTTATGATTTTCTAATAAATCCAGTCCTTGT 3042  
DB 1272 TTTTGTGATATAAATGTAAGTATTTTATAGGATTTGTAACTCCGCCACATATCTT 1331  
QY 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
DB 1332 ATTTATCTCCCAATTCATAAATTAATTTATCT 1366  
RESULT 37  
BD175432  
LOCUS Secreted and transmembrane polypeptide and nucleic acid encoding  
DEFINITION BD175432 1378 bp DNA linear PAT 18-MAR-2003

the same.  
 BD175432  
 BD175432.1 GI:29121130  
 JP 2002253280-A/214.  
 Homo sapiens (human)  
 Homo sapiens  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Wood, W.I., Gurney, A.L., Goddard, A., Pennica, D., Zheng, J. and  
 Yuan, J.  
 Secretory and transmembrane polypeptide and nucleic acid encoding  
 the same  
 Patent: JP 2002253280-A 214 10-SEP-2002;  
 GENENTECH INC  
 OS Homo sapiens (human)  
 PN JP 2002253280-A/214  
 PD 10-SEP-2002  
 PF 18-DEC-2001 JP 2001385319  
 PR 17-SEP-1997 US 60/059115, 17-SEP-1997 US 60/059184 PR  
 17-SEP-1997 US 60/059122, 17-SEP-1997 US 60/059117 PR  
 17-SEP-1997 US 60/059113, 17-SEP-1997 US 60/059121 PR  
 17-SEP-1997 US 60/059119, 18-SEP-1997 US 60/059263 PR  
 18-SEP-1997 US 60/059266, 15-OCT-1997 US 60/062125 PR  
 17-OCT-1997 US 60/062287, 17-OCT-1997 US 60/062285 PR  
 21-OCT-1997 US 60/063486, 24-OCT-1997 US 60/062816 PR  
 24-OCT-1997 US 60/062814, 24-OCT-1997 US 60/063127 PR  
 24-OCT-1997 US 60/063120, 24-OCT-1997 US 60/063121 PR  
 24-OCT-1997 US 60/063045, 24-OCT-1997 US 60/063128 PR  
 27-OCT-1997 US 60/063329, 27-OCT-1997 US 60/063327 PR  
 28-OCT-1997 US 60/063549, 28-OCT-1997 US 60/063541 PR  
 28-OCT-1997 US 60/063550, 28-OCT-1997 US 60/063542 PR  
 28-OCT-1997 US 60/063544, 28-OCT-1997 US 60/063564 PR  
 29-OCT-1997 US 60/063734, 29-OCT-1997 US 60/063738 PR  
 29-OCT-1997 US 60/063704, 29-OCT-1997 US 60/063435 PR  
 29-OCT-1997 US 60/064215, 29-OCT-1997 US 60/063735 PR  
 31-OCT-1997 US 60/063732, 31-OCT-1997 US 60/064103 PR  
 31-OCT-1997 US 60/063870, 03-NOV-1997 US 60/064248 PR  
 07-NOV-1997 US 60/064809, 12-NOV-1997 US 60/065186 PR  
 17-NOV-1997 US 60/065846, 18-NOV-1997 US 60/065693 PR  
 21-NOV-1997 US 60/066120, 21-NOV-1997 US 60/066364 PR  
 24-NOV-1997 US 60/066772, 24-NOV-1997 US 60/066466 PR  
 24-NOV-1997 US 60/066770, 24-NOV-1997 US 60/066511 PR  
 24-NOV-1997 US 60/066453, 25-NOV-1997 US 60/066840 PI  
 WILLIAM I WOOD, AUSTIN L GURNEY, AUDREY GODDARD, DIANE PENNICA, PI  
 JIAN ZHENG,  
 PI JEAN YUAN  
 PC C12N15/09, A61K45/00, A61P1/00, A61P13/12, A61P17/00, A61P17/06, PC  
 A61P25/00,  
 PC A61P25/16, A61P25/28, A61P31/12, A61P35/00, C07K14/47, C07K16/18,  
 PC C07K19/00,  
 PC C12N1/19, C12N1/21, C12N5/10/A61K38/00, A61K39/395, A61K39/395,  
 PC A61P43/00,  
 PC C12P21/08, (C12N1/19, C12R1:645), (C12N1/21, C12R1:19), (C12N5/10,  
 PC C12R1:91),  
 PC C12N15/00, C12N5/00, A61K37/02, (C12N5/00, C12R1:91) CC  
 Secretory and transmembrane polypeptide and nucleic acid CC  
 encoding the same  
 FH Key Location/Qualifiers  
 FT source 1..1378  
 FT Location/Qualifiers  
 1..1378  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

1272 TTTTGTATATAAATGTTAATGATTTTATAGTATTTTGTAACTGCTCCACATATCTT 1331  
 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
 1332 ATTATCTCCCAATTCATTAATTAATTTATCT 1366

RESULT 38  
 AY358396  
 LOCUS 1378 bp mRNA linear PRI 03-OCT-2003  
 DEFINITION Homo sapiens clone DNA43318 PRSS22 (UNQ302) mRNA, partial cds.  
 VERSION AY358396 GI:37181916  
 KEYWORDS FLI CDNA.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J.,  
 Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B.,  
 Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E.,  
 Heldens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S.,  
 Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C.,  
 Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V.,  
 Stinson, J., Vagts, A., Vandien, R., Watanabe, C., Wisand, D., Woods, K.,  
 Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z.,  
 Goddard, A., Wood, W.I. and Godowski, P.  
 The Secreted Protein Discovery Initiative (SPDI), a Large-Scale  
 Effort to Identify Novel Human Secreted and Transmembrane Proteins:  
 A Bioinformatics Assessment  
 Genome Res. 13 (10), 2285-2270 (2003)

JOURNAL PUBLISHED 12975309  
 REFERENCE 2 (bases 1 to 1378)  
 AUTHORS Clark, H.F.  
 TITLE Direct Submission  
 JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,  
 Inc., 1 DNA Way, South San Francisco, CA 94080, USA

FEATURES  
 source  
 1..1378  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="DNA43318"  
 <1..1378  
 /locus\_tag="UNQ302"  
 <1..1006  
 /locus\_tag="UNQ302"  
 /note="PRO343"  
 /codon\_start=2  
 /product="PRSS22"  
 /protein\_id="AAQ88762.1"  
 /db\_xref="GI:37181917"  
 /translation="HRPGLSEPAACSPAPPVMSGAPPALGGCLGTFTELLLLAST  
 ALNAAIPVPACPKQQLNRVGGSTDSSEWFIWISIQNGHTHCAGSLTSRW  
 IYAHCFKDLNPKYLFVLLGAWGLGPGSRQKGVAVWVPEVYVWKEGACADIA  
 LVRLESIQSERVLPICLPDASIHLPNTHCMISGWSIQDGVLPHPHQLKLV  
 IYDSEVCSHLYWRGAGQPIEDMLCAGVLEGRDACLGDSGGLMCCVDGAWLLAGI  
 ISWGEGCAERNRPVYISLSAHSRWEXIVQVQLRGRAGQGGALRAIPSGSGAARS"

gene  
 CDS  
 1..1006  
 /locus\_tag="UNQ302"  
 /note="PRO343"  
 /codon\_start=2  
 /product="PRSS22"  
 /protein\_id="AAQ88762.1"  
 /db\_xref="GI:37181917"

Query Match 0.7%; Score 24.6; DB 1; Length 1378;  
 Best Local Similarity 53.7%; Pred. No. 22;  
 Matches 51; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

2983 TCTATTTTACTTAAATGACCTATTTTATGATTTTCTTAATAAATCCAGTCTTGT 3042  
 1272 TTTTGTATATAAATGTTAATGATTTTATAGTATTTTGTAACTGCTCCACATATCTT 1331  
 3043 TTTTAAAAAGACTTTAAATTAATTAATTTCTCT 3077  
 1332 ATTATCTCCCAATTCATTAATTAATTTATCT 1366

gene

```

/clon="IMAGE:5764698"
/tissue type="Brain, adult, 6 pooled whole brains"
/clon_lib="NIH MGC_114"
/lab_host="DH10B"
/notes="Vector: pCMV-SPORT6"

Query Match
Best Local Similarity 0.7%; Score 24.2; DB 1; Length 1573;
Matches 50; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 1499 GGGAGCCCTTACAAATAGCTGTGAAAGAGAGAGAGTGAAGCAAGGAAAAAGGAAA 1558
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1470 GAGATCCCACTCAAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1529
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1559 GATAAAGCATCTGAATGCAGAGTTCCAAAGAA 1591
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1530 AAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1562
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 41
LOCUS PIGFIXA
DEFINITION Pig factor IX mRNA, partial cds.
ACCESSION M26235
VERSION M26235.1 GI:164450
KEYWORDS factor IX.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE
AUTHORS Sarkar,G., Koberl,D.D. and Sommer,S.S.
TITLE Direct sequencing of the activation peptide and the catalytic
JOURNAL domain of the factor IX gene in six species
MEDLINE Genomics 6 (1), 133-143 (1990)
PUBMED 90152675
COMMENT 2303254
Original source text: Pig liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
Location/Qualifiers
1..813
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
<1..>813
/notes="factor IX"
/codon_start=1
/protein_id="AAA31031.1"
/db_xref="GI:164451"
translation="SHSPPTTLTTRAEILFSDNDVNSTEVEPILDSLTESQSSDDFIR
IVGNAPKGFPPQVQLNGKIDAFCCGSIINEKXWVTAHCBPGVKITVVAEYNT
RETEDEQRVIRAPHSSTNATVKNKSHDIALDELDELPLNSVTPICIADEYNT
NIFLFGSGVSGWGRVNRGRSATILQYLKVLPLDRLCLRSKTVITVSNMFCAGPH
EGKDCSLGDSGPHVTEVEGTSFLTGIISWGECAVKGKGYITKVSRYVW"

Query Match
Best Local Similarity 0.7%; Score 23.8; DB 1; Length 813;
Matches 46; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2957 GACTTGATTTCTAATATTCTATTCTATTCTATTCTATTCTATTCTATTCTATTGTA 3016
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 33 GATTATTTTTCACATGCACTATGAAATCTACTGAAGTTGAACCAATTTGGATAG 92
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 3017 TTTTCTTAATAAATCCAGTCT 3039
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 93 CCTCACTGAAGCAACCAATCAT 115
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 42
LOCUS AF318182/c
DEFINITION Mus musculus anticoagulant protein C mRNA, complete cds.

/clon="IMAGE:5764698"
/tissue type="Brain, adult, 6 pooled whole brains"
/clon_lib="NIH MGC_114"
/lab_host="DH10B"
/notes="Vector: pCMV-SPORT6"

Query Match
Best Local Similarity 0.7%; Score 24.2; DB 1; Length 1573;
Matches 50; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 1499 GGGAGCCCTTACAAATAGCTGTGAAAGAGAGAGAGTGAAGCAAGGAAAAAGGAAA 1558
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1470 GAGATCCCACTCAAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1529
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1559 GATAAAGCATCTGAATGCAGAGTTCCAAAGAA 1591
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1530 AAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1562
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 41
LOCUS PIGFIXA
DEFINITION Pig factor IX mRNA, partial cds.
ACCESSION M26235
VERSION M26235.1 GI:164450
KEYWORDS factor IX.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE
AUTHORS Sarkar,G., Koberl,D.D. and Sommer,S.S.
TITLE Direct sequencing of the activation peptide and the catalytic
JOURNAL domain of the factor IX gene in six species
MEDLINE Genomics 6 (1), 133-143 (1990)
PUBMED 90152675
COMMENT 2303254
Original source text: Pig liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
Location/Qualifiers
1..813
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
<1..>813
/notes="factor IX"
/codon_start=1
/protein_id="AAA31031.1"
/db_xref="GI:164451"
translation="SHSPPTTLTTRAEILFSDNDVNSTEVEPILDSLTESQSSDDFIR
IVGNAPKGFPPQVQLNGKIDAFCCGSIINEKXWVTAHCBPGVKITVVAEYNT
RETEDEQRVIRAPHSSTNATVKNKSHDIALDELDELPLNSVTPICIADEYNT
NIFLFGSGVSGWGRVNRGRSATILQYLKVLPLDRLCLRSKTVITVSNMFCAGPH
EGKDCSLGDSGPHVTEVEGTSFLTGIISWGECAVKGKGYITKVSRYVW"

Query Match
Best Local Similarity 0.7%; Score 23.8; DB 1; Length 813;
Matches 46; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 2957 GACTTGATTTCTAATATTCTATTCTATTCTATTCTATTCTATTCTATTGTA 3016
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 33 GATTATTTTTCACATGCACTATGAAATCTACTGAAGTTGAACCAATTTGGATAG 92
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 3017 TTTTCTTAATAAATCCAGTCT 3039
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 93 CCTCACTGAAGCAACCAATCAT 115
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 42
LOCUS AF318182/c
DEFINITION Mus musculus anticoagulant protein C mRNA, complete cds.

```

```

AF318182
AF318182.1 GI:12802522
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Korfi.I.
Complete sequence of UC72A01
Unpublished
2 (bases 1 to 1580)
Direct Submission
Submitted (02-NOV-2000) Genetics, Washington University, 4444
Forest Park Avenue, St. Louis, MO 63108, USA
Location/Qualifiers
1..1580
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="dbEST:AA986009"
/db_xref="taxon:10090"
72..1454
/codon_start=1
/product="anticoagulant protein C"
/protein_id="AAK07918.1"
/db_xref="GI:12802523"
translation="WMQPRVFLLLMTGSSIPAHDPVFSSSHQVLRVRRANS
FLHEMEPSGLERECEMEICDLEAEQEIFQNVEDTLAFWKVFDQCSAPPLDHQDS
PCGGCTCIDGIGSCSCDKGWSKFCQQLRFQDCRVNNGGCLHYCLESSNGRCA
CAPGELADDMRCKSTVNFPGKLGRLKRRKILKRDLDLEEDPDLVNGTLT
KQDSDPAQLLDSKKKACGGVLHTSWLTAHCVGEGTKLTVRLGEYDLRRDDHW
EDLDITKEILVHPNTRSSNDIALRLAQPATLSKTIVPTCLFNGLAQLBTOAGQ
ETVTVGWQYSDRIKDGRRNRTFILTRIPLVARNCEVNMKNVSVSNMCLAGIIGD
TRDACDSDSGPMWVFRGTWFLVGLVSGWEGCGHTNNYGIYTKVGSYLKWHISYIG
KGVSLKSQL"

Query Match
Best Local Similarity 0.7%; Score 23.6; DB 1; Length 1580;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3245 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCT 3274
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1579 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCT 1550
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 43
LOCUS AX193364
DEFINITION Sequence 931 from Patent WO0149716.
ACCESSION AX193364
VERSION AX193364.1 GI:15211315
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Xu,J., Lodes,M.J., Secretist,H., Benson,D.R., Meagher,M.J.,
Stolk,J.A., King,G.E., Wang,T. and Jiang,Y.
TITLE Compounds for immunotherapy and diagnosis of colon cancer and
JOURNAL methods for their use
Patent: WO 0149716-A 931 12-JUL-2001;
CORIXA CORPORATION (US)
Location/Qualifiers
1..596
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 23.4; DB 1; Length 596;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;  
 QY 2560 GGCCACCTGATCAGAGAGCTGACTCACTGGAAGACCTGATGCTGGAGGATGGG 2619  
 DB 41 GGCCACATGACCCAGCCAGTGCAGTGCAGTGGAGCCGTTGGGGAAGAGGCGTTGGC 100  
 QY 2620 GGCCAGGAGGAAGGGGACGACAGGATGAGTGGCTGGATGCATCACTGACTCGATG 2679  
 DB 101 TGCAGGGAGGAGATGGCCGAGTGTACGGGAGAGAGTGTGGTCTGCTGAGTTGGAG 160  
 QY 2680 G-----ACGTGAGTCTGGGTGAACCTCTCGAGTTGGTGTGACAGGGAGG 2725  
 DB 161 GAGTCAATGTGCGCCTGGGAGCCCTCTCGAGGTAGTGGGTGGGGATG 212

RESULT 44  
 AR219285/c  
 LOCUS AR219285 1142 bp DNA linear PAT 25-SEP-2002  
 DEFINITION Sequence 8 from patent US 6420157.  
 ACCESSION AR219285  
 VERSION AR219285.1 GI:23320255  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1142)  
 AUTHORS Darow,A., Qi,J. and Andrade-Grodon,P.  
 TITLE Zymogen activation system  
 JOURNAL Patent: US 6420157-A 8 16-JUL-2002;  
 FEATURES Location/Qualifiers  
 source 1..1142  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match 0.7%; Score 23.4; DB 1; Length 1142;  
 Best Local Similarity 49.4%; Pred. No. 42;  
 Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;

QY 2560 GGCCACCTGATCAGAGAGCTGACTCACTGGAAGACCTGATGCTGGAGGATGGG 2619  
 DB 537 GGCCACATGACCCAGCCAGTGCAGTGCAGTGGAGCGCTGGGAGGAGCGTTGGC 478  
 QY 2620 GGCCAGGAGGAAGGGGACGACAGGATGAGTGGCTGGATGGATCACTGACTCGATG 2679  
 DB 477 TGCAGGGAGGAGATGGCCGAGTGTACGGGAGAGGATGAGTGGTCTGCTGAGTTGGAG 418  
 QY 2680 G-----ACGTGAGTCTGGGTGAACCTCTCGAGTTGGTGTGACAGGGAGG 2725  
 DB 417 GAGTCAATGTGCGCCTGGGAGCCCTCTCGAGGTAGTGGGTGGGGATG 366

RESULT 45  
 AX675581/c  
 LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 31 from Patent WO20205704.  
 ACCESSION AX675581  
 VERSION AX675581.1 GI:29333567  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens

REFERENCE 1  
 AUTHORS Padigar,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S.,  
 Spytek,K.A., Zhong,M., Gangolli,E.A., Burgess,C.E., Patturajan,M.,  
 Vermet,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X.,  
 Boldog,F.L., Grose,W.M., Alsobrook,J.P., Gerlach,V.,  
 Edingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J.,  
 Nallyankar,D., Millet,I., Peyman,J., Smithson,G., Gunther,E. and  
 Stone,D.J.  
 TITLE Proteins, polynucleotides encoding them and methods of using the  
 same  
 JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;

FEATURES  
 source  
 Location/Qualifiers  
 1..1161  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.7%; Score 23.4; DB 1; Length 1161;  
 Best Local Similarity 49.4%; Pred. No. 42;  
 Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;  
 QY 2560 GGCCACCTGATCAGAGAGCTGACTCACTGGAAGACCTGATGCTGGAGGATGGG 2619  
 DB 738 GGCCACATGACCCAGCCAGTGCAGTGCAGTGGAGCGCTGGGGAAGAGGCGTTGGC 679  
 QY 2620 GGCCAGGAGGAAGGGGACGACAGGATGAGTGGCTGGATGCATCACTGACTCGATG 2679  
 DB 678 TGCAGGGAGGAGATGGCCGAGTGTACGGGAGAGGATGGTCTGCTGAGTTGGAG 619  
 QY 2680 G-----ACGTGAGTCTGGGTGAACCTCTCGAGTTGGTGTGACAGGGAGG 2725  
 DB 618 GAGTCAATGTGCGCCTGGGAGCCCTCTCGAGGTAGTGGGTGGGGATG 567

RESULT 46  
 AR219284/c  
 LOCUS AR219284 1169 bp DNA linear PAT 25-SEP-2002  
 DEFINITION Sequence 7 from patent US 6420157.  
 ACCESSION AR219284  
 VERSION AR219284.1 GI:23320254  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1169)  
 AUTHORS Darow,A., Qi,J. and Andrade-Grodon,P.  
 TITLE Zymogen activation system  
 JOURNAL Patent: US 6420157-A 7 16-JUL-2002;  
 FEATURES Location/Qualifiers  
 source 1..1169  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match 0.7%; Score 23.4; DB 1; Length 1169;  
 Best Local Similarity 49.4%; Pred. No. 42;  
 Matches 85; Conservative 0; Mismatches 81; Indels 6; Gaps 1;

QY 2560 GGCCACCTGATCAGAGAGCTGACTCACTGGAAGACCTGATGCTGGAGGATGGG 2619  
 DB 564 GGCCACATGACCCAGCCAGTGCAGTGCAGTGGAGCGCTGGGGAAGAGGCGTTGGC 505  
 QY 2620 GGCCAGGAGGAAGGGGACGACAGGATGAGTGGCTGGATGGATCACTGACTCGATG 2679  
 DB 504 TGCAGGGAGGAGATGGCCGAGTGTACGGGAGAGGATGAGTGGTCTGCTGAGTTGGAG 445  
 QY 2680 G-----ACGTGAGTCTGGGTGAACCTCTCGAGTTGGTGTGACAGGGAGG 2725  
 DB 444 GAGTCAATGTGCGCCTGGGAGCCCTCTCGAGGTAGTGGGTGGGGATG 393

RESULT 47  
 AX774765/c  
 LOCUS AX774765 1507 bp DNA linear PAT 09-JUL-2003  
 DEFINITION Sequence 81 from Patent WO03038129.  
 ACCESSION AX774765  
 VERSION AX774765.1 GI:32486281  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 REFERENCE 1  
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
 Raponi,M.







```

/lab_host="DH10B"
/notes=vector: pcmv-sport6"
1..1541
/genes="F10"
/notes="synonyms: FX, FXA"
/db_xref="LocusID:2159"
/db_xref="MIM:227600"
39..1505
/codon_start=1
/product="coagulation factor X precursor"
/protein_id="AAH46125.1"
/db_xref="GI:28374356"
/db_xref="LocusID:2159"
/translation="MGSLPLHLVLSASLAGLLIGSLFIRRECAANNILARVTRANSF
LEMGKHLRECEHTECSYBEAREVEDSKTNFKNKYKDGQCCTSCQCGKCK
DGLGYTCCTLEGEGKNCLELTKLSLNGDCDQCFEBEONSVSCARGYFLADN
KACIPTGPGYCPGCTERRKRSVAQATSSSGEAPDSITWPKYDAALDPTENPFDLL
DFNQTQPGGNNTIRIVGQECDECPQWALLINEEGFCGGTILSFYILITAAH
CLYAKRKVRGRNTRVQEGGEAVHEVVIKHNRTKTYDFDIARLRLKTPIF
RMVAPACLPRDAESFLMTQKTVIGSGFGRTHKGRQSTRLAKMLEVPVYDRNSCKL
SSSLITQNMFCACVDTKQEDACQDGGGPHVTRKDTYFVTGIVSWGEGCARKGKYG
IYTKVAFKMLWIDRSMKTRGLDFKASHAPEVITSSPLK"
111..293
/notes="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
318..401
/notes="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
738..1424
/notes="Tryp SPc; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"

Query Match 0.7%; Score 23.4; DB 1; Length 1541;
Best Local Similarity 81.8%; Pred. NO. 44;
Matches 27; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3245 TTTTITTTTTTTTTTTTTTTTAAAGATGTCAT 3277
|||||
Db 1539 TTTTITTTTTTTTTTTTTTTTGGTGGGAT 1507
|||||

RESULT 50
BC034377
LOCUS BC034377 1792 bp mRNA linear PRI 12-NOV-2003
DEFINITION Homo sapiens protein C (inactivator of coagulation factors Va and
Viii), mRNA (cDNA clone MGC:34565 IMAGE:5189604), complete cds.
ACCESSION BC034377
VERSION BC034377.1 GI:21707770
KEYWORDS MGC.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1792)
Strausberg,R.I., Feingold,B.A., Grouse,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusina,K., Farmer,A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.P., Casavant,T.L.,
Scheetz,T.E., Brownstein,M.J., Ustin,T.B., Toshiyuki,S.,
Carninci,P., Frange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullaly,S.J., Bosak,S.A., McEwan,P.J.,

/lab_host="DH10B"
/notes=vector: pcmv-sport6"
1..1541
/genes="F10"
/notes="synonyms: FX, FXA"
/db_xref="LocusID:2159"
/db_xref="MIM:227600"
39..1505
/codon_start=1
/product="coagulation factor X precursor"
/protein_id="AAH46125.1"
/db_xref="GI:28374356"
/db_xref="LocusID:2159"
/translation="MGSLPLHLVLSASLAGLLIGSLFIRRECAANNILARVTRANSF
LEMGKHLRECEHTECSYBEAREVEDSKTNFKNKYKDGQCCTSCQCGKCK
DGLGYTCCTLEGEGKNCLELTKLSLNGDCDQCFEBEONSVSCARGYFLADN
KACIPTGPGYCPGCTERRKRSVAQATSSSGEAPDSITWPKYDAALDPTENPFDLL
DFNQTQPGGNNTIRIVGQECDECPQWALLINEEGFCGGTILSFYILITAAH
CLYAKRKVRGRNTRVQEGGEAVHEVVIKHNRTKTYDFDIARLRLKTPIF
RMVAPACLPRDAESFLMTQKTVIGSGFGRTHKGRQSTRLAKMLEVPVYDRNSCKL
SSSLITQNMFCACVDTKQEDACQDGGGPHVTRKDTYFVTGIVSWGEGCARKGKYG
IYTKVAFKMLWIDRSMKTRGLDFKASHAPEVITSSPLK"
111..293
/notes="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
318..401
/notes="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
738..1424
/notes="Tryp SPc; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"

Query Match 0.7%; Score 23.4; DB 1; Length 1541;
Best Local Similarity 81.8%; Pred. NO. 44;
Matches 27; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3245 TTTTITTTTTTTTTTTTTTTTAAAGATGTCAT 3277
|||||
Db 1539 TTTTITTTTTTTTTTTTTTTTGGTGGGAT 1507
|||||

RESULT 50
BC034377
LOCUS BC034377 1792 bp mRNA linear PRI 12-NOV-2003
DEFINITION Homo sapiens protein C (inactivator of coagulation factors Va and
Viii), mRNA (cDNA clone MGC:34565 IMAGE:5189604), complete cds.
ACCESSION BC034377
VERSION BC034377.1 GI:21707770
KEYWORDS MGC.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1792)
Strausberg,R.I., Feingold,B.A., Grouse,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusina,K., Farmer,A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.P., Casavant,T.L.,
Scheetz,T.E., Brownstein,M.J., Ustin,T.B., Toshiyuki,S.,
Carninci,P., Frange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullaly,S.J., Bosak,S.A., McEwan,P.J.,

McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
Villalon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Fahey,J., Helton,E., Kettaman,M., Madan,A., Rodrigues,S.,
Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smalhus,D.E.,
Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A., National Cancer
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mhc.nci.nih.gov
Contact: MGC help desk
Email: cgabs-r@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Baylor College of Medicine Human Genome
Sequencing Center
Center code: BCM-HGSC
Web site: http://www.hgsc.bcm.tmc.edu/cdna/
Contact: ang@bcm.tmc.edu
Gunaratne, P.H., Garcia, A.M., Lu, X., Hulyk, S.W., Loulseged, H.,
Kowis, C.R., Sneed, A.J., Martin, R.G., Muzny, D.M., Nanavati,
A.N., Gibbs, R.A.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAK Plate: 50 Row: h Column: 4
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 4506114.

FEATURES
source
1..1792
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:34565 IMAGE:5189604"
/tissue_type="Colon, Kidney, Stomach, adult, whole pooled"
/clone_lib="NIH MGC_116"
/lab_host="DH10B"
/notes=vector: pcmv-sport6"
1..1792
/genes="PROC"
/db_xref="LocusID:5624"
/db_xref="MIM:176860"
56..1441
/codon_start=1
/product="protein C (inactivator of coagulation factors Va
and Viii)"
/protein_id="AAH34377.1"
/db_xref="GI:21707771"
/db_xref="LocusID:5624"
/translation="MWQLTSLILFVATWGISCTPAPLDSVFSSSEPAHOVLRIRKAN
SLFEURHSLRECEIEECDEEAKEIFQNVDDTLAFWSKVDGQCCLVLEHPCA
SUCCGHGTCDIGSPSCDGRFCOREVSLNCSLDNGGQCHYCLIEEVGMRRRC
SCAGPYKGLDGLQCHPAVKPGFPGKRWKMRKSHKRDTEQDQVDFRLIDGKMT
SRAGDSQWVLLDSKKLACGAVLIHPSWLVTAACHCMDSKKLLVGLGYDRLRWKRW
ELDLDIKYFVHPNYSKSTNDIALHLAQAPATISQITVPICLPSGLAEELNQAG
QETLVNGWGHVSRRKEAKRNTFLNFIKIPVPHNECSVMNSVSNMLCAGTLG
DRDACEGSDGSPWASFTGTFVLGLVSWGEGCLLHNYGVYTKVSRVLDWIHGHIR
DKRAPKQSWAP"
125..316
/misc_feature
/notes="GLA; Region: Domain containing Gla

```

1690 AAACATCTATTTCTGCTTTTATTCACCTATGCAGAAAGCCTTTGACTGTGGGGGTACAAATA 174  
 Db 181 ATTGTGATAGCTAGCTAGTGGCTGGTGGGGAAGTCTTCAAAAGGGCGACCGCTAC 240

QY 1750 ACTGTGAAAATTTCTGAAAG 1769  
 Db 241 AATTCTTCAGTACCTTAAAG 260

RESULT 52  
 SHPFIKA  
 LOCUS Sheep factor IX mRNA, partial cds.  
 DEFINITION  
 ACCESSION M26233  
 VERSION M26233.1 GI:165878  
 KEYWORDS factor IX.  
 SOURCE Ovis aries (sheep)  
 ORGANISM Ovis aries  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
 Bovidae; Caprinae; Ovis.  
 1 (bases 1 to 823)  
 SARKAR,G., KOBERL,D.D. and SOMMER,S.S.  
 TITLE Direct sequencing of the activation peptide and the catalytic  
 domain of the factor IX gene in six species  
 JOURNAL Genomics 6 (1), 133-143 (1990)  
 MEDLINE 90152675  
 PUBMED 230254

COMMENT  
 Original source text: Sheep liver, cDNA to mRNA.  
 Draft entry and computer-readable sequence for [1] kindly provided  
 by G.Sarkar, 18-JUL-1989.

FEATURES  
 Location/Qualifiers  
 1..823  
 /organism="Ovis aries"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9940"  
 <1..>823  
 /note="factor IX"  
 /codon\_start=1  
 /protein\_id="AAA31520.1"  
 /db\_xref="GI:552419"  
 /translation="RASVLHTSKLTRAETISNNYENSSEABIIWNVTSNQSF  
 DFNRVGGEDAAAGQFPQVLLHGEIAAFCGGSIVNERKVVTAACHIKFPGVKITVVG  
 EYNTKPKPTQGRNVIRAIPIYGYNASINKYSHDIALDELDEPLNSYVTPICIA  
 REYTNIFIKFGGYGVGWRGVENRGSRASILQYLKVLVDRAITCLRSTFTIYNHMF  
 AGYHGEGKXDCQGDGSGPHVEVGTGSLTIGISWGECAMKKGVIYTKVSRVEY"

CDS  
 1..823  
 /note="factor IX"  
 /codon\_start=1  
 /protein\_id="AAA31520.1"  
 /db\_xref="GI:552419"  
 /translation="RASVLHTSKLTRAETISNNYENSSEABIIWNVTSNQSF  
 DFNRVGGEDAAAGQFPQVLLHGEIAAFCGGSIVNERKVVTAACHIKFPGVKITVVG  
 EYNTKPKPTQGRNVIRAIPIYGYNASINKYSHDIALDELDEPLNSYVTPICIA  
 REYTNIFIKFGGYGVGWRGVENRGSRASILQYLKVLVDRAITCLRSTFTIYNHMF  
 AGYHGEGKXDCQGDGSGPHVEVGTGSLTIGISWGECAMKKGVIYTKVSRVEY"

Query Match 0.6%; Score 23.2; DB 1; Length 823;  
 Best Local Similarity 54.8%; Pred. No. 44;  
 Matches 46; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 2957 GACTTGTATTCTCAATATTACTATTCTATTCTATTCTTTAAATGCACCTATTTTATGCA 3016  
 Db 45 GACTATTTTTCATATGCAACTATCAAAATCTCTGAGCTGAATAATTGGGATAA 104

QY 3017 TTTTCTATAATAATCCAGTCTTT 3040  
 Db 105 CGTCACTCAAGCAATCAATCATT 128

RESULT 53  
 AY023240  
 LOCUS Oryza sativa microsatellite MRG5565 containing (GGA)X8, genomic  
 DEFINITION  
 ACCESSION AY023240  
 VERSION AY023240  
 KEYWORDS AY023240.1 GI:12706456  
 SOURCE Oryza sativa  
 ORGANISM Oryza sativa  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
 Eriaraloideae; Oryzoae; Oryza.



```

Db      671 TCATTACGAT 661

RESULT 56
AF465275/c
LOCUS   1293 bp mRNA linear VRT 02-FEB-2003
DEFINITION Takifugu rubripes coagulation factor VIIc precursor, mRNA, complete cds.
ACCESSION AF465275
VERSION   AF465275.1 GI:28194021
KEYWORDS
SOURCE    Takifugu rubripes (Fugu rubripes)
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthomorpha; Acanthopterygii; Percormorpha; Tetraodontiformes;
            Tetraodontidae; Tetraodontidae; Takifugu.
REFERENCE 1 (bases 1 to 1293)
AUTHORS   Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
            Tuddenham,E.G.D. and McVey,J.H.
TITLE      Comparative sequence analysis and molecular evolution of blood
            coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL    Unpublished
REFERENCE 2 (bases 1 to 1293)
AUTHORS   McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
TITLE      Direct Submission
JOURNAL    Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
            Centre, The Faculty of Medicine, Imperial College, Hammersmith
            Campus, Du Cane Road, London W12 0NN, UK
FEATURES
            source
            Location/Qualifiers
                1..1293
                    /organism="Takifugu rubripes"
                    /mol_type="mRNA"
                    /db_xref="taxon:31033"
                1..1293
                    /c_number="3.4.21.21"
                    /function="serum prothrombinconversion accelerator"
                    /note="vitamin K dependent serine protease; similar to
                    factor VII precursor; synthesized in liver; similar to
                    Fugu rubripes FVII and FVIII; contains 2 EGF-like domains;
                    member of peptidase family S1/trypsin family"
                    /codon_start=1
                    /product="coagulation factor VIIc precursor"
                    /protein_id="AA033370.1"
                    /db_xref="GI:28194022"
                    /translation="MASFSRGTKRLFFIKLIITPVCGSPPEAGVFMKPEANVFLH
                    RTRANFLPEELKAGNLERCTEEKSYEEAKFALPQOLEAFWRTYTAVDCKLSP
                    CKNGATCTRRPETYACKANGFHGNCVKRLTNGCRYRNGCGCFHFRFPDRSYVC
                    PCAGVRLDKONSTCLPVKPCGRLQILFSPVRINGLCPKGHCPCAMLSNNIVT
                    CGTILSQWLVLTAAHCVRKPAHLFNTVSGEHREIPEKTEOHERVILKVLHPGYNK
                    TSSDKDLAMKLKGLIVPILCPAQNSTISRLIANRQSTVSGWGRLSRFGPP
                    ATILQRLTLPRVPEQLRHTKLNITRNMLCAGLTKGRDACEGDSGGPLVITYEKTW
                    FLTVGVSWGKGKANENLYGVYRVTFNLDWIGNIATN"

Query Match 0.6%; Score 23; DB 1; Length 1293;
Best Local Similarity 49.6%; Pred. No. 54;
Matches 59; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 171 CATACACGAGAAACTAGTCAATCTAATCATCACTAGGACACAGCCTTGCTCACTCAA 230
    |||
Db 160 CAAACAGGAAATTAGCCGCTCGAGTCGATGCGAGACGCTGGCCCTCGGGTTTTC 101
    |||

QY 231 TGAACCTAAGCATGCCGCTGGGGCAACCCAGATGCGATGCTGCGAGATCT 289
    |||
Db 100 TAAAACTCCCGCTTCCGGAACCCAGAGCATACTGGGACGGTAATGATGAAGAGTTT 42
    |||

RESULT 57
107991
LOCUS   2438 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 6 from Patent EP 0200421.
ACCESSION 107991
VERSION   107991.1 GI:589297

Query Match 0.6%; Score 22.8; DB 1; Length 264;
Best Local Similarity 54.9%; Pred. No. 42;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 4 AGGAAGCGCGGAGTGAAGGAGGTTACCTACCTCGTCCAAAGTAGGAGGAGTACTGCG 63
    |||
Db 26 AGGGAAGGGTGAAGGAGGTTACCGGCTTCCGCCAAGAGAGGCGCTGGAGCTCG 85
    |||
QY 64 GCTTTGCTGGAGCAGCGCTAAA 85
    |||

```

```

KEYWORDS Unknown.
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 2438)
AUTHORS   Hagen,F.S., Murray,M.J., Busby,S.J., Berkner,K.L., Insley,M.Y.,
            Woodbury,R.G. and Gray,C.L.
TITLE      Expression of factor VII and IX activities in mammalian cells
JOURNAL    Patent: EP 0200421-A2 6 10-DEC-1986;
FEATURES
            source
            Location/Qualifiers
                1..2438
                    /organism="unknown"
                    /mol_type="unassigned DNA"
                Query Match 0.6%; Score 23; DB 1; Length 2438;
                Best Local Similarity 50.5%; Pred. No. 61;
                Matches 56; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
                QY 1661 ATCATCGAAAGAACAGAGATTCAGAAAAACATCTATTCTGCTTTATTGCTATGCA 1720
                    |||
                Db 25 ATCATGGCAATACACAGGCGCTCATCCATCTGCTTTTAGGATATCTACTCAGTCT 84
                    |||
                QY 1721 AAGCCCTTTGACTGTGGGGTGCACATTAACCTGGAAAAATCTGAAAGGG 1771
                    |||
                Db 85 GAATGTACAGTGTCTTTTCTGATCATGAAACGCAACAAAATCTGAATCG 135
                    |||

RESULT 58
BD180174 264 bp DNA linear PAT 15-MAY-2003
LOCUS     Highly thermophilic bacterium-derived protein and gene encoding it.
DEFINITION BD180174
ACCESSION  BD180174.1 GI:30791092
VERSION     JP 2002325574-A/665.
KEYWORDS    Thermus thermophilus
SOURCE      Thermus thermophilus
ORGANISM    Bacteria; Deinococcus-Thermus; Deinococci; Thermales; Thermaceae;
            Thermus.
REFERENCE 1 (bases 1 to 264)
AUTHORS   Kuramitsu,N. and Yokoyama,S.
TITLE      Highly thermophilic bacterium-derived protein and gene encoding it
JOURNAL    Patent: JP 2002325574-A 665 12-NOV-2002;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH
COMMENT    OS Thermus thermophilus
            PN JP 2002325574-A/665
            PD 12-NOV-2002
            PF 23-FEB-2001 JP 2001116171
            PI NARUKI KURAMITSU, SHIGEYUKI YOKOYAMA
            PC C12N15/09,C12N15/09,C07K14/195,C12N1/15,C12N1/19,C12N1/21, PC
            C12N5/10,
            PC C12N9/88,C12P21/02,/(C12N9/88,C12R1/01),(C12N15/09,C12R1/01),
            PC (C12P21/02,C12R1/01),C12N15/00,C12N15/00,C12N5/00,(C12N15/00,
            CC C12R1/01)
            CC Highly thermophilic bacterium-derived protein and gene CC
            encoding it
            FH Key Location/Qualifiers
            FT CDS Location/Qualifiers
                1..264
                    /organism="Thermus thermophilus"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:274"

Query Match 0.6%; Score 22.8; DB 1; Length 264;
Best Local Similarity 54.9%; Pred. No. 42;
Matches 45; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

QY 4 AGGAAGCGCGGAGTGAAGGAGGTTACCTACCTCGTCCAAAGTAGGAGGAGTACTGCG 63
    |||
Db 26 AGGGAAGGGTGAAGGAGGTTACCGGCTTCCGCCAAGAGAGGCGCTGGAGCTCG 85
    |||
QY 64 GCTTTGCTGGAGCAGCGCTAAA 85
    |||

```

```

86 GCCTTCGGGTACGCCGAGAA 107
Db

RESULT 59
BOVPBC/c
LOCUS BOVPBC Bovine protein C mRNA. 1373 bp mRNA linear MAM 27-APR-1993
DEFINITION BOVPBC
ACCESSION K02435.1 GI:163486
VERSION autoprotehin IIA; protein C; serine protease.
KEYWORDS Bos taurus (cow)
SOURCE Bos taurus
ORGANISM Bos taurus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidae;
Bovidae; Bovinae; Bos.
REFERENCE 1 (bases 1 to 1373)
AUTHORS Long,G.L., Belagaje,R.M. and Macgillivray,R.T.
TITLE Cloning and sequencing of liver cDNA coding for bovine protein C
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)
MEDLINE 85014826
PUBMED 6091100
COMMENT Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and
pBC-7.
The sequence reported in [1] included homopolymeric tails on the 5'
and 3' ends (not shown here).
FEATURES
source
1..1373
Location/Qualifiers
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
<1..1370
/note="protein C prepropeptide"
/codon_start=3
/protein_id="AAA30685.1"
/db_xref="GI:163487"
/translaton="TSLLLFTVIGISTAPPDSVFSSQRAHQVLIRKTRANSLE
ELRPNPRECEEVEFEARELFQNTEDTMFWSKYSDGDCEDRPGSPCDLBPCC
GRGKIDGLGRCDAEGWGRFCLEHVRFSNGSAENGCAHYCMEEEGRRCSCAP
GYRLDDQLCVSKVTFCGLRGMRKKRLKRDNDNQVDKDLDPRIVDQGEAGW
GESPMOAVLLDSKKLVCGAVLIHVSWLTVAHLCLDRKKLIIVRLGEYDMRWESWEV
DLDIKEVLIHPNYTKSDNDIALILRLAKPATLSQTVPICLPDSGSRKLTPGOE
TVTWGWGRDSTKNRFVLFKIPVPPYNACHVANKENISEMLCAGILGPRDAC
BGDSGPWMVTFRGTWFLVGLVSWGEGCGRRITGVYIKVSRYLDWIYGHKAQEAPL
ESQP"
sig_peptide <1..86
/note="protein C signal peptide"
mat_peptide 117..581
/product="protein C light chain"
mat_peptide 588..1367
/product="protein C inactive heavy chain"
mat_peptide 630..1367
/product="protein C active heavy chain"

Query Match 0.6%; Score 22.8; DB 1; Length 1373;
Best Local Similarity 56.8%; Pred. No. 61;
Matches 42; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

QY 2651 GATGCTGATGCATCATCTACTCGATTGAGCGTGCTGGGTGAACCTCTGGAGTTGG 2710
Db 84 GCTGGCTGCTGGAGAACAATGAGTCAGGAGGAGCTGGTGTGCGAATAATCCCAGATGG 25
QY 2711 TCGTGGACAGGGAG 2724
Db 24 TCACGAACAGTAAG 11

RESULT 60
DLA6882
LOCUS DLA6882 Dicentrarchus labrax mRNA for trypsin, partial. VRT 12-OCT-1998
DEFINITION DLA6882
ACCESSION AJ006882
VERSION AJ006882.1 GI:3228220
KEYWORDS trypsin.

86 GCCTTCGGGTACGCCGAGAA 107
Source
```

Campus, Du Cane Road, London W12 0NN, UK

Location/Qualifiers

1. .1416

/organism="Gallus gallus"

/mol\_type="mRNA"

/db\_xref="taxon:9031"

1. .1416

/gene="p9"

1. .1416

/EC\_number="3.4.21.22"

/function="converts factor X to its active form in the presence of Ca++ ions, phospholipids, and factor VIIa"

/note="vitamin K dependent serine protease; Christmas factor; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"

/codon\_start=1

/product="coagulation factor IX precursor"

/protein\_id="AA033364.1"

/db\_xref="GI:28194010"

/translation="MAKIPILILFCLLEAFLEAEVSTVLSRTRGRNSNR LDELIPGLERECIEKCSFEAREVFENTKTFWKIYIDGQCNPNCKNGAVK DGVSVCEMCPGVGRNCEIDSTCATKNGCEHFRHDTPKAVCSGASGKLEHDG KSKPAVPVPCGRIIPAPMRGKVTRTENTIRWNITAHDEGDHDEALDITEPPPT TSAAPAKVPIPTKTRVGVGVDSVKGGLPQVHLVDSRGLGFCGGSILNEKVVTA HCLPQDNVAVAGTYNTKEDDHTQRQVVKILPYPTNTRNKHNDIALLEDQP LFNSTVPTICIGSDFNLLNSGFTVSGWMLYGRSAIVLQVLTVPFVDRVTC LKSTSTLHNSFCAGYTAGGDTCCGDSGPGPYTNSIGETWFLTGVTSWGECAKPGK YGIYTKVAKYVKKWIEETRLT"

Query Match 0.6%; Score 22.6; DB 1; Length 1416;

Best Local Similarity 55.8%; Pred. No. 69;

Matches 43; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 1461 CATGGAAGAAGAAATGCAAAAGCAAAATGGCTGCTGGGAGGCTTACAAATAGCTGT 1520

Db 156 CCTCGAGAGAGATGATAGAGAAATGACGCTTTGAAGAAGCCGCGGAAGTGTGA 215

QY 1521 GAAAGAGAGAGATGA 1537

Db 216 GAACACAGAGAAACGA 232

RESULT 62

AF515269

LOCUS

DEFINITION

1722 bp mRNA linear VRT 15-NOV-2002

AF515269

ACCESSION

AF515269.1 GI:25005098

KEYWORDS

SOURCE

ORGANISM

Danio rerio (zebrafish)

Danio rerio

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.

1 (bases 1 to 1722)

Comprehensive analysis of blood coagulation pathways in teleostei: Evolution of coagulation factor genes and identification of zebrafish factor VIII

Blood Cells Mol. Dis. (2002) In press

2 (bases 1 to 1722)

Jagadeeswaran, P. and Hanumanthaiah, R.

Submitted (24-MAY-2002) Cellular & Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA

Location/Qualifiers

1. .1722

/organism="Danio rerio"

/mol\_type="mRNA"

/db\_xref="taxon:7955"

27. .1358

CDS

FEATURES

source

1. .1416

/organism="Gallus gallus"

/mol\_type="mRNA"

/db\_xref="taxon:9031"

1. .1416

/gene="p9"

1. .1416

/EC\_number="3.4.21.22"

/function="converts factor X to its active form in the presence of Ca++ ions, phospholipids, and factor VIIa"

/note="vitamin K dependent serine protease; Christmas factor; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"

/codon\_start=1

/product="coagulation factor IX precursor"

/protein\_id="AA033364.1"

/db\_xref="GI:28194010"

/translation="MAKIPILILFCLLEAFLEAEVSTVLSRTRGRNSNR LDELIPGLERECIEKCSFEAREVFENTKTFWKIYIDGQCNPNCKNGAVK DGVSVCEMCPGVGRNCEIDSTCATKNGCEHFRHDTPKAVCSGASGKLEHDG KSKPAVPVPCGRIIPAPMRGKVTRTENTIRWNITAHDEGDHDEALDITEPPPT TSAAPAKVPIPTKTRVGVGVDSVKGGLPQVHLVDSRGLGFCGGSILNEKVVTA HCLPQDNVAVAGTYNTKEDDHTQRQVVKILPYPTNTRNKHNDIALLEDQP LFNSTVPTICIGSDFNLLNSGFTVSGWMLYGRSAIVLQVLTVPFVDRVTC LKSTSTLHNSFCAGYTAGGDTCCGDSGPGPYTNSIGETWFLTGVTSWGECAKPGK YGIYTKVAKYVKKWIEETRLT"

Query Match 0.6%; Score 22.6; DB 1; Length 1416;

Best Local Similarity 55.8%; Pred. No. 69;

Matches 43; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 1461 CATGGAAGAAGAAATGCAAAAGCAAAATGGCTGCTGGGAGGCTTACAAATAGCTGT 1520

Db 156 CCTCGAGAGAGATGATAGAGAAATGACGCTTTGAAGAAGCCGCGGAAGTGTGA 215

QY 1521 GAAAGAGAGAGATGA 1537

Db 216 GAACACAGAGAAACGA 232

RESULT 62

AF515269

LOCUS

DEFINITION

1722 bp mRNA linear VRT 15-NOV-2002

AF515269

ACCESSION

AF515269.1 GI:25005098

KEYWORDS

SOURCE

ORGANISM

Danio rerio (zebrafish)

Danio rerio

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.

1 (bases 1 to 1722)

Comprehensive analysis of blood coagulation pathways in teleostei: Evolution of coagulation factor genes and identification of zebrafish factor VIII

Blood Cells Mol. Dis. (2002) In press

2 (bases 1 to 1722)

Jagadeeswaran, P. and Hanumanthaiah, R.

Submitted (24-MAY-2002) Cellular & Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA

Location/Qualifiers

1. .1722

/organism="Danio rerio"

/mol\_type="mRNA"

/db\_xref="taxon:7955"

27. .1358

CDS

FEATURES

source

1. .1416

/organism="Gallus gallus"

/mol\_type="mRNA"

/db\_xref="taxon:9031"

1. .1416

/gene="p9"

1. .1416

/EC\_number="3.4.21.22"

/function="converts factor X to its active form in the presence of Ca++ ions, phospholipids, and factor VIIa"

/note="vitamin K dependent serine protease; Christmas factor; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"

/codon\_start=1

/product="coagulation factor IX precursor"

/protein\_id="AA033364.1"

/db\_xref="GI:28194010"

/translation="MAKIPILILFCLLEAFLEAEVSTVLSRTRGRNSNR LDELIPGLERECIEKCSFEAREVFENTKTFWKIYIDGQCNPNCKNGAVK DGVSVCEMCPGVGRNCEIDSTCATKNGCEHFRHDTPKAVCSGASGKLEHDG KSKPAVPVPCGRIIPAPMRGKVTRTENTIRWNITAHDEGDHDEALDITEPPPT TSAAPAKVPIPTKTRVGVGVDSVKGGLPQVHLVDSRGLGFCGGSILNEKVVTA HCLPQDNVAVAGTYNTKEDDHTQRQVVKILPYPTNTRNKHNDIALLEDQP LFNSTVPTICIGSDFNLLNSGFTVSGWMLYGRSAIVLQVLTVPFVDRVTC LKSTSTLHNSFCAGYTAGGDTCCGDSGPGPYTNSIGETWFLTGVTSWGECAKPGK YGIYTKVAKYVKKWIEETRLT"

Query Match 0.6%; Score 22.5999; DB 1; Length 1722;

Best Local Similarity 42.9%; Pred. No. 72;

Matches 112; Conservative 0; Mismatches 149; Indels 0; Gaps 0;

QY 2836 ATTCATATGATTAACAAATATTTTCAATATGTTGTTAGATAATAAGATTTTCAAT 2895

Db 1332 ATTCATATGTTTCCACTAAATTTAGTATTTAGTCTTAAACACAGATTTAAATGGCTGT 1391

QY 2896 GATTTTATCTTTGATTTTCTCTACTTATTTAAATTTGGGATTTTAACTATTTCTTCAA 2955

Db 1392 GATTTCTGATGAGCTTTGCTTTAGAGGAAATATGAGTTATGTTGGAAGTAAAGAC 1451

QY 2956 TGACTTGTATTTCTAATATTTACTTATTTCTTAAATTTGCACTTTATTTTATTG 3015

Db 1452 CCTCAAACTCTTTACTTCCACCTCATCTTGGATGATAATGATATATAATAAT 1511

QY 3016 ATTTTCTAATAAATCCAGTCTCTTTTAAAGACATTTAAATTTTAAATTTCT 3075

Db 1512 AATAACATATAAATCTTAGTATCATATTAAGAACACAGACTGATCAATAGCGTCTTC 1571

QY 3076 CTTTAGTGTTTTACCAGTTCT 3096

Db 1572 CTAAGGTTAATTAATCTTCT 1592

RESULT 63

E01075

LOCUS

DEFINITION

2177 bp RNA linear PAR 29-SEP-1997

E01075

ACCESSION

E01075

VERSION

1 GI:2169334

KEYWORDS

JP 1987000283-A/1

SOURCE

unidentified

ORGANISM

unclassified

REFERENCE

1 (bases 1 to 2177)

Fureditsuko, E.H., Maaku, J.M., Shiyaroon, J.B., Kiyasuriin, E.B., Maagaretsuto, W.I., Richiyaado, J.U. and Chiyaaruzu, E.G.

DNA ENCODING FACTOR VII

Patent: JP 1987000283-A 1 06-JAN-1987;

HOMOJENETEITSUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD, TOYO SODA MFG CO LTD

OS Human (Homo sapiens)

PN JP 1987000283-A/1

PD 06-JAN-1987

PF 16-APR-1986 JP 1986087861

PR 17-APR-1985 US 85-724311, 16-DEC-1985 US 85-810002 PI

FUREDEITSUKO ESU HAAGEN, MAKU JIEI MARII,

PI SHIYARON JIEI BAZUBII,

PI KIIYASURIIN ERU BAKUNAA, MAAGARETSUTO WAI INSUREE, PI RICHIIYADO JII UTSUDOBERRII, CHIYAARUZU ERU GUREI PC

C12N15/00, A61K37/465, C12N5/00, C12N9/50, (C12N9/50, C12R1:91); CC

Strandedness: Double;

CC topology: Linear;

CC hypothetical: No;

CC anti-sense: No;

CC \*source: tissue type=liver;

CC \*source: library=CDNA library, lambda dgt11 CDNA library; CC

\*source: clone=lambdavi 2115, lambda dgt11 1923; FH Key

notes="clotting factor"

/codon\_start=1

/product="coagulation factor VII"

/protein\_id="RAN71000.1"

/db\_xref="GI:25005099"

/translation="MTLGAARVLLCVLTIRTSAAVLSKDEASALLQRRFRANSGLFE EMKAGLRECEVEECDEYAEAREVDEDDRTQFMLSYNKPECTNPNRNGTCVYL ADSYCLCSEGEGYKCEQBELTACQVNGCEQFCDSGARRSCSCEAGYALADD GTSVQVDYPCGKIPIVQNTSQNQLGGIHGPRGHCPQWLIDYNGSVCCGALLLEG PWLITAAHCVKHOKTREFLKAVTGEHDLVDLGDSEBPEYSAVFIHPNVDPELTDLLA LLELRVQVRSLYAVPICLPQLARSELMAAREHTLSCMGTRTAGHNLREKGLKGP ASGTLORLAVPLLPAAQCGNANTANMFCAGYTEGDSHSCRGHDSPLVTRVGETSFL TGVVSWRGCGPGGYIWIYTKVENFLIMDVTNKTNTEDKSKQIANVSTKN"

Location/Qualifiers  
FH CDS 13..1128  
FT CDS /product='factor VII peptide' FT  
FT polyA\_signal 2106..2111  
FT exon 41..12  
FT 3'UTR 1129..2177.  
Location/Qualifiers  
1..2177  
/organism='unidentified'  
/mol\_type='genomic RNA'  
/db\_xref='taxon:32644'

Query Match 0.6%; Score 22.4; DB 1; Length 2177;  
Best Local Similarity 48.8%; Pred. No. 75;  
Matches 61; Conservative 0; Mismatches 64; Indels 0; Gaps 0;

QY 2186 TGTCAGACTTTATTTTGGGGGCTCCAAATCACTGCAGATGGTCACTGACGCCATGA 2245  
DB 2045 TTTCTCCCTTCGCTGGTGGCGGCTGCACAGACTATTCCTCCAGCTTCA 2104  
QY 2246 AATTAAGACACTTCTCTTGGAGAAAGTTAACCACTAGATAGCATATTGAAA 2305  
DB 2105 CAATAACGGTGGCTCTCTCGCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2164  
QY 2306 GCAGA 2310  
DB 2165 AAAAA 2169

RESULT 64  
AX310356/c  
LOCUS AX310356 196 bp DNA linear PAT 14-DEC-2001  
DEFINITION Sequence 3341 from Patent WO0190366.  
ACCESSION AX310356  
VERSION AX310356.1 GI:17896408  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE  
1  
Leach, M.D. and Shinkets, R.A.  
Human polynucleotides and polypeptides encoded thereby  
Patent: WO 0190366-A 3341 29-NOV-2001;  
Curagen Corporation (US)

FEATURES  
source  
1..186  
/organism='Homo sapiens'  
/mol\_type='unassigned DNA'  
/db\_xref='taxon:9606'

Query Match 0.6%; Score 22.4; DB 1; Length 186;  
Best Local Similarity 53.4%; Pred. No. 49;  
Matches 47; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 2670 TGACTCGATGGAGTCTGGTGAATCTCTGGAGTTGGTGGACAGGAGGCTG 2729  
DB 148 TGCCCCGGTTGAGTGGCGGTAGATCAAGTTCAGGCCCGGGTGTGCCCGAGTCCCGA 89  
QY 2730 TCTCGGGGATTCATGGGTCAACAAG 2757  
DB 88 GCAGGGGGGCTTGAATGTCTAGGTAG 61

RESULT 65  
AF465270  
LOCUS AF465270 1302 bp mRNA linear VRT 02-FEB-2003  
DEFINITION Gallus gallus anticoagulant protein C precursor (PROC) mRNA, complete cds.  
ACCESSION AF465270  
VERSION AF465270.1 GI:28194011  
KEYWORDS

SOURCE  
ORGANISM  
Gallus gallus (chicken)  
Gallus gallus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;  
Phasianinae; Gallus.  
REFERENCE  
1 (bases 1 to 1302)  
AUTHORS Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,  
Tuddenham, E.G.D. and McVey, J.H.  
Comparative sequence analysis and molecular evolution of blood  
coagulation genes from Gallus gallus and Fugu rubripes  
Unpublished  
JOURNAL  
REFERENCE  
2 (bases 1 to 1302)  
AUTHORS McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.  
Direct Submission  
TITLE Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences  
Centre, The Faculty of Medicine, Imperial College, Hammersmith  
Campus, Du Cane Road, London W12 0NN, UK  
FEATURES  
source  
1..1302  
/organism='Gallus gallus'  
/mol\_type='mRNA'  
/db\_xref='taxon:9031'  
1..1302  
/genes='PROC'  
1..1302  
/genes='PROC'  
/EC number='3.4.21.69'  
/function='inactivates factors Va and VIIIa in the  
presence of Ca++ ions and phospholipids'  
/note='vitamin K dependent serine protease;  
autoprothrombin IIa; coagulation factor XIV; contains 2  
EGF-like domains; member of peptidase family S1/trypsin  
family; synthesized in the liver and found in plasma'  
/codon\_start=1  
/product='anticoagulant protein C precursor'  
/protein\_id='AA033365.1'  
/db\_xref='GI:28194012'  
/translation='MMKLITIGVLLAACSPVCHASIFVSKDANOVLIKREANGFL  
EELKPGVERECNEECNFEASEIEFETREATLEFWSKYVDGQCAQKPCSGACKDN  
IGSYCTCDKRGWEGACNVKNGKGVNCGQCHFKEDPAKQCRKSCASGYLTN  
DNHMCPTVFPFGCRVMDYTEGAENFRLIGNSGGGRFSPRWVQLQKGLCG  
GVLIHPSWLTAAHCVTGETLKVRLGKYHRLIENSEQTIRVYKVRHNEVTKLSD  
NDIAMLHAPVNNKYALPICLPTRDLAHELTTRGQMLVTGWSTSDMENYSGAL  
LSYIEIPVKNCAQVMNTIISDNMLCAGSLGDRKDCSGSDSGGPMATKYKDTWFLV  
GLVWEGEGCKKEKFGVYKVSQLEWQHINKSGSWRG'

Query Match 0.6%; Score 22.4; DB 1; Length 1302;  
Best Local Similarity 56.9%; Pred. No. 76;  
Matches 41; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2234 CTGCAGCCATGAATTAAGACACTTACTCTTGAAGAAAAGTTAACCACTAGATA 2293  
DB 1139 CTATGGCCACTAATAATAGGACTTGGTTCTTGTAGACTGCTGGGGAAG 1198  
QY 2294 GCATATTGAAAA 2305  
DB 1199 GCTGTGGAAAA 1210

RESULT 66  
AF011900/c  
LOCUS AF011900 832 bp mRNA linear VRT 09-SEP-1997  
DEFINITION Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.  
ACCESSION AF011900  
VERSION AF011900.1 GI:2367498  
KEYWORDS  
SOURCE Petromyzon marinus (sea lamprey)  
ORGANISM Petromyzon marinus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;  
Petromyzontiformes; Petromyzontidae; Petromyzon.  
REFERENCE  
1 (bases 1 to 832)  
AUTHORS Roach, J.C.  
TITLE The Molecular Evolution of the Vertebrate Trypsinogens



```

JOURNAL      Unpublished
REFERENCE    2 (bases 1 to 832)
AUTHORS      Roach, J.C.
TITLE        Direct Submission
JOURNAL      Submitted (01-JUL-1997) Molecular Biotechnology, University of
              Washington, Seattle, WA 98195, USA
FEATURES
  source     Location/Qualifiers
            1..832
              /organism="Petromyzon marinus"
              /mol_type="mRNA"
              /db_xref="taxon:7757"
              /dev_stage="amocoete"
              /tissue_lib="anterior intestine"
  gene       <1..832
            </gene>
  CDS        <1..736
            </gene>
            </gene>
            /codon_start=2
            /product="trypsinogen B1"
            /protein_id="AAB69656.1"
            /db_xref="GI:2367499"
            /translation="LIFALLVGTAAAPYVEDHIVGGVECAAHSPQWQVNLINIGYHF
              CGSLISSWVVSAAHCYOTASRISVRIGEHNFVTEGTEGRIQAKAIRHPQYSAT
              INDIMLIKSSPATLNOVAQVPLPSSCVGTGVMCTISGGETOTSVSGSDVLMCVQ
              APVLDTSRNSYPGDITNNMILCGLYEGGKDCSCGDSGGPVVCGQLQGIVSWGRGC
              ALPNPGVYTKVYNINYSWIASTMAAN"
  sig_peptide <1..37
            /gene="TRYPB1"
            /evidence=not_experimental
  mat_peptide 38..733
            /gene="TRYPB1"
            /product="trypsin b1"
            /evidence=not_experimental

Query Match      0.6%; Score 22.2; DB 1; Length 832;
Best Local Similarity 77.1%; Pred. No. 78;
Matches 27; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3248 TTTTITTTTTTTTTTTTAAAGAAATGCTATTTT 3282
Db 832 TTTTITTTTTTTTTTTTCAATATTTTATTAAT 798

RESULT 67
AX527570/c
LOCUS      AX527570      534 bp      DNA      linear      PAT 21-NOV-2002
DEFINITION Sequence 97 from Patent WO0212331.
ACCESSION  AX527570
VERSION     AX527570.1  GI:25172149
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Pyle, R.A., Xu, J. and Kalos, M.D.
TITLE        Compositions and methods for the therapy and diagnosis of
              pancreatic cancer
JOURNAL      Patent: WO 0212331-A 97 14-FEB-2002;
              CORIXA CORPORATION (US)
FEATURES
  source     Location/Qualifiers
            1..534
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.6%; Score 22; DB 1; Length 534;
Best Local Similarity 63.0%; Pred. No. 80;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAACCTAACACCCAAAAGATGCTCTTCTCATTATAGGGGACTGGAA 974
Db 64 CCTCACAGATGTAGCCCCAACGATCTTGTCATCATCATCAAGGGGCGACGAA 11

JOURNAL      Unpublished
REFERENCE    2 (bases 1 to 832)
AUTHORS      Roach, J.C.
TITLE        Direct Submission
JOURNAL      Submitted (01-JUL-1997) Molecular Biotechnology, University of
              Washington, Seattle, WA 98195, USA
FEATURES
  source     Location/Qualifiers
            1..832
              /organism="Petromyzon marinus"
              /mol_type="mRNA"
              /db_xref="taxon:7757"
              /dev_stage="amocoete"
              /tissue_lib="anterior intestine"
  gene       <1..832
            </gene>
  CDS        <1..736
            </gene>
            </gene>
            /codon_start=2
            /product="trypsinogen B1"
            /protein_id="AAB69656.1"
            /db_xref="GI:2367499"
            /translation="LIFALLVGTAAAPYVEDHIVGGVECAAHSPQWQVNLINIGYHF
              CGSLISSWVVSAAHCYOTASRISVRIGEHNFVTEGTEGRIQAKAIRHPQYSAT
              INDIMLIKSSPATLNOVAQVPLPSSCVGTGVMCTISGGETOTSVSGSDVLMCVQ
              APVLDTSRNSYPGDITNNMILCGLYEGGKDCSCGDSGGPVVCGQLQGIVSWGRGC
              ALPNPGVYTKVYNINYSWIASTMAAN"
  sig_peptide <1..37
            /gene="TRYPB1"
            /evidence=not_experimental
  mat_peptide 38..733
            /gene="TRYPB1"
            /product="trypsin b1"
            /evidence=not_experimental

Query Match      0.6%; Score 22.2; DB 1; Length 832;
Best Local Similarity 77.1%; Pred. No. 78;
Matches 27; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3248 TTTTITTTTTTTTTTTTAAAGAAATGCTATTTT 3282
Db 832 TTTTITTTTTTTTTTTTCAATATTTTATTAAT 798

RESULT 67
AX527570/c
LOCUS      AX527570      534 bp      DNA      linear      PAT 21-NOV-2002
DEFINITION Sequence 97 from Patent WO0212331.
ACCESSION  AX527570
VERSION     AX527570.1  GI:25172149
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Pyle, R.A., Xu, J. and Kalos, M.D.
TITLE        Compositions and methods for the therapy and diagnosis of
              pancreatic cancer
JOURNAL      Patent: WO 0212331-A 97 14-FEB-2002;
              CORIXA CORPORATION (US)
FEATURES
  source     Location/Qualifiers
            1..534
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.6%; Score 22; DB 1; Length 534;
Best Local Similarity 63.0%; Pred. No. 80;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAACCTAACACCCAAAAGATGCTCTTCTCATTATAGGGGACTGGAA 974
Db 64 CCTCACAGATGTAGCCCCAACGATCTTGTCATCATCATCAAGGGGCGACGAA 11

```

```

RESULT 68
HUMMA/c
LOCUS      HUMMA      741 bp      mRNA      linear      PRI 10-FEB-1999
DEFINITION Human mRNA for mesotrypsinogen, partial cds.
ACCESSION  D45417
VERSION     D45417.1  GI:644884
KEYWORDS    mesotrypsinogen; trypsin.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  REFERENCE  1 (bases 1 to 741)
  AUTHORS    Fukuoka, S.
  JOURNAL    Unpublished
  REFERENCE  2 (bases 1 to 741)
  AUTHORS    Fukuoka, S.-I.
  TITLE      Direct Submission
  JOURNAL    Submitted (03-FEB-1995) Shin-Ichi Fukuoka, Kyoto University,
              Research Institute for Food Science, Gokancsho, Uji, Kyoto 611,
              Japan (E-mail: fukuoka@soya.food.kyoto-u.ac.jp, Tel:0774-33-6905,
              Fax:0774-33-3004)
  FEATURES
    Location/Qualifiers
    1..741
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="107-1,107-2,107-3"
      /clone_lib="lambda gt10"
      /dev_stage="adult"
    1..5741
      /EC number="3.4.21.4"
      /notes="An isoform of human trypsinogen which is not
        inhibited by naturally occurring trypsin inhibitors."
    /codon_start=1
    /product="mesotrypsinogen"
    /protein_id="BAA08257.1"
    /db_xref="GI:1321640"
    /translation="MNPFLILAFVGAAVPFDDDDKIVGGYTCENSLPYQVSLNSG
      SHPCGGLISEQWVSAACHYKTRIQVRLEHNIKVLGNEQFINAAKIIIRPKYNRD
      TLNDIMLIKSSPAVINARVSTISLPTAPPAAGTECLISGAGNTLSGADYVDELKC
      LDAPVLTQAEKASYPGKITNSMFCVGELEGKDCSQDSDSGSPVVCNGQLQGVSWGH
      GCANKRPGVYTKVYNIVDWIKDTAANS"
  sig_peptide 1..45
  mat_peptide 46..69
  mat_peptide 70..741
    /product="mature enzyme"

Query Match      0.6%; Score 22; DB 1; Length 741;
Best Local Similarity 63.0%; Pred. No. 86;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAACCTAACACCCAAAAGATGCTCTTCTCATTATAGGGGACTGGAA 974
Db 94 CCTCACAGGTGTAGCCCCAACATCTTGTCATCATCATCAAGGGGCGACGAA 41

RESULT 69
E01617/c
LOCUS      E01617      741 bp      RNA      linear      PAT 29-SEP-1997
DEFINITION cDNA encoding human pancreatic trypsinogen 3.
ACCESSION  E01617
VERSION     E01617.1  GI:2169870
KEYWORDS    JF 1988160582-A/1.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  REFERENCE  1 (bases 1 to 741)
  AUTHORS    Takiguchi, H., Tani, T. and Kawashima, I.
  TITLE      NOVEL HUMAN PANCREATIC TRYPSIN

```



```

JOURNAL Patent: JP 1988160582-A 1 04-JUL-1998;
SANKYO CO LTD
COMMENT OS Homo sapiens
PN JP 1988160582-A/1
PD 04-JUL-1988
PF 25-DEC-1986 JP 1986307770
PI TAKIGUCHI HIROSHI, TANI TOKIO, KAWASHIMA ICHIRO PC
C12N9/76,A61K37/24,C12N1/20,C12N15/00//C07K13/00,C12N9/76, PC
C12R1.91),
PC (C12N1/20,C12R1:19),(C12N1/20,C12R1:125);
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
CC *source: tissue_type=Pancreas;
FH Key Location/Qualifiers
FT sig_peptide 1..45
FT mat_peptide 46..741
FT mat_peptide /product='Pancratic trypsinogen 3' FT
mat_peptide replace(46..69,' '),
FT /product='Pancratic trypsin 3'.
FEATURES Location/Qualifiers
source 1..741
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'
Query Match 0.6%; Score 22; DB 1; Length 741;
Best Local Similarity 63.0%; Pred. No. 86;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 921 CCTTTAGAACTAACACCCCAAAAGATGCTCTTCATTATAGGGACTGGAA 974
|||||
DB 94 CCTCACAGGTAGTACCCCAACAATCTTGTCATCATCGTCAAAGGGGACAGCAA 41

RESULT 71
E15808/c
LOCUS Human mRNA for trypsinogen-like protein, complete cds.
DEFINITION E15808
ACCESSION E15808
VERSION E15808.1 GI:5710491
SOURCE JP 1998099080-A/1.
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 790)
AUTHORS Nakanishi,J. and Koyama,J.
TITLE DNA CAPABLE OF CODING TRYPSINOGEN-LIKE PROTEIN AND ITS PROTEIN
JOURNAL Patent: JP 1998099080-A 1 21-APR-1998;
COMMENT SHISEIDO CO LTD
OS Homo sapiens (human)
PN JP 1998099080-A/1
PD 21-APR-1998
PF 26-SEP-1996 JP 1996273923
PI NAKANISHI JIYOUTAROU, KOYAMA JUNICHI
PC C12N15/09,C07H21/04,C07K14/47,C12N9/64//A61K38/43; CC
strandedness: Double;
CC topology: Linear;
FH Key Location/Qualifiers
FT sig_peptide 1..48.
FT source 1..790
/organism='Homo sapiens'
/mol_type='keratinocyte',
FT CDS 1..723
/ft /product='trypsinogen-like protein' FT
FEATURES Location/Qualifiers
source 1..790
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'
Query Match 0.6%; Score 22; DB 1; Length 790;
Best Local Similarity 63.0%; Pred. No. 87;
Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;
QY 921 CCTTTAGAACTAACACCCCAAAAGATGCTCTTCATTATAGGGACTGGAA 974
|||||
DB 73 CCTCACAGGTAGTACCCCAACAATCTTGTCATCATCGTCAAAGGGGACAGCAA 20

RESULT 72
BC030238/c
LOCUS Homo sapiens, clone IMAGE:4537998, mRNA, partial cds.
DEFINITION BC030238
ACCESSION BC030238
VERSION BC030238.1 GI:20988416
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Patent: JP 1995184655-A 1 25-JUL-1995;
SANKYO CO LTD
COMMENT OS Homo sapiens (human)
PN JP 1995184655-A/1
PD 25-JUL-1995
PF 25-DEC-1986 JP 1994311512
PI TAKIGUCHI HIROSHI, TANI TOKIO, KAWASHIMA ICHIRO PC
C12N15/09,C07H21/04,C12N5/10,C12N9/76//A61K38/46; CC
strandedness: Double;
CC topology: Linear;
FH Key Location/Qualifiers
FT sig_peptide 1..45
FT mat_peptide 46..741
FT mat_peptide /product='Spleen TrypsinogenIII' FT
FT variation replace(744,'g')
FT variation replace(743,'g').

```

REFERENCE 1 (bases 1 to 821)  
 AUTHORS Strausberg, R.  
 TITLE Direct Submission  
 JOURNAL Submitted (07-MAY-2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
 COMMENT Contact: MGC help desk  
 Email: [cgabs@mail.nih.gov](mailto:cgabs@mail.nih.gov)  
 Tissue Procurement: DCTP/DTP  
 CDNA Library Preparation: Life Technologies, Inc.  
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: National Institutes of Health Intramural Sequencing Center (NISC), Gaithersburg, Maryland;  
 Web site: <http://www.nisc.nih.gov/>  
 Contact: [nisc.mgc@nih.gov](mailto:nisc.mgc@nih.gov)  
 Akhter, N., Ayala, K., Beckstrom-Sternberg, S.M., Benjamin, B., Blakesley, R.W., Bouffard, G.G., Breen, K., Brinkley, C., Brooks, S., Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghighi, P., Hansen, N., Ho, S.-L., Karlins, E., Laric, P., Legaspi, R., Maduro, Q.L., Masello, C., Maskeri, B., Mastrian, S.D., McCloskey, J.C., McDowell, J., Pearson, R., Staniripop, S., Thomas, P.J., Touchman, J.W., Tsurgeon, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wiggins, L., Young, A., Zhang, L.-H. and Green, E.D.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Series: IRAK Plate: 62 Row: C Column: 1  
 This clone was selected for full length sequencing because it passed the following selection criteria: Genomescan gene prediction.

FEATURES  
 source  
 1..821  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:4537998"  
 /tissue\_type="Prostate, adenocarcinoma."  
 /clone\_lib="NIH MGC\_91"  
 /lab\_host="DH10B"  
 /note="Vector: pCMV-SPORT6"  
 <1..756  
 /codon\_start=1  
 /product="Unknown (protein for IMAGE:4537998)"  
 /protein\_id="AAH30238.1"  
 /db\_xref="GI:20988417"  
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLSNGSHFCGSLISQWVVAHCVKTRIQVRLGHNKIVLEGNQFINAKIIRHPKYNRDLNDIMLKSSPAVINARVSTISLTPAAPAGTECLISGWNGLSFAGADYD ELKCLDAPLVTAECCKASYPGKINTSMFCVGLGGKXDCQDSDSGPVCNGLQGVV SWGHCAKNRPGVTKYNYVDVMDIKDTIAANS"

CDS  
 1..756  
 /codon\_start=1  
 /product="Unknown (protein for IMAGE:4537998)"  
 /protein\_id="AAH30238.1"  
 /db\_xref="GI:20988417"  
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLSNGSHFCGSLISQWVVAHCVKTRIQVRLGHNKIVLEGNQFINAKIIRHPKYNRDLNDIMLKSSPAVINARVSTISLTPAAPAGTECLISGWNGLSFAGADYD ELKCLDAPLVTAECCKASYPGKINTSMFCVGLGGKXDCQDSDSGPVCNGLQGVV SWGHCAKNRPGVTKYNYVDVMDIKDTIAANS"

Query Match 0.6%; Score 22; DB 1; Length 821;  
 Best Local Similarity 63.0%; Pred. NO. 87;  
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAACCTAACACCCAAAAGATGCTCTTCATTATAGGGACTGAA 974  
 Db 106 CCTCAGGTGTAGCCCCAACATCTTGTATCATCTCATGTCGTCAGGGGACAGCA 53

RESULT 73  
 HSTRPIV/c  
 LOCUS HSTRPIV 853 bp mRNA linear PRI 15-OCT-1999  
 DEFINITION Homo sapiens mRNA for trypsinogen IV a-form.  
 ACCESSION X72781  
 VERSION X72781.1 GI:3928429  
 KEYWORDS trypsin IV; trypsinogen; zymogen.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 (bases 1 to 821)  
 AUTHORS Strausberg, R.  
 TITLE Direct Submission  
 JOURNAL Submitted (07-MAY-2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
 COMMENT Contact: MGC help desk  
 Email: [cgabs@mail.nih.gov](mailto:cgabs@mail.nih.gov)  
 Tissue Procurement: DCTP/DTP  
 CDNA Library Preparation: Life Technologies, Inc.  
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: National Institutes of Health Intramural Sequencing Center (NISC), Gaithersburg, Maryland;  
 Web site: <http://www.nisc.nih.gov/>  
 Contact: [nisc.mgc@nih.gov](mailto:nisc.mgc@nih.gov)  
 Akhter, N., Ayala, K., Beckstrom-Sternberg, S.M., Benjamin, B., Blakesley, R.W., Bouffard, G.G., Breen, K., Brinkley, C., Brooks, S., Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghighi, P., Hansen, N., Ho, S.-L., Karlins, E., Laric, P., Legaspi, R., Maduro, Q.L., Masello, C., Maskeri, B., Mastrian, S.D., McCloskey, J.C., McDowell, J., Pearson, R., Staniripop, S., Thomas, P.J., Touchman, J.W., Tsurgeon, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wiggins, L., Young, A., Zhang, L.-H. and Green, E.D.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Series: IRAK Plate: 62 Row: C Column: 1  
 This clone was selected for full length sequencing because it passed the following selection criteria: Genomescan gene prediction.

FEATURES  
 source  
 1..821  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:4537998"  
 /tissue\_type="Prostate, adenocarcinoma."  
 /clone\_lib="NIH MGC\_91"  
 /lab\_host="DH10B"  
 /note="Vector: pCMV-SPORT6"  
 <1..756  
 /codon\_start=1  
 /product="Unknown (protein for IMAGE:4537998)"  
 /protein\_id="AAH30238.1"  
 /db\_xref="GI:20988417"  
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLSNGSHFCGSLISQWVVAHCVKTRIQVRLGHNKIVLEGNQFINAKIIRHPKYNRDLNDIMLKSSPAVINARVSTISLTPAAPAGTECLISGWNGLSFAGADYD ELKCLDAPLVTAECCKASYPGKINTSMFCVGLGGKXDCQDSDSGPVCNGLQGVV SWGHCAKNRPGVTKYNYVDVMDIKDTIAANS"

CDS  
 1..756  
 /codon\_start=1  
 /product="Unknown (protein for IMAGE:4537998)"  
 /protein\_id="AAH30238.1"  
 /db\_xref="GI:20988417"  
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLSNGSHFCGSLISQWVVAHCVKTRIQVRLGHNKIVLEGNQFINAKIIRHPKYNRDLNDIMLKSSPAVINARVSTISLTPAAPAGTECLISGWNGLSFAGADYD ELKCLDAPLVTAECCKASYPGKINTSMFCVGLGGKXDCQDSDSGPVCNGLQGVV SWGHCAKNRPGVTKYNYVDVMDIKDTIAANS"

Query Match 0.6%; Score 22; DB 1; Length 821;  
 Best Local Similarity 63.0%; Pred. NO. 87;  
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAACCTAACACCCAAAAGATGCTCTTCATTATAGGGACTGAA 974  
 Db 106 CCTCAGGTGTAGCCCCAACATCTTGTATCATCTCATGTCGTCAGGGGACAGCA 53

RESULT 73  
 HSTRPIV/c  
 LOCUS HSTRPIV 853 bp mRNA linear PRI 15-OCT-1999  
 DEFINITION Homo sapiens mRNA for trypsinogen IV a-form.  
 ACCESSION X72781  
 VERSION X72781.1 GI:3928429  
 KEYWORDS trypsin IV; trypsinogen; zymogen.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 (bases 1 to 821)  
 AUTHORS Strausberg, R.  
 TITLE Direct Submission  
 JOURNAL Submitted (07-MAY-2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
 COMMENT Contact: MGC help desk  
 Email: [cgabs@mail.nih.gov](mailto:cgabs@mail.nih.gov)  
 Tissue Procurement: DCTP/DTP  
 CDNA Library Preparation: Life Technologies, Inc.  
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: National Institutes of Health Intramural Sequencing Center (NISC), Gaithersburg, Maryland;  
 Web site: <http://www.nisc.nih.gov/>  
 Contact: [nisc.mgc@nih.gov](mailto:nisc.mgc@nih.gov)  
 Akhter, N., Ayala, K., Beckstrom-Sternberg, S.M., Benjamin, B., Blakesley, R.W., Bouffard, G.G., Breen, K., Brinkley, C., Brooks, S., Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghighi, P., Hansen, N., Ho, S.-L., Karlins, E., Laric, P., Legaspi, R., Maduro, Q.L., Masello, C., Maskeri, B., Mastrian, S.D., McCloskey, J.C., McDowell, J., Pearson, R., Staniripop, S., Thomas, P.J., Touchman, J.W., Tsurgeon, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wiggins, L., Young, A., Zhang, L.-H. and Green, E.D.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Series: IRAK Plate: 62 Row: C Column: 1  
 This clone was selected for full length sequencing because it passed the following selection criteria: Genomescan gene prediction.

FEATURES  
 source  
 1..821  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:4537998"  
 /tissue\_type="Prostate, adenocarcinoma."  
 /clone\_lib="NIH MGC\_91"  
 /lab\_host="DH10B"  
 /note="Vector: pCMV-SPORT6"  
 <1..756  
 /codon\_start=1  
 /product="Unknown (protein for IMAGE:4537998)"  
 /protein\_id="AAH30238.1"  
 /db\_xref="GI:20988417"  
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLSNGSHFCGSLISQWVVAHCVKTRIQVRLGHNKIVLEGNQFINAKIIRHPKYNRDLNDIMLKSSPAVINARVSTISLTPAAPAGTECLISGWNGLSFAGADYD ELKCLDAPLVTAECCKASYPGKINTSMFCVGLGGKXDCQDSDSGPVCNGLQGVV SWGHCAKNRPGVTKYNYVDVMDIKDTIAANS"

CDS  
 1..756  
 /codon\_start=1  
 /product="Unknown (protein for IMAGE:4537998)"  
 /protein\_id="AAH30238.1"  
 /db\_xref="GI:20988417"  
 /translation="PRVRAARDADGCEALGTVAVPFDDDDKIVGGYTCENSLPYQVLSNGSHFCGSLISQWVVAHCVKTRIQVRLGHNKIVLEGNQFINAKIIRHPKYNRDLNDIMLKSSPAVINARVSTISLTPAAPAGTECLISGWNGLSFAGADYD ELKCLDAPLVTAECCKASYPGKINTSMFCVGLGGKXDCQDSDSGPVCNGLQGVV SWGHCAKNRPGVTKYNYVDVMDIKDTIAANS"

Query Match 0.6%; Score 22; DB 1; Length 821;  
 Best Local Similarity 63.0%; Pred. NO. 87;  
 Matches 34; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 921 CCTTTTGAACCTAACACCCAAAAGATGCTCTTCATTATAGGGACTGAA 974  
 Db 106 CCTCAGGTGTAGCCCCAACATCTTGTATCATCTCATGTCGTCAGGGGACAGCA 53

RESULT 73  
 HSTRPIV/c  
 LOCUS HSTRPIV 853 bp mRNA linear PRI 15-OCT-1999  
 DEFINITION Homo sapiens mRNA for trypsinogen IV a-form.  
 ACCESSION X72781  
 VERSION X72781.1 GI:3928429  
 KEYWORDS trypsin IV; trypsinogen; zymogen.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 50 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCACATATACCCCTTCAGATGCA 109
    |||||
QY 845 CAGTA 849
    |||
Db 110 GAGCA 114

RESULT 75
AX265054/c
LOCUS AX265054 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2445 from Patent WO0173002.
ACCESSION AX265054
VERSION AX265054.1 GI:16513853
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2445 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 72 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCACATATACCCCTTCAGATGCA 13
    |||||
QY 845 CAGTA 849
    |||
Db 12 GAGCA 8

RESULT 76
AX265057
LOCUS AX265057 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2448 from Patent WO0173002.
ACCESSION AX265057
VERSION AX265057.1 GI:16513856
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2448 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 70 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCACATATACCCCTTCAGATGCA 11
    |||||
QY 845 CAGTA 849
    |||
Db 10 GAGCA 6

RESULT 77
AX265058/c
LOCUS AX265058 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2449 from Patent WO0173002.
ACCESSION AX265058
VERSION AX265058.1 GI:16513857
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2449 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
  source
    Location/Qualifiers
      1..121
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.6%; Score 21.8; DB 1; Length 121;
Best Local Similarity 58.5%; Pred. No. 63;
Matches 38; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCACAGGCAAAACCATTCATATCA 844
    |||||
Db 70 GAAGTTTGTGAACACTGAAGACACTGAGTATTTCACATATACCCCTTCAGATGCA 11
    |||||
QY 845 CAGTA 849
    |||
Db 10 GAGCA 6

RESULT 78
AX265059/c
LOCUS AX265059 170 bp DNA linear PRI 08-OCT-1996
DEFINITION H.sapiens gene encoding beta-myosin heavy chain, exon 3.
ACCESSION X04629
VERSION X04629.1 GI:34851
KEYWORDS beta-myosin; myosin; myosin heavy chain.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 170)
AUTHORS Licher, P., Umeda, P.K., Levin, J.E. and Vosberg, H.P.
TITLE Partial characterization of the human beta-myosin heavy-chain gene
which is expressed in heart and skeletal muscle
JOURNAL Eur. J. Biochem. 160 (2), 419-426 (1986)
MEDLINE 87030293
PUBMED 3021460
```

```

COMMENT see x04627-x04633 for beta-myosin gene.
FEATURES
  source      1..170
               Location/Qualifiers
               /organism="Homo sapiens"
               /mol_type="genomic DNA"
               /db_xref="taxon:9606"
               /clone=" (lambda) gMHC-1"
  gene        15..161
               /gene="beta-myosin heavy chain"
  exon        15..161
               /gene="beta-myosin heavy chain"
               /usedin=x04627:myosin_cds
               /usedin=x04627:myosin_mrna
               /label=ex3

Query Match      0.6%; Score 21.8; DB 1; Length 170;
Best Local Similarity 52.8%; Pred. No. 69;
Matches 47; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 972 GAATGCAAAAGTAGGAAGCAAGAAACACCTGGAGTAACAGGCAAAATTTGGCTTTGGAAAT 1031
Db 49 GCATGACCTGGAGCGAGCGAAGCGAAGCTGGAGCGACCTGAAGCTGACCCAGGAGA 108

QY 1032 ACCGANTGAAGCAGGCGCAAGACTATAG 1060
Db 109 GCATCATGGACCTGGAGAGATGACAAGCAG 137

RESULT 79
AY023453/c      227 bp DNA linear PLN 07-FEB-2001
LOCUS           Oryza sativa microsatellite MEG5778 containing (TCC)X9, genomic
DEFINITION      sequence.
ACCESSION       AY023453
VERSION         AY023453.1 GI:12706669
KEYWORDS        Oryza sativa
SOURCE          Oryza sativa
ORGANISM        Oryza sativa
REFERENCE       1 (bases 1 to 227)
AUTHORS         Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
TITLE           Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
JOURNAL         Ehrhartoideae; Oryzeae; Oryza.
  1 (bases 1 to 227)
AUTHORS         Tao,N., Barbazuk,W.B., Liu,J., Wu,K. and Barry,G.F.
TITLE           Simple sequence repeats from Monsanto rice genomic sequences
JOURNAL         Unpublished
  2 (bases 1 to 227)
AUTHORS         Tao,N., Barbazuk,W.B., Liu,J., Wu,K. and Barry,G.F.
TITLE           Direct Submission
JOURNAL         Submitted (10-JAN-2001) Genomics, Monsanto, 800 North Lindbergh
  Blvd., Creve Coeur, MO 63167, USA
COMMENT         Derived from rice genomic sequences generated from the Monsanto
  Rice Genome Sequencing project. Please see
  http://www.rice-research.org for more information. The sequence
  data were produced primarily in the laboratories of Dr. Leroy Hood
  at the University of Washington in Seattle.

FEATURES
  source      1..227
               Location/Qualifiers
               /organism="Oryza sativa"
               /mol_type="genomic DNA"
               /db_xref="taxon:4530"
  repeat_region 1..227
               /note="microsatellite MRG5778"
               /rpt_type=tandem
               /rpt_unit="tcc"

Query Match      0.6%; Score 21.8; DB 1; Length 227;
Best Local Similarity 56.2%; Pred. No. 74;
Matches 41; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 2593 AAGACCCCTGATGCTGGAGGAGTTGGGGCGACGAGGAGGAGGAGGACGAGGATGAGA 2652
Db 155 AAGAGGAGGACGACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 96

COMMENT see x04627-x04633 for beta-myosin gene.
FEATURES
  source      1..170
               Location/Qualifiers
               /organism="Homo sapiens"
               /mol_type="genomic DNA"
               /db_xref="taxon:9606"
               /clone=" (lambda) gMHC-1"
  gene        15..161
               /gene="beta-myosin heavy chain"
  exon        15..161
               /gene="beta-myosin heavy chain"
               /usedin=x04627:myosin_cds
               /usedin=x04627:myosin_mrna
               /label=ex3

Query Match      0.6%; Score 21.8; DB 1; Length 522;
Best Local Similarity 62.7%; Pred. No. 89;
Matches 32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 921 CCTTTAGAACTAACACCCAAAGAGATGCTCTTCATTAAGGGGACTG 971
Db 52 CTCACAGATGTAGCCCAACGATCTGTCTCATCATCATCAAGGGGNGC 2

RESULT 81
BTTHRO         BTTHRO      603 bp mRNA linear MAM 17-JUL-1995
LOCUS           Messenger RNA for bovine prothrombin.
DEFINITION      V00135
ACCESSION       V00135
VERSION         V00135.1 GI:772
KEYWORDS        thrombin.
SOURCE          Bos taurus (cow)
ORGANISM        Bos taurus
REFERENCE       1 (bases 1 to 603)
AUTHORS         Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE           Mammalia; Euthera; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
JOURNAL         Bovidae; Bovinae; Bos.
  1 (bases 1 to 603)
AUTHORS         MacGillivray,R.T., Degen,S.J., Chandra,T., Woo,S.L. and Davie,E.W.
TITLE           Cloning and analysis of a cDNA coding for bovine prothrombin
JOURNAL         Proc. Natl. Acad. Sci. U.S.A. 77 (9), 5153-5157 (1980)
MEDLINE         81054926
PUBMED          6254059
COMMENT         KST BTA. PROTHROMBIN.
FEATURES
  source      1..603
               Location/Qualifiers
               /organism="Bos taurus"
               /mol_type="mRNA"
               /db_xref="taxon:9913"
               <1..484
               /codon_start=2
               /product="prothrombin"
               /protein_id="CAA23451.1"
               /db_xref="GI:808945"
               /db_xref="GGA:P00735"
               /db_xref="SWISS-PROT:P00735"
               /translation="TALLKRPFLSDYIHVPLVDKQTAAKLHAGFKGKVTGWN
  RETWTSVAEQPSVLQVNLPLVPRVPCAKSTRIRTDNMFCAGYKPGEGKGDAC
  EGDGSGFPVWKSPYNNRWYQMGIVSWGECDRNGKYFYTHVFLKWKIQTIDRLGS
  "
  polyA_site 603

```





Db 326 TGCCTGCACACAGCATGTTCTCCGAGACACACATTCTTCATGACCTCCACGCACTCATTTTC 385

QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540

Db 386 GAGCAACCAAGAGGATGCGGATGA 409

RESULT 88  
MUSBALB6/c  
LOCUS  
DEFINITION Mouse gene for protein C (precursor of vitamin K-dependent serine protease), partial cds (catalytic region).  
ACCESSION D43755  
VERSION 1  
KEYWORDS protein C; serine protease zymogen; vitamin K-dependent serine protease; blood coagulation-related.  
SOURCE Mus musculus  
ORGANISM Mus musculus (house mouse)  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Nihoy.  
TITLE A comparative study of partial primary structures of the catalytic region of mammalian protein C  
JOURNAL Br. J. Haematol. 86 (3), 590-600 (1994)  
MEDLINE 94318474  
PUBMED 8043441  
REFERENCE 2 (bases 1 to 483)  
AUTHORS Murakawa, M.  
TITLE Direct Submission  
JOURNAL Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)  
FEATURES  
source 1. 483  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/strain="Balb/c"  
/db\_xref="taxon:10090"  
CDS <1..>483  
/function="regulation of blood coagulation"  
/note="catalytic region"  
/codon\_start=1  
/product="protein C"  
/protein\_id="BAA07812.1"  
/db\_xref="GI:1304147"  
/translation="DHWELDLDIKEILVHPNVTSSDNDIALRLAQPATLSKTIYP  
ICLPNGIAQQLTQAGQETVTGQVDSDFIKGRNRTFLLFIPLVARNECVG  
VMKNVSVENMLCAGLIGNTRDACDGDGSGPWFVFRGTWFLVGLVSGEGCHTNNY  
I"

Query Match 0.6%; Score 21.6; DB 1; Length 483;  
Best Local Similarity 53.6%; Pred. No. 98;  
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 3457 TGCCTTTAAAAGATTTTGGCTATTAAACATGATTAAGTCTTATTGGACTATAGTG 3516

Db 349 TGCTGACACAGCATGTTCTCCGAGACACACATTCTTCATGACCTCCACGCACTCATTTTC 290

QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540

Db 289 GAGCAACCAAGAGGATGCGGATGA 266

RESULT 89  
BV094002/c  
LOCUS  
DEFINITION RPAMSPC0005940 Roche Palo Alto Mus musculus STS genomic, sequence tagged site.  
ACCESSION BV094002  
VERSION BV094002.1  
KEYWORDS STS.  
GI:37671481

SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
AUTHORS 1 (bases 1 to 596)  
Usuka, J., Liao, G., Cheng, J., Nguyen, A., Bach, C., Puech, A., McPherson, J.D., Foerzler, D. and Peltz, G.  
TITLE Mus musculus SNPs  
JOURNAL Unpublished (2003)  
COMMENT Contact: Jonathan Usuka  
Roche Palo Alto Genetics and Genomics Department  
Roche Palo Alto  
3431 Hillview Ave, Mailstop S3-1, Palo Alto, CA 94024, USA  
Tel: 6508555807  
Email: Jonathan.Usuka@roche.com  
Primer A: No primer submitted  
Primer B: No primer submitted  
Location/Qualifiers  
source 1. 596  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
/map="18-10064-9474-AC126686.3.1.232817"  
/clone\_lib="Roche Palo Alto"  
/note="SNPs developed from assay sequences derived from 15 different strains of mice (as of October 1, 2003). Those strains include A/J, A/HeJ, -129/Sv, AKR/J, B10.D2-H2/OSnJ, BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, -CAST/Ei, DBA/2J, MRL/MpJ, NZB/BINJ, NZW/Lac, SPRET/Ei.."  
STS <1..>596  
Query Match 0.6%; Score 21.6; DB 1; Length 596;  
Best Local Similarity 53.6%; Pred. No. 1e+02;  
Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

QY 3457 TGCCTTTAAAAGATTTTGGCTATTAAACATGATTAAGTCTTATTGGACTATAGTG 3516

Db 344 TGCTGACACAGCATGTTCTCCGAGACACACATTCTTCATGACCTCCACGCACTCATTTTC 285

QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540

Db 284 GAGCAACCAAGAGGATGCGGATGA 261

RESULT 90  
MUSCP/c  
LOCUS  
DEFINITION Mouse mRNA for protein C, complete cds.  
ACCESSION D10445  
VERSION D10445.1  
KEYWORDS GI:220385  
anti-clotting activity; anti-coagulation factor; blood coagulation factor; calcium binding; mouse protein C; phospholipid binding; serine protease.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
AUTHORS 1 (bases 1 to 1499)  
Tada, N., Sato, M., Tsujimura, A., Iwase, R. and Hashimoto-Gotoh, T.  
TITLE Isolation and characterization of a mouse protein C cDNA  
JOURNAL J. Biochem. 111 (4), 491-495 (1992)  
MEDLINE 92316897  
PUBMED 1618739  
REFERENCE 2 (bases 1 to 1499)  
Sato, M.  
Direct Submission  
Submitted (31-JAN-1992) Masahiro Sato, Hoechst Japan Co., Ltd., Pharma Research Laboratories; 1-3-2 Minamidai, Kawagoe, Saitama 350, Japan (E-mail:rxikuno@dbj.nig.ac.jp, Tel:0492-43-6149, Fax:0492-41-6475)  
COMMENT Submitted (31-JAN-1992) to DDBJ by: Masahiro Sato  
Laboratory for Molecular Biology

|   |   |            |  |  |  |   |  |  |   |   |                              |  |   |   |  |   |  |
|---|---|------------|--|--|--|---|--|--|---|---|------------------------------|--|---|---|--|---|--|
| <p>Pharma Research Laboratories<br/>Hoechst Japan Co., Ltd.<br/>1-3-2 Minamida, Kawagoe<br/>Saitama 350<br/>Japan<br/>Phone: 0492-43-6149<br/>Fax: 0492-41-6475<br/>Email: rkikuno@dbj.nig.jc.ap.<br/>Location/Qualifiers</p> | <p>1. .1499<br/>/organism="Mus musculus"<br/>/mol_type="mRNA"<br/>/strain="BALB/c"<br/>/sub_species="domesticus"<br/>/db_xref="taxon:10090"<br/>11. .1396<br/>/codon_start=1<br/>/product="protein C"<br/>/protein_id="PAA01235.1"<br/>/db_xref="GI:220386"</p> | <p>CDS</p> | <p>sig_peptide<br/>mat_peptide<br/>mat_peptide</p> | <p>Query Match<br/>Best Local Similarity 0.6%; Score 21.6; DB 1; Length 1499;<br/>Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;</p> | <p>QY 3457 TGGCTTTAAAAGTATTTCGCTATTAACATGAATAAGTCTATTGTGACTATAGTG 3516<br/>   <br/>Db 1178 TGCCCTGCACAGCATGTTCTCCGAGACCACATCTTCATGCACCTCCACGCACTCATT 1119<br/>   <br/>QY 3517 GAGTCACAAAAGATTGACATGA 3540<br/>   <br/>Db 1118 GAGCAACCAAAGGATGCCGATGA 1095<br/>   </p> | <p>RESULT 91<br/>BC013896/c<br/>LOCUS<br/>DEFINITION<br/>ACCESSION<br/>VERSION<br/>KEYWORDS<br/>SOURCE<br/>ORGANISM</p> | <p>BC013896 1603 bp mRNA linear ROD 03-OCT-2003<br/>Mus musculus protein C, mRNA (CDNA clone MGC:13870 IMAGE:4211329), complete cds.</p> | <p>BC013896<br/>BC013896.1 GI:15530229<br/>MGC.<br/>Mus musculus (house mouse)</p> | <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.</p> | <p>1 (bases 1 to 1603)<br/>Strausberg,R.B., Feingold,E.A., Grouse,L.H., Derge,J.G., Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D., Altshul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K., Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J.M., Hsieh,F., Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.W., Hong,L., Stapleton,M., Soares,M.B., Bonaldo,M.P., Casavant,T.L., Scheetz,T.E., Brownstein,M.J., Uedin,T.B., Toshiyuki,S., Carrinci,P., Prange,C., Raha,S., Loquellano,N.A., Peters,G.J., Abramson,R.D., Mullaly,S.J., Bosak,S.A., McEwan,P.J., McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S., Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W., Willard,D.F., Mizrov,N.W., Sodervgren,F.I., Lu,X., Gibbs,R.A.</p> | <p>REFERENCE<br/>AUTHORS</p> | <p>Fahey J., Helton E., Kettelman M., Madan A., Rodriques S., Sanchez A., Whiting M., Young A., Green E., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmitt J., Myers R.M., Butterfield Y.S., Krzywinski M.I., Skalska U., Smalus D.E., Schnerch A., Schein J.E., Jones S.J. and Marra M.A.<br/>Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences<br/>Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)</p> | <p>TITLE<br/>JOURNAL<br/>MEDLINE<br/>PubMed<br/>REFERENCE<br/>AUTHORS<br/>TITLE<br/>JOURNAL</p> | <p>NIH-MGC Project URL: http://mgc.nci.nih.gov<br/>Contact: MGC help desk<br/>Email: cgapbs@mail.nih.gov<br/>Tissue Procurement: Jeffrey E. Green, M.D.<br/>cDNA Library Preparation: Life Technologies, Inc.<br/>cDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNL)<br/>DNA Sequencing by: Institute for Systems Biology<br/>http://www.systemsbio.org<br/>contact: amadan@systemsbiology.org<br/>Anup Madan, Jessica Fahey, Erin Helton, Mark Kettelman, Anuradha Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting</p> | <p>Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/ILNL at: http://image.llnl.gov Series: IRAK Plate: 18 Row: n Column: 8<br/>This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6679476.</p> | <p>FEATURES<br/>source<br/><br/>gene<br/><br/>CDS<br/><br/>misc_feature<br/><br/>misc feature</p> | <p>Location/Qualifiers<br/>1. .1603<br/>/organism="Mus musculus"<br/>/mol_type="mRNA"<br/>/strain="FVB/N"<br/>/db_xref="taxon:10090"<br/>/clone="MGC:13870 IMAGE:4211329"<br/>/tissue_type="Liver, normal, 5 month old male mouse."<br/>/clone_lib="NCI CGAP_L19"<br/>/lab_host="DH10B"<br/>/note="Vector: pCMV-SPORT6"<br/>1. .1603<br/>/gene="Proc"<br/>/note="synonym: PC"<br/>/db_xref="LocusID:19123"<br/>/db_xref="MGI:97771"<br/>100. .1482<br/>/codon_start=1<br/>/product="protein C"<br/>/protein_id="AAHI3896.1"<br/>/db_xref="GI:15530230"<br/>/db_xref="LocusID:19123"<br/>/translation="MWQFRVLLMTSGWISSIPAHDPVFSSSEHAHQVLVRNRANS FLEEMRPGSLRECEMEICDFEEAEIFQNVEDTLAFWKYFDGQCSAPPLDQCDS PCCGHGTCIDIGISFGSCDKGWGKFQCOELRFQDCRVNNGGCLHYCLEESNGRCA CAPGYELADHMRCSTWNPCGLRWIEKKIKLRKDLDLEDLPDRIVNGLTIT KQGSPQWAILDSSKKLACGVLIHTSWLTAACHVEGFKLVTLRGVLYDLRRRDHW ELDDIKVILHPNTSRSSNDIALRLAQPATLSKTIVPICLNPNGLAQOELTOAG QETVTMGYSODRIKDGRRNRTFILIRIPLVARNECVEMKNVSVENMLCAGIIG NTRDACDGSQGMVMVFFRGTFWLVLGVWSGEGCGHTNNYGIYTKVGSILKWIHSYIG EKGVLSKSQKL"</p> |
|---|---|------------|--|--|--|---|--|--|---|---|------------------------------|--|---|---|--|---|--|



/note="EGF; Region: EGF-like domain. There is no clear separation between noise and signal. pfam0053 is very similar, but has 8 instead of 6 conserved cysteines. Includes some cytokine receptors. The EGF domain misses the N-terminus regions of the Ca2+ binding EGF domains. The family is hard to model due to many similar but different sub-types of EGF domains. Pfam certainly misses a number of EGF domains"  
 /db\_xref="CDD:pfam00008"  
 730..1431  
 /note="Tryp SPC; Region: Trypsin-like serine protease"  
 /db\_xref="CDD:smart00020"

## misc\_feature

Query Match 0.6%; Score 21.6; DB 1; Length 1603;  
 Best Local Similarity 53.6%; Pred. No. 1.2e+02;  
 Matches 45; Conservative 0; Mismatches 39; Indels 0; Gaps 0;  
 QY 3457 TGGCTTTAAAGATTTGCTGCTATTAAACATGAATTAAGTCTTATTGACATATAGTG 3516  
 Db |||||  
 QY 1264 TGCCTGCACACAGCATGTTCTCCGAGACCATCTTCATGACCTCCAGGACTCATTTC 1205  
 Db |||||  
 QY 3517 GAGTCACAAAAGAGTTGGACATGA 3540  
 Db |||||  
 QY 1204 GAGCAACCAAGGGATGGGATGA 1181  
 Db |||||

RESULT 92  
 AF515269/c AF515269 1722 bp mRNA linear VRT 15-NOV-2002  
 LOCUS Danio rerio coagulation factor VIII mRNA, complete cds.  
 DEFINITION  
 ACCESSION AF515269  
 VERSION AF515269.1 GI:25005098  
 KEYWORDS  
 SOURCE Danio rerio (zebrafish)  
 ORGANISM Danio rerio  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.  
 Hanumanthaiah, R., Day, K. and Jagadeeswaran, P.  
 Comprehensive analysis of blood coagulation pathways in teleostei: evolution of coagulation factor genes and identification of zebrafish factor VIII  
 Blood Cells Mol. Dis. (2002) In press  
 2 (bases 1 to 1722)  
 Jagadeeswaran, P. and Hanumanthaiah, R.  
 Direct Submission  
 Submitted (24-MAY-2002) Cellular & Structural Biology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA  
 Location/Qualifiers  
 1..1722  
 /organism="Danio rerio"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:7955"  
 27..1358  
 /note="clotting factor"  
 /codon\_start=1  
 /product="coagulation factor VIII"  
 /protein\_id="AA071000.1"  
 /db\_xref="GI:25005098"  
 /translation="MTGAAAVLLCVTLASTSVFLSKDEAGALLQFRFRANSFGLFEMKAGNERCEVEICDEAREVFDDDTKQFWSYKNKEPCLINPCRNNGTCVYLADSYCEGSEYGEKYCEKLEETLKQYVNGGCEQFCDSGARRSCSCAEGYALADGTSVCSQVDPGKIPYQKNTSQNQLGSHCPRGHCQVQLIDYNGESVCGGALLDGLPWLITAAHCHVKQTRFLKAVTGHDLVDLGGSEPEYVAFTHPNYDPTETLSDLLRLRVQVRSLYAVPICLPTPOLARSELWAARPTLSGWTGTRTGNLRLREKLGKPLASGTLQRLAVPLLPAAQGNANTTANPCAGYTGEDHASCSDGSGPLVTRYGETSFLTGVSWSRGCGGPGGYIYTKVENFLIMDTWKINTEDKSEQIANVSTKN"

## FEATURES

source  
 1..1722  
 /organism="Danio rerio"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:7955"  
 27..1358  
 /note="clotting factor"  
 /codon\_start=1  
 /product="coagulation factor VIII"  
 /protein\_id="AA071000.1"  
 /db\_xref="GI:25005098"  
 /translation="MTGAAAVLLCVTLASTSVFLSKDEAGALLQFRFRANSFGLFEMKAGNERCEVEICDEAREVFDDDTKQFWSYKNKEPCLINPCRNNGTCVYLADSYCEGSEYGEKYCEKLEETLKQYVNGGCEQFCDSGARRSCSCAEGYALADGTSVCSQVDPGKIPYQKNTSQNQLGSHCPRGHCQVQLIDYNGESVCGGALLDGLPWLITAAHCHVKQTRFLKAVTGHDLVDLGGSEPEYVAFTHPNYDPTETLSDLLRLRVQVRSLYAVPICLPTPOLARSELWAARPTLSGWTGTRTGNLRLREKLGKPLASGTLQRLAVPLLPAAQGNANTTANPCAGYTGEDHASCSDGSGPLVTRYGETSFLTGVSWSRGCGGPGGYIYTKVENFLIMDTWKINTEDKSEQIANVSTKN"  
 Query Match 0.6%; Score 21.6; DB 1; Length 1722;  
 Best Local Similarity 45.3%; Pred. No. 1.2e+02;  
 Matches 78; Conservative 0; Mismatches 94; Indels 0; Gaps 0;

QY 2966 TTCTAATATTACTTATTCTTATTCTTAAATTCGACTTATTATTGATTTCTAA 3025  
 Db |||||  
 QY 1547 TTTTCATAATATCATCTAAGATTATATGTTTATTATTATTATATATATATAT 1488  
 Db |||||  
 QY 3026 TAAATCCAGTCTCTGTTTATTAAGACCTTAAATATTAAATTCCTTTAGTGT 3085  
 Db |||||  
 QY 1487 CCATCCAGATGAGGTGGAGTAAAGAGTTGAGGGCTCTTTACTTCCACATACTCAT 1428  
 Db |||||  
 QY 3086 TTACCAAGTCTCTTTCAGCTACTTCTTTGATTTATTGTCCTATCTTTCT 3137  
 Db |||||  
 QY 1427 ATTTCTCTTAAAGCAACCTCATCACAGAAATCACAGCCATTTAATCT 1376  
 Db |||||

RESULT 93  
 AX565990 AX565990 6098 bp DNA linear PAT 29-NOV-2002  
 LOCUS Sequence 2 from Patent WO02077218.  
 DEFINITION  
 ACCESSION AX565990  
 VERSION AX565990.1 GI:26001242  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 REFERENCE 1  
 AUTHORS Persson, B.  
 TITLE Coagulation factor vii derivatives  
 JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;  
 NOVO NORDISK A/S (DK)  
 FEATURES  
 Location/Qualifiers  
 source  
 1..6098  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Plasmid DNA pLN174"

Query Match 0.6%; Score 21.6; DB 1; Length 6098;  
 Best Local Similarity 55.3%; Pred. No. 1.2e+02;  
 Matches 42; Conservative 0; Mismatches 34; Indels 0; Gaps 0;  
 QY 3000 GCACCTATTATTGATTTCTTCTAATAAAATCCAGTCTCTGTTTAAAAAGCTTT 3059  
 Db |||||  
 QY 2690 GAACCCCTATTGTTTATTATTCTTAATACATTCATCAATATGATCGCTCATGAGACAAT 2749  
 Db |||||  
 QY 3060 AAAATTATTAAATTTCT 3075  
 Db |||||  
 QY 2750 AACCTGTATAATGCT 2765  
 Db |||||

RESULT 94  
 AX814615 AX814615 172 bp DNA linear PAT 05-DEC-2003  
 LOCUS Sequence 53 from Patent WO03064641.  
 DEFINITION  
 ACCESSION AX814615  
 VERSION AX814615.1 GI:39103828  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens

REFERENCE 1  
 AUTHORS Bougueleret, L., Niknejad, A. and Saudrais, C.  
 TITLE Gene encoding serine proteases  
 JOURNAL Patent: WO 03064641-A 53 07-AUG-2003;  
 Geneprot, Inc. (CH)  
 FEATURES  
 Location/Qualifiers  
 source  
 1..172  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 1..172  
 /note="exon 11"

misc\_feature  
 1..172  
 /note="exon 11"



```

RESULT 98
HUMPS02
LOCUS
DEFINITION Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION M57841 J02917
VERSION M57841.1 GI:1290535
KEYWORDS S protein; anticoagulant cofactor; vitamin K-dependent protein.
SEGMENT 2 of 14
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 352)
Schmidel,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
Organization of the human protein S genes
Biochemistry 29 (34), 7845-7852 (1990)
MEDLINE 91084444
PUBMED 2148110
COMMENT Original source text: Human liver DNA.
FEATURES
source
1..352
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="3p11-q11.2"
/tissue_type="liver"
join(M57840.1:837..912,135..181)
/gene="PS-alpha"
order(M57840.1:913..1014,1..134)
/gene="PROS1"
/number=1
135..292
/gene="PROS1"
/note="G00-120-721"
/number=2

sig_peptide
intron
exon

Query Match 0.6%; Score 21.4; DB 1; Length 352;
Best Local Similarity 54.4%; Pred. No.1e+02;
Matches 43; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

Qy 3200 TCATATTCCTTGATACAGCTTCAGTCTCTATGCTTTAATAAGTTTCTTTTCTTTT 3259
Db 10 TCATACGATTTTAAATGTCATACAAATTCATAGCAGAAATGATTTAACTCTTATGT 69

Qy 3260 TTTTTRAAAGATGTCATT 3278
Db 70 TTAATAAACATATATT 88

RESULT 99
AF011352/c
LOCUS
DEFINITION Petromyzon marinus trypsinogen A1 mRNA, complete cds.
ACCESSION AF011352
VERSION AF011352.1 GI:2293477
KEYWORDS
SOURCE Petromyzon marinus (sea lamprey)
ORGANISM Petromyzon marinus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE
1 (bases 1 to 861)
Roach,J.C.
The molecular evolution of the vertebrate trypsinogenase
JOURNAL Unpublished
2 (bases 1 to 861)
Roach,J.C.
Direct Submission
JOURNAL Submitted (25-JUN-1997) Molecular Biotechnology, University of
Washington, Seattle, WA 98185, USA
FEATURES
source
1..861
Location/Qualifiers

```

```

/organism="Petromyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/tissue_type="anterior intestine"
/dev_stage="ammocoete"
6..749
/codon_start=1
/product="trypsinogen A1"
/protein_id="AAB63411.1"
/db_xref="GI:2293478"
/translation="MHGILALLVGAAPWYEDHIVGGSECAHSPQWQVSLNIG
YHFCGSLINSQWVVAACFQVTSRIVRIGEHNFVNEGTQEIQASKAIHQPOYN
SWTIDNDIMLIKSSPATINQYQAIALPSSCGVNTGCTTISGWTQTTSVGSPPVLM
CVOAPVLSITCRNSYPGDIITNNMICLVLEGGKDCQCGSGPVCNGELQIVSWG
RCCALPNYGVYTKVCYNNAIAQTIAAN"
sig_peptide 6..50
evidence=not_experimental
mat_peptide 51..746
product="trypsin A1"
evidence=not_experimental

Query Match 0.6%; Score 21.4; DB 1; Length 861;
Best Local Similarity 66.0%; Pred. No.1.2e+02;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 3250 TTTTITTTTTTTTTTAAAGATGTCATTCTTTGTGAAGTTTGTACA 3296
Db 861 TTTTITTTTTTTTTTATGATGTCATTTTATTCATTGTTGTTACA 815

RESULT 100
AF465274
LOCUS
DEFINITION Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete
cds.
ACCESSION AF465274
VERSION AF465274.1 GI:28194019
KEYWORDS
ORGANISM Takifugu rubripes (Fugu rubripes)
SOURCE Takifugu rubripes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
Tetraodontidae; Tetraodontidae; Takifugu.
REFERENCE
1 (bases 1 to 1329)
Tuddenham,E.G.D. and McVey,J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
2 (bases 1 to 1329)
McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
FEATURES
source
1..1329
Location/Qualifiers
/organism="Takifugu rubripes"
/mol_type="mRNA"
/db_xref="taxon:31033"
1..1329
/EC_number="3.4.21.21"
/function="serum prothrombinconversion accelerator"
/note="vitamin K dependent serine protease; similar to
Fugu rubripes FVII; synthesized in liver; contains 2
EGF-like domains; member of peptidase family S1/trypsin
family"
/codon_start=1
/product="coagulation factor VIIb precursor"
/protein_id="AAO33369.1"
/db_xref="GI:28194020"
/translation="MLIRICCTTWILFSATAAAAVFVERDASTVLQRRRRANSQFLE

```



ACCESSION AX360070  
VERSION AX360070.1 GI:18675696  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE Plowman, G., Whyte, D., Sudarsanam, S., Manning, G., Caenepeel, S. and Charyczak, G.  
AUTHORS Novel proteases  
TITLE Patent: WO 0200860-A 26 03-JAN-2002;  
JOURNAL Sugen, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..888  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 21.2; DB 1; Length 888;  
Best Local Similarity 52.2%; Pred. No. 1.4e+02;  
Matches 47; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 2683 GTGACTCTGGTGAACCTCGAGTTGGTATGGACAGGAGGCGCTGTCCTGCGCGGATT 2742  
DB 620 GGGATTCATGTTTGTCTGCTGCTGAGGATGGCAGTGTAGACACCTGCAAGGTGACT 679

QY 2743 CATGGGGTCAACAAGAGTTGGACAGCACTG 2772  
DB 680 CAGGTGGACCTTGTCTGTGCAAGGATG 709

RESULT 105  
AR234337/c  
LOCUS AR234337 1130 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 8 from patent US 6458564.  
ACCESSION AR234337  
VERSION AR234337.1 GI:27277021  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 1130)  
Darrow, A., Qi, J., and Andrade-Grodon, P.  
TITLE DNA encoding the human serine protease T  
JOURNAL Patent: US 6458564-A 8 01-OCT-2002;  
FEATURES Location/Qualifiers  
source 1..1130  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 21.2; DB 1; Length 1130;  
Best Local Similarity 50.0%; Pred. No. 1.5e+02;  
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2860 TCATAATGTTGGTTAAGATAATAAGATTTTCAAAATGATTTTATCTTTGATTTTCT 2919  
DB 1110 TTATAATGTTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAGCATTTTTC 1051

QY 2920 ACTTATTAAATTTGGATTTTAACTATTCTTCAATGACTTGAT 2965  
DB 1050 ACTGCATCTAGTTGGTTTGTGCCAAACTCATCAATGATCTTAT 1005

RESULT 106  
AR221273/c  
LOCUS AR221273 1166 bp DNA linear PAT 26-SEP-2002  
DEFINITION Sequence 2 from patent US 6426199.  
ACCESSION AR221273  
VERSION AR221273.1 GI:23328188  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.

Unclassified.  
REFERENCE 1 (bases 1 to 1166)  
AUTHORS Darrow, A., Qi, J., and Andrade-Grodon, P.  
TITLE DNA  
JOURNAL Patent: US 6426199-A 2 30-JUL-2002;  
FEATURES Location/Qualifiers  
source 1..1166  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 21.2; DB 1; Length 1166;  
Best Local Similarity 50.0%; Pred. No. 1.5e+02;  
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2860 TCATAATGTTGGTTAAGATAATAAGATTTTCAAAATGATTTTATCTTTGATTTTCT 2919  
DB 1146 TTATAATGTTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAGCATTTTTC 1087

QY 2920 ACTTATTAAATTTGGATTTTAACTATTCTTCAATGACTTGAT 2965  
DB 1086 ACTGCATCTAGTTGGTTTGTGCCAAACTCATCAATGATCTTAT 1041

RESULT 107  
AX565990/c  
LOCUS AX565990 6098 bp DNA linear PAT 29-NOV-2002  
DEFINITION Sequence 2 from Patent WO02077218.  
ACCESSION AX565990  
VERSION AX565990.1 GI:26001242  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.

REFERENCE 1  
AUTHORS Persson, E.  
TITLE Coagulation factor vii derivatives  
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;  
FEATURES Location/Qualifiers  
source 1..6098  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Plasmid DNA pLN174"

Query Match 0.6%; Score 21.2; DB 1; Length 6098;  
Best Local Similarity 50.0%; Pred. No. 1.4e+02;  
Matches 53; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2860 TCATAATGTTGGTTAAGATAATAAGATTTTCAAAATGATTTTATCTTTGATTTTCT 2919  
DB 4956 TTATAATGTTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAGCATTTTTC 4897

QY 2920 ACTTATTAAATTTGGATTTTAACTATTCTTCAATGACTTGAT 2965  
DB 4896 ACTGCATCTAGTTGGTTTGTGCCAAACTCATCAATGATCTTAT 4851

RESULT 108  
HSU29534  
LOCUS HSU29534 252 bp DNA linear PRI 18-APR-1997  
DEFINITION Human MHC class II antigen HLA-DP-beta (HLA-DPB1) gene, exon 2, partial cds.  
ACCESSION U29534  
VERSION U29534.1 GI:903973  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS 1 (bases 1 to 252)  
Noble, J.A., Cavalli, A.S. and Erlich, H.A.  
TITLE DBP1\*5901a: a novel HLA-DPB1 allele from a Caucasian family with

```

insulin-dependent diabetes mellitus
Tissue Antigens 47 (2), 159-162 (1996)
JOURNAL MEDLINE 97004423
PUBMED 8851734
REFERENCE 2 (bases 1 to 252)
AUTHORS Noble, J.A. and Erlich, H.A.
TITLE Direct Submission
JOURNAL Submitted (19-JUN-1995) Janelle A. Noble, Human Genetics, Roche
Molecular Systems, 1145 Atlantic Ave., Alameda, CA 94501, USA
FEATURES
    source
        Location/Qualifiers
            1..252
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /chromosomes="6"
                /map="6p"
                /cell_line="cell lines HB01242, HB01243, HB01244 available
                from the Human Biological Data Interchange (HBDI),
                Philadelphia, PA"
                /note="cloned from PCR amplification products"
            1..252
                /gene="HLA-DPB1"
            <1..>252
                /gene="HLA-DPB1"
                /codon_start=1
                /product="MHC class II antigen HLA-DP-beta"
                /protein_id="AAB52511.1"
                /db_xref="GI:903974"
                /translation="NYLFGROECYAFNGTQRFLERYIYNREEFVRFSDVGEFRAVT
                ELGRPDEEYVNSQDLLEKRAVPDRMCRHNYELGSPMTL"

Query Match 0.6%; Score 21; DB 1; Length 252;
Best Local Similarity 49.5%; Pred. No. 1.2e+02;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2551 CAGTACTTTGGCCACCTGATCAGAGAGCTGACTCACTGGAAAGACCCCTGATGCTGGGA 2610
DB 131 CGGAGCTGGGGCGGCTGATGAGGAGTACTGGAACAGCCAGGACCTCTCTGGAGGAGA 190
QY 2611 GCGATTGGGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2659
DB 191 AGCGGCGAGTGGCGGACAGGAGTGTGCAGACAACTACGAGCTGGGCGG 239

RESULT 109
HSU59442
LOCUS Human MHC class II antigen DPbeta1 gene (DPB1*5901 allele), partial
DEFINITION cds.
ACCESSION U59442
VERSION U59442.1 GI:4097404
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 255)
AUTHORS Noreen, H., Steiner, L., Davidson, M., Johnson, S., Segall, M. and
Begovich, A.B.
TITLE Six new DPB1 alleles identified in a study of 1,302 unrelated bone
marrow donor-recipient pairs
JOURNAL Tissue Antigens 49 (5), 512-516 (1997)
MEDLINE 97316872
PUBMED 9174146
REFERENCE 2 (bases 1 to 255)
AUTHORS Steiner, L., Begovich, A. and Noreen, H.
TITLE Direct Submission
JOURNAL Submitted (29-MAY-1996) Human Genetics, Roche Molecular Systems,
1145 Atlantic Avenue, Alameda, CA 94501, USA
FEATURES
    source
        Location/Qualifiers
            1..255
                /organism="Homo sapiens"
                /mol_type="genomic DNA"

```

```

        /db_xref="taxon:9606"
        /chromosomes="6"
        1..255
            /genes="HLA-DPB1"
            <1..>255
                /genes="HLA-DPB1"
                /note="Allele: DPB1*5901"
                /codon_start=1
                /product="MHC class II antigen DPbeta1"
                /protein_id="AAB52511.1"
                /db_xref="GI:4097405"
                /translation="NYLFGROECYAFNGTQRFLERYIYNREEFVRFSDVGEFRAVT
                ELGRPDEEYVNSQDLLEKRAVPDRMCRHNYELGSPMTL"

Query Match 0.6%; Score 21; DB 1; Length 255;
Best Local Similarity 49.5%; Pred. No. 1.2e+02;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2551 CAGTACTTTGGCCACCTGATCAGAGAGCTGACTCACTGGAAAGACCCCTGATGCTGGGA 2610
DB 131 CGGAGCTGGGGCGGCTGATGAGGAGTACTGGAACAGCCAGGACCTCTCTGGAGGAGA 190
QY 2611 GCGATTGGGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2659
DB 191 AGCGGCGAGTGGCGGACAGGAGTGTGCAGACAACTACGAGCTGGGCGG 239

RESULT 110
HUMHCD21A
LOCUS Human major histocompatibility complex class II (HLA-DPB21) gene,
DEFINITION exon 2.
ACCESSION M84617
VERSION M84617.1 GI:187834
KEYWORDS cell surface glycoprotein; class II gene; integral membrane
protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 260)
AUTHORS Begovich, A.B., Moonsamey, P., Suraj, V., Bugawan, T.L., Stoneking, M.,
Roudier, J. and Hills, A.V.S.
TITLE Genetic diversity within the HLA class II region: ten new DPB1
alleles and their population distribution
JOURNAL Immunogenetics 40, 153-157 (1992)
COMMENT Original source text: Homo sapiens (individual isolate Indonesian
57) DNA.
FEATURES
    source
        Location/Qualifiers
            1..260
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /isolate="Indonesian 57"
                /db_xref="taxon:9606"
                /map="6p21.3"
                /haplotypes="DPB21"
                /cell_type="lymphocyte"
            1..260
                /gene="HLA-DPB21"
            1..260
                /gene="HLA-DPB21"
                /number=2

Query Match 0.6%; Score 21; DB 1; Length 260;
Best Local Similarity 49.5%; Pred. No. 1.2e+02;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2551 CAGTACTTTGGCCACCTGATCAGAGAGCTGACTCACTGGAAAGACCCCTGATGCTGGGA 2610
DB 136 CGGAGCTGGGGCGGCTGATGAGGAGTACTGGAACAGCCAGGACCTCTCTGGAGGAGA 195
QY 2611 GCGATTGGGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2659

```

sig peptide

```

mat_peptide      /gene="TRYPB2"
                 /evidence=not_experimental
                 42..737
                 /gene="TRYPB2"
                 /product="trypsin b2"
                 /evidence=not_experimental

Query Match      0.6%; Score 21; DB 1; Length 836;
Best Local Similarity 50.5%; Pred. No. 1.5e+02;
Matches 51; Conservative 0; Mismatches 50; Indels 0; Gaps 0;

QY 2622 CAGGAGGAGAGGGGACGACGAGGATGAGTGGTGGATGCATCAGTACGTGATGCA 2681
      |||||
Db 476 CATGAGGACATCGGGCTCGGACGCTGCTGGTCTCGCCCGGAGAGTGTGCA 417

QY 2682 CGTGAGTCTGGGTGACTCTCTGAGTCTGGTGGATGACAGGG 2722
      |||||
Db 416 CATGACTCCGGTGCCCAACGACGAGGAGGTAGCGGGATGG 376

RESULT 114
AX333266/c      850 bp DNA linear PAT 09-JAN-2002
LOCUS           Sequence 3775 from Patent WO0194629.
DEFINITION      AX333266
ACCESSION       AX333266
VERSION         AX333266.1 GI:18123900
KEYWORDS        Homo sapiens (human)
SOURCE          Homo sapiens
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE       1
AUTHORS         Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,
                Horrigan, S., Soppet, D.R. and Weaver, Z.
TITLE           Cancer gene determination and therapeutic screening using signature
                gene sets
JOURNAL         Patent: WO 0194629-A 3775 13-DEC-2001;
                Avalon Pharmaceuticals (US)
FEATURES        Location/Qualifiers
source          1..850
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.6%; Score 21; DB 1; Length 850;
Best Local Similarity 62.3%; Pred. No. 1.6e+02;
Matches 33; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 922 CTTTGAAGTAAACACCCAAAGATGCTCTCTCATTATAGGGGACTGGAA 974
      |||||
Db 136 CTCACAGGTGATAGCCCCCAACATCTTGTCTCATCTGTCATCAAGGGGACAGCA 84

RESULT 115
HSTRYIVB/c      850 bp mRNA linear PRI 04-DEC-1998
LOCUS           HSTRYIVB
DEFINITION      H.sapiens mRNA for trypsinogen IV b-form.
ACCESSION       X71345
VERSION         X71345.1 GI:405755
KEYWORDS        Brain specific protein; trypsinogen.
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE       1
AUTHORS         Wiegand, U., Corbach, S., Minn, A., Kang, J. and Muller-Hill, B.
TITLE           Cloning of the cDNA encoding human brain trypsinogen and
                characterization of its product
JOURNAL         Gene 136 (1-2), 167-175 (1993)
PUBMED          8294000
AUTHORS         Wiegand, U.

mat_peptide      /gene="TRYPB2"
                 /evidence=not_experimental
                 42..737
                 /gene="TRYPB2"
                 /product="trypsin b2"
                 /evidence=not_experimental

Query Match      0.6%; Score 21; DB 1; Length 836;
Best Local Similarity 50.5%; Pred. No. 1.5e+02;
Matches 51; Conservative 0; Mismatches 50; Indels 0; Gaps 0;

QY 2622 CAGGAGGAGAGGGGACGACGAGGATGAGTGGTGGATGCATCAGTACGTGATGCA 2681
      |||||
Db 476 CATGAGGACATCGGGCTCGGACGCTGCTGGTCTCGCCCGGAGAGTGTGCA 417

QY 2682 CGTGAGTCTGGGTGACTCTCTGAGTCTGGTGGATGACAGGG 2722
      |||||
Db 416 CATGACTCCGGTGCCCAACGACGAGGAGGTAGCGGGATGG 376

RESULT 114
AX333266/c      850 bp DNA linear PAT 09-JAN-2002
LOCUS           Sequence 3775 from Patent WO0194629.
DEFINITION      AX333266
ACCESSION       AX333266
VERSION         AX333266.1 GI:18123900
KEYWORDS        Homo sapiens (human)
SOURCE          Homo sapiens
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE       1
AUTHORS         Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,
                Horrigan, S., Soppet, D.R. and Weaver, Z.
TITLE           Cancer gene determination and therapeutic screening using signature
                gene sets
JOURNAL         Patent: WO 0194629-A 3775 13-DEC-2001;
                Avalon Pharmaceuticals (US)
FEATURES        Location/Qualifiers
source          1..850
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.6%; Score 21; DB 1; Length 850;
Best Local Similarity 62.3%; Pred. No. 1.6e+02;
Matches 33; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 922 CTTTGAAGTAAACACCCAAAGATGCTCTCTCATTATAGGGGACTGGAA 974
      |||||
Db 136 CTCACAGGTGATAGCCCCCAACATCTTGTCTCATCTGTCATCAAGGGGACAGCA 84

RESULT 115
HSTRYIVB/c      850 bp mRNA linear PRI 04-DEC-1998
LOCUS           HSTRYIVB
DEFINITION      H.sapiens mRNA for trypsinogen IV b-form.
ACCESSION       X71345
VERSION         X71345.1 GI:405755
KEYWORDS        Brain specific protein; trypsinogen.
SOURCE          Homo sapiens (human)
ORGANISM        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE       1
AUTHORS         Wiegand, U., Corbach, S., Minn, A., Kang, J. and Muller-Hill, B.
TITLE           Cloning of the cDNA encoding human brain trypsinogen and
                characterization of its product
JOURNAL         Gene 136 (1-2), 167-175 (1993)
PUBMED          8294000
AUTHORS         Wiegand, U.

```

```

TITLE           Direct Submission
JOURNAL         Submitted (06-APR-1993) U. Wiegand, Institut fuer Genetik der Univ
                zu Koeln,, Weyertal 121, 5000 Koeln 41, FRG
FEATURES        Location/Qualifiers
source          1..850
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /tissue_type="brain"
                join(1..79,80..236,237..490,491..627,628..850)
                <1..79
                /number=1
                join(5..79,80..236,237..490,491..627,628..784)
                /codon_start=1
                /product="trypsinogen IV b-form"
                /protein_id="CAA50484.1"
                /db_xref="GI:3980129"
                /db_xref="GOA:P35030"
                /db_xref="SWISS-PROT:P35030"
                /translation="MELHPLLGRTWRAARDADGCEALGTVAVFPDDDDKIVGGVTCE
                NSLPYQVSLNSGSHFCGSLISEOWVVAHCVKTRIOVRLGEHNKVLKLEGEQFINA
                AKTIHPKYNRDTLDNDIMLIKLSPAVINARVSTISLTPAPAAAGTECLISGMNTL
                SFGADYDDELKCLDAPVLTCACCKASYPGKITSMPGVGLEGGKDSQORDSGGPPVC
                NGOLQGVSVGHWGCAWKNRPVTVTVYNYVDWIKDTIAANS"
                80..236
                /number=2
                237..490
                /number=3
                491..627
                /number=4
                628..850
                /number=5

Query Match      0.6%; Score 21; DB 1; Length 850;
Best Local Similarity 62.3%; Pred. No. 1.6e+02;
Matches 33; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 922 CTTTGAAGTAAACACCCAAAGATGCTCTCTCATTATAGGGGACTGGAA 974
      |||||
Db 136 CTCACAGGTGATAGCCCCCAACATCTTGTCTCATCTGTCATCAAGGGGACAGCA 84

RESULT 116
AR253972        933 bp DNA linear PAT 20-DEC-2002
LOCUS           AR253972
DEFINITION      Sequence 29 from patent US 6479274.
ACCESSION       AR253972
VERSION         AR253972.1 GI:27302467
KEYWORDS        Unknown.
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 933)
AUTHORS         Antalis, T.M. and Hooper, J.D.
TITLE           DNA molecules encoding human HELA2 or testisin serine proteinases
JOURNAL         Patent: US 6479274-A 29 12-NOV-2002;
FEATURES        Location/Qualifiers
source          1..933
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      0.6%; Score 21; DB 1; Length 933;
Best Local Similarity 54.5%; Pred. No. 1.6e+02;
Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 813 TGTTCCTTTCCAGGCAACCATTCATATATCATATATCATATATCATATATCATATAT 872
      |||||
Db 766 TGTCTGGGGCCGCCGAGGTGCCCGGATGCCCTCAGGACCTCCAGATCCACCCAG 825

QY 873 TAATGCTGAAGAAGCTG 889
      |||||
Db 826 TGCTGCTGCTTGAGCTG 842

```



```

RESULT 117
AF465269/c
LOCUS
DEFINITION
AF465269
1416 bp mRNA linear VRT 02-FEB-2003
Gallus gallus coagulation factor IX precursor (F9) mRNA, complete
cde.
ACCESSION
AF465269
VERSION
AF465269.1 GI:28194009
KEYWORDS
SOURCE
ORGANISM
Gallus gallus (chicken)
Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 1416)
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G.,
Tuddenham, E.G.D. and McVey, J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
JOURNAL
REFERENCE
2 (bases 1 to 1416)
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
Direct Submission
TITLE
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
FEATURES
Location/Qualifiers
1..1416
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1..1416
/gene="F9"
1..1416
/gene="F9"
1..1416
/gene="F9"
/EC_number="3.4.21.22"
/function="converts factor X to its active form in the
presence of Ca++ ions, phospholipids, and factor VIIa"
/notes="vitamin K dependent serine protease; Christmas
factor; contains 2 EGF-like domains; member of peptidase
family S1/trypsin family"
/codon_start=1
/product="coagulation factor IX precursor"
/protein_id="AAO33364.1"
/db_xref="GI:28194010"
/translation="MAKIPLILSLLEAFLEAEVFIENKEASTVLSRTRGNSNR
LEELIPGNLERECIEKESFBEAREVFENTKEFWKIYIDGQCNSECKNGAVCK
DGVSYECMCPGGRNCEIDSTCATKNGGCEHFCHRDTPQKAVCSAGYKLUHEDG
KSCPAPVPCGRITAPEMRGKVTRENTIERNWTAHDEGDAEDALDITEPPPTT
TSAAPKIVPTIKNDTRVGGYDSVKQLPQVHLVDSRGLGFCGSGIINEKWVYTA
HLRPGDNVTAVGYNTEKDDHTEQROVVKILPYPTYNRKNHNDIALLELDQ
LTFNSYVTPICIGSEDFTNLLSNGPGTVSCGSMLYGRSAIVLVLTVPVDRVTC
LKSTSTILHNFCAGYTAGKDCGDSGSGPYTNSIGETWFLTGVTISWGECAKPGK
YGIYTKVAKYVKNIREITRLI"
Query Match 0.6%; Score 21; DB 1; Length 1416;
Best Local Similarity 54.5%; Pred. No. 1.7e+02;
Matches 42; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 1209 GTCACAAAACAGACGAGGCTTACTGTGGCTCAGATCATGACCTCTATTGCCAA 1269
DB 340 GTGGACATGCACCTATAGGAGCTACTTCGCTCTTGACACGCTCCATTITGATG 281
QY 1269 ATTACAGACTTAATGGA 1285
DB 280 GGTGGAGTTACTGTA 264
RESULT 118
AX147505
LOCUS
DEFINITION
AX147505
1551 bp DNA linear PAT 08-JUN-2001
Sequence 59 from Patent WO0136632.
ACCESSION
AX147505

```

```

VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.
Variants of alternative splicing
Patent: WO 0136632-A 59 25-MAY-2001;
Compugen Ltd. (IL)
FEATURES
Location/Qualifiers
1..1551
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 21; DB 1; Length 1551;
Best Local Similarity 48.7%; Pred. No. 1.7e+02;
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
QY 1390 GACAGAGTACCTAATGAACATGACAGAGGTTATGACATGTTACAGAGACAGGATC 1449
DB 108 GAGGAAGCACATGGTGTCTCTACACAGGCAAGCGTGCCAACTCACTCTCGAGGAGCTT 167
QY 1450 GAGACCATCCCATGGAAGAAATGCAAAAAGCAAAATGGCTGTCTGGGAGGCC 1506
DB 168 TGGCCCGGCTCTCTGGAGAGAGTGCATGAGACAGTGTCTCTTGAGGAGGCC 224
RESULT 119
MMU44795
LOCUS
DEFINITION
U44795
1850 bp mRNA linear ROD 23-MAY-1996
Mus musculus coagulation factor VII (fVII) mRNA, complete cds.
VERSION
U44795.1 GI:1184738
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 1850)
Idusogie, E., Rosen, E., Geng, J.P., Carmeliet, P., Collen, D. and
Castellino, P.J.
Characterization of a cDNA encoding murine coagulation factor VII
Thromb. Haemost. 75 (3), 481-487 (1996)
95276538
8701412
2 (bases 1 to 1850)
Rosen, E.D., Idusogie, E., Carmeliet, P., Collen, D. and
Castellino, P.J.
Direct Submission
TITLE
Submitted (05-JAN-1996) Elliot D. Rosen, Chemistry, Univ. of Notre
Dame, Notre Dame, IN 46556, USA
FEATURES
Location/Qualifiers
1..1850
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/tissue_type="liver"
1..1850
/gene="fVII"
16..1356
/gene="fVII"
/notes="initiation of extrinsic pathway of blood
coagulation; serine protease"
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAC52570.1"
/db_xref="GI:1184739"
gene
CDS
LLEELPGLSLRECEKESFEAREVFENTKEFWKIYIDGQCNSECKNGAVCK
LLEELPGLSLRECEKESFEAREVFENTKEFWKIYIDGQCNSECKNGAVCK
QDHLKSYVPCLLDFEGRNCEKSKNEQLICANENGDCDQYCRDHVGTREKTSCHDYT

```

LOPDEVCKPKVEYPCGRIPVVEKRNSSRQRIYGVNCPKGECPQWALVKINGLL  
 CGAVLLDARIWVTAACFDNIYWGNIITVMGEHDFSEKDGDEQVRVTQVIMPKYI  
 RKNHIDIALRLHRPVTDTVVPLCLPEKSFSENTLARIKFSRVSGWGLDRGAT  
 ALEMSIEVPLMTODCLHAKHSNTPKITENMFACGYMDGTCKACKDGGGPHATH  
 YHGTWYLTGVVSGGCAALGHIGYTRVSQIDVLRHMDSKLVGVFRPLLL  
 1850

## polyA\_site

/gene="fVII"  
 /note="54 A nucleotides"

Query Match 0.6%; Score 21; DB 1; Length 1850;

Best Local Similarity 48.7%; Pred. No. 1.7e+02;  
Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1390 GACAGAGTACCTAATAAGTATGGACAGAGGTTTCATGACATTGTACAGGACAGGATC 1449  
 |||||  
 Db 103 GAGGAGACATGCTGCTCCTACACAGGCAAGGCGTGCACACTCACTCTCTGAGGAGCTT 162  
 |||||  
 QY 1450 GAGACCATCCCATGAAAGAAATGCCAAAGAGAAATGCTCTCTGGGAGGCC 1506  
 |||||  
 Db 163 TGCCCCGGCTCTCTGAGAGAGAGTCAATGAGGACAGTGTCTCTTTGAGGAGGCC 219  
 |||||

## RESULT 120

BC061149

LOCUS

DEFINITION Mus musculus coagulation factor VII, mRNA (CDNA clone MGC:74281 IMAGE:30305571), complete cds.

ACCESSION

BC061149

VERSION

MGC.

KEYWORDS

MGC.

SOURCE

Mus musculus (house mouse)

ORGANISM

REFERENCE

AUTHORS

Bukaryoca; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 1869)  
 Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,  
 Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,  
 Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,  
 Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,  
 Diachenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,  
 Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,  
 Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,  
 Carninci, P., Prange, C., Raha, S., Loquellano, N.A., Peters, G.J.,  
 Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,  
 McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,  
 Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,  
 Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,  
 Fahey, J., Helton, E., Kettner, M., Madan, A., Rodriguez, S.,  
 Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y.,  
 Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,  
 Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,  
 Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalios, D.E.,  
 Scherch, A., Schein, J.E., Jones, S.J. and Marra, M.A.  
 Generation and initial analysis of more than 15,000 full-length  
 human and mouse cDNA sequences  
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
 22388257  
 MEDLINE  
 PUBMED  
 12477932  
 REFERENCE  
 2 (bases 1 to 1869)  
 Strausberg, R.  
 Direct Submission  
 Submitted (03-NOV-2003) National Institutes of Health, Mammalian  
 Gene Collection (MGC), Cancer Genomics Office, National Cancer  
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
 USA  
 NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
 Contact: MGC help desk  
 Email: [cgabbs@mail.nih.gov](mailto:cgabbs@mail.nih.gov)  
 Tissue Procurement: Dr. Michael Brownstein  
 cDNA Library Preparation: Michael Brownstein / Ted Usdin  
 Laboratory  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Sequencing Group at the Stanford Human Genome

Center, Stanford University School of Medicine, Stanford, CA 94305  
 Web site: <http://www-sgsc.stanford.edu>  
 Contact: (Dickson, Mark) [mcd@paxil.stanford.edu](mailto:mcd@paxil.stanford.edu)  
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,  
 R. M.

Clone distribution: MGC clone distribution information can be found  
 through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Series: IRAL Plate: 53 Row: n Column: 1  
 This clone was selected for full length sequencing because it  
 passed the following selection criteria: matched mRNA gi: 6753805.

## FEATURES

## source

1. .1869  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:10090"  
 /clone="MGC:74281 IMAGE:30305571"  
 /tissue\_type="Liver, mouse"  
 /clone\_lib="NIH\_MGC\_177"  
 /lab\_host="DH10B"  
 /notes="Vector: pDNR-LIB"  
 1. .1869  
 /gene="F7"  
 /note="synonyms: FVII, mFVII"  
 /db\_xref="LocusID:14068"  
 /db\_xref="MGI:109325"  
 10. .1350  
 /codon\_start=1  
 /product="coagulation factor VII"  
 /protein\_id="AAH61149.1"  
 /db\_xref="GI:38511702"  
 /db\_xref="LocusID:14068"  
 /translation="MPSQAHGLLLCLLQGLGPTAVFTQEAHGVLRHRRANS  
 LLELWPGVSEKNEECSEAREIFKSPRTQFVIYSDGDCASNPQCGGTC  
 OHLKSYGFCILLDFEGRECKSKNEQLCANENGDCQYCRDHVGTKRTSCSHDYT  
 LOPDEVCKPKVEYPCGRIPVVEKRNSSRQRIYGVNCPKGECPQWALVKINGLL  
 CGAVLLDARIWVTAACFDNIYWGNIITVMGEHDFSEKDGDEQVRVTQVIMPKYI  
 RKNHIDIALRLHRPVTDTVVPLCLPEKSFSENTLARIKFSRVSGWGLDRGAT  
 ALEMSIEVPLMTODCLHAKHSNTPKITENMFACGYMDGTCKACKDGGGPHATH  
 YHGTWYLTGVVSGGCAALGHIGYTRVSQIDVLRHMDSKLVGVFRPLLL"  
 79. .264  
 /notes="GLA; Region: Domain containing Gla  
 (gamma-carboxyglutamate) residues"  
 /db\_xref="CDD:smart00069"  
 268. .378  
 /notes="EGF\_CA; Region: Calcium-binding EGF-like domain,  
 present in a large number of membrane-bound and  
 extracellular (mostly animal) proteins. Many of these  
 proteins require calcium for their biological function and  
 calcium-binding sites have been found to be located at the  
 N-terminus of particular EGF-like domains"  
 /db\_xref="CDD:cd00054"  
 589. .1302  
 /notes="Tryp\_SPC; Region: Trypsin-like serine protease"  
 /db\_xref="CDD:cd00190"

## gene

## CDS

## misc\_feature

## misc\_feature

## misc\_feature

Query Match 0.6%; Score 21; DB 1; Length 1869;  
 Best Local Similarity 48.7%; Pred. No. 1.7e+02;  
 Matches 57; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

QY 1390 GACAGAGTACCTAATAAGTATGGACAGAGGTTTCATGACATTGTACAGGACAGGATC 1449  
 |||||  
 Db 97 GAGGAAGCATGTGTTCTCTACACAGGCAAGCGTGCACACTCACTCTCTGGAGAGCTT 156  
 |||||  
 QY 1450 GAGACCATCCCATGAAAGAAATGCCAAAGAGAAATGCTCTCTGGGAGGCC 1506  
 |||||  
 Db 157 TGCCCCGGCTCTCTGAGAGAGAGTGCATGAGGACAGTGTCTCTTTGAGGAGGCC 213  
 |||||

## RESULT 121

AF272773

LOCUS

DEFINITION Synthetic construct mutated mouse factor VII molecule





|                       |  |   |       |             |                 |
|-----------------------|--|---|-------|-------------|-----------------|
| RESULT 131            | S55227   | 290 bp  | DNA   | linear      | PRI 08-MAY-1993 |
| LOCUS                 | S55227/c   |   |       |             |                 |
| DEFINITION            | protein C (exon IX) [human, peripheral blood, Genomic Mutant, 290 nt].   |   |       |             |                 |
| ACCESSION             | S55227   |   |       |             |                 |
| VERSION               | S55227.1   | GI:265667   |       |             |                 |
| KEYWORDS              |  |   |       |             |                 |
| SOURCE                | Homo sapiens (human)   |   |       |             |                 |
| ORGANISM              | Homo sapiens   |   |       |             |                 |
| REFERENCE             | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.                                 |   |       |             |                 |
| AUTHORS               | Tokunaga, F., Wakabayashi, S., Sato, H., Arakawa, M., Tawarayama, H. and Koide, T.   |   |       |             |                 |
| TITLE                 | Identification of one base deletion in exon IX of the protein C gene that causes a type I deficiency   |   |       |             |                 |
| JOURNAL               | Thromb. Res. 68 (4-5), 417-423 (1992)  |   |       |             |                 |
| MEDLINE               | 93174420   |   |       |             |                 |
| PUBMED                | 1290170  |   |       |             |                 |
| REMARK                | GenBank staff at the National Library of Medicine created this entry [NCBI gbbseq 12544] from the original journal article. This sequence comes from Fig. 3. |   |       |             |                 |
| COMMENT               | deletion of a G in codon for Gly381.   |   |       |             |                 |
| FEATURES              | Location/Qualifiers  |   |       |             |                 |
| source                | 1..290   |   |       |             |                 |
|                       | /organism="Homo sapiens"   |   |       |             |                 |
|                       | /mol_type="genomic DNA"  |   |       |             |                 |
| gene                  | 1..255   |   |       |             |                 |
|                       | /db_xref="taxon:9606"  |   |       |             |                 |
| CDS                   | 1..255   |   |       |             |                 |
|                       | /gene="protein C"  |   |       |             |                 |
|                       | /gene="protein C"  |   |       |             |                 |
|                       | /note="This sequence comes from Fig. 3"  |   |       |             |                 |
|                       | /codon_start=1   |   |       |             |                 |
|                       | /product="protein C"   |   |       |             |                 |
|                       | /protein_id="AA25410.1"  |   |       |             |                 |
|                       | /db_xref="GI:265668"   |   |       |             |                 |
|                       | /translation="VSWVRVGSFTTFTPKSAATSTGSMGTSETRKPPRRAGHLSDPCCRAGLLHGNGWDIKGTCNKHGTLFCPSIPLGSSGK"  |   |       |             |                 |
| Query Match           | 0.6%;  | Score 20.8;   | DB 1; | Length 290; |                 |
| Best Local Similarity | 57.8%;   | Pred. No. 1.4e+02;  |       |             |                 |
| Matches               | 37;  | Conservative  | 0;    | Mismatches  | 27;             |
|                       |  |   |       | Indels      | 0;              |
|                       |  |   |       | Gaps        | 0;              |
| Qy                    | 453  | CTCCAGAAAGATGAAGAGATGGAGCGCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC | 512   |             |                 |
|                       |  |   |       |             |                 |
| Db                    | 247  | CTCCAGAGAGCCCAAGAGGGATGGAGGACAGACAGACAGCCGGTGTGTTGTAC       | 188   |             |                 |
|                       |  |   |       |             |                 |
| Qy                    | 513  | TGQT 516  |       |             |                 |
|                       |  |   |       |             |                 |
| Db                    | 187  | ATGT 184  |       |             |                 |
| RESULT 132            | BD076788/c   |   |       |             |                 |
| LOCUS                 | BD076788   | 323 bp  | DNA   | linear      | PAT 27-AUG-2002 |
| DEFINITION            | 5' EST of secretory protein expressed in prostate.   |   |       |             |                 |
| ACCESSION             | BD076788   |   |       |             |                 |
| VERSION               | BD076788.1   | GI:22622391   |       |             |                 |
| KEYWORDS              | JP 2001512013-A/35   |   |       |             |                 |
| SOURCE                | Homo sapiens (human)   |   |       |             |                 |
| ORGANISM              | Homo sapiens   |   |       |             |                 |
|                       | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.                                 |   |       |             |                 |
| REFERENCE             | 1 (bases 1 to 323)   |   |       |             |                 |
| AUTHORS               | Edwards, J.B.D.M., Duclert, A. and Lacroix, B.   |   |       |             |                 |
| TITLE                 | 5' EST of secretory protein expressed in prostate  |   |       |             |                 |
| JOURNAL               | Patent: JP 2001512013-A 35 21-AUG-2001;  |   |       |             |                 |
|                       | GENSET   |   |       |             |                 |
| COMMENT               | OS Homo sapiens (human)  |   |       |             |                 |
|                       | PN JP 2001512013-A/35  |   |       |             |                 |
|                       | PD 21-AUG-2001   |   |       |             |                 |

```
PF 31-JUL-1998 JP 2000505291
PR 01-AUG-1997 US 08/905144
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,AYMERIC DUCLERT,BRUNO PI
LACROIX
PC C12N15/09,C07K14/47,C12P21/02,C12Q1/02,C12Q1/68,C12N15/00 CC
Von Heijne matrix
CC score 10.7
CC seq LILLALATGLVGG/ET
CC n=a, g, c or t
FT Key Location/Qualifiers
FT sig peptide 117..170
FT misc feature 67
FT misc Location/Qualifiers
FEATURES
source
1..323
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.8; DB 1; Length 323;
Best Local Similarity 46.5%; Pred. No. 1.4e+02;
Matches 67; Conservative 0; Mismatches 77; Indels 0; Gaps 0;
QY 249 GTGGGGACCCCAAGATGGCGAGGTGATGTCGAGAGATCTGACAGAAATGGTCCACTG 308
DB 267 GCGTCCGCCACAGAGTAGCCGCTTCTCTGCAACAGGGCTGCTGCCAGGGCTGGGAGT 208
QY 309 GAGAGGGGAATCAACACCTTCAGTATCTTCGCTTGAGAACCCCAACAGTATGAA 368
DB 207 GAGGCTTGCACTCGAACCCCTTGATGATCCTGCTCTCCCTTACAAAGCCCTGTGCCA 148
QY 369 AAGGCAAAATGATAGGATCTGAA 392
DB 147 GAGCAAGCAGGATTACTGCAGAA 124
RESULT 133
AX262154/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
REFERENCE
AUTHORS
Williams,L.T., Escobedo,J., Innis,M.A., Garcia,P.D.,
Sudduth-Klinger,J., Reinhard,C., He,Z., Randazzo,F., Kennedy,G.C.,
Pot,D., Kassam,A., Lamson,G., Drmanac,R., Crkvenjakov,R.,
Dickson,M., Drmanac,S., Labat,I., Leshkowitz,D., Kita,D.,
Garcia,V., Jones,L.W. and Stache-Crain,B.
JOURNAL
Patent: WO 0172781-A 234 04-OCT-2001;
Chiron Corporation (US); Hyseq Inc. (US)
FEATURES
source
1..380
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.8; DB 1; Length 380;
Best Local Similarity 44.3%; Pred. No. 1.5e+02;
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
QY 3129 ATCTTTCTCAAGTTTGAATGGTAGTAACTCACTTATCTTTATTTTGTAAATTA 3188
DB 259 AGCTCTGCAAGAGAAATATCATAGTCATGTCGATGGTGTGTTTATTTTCAAGCAATT 200
QY 3189 GCTCTTTAAATTCATATCTTTTGATACAGCTTCAGTTCATGCTTTTAAATAGTTT 3248
DB 199 ATTCTCCGAGACCCCGTTCATTTTCGAAGGTTTATTTGTTACTCCAAAGGAAGCAGTC 140
3249 TTTTCTTTTCTTTTAAAGAAATGTCATCTTTGTGAAGTTTTCACAAATGCTTTGAGCA 3308
RESULT 135
SHPFIXA/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
SHPFIXA
Sheep factor IX mRNA, partial cds.
M26233
M26233.1 GI:165878
factor IX.
factor IX.
Ovis aries (sheep)
Ovis aries
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
REFERENCE
AUTHORS
Sarker,G., Koeberl,D.D. and Sommer,S.S.
TITLE
Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL
Genomics 6 (1), 133-143 (1990)
MEDLINE
90152675
PUBMED
2303254
```

```
DB 139 CATCTGGCAGGGTCTTATATATGTTGTAAACAGTGAGCAGCACTCACAAGCCATGTGGCA 80
QY 3309 ATAATTTAGGAT 3320
DB 79 TTAATTAAGGTT 68
RESULT 134
AX262150/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
REFERENCE
AUTHORS
Williams,L.T., Escobedo,J., Innis,M.A., Garcia,P.D.,
Sudduth-Klinger,J., Reinhard,C., He,Z., Randazzo,F., Kennedy,G.C.,
Pot,D., Kassam,A., Lamson,G., Drmanac,R., Crkvenjakov,R.,
Dickson,M., Drmanac,S., Labat,I., Leshkowitz,D., Kita,D.,
Garcia,V., Jones,L.W. and Stache-Crain,B.
JOURNAL
Patent: WO 0172781-A 230 04-OCT-2001;
Chiron Corporation (US); Hyseq Inc. (US)
FEATURES
source
1..400
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.8; DB 1; Length 400;
Best Local Similarity 44.3%; Pred. No. 1.5e+02;
Matches 85; Conservative 0; Mismatches 107; Indels 0; Gaps 0;
QY 3129 ATCTTTCTCAAGTTTGAATGGTAGTAACTCACTTATCTTTATTTTGTAAATTA 3188
DB 276 AGCTCTGCAAGAGAAATATCATAGTCATGTCGATGGTGTGTTTATTTTCAAGCAATT 217
QY 3189 GCTCTTTAAATTCATATCTTTTGATACAGCTTCAGTTCATGCTTTTAAATAGTTT 3248
DB 216 ATTCTCCGAGACCCCGTTCATTTTCGAAGGTTTATTTGTTACTCCAAAGGAAGCAGTC 157
3249 TTTTCTTTTCTTTTAAAGAAATGTCATCTTTGTGAAGTTTTCACAAATGCTTTGAGCA 3308
DB 156 CATCTGGCAGGGTCTTATATATGTTGTAAACAGTGAGCAGCACTCACAAGCCATGTGGCA 97
QY 3309 ATAATTTAGGAT 3320
DB 96 TTAATTAAGGTT 85
RESULT 135
SHPFIXA/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
SHPFIXA
Sheep factor IX mRNA, partial cds.
M26233
M26233.1 GI:165878
factor IX.
factor IX.
Ovis aries (sheep)
Ovis aries
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
REFERENCE
AUTHORS
Sarker,G., Koeberl,D.D. and Sommer,S.S.
TITLE
Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL
Genomics 6 (1), 133-143 (1990)
MEDLINE
90152675
PUBMED
2303254
```

```
COMMENT      Original source text: Sheep liver, cDNA to mRNA.
              Draft entry and computer-readable sequence for [1] kindly provided
              by G.Sarkar, 18-JUL-1989.
FEATURES     Location/Qualifiers
             1..823
             /organism="Ovis aries"
             /mol_type="mRNA"
             /db_xref="taxon:9940"
             <1..>823
             /note="Factor IX"
             /codon_start=1
             /protein_id="AAA31520.1"
             /db_xref="GI:552419"
             /translation="RASVLTHTSKLTRAETIFSNVNSSEAEIWDNVTQSNQSPD
DNFVVGGEAARQGPQWVLLHGEIAFCGGSIVNEKVVYTAHCITKPGVKITVVG
EHNTEKPEPTQKRNVRAPYHGYNASINKYSHDIALBELDFPLELNSVYPTICAD
REYNTIFLFGYGVSGVNRFRSALIQYLKPLVDRAICLRSTKRTIYNHMP
AGYHEGKDKSQCGSGPHVTEVEGTSLTGLIISWGECAKMGYGIYTKVSRYEY"
             Query Match      0.6%; Score 20.8; DB 1; Length 823;
             Best Local Similarity 57.8%; Pred. No. 1.7e+02;
             Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 1048 CAAGACTAATAGAGTTTGGCAGAAATGCATGTCATAGCAACACCTCTTCCAA 1107
      |||
Db 223 CACAGATGCACCAATTTCCATGCACAAAGGACCTGCCAAGGATTCACCTCTGCAG 164
      |||

QY 1108 CAAC 1111
      |||
Db 163 CATC 160

RESULT 136
AF011898/c
LOCUS      AF011898      860 bp      mRNA      linear      VRT 09-SEP-1997
DEFINITION Petromyzon marinus trypsinogen a2 (TRYPA2) mRNA, complete cds.
ACCESSION AF011898
VERSION    AF011898.1 GI:2367494
KEYWORDS   SOURCE
SOURCE     Petromyzon marinus (sea lamprey)
           Petromyzon marinus
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
           Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE  1 (bases 1 to 860)
            Roach,J.C.
            The Molecular Evolution of the Vertebrate Trypsinogens
            Unpublished
REFERENCE  2 (bases 1 to 860)
            Roach,J.C.
            Direct Submission
            Submitted (01-JUL-1997) Molecular Biotechnology, University of
            Washington, Seattle, WA 98195, USA
FEATURES   Location/Qualifiers
             1..860
             /organism="Petromyzon marinus"
             /mol_type="mRNA"
             /db_xref="taxon:7757"
             /dev_stage="amocoete"
             /tissue_lib="anterior intestine"
             1..860
             /gene="TRYPA2"
             6..749
             /gene="TRYPA2"
             /codon_start=1
             /product="trypsinogen a2"
             /protein_id="AAB69654.1"
             /db_xref="GI:2367495"
             /translation="MHGILALLVGVAAAPMYEDHIVGSECAHSPQWVSLNIG
YHFCGSLNSCWVSAHCYQTSARLSVRIGNEITQEQIOASKAIQHPQVY
SWTINDIMLKLKSPATLNQYAAIALPSSCVNTGYMCTISGNETQTSGISPDILM
CQAPVLDSTSCRNSYPGDITNNMICLGLIEGKDKSCQSGSGPVCNGLQGLVSWG
RGCALPNYPGYTKVYNWIAQTIAAN"
             sig_peptide      6..50

mat_peptide      /gene="TRYPA2"
                  /evidence=not_experimental
                  51..746
                  /gene="TRYPA2"
                  /product="trypsin a2"

Query Match      0.6%; Score 20.8; DB 1; Length 860;
Best Local Similarity 47.1%; Pred. No. 1.7e+02;
Matches 64; Conservative 0; Mismatches 72; Indels 0; Gaps 0;

QY 2587 CTGAAAAACCCGTGATGCTGGAGGAGATTGGGGCAGGAGGAGGAGGAGGAGGAGG 2646
      |||
Db 520 CAGGAGGTGCTGCATCAGCACGGCGGCTGCAGCACATGAGGACGCTGCCGATG 461
      |||

QY 2647 ATGAGATGCTGGATGGCATCTACTGACTGATGAGGAGCTGAGTGGTGAACCTCCTGGAG 2706
      |||
Db 460 CTGCTCTGGTCTCGCCCGGAGATGTTGCATCATCTCCGCTGTTGAGGAGGAG 401
      |||

QY 2707 TTGGTCATGACAGGG 2722
      |||
Db 400 GAGGGCAGCGCATGG 385

RESULT 137
HUMPRC7/c
LOCUS      HUMPRC7      1259 bp      DNA      linear      PRI 08-JAN-1995
DEFINITION Human protein C gene, exon 9 of 9.
ACCESSION M12712
VERSION    M12712.1 GI:190330
KEYWORDS   glycoprotein; protease; protein C; serine protease.
SEGMENT    7 of 7
SOURCE     Homo sapiens (human)
           Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1259)
            Plutsky,J., Hoskins,J.A., Long,G.L. and Crabtree,G.R.
            Evolution and organization of the human protein C gene
            Proc. Natl. Acad. Sci. U.S.A. 83 (3), 546-550 (1986)
            86120978
            PUBMED
            3511471
COMMENT     Original source text: Human liver, DNA clones lambda-pc4,
            lambda-pc14 and lambda-pc17.
FEATURES   Location/Qualifiers
             1..1259
             /organism="Homo sapiens"
             /mol_type="genomic DNA"
             /db_xref="taxon:9606"
             /map="2q13-q21"
             join(M12682.1:198..300,M12683.1:1..430,M12684.1:1..710,
M12685.1:1..733,M12686.1:1..411,M12687.1:1..1190,1..797)
             /gene="PROC"
             join(M12683.1:106..175,M12684.1:354..520,M12685.1:58..82,
M12685.1:1174..311,M12685.1:414..548,M12686.1:45..187,
M12687.1:397..514,205..797)
             /gene="PROC"
             /note="Protein C"
             /codon_start=1
             /protein_id="AAA60165.1"
             /db_xref="GI:190332"
             /translation="MWQLTSLLLFVATWGISCTPAPLDSVFSSSRAHQVLRIRKAN
SFLELRHSLRECIETEDFEAKEIFQNVDDTLAFWSKHVDGQCLVLPLEHPCA
SLCCGHTCIDIGISPCDCRSRGWRPCOREVSFLNCSLDNGGCTHYCLEVGNWRC
SCAPGYKLGDDLLQHPVFCGPRWMEKRSKLEDTEDDQDQVDPRLDQKVT
RKGDSFWQVLLDSKKKACGAVLIHPSWLTAHCNDSKLLVRLGYDRLREKW
ELDLTIKEVFPHPNSKSTNDIALLAHQATISQTIPTICLPDPSGLAEELNQAG
QETLVGWGYSREKAKRNRTFVLFIKIETVPHNECSYVMSNMVSEMLCAGILG
DRQDACEGSGGPMVASFHTWFLVGLVSGGCGLLHNYGVYTKVSRVLDWLHGI
RKEAPKQKSWAP"
             prim_transcript <1..>1093
             intron          <1..>204
             /gene="PROC"
```

```

exon
    /note="Proc intron H"
    205...>797
    /gene="PROC"
    /note="Protein C; G00-120-317"
    /number=9

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1259;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 453 CTCGGAAGAATGAAGATGAGCCCAAGCAAAAGAAATACCCAGTGTGGATGTGAC 512
    |||||
    916 CTCGAGAAGCCCAAGAGGATGGAAGGACAGACAGAGCGCGGTGTGTGTAC 857

QY 513 TGGT 516
    ||
    856 ATGT 853

RESULT 138
AX211659 1338 bp DNA linear PAT 06-SEP-2001
DEFINITION Sequence 2 from Patent WO0158935.
ACCESSION AX211659
VERSION AX211659.1 GI:15523891
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
    1
    AUTHORS Andersen,K.V., Pedersen,A.H. and born S.C.
    TITLE Factor vii or viia-like molecules
    JOURNAL Patent: WO 0158935-A 2 16-AUG-2001;
    Maxygen Aps (DK)
FEATURES
    source
        Location/Qualifiers
            1..1338
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
            <115..1335
            /note="unnamed protein product"
            /codon_start=1
            /protein_id="CAC69301.1"
            /db_xref="GI:15523892"
            /translation="ANAFLEELRFGSLERCKEKCQSFEEAREIFKDAERTKLPWISY
            SDGDCASPCQNGSKDQLQSYICFLPAFEGNCEETHKDDOLICVNENGCEQYVC
            SDHTKRSRCRCHGYSLADGVSCTPTVEYPCGKIPILEKRNASKPQGVIGVKVCP
            KGCEPQVLLVNGAQLCGTTLINTIWWVSAHCFDKIKWRNLIIVLGEHDLSEHDG
            DEQSRVAVQIIPSTYVPGTTHDIALRLHQPVLTDHVPLCLPRTSEPTLAV
            RFLSVGQQLDRALALEMLVNLVPLMTQDCLQSKRVKGDSPNITETMFCAGYSD
            GSKSCKDSGGPHATHYRGTYLTIIVSWGQCATVGHFGVYTRVSQYIEWLQKLKMR
            SEPRGVLLRAPFP"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1338;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 1443 AGGATTCGAGACCATCCCGCAAGAAAGAAATGCAAAAGCAAAATGGCTGTCTGGGA 1502
    |||||
    132 AGAGCTCCGCCCTGCTCCCTGGAACCGAATGCAAGAGGACAGTGCAGCTTGAGGA 191

QY 1503 GGCC 1506
    |||
    192 AGCC 195

RESULT 139
AX211661 1357 bp DNA linear PAT 06-SEP-2001
DEFINITION Sequence 4 from Patent WO0158935.
ACCESSION AX211661
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
    1
    AUTHORS Andersen,K.V., Pedersen,A.H. and born S.C.
    TITLE Factor vii or viia-like molecules
    JOURNAL Patent: WO 0158935-A 2 16-AUG-2001;
    Maxygen Aps (DK)
FEATURES
    source
        Location/Qualifiers
            1..1338
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
            <115..1335
            /note="unnamed protein product"
            /codon_start=1
            /protein_id="CAC69301.1"
            /db_xref="GI:15523892"
            /translation="ANAFLEELRFGSLERCKEKCQSFEEAREIFKDAERTKLPWISY
            SDGDCASPCQNGSKDQLQSYICFLPAFEGNCEETHKDDOLICVNENGCEQYVC
            SDHTKRSRCRCHGYSLADGVSCTPTVEYPCGKIPILEKRNASKPQGVIGVKVCP
            KGCEPQVLLVNGAQLCGTTLINTIWWVSAHCFDKIKWRNLIIVLGEHDLSEHDG
            DEQSRVAVQIIPSTYVPGTTHDIALRLHQPVLTDHVPLCLPRTSEPTLAV
            RFLSVGQQLDRALALEMLVNLVPLMTQDCLQSKRVKGDSPNITETMFCAGYSD
            GSKSCKDSGGPHATHYRGTYLTIIVSWGQCATVGHFGVYTRVSQYIEWLQKLKMR
            SEPRGVLLRAPFP"

Query Match
Best Local Similarity 0.6%; Score 20.8; DB 1; Length 1357;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 1443 AGGATTCGAGACCATCCCGCAAGAAAGAAATGCAAAAGCAAAATGGCTGTCTGGGA 1502
    |||||
    145 AGAGCTCCGCCCTGCTCCCTGGAACCGAATGCAAGAGGACAGTGCAGCTTGAGGA 204

QY 1503 GGCC 1506
    |||
    205 AGCC 208

RESULT 140
HUMPRC Human protein C, mRNA.
LOCUS K02059 1366 bp mRNA linear PRI 08-JAN-1995
DEFINITION Human protein C, mRNA.
ACCESSION K02059.1 GI:190322
VERSION K02059.1
KEYWORDS glycoprotein; protease; protein C; serine protease.
SOURCE Homo sapiens
ORGANISM
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
    1 (bases 1 to 1366)
    FOSTER,D. and DAVIE,E.W.
    TITLE Characterization of a cDNA coding for human protein C
    JOURNAL Proc. Natl. Acad. Sci. U.S.A. 81 (15), 4766-4770 (1984)
    MEDLINE 84272714
    PUBMED 6589523
    COMMENT
        Original source text: Human liver, cDNA (library of Woo) to mRNA,
        clones lambda-HC1026 and lambda-HC1375.
        Protein C is a precursor to a serine protease called 'activated
        protein C' that has a strong anticoagulant activity. The amino acid
        sequence as determined from the cDNA indicates that protein C is
        synthesized as a single-chain polypeptide containing the light
        chain and the heavy chain connected by a dipeptide of Lys-Arg. This
        precursor peptide is then converted to the light and heavy chains
        by cleavage of two or more internal peptide bonds. The amino acid
        sequence of human protein C shows a high homology with that of the
        bovine molecule. Two clones were sequenced in [1] and shown to
        code for human protein C. Clone lambda-HC1026 covers bp 146-1140,
        and clone lambda-HC1375 covers bp 1-1366. The two cDNA clones had
        a poly-A tail at different positions; both poly-A sites were
        preceded by poly-A signals [1].
FEATURES
    source
        Location/Qualifiers
            1..1366
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /map="2q13-q21"
            /tissue type="liver"
            /tissue lib="of Woo"
            1..1366
            /gene="PROC"
    gene
```



```
mRNA
<1..1366
/gene="PROC"
/note="G00-120-317"
<1..1140
/gene="PROC"
/note="G00-120-317"
<1..1073
/gene="PROC"
/codon_start=2
/product="protein C"
/protein_id="AAA60164.1"
/db_xref="GI:190323"
/db_xref="GDB:G00-120-317"
/translation="QGHTCTDGTGSPSCDSCRSWGGRFCQREVSFLNCSLDNGGCTH
YCLEVGRRCSCAPGYKLGDLLOCHPAVKPCGPRPKMKRSHLXRDTEQEDQ
VDPRLDGKTRRSDSPQVLLDSKKLAGAVLIIPSPVITAAHCDMSKLLVRL
GEYDLRWEKWELELDKEVHPNYSKSTDDIALHLAQATLSQTIPICLPDS
GLARELNQAGQTLVTGWGSHREKRNRTFVLNFKIPVPHNECSYMSNV
SENLKAGILGDRQACEGDSGPGMVASFHGTWFLVGLVSGEGCLLHNYGVYTKVS
RYLDWIGHIRDKAPQKSWAP"
mat_peptide
<1..277
/gene="PROC"
/product="protein C light chain"
/note="G00-120-317"
284..1069
/gene="PROC"
/product="protein C heavy chain"
/note="G00-120-317"
320..1069
/gene="PROC"
/product="protein C activated heavy chain"
/note="G00-120-317"
Query Match 0.6%; Score 20.8; DB 1; Length 1366;
Best Local Similarity 57.8%; Pred. No. 1.9e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
Qy 453 CTCAGAAGAATGAAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
|||||
Db 1191 CTCAGAAGAGCCCAAGAGGATGGAGGACAGACAGCAGGCGCGTGTGCTTTGTAC 1132
Qy 513 TGGT 516
Db 1131 ATGT 1128
RESULT 141
AR363767/c AR363767 1755 bp DNA linear PAT 03-SEP-2003
LOCUS
DEFINITION Sequence 1 from patent US 5225537.
ACCESSION AR363767
VERSION AR363767.1 GI:34425772
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Foster,D.C.
AUTHORS Methods for producing hybrid phospholipid-binding proteins
JOURNAL Patent: US 5225537-A 1 06-JUL-1993;
FEATURES Location/Qualifiers
source 1..1755
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 20.8; DB 1; Length 1755;
Best Local Similarity 57.8%; Pred. No. 1.9e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
Qy 453 CTCAGAAGAATGAAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
Db 1574 CTCAGAAGAGCCCAAGAGGATGGAGGACAGACAGCAGGCGCGTGTGCTTTGTAC 1515
mRNA
<1..1366
/gene="PROC"
/note="G00-120-317"
<1..1140
/gene="PROC"
/note="G00-120-317"
<1..1073
/gene="PROC"
/codon_start=2
/product="protein C"
/protein_id="AAA60164.1"
/db_xref="GI:190323"
/db_xref="GDB:G00-120-317"
/translation="QGHTCTDGTGSPSCDSCRSWGGRFCQREVSFLNCSLDNGGCTH
YCLEVGRRCSCAPGYKLGDLLOCHPAVKPCGPRPKMKRSHLXRDTEQEDQ
VDPRLDGKTRRSDSPQVLLDSKKLAGAVLIIPSPVITAAHCDMSKLLVRL
GEYDLRWEKWELELDKEVHPNYSKSTDDIALHLAQATLSQTIPICLPDS
GLARELNQAGQTLVTGWGSHREKRNRTFVLNFKIPVPHNECSYMSNV
SENLKAGILGDRQACEGDSGPGMVASFHGTWFLVGLVSGEGCLLHNYGVYTKVS
RYLDWIGHIRDKAPQKSWAP"
mat_peptide
<1..277
/gene="PROC"
/product="protein C light chain"
/note="G00-120-317"
284..1069
/gene="PROC"
/product="protein C heavy chain"
/note="G00-120-317"
320..1069
/gene="PROC"
/product="protein C activated heavy chain"
/note="G00-120-317"
Query Match 0.6%; Score 20.8; DB 1; Length 1366;
Best Local Similarity 57.8%; Pred. No. 1.9e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
Qy 453 CTCAGAAGAATGAAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
Db 1191 CTCAGAAGAGCCCAAGAGGATGGAGGACAGACAGCAGGCGCGTGTGCTTTGTAC 1132
Qy 513 TGGT 516
Db 1131 ATGT 1128
RESULT 141
AR363767/c AR363767 1755 bp DNA linear PAT 03-SEP-2003
LOCUS
DEFINITION Sequence 1 from patent US 5225537.
ACCESSION AR363767
VERSION AR363767.1 GI:34425772
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Foster,D.C.
AUTHORS Methods for producing hybrid phospholipid-binding proteins
JOURNAL Patent: US 5225537-A 1 06-JUL-1993;
FEATURES Location/Qualifiers
source 1..1755
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 20.8; DB 1; Length 1755;
Best Local Similarity 57.8%; Pred. No. 1.9e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
Qy 453 CTCAGAAGAATGAAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
Db 1574 CTCAGAAGAGCCCAAGAGGATGGAGGACAGACAGCAGGCGCGTGTGCTTTGTAC 1515
```

```
Qy 513 TGGT 516
Db 1514 ATGT 1511
RESULT 142
105477/c 105477 1756 bp DNA linear PAT 02-DEC-1994
LOCUS
DEFINITION Sequence 12 from Patent EP 0266190.
ACCESSION 105477
VERSION 105477.1 GI:591031
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Foster,D.C., Murray,M.J. and Berkner,K.L.
AUTHORS Expression of protein C
TITLE Patent: EP 0266190-A2 12 04-MAY-1988;
JOURNAL Location/Qualifiers
FEATURES
source 1..1756
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 20.8; DB 1; Length 1756;
Best Local Similarity 57.8%; Pred. No. 1.9e+02;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
Qy 453 CTCAGAAGAATGAAGATGGAGCCCAAGCAAAAGAAATACCCAGCTGTGGATGTGAC 512
Db 1575 CTCAGAAGAGCCCAAGAGGATGGAGGACAGACAGCAGGCGCGTGTGCTTTGTAC 1516
Qy 513 TGGT 516
Db 1515 ATGT 1512
RESULT 143
AX886683/c AX886683 228 bp DNA linear PAT 18-DEC-2003
LOCUS
DEFINITION Sequence 2546 from Patent EP1033401.
ACCESSION AX886683
VERSION AX886683.1 GI:40044089
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
AUTHORS Expressed sequence tags and encoded human proteins
TITLE Patent: EP 1033401-A 2546 06-SEP-2000;
JOURNAL Genset (FR)
FEATURES Location/Qualifiers
source 1..228
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
44..>226
/note="unnamed protein product"
/codon_start=1
/protein_id="CAF00821.1"
/db_xref="GI:40044090"
/translation="MLVHCHPSAXCQDVHSLTSLWIPXFAXXXRXXSDLYLSNVSL
SXDFEXALALXPFQSV"
CDS
Query Match 0.6%; Score 20.6; DB 1; Length 228;
Best Local Similarity 47.8%; Pred. No. 1.5e+02;
Matches 33; Conservative 8; Mismatches 28; Indels 0; Gaps 0;
Qy 773 CAGTACTTGGATGCAGTCTCAAAAACGACAGATGATCTCTGTTCTTCCAGGCAAC 832
Db 188 CAAATCTTKAGACATGACATTTTGTATAGATACAGATCTGAGMWTTCCTWAKKAAG 129
```



```

Db      819 ATGTTAAACACCTTGATTAAACAGCATGGCGCTTAATCAATC 777
LOCUS   867 bp      mRNA      linear      VRT 23-JAN-1995
DEFINITION   G.morhua mRNA for prechymotrypsinogen.
ACCESSION   X78490
VERSION     X78490.1 GI:468750
KEYWORDS    chymotrypsin; prechymotrypsinogen.
SOURCE      Gadus morhua
ORGANISM    Gadus morhua
REFERENCE   1 (bases 1 to 867)
AUTHORS    Bjarnason,J.B.
TITLE      Atlantic cod cDNA encoding a psychrophilic chymotrypsinogen
JOURNAL    Biochim. Biophys. Acta 1219 (1), 211-214 (1994)
MEDLINE    94368860
PUBMED     8086467
REFERENCE   2 (bases 1 to 867)
AUTHORS    Gudmundsdottir,A., Oskarsson,S., Ekin,A.E., Craik,C.S. and Bjarnason,J.B.
TITLE      Atlantic cod cDNA encoding a psychrophilic chymotrypsinogen
JOURNAL    Submitted (24-MAR-1994) A. Gudmundsdottir, Science Institute, University of Iceland, Dunhagi 3, IS-107 Reykjavik, ICELAND
FEATURES    Location/Qualifiers
             source
               1..867
               /organism="Gadus morhua"
               /mol_type="mRNA"
               /db_xref="taxon:8049"
               /tissue_type="pyloric caeca"
               /clone_lib="lambda UNI-ZAP XR"
               1..18
               /EC_number="3.4.21.1"
               /note="prechymotrypsinogen"
               /codon_start=1
               /product="chymotrypsin"
               /protein_id="CAA55242.1"
               /db_xref="GI:468751"
               /db_xref="GOA:P47796"
               /db_xref="SWISS-PROT:P47796"
               /translation="MGHEVDSVLPGLFRRTYCGRPAISPVITYSRVINGEERAVPHS
               WSOVSLQDQTFHF CGSLINENWVTAARKNYHRVVLGHEHRSNSSEGVQVMT
               VGOVFKHPRYNGFTINNDLLVLKATPATLNMVSPVLAETDDVDFEGMKCVTSGMG
               LTRNAADPTALLQALPLLTNEQCKFWGNKI SLMICAGAAGASSCMGDSGGPLV
               CQKAGSWTLGVISWGSCTCTPTWEGVYARVTELRAWVDQTIAAN"
               34..791
               /product="chymotrypsin"
               /note="prechymotrypsinogen"
               /EC_number="3.4.21.1"

mat_peptide
Query Match      0.6%; Score 20.6; DB 1; Length 867;
Best Local Similarity 48.0%; Pred. No. 1.9e+02;
Matches 59; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 2374 GGAATGTGAGAGTGGACTGTGAGAAAGCTGAGCACTCAAGAATGTGCTTTTGAACGTG 2433
DB 46 GCACGTATGGCTGTGGCGTGCAGGCATCTCCAGTAATCACTGGTTACTCCCGTATTG 105
QY 2434 TGGTGTGGAGAGACTCTTGAGACTCCCTGGACTGCAAGAGATCCAAACGATCCATT 2493
DB 106 TCAACGGAGAGGAGGAGCTGTCCCACTCTCTGTCGTGGCAGGATGTCCTCGAGGACCAAA 165
QY 2494 CTG 2496
DB 166 CTG 168

RESULT 148
AF191307/c

LOCUS   1514 bp      mRNA      linear      MAM 01-NOV-2000
DEFINITION   Sus scrofa protein C mRNA, complete cds.
ACCESSION   AF191307
VERSION     AF191307.1 GI:11065893
KEYWORDS    Sus scrofa (pig)
ORGANISM    Sus scrofa
REFERENCE   1 (bases 1 to 1514)
AUTHORS    Grimm,D.R., Colter,M.B. and Kim,H.
TITLE      Cloning of the complete cDNA sequences encoding porcine factor V
JOURNAL    and protein C
REFERENCE   2 (bases 1 to 1514)
AUTHORS    Grimm,D.R., Colter,M.B. and Kim,H.
TITLE      Direct Submission
JOURNAL    Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
           North Pine Drive, Tampa, FL 33612, USA
FEATURES    Location/Qualifiers
             source
               1..1514
               /organism="Sus scrofa"
               /mol_type="mRNA"
               /db_xref="taxon:9823"
               /clone="92N.4; 58/86.2; 12N3.1"
               /tissue_type="liver"
               22..1401
               /note="serine protease"
               /codon_start=1
               /product="protein C"
               /protein_id="AAG28380.1"
               /db_xref="GI:11065894"
               /translation="KMQLASLLLLIIWAVSTPVPDPDVFSSSORAHQMLRSKRANS
               FLELRPSSLERECKEETCDFEAREIFQNTENTMAFSKYHDGQCAVSPPEHLCD
               PCGRGTCDGLGFRCDCAQGWGRFCLHEVRFNGSTENGCGCAHYCLEEGGRRCA
               CAGVELGDHLCQEPKVRSPCGRGNRMEKKRNLKRDITDQVDKEDDIDRLVNGK
               QSPWGESPWQVILLDSKKLACGAVLIHVSWLTAHCLDDYKCLTVRLGEYDLRRE
               KMEVDLDIKFVLHENTRSTSDNALRLAEPAETFSQTIIVPICLPDGLSERELTR
               VQGETVVTGWYRSEAKTRSFILNFKVPVAPHNECVQAMHNKISENMLCAGILGDS
               RDACGDSGSPVASFRTGTFWLVGLVSWGEGGRLHNYGVYTKVSKYLDWIHGRME
               EAFHKQNP"

QY 3109 CTTTGTATTATTGGTCTCTATCTTTCTCAAGTT 3143
DB 660 CCTCGGATCTATTGGTCTCTTTTGTCAACTT 626

Query Match      0.6%; Score 20.6; DB 1; Length 1514;
Best Local Similarity 74.3%; Pred. No. 2.1e+02;
Matches 28; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 3109 CTTTGTATTATTGGTCTCTATCTTTCTCAAGTT 3143
DB 660 CCTCGGATCTATTGGTCTCTTTTGTCAACTT 626

RESULT 149
AR390799
LOCUS   1843 bp      DNA      linear      PAT 18-DEC-2003
DEFINITION   Sequence 49 from patent US 6610906.
ACCESSION   AR390799
VERSION     AR390799.1 GI:40113146
KEYWORDS    Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 1843)
AUTHORS    Kurachi,K. and Kurachi,S.
TITLE      Nucleotide sequences for gene regulation and methods of use thereof
JOURNAL    Patent: US 6610906-A 49 26-AUG-2003;
           Location/Qualifiers
             source
               1..1843
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 20.6; DB 1; Length 1843;
Best Local Similarity 59.3%; Pred. No. 2.1e+02;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

```

QY 1507 TTACAAATAGCTGTGAAAGAGAGAGAGCTGAAAGCAAGCAAGGAAAAAGGAAAGATATAA 1565  
 Db 1748 TTATGAAAAGAGATATAAAGCAACACCAAGCAAGGAAAAAGGAAAGATATAA 1806  
 RESULT 150  
 AX411026 1843 bp DNA linear PAT 14-JUN-2002  
 LOCUS Sequence 3673 from Patent WO0229103.  
 DEFINITION AX411026  
 ACCESSION AX411026 GI:21443731  
 VERSION  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE  
 1  
 ALVARES, C., HORNE, D., PERES-DA-SILVA, S. and VOCKLEY, J. G.  
 TITLE Gene expression profiles in liver cancer  
 JOURNAL Patent: WO 0229103-A 3673 11-APR-2002;  
 GENE LOGIC INC (US)  
 FEATURES  
 source  
 1..1843  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 /note="EMBL/GenBank Accession No. X02750"  
 Query Match 0.6%; Score 20.6; DB 1; Length 1843;  
 Best Local Similarity 59.3%; Pred. No. 2.1e+02;  
 Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
 QY 1507 TTACAAATAGCTGTGAAAGAGAGAGAGCTGAAAGCAAGCAAGGAAAAAGGAAAGATATAA 1565  
 Db 1748 TTATGAAAAGAGATATAAAGCAACACCAAGCAAGGAAAAAGGAAAGATATAA 1806  
 RESULT 151  
 HSPROT C 1843 bp mRNA linear PRI 05-APR-1995  
 LOCUS Human liver mRNA for protein C.  
 DEFINITION X02750  
 ACCESSION X02750  
 VERSION X02750.1 GI:35689  
 KEYWORDS protein C; signal peptide.  
 SOURCE Homo sapiens (human)  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE  
 1 (bases 1 to 1843)  
 BECKMANN, R. J., SCHMIDT, R. J., SANTERRE, R. F., PLUTZKY, J.,  
 CRABTREE, G. R. and LONG, G. L.  
 TITLE The structure and evolution of a 461 amino acid human protein C  
 precursor and its messenger RNA, based upon the DNA sequence of  
 cloned human liver cDNAs  
 JOURNAL Nucleic Acids Res. 13 (14), 5233-5247 (1985)  
 MEDLINE  
 PUBMED 85269639  
 COMMENT Data kindly reviewed (27-MAR-1986) by G. Long.  
 FEATURES  
 source  
 1..1843  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 98..1483  
 /note="unnamed protein product; protein C precursor"  
 /codon\_start=1  
 /protein\_id="CAA26528.1"  
 /db\_xref="GI:763120"  
 /db\_xref="GOA:P04070"  
 /db\_xref="SWISS-PROT:P04070"  
 /translation="MWLTSLILFVATWGISGTPALDVSFSSSERAHQVLRKPRAN  
 SFLELRSSUERECEICDFEAKEIFQNVDDTLAFWSKHVDQDQCLVLPHEPCA

SLCCGHTCTDGTGSGCDRCWEGRCFCOREVSNFLNSLDNGGCTHYCLEBVGWRRRC  
 SCAPGYKLGDLLQCHPAVKFPCGRPWKEMKKRSHLKEDTDOQSDQVDPRLIDGKMT  
 RGDSPWQVLLDSKKKACGAVLHPSWILTAACHMDESKLLVRLGEYDLRRWEKW  
 ELDLDIKFVHPNYSKSTDDNDIALHLAQATLSQTIPICLDPSGLAEELNQAG  
 QETLVGWGYSRSREKAKRNTFVLNFIKIPVPHNECEYMSNVNSENMLCAGILG  
 DRQDACEGSDSGPMVASFHGTWFLVGLVSGEGCGLLHNYGYTYKSYRLDIHGHIR  
 DKEAPOKSWAP"  
 98..196  
 /note="signal peptide (aa -42 to -10)"  
 197..223  
 /note="propeptide (aa -9 to -1)"  
 224..688  
 /note="light chain (aa 1-155)"  
 224..358  
 /note="gamma carboxylation domain (aa 1-45)"  
 359..496  
 /note="EGF-domain I (aa 46-91)"  
 497..634  
 /note="EGF-domain II (aa 92-137)"  
 635..730  
 /note="activation peptide region (aa 144-169)"  
 695..1531  
 /note="heavy chain (aa 57-419)"  
 731..1531  
 /note="serine protease region (aa 170-419)"  
 1759..1764  
 /note="polyA signal"  
 Query Match 0.6%; Score 20.6; DB 1; Length 1843;  
 Best Local Similarity 59.3%; Pred. No. 2.1e+02;  
 Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
 QY 1507 TTACAAATAGCTGTGAAAGAGAGAGAGCTGAAAGCAAGCAAGGAAAAAGGAAAGATATAA 1565  
 Db 1748 TTATGAAAAGAGATATAAAGCAACACCAAGCAAGGAAAAAGGAAAGATATAA 1806  
 RESULT 152  
 AX265021 121 bp DNA linear PAT 26-OCT-2001  
 LOCUS Sequence 2412 from Patent WO0173002.  
 DEFINITION AX265021  
 ACCESSION AX265021  
 VERSION AX265021.1 GI:16513820  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE  
 1  
 KNIEC, E. B., GAMPER, H. B. and RICE, M. C.  
 TITLE Targeted chromosomal genomic alterations with modified single  
 stranded oligonucleotides  
 JOURNAL Patent: WO 0173002-A 2412 04-OCT-2001;  
 UNIVERSITY OF DELAWARE (US)  
 FEATURES  
 Location/Qualifiers  
 source  
 1..121  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 Query Match 0.6%; Score 20.4; DB 1; Length 121;  
 Best Local Similarity 61.1%; Pred. No. 1.4e-02;  
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
 QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGCAACCATTCAC 838  
 Db 68 GAAGTTTGAAGAAACACTGAAAGACAGTGAAGTATTCACATATACCTTCA 121  
 RESULT 153  
 AX265022/c 121 bp DNA linear PAT 26-OCT-2001  
 LOCUS Sequence 2413 from Patent WO0173002.  
 DEFINITION

```
ACCESSION AX265022
VERSION AX265022.1 GI:16513821
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
           Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
        stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2413 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAACCAATTCA 838
Db 54 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 1

RESULT 154
AX265033
LOCUS AX265033 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2424 from Patent WO0173002.
ACCESSION AX265033
VERSION AX265033.1 GI:16513832
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
        stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2424 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAACCAATTCA 838
Db 54 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 1

RESULT 155
AX265034/c
LOCUS AX265034 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2425 from Patent WO0173002.
ACCESSION AX265034
VERSION AX265034.1 GI:16513833
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
        stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2425 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAACCAATTCA 838
Db 63 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 116

RESULT 157
AX265038/c
LOCUS AX265038 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2429 from Patent WO0173002.
ACCESSION AX265038
VERSION AX265038.1 GI:16513837
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
        stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2429 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAACCAATTCA 838
Db 63 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 116

TITLE Targeted chromosomal genomic alterations with modified single
        stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2425 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAACCAATTCA 838
Db 59 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 6

RESULT 156
AX265037
LOCUS AX265037 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2428 from Patent WO0173002.
ACCESSION AX265037
VERSION AX265037.1 GI:16513836
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
        stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2428 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source
Query Match 0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTGTTTCCAAAGGCAACCAATTCA 838
Db 59 GAAGTTTGTGAAACACTGAAAGACAGTGAAGTATTTCCACATAATACCCCTTCA 6
```

```
Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGAAATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 59 GAAGTTTTTGAAACACTGAAGACAGTGAGTATTTCCACATATACCTTC A 6

RESULT 158
AX265041
LOCUS AX265041 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2432 from Patent WO0173002.
ACCESSION AX265041
VERSION AX265041.1 GI:16513840
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2432 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGAAATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 64 GAAGTTTTTGAAACACTGAAGACAGTGAGTATTTCCACATATACCTTC A 117

RESULT 159
AX265042/c
LOCUS AX265042 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2433 from Patent WO0173002.
ACCESSION AX265042
VERSION AX265042.1 GI:16513841
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2433 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGAAATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 64 GAAGTTTTTGAAACACTGAAGACAGTGAGTATTTCCACATATACCTTC A 117

RESULT 160
AX265045
LOCUS AX265045 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2436 from Patent WO0173002.
ACCESSION AX265045
VERSION AX265045.1 GI:16513844
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2436 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGAAATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 61 GAAGTTTTTGAAACACTGAAGACAGTGAGTATTTCCACATATACCTTC A 114

RESULT 161
AX265046/c
LOCUS AX265046 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2437 from Patent WO0173002.
ACCESSION AX265046
VERSION AX265046.1 GI:16513845
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2437 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 121;
Best Local Similarity 61.1%; Pred. No. 1.4e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGAAATGATCTCTGTTGTTTCCAAAGGCAAAACCATTC A 838
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 61 GAAGTTTTTGAAACACTGAAGACAGTGAGTATTTCCACATATACCTTC A 114

RESULT 162
AX265049
LOCUS AX265049 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2440 from Patent WO0173002.
ACCESSION AX265049
VERSION AX265049.1 GI:16513848
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
```

ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 1 Kmiec.E.B., Camper.H.B. and Rice.M.C.  
 Targeted chromosomal genomic alterations with modified single  
 stranded oligonucleotides  
 JOURNAL Patent: WO 0173002-A 2440 04-OCT-2001;  
 UNIVERSITY OF DELAWARE (US)

FEATURES  
 source Location/Qualifiers  
 1..121  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 121;  
 Best Local Similarity 61.1%; Pred. No. 1.4e+02;  
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAACCATTC 838  
 DB 61 GAAGTTTTTGAACACTGAAAGACAGTGTGATTTCCACATAATACCTTCA 114

RESULT 163  
 AX265050/c  
 LOCUS 121 bp DNA linear PAT 26-OCT-2001  
 DEFINITION Sequence 2441 from Patent WO0173002.  
 ACCESSION AX265050  
 VERSION AX265050.1 GI:165113849  
 KEYWORDS Homo sapiens (human)  
 SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 1 Kmiec.E.B., Camper.H.B. and Rice.M.C.  
 Targeted chromosomal genomic alterations with modified single  
 stranded oligonucleotides  
 JOURNAL Patent: WO 0173002-A 2441 04-OCT-2001;  
 UNIVERSITY OF DELAWARE (US)

FEATURES  
 source Location/Qualifiers  
 1..121  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 121;  
 Best Local Similarity 61.1%; Pred. No. 1.4e+02;  
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 785 GCAGTCTCAAAACGACAGATGATCTCTGTTTGTTCACAGGCAACCATTC 838  
 DB 61 GAAGTTTTTGAACACTGAAAGACAGTGTGATTTCCACATAATACCTTCA 8

RESULT 164  
 AY254094/c  
 LOCUS 160 bp DNA linear PRI 28-MAY-2003  
 DEFINITION Homo sapiens nonfunctional trypsin 1 (PRSS1) gene, PRSS1-Y37X  
 allele, partial cds.  
 ACCESSION AY254094  
 VERSION AY254094.1 GI:31095598  
 KEYWORDS Homo sapiens (human)  
 SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 1 (bases 1 to 160)  
 Chen,J.M., Le Marechal,C., Lucas,D., Raguene,O., and Ferec,C.  
 'Loss of function' mutations in the cationic trypsinogen gene  
 (PRSS1) may act as a protective factor against pancreatitis  
 JOURNAL Mol. Genet. Metab. 79 (1), 67-70 (2003)

22651503  
 12765848  
 2 (bases 1 to 160)  
 Chen,J.-M., Le Marechal,C., Raguene,O. and Ferec,C.  
 Direct Submission  
 Submitted (11-MAR-2003) INSERM 0115, Universite de Bretagne  
 Occidentale, 46 rue Felix Le Dantec, Brest 29275, France

FEATURES  
 source Location/Qualifiers  
 1..160  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /chromosome="7"  
 /map="7q34"  
 <1..>160  
 /genes="PRSS1"  
 /allele="Y37X"  
 <1..>160  
 /gene="PRSS1"  
 /product="truncated trypsin 1"  
 1..160  
 /gene="PRSS1"  
 /number=2  
 <1..>71  
 /gene="PRSS1"  
 /EC\_number="3.4.21.4"  
 /note="ssrine protease 1; cationic trypsinogen; truncated  
 protein results from a mutation that creates a premature  
 stop codon"  
 /codon\_start=3  
 /product="nonfunctional trypsin 1"  
 /protein\_id="AAP42827.1"  
 /db\_xref="GI:31095599"  
 /translation="AAPFDDDDKIVGYNCENSVP"

Query Match 0.6%; Score 20.4; DB 1; Length 160;  
 Best Local Similarity 61.1%; Pred. No. 1.5e+02;  
 Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 921 CCCTTTAGACTAACACCCCAAGATGCTCTCTCATATAGGGACTGGAA 974  
 DB 54 CCTCACAGTTGTAGCCCCCAACGATCTTGTCATCATCAATCAAGGGGCGACAA 1

RESULT 165  
 AY307359/c  
 LOCUS 160 bp DNA linear PRI 25-JUN-2003  
 DEFINITION Homo sapiens cationic trypsinogen (PRSS1) gene, PRSS1-K23R allele,  
 exon 2 and partial cds.  
 ACCESSION AY307359  
 VERSION AY307359.1 GI:32250961  
 KEYWORDS Homo sapiens (human)  
 SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 1 (bases 1 to 160)  
 Ferec,C., Raguene,O., Salomon,R., Roche,C., Bernard,J.P.,  
 Guillot,M., Quere,I., Faure,C., Mercier,B., Audrezet,M.P.,  
 Guillausseau,P.J., Dupont,C., Munnich,A., Bignon,J.D. and Le  
 Bodic,L.  
 Mutations in the cationic trypsinogen gene and evidence for genetic  
 heterogeneity in hereditary pancreatitis  
 J. Med. Genet. 36 (3), 228-232 (1999)

TITLE  
 JOURNAL 99219545  
 MEDLINE 10204851  
 PUBMED  
 REFERENCE 2 (bases 1 to 160)  
 Chen,J.M., Piepoli Bis,A., Le Bodic,L., Ruszniewski,P.,  
 Robaszkiewicz,M., Deprez,P.H., Raguene,O., Quere,I., Andriulli,A.  
 and Ferec,C.  
 Mutational screening of the cationic trypsinogen gene in a large  
 cohort of subjects with idiopathic chronic pancreatitis  
 Clin. Genet. 59 (3), 189-193 (2001)

```

MEDLINE      21159653
PUBMED      11260229
REFERENCE    3 (bases 1 to 160)
AUTHORS      Chen,J.M., Raguenes,O. and Ferec,C.
TITLE        Direct Submission
JOURNAL      Bretagne Occidentale, 46 rue Felix Le Dantec, Brest 29220, France
FEATURES
source      1..160
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /chromosome="7"
            /map="7q34"
            <1..>160
            /gene="PRSS1"
            /allele="K23R"
            <1..>160
            /genes="PRSS1"
            /product="cationic trypsinogen"
            <1..>160
            /gene="PRSS1"
            /EC_number="3.4.21.4"
            /note="digestive zymogen"
            /codon_start=3
            /product="cationic trypsinogen"
            /protein_id="AAP74363.1"
            /db_xref="GI:32250962"
            /translation="AAPFDDDDRIKIVGYNCENSVYQVSLNSGYHFCGSLINEQWV
            VSAGHCYKS"
            1..160
            /gene="PRSS1"
            /number=2

gene
mRNA
CDS

Query Match      0.6%; Score 20.4; DB 1; Length 160;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY      921 CTTTGTAGAACTAACCCCAAAAAGATGCTCTTCATTATAGGGGACTGGAA 974
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      54 CCTCACAGTTGTAGCCCCCAACGATCTTGTGCATCATCAAGGGGGCAGCAA 1

RESULT 165
LOCUS      AY307360/c
DEFINITION Homo sapiens cationic trypsinogen (PRSS1) gene, PRSS1-P36R allele,
            exon 2 and partial cds.
ACCESSION  AY307360
VERSION     AY307360.1 GI:32250963
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 160)
AUTHORS      Chen,J.M., Raguenes,O., and Ferec,C.
TITLE        Mutational screening of the cationic trypsinogen gene in a large
            cohort of subjects with idiopathic chronic pancreatitis
JOURNAL      Clin. Genet. 59 (3), 189-193 (2001)
MEDLINE     21159653
PUBMED      11260229
REFERENCE   2 (bases 1 to 160)
AUTHORS      Chen,J.M., Raguenes,O. and Ferec,C.
TITLE        Direct Submission
JOURNAL      Bretagne Occidentale, 46 rue Felix Le Dantec, Brest 29220, France
FEATURES
source      1..160
            /organism="Homo sapiens"
            /mol_type="genomic DNA"

```

```

            /db_xref="taxon:9606"
            /chromosome="7"
            /map="7q34"
            <1..>160
            /gene="PRSS1"
            /allele="P36R"
            <1..>160
            /gene="PRSS1"
            /product="cationic trypsinogen"
            <1..>160
            /gene="PRSS1"
            /EC_number="3.4.21.4"
            /note="digestive zymogen"
            /codon_start=3
            /product="cationic trypsinogen"
            /protein_id="AAP74364.1"
            /db_xref="GI:32250964"
            /translation="AAPFDDDDKIVGYNCENSVYQVSLNSGYHFCGSLINEQWV
            VSAGHCYKS"
            1..160
            /gene="PRSS1"
            /number=2

gene
mRNA
CDS

Query Match      0.6%; Score 20.4; DB 1; Length 160;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY      921 CTTTGTAGAACTAACCCCAAAAAGATGCTCTTCATTATAGGGGACTGGAA 974
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      54 CCTCACAGTTGTAGCCCCCAACGATCTTGTGCATCATCAAGGGGGCAGCAA 1

RESULT 167
LOCUS      AY254095/c
DEFINITION Homo sapiens nonfunctional trypsin 1 (PRSS1) gene, PRSS1-IVS2+IG>A
            allele, partial cds.
ACCESSION  AY254095
VERSION     AY254095.1 GI:31095600
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 162)
AUTHORS      Chen,J.-M., Le Marechal,C., Lucas,D., Raguenes,O. and Ferec,C.
TITLE        'Loss of function' mutations in the cationic trypsinogen gene
            (PRSS1) may act as a protective factor against pancreatitis
JOURNAL      Mol. Genet. Metab. 79 (1), 67-70 (2003)
MEDLINE     22651503
PUBMED      12765848
REFERENCE   2 (bases 1 to 162)
AUTHORS      Chen,J.-M., Le Marechal,C., Raguenes,O. and Ferec,C.
TITLE        Direct Submission
JOURNAL      Submitted (11-MAR-2003) INSERM 0115, Universite de Bretagne
            Occidentale, 46 rue Felix Le Dantec, Brest 29275, France
FEATURES
source      1..162
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /chromosome="7"
            /map="7q34"
            <1..>162
            /gene="PRSS1"
            /allele="IVS2+IG>A"
            <1..>162
            /gene="PRSS1"
            /product="trypsin 1"
            <1..>162
            /gene="PRSS1"
            /EC_number="3.4.21.4"
            /note="serine protease 1; cationic trypsinogen"

```



```

/codon_start=3
/product="nonfunctional trypsin 1"
/protein_id="AAP42828.1"
/db_xref="GI:31095601"
/translation="AAPFDDDDKIVGGYCNCEENSVPYQVSLNSYHFCGSLNEQWV
VSAGHCYKS"
1..>162
/gene="PRSS1"
/number=2

variation
161
/gene="PRSS1"
/note="mutation in the splice donor consensus site results
in an aberrant spliced mRNA"
/replace="g"

Query Match      0.6%; Score 20.4; DB 1; Length 162;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Oy 921 CCTTTGAAGTACACCCAAAAGATGCTCTCTCTATATAGGGACTGGAA 974
    |||||
Db 54 COTCAGTTAGCCCCCAACGATCTTGTCTCATCATCAAGGGGGCAGCA 1

RESULT 168
HSA238514      196 bp DNA linear PRI 01-DEC-2000
LOCUS          Homo sapiens MVP gene, partial, exon 3.
DEFINITION     AJ238514
ACCESSION      AJ238514
VERSION        AJ238514.1 GI:5851634
KEYWORDS       major vault protein; MVP gene.
SOURCE         Homo sapiens
ORGANISM       Homo sapiens (human)
REFERENCE      1 Lange, C., Walther, W., Schwabe, H. and Stein, U.
AUTHORS        Cloning and initial analysis of the human multidrug
TITLE          resistance-related MVP/LRP gene promoter
JOURNAL        Biochem. Biophys. Res. Commun. 278 (1), 125-133 (2000)
MEDLINE        20525416
PUBMED         11071864
REFERENCE      2 (bases 1 to 196)
AUTHORS        Stein, U.
TITLE          Direct Submission
JOURNAL        Submitted (21-APR-1999) Stein U., Oncology and Surgical Oncology,
                Max Delbrueck Center for Molecular Medicine, Robert-Roessle-Str.
                10, Berlin 13092, Germany
                Location/Qualifiers
                1..196
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /cell_line="SW 1573"
                /cell_type="non small cell lung cancer"
                1..196
                /gene="MVP"
                1..196
                /gene="MVP"
                /number=3
                /usedin=AJ238512:MVP_CDS
                /usedin=AJ238519:MVP_alt

gene
exon

Query Match      0.6%; Score 20.4; DB 1; Length 196;
Best Local Similarity 58.1%; Pred. No. 1.6e+02;
Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Oy 1445 GGATCAGACCATCCCATCGGAAGAAATGCAAAAGCAAAATGGCTGCTGGGAGG 1504
    |||||
Db 21 GCATGTGACCGCTCCCGCCACGTCACACTGACAGTGGCCACCGCTGTCTCGGATG 80

Oy 1505 CC 1506
    |||

```

```

Db 81 CC 82

RESULT 169
S68634
LOCUS          199 bp DNA linear PRI 17-AUG-2001
DEFINITION     CRM+ factor IX Strasbourg 2-cross reacting material positive factor
                IX Strasbourg 2 [exon 2] [human, hemophilia B patient J-C L, blood,
                Genomic Mutant, 199 nt].
ACCESSION      S68634
VERSION        S68634.1 GI:545020
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 199)
AUTHORS        de la Salle, C., Charmantier, J.L., Ravanat, C., Ohlmann, P.,
                Hartmann, M.L., Schuhler, S., Bischoff, R., Ebel, C., Roecklin, D.,
                Balland, A. et al.
TITLE          The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation
                by factor Xla
JOURNAL        Nouv. Rev. Fr. Hematol. 35 (5), 473-480 (1993)
MEDLINE        94126308
PUBMED         8295921
REMARK         GenBank staff at the National Library of Medicine created this
                entry [NCBI gibbsg 143652] from the original journal article.
COMMENT        G6365 to A transition.
FEATURES       Location/Qualifiers
                1..199
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /isolate="hemophilia B patient J-C L"
                /db_xref="taxon:9606"
                /tissue_type="blood"
                <4..>168
                /note="cross reacting material positive factor IX
                Strasbourg 2; Arg-4 to Gln transition; Method: conceptual
                translation with partial peptide sequencing"
                /codon_start=1
                /product="CRM+ factor IX Strasbourg 2"
                /protein_id="AA329758.1"
                /db_xref="GI:545021"
                /translation="VFLDHENANKILNQPKRYNSGKLEFVQGNLERECWEKCSFEE
                AREVFENTERT"

CDS
Query Match      0.6%; Score 20.4; DB 1; Length 199;
Best Local Similarity 61.1%; Pred. No. 1.6e+02;
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Oy 785 GCAGTCTCAAAAACGACAGATGATCTCTGTTTGTTCGAAGCAACCATTTCA 838
    |||||
Db 142 GAAGTTTTTGAAACACTGAAGACAGTGAAGTATTTCACATAATACCTTCA 195

RESULT 170
AX040017/c     315 bp DNA linear PAT 18-NOV-2000
LOCUS          Sequence 33 from Patent WO0063435.
DEFINITION     AX040017
ACCESSION      AX040017
VERSION        AX040017.1 GI:11230031
KEYWORDS       Rattus sp.
SOURCE         Rattus sp.
ORGANISM       Rattus sp.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE      1 Gould-Rothberg, B.E. and Dipippo, V.A.
AUTHORS        Method of identifying toxic agents using differential gene express
                ion
TITLE          Patent: WO 0063435-A 33 26-OCT-2000;
                Curagen Corporation (US)
JOURNAL

```



/db\_xref="GI:1256428"  
/translation="FVRGNLERIEIEBKCFEAREVPEKTEKNEFWKOVYDGDQCE  
BNPCLNGCLKDDINSYECMCOVGFEGKNCELDATCNKGRCKQFCKTGADSKVLCS  
CTTGRLAPDDQSKCPAAPPFCGRVSUSHSFTILTR"

Query Match 0.6%; Score 20.4; DB 1; Length 414;  
Best Local Similarity 52.3%; Pred. No. 1.9e+02;  
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 2919 TACTATTATTTGGGATTTTAACTATTCTTCAATGACTCTGTTATTTCAATATTAC 2978  
|||||  
Db 107 TGCITCCAAATTCATTAGTTTCTCAGTGTTTCAAAAACCTCTCGTGTCTTCAAAA 48  
|||||

QY 2979 TTATTCTATTATTTCAATTTAATGCACT 3004  
|||||  
Db 47 CTACACTTTTCTCTATACATTTCTCT 22  
|||||

RESULT 174  
AF011899/c  
LOCUS  
DEFINITION Petromyzon marinus trypsinogen a3 (TRYP3) mRNA, complete cds.  
ACCESSION AF011899  
VERSION AF011899.1 GI:2367496  
KEYWORDS  
SOURCE Petromyzon marinus (sea lamprey)  
ORGANISM Petromyzon marinus

REFERENCE 1 (bases 1 to 855)  
Roach,J.C.

AUTHORS Roach,J.C.

TITLE The Molecular Evolution of the Vertebrate Trypsinogens

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 855)

AUTHORS Roach,J.C.

TITLE Direct Submission

JOURNAL Submitted (01-JUL-1997) Molecular Biotechnology, University of

Washington, Seattle, WA 98195, USA

FEATURES  
Location/Qualifiers

1..855  
/organism="Petromyzon marinus"

/mol\_type="mRNA"

/db\_xref="taxon:7757"

/dev\_stage="amocoete"

/tissue\_lib="anterior intestine"

1..855  
/gene="TRYP3"

1..744  
/gene="TRYP3"

/codon\_start=1

/product="trypsinogen a3"

/protein\_id="AAB69655.1"

/db\_xref="GI:2367497"

/translation="MHGLIALLVGVAAAAPWYEDHIVGSGCAHSPQWQVSLNIG  
YHFCGSLNSQWVYSAACHQVTSRISVIRGEHNI FVNEGTQEQIQAQAIQHPQYN  
SWTIDNDMLIKSLSPATLNOVAIAIPSSCVNTGVMCT:SGWGETQTSVSGPDVLM  
CVOAPVLSDTSCNSYVPGDITNNMICLVLEGKXDS CQDGGGPPVVCNGLQGVISWG  
RGCALPNYFEGVYKVCNNYNAQTIAAN"

1..45  
/gene="TRYP3"

/evidence=not\_experimental

46..741  
/gene="TRYP3"

/product="trypsin a3"

/evidence=not\_experimental

sig\_peptide

mat\_peptide

Query Match 0.6%; Score 20.4; DB 1; Length 855;  
Best Local Similarity 71.1%; Pred. No. 2.2e+02;  
Matches 27; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3245 TTTTITTTTTTTTTTTTTTAAAGATGTCATTTCTT 3282  
|||||

Db 855 TTTTITTTTTTTTTTGNATGATTCACATTTTATTCATT 818  
|||||

RESULT 175  
AF465273/c  
LOCUS

DEFINITION Takifugu rubripes coagulation factor VII precursor, mRNA, complete cds.

ACCESSION AF465273

VERSION AF465273.1 GI:28194017

KEYWORDS

SOURCE Takifugu rubripes (Fugu rubripes)

ORGANISM Takifugu rubripes

REFERENCE 1 (bases 1 to 1326)

AUTHORS Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,

Tuddenham,E.G.D. and McVey,J.H.

TITLE Comparative sequence analysis and molecular evolution of blood

JOURNAL coagulation genes from Gallus gallus and Fugu rubripes

REFERENCE 2 (bases 1 to 1326)

AUTHORS McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.

TITLE Direct Submission

JOURNAL Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences

Centre, The Faculty of Medicine, Imperial College, Hammersmith

Campus, Du Cane Road, London W12 0NN, UK

FEATURES  
Location/Qualifiers

1..1326  
/organism="Takifugu rubripes"

/mol\_type="mRNA"

/db\_xref="taxon:31033"

1..1326  
/EC\_number="3.4.21.21"

/function="serum prothrombinconversion accelerator"

/notes="vitamin K dependent serine protease; contains 2

EGF-like domains; member of peptidase family S1/trypsin

family; found in plasma"

/codon\_start=1

/product="coagulation factor VII precursor"

/protein\_id="AA033368.1"

/db\_xref="GI:28194018"

/translation="MRLRVFTLVFTTHCRASVFLDADKAHDLVLRVYNSGWLE  
ELQKGLKRELEICSYBEAREVFEHTKTDFWKIYNRPNSCKNPCLNGSCSAE  
GSSVTCFCLPEFSGVDELEYOTVPTCLENGSCFHFCHENSAGRGKSCADGVDL  
DVGDLCKAKESVACGVLSAQFEHNLNPRARIVGNECPKCECPKQVLLVYKGGKF  
CGGVYKPTWILLTASHCMADIDVQFLKVGAGENIEVDEGTQIIQVSIIMHEKYVP  
RTADNDIALHLAVPTTYTTPALPCLPTPLAELRELWAVSLHVTGWSGRRSNGPTP  
HLRLQLKVPRIQTQCCIEESGVLTQMF CAGYMEGRQDSCKDGGGLVTKYKKTVP  
LLGIVSGKGCAPGNGYIVRVANYLEWHNRATVNTQPTNNTENFTT"

Query Match 0.6%; Score 20.4; DB 1; Length 1326;  
Best Local Similarity 61.1%; Pred. No. 2.3e+02;  
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 2592 AAAGACCTGATGCTGGAGGATTGGGGCAGGAGAGAGGAGGACGACAG 2645  
|||||

Db 68 AGAAACACTGATGCTGCCGACAATGTGTGAAGGTGAAGACGAGGTGAAGAAG 15  
|||||

RESULT 176  
AX427734/c  
LOCUS

DEFINITION Sequence 1 from Patent WO0232461.

ACCESSION AX427734

VERSION AX427734.1 GI:21537841

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 1383)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1

```

AUTHORS      Andersen,K.V., Freskgaard,P.O. and Pedersen,A.H.
TITLE         Protein C or activated protein C-like molecules
JOURNAL       Patent: WO 022461-A 1 25-APR-2002;
              MAXYGEN APS (DK); MAXYGEN HOLDINGS LTD (US)
FEATURES
  source      1..1383
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
  CDS         1..1383
              /note="unassigned protein product"
              /codon_start=1
              /protein_id="CAD35979.1"
              /db_xref="GI:21537842"
              /db_xref="REMBL:CAD35979"
              /translation="MWQLTSLLLFVATWIGISGTPAPLDSVSSSERAHQVLRIRKAN
              SFLEIRHSLRECEIEECFEAEKEIFQNVDDTLAFWSKHVDGQCLVLPBHPCA
              SLCCGGTIDIGIGSCDCRSGWGRFCQREVSFLNGSGGTHYCLEEVGWRRC
              SCAPGYLGDLLQCHPAVKPCGRPWKRMEKKRSHLRKRDTEDDQVDVPLRDKGMT
              RGDSPQVVLDSKKLACGAVLTHPSWLTAAECMDSEKKLVRLGELYDLRLWEKW
              ELDDIKKEVHPNYSKSTNDIALHLAGPNTLSOTIVPICLPDSEGLAERELNQG
              QSLTVGWSYHSSRKEAKRNTFVLNFIKIFVPHNECSEVMNSNENMLCAGILG
              DRQDACEGDSGGVPWASFHGTWFLVLVSWGEGGCLLHNYGVYTKVSKRYLDWIHGHIR
              DEAPQKSWAP"
              /product="unnamed"
              127..1383
  mat_peptide 127..1383

Query Match      0.6%; Score 20.4; DB 1; Length 1383;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGCGAGCTGAGTCTGGGTGAACCTCTCGAGTTGG 2710
DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGCTGCGGAAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
DB 34 CCACGAACAG 25

RESULT 177
AX149644/C
LOCUS      AX149644      1386 bp      DNA      linear      PAT 08-JUN-2001
DEFINITION Sequence 14 from Patent WO0136462.
ACCESSION  AX149644
VERSION     AX149644.1 GI:14348043
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE   1
AUTHORS     Gerlitz,B.E., Grinnell,B.W., Huang,L. and Jones,B.E.
TITLE       Protein C derivatives
JOURNAL     Patent: WO 0136462-A 14 25-MAY-2001;
            ELI LILLY AND COMPANY (US)
FEATURES
  source      1..1386
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGCGAGCTGAGTCTGGGTGAACCTCTCGAGTTGG 2710
DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGCTGCGGAAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
DB 34 CCACGAACAG 25

RESULT 179
I06643/C
LOCUS      I06643      1386 bp      DNA      linear      PAT 02-DEC-1994
DEFINITION Sequence 1 from Patent EP 0323149.
ACCESSION  I06643
VERSION     I06643.1 GI:590170
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
            1 (bases 1 to 1386)
            Bang,N.U., Ehrlich,H.J., Grinnell,B.W. and Van,S.-C.B.
            Vectors and compounds for expression of zymogen forms of human
            protein C
JOURNAL     Patent: EP 0323149-A2 1 05-JUL-1989;
            ELI LILLY AND COMPANY (US)
FEATURES
  source      1..1386
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGCGAGCTGAGTCTGGGTGAACCTCTCGAGTTGG 2710
DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGCTGCGGAAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
DB 34 CCACGAACAG 25
```

```

RESULT 178
BD246883/C
LOCUS      BD246883      1386 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Protein C derivatives.
ACCESSION  BD246883
VERSION     BD246883.1 GI:33056653
KEYWORDS    JP 2002542832-A/2.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
            Gerlitz,B.E. and Jones,B.E.
            Protein C derivatives
            Patent: JP 2002542832-A 2 17-DEC-2002;
            ELI LILLY AND CO
            OS Homo sapiens (human)
            PN JP 2002542832-A/2
            PD 17-DEC-2002
            PF 13-APR-2000 JP 2000615776
            PR 30-APR-1999 US 60/131801
            PI BRUCE EDWARD GERLITZ,BRYAN EDWARD JONES
            PC C12N15/09,A61K38/48,A61P7/02,A61P7/06,A61P9/10,A61P11/00, PC
            A61P13/00,
            PC A61P17/02,A61P31/00,A61P31/12,A61P37/06,C12N1/15,C12N1/19, PC
            C12N1/21
            PC C12N5/10,C12N9/64,C12N15/00,C12N5/00,A61K37/547 CC Protein C
            derivatives
            FH Key
            FT source 1..1386
            FT source /organism="Homo sapiens (human)".
            FT source Location/Qualifiers
            FT source 1..1386
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGCGAGCTGAGTCTGGGTGAACCTCTCGAGTTGG 2710
DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGCTGCGGAAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
DB 34 CCACGAACAG 25

RESULT 179
I06643/C
LOCUS      I06643      1386 bp      DNA      linear      PAT 02-DEC-1994
DEFINITION Sequence 1 from Patent EP 0323149.
ACCESSION  I06643
VERSION     I06643.1 GI:590170
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
            1 (bases 1 to 1386)
            Bang,N.U., Ehrlich,H.J., Grinnell,B.W. and Van,S.-C.B.
            Vectors and compounds for expression of zymogen forms of human
            protein C
JOURNAL     Patent: EP 0323149-A2 1 05-JUL-1989;
            ELI LILLY AND COMPANY (US)
FEATURES
  source      1..1386
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGCGAGCTGAGTCTGGGTGAACCTCTCGAGTTGG 2710
DB 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGCTGCGGAAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
DB 34 CCACGAACAG 25
```

```
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 2651 GATGCTGGATGCATCACTGACCTCGATGGACGTCGTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

Qy 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 180
108112/c
LOCUS 108112 1386 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 1 from Patent EP 0319312.
ACCESSION 108112
VERSION 108112.1 GI:589175
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Bang,N.U., Ehrlich,H.J., Grinnell,B.W. and Jaskunas,S.R.J.
TITLE Vectors and compounds for direct expression of activated human
protein C
JOURNAL Patent: EP 0319312-A2 1 07-JUN-1989;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 2651 GATGCTGGATGCATCACTGACCTCGATGGACGTCGTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

Qy 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 181
AR404692/c
LOCUS AR404692 1386 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 8 from patent US 6630138.
ACCESSION AR404692
VERSION AR404692.1 GI:40153404
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE Protein C derivatives
JOURNAL Patent: US 6630138-A 8 07-OCT-2003;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 2651 GATGCTGGATGCATCACTGACCTCGATGGACGTCGTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

Qy 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 182
AR404695/c
LOCUS AR404695 1386 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 11 from patent US 6630138.
ACCESSION AR404695
VERSION AR404695.1 GI:40153407
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE Protein C derivatives
JOURNAL Patent: US 6630138-A 11 07-OCT-2003;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 2651 GATGCTGGATGCATCACTGACCTCGATGGACGTCGTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

Qy 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 183
AR404696/c
LOCUS AR404696 1386 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 12 from patent US 6630138.
ACCESSION AR404696
VERSION AR404696.1 GI:40153408
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1386)
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE Protein C derivatives
JOURNAL Patent: US 6630138-A 12 07-OCT-2003;
FEATURES
source
Location/Qualifiers
1..1386
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 2651 GATGCTGGATGCATCACTGACCTCGATGGACGTCGTGGTGAACCTCTGGAGTTGG 2710
Db 94 GCTGCTGCTGGAGAACACTGAGTCACAGAGAGCTGGTGTCCCGAAATTCCTCCAGGTGG 35

Qy 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 184
AX044042/c
LOCUS AX044042 1386 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 7 from Patent WO0066754.
ACCESSION AX044042
```



REFERENCE 1  
AUTHORS Gerlitz,B.E., Grinnell,B.W., Huang,L. and Jones,B.E.  
TITLE Protein c derivatives  
JOURNAL Patent: WO 0136462-A 16 25-MAY-2001;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 189  
AX207784/c  
LOCUS AX207784 1386 bp DNA linear PAT 31-AUG-2001  
DEFINITION Sequence 8 from Patent WO0157193.  
ACCESSION AX207784  
VERSION AX207784.1 GI:15422460  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz,B.E. and Jones,B.E.  
TITLE Protein c derivatives  
JOURNAL Patent: WO 0157193-A 8 09-AUG-2001;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 190  
AX212331/c  
LOCUS AX212331 1386 bp DNA linear PAT 06-SEP-2001  
DEFINITION Sequence 7 from Patent WO0159084.  
ACCESSION AX212331  
VERSION AX212331.1 GI:15524087  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.  
TITLE Protein c derivatives

JOURNAL Patent: WO 0159084-A 7 16-AUG-2001;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 191  
AR070468/c  
LOCUS AR070468 1386 bp DNA linear PAT 18-FEB-2000  
DEFINITION Sequence 3 from patent US 5905185.  
ACCESSION AR070468  
VERSION AR070468.1 GI:7221356  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 1386)  
AUTHORS Garner,I., Cottingham,I.R., Temperley,S.M., Foster,D.C.,  
Sprecher,C.A. and Prunkard,D.E.  
TITLE Protein C production in non-human transgenic mammals  
JOURNAL Patent: US 5905185-A 3 18-MAY-1999;  
FEATURES  
source Location/Qualifiers  
1..1386  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 192  
BD246884/c  
LOCUS BD246884 1386 bp DNA linear PAT 17-JUL-2003  
DEFINITION Protein C derivatives.  
ACCESSION BD246884  
VERSION BD246884.1 GI:33056654  
KEYWORDS JP 2002542832-A/3  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 1386)  
AUTHORS Gerlitz,B.E. and Jones,B.E.  
TITLE Protein C derivatives  
JOURNAL Patent: JP 2002542832-A 3 17-DEC-2002;  
ELI LILLY AND CO  
COMMENT OS Homo sapiens (human)  
PN JP 2002542832-A/3  
PD 17-DEC-2002

PF 13-APR-2000 JP 2000615776  
PR 30-APR-1999 US 60/131801  
PI BRUCE EDWARD GERLITZ, BRYAN EDWARD JONES  
PC C12N15/09, A61K38/48, A61P7/02, A61P7/06, A61P9/10, A61P11/00, PC  
A61P13/00,  
PC A61P17/02, A61P31/00, A61P31/12, A61P37/06, C12N1/15, C12N1/19, PC  
C12N1/21,  
PC C12N5/10, C12N9/64, C12N15/00, C12N5/00, A61K37/547 CC Protein C  
derivatives  
FH Key Location/Qualifiers  
FT source 1..1386  
/organism="Homo sapiens (human)".  
Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGTGGTGTGCCGGAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25

RESULT 193  
AX044693/c  
LOCUS 1386 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 9 from patent US 6630138.  
ACCESSION AR044693  
VERSION AR044693.1 GI:40153405  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 1386)  
AUTHORS Gerlitz, B.E., Grinnell, B.W. and Jones, B.E.  
TITLE Protein C derivatives  
JOURNAL Patent: US 6630138-A 9 07-OCT-2003;  
FEATURES  
source 1..1386  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGTGGTGTGCCGGAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25

RESULT 194  
AX044043/c  
LOCUS 1386 bp DNA linear PAT 24-NOV-2000  
DEFINITION Sequence 8 from Patent WO0066754.  
ACCESSION AX044043  
VERSION AX044043.1 GI:11342922  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz, B.E. and Jones, B.E.  
TITLE Protein C derivatives  
JOURNAL Patent: WO 0066754-A 8 09-NOV-2000;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source 1..1386  
Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGTGGTGTGCCGGAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25

RESULT 195  
AX149642/c  
LOCUS 1386 bp DNA linear PAT 08-JUN-2001  
DEFINITION Sequence 12 from Patent WO0136462.  
ACCESSION AX149642  
VERSION AX149642.1 GI:14348041  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz, B.E., Grinnell, B.W., Huang, L. and Jones, B.E.  
TITLE Protein C derivatives  
JOURNAL Patent: WO 0136462-A 12 25-MAY-2001;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source 1..1386  
Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGACGCTGAGTCTGGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGAGAGTGGTGTGCCGGAATTCCTCCAGGTGG 35

QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25

RESULT 196  
AX149645/c  
LOCUS 1386 bp DNA linear PAT 08-JUN-2001  
DEFINITION Sequence 15 from Patent WO0136462.  
ACCESSION AX149645  
VERSION AX149645.1 GI:14348044  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz, B.E., Grinnell, B.W., Huang, L. and Jones, B.E.



```

TITLE      Protein c derivatives
JOURNAL    Patent: WO 0136462-A 15 25-MAY-2001;
           ELI LILLY AND COMPANY (US)
FEATURES   source
           1..1386
           /location/Qualifiers
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTCGAGTCGGTGGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 197
AX207785/c
LOCUS      AX212332      1386 bp      DNA      linear      PAT 31-AUG-2001
DEFINITION Sequence 9 from Patent WO0157193.
ACCESSION AX212332
VERSION    AX207785.1 GI:15422461
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Gerlitz,B.E. and Jones,B.E.
TITLE      Protein c derivatives
JOURNAL    Patent: WO 0157193-A 9 09-AUG-2001;
           ELI LILLY AND COMPANY (US)
FEATURES   source
           1..1386
           /location/Qualifiers
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTCGAGTCGGTGGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 198
AX207787/c
LOCUS      AX207787      1386 bp      DNA      linear      PAT 31-AUG-2001
DEFINITION Sequence 11 from Patent WO0157193.
ACCESSION AX207787
VERSION    AX207787.1 GI:15422463
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Gerlitz,B.E. and Jones,B.E.
TITLE      Protein c derivatives
JOURNAL    Patent: WO 0157193-A 11 09-AUG-2001;
           ELI LILLY AND COMPANY (US)

```

```

FEATURES   Location/Qualifiers
           1..1386
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTCGAGTCGGTGGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 199
AX212332/c
LOCUS      AX212332      1386 bp      DNA      linear      PAT 06-SEP-2001
DEFINITION Sequence 8 from Patent WO0159084.
ACCESSION AX212332
VERSION    AX212332.1 GI:15524088
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE      Protein c derivatives
JOURNAL    Patent: WO 0159084-A 8 16-AUG-2001;
           ELI LILLY AND COMPANY (US)
FEATURES   Location/Qualifiers
           1..1386
           /organism="Homo sapiens"
           /mol_type="unassigned DNA"
           /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGCATCACTGACTCGATGGACGTCGAGTCGGTGGAACCTCTGGAGTTGG 2710
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTTCCCGAGTTGG 35

QY 2711 TGATGGACAG 2720
Db 34 CCACGAACAG 25

RESULT 200
BD246885/c
LOCUS      BD246885      1386 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Protein C derivatives.
ACCESSION BD246885
VERSION    BD246885.1 GI:33056655
KEYWORDS   JP 2002542832-A/4.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 1386)
AUTHORS    Gerlitz,B.E. and Jones,B.E.
TITLE      Protein C derivatives
JOURNAL    Patent: JP 2002542832-A 4 17-DEC-2002;
           ELI LILLY AND CO
COMMENT     OS Homo sapiens (human)
           PN JP 2002542832-A/4
           PD 17-DEC-2002

```

PF 13-APR-2000 JP 2000615776  
PR 30-APR-1999 US 60/131801  
PI BRUCE EDWARD GERLITZ, BRYAN EDWARD JONES  
PC C12N15/09, A61K38/48, A61P7/02, A61P7/06, A61P9/10, A61P11/00, PC  
A61P13/00,  
PC A61P17/02, A61P31/00, A61P31/12, A61P37/06, C12N1/15, C12N1/19, PC  
C12N1/21,  
PC C12N5/10, C12N9/64, C12N15/00, C12N5/00, A61K37/547 CC Protein C  
derivatives"  
FH Key Location/Qualifiers  
FT source 1..1386  
FT /organism="Homo sapiens (human)".  
FEATURES  
source  
Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTGATGAGAGTGTGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGTGTGTGCCGGAATTCGCCAGGTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 201  
LOCUS AR404694/c 1386 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 10 from patent US 6630138.  
ACCESSION AR404694  
VERSION AR404694.1 GI:40153406  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 1386)  
AUTHORS Gerlitz, B.E., Grinnell, B.W. and Jones, B.E.  
TITLE Protein C derivatives  
JOURNAL Patent: US 6630138-A 10 07-OCT-2003;  
FEATURES  
source  
Location/Qualifiers  
1..1386  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTGATGAGAGTGTGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGTGTGTGCCGGAATTCGCCAGGTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 202  
LOCUS AX044044/c 1386 bp DNA linear PAT 24-NOV-2000  
DEFINITION Sequence 9 from Patent WO0066754.  
ACCESSION AX044044  
VERSION AX044044.1 GI:11342923  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz, B.E. and Jones, B.E.  
TITLE Protein C derivatives  
JOURNAL Patent: WO 0066754-A 9 09-NOV-2000;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source  
Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTGATGAGAGTGTGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGTGTGTGCCGGAATTCGCCAGGTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 203  
LOCUS AX207786/c 1386 bp DNA linear PAT 31-AUG-2001  
DEFINITION Sequence 10 from Patent WO0157193.  
ACCESSION AX207786  
VERSION AX207786.1 GI:15422462  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz, B.E. and Jones, B.E.  
TITLE Protein C derivatives  
JOURNAL Patent: WO 0157193-A 10 09-AUG-2001;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source  
Location/Qualifiers  
1..1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGGATGCATCACTGACTGATGAGAGTGTGGTGAACCTCTGGAGTTGG 2710  
Db 94 GCTCGCTGCTGGAGAACACTGAGTCAAGAGGAGTGTGTGCCGGAATTCGCCAGGTGG 35  
QY 2711 TGATGGACAG 2720  
Db 34 CCACGAACAG 25  
RESULT 204  
LOCUS AX207788/c 1386 bp DNA linear PAT 31-AUG-2001  
DEFINITION Sequence 12 from Patent WO0157193.  
ACCESSION AX207788  
VERSION AX207788.1 GI:15422464  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Gerlitz, B.E. and Jones, B.E.

```

TITLE      Protein c derivatives
JOURNAL    Patent: WO 0157193-A 12 09-AUG-2001;
            ELI LILLY AND COMPANY (US)
FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGACTGATGGACGTCGAGTCTGGGTCGAACTCCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 205
AX212333/c
LOCUS      AX212333      1386 bp      DNA      linear      PAT 06-SEP-2001
DEFINITION Sequence 9 from Patent WO0159084.
ACCESSION  AX212333
VERSION     AX212333.1 GI:15524089
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS    Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.
TITLE      Protein c derivatives
JOURNAL    Patent: WO 0159084-A 9 16-AUG-2001;
            ELI LILLY AND COMPANY (US)
FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGACTGATGGACGTCGAGTCTGGGTCGAACTCCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 206
BD246886/c
LOCUS      BD246886      1386 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Protein c derivatives.
ACCESSION  BD246886
VERSION     BD246886.1 GI:33056656
KEYWORDS   JP 2002542832-A/5
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1 (bases 1 to 1386)
AUTHORS    Gerlitz,B.E. and Jones,B.E.
TITLE      Protein c derivatives
JOURNAL    Patent: JP 2002542832-A 5 17-DEC-2002;
            ELI LILLY AND CO

COMMENT    OS Homo sapiens (human)
            PN JP 2002542832-A/5
            PD 17-DEC-2002
            PP 13-APR-2000 JP 2000615776
            PR 30-APR-1999 US 60/131801
            PT BRUCE EDWARD GERLITZ,BRYAN EDWARD JONES
            PC C12N15/09,A61K38/48,A61P7/02,A61P9/10,A61P11/00,PC
            A61P13/00,
            PC A61P17/02,A61P31/00,A61P31/12,A61P37/06,C12N1/15,C12N1/19,PC
            C12N1/21,
            PC C12N5/10,C12N9/64,C12N15/00,C12N5/00,A61K37/547 CC Protein C
            derivatives
            FH Key Location/Qualifiers
            FT source 1..1386
            FT /organism="Homo sapiens (human)"

FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGACTGATGGACGTCGAGTCTGGGTCGAACTCCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 207
AX044045/c
LOCUS      AX044045      1386 bp      DNA      linear      PAT 24-NOV-2000
DEFINITION Sequence 10 from Patent WO0066754.
ACCESSION  AX044045
VERSION     AX044045.1 GI:11342924
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS    Gerlitz,B.E. and Jones,B.E.
TITLE      Protein c derivatives
JOURNAL    Patent: WO 0066754-A 10 09-NOV-2000;
            ELI LILLY AND COMPANY (US)
FEATURES   source
            Location/Qualifiers
            1..1386
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 20.4; DB 1; Length 1386;
Best Local Similarity 55.7%; Pred. No. 2.3e+02;
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2651 GATGGCTGGATGGCATCACTGACTGATGGACGTCGAGTCTGGGTCGAACTCCTGGAGTTGG 2710
      |||||
Db 94 GCTGCTGCTGGAGAACACTGAGTCAAGAGGAGCTGGTGTGCCGGAATTCGCCAGGTGG 35

QY 2711 TGATGGACAG 2720
      |||||
Db 34 CCACGAACAG 25

RESULT 208
AX212334/c
LOCUS      AX212334      1386 bp      DNA      linear      PAT 06-SEP-2001
DEFINITION Sequence 10 from Patent WO0159084.
```

ACCESSION AX212334  
VERSION AX212334.1 GI:15524090  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Gerlitz,B.E., Grinnell,B.W. and Jones,B.E.  
TITLE Protein c derivatives  
JOURNAL Patent: WO 0159084-A 10 16-AUG-2001;  
ELI LILLY AND COMPANY (US)  
FEATURES  
source  
1. .1386  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 20.4; DB 1; Length 1386;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGATGGCATCACTGACTGATGAGTCTGGTGAACCTCTGGAGTTGG 2710  
DB 94 GCTCGCTGCTGGAGAACTGAGTCAAGAGAGTGGTGTCCCGAAATTCCTCCAGGTGG 35  
QY 2711 TGATGGACAG 2720  
DB 34 CCACGAACAG 25  
RESULT 209  
LOCUS AR364387/c 1387 bp DNA linear PAT 03-SEP-2003  
DEFINITION Sequence 1 from patent US 5270178.  
ACCESSION AR364387  
VERSION AR364387.1 GI:34426931  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1387)  
AUTHORS Gerlitz,B.E. and Grinnell,B.W.  
TITLE Vectors and compounds for expression of zymogen forms of human protein C  
JOURNAL Patent: US 5270178-A 1 14-DEC-1993;  
FEATURES  
source  
1. .1387  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.6%; Score 20.4; DB 1; Length 1387;  
Best Local Similarity 55.7%; Pred. No. 2.3e+02;  
Matches 39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
QY 2651 GATGGCTGATGGCATCACTGACTGATGAGTCTGGTGAACCTCTGGAGTTGG 2710  
DB 94 GCTCGCTGCTGGAGAACTGAGTCAAGAGAGTGGTGTCCCGAAATTCCTCCAGGTGG 35  
QY 2711 TGATGGACAG 2720  
DB 34 CCACGAACAG 25  
RESULT 210  
LOCUS AR030786 2422 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 1 from patent US 5861374.  
ACCESSION AR030786  
VERSION AR030786.1 GI:5944000  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

Unclassified.  
REFERENCE 1 (bases 1 to 2422)  
AUTHORS Berkner,K.L., Petersen,L.Christian. and Hart,C.E.  
TITLE Modified Factor VII  
JOURNAL Patent: US 5861374-A 1 19-JAN-1999;  
FEATURES  
source  
1. .2422  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.6%; Score 20.4; DB 1; Length 2422;  
Best Local Similarity 52.3%; Pred. No. 2.3e+02;  
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;  
QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCCAAGCAAAAGATACCCAGCTGTGGATGCA 511  
DB 1870 ACACACGGATGTCACACACAGATGGTCCACAGAGATACGCAACACACACCGATGCACACGC 1929  
QY 512 CTGGTGATATAAGCAAGGTCGGATGC 537  
DB 1930 ACATAGAGATATGCACACACAGATGC 1955  
RESULT 211  
LOCUS AR045090 2422 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 1 from patent US 5817788.  
ACCESSION AR045090  
VERSION AR045090.1 GI:5966555  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 2422)  
AUTHORS Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and Bregengaard,C.  
TITLE Modified factor VII  
JOURNAL Patent: US 5817788-A 1 06-OCT-1998;  
FEATURES  
source  
1. .2422  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.6%; Score 20.4; DB 1; Length 2422;  
Best Local Similarity 52.3%; Pred. No. 2.3e+02;  
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;  
QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCCAAGCAAAAGATACCCAGCTGTGGATGCA 511  
DB 1870 ACACACGGATGTCACACACAGATGGTCCACAGAGATACGCAACACACACCGATGCACACGC 1929  
QY 512 CTGGTGATATAAGCAAGGTCGGATGC 537  
DB 1930 ACATAGAGATATGCACACACAGATGC 1955  
RESULT 212  
LOCUS AR052946 2422 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 1 from patent US 5833982.  
ACCESSION AR052946  
VERSION AR052946.1 GI:5977808  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 2422)  
AUTHORS Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and Bregengaard,C.  
TITLE Modified factor VII  
JOURNAL Patent: US 5833982-A 1 10-NOV-1998;  
FEATURES  
source  
1. .2422  
/organism="unknown"  
/mol\_type="unassigned DNA"

```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGGA 511
DB 1870 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1929

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1930 ACATAGAGATATGCACACAGATGC 1955

RESULT 213
LOCUS AR122899 2422 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1 from patent US 6168789.
ACCESSION AR122899
VERSION AR122899.1 GI:14107865
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and Bregengaard,C.
TITLE Modified factor VII
JOURNAL Patent: US 6168789-A 1 02-JAN-2001;
FEATURES Location/Qualifiers
source 1. 2422
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGGA 511
DB 1870 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1929

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1930 ACATAGAGATATGCACACAGATGC 1955

RESULT 214
LOCUS AR127821 2422 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1 from patent US 6183743.
ACCESSION AR127821
VERSION AR127821.1 GI:14115483
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2422)
AUTHORS Hart,C.E., Petersen,L.C., Hedner,U. and Rasmussen,M.E.
TITLE Modified factor VII
JOURNAL Patent: US 6183743-A 1 06-FEB-2001;
FEATURES Location/Qualifiers
source 1. 2422
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2422;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGGA 511
DB 1870 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1929

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1930 ACATAGAGATATGCACACAGATGC 1955

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1931 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1990

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGGA 511
DB 1931 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1990

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGGA 511
DB 1931 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1990

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016
```

```
DB 1870 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1929

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1930 ACATAGAGATATGCACACAGATGC 1955

RESULT 215
LOCUS AR095304 2462 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 25 from patent US 6004555.
ACCESSION AR095304
VERSION AR095304.1 GI:10023060
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2462)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods for the specific coagulation of vasculature
JOURNAL Patent: US 6004555-A 25 21-DEC-1999;
FEATURES Location/Qualifiers
source 1. 2462
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGGA 511
DB 1931 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1990

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016

RESULT 216
LOCUS AR103988 2462 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 25 from patent US 6093399.
ACCESSION AR103988
VERSION AR103988.1 GI:12816696
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 2462)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods and compositions for the specific coagulation of vasculature
JOURNAL Patent: US 6093399-A 25 25-JUL-2000;
FEATURES Location/Qualifiers
source 1. 2462
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 452 ACTCCAGAAAGATGAAGAGATGGAGCCAAAGCAAAAGATACCCAGCTGTGGATGGA 511
DB 1931 ACACACGGATGCACACACAGATGGTTCACACAGATACGCAAAACACACCGATGCACACGC 1990

QY 512 CTGGTGATATAGCAAGGTCCGATGC 537
DB 1991 ACATAGAGATATGCACACAGATGC 2016
```

```

RESULT 217
AX335083
LOCUS AX335083 2462 bp DNA linear PAT 09-JAN-2002
DEFINITION Sequence 5592 from Patent WO0194629.
ACCESSION AX335083
VERSION AX335083.1 GI:18125802
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,
Horigan, S., Soppet, D.R. and Weaver, Z.
TITLE Cancer gene determination and therapeutic screening using signature
gene sets
JOURNAL Patent: WO 0194629-A 5592 13-DEC-2001;
Avalon Pharmaceuticals (US)
FEATURES
source
1. .2462
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
QY 452 ACTCCAGAAAGATGAAGATGGAGCGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGA 511
|||
Db 1931 ACACACGGATGCACACACAGATGGTCACACAGATACGCAACACACCGATGCACAGC 1990
|||
QY 512 CTGGTGATATAGCAAGTCCGATGC 537
|||
Db 1991 ACATAGATATGCACACAGATGC 2016
|||

RESULT 218
AX409604
LOCUS AX409604 2462 bp DNA linear PAT 14-JUN-2002
DEFINITION Sequence 2251 from Patent WO0229103.
ACCESSION AX409604
VERSION AX409604.1 GI:21442309
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Alvares, C., Horne, D., Peres-da-Silva, S. and Vockley, J.G.
TITLE Gene expression profiles in liver cancer
JOURNAL Patent: WO 0229103-A 2251 11-APR-2002;
GENE LOGIC INC (US)
FEATURES
source
1. .2462
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/notes="EMBL/GenBank Accession No. M13232"
Query Match 0.6%; Score 20.4; DB 1; Length 2462;
Best Local Similarity 52.3%; Pred. No. 2.3e+02;
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
QY 452 ACTCCAGAAAGATGAAGATGGAGCGCCAAAGCAAAAGAAATACCCAGCTGTGGATGTGA 511
|||
Db 1931 ACACACGGATGCACACACAGATGGTCACACAGATACGCAACACACCGATGCACAGC 1990
|||
QY 512 CTGGTGATATAGCAAGTCCGATGC 537
|||
Db 1991 ACATAGATATGCACACAGATGC 2016
|||

RESULT 219
HUMFVII
LOCUS HUMFVII 2462 bp mRNA linear PRI 13-FEB-1996
DEFINITION Human factor VII serine protease precursor mRNA, complete cds,
cloned lambda-HVII2463.
ACCESSION M13232
VERSION M13232.1 GI:182799
KEYWORDS factor VII; serine protease; serum glycoprotein.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Hagen, F.S., Gray, C.L., O'Hara, P.J., Grant, F.J., Saari, G.C.,
Woodbury, R.G., Hart, C.E., Insley, M., Kistler, W., Kurachi, K. and
Davie, E.W.
TITLE Characterization of a cDNA coding for human factor VII
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 83 (8), 2412-2416 (1986)
MEDLINE 86205965
PUBMED 3486420
COMMENT Original source text: Homo sapiens liver cDNA to mRNA.
Draft entry and sequence in computer-readable form for [1] kindly
provided by F.S.Hagen.
[1] sequenced two alternatively spliced mRNAs that produced
shortened signal peptides. One is presented as factor VIIb below.
FEATURES
source
1. .2462
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue_type="liver"
<1. .2462
/product="FVIIa mRNA"
36. .1436
/notes="precursor for factor VIIa and b"
/codon_start=1
/product="coagulation factor VII"
/protein_id="A88804.1"
/db_xref="GI:182801"
/translation="MVSQALRLCLLGLQGLAAGVAVKASGGTRDMPWPKPHRV
FYTQEEAHGLHRRRAAFBELRPGSLRECKEEQCFEAREIFKDAERTKLFWI
SYSDGDQSCASPCNGGCKDQISYICFLPAFGKNCETKDKDQLICVNEGCEQ
YCSDHGTNRKSCRCHEGSLADGVSCTVPGKIPILKRNASKPQGRIVGKVK
CPKCECPMVLVAVGAQICGGTLINTWVSAACFCFKIKNRNLIAVLGHDISEH
DGDEQSRVAQVLIPTSTYPTGTHDIALRLHQPVLTDHVPVLCIPERTSEETLA
FRFSLVSGWGLDGRGATALEMNLNPRMLMIQCLQSKRGVGSFNITFMCAGY
SOGSKDCKDGGPHATHTGTWLTGIVSWGQCATVGHFGVTRVSVQYIEWLQKL
MRSEPRPGVLLRAPFP"
36. .215
/notes="factor VIIa signal peptide"
join(36. .99, 166. .1436)
/notes="preprofactor VIIb"
/codon_start=1
/protein_id="A88804.1"
/db_xref="GI:182800"
/translation="MVSQALRLCLLGLQGLAAGVAVTQEEAHGLHRRRAAFLE
EURPGSLRECKEEQCFEAREIFKDAERTKLFWISYSDGDQSCASPCNGGCKDQ
LOSYYICFLPAFGKNCETKDKDQLICVNEGCEQYCSDHGTNRKSCRCHEGSLA
DGVSCTPTVPGKIPILKRNASKPQGRIVGKVKCPKCECPMVLVAVGAQICGG
TLINTWVSAACFCFKIKNRNLIAVLGHDISEHDEQSRVAQVLIPTSTYPTGT
TNHDIALLRLHQPVLTDHVPVLCIPERTSEETLAIFRFLVSGWGLDGRGATLE
LNLVNLPRMLTIQCLQSKRGVGSFNITFMCAGYSDGSKDCKDGGPHATHTGRG
LWLTGIVSWGQCATVGHFGVTRVSVQYIEWLQKLMRSEPRPGVLLRAPFP"
join(36. .99, 166. .215)
/notes="factor VIIb signal peptide"
216. .671
/product="coagulation factor VII"
/notes="light chain"
672. .1433
/product="coagulation factor VII"
/notes="heavy chain"
<36. .99
/notes="preprofactor VIIb"
sig_peptide
CDS
join(36. .99, 166. .1436)
/notes="preprofactor VIIb"
mat_peptide
mat_peptide
exon

```

|                          |  |
|--------------------------|--|
| exon                     | /number=1<br>100..165<br>/notes="alternate exon; putative"   |
| exon                     | 166..2462<br>/notes="factor VIIb"<br>/number=2   |
| Query Match              | 0.6%; Score 20.4; DB 1; Length 2462;   |
| Best Local Similarity    | 52.3%; Pred. No. 2.3e+02;  |
| Matches 45; Conservative | 0; Mismatches 41; Indels 0; Gaps 0;  |
| QY                       | 452 ACTCCAGAAAGAATGAAGAGATGGAGCCAAAGCAAAAAGAAATACCCAGCTGTGGATGTGA 511  |
| Dd                       | 1931 ACACACGATGCACACACAGATGTCACACAGAGATACGCAACACACCAGTGCACACGC 1990  |
| QY                       | 512 CTGTGATATAAGCAAGTCCGATGC 537   |
| Dd                       | 1991 ACATAGAGATATGCACACACAGATGC 2016   |
| RESULT 220               |  |
| E01076                   | LOCUS E01076 2483 bp RNA linear PAT 29-SEP-1997  |
| DEFINITION               | cDNA sequence of Factor VII fragment.  |
| ACCESSION                | E01076   |
| VERSION                  | E01076.1 GI:2169335  |
| KEYWORDS                 | JP 1987000283-A/2.   |
| SOURCE                   | unidentified   |
| ORGANISM                 | unidentified   |
| REFERENCE                | 1 (bases 1 to 2483)  |
| AUTHORS                  | Furederitsuku,E.H., Maaku,J.M., Shiyaaron,J.B., Kiyasuriin,E.B.,<br>Maagaretuto,W.I., Richiyaado,J.U. and Chiyaaruzu,E.G.  |
| TITLE                    | DNA ENCODING FACTOR VII  |
| JOURNAL                  | Patient: JP 1987000283-A 2 06-JAN-1987;<br>HEMOJENETISUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD,<br>TOYO SODA MFG CO LTD<br>PN JP 1987000283-A/2<br>PD 06-JAN-1987<br>PF 16-APR-1986 JP 1986087861<br>PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI<br>PI SHIYAARON JIEI BAZUBII,<br>KIYASURIIN ERU BAKUNAA, MAAGARETSUTO WAI INSUREE, PI<br>RICHIYAADO JII UTSUDOBERRI, CHIYAARUZU ERU GURRI PC<br>C12N15/00,A6IK37/465,C12N5/00,C12N9/50,(C12N9/50,C12R1:91); CC<br>strandedness: Double;<br>CC topology: Linear;<br>CC hypothetical: No;<br>CC anti-sense: No;<br>CC *source: library=cDNA library;<br>CC *source: clone=lambdaVII 2463;<br>FH Key Location/Qualifiers<br>FT 5'UTR 1..35<br>FT sig_peptide 36..215<br>FT CDS 216..1436<br>FT /product='factor VII'<br>FT 3'UTR 1437..2462<br>FT misc_recomb 2462..<2480<br>FT /notes='polyA tail'.<br>Location/Qualifiers<br>FEATURES<br>source 1..2483<br>/organism="unidentified"<br>/mol_type="genomic RNA"<br>/db_xref="taxon:32644" |
| Query Match              | 0.6%; Score 20.4; DB 1; Length 2483;   |
| Best Local Similarity    | 52.3%; Pred. No. 2.3e+02;  |
| Matches 45; Conservative | 0; Mismatches 41; Indels 0; Gaps 0;  |
| QY                       | 452 ACTCCAGAAAGAATGAAGAGATGGAGCCAAAGCAAAAAGAAATACCCAGCTGTGGATGTGA 511  |







Query Match 0.6%; Score 20.2; DB 1; Length 582;  
 Best Local Similarity 53.1%; Pred. No. 2.3e+02;  
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 703 TACTACTGGCGGAGGAGTCCCTCAGAGAAATGGAGTAGCCATCATGTGTCAACAAAAGA 762  
 DB 92 TGCACCTGGGGAGAGGCTCCCGACGCCCACTGTGACTGTGCCCTCTGCCCTGCAGGAGA 151

QY 763 GTCCGAAATGCAGTACTTGA 783  
 DB 152 GTATGACCTGGCGGCTGGGA 172

RESULT 228  
 AB083690 694 bp DNA linear PRI 16-OCT-2002  
 LOCUS Homo sapiens PROC gene for Protein C, partial cds, isolate:patient;  
 DEFINITION PC 4.  
 ACCESSION AB083690  
 VERSION AB083690.1 GI:23978599  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1.  
 AUTHORS Kinoshita, S., Iida, H., Inoue, S., Watanabe, K., Kurihara, M., Wada, Y.,  
 Ono, M., Dongchon, K. and Hamasaki, N.  
 TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic  
 Patients. Genetic Background of Thrombophilia in Japan  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 694)  
 AUTHORS Hamasaki, N.  
 TITLE Direct Submission  
 JOURNAL Submitted (13-APR-2002) Naotaka Hamasaki, Kyushu University  
 Hospital, Department of clinical chemistry and laboratory medicine;  
 3-1-1 maidashi, Higashi-ku Fukuoka 812-8582, Japan  
 (E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,  
 Fax:81-92-642-5772)

FEATURES  
 source  
 1..694  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /isolate="patient: PC 4"  
 /db\_xref="taxon:9606"  
 61..694  
 /gene="PROC"  
 CDS  
 <61..694  
 /gene="PROC"  
 /codon\_start=3  
 /product="Protein C"  
 /protein\_id="BAC21165.1"  
 /db\_xref="GI:23978600"  
 /translation="EYDLRRWEKWLDDIKFVFNHYSKSTTNDIALHLAQPAT  
 LSQTIPICLPDSLAERLNQAGQETLVGTGWYHSSREKAKRRTFVNLFIPIPV  
 PHNECEVMSNMVSNMILCAGILGDRQDACEGSGPMVASFHGTWFLVLVSWGEGC  
 GLLNHYGVVTSOPLRLDPWAHQSGSPPEELGTLATLPAGLGFCAMDGT"

exon  
 61..694  
 /gene="PROC"  
 /product="Protein C"  
 /number=9  
 variation  
 573..574  
 /gene="PROC"  
 /replace="aa"

Query Match 0.6%; Score 20.2; DB 1; Length 594;  
 Best Local Similarity 53.1%; Pred. No. 2.3e+02;  
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 703 TACTACTGGCGGAGGAGTCCCTCAGAGAAATGGAGTAGCCATCATGTGTCAACAAAAGA 762  
 DB 5 TGCACCTGGGGAGAGGCTCCCGACGCCCACTCTGTGACTGTGCCCTCTGCCCTGCAGGAGA 64

QY 763 GTCCGAAATGCAGTACTTGA 783  
 DB 65 GTATGACCTGGCGGCTGGGA 85

RESULT 229  
 AB086852 696 bp DNA linear PRI 07-JAN-2003  
 LOCUS Homo sapiens PROC1 gene for Protein C, partial cds,  
 DEFINITION isolate:Patient:PC11.  
 ACCESSION AB086852  
 VERSION AB086852.1 GI:27531708  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1.  
 AUTHORS Kinoshita, S., Iida, H., Inoue, S., Watanabe, K., Kurihara, M., Wada, Y.,  
 Ono, M., Dongchon, K. and Hamasaki, N.  
 TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic  
 Patients. Genetic Background of Thrombophilia in Japan  
 JOURNAL Unpublished  
 REFERENCE 2 (bases 1 to 696)  
 AUTHORS Hamasaki, N.  
 TITLE Direct Submission  
 JOURNAL Submitted (23-JUN-2002) Naotaka Hamasaki, Kyushu University  
 Hospital, Department of clinical chemistry and laboratory medicine;  
 3-1-1 maidashi, Higashi-ku Fukuoka 812-8582, Japan  
 (E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,  
 Fax:81-92-642-5772)

FEATURES  
 Location/Qualifiers  
 1..696  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /isolate="Patient:PC11"  
 /db\_xref="taxon:9606"  
 61..650  
 /gene="PROC1"  
 CDS  
 <61..650  
 /gene="PROC1"  
 /codon\_start=3  
 /product="Protein C"  
 /protein\_id="BAC54280.1"  
 /db\_xref="GI:27531709"  
 /translation="EYDLRRWEKWLDDIKFVFNHYSKSTTNDIALHLAQPAT  
 LSQTIPICLPDSLAERLNQAGQETLVGTGWYHSSREKAKRRTFVNLFIPIPV  
 PHNECEVMSNMVSNMILCAGILGDRQDACEGSGPMVASFHGTWFLVLVSWGEGC  
 GLLNHYGVVTKVSRYLDMIHGHIRDKEAPKSWAP"  
 61..650  
 /gene="PROC1"  
 /product="Protein C"  
 /number=9  
 variation  
 234  
 /gene="PROC1"  
 /replace="g"

Query Match 0.6%; Score 20.2; DB 1; Length 696;  
 Best Local Similarity 53.1%; Pred. No. 2.3e+02;  
 Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 703 TACTACTGGCGGAGGAGTCCCTCAGAGAAATGGAGTAGCCATCATGTGTCAACAAAAGA 762  
 DB 5 TGCACCTGGGGAGAGGCTCCCGACGCCCACTCTGTGACTGTGCCCTCTGCCCTGCAGGAGA 64

QY 763 GTCCGAAATGCAGTACTTGA 783  
 DB 65 GTATGACCTGGCGGCTGGGA 85

RESULT 230  
 AB083693 696 bp DNA linear PRI 16-OCT-2002  
 LOCUS

DEFINITION Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:  
PC 3.  
ACCESSION AB083693  
VERSION AB083693.1 GI:23978603  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE  
AUTHORS 1 Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,  
Ono,M., Dongchon,K. and Hamasaki,N.  
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic  
Patients. Genetic Background of Thrombophilia in Japan  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 696)  
AUTHORS Hamasaki,N.  
TITLE Direct Submission  
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University  
Hospital, Department of clinical chemistry and laboratory medicine;  
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan  
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,  
Fax:81-92-642-5772)  
FEATURES  
source  
Location/Qualifiers  
1..696  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/isolate="patient:PC 3"  
/db\_xref="taxon:9606"  
61..650  
/gene="PROC"  
/name="PROC"  
/codon\_start=3  
/product="Protein C"  
/protein\_id="BAC21166.1"  
/db\_xref="GI:23978604"  
translation="EYDLRWEKWEKLDLKEVFPVHPNYSKSTTDNDIALHLAQPAT  
LSQTVPLCLPDSGLAEIRLNQAGQETLVGTGYHSSREKEAKRNTFVLNFKIPV  
PHNECEVSNMVSNNLCAGLIGRDQACEGSGPVMVAFHGTWFLVGLVSWGEGC  
GLLHNYGVYTKVSRVLDWIHGHIRKEAPQKSWAP"  
61..650  
/gene="PROC"  
/codon\_start=3  
/product="Protein C"  
/protein\_id="BAC21166.1"  
/db\_xref="GI:23978604"  
translation="EYDLRWEKWEKLDLKEVFPVHPNYSKSTTDNDIALHLAQPAT  
LSQTVPLCLPDSGLAEIRLNQAGQETLVGTGYHSSREKEAKRNTFVLNFKIPV  
PHNECEVSNMVSNNLCAGLIGRDQACEGSGPVMVAFHGTWFLVGLVSWGEGC  
GLLHNYGVYTKVSRVLDWIHGHIRKEAPQKSWAP"  
61..650  
/gene="PROC"  
/number=9  
variation  
Query Match 0.6%; Score 20.2; DB 1; Length 696;  
Best Local Similarity 53.1%; Pred. No. 2.3e+02;  
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;  
QY 703 TACTACTGCGGCGAGGAGTCCCTCAGAGAAATGGAGTACCATCATGTGTCAACAAAGA 762  
Db 5 TGCCACTGGGGAGAGCTCCCGCAGCCACTGTGACTGTGCCCTCTGCCCTGCAGGAGA 64  
QY 763 GTCCGAAATGCAGTACTTGA 783  
Db 65 GTATGACCTGGCGCGCTGGA 85  
RESULT 231  
AB083695  
LOCUS Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:  
DEFINITION PC 6.  
ACCESSION AB083695  
VERSION AB083695.1 GI:23978610  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE  
AUTHORS 1 Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,  
Ono,M., Dongchon,K. and Hamasaki,N.  
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic  
Patients. Genetic Background of Thrombophilia in Japan  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 696)  
AUTHORS Hamasaki,N.  
TITLE Direct Submission  
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University  
Hospital, Department of clinical chemistry and laboratory medicine;  
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan  
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,  
Fax:81-92-642-5772)  
FEATURES  
source  
Location/Qualifiers  
1..696  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/isolate="patient:PC 3"  
/db\_xref="taxon:9606"  
61..650  
/gene="PROC"  
/name="PROC"  
/codon\_start=3  
/product="Protein C"  
/protein\_id="BAC21166.1"  
/db\_xref="GI:23978604"  
translation="EYDLRWEKWEKLDLKEVFPVHPNYSKSTTDNDIALHLAQPAT  
LSQTVPLCLPDSGLAEIRLNQAGQETLVGTGYHSSREKEAKRNTFVLNFKIPV  
PHNECEVSNMVSNNLCAGLIGRDQACEGSGPVMVAFHGTWFLVGLVSWGEGC  
GLLHNYGVYTKVSRVLDWIHGHIRKEAPQKSWAP"  
61..650  
/gene="PROC"  
/codon\_start=3  
/product="Protein C"  
/protein\_id="BAC21166.1"  
/db\_xref="GI:23978604"  
translation="EYDLRWEKWEKLDLKEVFPVHPNYSKSTTDNDIALHLAQPAT  
LSQTVPLCLPDSGLAEIRLNQAGQETLVGTGYHSSREKEAKRNTFVLNFKIPV  
PHNECEVSNMVSNNLCAGLIGRDQACEGSGPVMVAFHGTWFLVGLVSWGEGC  
GLLHNYGVYTKVSRVLDWIHGHIRKEAPQKSWAP"  
61..650  
/gene="PROC"  
/number=9  
variation  
Query Match 0.6%; Score 20.2; DB 1; Length 696;  
Best Local Similarity 53.1%; Pred. No. 2.3e+02;  
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;  
QY 703 TACTACTGCGGCGAGGAGTCCCTCAGAGAAATGGAGTACCATCATGTGTCAACAAAGA 762  
Db 5 TGCCACTGGGGAGAGCTCCCGCAGCCACTGTGACTGTGCCCTCTGCCCTGCAGGAGA 64  
QY 763 GTCCGAAATGCAGTACTTGA 783  
Db 65 GTATGACCTGGCGCGCTGGA 85  
RESULT 231  
AB083695  
LOCUS Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:  
DEFINITION PC 6.  
ACCESSION AB083695  
VERSION AB083695.1 GI:23978610  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE  
AUTHORS 1 Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,  
Ono,M., Dongchon,K. and Hamasaki,N.  
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic  
Patients. Genetic Background of Thrombophilia in Japan  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 696)  
AUTHORS Hamasaki,N.  
TITLE Direct Submission  
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University  
Hospital, Department of clinical chemistry and laboratory medicine;  
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan  
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,  
Fax:81-92-642-5772)  
FEATURES  
source  
Location/Qualifiers  
1..896  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/isolate="patient:PC 6"  
/db\_xref="taxon:9606"  
61..650  
/gene="PROC"  
/name="PROC"  
/codon\_start=3  
/product="Protein C"  
/protein\_id="BAC21167.1"  
/db\_xref="GI:23978611"  
translation="EYDLRWEKWEKLDLKEVFPVHPNYSKSTTDNDIALHLAQPAT  
LSQTVPLCLPDSGLAEIRLNQAGQETLVGTGYHSSREKEAKRNTFVLNFKIPV  
PHNECEVSNMVSNNLCAGLIGRDQACEGSGPVMVAFHGTWFLVGLVSWGEGC  
GLLHNYGVYTKVSRVLDWIHGHIRKEAPQKSWAP"  
61..650  
/gene="PROC"  
/product="Protein C"  
/number=9  
variation  
Query Match 0.6%; Score 20.2; DB 1; Length 696;  
Best Local Similarity 53.1%; Pred. No. 2.3e+02;  
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;  
QY 703 TACTACTGCGGCGAGGAGTCCCTCAGAGAAATGGAGTACCATCATGTGTCAACAAAGA 762  
Db 5 TGCCACTGGGGAGAGCTCCCGCAGCCACTGTGACTGTGCCCTCTGCCCTGCAGGAGA 64  
QY 763 GTCCGAAATGCAGTACTTGA 783  
Db 65 GTATGACCTGGCGCGCTGGA 85  
RESULT 232  
AB083696  
LOCUS Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:  
DEFINITION PC 2.  
ACCESSION AB083696  
VERSION AB083696.1 GI:23978613  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE  
AUTHORS 1 Kinoshita,S., Iida,H., Inoue,S., Watanabe,K., Kurihara,M., Wada,Y.,  
Ono,M., Dongchon,K. and Hamasaki,N.  
TITLE Gene Analysis of Anticoagulation Factors in Japanese Thrombotic  
Patients. Genetic Background of Thrombophilia in Japan  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 696)  
AUTHORS Hamasaki,N.  
TITLE Direct Submission  
JOURNAL Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University  
Hospital, Department of clinical chemistry and laboratory medicine;  
3-1-1 maidashi, Higashi-ku Fukuoka, Japan 812-8582, Japan  
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp, Tel:81-92-642-5770,  
Fax:81-92-642-5772)

**AUTHORS** Hamasaki, N.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University Hospital, Department of Clinical chemistry and laboratory medicine; 3-1-1 maidaishi, Higashi-ku Fukuokasi, Fukuoka 812-8582, Japan (E-mail:hamasaki@ccim.med.kyushu-u.ac.jp, Tel:81-92-642-5770, Fax:81-92-642-5772)

**FEATURES**  
**source** 1..697  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /isolate="patient: PC 2"  
 /db\_xref="taxon:9606"  
 61..650  
 /gene="PROC"  
 <61..650  
 /gene="PROC"  
 /codon\_start=3  
 /product="Protein C"  
 /protein\_id="BAC21168.1"  
 /db\_xref="GI:23978614"  
 /translation="EVDLRWEKWEKWDLDIKEVDFVHPNYSKSTTDNDIALHLAQPAT  
 LSQTVPLCLPDSGLAERLNQAGQETLVGWHYSRSEKAKRNTLVLFKIPV  
 PNECEVMSNVSNMLCAGILGRQDCEGDSGGMVASFHGTWFLVGLVSWGEGC  
 GLLHNVSVTVKVSRYLDWTHGHRDKEAPQKSWAP"  
 61..650  
 /gene="PROC"  
 /product="Protein C"  
 /number=9  
 561  
 /gene="PROC"  
 /replace="g"

**gene**  
**CDS**

**variation**  
 561  
 /gene="PROC"  
 /replace="g"

**Query Match** 0.6%; Score 20.2; DB 1; Length 696;  
**Best Local Similarity** 53.1%; Pred.No. 2.3e+02;  
**Matches** 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

**QY** 703 TACTACTGGCGGAGAGAAATCCCTCAGAGAAATGGAGTAGCCATCATGTGTCAACAAAGA 762  
 |||||  
**Db** 5 TGCCACTGGGAGAGGCTCCCGCAGCCACTCTGACTGTGCCCTCGCCCTGCAGGAGA 64  
 |||||

**QY** 763 GTCCGAAATGCAGTACTTGA 783  
 |||||  
**Db** 65 GTATGACCTCGCGCGCTGGGA 85  
 |||||

**RESULT 233**  
**AB083694**  
**LOCUS** AB083694.1 GI:23978607  
**DEFINITION** Homo sapiens PROC gene for Protein C, partial cds, isolate:patient:PC 9.  
**ACCESSION** AB083694  
**VERSION** AB083694.1  
**KEYWORDS**  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
**REFERENCE** 1  
**AUTHORS** Kinoshta, S., Iida, H., Inoue, S., Watanabe, K., Kurihara, M., Wada, Y., Ono, M., Dongchon, K. and Hamasaki, N.  
**TITLE** Gene Analysis of Anticoagulation Factors in Japanese Thrombotic Patients. Genetic Background of Thrombophilia in Japan  
**JOURNAL** Unpublished  
**REFERENCE** 2 (bases 1 to 697)  
**AUTHORS** Hamasaki, N.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (14-APR-2002) Naotaka Hamasaki, Kyushu University Hospital, Department of clinical chemistry and laboratory medicine; 3-1-1 maidaishi, Higashi-ku Fukuokasi, Fukuoka 812-8582, Japan (E-mail:hamasaki@ccim.med.kyushu-u.ac.jp, Tel:81-92-642-5770, Fax:81-92-642-5772)  
**FEATURES** Location/Qualifiers

**source** 1..697  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /isolate="patient: PC 9"  
 /db\_xref="taxon:9606"  
 61..651  
 /gene="PROC"  
 61..651  
 /gene="PROC"  
 /product="Protein C"  
 /number=9  
 <61..651  
 /gene="PROC"  
 /product="Protein C"  
 /note="unfunctional CDS region"  
 477  
 /gene="PROC"  
 /replace=""

**gene**  
**exon**  
 61..651  
 /gene="PROC"  
 /product="Protein C"  
 /number=9  
 <61..651  
 /gene="PROC"  
 /product="Protein C"  
 /note="unfunctional CDS region"  
 477  
 /gene="PROC"  
 /replace=""

**misc\_feature**  
 <61..651  
 /gene="PROC"  
 /product="Protein C"  
 /note="unfunctional CDS region"  
 477  
 /gene="PROC"  
 /replace=""

**variation**  
 477  
 /gene="PROC"  
 /replace=""

**Query Match** 0.6%; Score 20.2; DB 1; Length 697;  
**Best Local Similarity** 53.1%; Pred.No. 2.3e+02;  
**Matches** 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

**QY** 703 TACTACTGGCGGAGAGAAATCCCTCAGAGAAATGGAGTAGCCATCATGTGTCAACAAAGA 762  
 |||||  
**Db** 5 TGCCACTGGGAGAGGCTCCCGCAGCCACTCTGACTGTGCCCTCGCCCTGCAGGAGA 64  
 |||||

**QY** 763 GTCCGAAATGCAGTACTTGA 783  
 |||||  
**Db** 65 GTATGACCTCGCGCGCTGGGA 85  
 |||||

**RESULT 234**  
**AY454079**  
**LOCUS** AY454079.1 GI:38532376  
**DEFINITION** Homo sapiens protein C gene, exon 9 and partial cds.  
**ACCESSION** AY454079  
**VERSION** AY454079.1  
**KEYWORDS**  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
**REFERENCE** 1  
**AUTHORS** Liu, J. and Sun, H.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (30-OCT-2003) School of Life Sciences, Northeast Normal University, Renming Street No138, Changchun, Jilin 130024, China  
**FEATURES** Location/Qualifiers  
**source** 1..747  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /chromosome="2"  
 /map="2q13-q21"  
 /country="China"  
 <70..726  
 /product="protein C"  
 70..726  
 /number=9  
 <70..659  
 /codon\_start=3  
 /product="protein C"  
 /protein\_id="AA223427.1"  
 /db\_xref="GI:38532377"  
 /translation="EYDURWEKWEKWDLDIKEVDFVHPNYSKSTTDNDIALHLAQPAT  
 LSQTVPLCLPDSGLAERLNQAGQETLVGWHYSRSEKAKRNTLVLFKIPV  
 PNECEVMSNVSNMLCAGILGRQDCEGDSGGMVASFHGTWFLVGLVSWGEGC  
 GLLHNVSVTVKVSRYLDWTHGHRDKEAPQKSWAP"  
 706..726  
 /note="affects mRNA processing"  
 /replace="ATTAAGGACATGTACA"  
 706..711  
 /polyA\_signal

|                       |   |  |
|-----------------------|---|--|
| Query Match           | 0.6%; Score 20.2; DB 1; Length 747;                                 |  |
| Best Local Similarity | 53.1%; Pred. No. 2.4e+02;   |  |
| Matches               | 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;                |  |
| QY                    | 703 TACTACTGGCGGAGAGTCCCTCAGAGAAATGGAGTAGGCATCATGCTCAACAAGA 762     |  |
| Db                    | 14 TGCCACTGGGAGAGCTCCCGCAGCCCACTCTGACTGTGCCCTGTGCCTGAGGAGA 73       |  |
| QY                    | 763 GTCCGAATGCAGTACTTGG 783   |  |
| Db                    | 74 GTATGACCTGGCGGCTTGGGA 94   |  |
| RESULT 235            |   |  |
| AF532184/c            | 1341 bp mRNA linear ROD 21-AUG-2002                                 |  |
| LOCUS                 | Rattus norvegicus coagulation factor VII mRNA, complete cds.        |  |
| DEFINITION            | AF532184  |  |
| ACCESSION             | AF532184.1 GI:22347744  |  |
| VERSION               |   |  |
| KEYWORDS              |   |  |
| SOURCE                | Rattus norvegicus (Norway rat)                                      |  |
| ORGANISM              | Rattus norvegicus   |  |
| REFERENCE             | Murphy, K. and Ramaker, M.  |  |
| AUTHORS               | Nucleotide sequence of the cDNA encoding rat coagulation factor VII |  |
| TITLE                 | Unpublished   |  |
| JOURNAL               | 2 (bases 1 to 1341)   |  |
| REFERENCE             | Murphy, K. and Ramaker, M.  |  |
| AUTHORS               | Direct Submission   |  |
| TITLE                 | Submitted (24-JUL-2002) Biotechnology, Bristol-Myers Squibb, P.O.   |  |
| JOURNAL               | Box 80336, Wilmington, DE 19880-0336, USA                           |  |
| FEATURES              | Location/Qualifiers   |  |
| source                | 1..1341   |  |
|                       | /organism="Rattus norvegicus"                                       |  |
|                       | /mol_type="mRNA"  |  |
|                       | /strain="Sprague-Dawley"  |  |
|                       | /db_xref="taxon:10115"  |  |
|                       | 1..1341   |  |
|                       | /codon_start=1  |  |
|                       | /product="coagulation factor VII"                                   |  |
|                       | /protein_id="AA095967.1"  |  |
|                       | /db_xref="GI:22347745"  |  |
|                       | /translation="MVPTQHGILLFLQLQGLGAVVFTQERHGVHLHRRANS                 |  |
|                       | LLLELWSLIERNEERCSFEAREIFKSPRTQFWITSDGDCASNPQNGGIC                   |  |
|                       | LQDKSVFCPLDFGRCEKNEQLICANENGDCDQYCRDHVGTGRTCSCHEDYV                 |  |
|                       | LDPEKVCSPKVPQGRIPVVEKRNFRPQGRIVGVYKPGCEPQAVLKFEALIL                 |  |
|                       | CGAVLDTRIVTAACFCFKFKGLVNIITVLGEHDFSEKEGEQVRLVEQVIMPNKYT             |  |
|                       | RGRTDHDIALVRLHRTVTIDYVPLCLPERAPSENTLASIFRSVSGWGLDRGAT               |  |
|                       | ALEMLVTEVRLMQDCEHAKHNSAPRITENMFCAGMGTGCKACKDGGGPHATH                |  |
|                       | YHGTWLTGVVSGEGCAAGHIGTVTVSVQIDMLVTKVMSKLRVGI.SRVSL"                 |  |
| Query Match           | 0.6%; Score 20.2; DB 1; Length 1341;                                |  |
| Best Local Similarity | 46.2%; Pred. No. 2.5e+02;   |  |
| Matches               | 67; Conservative 0; Mismatches 78; Indels 0; Gaps 0;                |  |
| QY                    | 41 CCAAGGTAAGAGGAGTAGTGGCTTTGCTGGAGAGCGCGTAAGAGATACCCACGCC 100      |  |
| Db                    | 1027 CCTCGATGACCATGAGCTCCAGAGCTGTGGACACCGTCCAGTAGCTGGCCCGCAGCGC 968 |  |
| QY                    | 101 CAAGGTAAGAGAACCAAGTAAGATGAGTGGTGTGTGAGAGGGGATCAGAGGGCAGAC 160   |  |
| Db                    | 967 TGACCTCGAAGCGGATGCTGGCTAGGGTGTCTCGGAGAGGCCGCTTCAGGAGAC 908      |  |
| QY                    | 161 ATACTGAACCATACACCGAGAAA 185                                     |  |
| Db                    | 907 ACAGAGGTACACAGTAGTCACTGAA 883                                   |  |

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 2462)  
AUTHORS Thorpe, P.E. and Edgington, T.S.  
TITLE Methods and compositions for the specific coagulation of vasculature  
JOURNAL Patent: US 6093399-A 25 JUL-2000;  
FEATURES Location/Qualifiers  
source 1..2462  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 20.2; DB 1; Length 2462;  
Best Local Similarity 49.5%; Pred. No. 2.5e+02;  
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2571 CAGAAGAGCTGACTCACTGGAAGACCTGATGCTGGGAGGATTGGGGCAGGAGGAG 2630  
|||||  
DB 1846 CAGAGCAGAGCTGAGGGCCAGCAGATCAGCGTCAGGTGGGCTTGGCTGAAGGGAGGT 1787  
|||||

QY 2631 AAGGGACGACAGAGGATGAGTGGCTGGATGCATCACTGACTC 2675  
|||||  
DB 1786 AAGGAGGCTCAGCTGGGCTGTGCTCCAGGACACCTTGGCAC 1742  
|||||

RESULT 239  
AX335083/c  
LOCUS AX335083 2462 bp DNA linear PAT 09-JAN-2002  
DEFINITION Sequence 5592 from Patent WO0194629.  
ACCESSION AX335083  
VERSION AX335083.1 GI:18125802  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,  
Horrigan, S., Soppet, D.R. and Weaver, Z.  
TITLE Cancer gene determination and therapeutic screening using signature  
gene sets  
JOURNAL Patent: WO 0194629-A 5592 13-DEC-2001;  
Avalon Pharmaceuticals (US)  
FEATURES Location/Qualifiers  
source 1..2462  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 20.2; DB 1; Length 2462;  
Best Local Similarity 49.5%; Pred. No. 2.5e+02;  
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2571 CAGAAGAGCTGACTCACTGGAAGACCTGATGCTGGGAGGATTGGGGCAGGAGGAG 2630  
|||||  
DB 1846 CAGAGCAGAGCTGAGGGCCAGCAGATCAGCGTCAGGTGGGCTTGGCTGAAGGGAGGT 1787  
|||||

QY 2631 AAGGGACGACAGAGGATGAGTGGCTGGATGCATCACTGACTC 2675  
|||||  
DB 1786 AAGGAGGCTCAGCTGGGCTGTGCTCCAGGACACCTTGGCAC 1742  
|||||

RESULT 240  
AX409604/c  
LOCUS AX409604 2462 bp DNA linear PAT 14-JUN-2002  
DEFINITION Sequence 2251 from Patent WO0229103.  
ACCESSION AX409604  
VERSION AX409604.1 GI:21442309  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Alvares, C., Horne, D., Peres-da-silva, S. and Vockley, J.G.  
TITLE Gene expression profiles in liver cancer  
JOURNAL Patent: WO 0229103-A 2251 11-APR-2002;  
GENE LOGIC INC (US)  
FEATURES Location/Qualifiers  
source 1..2462  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="EMBL/GenBank Accession No. M13232"

Query Match 0.6%; Score 20.2; DB 1; Length 2462;  
Best Local Similarity 49.5%; Pred. No. 2.5e+02;  
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

QY 2571 CAGAAGAGCTGACTCACTGGAAGACCTGATGCTGGGAGGATTGGGGCAGGAGGAG 2630  
|||||  
DB 1846 CAGAGCAGAGCTGAGGGCCAGCAGATCAGCGTCAGGTGGGCTTGGCTGAAGGGAGGT 1787  
|||||

QY 2631 AAGGGACGACAGAGGATGAGTGGCTGGATGCATCACTGACTC 2675  
|||||  
DB 1786 AAGGAGGCTCAGCTGGGCTGTGCTCCAGGACACCTTGGCAC 1742  
|||||

RESULT 241  
HUMFVII/c  
LOCUS HUMFVII 2462 bp mRNA linear PRI 13-FEB-1996  
DEFINITION Human factor VII serine protease precursor mRNA, complete cds,  
clone lambda-HVII2463.  
ACCESSION M13232  
VERSION M13232.1 GI:182799  
KEYWORDS factor VII; serine protease; serum glycoprotein.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 2462)  
AUTHORS Hagen, F.S., Gray, C.L., O'Hara, P.J., Grant, F.J., Saari, G.C.,  
Woodbury, R.G., Hart, C.E., Insley, M., Kiesel, W., Kurachi, K. and  
Davie, E.W.  
TITLE Characterization of a cDNA coding for human factor VII  
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 83 (8), 2412-2416 (1986)  
MEDLINE 86205965  
PubMed 3486420  
COMMENT Original source text: Homo sapiens liver cDNA to mRNA.  
Draft entry and sequence in computer-readable form for [1] kindly  
provided by F.S.Hagen.  
[1] sequenced two alternatively spliced mRNAs that produced  
shortened signal peptides. One is presented as factor VIIb below.

FEATURES Location/Qualifiers  
source 1..2462  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/tissue type="liver"  
<1..2462  
/product="FVIIa mRNA"  
36..1436  
/note="precursor for factor VIIa and b"  
/codon\_start=1  
/product="coagulation factor VII"  
/protein\_id="AAA88040.1"  
/db\_xref="GI:182801"

mRNA  
CDS

translation="MWSQALRLCLLGLQCLLAGGVAKASGGSTRDMPKPHGRV  
FVTEAEAVLHRRRANAFLEELPGSLERECEEQCFBEARIFDKAERLKLFI  
YSDGDDQASSPCQNGSKQDQSYICFLPAFEGNCTHKKDQLTCVNEGSCQ  
YSDHTGTRSCRCHEGYSLLADGVSCTPTVPCGKIPILEKNASPOGRIVGGKV  
CPKGCPOVILLVNGAQLCGGTLINT:WVSAACFDKIKNRNLIATLGHDLSEH  
DGDEQSRRAVQIIIPSTVPGTTHDIALHLHOPVLTLDHVPLCLPRTFSRETLA  
FVRFSLVSGMQLDRGATALEMLVLPRLMTQDCLQOSRKVGSFNITVMPGAGY  
SDGSKDSCKSGGSGPHATHTGWTLTGIVSWGQCATVGHFVYTRVSQVLEWLQKL

```

sig_peptide
36. .215
/note="factor VIIa signal peptide"
join(36. .99,166. .1436)
CDS
/note="preprofactor VIIb"
/codon_start=1
/protein_id="AA08041.1"
/db_xref="GI:182800"
/translation="MVSOALLCLLLGLQCLAAVFTQBEAHGVLRHRRANAFLE
ELRPSLERECKEQCFEAREIFKDAERTKLFWSYSDQDQCCASSPCQNGGCKDQ
LQSYICFLPAFEGNCEHDKDOLI CVNENGCEQYCSDHGTGTRKSCRCHEGYSLIA
DGVSTPVEPCGKIPILEKNASKPQIVGGKVPKGCEPMOVLVLLVNGAQLCGG
TLNITMVVSAHCFDKIKWNLIAVLGHDLSEHGDQSRRAOVIIIPSTVTPGT
TNHIALRLHQPVLVDHVPVLCIPERTSERPLAFVRESLUSGQQLDRGATALE
LWLVNPKMLTQDCLQGRKVGSDPNITFYNFCAGYSDGSKGSGSGPETHRNG
TWYLTGIVSMWQGCATGVHGFYTRVSQYIEWLQKMRSEPRPGVILLRAPPF"
join(36. .99,166. .215)
/note="factor VIIb signal peptide"
mat_peptide
216. .671
/product="coagulation factor VII"
/note="light chain"
672. .1433
/product="coagulation factor VII"
/note="heavy chain"
<36. .99
/note="preprofactor VIIb"
/number=1
exon
100. .165
/note="alternate exon; putative"
166. .2462
/note="factor VIIb"
/number=2
Query Match 0.6%; Score 20.2; DB 1; Length 2462;
Best Local Similarity 49.5%; Pred. No. 2.5e+02;
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;
QY 2571 CAGAGAGTGCTACTGCAAGAACCTGATGCTGGAGGAGTGGGGCAGGAGGAG 2630
|||||
DB 1846 CAGACGACAGCTGAGGCGCCAGACATCAGCTGCGAGTGGGGCTTGCTGAAGGAGCT 1787
|||||
QY 2631 AAGGGAGCAGACAGAGATGAGATGGCTGGATGGCTACTGACTC 2675
|||||
DB 1786 AAGGAGGCTCAGCTGGGCTGTCTGCTCCAGGACACCTTGGCAC 1742
|||||
RESULT 242
AX655170/c 199 bp DNA linear PAT 22-MAR-2003
LOCUS
Sequence 5040 from Patent WO03000898.
ACCESSION AX655170
VERSION AX655170.1 GI:29157984
KEYWORDS
SOURCE Oryza sativa
ORGANISM Oryza sativa
REFERENCE
1 Chang,H.S., Chen,W., Cooper,B., Glazebrook,J., Goff,S.A., Hou,Y.M.,
Katagiri,F., Quan,S., Tag,Y., Whitham,S., Xie,Z., Zhu,T. and Zou,G.
Plant genes involved in defense against pathogens
Patent: WO 03000898-A 5040 03-JAN-2003;
Syngenta Participations AG (CH)
FEATURES
Location/Qualifiers
1. .199
/organism="Oryza sativa"
/mol_type="unassigned DNA"
/db_xref="taxon:4530"
Query Match 0.6%; Score 20; DB 1; Length 199;
Best Local Similarity 47.6%; Pred. No. 2.1e+02;
Matches 59; Conservative 0; Mismatches 65; Indels 0; Gaps 0;
MRSEPRPGVLLRAPFP"
36. .215
/note="factor VIIa signal peptide"
join(36. .99,166. .1436)
CDS
/note="preprofactor VIIb"
/codon_start=1
/protein_id="AA08041.1"
/db_xref="GI:182800"
/translation="MVSOALLCLLLGLQCLAAVFTQBEAHGVLRHRRANAFLE
ELRPSLERECKEQCFEAREIFKDAERTKLFWSYSDQDQCCASSPCQNGGCKDQ
LQSYICFLPAFEGNCEHDKDOLI CVNENGCEQYCSDHGTGTRKSCRCHEGYSLIA
DGVSTPVEPCGKIPILEKNASKPQIVGGKVPKGCEPMOVLVLLVNGAQLCGG
TLNITMVVSAHCFDKIKWNLIAVLGHDLSEHGDQSRRAOVIIIPSTVTPGT
TNHIALRLHQPVLVDHVPVLCIPERTSERPLAFVRESLUSGQQLDRGATALE
LWLVNPKMLTQDCLQGRKVGSDPNITFYNFCAGYSDGSKGSGSGPETHRNG
TWYLTGIVSMWQGCATGVHGFYTRVSQYIEWLQKMRSEPRPGVILLRAPPF"
join(36. .99,166. .215)
/note="factor VIIb signal peptide"
mat_peptide
216. .671
/product="coagulation factor VII"
/note="light chain"
672. .1433
/product="coagulation factor VII"
/note="heavy chain"
<36. .99
/note="preprofactor VIIb"
/number=1
exon
100. .165
/note="alternate exon; putative"
166. .2462
/note="factor VIIb"
/number=2
Query Match 0.6%; Score 20; DB 1; Length 2462;
Best Local Similarity 49.5%; Pred. No. 2.5e+02;
Matches 52; Conservative 0; Mismatches 53; Indels 0; Gaps 0;
QY 2571 CAGAGAGTGCTACTGCAAGAACCTGATGCTGGAGGAGTGGGGCAGGAGGAG 2630
|||||
DB 1846 CAGACGACAGCTGAGGCGCCAGACATCAGCTGCGAGTGGGGCTTGCTGAAGGAGCT 1787
|||||
QY 2631 AAGGGAGCAGACAGAGATGAGATGGCTGGATGGCTACTGACTC 2675
|||||
DB 1786 AAGGAGGCTCAGCTGGGCTGTCTGCTCCAGGACACCTTGGCAC 1742
|||||
RESULT 242
AX655170/c 199 bp DNA linear PAT 22-MAR-2003
LOCUS
Sequence 5040 from Patent WO03000898.
ACCESSION AX655170
VERSION AX655170.1 GI:29157984
KEYWORDS
SOURCE Oryza sativa
ORGANISM Oryza sativa
REFERENCE
1 Chang,H.S., Chen,W., Cooper,B., Glazebrook,J., Goff,S.A., Hou,Y.M.,
Katagiri,F., Quan,S., Tag,Y., Whitham,S., Xie,Z., Zhu,T. and Zou,G.
Plant genes involved in defense against pathogens
Patent: WO 03000898-A 5040 03-JAN-2003;
Syngenta Participations AG (CH)
FEATURES
Location/Qualifiers
1. .199
/organism="Oryza sativa"
/mol_type="unassigned DNA"
/db_xref="taxon:4530"
Query Match 0.6%; Score 20; DB 1; Length 199;
Best Local Similarity 47.6%; Pred. No. 2.1e+02;
Matches 59; Conservative 0; Mismatches 65; Indels 0; Gaps 0;

```

```

QY 2605 CTGGGAGGATTGGGGCAGAGGAGGAGGAGGAGGAGGATGAGATGGCTGGATGC 2664
|||||
DB 147 CTGGGATTCTTCGCGACGCGAGGAGGAGGAGGAGGCGGGGTGGGAATTTGGGGATTTC 88
|||||
QY 2665 ATCACTGACTCGATGACCTGAGTCTGGGTGAACCTCTCTGAGTTGGTATGACAGGAG 2724
|||||
DB 87 GGCGTCGGGAAGGAAGTTGGGGCGGAGATTGGAAAGTTGGGATATTTAGGGC 28
|||||
QY 2725 GCCT 2728
|||||
DB 27 GCCT 24
|||||
RESULT 243
AF542508
LOCUS Rattus norvegicus adenyl cyclase 7 mRNA linear ROD 03-OCT-2002
DEFINITION Rattus norvegicus adenyl cyclase 7 mRNA, partial cds.
ACCESSION AF542508
VERSION AF542508.1 GI:23477371
KEYWORDS Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1 (bases 1 to 256)
AUTHORS Haunso,A. and Antoni,P.
TITLE Direct Submission
JOURNAL Submitted (02-SEP-2002) Department of Neuroscience, University of
Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK
FEATURES
Location/Qualifiers
1. .256
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Sprague-Dawley"
/db_xref="taxon:10116"
/tissue_type="anterior pituitary gland"
<1. .256
/codon_start=2
/product="adenyl cyclase 7"
/protein_id="AAN34659.1"
/db_xref="GI:23477372"
/translation="LLLPKFSQVEKIKTIGSTYMAAGISVPFSGHENQDLERKHVHI
GVLFVFSMALMSKLDGINRHSFNSFRLRVGINHPVIAGVI"
Query Match 0.6%; Score 20; DB 1; Length 256;
Best Local Similarity 51.1%; Pred. No. 2.2e+02;
Matches 47; Conservative 0; Mismatches 45; Indels 0; Gaps 0;
QY 651 CGAAGTAAATGGACTGGAATGGTGAATTAAGTCAATGACATGACATATATCTACTG 710
|||||
DB 15 CCAAGTTTCAGTGTGTGGAGAGATCAAGACCATTTGGCAGCACCCTACATGGTCTGAG 74
|||||
QY 711 CGGGCAGGAATCCCTCAGAGAAATGGAGTAG 742
|||||
DB 75 GGCTCAGTGTCCCTCAGGACATGAGAACCCAG 106
|||||
RESULT 244
AF005089
LOCUS Triticum aestivum phenylalanine ammonia lyase (War7.2) mRNA,
DEFINITION partial cds.
ACCESSION AF005089
VERSION AF005089.1 GI:6996627
KEYWORDS Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Pooidae; Triticeae; Triticum.
REFERENCE 1 (bases 1 to 276)

```

AUTHORS Hamel, F., Breton, C. and Houde, M.  
 TITLE Isolation and characterization of wheat aluminum-regulated genes:  
 possible involvement of aluminum as a pathogenesis response  
 elicitor  
 JOURNAL Planta 205 (4), 531-538 (1998)  
 MEDLINE 98348982  
 PUBMED 9684357  
 REFERENCE 2 (bases 1 to 276)  
 AUTHORS Hamel, F., Breton, C. and Houde, M.  
 TITLE Direct Submission  
 JOURNAL Submitted (22-MAY-1997) Departement des Sciences Biologiques,  
 Universite du Quebec a Montreal, C.P. 8888, Succ. Centre-ville,  
 Montreal, Quebec H3C 3P8, Canada  
 FEATURES  
 source Location/Qualifiers  
 1..276  
 /organism="Triticum aestivum"  
 /mol\_type="mRNA"  
 /cultivar="Atlas-66"  
 /db\_xref="taxon:4565"  
 /clone="WAR13.2"  
 /tissue\_type="root tips"  
 /dev\_stage="5 days old seedlings"  
 /note="hexaploid"  
 <1..>276  
 /gene="War7.2"  
 <1..>276  
 /gene="War7.2"  
 /note="up-regulated by aluminum"  
 /codon\_start=2  
 /product="phenylalanine ammonia lyase"  
 /protein\_id="AAF34815.1"  
 /db\_xref="GI:6986828"  
 /translation="RARGEDRGRLRVQGVAAVAQKASGISVELDEEARPRVKASS  
 EWILSLGARHLRHRLRHLPFHQGRARPPGGAPOASERNWLP"  
 Query Match 0.6%; Score 20; DB 1; Length 276;  
 Best Local Similarity 55.9%; Pred. No. 2.2e+02;  
 Matches 38; Conservative 0; Mismatches 30; Indels 0; Gaps 0;  
 QY 1192 TGGAGAGCTCTATACAGTCACGACAAACAAACAGCAGGACTTACTGTGGCTCAGATCAT 1251  
 DB 10 TGGTGAAGATCAGGCGCGCAGCTCGGTCGCGCAGGTGGCGCGTGGCGCCAGGCCAA 69  
 QY 1252 GAATCCT 1259  
 DB 70 GGACGGT 77  
 RESULT 245  
 LOCUS AR424808/c 300 bp DNA linear PAT 18-DEC-2003  
 DEFINITION Sequence 16305 from patent US 6639063.  
 ACCESSION AR424808  
 VERSION AR424808.1 GI:40179918  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 300)  
 AUTHORS Edwards, J.-B.D.M., Jobert, S. and Giordano, J.-Y.  
 TITLE EST's and encoded human proteins  
 JOURNAL Patent: US 6639063-A 16305 28-OCT-2003;  
 FEATURES  
 source Location/Qualifiers  
 1..300  
 /organism="unknown"  
 /mol\_type="genomic DNA"  
 Query Match 0.6%; Score 20; DB 1; Length 300;  
 Best Local Similarity 48.9%; Pred. No. 2.2e+02;  
 Matches 44; Conservative 3; Mismatches 43; Indels 0; Gaps 0;  
 QY 11 GCGGAGTGAGGAGGAGTACCTACCTCGTCCAAAGGTAAGGAGCAGTAGCTGGCTTGC 70  
 DB 10 TGGTGAAGATCAGGCGCGCAGCTCGGTCGCGCAGGTGGCGCGTGGCGCCAGGCCAA 69  
 QY 1252 GAATCCT 1259  
 DB 70 GGACGGT 77  
 RESULT 246  
 LOCUS BD120361/c 300 bp DNA linear PAT 18-SEP-2002  
 DEFINITION EST and encoded human protein.  
 ACCESSION BD120361  
 VERSION BD120361.1 GI:23215271  
 KEYWORDS JP 2002010789-A/12438.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 300)  
 AUTHORS Edwards, J.B.D.M., Jobert, S. and Giordano, J.E.  
 TITLE EST and encoded human protein  
 JOURNAL Patent: JP 2002010789-A 12438 15-JAN-2002;  
 COMMENT GENSET CORP  
 OS Homo sapiens (human)  
 PN JP 2002010789-A/12438  
 PD 15-JAN-2002  
 PF 07-AUG-2000 JP 2002080989  
 PR 05-AUG-1999 US 60/147499  
 PI JEAN BAPTIST DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI  
 GIORDANO  
 PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC  
 C12N1/21,  
 PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC  
 C12N15/00  
 CC EST and encoded human protein  
 FH Key Location/Qualifiers  
 FT source 1..300  
 /organism="Homo sapiens (human)"  
 FEATURES  
 source Location/Qualifiers  
 1..300  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 Query Match 0.6%; Score 20; DB 1; Length 300;  
 Best Local Similarity 48.9%; Pred. No. 2.2e+02;  
 Matches 44; Conservative 3; Mismatches 43; Indels 0; Gaps 0;  
 QY 11 GCGGAGTGAGGAGGAGTACCTACCTCGTCCAAAGGTAAGGAGCAGTAGCTGGCTTGC 70  
 DB 10 TGGTGAAGATCAGGCGCGCAGCTCGGTCGCGCAGGTGGCGCGTGGCGCCAGGCCAA 69  
 QY 71 TGGAGCAGCGGTAAAGAGATACCCACGCC 100  
 DB 108 TCGTGAACCATSSAAACAGCCGCCSCGC 79  
 RESULT 247  
 LOCUS DOGCFVII 478 bp DNA linear MAM 05-FEB-1999  
 DEFINITION Dog gene for coagulation factor VII, partial cds.  
 ACCESSION D21213  
 VERSION D21213.1 GI:415264  
 KEYWORDS coagulation factor VII.  
 SOURCE Canis familiaris (dog)  
 ORGANISM Canis familiaris  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
 REFERENCE 1 (bases 1 to 478)  
 AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and  
 Niho, Y.  
 TITLE Analysis of the partial nucleotide sequences and deduced primary  
 structures of the protease domains of mammalian blood coagulation

Db 168 GCTGCTCTGCACCTSGAGCCACCCCTGGCCATGGGATGAGCAGCTGGTGGTCTCTAA 109  
 QY 71 TGGAGCAGCGGTAAAGAGATACCCACGCC 100  
 DB 108 TCGTGAACCATSSAAACAGCCGCCSCGC 79  
 RESULT 246  
 LOCUS BD120361/c 300 bp DNA linear PAT 18-SEP-2002  
 DEFINITION EST and encoded human protein.  
 ACCESSION BD120361  
 VERSION BD120361.1 GI:23215271  
 KEYWORDS JP 2002010789-A/12438.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 300)  
 AUTHORS Edwards, J.B.D.M., Jobert, S. and Giordano, J.E.  
 TITLE EST and encoded human protein  
 JOURNAL Patent: JP 2002010789-A 12438 15-JAN-2002;  
 COMMENT GENSET CORP  
 OS Homo sapiens (human)  
 PN JP 2002010789-A/12438  
 PD 15-JAN-2002  
 PF 07-AUG-2000 JP 2002080989  
 PR 05-AUG-1999 US 60/147499  
 PI JEAN BAPTIST DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI  
 GIORDANO  
 PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC  
 C12N1/21,  
 PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC  
 C12N15/00  
 CC EST and encoded human protein  
 FH Key Location/Qualifiers  
 FT source 1..300  
 /organism="Homo sapiens (human)"  
 FEATURES  
 source Location/Qualifiers  
 1..300  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 Query Match 0.6%; Score 20; DB 1; Length 300;  
 Best Local Similarity 48.9%; Pred. No. 2.2e+02;  
 Matches 44; Conservative 3; Mismatches 43; Indels 0; Gaps 0;  
 QY 11 GCGGAGTGAGGAGGAGTACCTACCTCGTCCAAAGGTAAGGAGCAGTAGCTGGCTTGC 70  
 DB 108 TCGTGAACCATSSAAACAGCCGCCSCGC 79  
 RESULT 247  
 LOCUS DOGCFVII 478 bp DNA linear MAM 05-FEB-1999  
 DEFINITION Dog gene for coagulation factor VII, partial cds.  
 ACCESSION D21213  
 VERSION D21213.1 GI:415264  
 KEYWORDS coagulation factor VII.  
 SOURCE Canis familiaris (dog)  
 ORGANISM Canis familiaris  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
 REFERENCE 1 (bases 1 to 478)  
 AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and  
 Niho, Y.  
 TITLE Analysis of the partial nucleotide sequences and deduced primary  
 structures of the protease domains of mammalian blood coagulation



|   |   |  |  |  |
|---|---|--|--|--|
| JOURNAL<br>MEDLINE<br>PUBMED<br>REFERENCE<br>AUTHORS<br>TITLE<br>JOURNAL<br>COMMENT | factors VII and X<br>Eur. J. Haematol. 52 (3), 162-168 (1994)<br>94222160<br>8168596<br>2 (bases 1 to 478)<br>Murakawa,M.<br>Direct Submission<br>Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General<br>Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,<br>Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)<br>Submitted (18-Oct-1993) to DDBJ by:<br>Masahiro Murakawa<br>Division of Hematology<br>Harasanshin General Hospital<br>1-8 Taihaku-machi, Hakata-ku<br>Fukuoka, Fukuoka 812<br>Japan<br>Phone: 092-291-3434<br>Fax : 092-291-3266.  |  | Location/Qualifiers<br>1..478<br>/organism="Mus musculus"<br>/mol_type="genomic DNA"<br>/strain="Balb/c"<br>/db_xref="taxon:10090"<br><1..>483<br>/function="regulation of blood coagulation"<br>/note="catalytic region"<br>/codon_start=1<br>/product="protein C"<br>/protein_id="BAA07812.1"<br>/db_xref="GI:1304147"<br>/translation="DHWEIDLDI KEILVHPNTRSSNDIALLRLAQPATLSKTIIVP<br>ICLPNGLAQBELTQAGQETVATGWSQSDRIKDGERNFTFILTFIRIPLVARNECVE<br>VMNVVSENNLCAGIIGNTRDADGSDSGPMVFFRGTFWFLVGLVSWGSGCGHTNNY<br>I" |  |
|   | FEATURES<br>source  |  | Query Match 0.6%; Score 20; DB 1; Length 483;<br>Best Local Similarity 47.6%; Pred. No. 2.5e+02;<br>Matches 59; Conservative 0; Mismatches 65; Indels 0; Gaps 0;   |  |
|   | CDS   |  | QY 1447 ATCGACACATCCCATGGAAGAATGCAAAAAGCAAAATGGCTGTGGGAGGCC 1506<br>   <br>DB 124 ATAGTGCCCATCTGCCTGCGCAACAATGGCTCGCTCAGCAGAGCTCACTCAGGTGGC 183<br>   <br>QY 1507 TTACAAATAGCTGTGAAAGAGAGAGAGTCAAAAGCAAAAGCAAAAGCAAAAGATAAAG 1566<br>   <br>DB 184 CAGGAGACAGTGTGTGACAGCTGGGCTATCAAGGCACAGATCAAGATGCGAGAAG 243<br>   <br>QY 1567 CATC 1570<br>   <br>DB 244 AAC 247  |  |
|   | FEATURES<br>source  |  | RESULT 249<br>AR263931<br>LOCUS AR263931 488 bp DNA linear PAT 29-JAN-2003<br>DEFINITION Sequence 109 from patent US 6331427.<br>ACCESSION AR263931<br>VERSION AR263931.1 GI:28075935<br>KEYWORDS<br>SOURCE Unknown.<br>ORGANISM Unclassified.<br>REFERENCE 1 (bases 1 to 488)<br>AUTHORS Robison,K.E.<br>TITLE Protease homologs<br>JOURNAL Patent: US 6331427-A 109 18-DEC-2001;<br>FEATURES Location/Qualifiers<br>source 1..488<br>/organism="unknown"<br>/mol_type="genomic DNA"                              |  |
| JOURNAL<br>MEDLINE<br>PUBMED<br>REFERENCE<br>AUTHORS<br>TITLE<br>JOURNAL<br>COMMENT | MUSBALB6<br>483 bp DNA linear ROD 09-FEB-1999<br>Mouse gene for protein C (precursor of vitamin K-dependent serine<br>protease), partial cds (catalytic region).<br>D43755<br>D43755.1 GI:601897<br>protein C; serine protease zymogen; vitamin K-dependent serine<br>protease; blood coagulation-related.<br>Mus musculus (house mouse)<br>Mus musculus<br>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;<br>Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.<br>1 (bases 1 to 483)<br>Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and<br>Niho,Y.<br>A comparative study of partial primary structures of the catalytic<br>region of mammalian protein C<br>Br. J. Haematol. 86 (3), 590-600 (1994)<br>94318474<br>8043441<br>2 (bases 1 to 483)<br>Murakawa,M.<br>Direct Submission<br>Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General<br>Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,<br>Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266) |  | Query Match 0.6%; Score 20; DB 1; Length 478;<br>Best Local Similarity 55.9%; Pred. No. 2.5e+02;<br>Matches 38; Conservative 0; Mismatches 30; Indels 0; Gaps 0;   |  |
|   | QY 700 ATCTACTCTGGGCGAGGAATCCCTCAGAGAATGGAGTAGCCATCATGTCACACAA 759<br>   <br>DB 278 ACCGAGACTGCGAGGACGATCCCGCAGGAGAGTGGCTCCCGCCATCACTCAGGAT 337<br>   <br>QY 760 AGAGTCGG 767<br>   <br>DB 338 ATGTCTG 345  |  | QY 2207 GGGTCCAAAATCACTGCAGATGTGACTGCAGCCA-2242<br>   <br>DB 160 GCGGCGCAACATCACTCGGAGGCTTCTCTGCTGCA 195   |  |
|   | RESULT 248<br>MUSBALB6<br>LOCUS AR263931 488 bp DNA linear PAT 29-JAN-2003<br>DEFINITION Sequence 109 from patent US 6331427.<br>ACCESSION AR263931<br>VERSION AR263931.1 GI:28075935<br>KEYWORDS<br>SOURCE Unknown.<br>ORGANISM Unclassified.<br>REFERENCE 1 (bases 1 to 488)<br>AUTHORS Robison,K.E.<br>TITLE Protease homologs<br>JOURNAL Patent: US 6331427-A 109 18-DEC-2001;<br>FEATURES Location/Qualifiers<br>source 1..488<br>/organism="unknown"<br>/mol_type="genomic DNA"   |  | Query Match 0.6%; Score 20; DB 1; Length 488;<br>Best Local Similarity 72.2%; Pred. No. 2.5e+02;<br>Matches 26; Conservative 0; Mismatches 10; Indels 0; Gaps 0;   |  |
|   | RESULT 250<br>AX464088/c<br>LOCUS AX464088 1129 bp DNA linear PAT 16-JUL-2002<br>DEFINITION Sequence 221 from Patent WO0140466.<br>ACCESSION AX464088<br>VERSION AX464088.1 GI:21899060<br>KEYWORDS<br>SOURCE Homo sapiens (human)<br>ORGANISM Homo sapiens<br>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  |  | Query Match 0.6%; Score 20; DB 1; Length 488;<br>Best Local Similarity 72.2%; Pred. No. 2.5e+02;<br>Matches 26; Conservative 0; Mismatches 10; Indels 0; Gaps 0;   |  |
| JOURNAL<br>MEDLINE<br>PUBMED<br>REFERENCE<br>AUTHORS<br>TITLE<br>JOURNAL<br>COMMENT | factors VII and X<br>Eur. J. Haematol. 52 (3), 162-168 (1994)<br>94222160<br>8168596<br>2 (bases 1 to 478)<br>Murakawa,M.<br>Direct Submission<br>Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General<br>Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,<br>Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)<br>Submitted (18-Oct-1993) to DDBJ by:<br>Masahiro Murakawa<br>Division of Hematology<br>Harasanshin General Hospital<br>1-8 Taihaku-machi, Hakata-ku<br>Fukuoka, Fukuoka 812<br>Japan<br>Phone: 092-291-3434<br>Fax : 092-291-3266.  |  | Location/Qualifiers<br>1..478<br>/organism="Canis familiaris"<br>/mol_type="genomic DNA"<br>/db_xref="taxon:9615"<br><1..>478<br>/codon_start=2<br>/product="coagulation factor VII"<br>/protein_id="BAA04754.1"<br>/db_xref="GI:455390"<br>/translation="EDDGEQERHVARVIVDPKVIPLKTNHDIALLHLRTPVATDHW<br>VPLCLPFTFERTLAFIRFTVSGQLDRGATLQIMADIVRYMTQCPQSR<br>RSGSPAITENFCAGYLDGSKDACQDGGSPHATKFGQTYLTGWSWEGCAAEGH"   |  |
|   | FEATURES<br>source  |  | Query Match 0.6%; Score 20; DB 1; Length 478;<br>Best Local Similarity 55.9%; Pred. No. 2.5e+02;<br>Matches 38; Conservative 0; Mismatches 30; Indels 0; Gaps 0;   |  |
|   | CDS   |  | QY 1447 ATCGACACATCCCATGGAAGAATGCAAAAAGCAAAATGGCTGTGGGAGGCC 1506<br>   <br>DB 124 ATAGTGCCCATCTGCCTGCGCAACAATGGCTCGCTCAGCAGAGCTCACTCAGGTGGC 183<br>   <br>QY 1507 TTACAAATAGCTGTGAAAGAGAGAGTCAAAAGCAAAAGCAAAAGCAAAAGATAAAG 1566<br>   <br>DB 184 CAGGAGACAGTGTGTGACAGCTGGGCTATCAAGGCACAGATCAAGATGCGAGAAG 243<br>   <br>QY 1567 CATC 1570<br>   <br>DB 244 AAC 247  |  |
|   | FEATURES<br>source  |  | RESULT 249<br>AR263931<br>LOCUS AR263931 488 bp DNA linear PAT 29-JAN-2003<br>DEFINITION Sequence 109 from patent US 6331427.<br>ACCESSION AR263931<br>VERSION AR263931.1 GI:28075935<br>KEYWORDS<br>SOURCE Unknown.<br>ORGANISM Unclassified.<br>REFERENCE 1 (bases 1 to 488)<br>AUTHORS Robison,K.E.<br>TITLE Protease homologs<br>JOURNAL Patent: US 6331427-A 109 18-DEC-2001;<br>FEATURES Location/Qualifiers<br>source 1..488<br>/organism="unknown"<br>/mol_type="genomic DNA"                              |  |

| REFERENCE<br>AUTHORS  | TITLE  | JOURNAL  | FEATURES  | source |
|---|--|--|---|--------|
| Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.   |  |  |   |        |
| Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,<br>Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L.,<br>Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K.,<br>Wood, W.L. and Zhang, Z. | Secreted and transmembrane polypeptides and nucleic acids encoding<br>same | Patent: WO 0140466-A 221 07-JUN-2001;<br>Genentech Inc. (US) | Location/Qualifiers<br>1. 1129<br>/organism="Homo sapiens"<br>/mol_type="unassigned DNA"<br>/db_xref="taxon:9606" |        |
| Query Match   | 0.6%   | Score 20; DB 1; Length 1129;                                 |   |        |
| Best Local Similarity   | 53.9%  | Pred. No. 2.8e+02;   |   |        |
| Matches   | 41; Conservative   | 0; Mismatches 35; Indels                                     | 0; Gaps   | 0;     |
| QY 3004   | TTATTTTATTGATTTTCTTAATAAATCCAGCTCTCTGTTTTTAAAGACTTTAAA 3063                |  |   |        |
| 1128  | TTTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTTTATTGGGAGAAACATAA 1069              |  |   |        |
| Db  |  |  |   |        |
| QY 3064   | TTATTAATTTCTCTTT 3079  |  |   |        |
| 1068  | TAAATAAGGGTATTT 1053   |  |   |        |
| Db  |  |  |   |        |

Search completed: August 9, 2004, 15:51:29  
Job time : 1110 secs



Creation date: 08-26-2004  
Indexing Officer: NKIDANE - NIGIST M. KIDANE  
Team: OIPEScanning  
Dossier: 10664775

Legal Date: 08-05-2004

| No. | Doccode | Number of pages |
|-----|---------|-----------------|
| 1   | SRNT    | 296             |

Total number of pages: 296

Remarks:

Order of re-scan issued on .....

